1	From	IN	O	from	_	0	SENT_1	[p1l93t679r157b701],
2	the	DT	O	the	det	3	SENT_1	[p1l170t677r211b701],
3	Division	NN	O	division	prep_from	51	SENT_1	[p1l225t679r328b701],
4	of	IN	O	of	_	0	SENT_1	[p1l342t677r370b701],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_1	[p1l380t677r480b701],
6	Oncology	NNP	ORGANIZATION	Oncology	prep_of	3	SENT_1	[p1l493t677r625b708],
7	,	,	O	,	_	0	SENT_1	[p1l493t677r625b708],
8	Department	NNP	O	Department	nn	9	SENT_1	[p1l93t717r251b745],
9	ofE	NNP	O	ofE	dep	10	SENT_1	[p1l260t714r464b746],
10	>	JJR	O	>	prep_from	51	SENT_1	[p1l260t714r464b746],
11	<	JJR	O	<	amod	13	SENT_1	[p1l260t714r464b746],
12	perimenta	NN	O	perimenta	nn	13	SENT_1	[p1l260t714r464b746],
13	|	NN	O	|	dep	10	SENT_1	[p1l260t714r464b746],
14	and	CC	O	and	_	0	SENT_1	[p1l475t715r521b738],
15	Clinical	JJ	O	clinical	amod	16	SENT_1	[p1l531t715r625b738],
16	Medicine	NN	O	medicine	conj_and	10	SENT_1	[p1l93t752r211b776],
17	and	CC	O	and	_	0	SENT_1	[p1l221t752r267b776],
18	Surgery	NNP	PERSON	Surgery	nn	20	SENT_1	[p1l278t754r377b783],
19	F.	NNP	PERSON	F.	nn	20	SENT_1	[p1l388t754r405b776],
20	Magrassi	NNP	PERSON	Magrassi	conj_and	10	SENT_1	[p1l417t754r533b783],
21	and	CC	O	and	_	0	SENT_1	[p1l544t752r589b776],
22	A.	NNP	PERSON	A.	nn	23	SENT_1	[p1l599t754r625b776],
23	Lanzara	NNP	PERSON	Lanzara	conj_and	20	SENT_1	[p1l93t792r200b818],
24	,	,	O	,	_	0	SENT_1	[p1l93t792r200b818],
25	Second	NNP	ORGANIZATION	Second	nn	26	SENT_1	[p1l223t790r317b814],
26	University	NNP	ORGANIZATION	University	prep_from	51	SENT_1	[p1l340t792r471b821],
27	of	IN	ORGANIZATION	of	_	0	SENT_1	[p1l491t790r519b814],
28	Naples	NNP	ORGANIZATION	Naples	prep_of	26	SENT_1	[p1l537t790r625b821],
29	(	CD	NUMBER	(	num	28	SENT_1	[p1l93t829r166b859],
30	F.C.	NNP	ORGANIZATION	F.C.	dep	26	SENT_1	[p1l93t829r166b859],
31	)	CD	NUMBER	)	num	30	SENT_1	[p1l93t829r166b859],
32	;	:	O	;	_	0	SENT_1	[p1l93t829r166b859],
33	and	CC	O	and	_	0	SENT_1	[p1l176t827r222b851],
34	the	DT	O	the	det	37	SENT_1	[p1l230t827r271b851],
35	Division	NNP	O	Division	nn	37	SENT_1	[p1l282t830r385b851],
36	ofMedical	NNP	O	ofMedical	nn	37	SENT_1	[p1l395t827r529b851],
37	Oncology	NNP	O	Oncology	conj_and	3	SENT_1	[p1l539t827r626b851, p1l91t873r142b896],
38	,	,	O	,	_	0	SENT_1	[p1l539t827r626b851, p1l91t873r142b896],
39	Department	NNP	ORGANIZATION	Department	conj_and	3	SENT_1	[p1l156t867r314b896],
40	of	IN	ORGANIZATION	of	_	0	SENT_1	[p1l325t865r353b889],
41	Molecular	JJ	ORGANIZATION	molecular	amod	44	SENT_1	[p1l361t865r491b889],
42	and	CC	ORGANIZATION	and	_	0	SENT_1	[p1l501t865r547b889],
43	Clinical	JJ	ORGANIZATION	clinical	conj_and	41	SENT_1	[p1l560t865r626b889, p1l91t903r124b926],
44	Endocrinology	NN	ORGANIZATION	endocrinology	prep_of	39	SENT_1	[p1l137t903r325b934],
45	and	CC	O	and	_	0	SENT_1	[p1l334t903r380b926],
46	Oncology	NN	O	oncology	conj_and	37	SENT_1	[p1l391t903r522b934],
47	,	,	O	,	_	0	SENT_1	[p1l391t903r522b934],
48	University	NNP	ORGANIZATION	University	nn	50	SENT_1	[p1l534t905r626b926, p1l91t942r135b971],
49	ofNap	NNP	O	ofNap	nn	50	SENT_1	[p1l143t940r265b971],
50	|	NNP	O	|	nsubj	51	SENT_1	[p1l143t940r265b971],
51	es	VBZ	O	e	_	0	SENT_1	[p1l143t940r265b971],
52	Federico	NNP	PERSON	Federico	nn	55	SENT_1	[p1l276t940r386b964],
53	II	NNP	PERSON	II	nn	55	SENT_1	[p1l396t942r408b963],
54	(	CD	NUMBER	(	num	55	SENT_1	[p1l422t942r488b971],
55	G.T.	NNP	LOCATION	G.T.	nsubj	58	SENT_1	[p1l422t942r488b971],
56	)	CD	NUMBER	)	number	57	SENT_1	[p1l422t942r488b971],
57	—	CD	NUMBER	—	num	58	SENT_1	[p1l497t955r529b957],
58	both	DT	O	both	xcomp	51	SENT_1	[p1l537t940r594b964],
59	in	IN	O	in	_	0	SENT_1	[p1l604t942r625b963],
60	Naples	NNP	LOCATION	Naples	nn	62	SENT_1	[p1l93t978r189b1008],
61	,	,	O	,	_	0	SENT_1	[p1l93t978r189b1008],
62	Italy	NNP	LOCATION	Italy	prep_in	58	SENT_1	[p1l202t978r259b1008],
63	.	.	O	.	_	0	SENT_1	[p1l202t978r259b1008],

1	Address	NN	O	address	nsubj	2	SENT_2	[p1l269t978r374b1001],
2	reprint	VB	O	reprint	ccomp	31	SENT_2	[p1l385t980r472b1008],
3	requests	NNS	O	request	dobj	2	SENT_2	[p1l482t982r592b1008],
4	to	TO	O	to	_	0	SENT_2	[p1l601t982r626b1001],
5	Dr.	NNP	O	Dr.	nn	6	SENT_2	[p1l93t1017r128b1039],
6	Ciardiello	NNP	PERSON	Ciardiello	prep_to	2	SENT_2	[p1l142t1015r265b1039],
7	at	IN	O	at	_	0	SENT_2	[p1l278t1020r301b1039],
8	the	DT	O	the	det	9	SENT_2	[p1l313t1015r354b1039],
9	Division	NN	O	division	prep_at	6	SENT_2	[p1l368t1017r472b1039],
10	of	IN	O	of	_	0	SENT_2	[p1l486t1015r514b1039],
11	Medical	NNP	MISC	Medical	nn	12	SENT_2	[p1l525t1015r625b1039],
12	Oncology	NNP	MISC	Oncology	prep_of	9	SENT_2	[p1l91t1053r222b1084],
13	,	,	O	,	_	0	SENT_2	[p1l91t1053r222b1084],
14	Department	NNP	O	Department	prep_at	6	SENT_2	[p1l241t1055r399b1083],
15	of	IN	O	of	_	0	SENT_2	[p1l414t1052r442b1076],
16	Experimental	JJ	O	experimental	amod	19	SENT_2	[p1l455t1053r625b1083],
17	and	CC	O	and	_	0	SENT_2	[p1l91t1090r137b1114],
18	Clinical	JJ	ORGANIZATION	clinical	conj_and	16	SENT_2	[p1l148t1090r241b1114],
19	Medicine	NN	ORGANIZATION	medicine	prep_of	14	SENT_2	[p1l254t1090r372b1114],
20	and	CC	O	and	_	0	SENT_2	[p1l382t1090r428b1114],
21	Surgery	NNP	PERSON	Surgery	nn	23	SENT_2	[p1l439t1092r538b1121],
22	F.	NNP	PERSON	F.	nn	23	SENT_2	[p1l549t1092r566b1114],
23	Magrassi	NNP	PERSON	Magrassi	prep_at	6	SENT_2	[p1l578t1092r626b1114, p1l91t1130r165b1159],
24	and	CC	O	and	_	0	SENT_2	[p1l177t1128r222b1151],
25	A.	NNP	PERSON	A.	nn	26	SENT_2	[p1l232t1129r258b1151],
26	Lanzara	NNP	PERSON	Lanzara	conj_and	23	SENT_2	[p1l271t1130r378b1156],
27	,	,	O	,	_	0	SENT_2	[p1l271t1130r378b1156],
28	Second	NNP	ORGANIZATION	Second	nn	30	SENT_2	[p1l390t1128r484b1151],
29	University	NNP	ORGANIZATION	University	nn	30	SENT_2	[p1l496t1130r627b1159],
30	ofNap	NNP	O	ofNap	nsubj	31	SENT_2	[p1l91t1165r221b1196],
31	|	VBD	O	|	_	0	SENT_2	[p1l91t1165r221b1196],
32	es	NNS	O	e	dobj	31	SENT_2	[p1l91t1165r221b1196],
33	,	,	O	,	_	0	SENT_2	[p1l91t1165r221b1196],
34	Via	NNP	PERSON	Via	nn	35	SENT_2	[p1l230t1168r270b1189],
35	S.	NNP	PERSON	S.	appos	32	SENT_2	[p1l279t1167r301b1189],
36	Pansini	NNP	PERSON	Pansini	dep	35	SENT_2	[p1l312t1168r403b1189],
37	5	CD	NUMBER	5	num	36	SENT_2	[p1l414t1168r433b1193],
38	,	,	O	,	_	0	SENT_2	[p1l414t1168r433b1193],
39	80131	CD	NUMBER	80131	num	36	SENT_2	[p1l443t1167r517b1189],
40	Naples	NNP	LOCATION	Naples	nn	42	SENT_2	[p1l528t1165r625b1196],
41	,	,	O	,	_	0	SENT_2	[p1l528t1165r625b1196],
42	Italy	NNP	LOCATION	Italy	tmod	31	SENT_2	[p1l93t1203r150b1234],
43	,	,	O	,	_	0	SENT_2	[p1l93t1203r150b1234],
44	or	CC	O	or	_	0	SENT_2	[p1l167t1211r193b1227],
45	at	IN	O	at	advmod	42	SENT_2	[p1l208t1207r231b1227],
46	fortunato	NN	O	fortunato	tmod	31	SENT_2	[p1l245t1203r625b1231],
47	.	.	O	.	_	0	SENT_2	[p1l245t1203r625b1231],

1	ciardie	NN	O	ciardie	_	0	SENT_3	[p1l245t1203r625b1231],
2	|	CD	NUMBER	|	num	4	SENT_3	[p1l245t1203r625b1231],
3	|	NN	O	|	nn	4	SENT_3	[p1l245t1203r625b1231],
4	o@unina2	NN	O	o@unina2	dep	1	SENT_3	[p1l245t1203r625b1231],
5	.	.	O	.	_	0	SENT_3	[p1l245t1203r625b1231],

1	it	PRP	O	it	_	0	SENT_4	[p1l92t1243r114b1264],
2	.	.	O	.	_	0	SENT_4	[p1l92t1243r114b1264],

1	N	NN	MISC	n	nn	3	SENT_5	[p1l93t1316r110b1338],
2	Englj	NNP	MISC	Englj	nn	3	SENT_5	[p1l124t1314r192b1345],
3	Med	NNP	O	Med	_	0	SENT_5	[p1l205t1314r260b1338],
4	2008	CD	DATE	2008	num	3	SENT_5	[p1l271t1316r505b1342],
5	;	:	O	;	_	0	SENT_5	[p1l271t1316r505b1342],
6	358:1160	CD	NUMBER	358:1160	number	7	SENT_5	[p1l271t1316r505b1342],
7	-74	CD	NUMBER	-74	dep	3	SENT_5	[p1l271t1316r505b1342],
8	.	.	O	.	_	0	SENT_5	[p1l271t1316r505b1342],

1	Copyright	NN	O	copyright	_	0	SENT_6	[p1l91t1356r185b1381],
2	©	CD	NUMBER	©	num	6	SENT_6	[p1l194t1358r215b1379],
3	2008	CD	DATE	2008	num	6	SENT_6	[p1l225t1357r274b1375],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_6	[p1l283t1356r423b1375],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_6	[p1l432t1356r509b1375],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_6	[p1l517t1357r589b1381],
7	.	.	O	.	_	0	SENT_6	[p1l517t1357r589b1381],

1	The	DT	O	the	det	4	SENT_7	[p1l957t81r1003b102],
2	NEW	NNP	O	NEW	nn	4	SENT_7	[p1l1021t83r1107b102],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_7	[p1l1126t83r1314b102],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_7	[p1l1333t83r1512b109],
5	of	IN	O	of	_	0	SENT_7	[p1l1532t81r1560b108],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_7	[p1l1572t83r1771b102],

1	l	NN	O	l	_	0	SENT_8	[p1l664t184r667b303],
2	REVIEW	NNP	O	REVIEW	nn	3	SENT_8	[p1l1179t234r1353b260],
3	ARTICLE	NN	O	article	dep	1	SENT_8	[p1l1365t234r1550b260],
4	l	NN	O	l	tmod	3	SENT_8	[p1l2062t184r2065b303],

1	DRUG	NN	O	drug	nn	2	SENT_9	[p1l1229t378r1327b401],
2	THERAPY	NN	O	therapy	_	0	SENT_9	[p1l1342t378r1503b401],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_10	[p1l749t458r932b513],
2	Antagonists	NNS	O	antagonist	_	0	SENT_10	[p1l952t455r1314b525],
3	in	IN	O	in	_	0	SENT_10	[p1l1344t455r1401b508],
4	Cancer	NNP	O	Cancer	nn	5	SENT_10	[p1l1430t458r1641b509],
5	Treatment	NN	O	treatment	prep_in	2	SENT_10	[p1l1665t458r1983b509],

1	Fortunato	NNP	PERSON	Fortunato	nn	6	SENT_11	[p1l761t581r926b609],
2	Ciardiello	NNP	PERSON	Ciardiello	nn	6	SENT_11	[p1l940t578r1109b614],
3	,	,	O	,	_	0	SENT_11	[p1l940t578r1109b614],
4	M.D.	NNP	O	M.D.	appos	6	SENT_11	[p1l1126t581r1216b614],
5	,	,	O	,	_	0	SENT_11	[p1l1126t581r1216b614],
6	Ph.D.	NNP	O	Ph.D.	_	0	SENT_11	[p1l1233t578r1332b614],
7	,	,	O	,	_	0	SENT_11	[p1l1233t578r1332b614],
8	and	CC	O	and	_	0	SENT_11	[p1l1347t578r1407b609],
9	Giampaolo	NNP	PERSON	Giampaolo	nn	10	SENT_11	[p1l1422t578r1610b618],
10	Tortora	NNP	PERSON	Tortora	conj_and	6	SENT_11	[p1l1621t581r1756b614],
11	,	,	O	,	_	0	SENT_11	[p1l1621t581r1756b614],
12	M.D.	NNP	O	M.D.	nn	14	SENT_11	[p1l1773t581r1863b614],
13	,	,	O	,	_	0	SENT_11	[p1l1773t581r1863b614],
14	Ph.D.	NNP	O	Ph.D.	appos	6	SENT_11	[p1l1881t578r1969b609],
15	.	.	O	.	_	0	SENT_11	[p1l1881t578r1969b609],

1	ANCER	JJ	O	ancer	amod	2	SENT_12	[p1l784t679r906b701],
2	CELLS	NNS	O	cell	nsubj	36	SENT_12	[p1l918t679r1020b701],
3	MAY	NNP	DATE	MAY	nsubj	4	SENT_12	[p1l1033t679r1108b701],
4	ACQUIRE	VB	O	acquire	rcmod	2	SENT_12	[p1l1117t679r1277b708],
5	THE	DT	O	the	det	6	SENT_12	[p1l1289t679r1361b701],
6	CAPACITY	NN	O	capacity	dobj	4	SENT_12	[p1l1374t679r1541b701],
7	FOR	IN	O	for	_	0	SENT_12	[p1l1553t679r1623b701],
8	AUTONOMOUS	NNPS	O	AUTONOMOUS	prep_for	6	SENT_12	[p1l1632t679r1884b701],
9	AND	CC	O	and	nsubj	10	SENT_12	[p1l1896t679r1976b701],
10	DYSregulated	VBN	O	dysregulate	rcmod	6	SENT_12	[p1l1990t679r2063b701, p1l785t721r940b760],
11	proliferation	NN	O	proliferation	dobj	10	SENT_12	[p1l953t720r1159b760],
12	through	IN	O	through	_	0	SENT_12	[p1l1174t721r1306b760],
13	the	DT	O	the	det	15	SENT_12	[p1l1321t721r1371b751],
14	uncontrolled	JJ	O	uncontrolled	amod	15	SENT_12	[p1l1386t721r1595b751],
15	production	NN	O	production	prep_through	10	SENT_12	[p1l1609t721r1789b760],
16	of	IN	O	of	_	0	SENT_12	[p1l1804t720r1842b751],
17	speciﬁc	NN	O	speciﬁc	nn	18	SENT_12	[p1l1850t720r1975b760],
18	molecules	NNS	O	molecule	prep_of	15	SENT_12	[p1l1989t721r2063b751, p1l786t771r885b802],
19	that	WDT	O	that	nsubj	20	SENT_12	[p1l902t771r967b801],
20	promote	VBP	O	promote	rcmod	15	SENT_12	[p1l981t777r1119b810],
21	cell	NN	O	cell	nn	25	SENT_12	[p1l1136t771r1191b801],
22	growth	NN	O	growth	nn	25	SENT_12	[p1l1207t771r1327b810],
23	(	CD	NUMBER	(	num	25	SENT_12	[p1l1345t771r1476b810],
24	growth	NN	O	growth	nn	25	SENT_12	[p1l1345t771r1476b810],
25	factors	NNS	O	factor	nsubj	26	SENT_12	[p1l1493t770r1612b806],
26	)	CD	NUMBER	)	xcomp	20	SENT_12	[p1l1493t770r1612b806],
27	or	CC	O	or	_	0	SENT_12	[p1l1631t781r1665b801],
28	through	IN	O	through	conj_or	26	SENT_12	[p1l1680t771r1812b810],
29	abnormal	JJ	O	abnormal	amod	32	SENT_12	[p1l1828t771r1995b808],
30	,	,	O	,	_	0	SENT_12	[p1l1828t771r1995b808],
31	enhanced	VBN	O	enhance	amod	32	SENT_12	[p1l2014t781r2063b801, p1l666t821r784b852],
32	expression	NN	O	expression	pobj	28	SENT_12	[p1l792t821r965b860],
33	of	IN	O	of	_	0	SENT_12	[p1l973t821r1011b852],
34	specific	JJ	O	specific	amod	35	SENT_12	[p1l1013t821r1138b860],
35	proteins	NNS	O	protein	prep_of	2	SENT_12	[p1l1145t821r1279b860],
36	(	VBP	O	(	_	0	SENT_12	[p1l1289t821r1421b860],
37	growth	NN	O	growth	nn	39	SENT_12	[p1l1289t821r1421b860],
38	factor	NN	O	factor	nn	39	SENT_12	[p1l1429t821r1524b852],
39	receptors	NNS	O	receptor	nsubj	40	SENT_12	[p1l1530t824r1690b860],
40	)	VBP	O	)	ccomp	36	SENT_12	[p1l1530t824r1690b860],
41	on	IN	O	on	_	0	SENT_12	[p1l1700t831r1741b852],
42	the	DT	O	the	det	44	SENT_12	[p1l1749t821r1800b851],
43	cell	NN	O	cell	nn	44	SENT_12	[p1l1808t821r1863b851],
44	membranes	NNS	O	membrane	prep_on	40	SENT_12	[p1l1871t821r2063b852],
45	to	TO	O	to	_	0	SENT_12	[p1l666t877r697b902],
46	which	WDT	O	which	rel	50	SENT_12	[p1l711t871r811b902],
47	growth	NN	O	growth	nn	48	SENT_12	[p1l825t871r945b910],
48	factors	NNS	O	factor	nsubj	50	SENT_12	[p1l960t871r1070b902],
49	selectively	RB	O	selectively	advmod	50	SENT_12	[p1l1086t871r1249b910],
50	bind	VBP	O	bind	rcmod	44	SENT_12	[p1l1262t871r1344b902],
51	.	.	O	.	_	0	SENT_12	[p1l1262t871r1344b902],

1	Both	DT	O	both	det	2	SENT_13	[p1l1360t871r1439b902],
2	processes	NNS	O	process	nsubj	3	SENT_13	[p1l1452t881r1610b910],
3	trigger	VBP	O	trigger	dep	33	SENT_13	[p1l1621t871r1732b910],
4	a	DT	O	a	det	5	SENT_13	[p1l1745t881r1762b901],
5	series	NN	O	series	dobj	3	SENT_13	[p1l1777t871r1868b901],
6	of	IN	O	of	_	0	SENT_13	[p1l1883t871r1922b902],
7	intracellular	JJ	O	intracellular	amod	8	SENT_13	[p1l1929t871r2063b901, p1l665t921r741b952],
8	signals	NNS	O	signal	prep_of	5	SENT_13	[p1l754t921r867b960],
9	that	WDT	O	that	nsubj	11	SENT_13	[p1l881t921r947b951],
10	ultimately	RB	O	ultimately	advmod	11	SENT_13	[p1l957t921r1123b960],
11	lead	VBP	O	lead	rcmod	5	SENT_13	[p1l1134t921r1200b952],
12	to	TO	O	to	_	0	SENT_13	[p1l1213t927r1244b952],
13	the	DT	O	the	det	14	SENT_13	[p1l1258t921r1309b951],
14	proliferation	NN	O	proliferation	prep_to	11	SENT_13	[p1l1321t921r1527b960],
15	of	IN	O	of	_	0	SENT_13	[p1l1540t921r1578b952],
16	cancer	NN	O	cancer	nn	17	SENT_13	[p1l1585t931r1691b951],
17	cells	NNS	O	cell	prep_of	14	SENT_13	[p1l1703t921r1783b958],
18	,	,	O	,	_	0	SENT_13	[p1l1703t921r1783b958],
19	induction	NN	O	induction	conj_and	14	SENT_13	[p1l1798t921r1955b952],
20	of	IN	O	of	_	0	SENT_13	[p1l1968t921r2006b952],
21	angiogenesis	NN	O	angiogenesis	prep_of	19	SENT_13	[p1l2012t931r2063b951, p1l666t971r846b1010],
22	,	,	O	,	_	0	SENT_13	[p1l2012t931r2063b951, p1l666t971r846b1010],
23	and	CC	O	and	_	0	SENT_13	[p1l860t971r921b1002],
24	metastasis	NN	O	metastasis	conj_and	14	SENT_13	[p1l933t971r1129b1002],
25	}	CD	NUMBER	}	num	24	SENT_13	[p1l933t971r1129b1002],
26	The	DT	O	the	det	27	SENT_13	[p1l1136t971r1198b1001],
27	majority	NN	O	majority	dep	24	SENT_13	[p1l1210t971r1347b1010],
28	of	IN	O	of	_	0	SENT_13	[p1l1358t971r1396b1002],
29	human	JJ	O	human	amod	31	SENT_13	[p1l1402t971r1518b1002],
30	epithelial	JJ	O	epithelial	amod	31	SENT_13	[p1l1531t971r1682b1010],
31	cancers	NNS	O	cancer	prep_of	27	SENT_13	[p1l1695t981r1816b1001],
32	are	VBP	O	be	auxpass	33	SENT_13	[p1l1829t981r1879b1001],
33	marked	VBN	O	mark	_	0	SENT_13	[p1l1891t971r2016b1002],
34	by	IN	O	by	_	0	SENT_13	[p1l2028t971r2065b1010],
35	functional	JJ	O	functional	amod	36	SENT_13	[p1l666t1021r835b1052],
36	activation	NN	O	activation	agent	33	SENT_13	[p1l847t1022r1005b1052],
37	of	IN	O	of	_	0	SENT_13	[p1l1018t1021r1057b1052],
38	growth	NN	O	growth	nn	39	SENT_13	[p1l1062t1021r1182b1060],
39	factors	NNS	O	factor	prep_of	36	SENT_13	[p1l1194t1021r1304b1052],
40	and	CC	O	and	_	0	SENT_13	[p1l1317t1021r1378b1052],
41	receptors	NNS	O	receptor	conj_and	39	SENT_13	[p1l1390t1027r1540b1060],
42	of	IN	O	of	_	0	SENT_13	[p1l1554t1021r1592b1052],
43	the	DT	O	the	det	47	SENT_13	[p1l1598t1021r1648b1052],
44	epidermal	JJ	O	epidermal	amod	47	SENT_13	[p1l1661t1021r1825b1060],
45	growth	NN	O	growth	nn	47	SENT_13	[p1l1838t1021r1957b1060],
46	factor	NN	O	factor	nn	47	SENT_13	[p1l1970t1021r2065b1052],
47	receptor	NN	O	receptor	prep_of	36	SENT_13	[p1l666t1078r801b1110],
48	(	CD	NUMBER	(	num	51	SENT_13	[p1l816t1073r933b1107],
49	EGFR	NN	ORGANIZATION	egfr	nn	51	SENT_13	[p1l816t1073r933b1107],
50	)	NN	O	)	nn	51	SENT_13	[p1l816t1073r933b1107],
51	family	NN	O	family	nsubjpass	33	SENT_13	[p1l950t1071r1060b1110],
52	.	.	O	.	_	0	SENT_13	[p1l950t1071r1060b1110],

1	Given	VBN	O	give	prep	6	SENT_14	[p1l1077t1072r1170b1102],
2	this	DT	O	this	det	3	SENT_14	[p1l1185t1071r1245b1102],
3	phenomenon	NN	O	phenomenon	dep	1	SENT_14	[p1l1260t1071r1485b1110],
4	,	,	O	,	_	0	SENT_14	[p1l1260t1071r1485b1110],
5	EGFR	NN	ORGANIZATION	egfr	appos	3	SENT_14	[p1l1502t1073r1600b1104],
6	was	VBD	O	be	_	0	SENT_14	[p1l1609t1081r1671b1102],
7	the	DT	O	the	det	11	SENT_14	[p1l1687t1071r1738b1102],
8	first	JJ	ORDINAL	first	amod	11	SENT_14	[p1l1753t1071r1822b1102],
9	growth	NN	O	growth	nn	11	SENT_14	[p1l1835t1071r1955b1110],
10	factor	NN	O	factor	nn	11	SENT_14	[p1l1970t1071r2065b1102],
11	receptor	NN	O	receptor	nsubj	6	SENT_14	[p1l666t1128r801b1160],
12	to	TO	O	to	aux	14	SENT_14	[p1l811t1128r842b1152],
13	be	VB	O	be	auxpass	14	SENT_14	[p1l854t1121r891b1152],
14	proposed	VBN	O	propose	infmod	11	SENT_14	[p1l902t1121r1055b1160],
15	as	IN	O	as	_	0	SENT_14	[p1l1066t1131r1098b1152],
16	a	DT	O	a	det	17	SENT_14	[p1l1110t1131r1128b1152],
17	target	NN	O	target	prep_as	14	SENT_14	[p1l1138t1128r1235b1160],
18	for	IN	O	for	_	0	SENT_14	[p1l1244t1121r1292b1152],
19	cancer	NN	O	cancer	nn	20	SENT_14	[p1l1302t1131r1409b1152],
20	therapy	NN	O	therapy	prep_for	17	SENT_14	[p1l1419t1121r1546b1160],
21	.	.	O	.	_	0	SENT_14	[p1l1419t1121r1546b1160],

1	After	IN	O	after	_	0	SENT_15	[p1l1558t1121r1642b1152],
2	20	CD	DURATION	20	num	3	SENT_15	[p1l1653t1124r1691b1152],
3	years	NNS	NUMBER	year	prep_after	13	SENT_15	[p1l1700t1131r1784b1160],
4	of	IN	O	of	_	0	SENT_15	[p1l1796t1121r1835b1152],
5	drug	NN	O	drug	nn	6	SENT_15	[p1l1839t1121r1917b1160],
6	development	NN	O	development	prep_of	3	SENT_15	[p1l1927t1121r2063b1160, p1l666t1178r758b1209],
7	,	,	O	,	_	0	SENT_15	[p1l1927t1121r2063b1160, p1l666t1178r758b1209],
8	four	CD	NUMBER	four	num	10	SENT_15	[p1l774t1171r843b1202],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_15	[p1l855t1174r953b1204],
10	antagonists	NNS	O	antagonist	nsubj	13	SENT_15	[p1l963t1172r1153b1211],
11	are	VBP	O	be	cop	13	SENT_15	[p1l1167t1182r1216b1202],
12	currently	RB	DATE	currently	advmod	13	SENT_15	[p1l1231t1171r1379b1210],
13	available	JJ	O	available	_	0	SENT_15	[p1l1391t1171r1531b1202],
14	for	IN	O	for	_	0	SENT_15	[p1l1545t1171r1592b1202],
15	the	DT	O	the	det	16	SENT_15	[p1l1606t1171r1656b1202],
16	treatment	NN	O	treatment	prep_for	13	SENT_15	[p1l1671t1178r1831b1202],
17	of	IN	O	of	_	0	SENT_15	[p1l1844t1171r1882b1202],
18	four	CD	NUMBER	four	num	21	SENT_15	[p1l1889t1171r1958b1202],
19	metastatic	JJ	O	metastatic	amod	21	SENT_15	[p1l1971t1178r2063b1202, p1l666t1222r753b1252],
20	epithelial	JJ	O	epithelial	amod	21	SENT_15	[p1l764t1221r916b1260],
21	cancers	NNS	O	cancer	prep_of	16	SENT_15	[p1l927t1231r1058b1252],
22	:	:	O	:	_	0	SENT_15	[p1l927t1231r1058b1252],
23	non	JJ	O	non	amod	16	SENT_15	[p1l1071t1221r1315b1252],
24	—	JJ	O	—	amod	27	SENT_15	[p1l1071t1221r1315b1252],
25	small-cell	NN	O	small-cell	nn	27	SENT_15	[p1l1071t1221r1315b1252],
26	lung	NN	O	lung	nn	27	SENT_15	[p1l1326t1221r1400b1261],
27	cancer	NN	O	cancer	dep	16	SENT_15	[p1l1410t1231r1524b1259],
28	,	,	O	,	_	0	SENT_15	[p1l1410t1231r1524b1259],
29	squamous-cell	JJ	O	squamous-cell	amod	30	SENT_15	[p1l1538t1221r1775b1260],
30	carcinoma	NN	O	carcinoma	attr	13	SENT_15	[p1l1786t1222r1959b1252],
31	of	IN	O	of	_	0	SENT_15	[p1l1970t1221r2008b1252],
32	the	DT	O	the	det	33	SENT_15	[p1l2013t1222r2063b1252],
33	head	NN	O	head	prep_of	30	SENT_15	[p1l666t1271r743b1302],
34	and	CC	O	and	_	0	SENT_15	[p1l754t1271r814b1302],
35	neck	NN	O	neck	prep_of	30	SENT_15	[p1l825t1271r909b1308],
36	,	,	O	,	_	0	SENT_15	[p1l825t1271r909b1308],
37	colorectal	JJ	O	colorectal	amod	38	SENT_15	[p1l922t1271r1081b1302],
38	cancer	NN	O	cancer	prep_of	30	SENT_15	[p1l1092t1281r1206b1308],
39	,	,	O	,	_	0	SENT_15	[p1l1092t1281r1206b1308],
40	and	CC	O	and	_	0	SENT_15	[p1l1218t1271r1279b1302],
41	pancreatic	JJ	O	pancreatic	amod	42	SENT_15	[p1l1289t1271r1459b1310],
42	cancer	NN	O	cancer	prep_of	30	SENT_15	[p1l1470t1281r1583b1302],
43	.	.	O	.	_	0	SENT_15	[p1l1470t1281r1583b1302],

1	Less	RBR	O	less	amod	2	SENT_16	[p1l1595t1274r1666b1301],
2	information	NN	O	information	nsubj	4	SENT_16	[p1l1677t1271r1876b1302],
3	is	VBZ	O	be	cop	4	SENT_16	[p1l1886t1271r1911b1301],
4	available	JJ	O	available	_	0	SENT_16	[p1l1923t1271r2064b1302],
5	about	IN	O	about	_	0	SENT_16	[p1l666t1320r759b1351],
6	the	DT	O	the	det	7	SENT_16	[p1l770t1320r821b1350],
7	use	NN	O	use	prep_about	4	SENT_16	[p1l835t1330r889b1351],
8	of	IN	O	of	_	0	SENT_16	[p1l903t1320r941b1351],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_16	[p1l947t1322r1045b1352],
10	antagonists	NNS	O	antagonist	prep_of	7	SENT_16	[p1l1054t1321r1244b1359],
11	in	IN	O	in	_	0	SENT_16	[p1l1258t1320r1290b1350],
12	the	DT	O	the	det	13	SENT_16	[p1l1304t1320r1355b1350],
13	treatment	NN	O	treatment	prep_in	10	SENT_16	[p1l1369t1326r1530b1350],
14	of	IN	O	of	_	0	SENT_16	[p1l1542t1320r1580b1351],
15	earlier	JJR	O	earlier	amod	16	SENT_16	[p1l1587t1320r1691b1350],
16	stages	NNS	O	stage	prep_of	13	SENT_16	[p1l1704t1326r1804b1359],
17	of	IN	O	of	_	0	SENT_16	[p1l1818t1320r1857b1351],
18	cancer	NN	O	cancer	prep_of	16	SENT_16	[p1l1864t1330r1977b1351],
19	.	.	O	.	_	0	SENT_16	[p1l1864t1330r1977b1351],

1	This	DT	O	this	det	2	SENT_17	[p1l1991t1320r2063b1350],
2	article	NN	O	article	nsubj	22	SENT_17	[p1l666t1370r767b1400],
3	summarizes	VBZ	O	summarize	_	0	SENT_17	[p1l780t1370r981b1401],
4	the	DT	O	the	det	5	SENT_17	[p1l995t1370r1045b1400],
5	mechanisms	NNS	O	mechanism	dobj	3	SENT_17	[p1l1058t1370r1265b1400],
6	of	IN	O	of	_	0	SENT_17	[p1l1278t1370r1317b1401],
7	action	NN	O	action	prep_of	5	SENT_17	[p1l1322t1370r1422b1401],
8	of	IN	O	of	_	0	SENT_17	[p1l1434t1370r1473b1401],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_17	[p1l1478t1372r1576b1402],
10	inhibitors	NNS	O	inhibitor	prep_of	7	SENT_17	[p1l1584t1370r1753b1407],
11	,	,	O	,	_	0	SENT_17	[p1l1584t1370r1753b1407],
12	presents	VBZ	O	present	conj_and	3	SENT_17	[p1l1767t1377r1903b1409],
13	the	DT	O	the	det	15	SENT_17	[p1l1916t1370r1967b1400],
14	clinical	JJ	O	clinical	amod	15	SENT_17	[p1l1980t1370r2063b1400, p1l666t1419r712b1449],
15	evidence	NN	O	evidence	dobj	12	SENT_17	[p1l724t1419r863b1450],
16	of	IN	O	of	_	0	SENT_17	[p1l876t1419r914b1450],
17	their	PRP$	O	they	poss	19	SENT_17	[p1l919t1419r997b1449],
18	anticancer	JJ	O	anticancer	amod	19	SENT_17	[p1l1008t1419r1179b1449],
19	activity	NN	O	activity	prep_of	15	SENT_17	[p1l1190t1419r1312b1458],
20	,	,	O	,	_	0	SENT_17	[p1l1190t1419r1312b1458],
21	and	CC	O	and	_	0	SENT_17	[p1l1326t1419r1386b1450],
22	considers	VBZ	O	consider	conj_and	3	SENT_17	[p1l1399t1419r1552b1450],
23	the	DT	O	the	det	30	SENT_17	[p1l1565t1419r1616b1449],
24	current	JJ	DATE	current	amod	30	SENT_17	[p1l1628t1425r1755b1456],
25	,	,	O	,	_	0	SENT_17	[p1l1628t1425r1755b1456],
26	and	CC	O	and	_	0	SENT_17	[p1l1769t1419r1830b1450],
27	controversial	JJ	O	controversial	conj_and	24	SENT_17	[p1l1842t1419r2062b1456],
28	,	,	O	,	_	0	SENT_17	[p1l1842t1419r2062b1456],
29	clinical	JJ	O	clinical	amod	30	SENT_17	[p1l666t1468r785b1498],
30	issues	NNS	O	issue	dobj	22	SENT_17	[p1l802t1468r898b1499],
31	with	IN	O	with	_	0	SENT_17	[p1l915t1468r989b1499],
32	respect	NN	O	respect	prep_with	30	SENT_17	[p1l1007t1475r1124b1507],
33	to	TO	O	to	_	0	SENT_17	[p1l1140t1474r1171b1499],
34	their	PRP$	O	they	poss	36	SENT_17	[p1l1189t1468r1267b1498],
35	optimal	JJ	O	optimal	amod	36	SENT_17	[p1l1283t1468r1411b1507],
36	use	NN	O	use	prep_to	22	SENT_17	[p1l1429t1478r1482b1499],
37	in	IN	O	in	_	0	SENT_17	[p1l1500t1468r1532b1498],
38	the	DT	O	the	det	39	SENT_17	[p1l1549t1468r1600b1498],
39	treatment	NN	O	treatment	prep_in	36	SENT_17	[p1l1618t1474r1779b1498],
40	of	IN	O	of	_	0	SENT_17	[p1l1795t1468r1833b1499],
41	patients	NNS	O	patient	prep_of	39	SENT_17	[p1l1843t1468r1972b1507],
42	with	IN	O	with	_	0	SENT_17	[p1l1989t1468r2063b1499],
43	cancer	NN	O	cancer	prep_with	41	SENT_17	[p1l666t1517r779b1538],
44	.	.	O	.	_	0	SENT_17	[p1l666t1517r779b1538],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_18	[p1l977t1623r1088b1646],
2	IN	IN	O	in	dep	1	SENT_18	[p1l1107t1623r1155b1646],
3	HUMAN	NNP	O	HUMAN	nn	4	SENT_18	[p1l1178t1623r1343b1646],
4	CARCINOGENESIS	NNS	O	carcinogenesis	pobj	2	SENT_18	[p1l1365t1623r1753b1646],

1	EGFR	NN	ORGANIZATION	egfr	nsubj	14	SENT_19	[p1l665t1709r765b1739],
2	is	VBZ	O	be	cop	5	SENT_19	[p1l776t1707r801b1737],
3	a	DT	O	a	det	5	SENT_19	[p1l817t1717r835b1737],
4	transmembrane	NN	O	transmembrane	nn	5	SENT_19	[p1l850t1707r1115b1738],
5	receptor	NN	O	receptor	rcmod	1	SENT_19	[p1l1131t1714r1269b1746],
6	belonging	VBG	O	belong	partmod	5	SENT_19	[p1l1283t1707r1452b1746],
7	to	TO	O	to	_	0	SENT_19	[p1l1466t1714r1498b1738],
8	a	DT	O	a	det	9	SENT_19	[p1l1514t1717r1531b1737],
9	family	NN	O	family	prep_to	6	SENT_19	[p1l1546t1707r1652b1746],
10	of	IN	O	of	_	0	SENT_19	[p1l1667t1707r1705b1738],
11	four	CD	NUMBER	four	num	13	SENT_19	[p1l1713t1707r1783b1738],
12	related	JJ	O	related	amod	13	SENT_19	[p1l1798t1707r1911b1738],
13	proteins	NNS	O	protein	prep_of	9	SENT_19	[p1l1926t1707r2063b1746],
14	(	VBP	O	(	_	0	SENT_19	[p1l668t1756r737b1795],
15	Fig	NN	O	fig	dobj	14	SENT_19	[p1l668t1756r737b1795],
16	.	.	O	.	_	0	SENT_19	[p1l668t1756r737b1795],

1	1	CD	NUMBER	1	_	0	SENT_20	[p1l755t1758r808b1791],
2	)	NN	O	)	dep	1	SENT_20	[p1l755t1758r808b1791],
3	.	.	O	.	_	0	SENT_20	[p1l755t1758r808b1791],

1	’	NN	O	’	npadvmod	3	SENT_21	[p1l755t1758r808b1791],
2	Ten	CD	NUMBER	ten	num	1	SENT_21	[p1l821t1758r881b1786],
3	different	JJ	O	different	amod	4	SENT_21	[p1l896t1756r1042b1787],
4	ligands	NNS	O	ligand	nsubj	7	SENT_21	[p1l1054t1756r1175b1795],
5	can	MD	O	can	aux	7	SENT_21	[p1l1191t1766r1249b1786],
6	selectively	RB	O	selectively	advmod	7	SENT_21	[p1l1263t1756r1431b1795],
7	bind	VB	O	bind	_	0	SENT_21	[p1l1444t1756r1519b1787],
8	to	TO	O	to	_	0	SENT_21	[p1l1533t1762r1565b1787],
9	each	DT	O	each	det	10	SENT_21	[p1l1580t1756r1654b1786],
10	receptor	NN	O	receptor	prep_to	7	SENT_21	[p1l1669t1763r1814b1795],
11	.	.	O	.	_	0	SENT_21	[p1l1669t1763r1814b1795],

1	After	IN	O	after	mark	4	SENT_22	[p1l1829t1756r1915b1786],
2	a	DT	O	a	det	3	SENT_22	[p1l1928t1766r1945b1786],
3	ligand	NN	O	ligand	nsubj	4	SENT_22	[p1l1959t1756r2064b1795],
4	binds	VBZ	O	bind	advcl	12	SENT_22	[p1l666t1805r757b1836],
5	to	TO	O	to	_	0	SENT_22	[p1l772t1812r804b1836],
6	a	DT	O	a	det	8	SENT_22	[p1l819t1815r836b1835],
7	single-chain	JJ	O	single-chain	amod	8	SENT_22	[p1l851t1805r1056b1844],
8	EGFR	NN	ORGANIZATION	egfr	prep_to	4	SENT_22	[p1l1070t1807r1175b1842],
9	,	,	O	,	_	0	SENT_22	[p1l1070t1807r1175b1842],
10	the	DT	O	the	det	11	SENT_22	[p1l1192t1805r1243b1835],
11	receptor	NN	O	receptor	nsubj	12	SENT_22	[p1l1258t1811r1396b1844],
12	forms	VBZ	O	form	_	0	SENT_22	[p1l1410t1805r1507b1836],
13	a	DT	O	a	det	14	SENT_22	[p1l1522t1815r1540b1835],
14	dimer3	NN	O	dimer3	dobj	12	SENT_22	[p1l1554t1805r1665b1836],
15	that	WDT	O	that	nsubj	16	SENT_22	[p1l1677t1805r1744b1835],
16	signals	VBZ	O	signal	rcmod	14	SENT_22	[p1l1757t1805r1873b1844],
17	within	IN	O	within	_	0	SENT_22	[p1l1887t1805r1997b1836],
18	the	DT	O	the	det	19	SENT_22	[p1l2012t1805r2064b1835],
19	cell	NN	O	cell	prep_within	16	SENT_22	[p1l666t1854r723b1884],
20	by	IN	O	by	_	0	SENT_22	[p1l740t1854r778b1893],
21	activating	VBG	O	activate	prepc_by	16	SENT_22	[p1l794t1854r957b1893],
22	receptor	NN	O	receptor	nn	23	SENT_22	[p1l973t1860r1111b1893],
23	autophosphorylation	NN	O	autophosphorylation	dobj	21	SENT_22	[p1l1128t1854r1475b1893],
24	through	IN	O	through	_	0	SENT_22	[p1l1493t1854r1628b1893],
25	tyrosine	NN	O	tyrosine	nn	27	SENT_22	[p1l1646t1854r1780b1893],
26	kinase	NN	O	kinase	nn	27	SENT_22	[p1l1797t1854r1906b1885],
27	activity	NN	O	activity	prep_through	21	SENT_22	[p1l1923t1854r2063b1893],
28	.3	NN	NUMBER	.3	nn	29	SENT_22	[p1l1923t1854r2063b1893],
29	Autophosphorylation	NN	O	autophosphorylation	nsubj	30	SENT_22	[p1l664t1903r1020b1942],
30	triggers	VBZ	O	trigger	rcmod	27	SENT_22	[p1l1035t1904r1165b1942],
31	a	DT	O	a	det	32	SENT_22	[p1l1181t1913r1198b1933],
32	series	NN	O	series	dobj	30	SENT_22	[p1l1213t1903r1306b1933],
33	of	IN	O	of	_	0	SENT_22	[p1l1323t1903r1361b1934],
34	intracellular	JJ	O	intracellular	amod	35	SENT_22	[p1l1370t1903r1575b1934],
35	pathways	NNS	O	pathway	prep_of	32	SENT_22	[p1l1589t1903r1743b1942],
36	that	WDT	O	that	nsubj	38	SENT_22	[p1l1760t1903r1827b1933],
37	may	MD	O	may	aux	38	SENT_22	[p1l1840t1913r1910b1942],
38	result	VB	O	result	rcmod	32	SENT_22	[p1l1923t1903r2018b1934],
39	in	IN	O	in	_	0	SENT_22	[p1l2031t1903r2064b1933],
40	cancer-cell	JJ	O	cancer-cell	amod	41	SENT_22	[p1l666t1952r846b1982],
41	proliferation	NN	O	proliferation	prep_in	38	SENT_22	[p1l864t1952r1084b1991],
42	,	,	O	,	_	0	SENT_22	[p1l864t1952r1084b1991],
43	blocking	VBG	O	block	prepc_by	16	SENT_22	[p1l1105t1952r1252b1991],
44	apoptosis	NN	O	apoptosis	dobj	43	SENT_22	[p1l1269t1952r1437b1991],
45	,	,	O	,	_	0	SENT_22	[p1l1269t1952r1437b1991],
46	activating	VBG	O	activate	prepc_by	16	SENT_22	[p1l1458t1952r1622b1991],
47	invasion	NN	O	invasion	dobj	46	SENT_22	[p1l1639t1952r1778b1983],
48	and	CC	O	and	_	0	SENT_22	[p1l1796t1952r1858b1983],
49	metastasis	NN	O	metastasis	dobj	46	SENT_22	[p1l1876t1952r2062b1989],
50	,	,	O	,	_	0	SENT_22	[p1l1876t1952r2062b1989],
51	and	CC	O	and	_	0	SENT_22	[p1l666t2001r727b2032],
52	stimulating	VBG	O	stimulate	prepc_by	16	SENT_22	[p1l741t2001r935b2040],
53	tumor-induced	JJ	O	tumor-induced	amod	54	SENT_22	[p1l947t2001r1195b2032],
54	neovascularization	NN	O	neovascularization	dobj	52	SENT_22	[p1l1208t2001r1571b2032],
55	.	.	O	.	_	0	SENT_22	[p1l1208t2001r1571b2032],

1	“	NN	O	“	_	0	SENT_23	[p1l1208t2001r1571b2032],

1	DEVELOPMENT	NNP	O	DEVELOPMENT	_	0	SENT_24	[p1l939t2129r1262b2152],
2	OF	IN	O	of	_	0	SENT_24	[p1l1281t2129r1332b2152],
3	EGFR	NN	O	egfr	nn	4	SENT_24	[p1l1353t2129r1464b2152],
4	ANTAGONISTS	NNS	O	antagonist	prep_of	1	SENT_24	[p1l1480t2129r1791b2152],

1	FOR	IN	O	for	_	0	SENT_25	[p1l1063t2170r1146b2193],
2	ANTICANCER	NN	O	anticancer	nn	3	SENT_25	[p1l1163t2170r1452b2193],
3	THERAPY	NN	O	therapy	pobj	1	SENT_25	[p1l1468t2170r1669b2193],

1	The	DT	O	the	det	4	SENT_26	[p1l664t2261r727b2291],
2	first	JJ	ORDINAL	first	amod	4	SENT_26	[p1l740t2261r812b2291],
3	anti-EGFR	JJ	O	anti-egfr	amod	4	SENT_26	[p1l823t2261r1000b2293],
4	drugs	NNS	O	drug	nsubjpass	6	SENT_26	[p1l1009t2261r1104b2300],
5	were	VBD	O	be	auxpass	6	SENT_26	[p1l1116t2271r1195b2292],
6	developed	VBN	O	develop	_	0	SENT_26	[p1l1208t2261r1374b2300],
7	in	IN	O	in	_	0	SENT_26	[p1l1387t2261r1420b2291],
8	the	DT	O	the	det	11	SENT_26	[p1l1433t2261r1485b2291],
9	19803.13	CD	NUMBER	19803.13	num	11	SENT_26	[p1l1499t2263r1634b2292],
10	Two	CD	NUMBER	two	num	11	SENT_26	[p1l1647t2263r1715b2292],
11	classes	NNS	O	class	prep_in	6	SENT_26	[p1l1729t2261r1843b2291],
12	of	IN	O	of	_	0	SENT_26	[p1l1858t2261r1897b2292],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_26	[p1l1902t2263r2002b2293],
14	antagonists	NNS	O	antagonist	prep_of	11	SENT_26	[p1l2011t2271r2063b2291, p1l666t2310r818b2349],
15	have	VBP	O	have	aux	18	SENT_26	[p1l831t2310r904b2341],
16	been	VBN	O	be	auxpass	18	SENT_26	[p1l916t2310r994b2341],
17	successfully	RB	O	successfully	advmod	18	SENT_26	[p1l1006t2310r1207b2349],
18	tested	VBN	O	test	rcmod	14	SENT_26	[p1l1217t2310r1315b2341],
19	in	IN	O	in	_	0	SENT_26	[p1l1327t2310r1359b2340],
20	phase	NN	O	phase	nn	22	SENT_26	[p1l1370t2310r1466b2349],
21	3	CD	NUMBER	3	num	22	SENT_26	[p1l1478t2312r1495b2341],
22	trials	NNS	O	trial	prep_in	18	SENT_26	[p1l1508t2310r1594b2340],
23	and	CC	O	and	_	0	SENT_26	[p1l1606t2310r1667b2341],
24	are	VBP	O	be	conj_and	18	SENT_26	[p1l1678t2320r1728b2340],
25	now	RB	DATE	now	advmod	24	SENT_26	[p1l1740t2320r1811b2341],
26	in	IN	O	in	_	0	SENT_26	[p1l1821t2310r1854b2340],
27	clinical	JJ	O	clinical	amod	28	SENT_26	[p1l1865t2310r1987b2340],
28	use	NN	O	use	prep_in	24	SENT_26	[p1l1998t2320r2062b2341],
29	:	:	O	:	_	0	SENT_26	[p1l1998t2320r2062b2341],
30	anti	JJ	O	anti	dep	14	SENT_26	[p1l666t2359r842b2391],
31	.	.	O	.	_	0	SENT_26	[p1l666t2359r842b2391],

1	—	NN	O	—	_	0	SENT_27	[p1l666t2359r842b2391],
2	.	.	O	.	_	0	SENT_27	[p1l666t2359r842b2391],

1	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l666t2359r842b2391],
2	monoclonal	JJ	O	monoclonal	dep	106	SENT_28	[p1l857t2359r1056b2390],
3	antibodies	NNS	O	antibody	dep	106	SENT_28	[p1l1075t2359r1250b2390],
4	and	CC	O	and	dep	106	SENT_28	[p1l1269t2359r1331b2390],
5	small-molecule	JJ	O	small-molecule	dep	106	SENT_28	[p1l1350t2359r1604b2390],
6	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l1623t2361r1723b2391],
7	tyrosine	NN	O	tyrosine	dep	106	SENT_28	[p1l1738t2359r1872b2398],
8	kinase	NN	O	kinase	dep	106	SENT_28	[p1l1891t2359r2000b2390],
9	inhibitors	NNS	O	inhibitor	dep	106	SENT_28	[p1l2019t2359r2063b2389, p1l666t2408r795b2439],
10	(	VBP	O	(	dep	106	SENT_28	[p1l810t2408r927b2444],
11	Tables	NNS	O	table	dep	106	SENT_28	[p1l810t2408r927b2444],
12	1	CD	NUMBER	1	dep	106	SENT_28	[p1l942t2410r960b2439],
13	and	CC	O	and	dep	106	SENT_28	[p1l973t2408r1034b2439],
14	2	CD	NUMBER	2	dep	106	SENT_28	[p1l1048t2410r1236b2444],
15	)	CD	NUMBER	)	dep	106	SENT_28	[p1l1048t2410r1236b2444],
16	.4	CD	NUMBER	.4	dep	106	SENT_28	[p1l1048t2410r1236b2444],
17	»	NN	O	»	dep	106	SENT_28	[p1l1048t2410r1236b2444],
18	5:1	CD	NUMBER	5:1	dep	106	SENT_28	[p1l1048t2410r1236b2444],
19	°	CD	NUMBER	°	dep	106	SENT_28	[p1l1048t2410r1236b2444],
20	‘	NN	O	‘	dep	106	SENT_28	[p1l1048t2410r1236b2444],
21	12	CD	NUMBER	12	dep	106	SENT_28	[p1l1048t2410r1236b2444],
22	»	CD	NUMBER	»	dep	106	SENT_28	[p1l1048t2410r1236b2444],
23	13	CD	NUMBER	13	dep	106	SENT_28	[p1l1048t2410r1236b2444],
24	Anti-EGFR	JJ	O	anti-egfr	dep	106	SENT_28	[p1l714t2458r896b2490],
25	monoclonal	JJ	O	monoclonal	dep	106	SENT_28	[p1l908t2458r1103b2489],
26	antibodies	NNS	O	antibody	dep	106	SENT_28	[p1l1119t2458r1299b2495],
27	,	,	O	,	_	0	SENT_28	[p1l1119t2458r1299b2495],
28	such	JJ	O	such	dep	106	SENT_28	[p1l1318t2458r1392b2489],
29	as	IN	O	as	dep	106	SENT_28	[p1l1408t2468r1440b2488],
30	cetuximab	NN	O	cetuximab	dep	106	SENT_28	[p1l1458t2458r1638b2495],
31	,	,	O	,	_	0	SENT_28	[p1l1458t2458r1638b2495],
32	bind	VBP	O	bind	dep	106	SENT_28	[p1l1656t2458r1729b2489],
33	to	TO	O	to	dep	106	SENT_28	[p1l1746t2464r1777b2489],
34	the	DT	O	the	dep	106	SENT_28	[p1l1794t2458r1845b2488],
35	extracellular	JJ	O	extracellular	dep	106	SENT_28	[p1l1861t2458r2065b2489],
36	domain	NN	O	domain	dep	106	SENT_28	[p1l666t2507r792b2538],
37	of	IN	O	of	dep	106	SENT_28	[p1l805t2507r843b2538],
38	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l848t2509r946b2539],
39	when	WRB	O	when	dep	106	SENT_28	[p1l953t2507r1043b2538],
40	it	PRP	O	it	dep	106	SENT_28	[p1l1055t2507r1078b2537],
41	is	VBZ	O	be	dep	106	SENT_28	[p1l1088t2507r1113b2537],
42	in	IN	O	in	dep	106	SENT_28	[p1l1126t2507r1158b2537],
43	the	DT	O	the	dep	106	SENT_28	[p1l1171t2507r1222b2537],
44	inactive	JJ	O	inactive	dep	106	SENT_28	[p1l1234t2507r1359b2538],
45	configuration	NN	O	configuration	dep	106	SENT_28	[p1l1373t2507r1607b2546],
46	,	,	O	,	_	0	SENT_28	[p1l1373t2507r1607b2546],
47	compete	VB	O	compete	dep	106	SENT_28	[p1l1622t2514r1760b2546],
48	for	IN	O	for	dep	106	SENT_28	[p1l1773t2507r1820b2538],
49	receptor	NN	O	receptor	dep	106	SENT_28	[p1l1832t2514r1967b2546],
50	binding	NN	O	binding	dep	106	SENT_28	[p1l1979t2507r2063b2538, p1l666t2556r719b2595],
51	by	IN	O	by	dep	106	SENT_28	[p1l731t2556r769b2595],
52	occluding	VBG	O	occlude	dep	106	SENT_28	[p1l781t2556r942b2595],
53	the	DT	O	the	dep	106	SENT_28	[p1l954t2556r1005b2586],
54	ligand	NN	O	ligand	dep	106	SENT_28	[p1l1018t2556r1263b2595],
55	—	NN	O	—	dep	106	SENT_28	[p1l1018t2556r1263b2595],
56	binding	NN	O	binding	dep	106	SENT_28	[p1l1018t2556r1263b2595],
57	region	NN	O	region	dep	106	SENT_28	[p1l1275t2556r1388b2595],
58	,	,	O	,	_	0	SENT_28	[p1l1275t2556r1388b2595],
59	and	CC	O	and	dep	106	SENT_28	[p1l1404t2556r1464b2587],
60	thereby	RB	O	thereby	dep	106	SENT_28	[p1l1478t2556r1599b2595],
61	block	VB	O	block	dep	106	SENT_28	[p1l1611t2556r1701b2587],
62	ligand-induced	JJ	O	ligand-induced	dep	106	SENT_28	[p1l1712t2556r1957b2595],
63	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l1970t2558r2068b2588],
64	tyrosine	NN	O	tyrosine	dep	106	SENT_28	[p1l666t2605r797b2644],
65	kinase	NN	O	kinase	dep	106	SENT_28	[p1l809t2605r915b2636],
66	activation	NN	O	activation	dep	106	SENT_28	[p1l927t2605r1164b2636],
67	.4	CD	NUMBER	.4	dep	106	SENT_28	[p1l927t2605r1164b2636],
68	v5	NN	O	v5	dep	106	SENT_28	[p1l927t2605r1164b2636],
69	’19	CD	NUMBER	’19	dep	106	SENT_28	[p1l927t2605r1164b2636],
70	Small-molecule	JJ	O	small-molecule	dep	106	SENT_28	[p1l1177t2605r1429b2636],
71	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l1440t2607r1538b2637],
72	tyrosine	NN	O	tyrosine	dep	106	SENT_28	[p1l1546t2605r1677b2644],
73	kinase	NN	O	kinase	dep	106	SENT_28	[p1l1689t2605r1795b2636],
74	inhibitors	NNS	O	inhibitor	dep	106	SENT_28	[p1l1806t2605r1975b2642],
75	,	,	O	,	_	0	SENT_28	[p1l1806t2605r1975b2642],
76	such	JJ	O	such	dep	106	SENT_28	[p1l1990t2605r2064b2636],
77	as	IN	O	as	dep	106	SENT_28	[p1l666t2664r698b2684],
78	erlotinib	NN	O	erlotinib	dep	106	SENT_28	[p1l716t2654r855b2685],
79	and	CC	O	and	dep	106	SENT_28	[p1l871t2654r932b2685],
80	gefitinib	NN	O	gefitinib	dep	106	SENT_28	[p1l948t2654r1097b2693],
81	,	,	O	,	_	0	SENT_28	[p1l948t2654r1097b2693],
82	compete	VB	O	compete	dep	106	SENT_28	[p1l1116t2660r1254b2693],
83	reversibly	RB	O	reversibly	dep	106	SENT_28	[p1l1270t2654r1425b2693],
84	with	IN	O	with	dep	106	SENT_28	[p1l1438t2654r1513b2685],
85	ATP	NN	ORGANIZATION	atp	dep	106	SENT_28	[p1l1528t2656r1596b2684],
86	to	TO	O	to	dep	106	SENT_28	[p1l1611t2660r1643b2685],
87	bind	VB	O	bind	dep	106	SENT_28	[p1l1660t2654r1733b2685],
88	to	TO	O	to	dep	106	SENT_28	[p1l1749t2661r1781b2685],
89	the	DT	O	the	dep	106	SENT_28	[p1l1798t2654r1848b2684],
90	intracellular	JJ	O	intracellular	dep	106	SENT_28	[p1l1864t2654r2065b2685],
91	catalytic	JJ	O	catalytic	dep	106	SENT_28	[p1l666t2703r802b2742],
92	domain	NN	O	domain	dep	106	SENT_28	[p1l815t2703r941b2734],
93	of	IN	O	of	dep	106	SENT_28	[p1l955t2703r993b2734],
94	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l999t2705r1097b2735],
95	tyrosine	NN	O	tyrosine	dep	106	SENT_28	[p1l1106t2703r1238b2742],
96	kinase	NN	O	kinase	dep	106	SENT_28	[p1l1251t2703r1357b2734],
97	and	CC	O	and	dep	106	SENT_28	[p1l1370t2703r1439b2740],
98	,	,	O	,	_	0	SENT_28	[p1l1370t2703r1439b2740],
99	thus	RB	O	thus	dep	106	SENT_28	[p1l1455t2703r1534b2740],
100	,	,	O	,	_	0	SENT_28	[p1l1455t2703r1534b2740],
101	inhibit	VBP	O	inhibit	dep	106	SENT_28	[p1l1549t2703r1659b2734],
102	EGFR	NN	ORGANIZATION	egfr	dep	106	SENT_28	[p1l1670t2705r1768b2735],
103	autophosphorylation	NN	O	autophosphorylation	dep	106	SENT_28	[p1l1777t2703r2063b2742, p1l666t2753r730b2783],
104	and	CC	O	and	dep	106	SENT_28	[p1l744t2752r804b2783],
105	downstream	JJ	O	downstream	dep	106	SENT_28	[p1l818t2752r1024b2783],
106	signaling	NN	O	signaling	_	0	SENT_28	[p1l1038t2752r1198b2791],
107	.	.	O	.	_	0	SENT_28	[p1l1038t2752r1198b2791],

1	Anti-EGFR	JJ	O	anti-egfr	amod	3	SENT_29	[p1l1212t2752r1393b2784],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_29	[p1l1403t2752r1598b2783],
3	antibodies	NNS	O	antibody	nsubj	4	SENT_29	[p1l1611t2752r1782b2783],
4	recognize	VBP	O	recognize	_	0	SENT_29	[p1l1796t2752r1957b2791],
5	EGFR	NN	ORGANIZATION	egfr	dobj	4	SENT_29	[p1l1970t2754r2068b2784],

1	N	NN	O	n	nn	3	SENT_30	[p1l857t2860r870b2875],
2	ENGLJ	NN	O	englj	nn	3	SENT_30	[p1l885t2860r963b2882],
3	MED	NN	O	med	_	0	SENT_30	[p1l978t2860r1029b2875],
4	358	CD	NUMBER	358	num	6	SENT_30	[p1l1040t2854r1108b2882],
5	;	:	O	;	_	0	SENT_30	[p1l1040t2854r1108b2882],
6	11	CD	NUMBER	11	dep	3	SENT_30	[p1l1040t2854r1108b2882],
7	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	8	SENT_30	[p1l1144t2860r1345b2882],
8	MARCH	NNP	DATE	MARCH	dep	3	SENT_30	[p1l1382t2860r1467b2875],
9	13	CD	DATE	13	num	8	SENT_30	[p1l1481t2860r1513b2882],
10	,	,	DATE	,	_	0	SENT_30	[p1l1481t2860r1513b2882],
11	2008	CD	DATE	2008	num	8	SENT_30	[p1l1524t2854r1587b2876],

1	The	DT	O	the	det	4	SENT_31	[p1l878t2917r929b2941],
2	New	NNP	O	New	nn	4	SENT_31	[p1l938t2918r1000b2941],
3	England	NNP	O	England	nn	4	SENT_31	[p1l1009t2917r1120b2948],
4	Journal	NNP	O	Journal	_	0	SENT_31	[p1l1129t2917r1226b2941],
5	of	IN	O	of	_	0	SENT_31	[p1l1236t2917r1265b2941],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_31	[p1l1272t2917r1397b2941],

1	Downloaded	VBN	O	download	_	0	SENT_32	[p1l320t2958r490b2981],
2	from	IN	O	from	_	0	SENT_32	[p1l499t2958r564b2981],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_32	[p1l572t2958r691b2988],
4	at	IN	O	at	_	0	SENT_32	[p1l701t2962r724b2981],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_32	[p1l732t2958r915b2981],
6	on	IN	O	on	_	0	SENT_32	[p1l924t2965r957b2981],
7	January	NNP	DATE	January	prep_on	1	SENT_32	[p1l965t2958r1068b2988],
8	5	CD	DATE	5	num	7	SENT_32	[p1l1078t2958r1101b2985],
9	,	,	DATE	,	_	0	SENT_32	[p1l1078t2958r1101b2985],
10	2014	CD	DATE	2014	num	7	SENT_32	[p1l1111t2958r1184b2981],
11	.	.	O	.	_	0	SENT_32	[p1l1111t2958r1184b2981],

1	For	IN	O	for	_	0	SENT_33	[p1l1194t2958r1241b2981],
2	personal	JJ	O	personal	amod	3	SENT_33	[p1l1249t2958r1361b2988],
3	use	NN	O	use	pobj	1	SENT_33	[p1l1370t2965r1414b2981],
4	only	RB	O	only	advmod	3	SENT_33	[p1l1423t2958r1488b2988],
5	.	.	O	.	_	0	SENT_33	[p1l1423t2958r1488b2988],

1	No	DT	O	no	det	3	SENT_34	[p1l1499t2958r1538b2981],
2	other	JJ	O	other	amod	3	SENT_34	[p1l1548t2958r1616b2981],
3	uses	NNS	O	use	_	0	SENT_34	[p1l1625t2965r1681b2981],
4	without	IN	O	without	_	0	SENT_34	[p1l1691t2958r1792b2981],
5	permission	NN	O	permission	prep_without	3	SENT_34	[p1l1800t2958r1953b2988],
6	.	.	O	.	_	0	SENT_34	[p1l1800t2958r1953b2988],

1	Copyright	NN	O	copyright	_	0	SENT_35	[p1l671t2999r805b3030],
2	©	CD	NUMBER	©	num	6	SENT_35	[p1l814t2999r838b3023],
3	2008	CD	DATE	2008	num	6	SENT_35	[p1l848t2999r912b3023],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_35	[p1l922t2999r1113b3023],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_35	[p1l1123t2999r1231b3023],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_35	[p1l1242t2999r1347b3030],
7	.	.	O	.	_	0	SENT_35	[p1l1242t2999r1347b3030],

1	All	DT	O	all	det	2	SENT_36	[p1l1358t2999r1399b3023],
2	rights	NNS	O	rights	nsubj	3	SENT_36	[p1l1408t2999r1483b3030],
3	reserved	VBN	O	reserve	_	0	SENT_36	[p1l1493t2999r1611b3023],
4	.	.	O	.	_	0	SENT_36	[p1l1493t2999r1611b3023],

1	DRUG	NN	O	drug	nn	2	SENT_37	[p1l809t3043r901b3062],
2	THERAPY	NN	O	therapy	_	0	SENT_37	[p1l913t3043r1067b3062],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_38	[p2l1332t108r1447b141],
2	,	,	O	,	_	0	SENT_38	[p2l1332t108r1447b141],
3	mH	NN	O	mh	nn	4	SENT_38	[p2l1332t108r1447b141],
4	R2	NN	O	r2	conj_or	1	SENT_38	[p2l1471t113r1511b141],
5	,	,	O	,	_	0	SENT_38	[p2l1471t113r1511b141],
6	HER3	NN	O	her3	conj_or	1	SENT_38	[p2l1317t153r1400b181],
7	,	,	O	,	_	0	SENT_38	[p2l1317t153r1400b181],
8	or	CC	O	or	_	0	SENT_38	[p2l1411t160r1440b177],
9	H	NN	O	h	conj_or	1	SENT_38	[p2l1451t153r1470b176],
10	ER4	NN	O	er4	dep	1	SENT_38	[p2l1477t153r1527b176],
11	'	''	O	'	_	0	SENT_38	[p2l401t144r686b225],

1	|	NN	O	|	_	0	SENT_39	[p2l401t144r686b225],
2	.	.	O	.	_	0	SENT_39	[p2l401t144r686b225],

1	—	NN	O	—	_	0	SENT_40	[p2l401t144r686b225],
2	.	.	O	.	_	0	SENT_40	[p2l401t144r686b225],

1	Receptor-speciﬁc	JJ	O	receptor-speciﬁc	amod	2	SENT_41	[p2l401t144r686b225],
2	ligands	NNS	O	ligand	nsubj	3	SENT_41	[p2l696t163r832b225],
3	—	VBP	O	—	_	0	SENT_41	[p2l696t163r832b225],
4	|	CD	NUMBER	|	num	6	SENT_41	[p2l696t163r832b225],
5	EGF	NN	ORGANIZATION	egf	nn	6	SENT_41	[p2l388t236r442b259],
6	NRGS	NNS	ORGANIZATION	nrg	dobj	3	SENT_41	[p2l605t236r683b259],
7	N	NN	O	n	prep	3	SENT_41	[p2l792t236r811b259],
8	RGS	NN	O	rg	dep	7	SENT_41	[p2l818t236r871b259],
9	.	.	O	.	_	0	SENT_41	[p2l878t253r910b264],

1	_	NN	O	_	_	0	SENT_42	[p2l878t253r910b264],
2	TGFa	NN	MISC	tgfa	nn	5	SENT_42	[p2l374t276r452b299],
3	B-cellulin	NN	MISC	b-cellulin	nn	5	SENT_42	[p2l578t274r705b306],
4	Amphiregulin	NN	MISC	amphiregulin	nn	5	SENT_42	[p2l320t314r506b347],
5	HB-EGF	NN	O	hb-egf	dep	1	SENT_42	[p2l590t316r699b339],
6	/	:	O	/	punct	1	SENT_42	[p2l349t354r476b386],
7	3-cellulin	JJ	O	3-cellulin	amod	8	SENT_42	[p2l349t354r476b386],
8	HB-EGF	NN	O	hb-egf	dep	1	SENT_42	[p2l360t396r470b419],
9	Epiregulin	NN	O	epiregulin	dep	8	SENT_42	[p2l347t434r482b467],

1	Cytoplasm	NN	O	cytoplasm	_	0	SENT_43	[p2l1796t1624r1939b1657],

1	Figure	NNP	O	Figure	_	0	SENT_44	[p2l122t1724r206b1756],
2	1	CD	NUMBER	1	dep	1	SENT_44	[p2l218t1726r240b1749],
3	.	.	O	.	_	0	SENT_44	[p2l218t1726r240b1749],

1	Signal	NN	O	signal	nn	3	SENT_45	[p2l251t1724r334b1757],
2	Transduction	NNP	O	Transduction	nn	3	SENT_45	[p2l345t1724r526b1749],
3	Pathways	NNP	O	Pathways	nsubj	4	SENT_45	[p2l540t1724r668b1757],
4	Controlled	VBN	O	control	_	0	SENT_45	[p2l679t1724r822b1749],
5	by	IN	O	by	_	0	SENT_45	[p2l835t1724r865b1757],
6	the	DT	O	the	det	7	SENT_45	[p2l874t1724r918b1749],
7	Activation	NN	O	activation	prep_by	4	SENT_45	[p2l928t1724r1067b1749],
8	of	IN	O	of	_	0	SENT_45	[p2l1078t1723r1110b1749],
9	EGFR	NN	ORGANIZATION	egfr	prep_of	7	SENT_45	[p2l1117t1726r1200b1749],
10	.	.	O	.	_	0	SENT_45	[p2l1117t1726r1200b1749],

1	Three	CD	NUMBER	three	num	2	SENT_46	[p2l119t1774r198b1799],
2	steps	NNS	O	step	nsubjpass	6	SENT_46	[p2l210t1778r282b1806],
3	can	MD	O	can	aux	6	SENT_46	[p2l294t1782r340b1799],
4	be	VB	O	be	auxpass	6	SENT_46	[p2l354t1774r384b1799],
5	schematically	RB	O	schematically	advmod	6	SENT_46	[p2l396t1774r584b1807],
6	defined	VBN	O	define	_	0	SENT_46	[p2l595t1773r698b1799],
7	in	IN	O	in	_	0	SENT_46	[p2l712t1776r734b1798],
8	the	DT	O	the	det	9	SENT_46	[p2l745t1774r789b1799],
9	activation	NN	O	activation	prep_in	6	SENT_46	[p2l800t1776r934b1799],
10	of	IN	O	of	_	0	SENT_46	[p2l947t1773r977b1799],
11	EGFR-dependent	JJ	O	egfr-dependent	amod	13	SENT_46	[p2l986t1774r1222b1806],
12	intracellular	JJ	O	intracellular	amod	13	SENT_46	[p2l1234t1774r1397b1799],
13	signaling	NN	O	signaling	prep_of	9	SENT_46	[p2l1408t1773r1585b1807],
14	?	.	O	?	_	0	SENT_46	[p2l1408t1773r1585b1807],

1	”	NNP	O	”	nn	2	SENT_47	[p2l1408t1773r1585b1807],
2	First	NNP	ORDINAL	First	nsubj	18	SENT_47	[p2l1598t1776r1665b1803],
3	,	,	O	,	_	0	SENT_47	[p2l1598t1776r1665b1803],
4	the	DT	O	the	det	6	SENT_47	[p2l1677t1774r1720b1799],
5	binding	NN	O	binding	nn	6	SENT_47	[p2l1733t1774r1836b1807],
6	ofa	NN	O	ofa	appos	2	SENT_47	[p2l1847t1773r1897b1799],
7	receptorspecific	JJ	O	receptorspecific	amod	8	SENT_47	[p2l1910t1778r2032b1806, p2l121t1815r227b1848],
8	ligand	NN	O	ligand	nsubj	9	SENT_47	[p2l238t1815r320b1849],
9	occurs	VBZ	O	occur	rcmod	6	SENT_47	[p2l332t1824r423b1841],
10	in	IN	O	in	_	0	SENT_47	[p2l436t1818r458b1840],
11	the	DT	O	the	det	15	SENT_47	[p2l469t1815r513b1841],
12	extracellular	JJ	O	extracellular	amod	15	SENT_47	[p2l524t1815r693b1841],
13	portion	NN	O	portion	nn	15	SENT_47	[p2l705t1818r805b1848],
14	ofthe	NN	O	ofthe	nn	15	SENT_47	[p2l818t1815r897b1841],
15	EGFR	NN	ORGANIZATION	egfr	prep_in	9	SENT_47	[p2l910t1817r984b1841],
16	or	CC	O	or	_	0	SENT_47	[p2l995t1824r1023b1841],
17	ofone	NN	O	ofone	prep_in	9	SENT_47	[p2l1033t1815r1120b1841],
18	ofthe	VBP	O	ofthe	_	0	SENT_47	[p2l1131t1815r1211b1841],
19	EGFR-related	JJ	O	egfr-related	amod	20	SENT_47	[p2l1224t1815r1402b1841],
20	receptors	NNS	O	receptor	nsubj	21	SENT_47	[p2l1417t1820r1545b1848],
21	(	VBP	O	(	ccomp	18	SENT_47	[p2l1560t1817r1590b1848],
22	H	NN	O	h	nn	23	SENT_47	[p2l1560t1817r1590b1848],
23	ER2	NN	O	er2	dobj	21	SENT_47	[p2l1597t1818r1655b1845],
24	,	,	O	,	_	0	SENT_47	[p2l1597t1818r1655b1845],
25	HER3	NN	O	her3	conj_or	23	SENT_47	[p2l1670t1817r1752b1845],
26	,	,	O	,	_	0	SENT_47	[p2l1670t1817r1752b1845],
27	or	CC	O	or	_	0	SENT_47	[p2l1765t1824r1793b1841],
28	HER4	NN	O	her4	nn	29	SENT_47	[p2l1805t1817r1898b1848],
29	)	NN	O	)	dobj	21	SENT_47	[p2l1805t1817r1898b1848],
30	.	.	O	.	_	0	SENT_47	[p2l1805t1817r1898b1848],

1	Second	RB	ORDINAL	second	advmod	26	SENT_48	[p2l1911t1815r2020b1845],
2	,	,	O	,	_	0	SENT_48	[p2l1911t1815r2020b1845],
3	the	DT	O	the	det	5	SENT_48	[p2l119t1857r162b1882],
4	formation	NN	O	formation	nn	5	SENT_48	[p2l173t1857r310b1882],
5	ofa	NN	O	ofa	nsubj	26	SENT_48	[p2l322t1857r372b1882],
6	functionally	RB	O	functionally	advmod	26	SENT_48	[p2l383t1857r547b1890],
7	active	JJ	O	active	amod	10	SENT_48	[p2l558t1859r637b1882],
8	EGFR-EGFR	NN	O	egfr-egfr	nn	10	SENT_48	[p2l651t1859r812b1882],
9	dimer	NN	O	dimer	nn	10	SENT_48	[p2l823t1857r905b1882],
10	(	NN	O	(	nsubj	26	SENT_48	[p2l918t1857r1100b1890],
11	homodimer	NN	O	homodimer	dep	10	SENT_48	[p2l918t1857r1100b1890],
12	)	CD	NUMBER	)	num	11	SENT_48	[p2l918t1857r1100b1890],
13	or	CC	O	or	_	0	SENT_48	[p2l1114t1866r1143b1882],
14	of	IN	O	of	dep	10	SENT_48	[p2l1153t1857r1183b1882],
15	an	DT	O	a	det	16	SENT_48	[p2l1190t1866r1220b1882],
16	EGFR-HER2	NN	O	egfr-her2	pobj	14	SENT_48	[p2l1235t1859r1406b1887],
17	,	,	O	,	_	0	SENT_48	[p2l1235t1859r1406b1887],
18	EGFR-HER3	NN	O	egfr-her3	pobj	14	SENT_48	[p2l1421t1859r1591b1887],
19	,	,	O	,	_	0	SENT_48	[p2l1421t1859r1591b1887],
20	or	CC	O	or	_	0	SENT_48	[p2l1604t1866r1632b1882],
21	EGFR-HER4	NN	O	egfr-her4	nn	23	SENT_48	[p2l1644t1859r1806b1882],
22	dimer	NN	O	dimer	nn	23	SENT_48	[p2l1818t1857r1899b1882],
23	(	NN	O	(	pobj	14	SENT_48	[p2l1912t1857r2047b1890, p2l121t1901r183b1932],
24	heterodimer	NN	O	heterodimer	dep	23	SENT_48	[p2l1912t1857r2047b1890, p2l121t1901r183b1932],
25	)	CD	NUMBER	)	num	24	SENT_48	[p2l1912t1857r2047b1890, p2l121t1901r183b1932],
26	causes	VBZ	O	cause	_	0	SENT_48	[p2l197t1907r290b1924],
27	the	DT	O	the	det	29	SENT_48	[p2l301t1899r345b1924],
28	ATP-dependent	JJ	O	atp-dependent	amod	29	SENT_48	[p2l355t1899r572b1931],
29	phosphorylation	NN	O	phosphorylation	dobj	26	SENT_48	[p2l584t1899r810b1932],
30	of	IN	O	of	_	0	SENT_48	[p2l822t1898r853b1924],
31	specific	JJ	O	specific	amod	33	SENT_48	[p2l860t1898r965b1931],
32	tyrosine	NN	O	tyrosine	nn	33	SENT_48	[p2l975t1901r1086b1932],
33	residues	NNS	O	residue	prep_of	29	SENT_48	[p2l1099t1899r1213b1924],
34	in	IN	O	in	_	0	SENT_48	[p2l1226t1901r1248b1923],
35	the	DT	O	the	det	38	SENT_48	[p2l1260t1899r1303b1924],
36	EGFR	NN	ORGANIZATION	egfr	nn	38	SENT_48	[p2l1317t1901r1390b1924],
37	intracellular	JJ	O	intracellular	amod	38	SENT_48	[p2l1402t1899r1566b1924],
38	domain	NN	O	domain	prep_in	33	SENT_48	[p2l1576t1899r1689b1924],
39	.	.	O	.	_	0	SENT_48	[p2l1576t1899r1689b1924],

1	Third	NNP	ORDINAL	Third	nsubj	7	SENT_49	[p2l1700t1899r1781b1928],
2	,	,	O	,	_	0	SENT_49	[p2l1700t1899r1781b1928],
3	this	DT	O	this	det	6	SENT_49	[p2l1792t1899r1842b1924],
4	phosphory	NN	O	phosphory	nn	6	SENT_49	[p2l1856t1899r2037b1932, p2l119t1943r172b1966],
5	|	NN	O	|	nn	6	SENT_49	[p2l1856t1899r2037b1932, p2l119t1943r172b1966],
6	ation	NN	O	ation	appos	1	SENT_49	[p2l1856t1899r2037b1932, p2l119t1943r172b1966],
7	triggers	VBZ	O	trigger	_	0	SENT_49	[p2l184t1943r289b1974],
8	a	DT	O	a	det	10	SENT_49	[p2l302t1949r315b1966],
9	complex	JJ	O	complex	amod	10	SENT_49	[p2l327t1940r443b1973],
10	program	NN	O	program	dobj	7	SENT_49	[p2l455t1949r571b1974],
11	ofintracellular	JJ	O	ofintracellular	amod	12	SENT_49	[p2l584t1940r785b1966],
12	signals	NNS	O	signal	tmod	7	SENT_49	[p2l796t1940r890b1974],
13	to	TO	O	to	_	0	SENT_49	[p2l901t1945r928b1966],
14	the	DT	O	the	det	15	SENT_49	[p2l938t1940r982b1966],
15	cytoplasm	NN	O	cytoplasm	prep_to	12	SENT_49	[p2l993t1940r1135b1973],
16	and	CC	O	and	cc	12	SENT_49	[p2l1148t1940r1197b1966],
17	then	RB	O	then	advmod	12	SENT_49	[p2l1208t1940r1269b1966],
18	to	TO	O	to	dep	12	SENT_49	[p2l1281t1945r1308b1966],
19	the	DT	O	the	det	20	SENT_49	[p2l1318t1940r1362b1966],
20	nucleus	NN	O	nucleus	pobj	18	SENT_49	[p2l1375t1940r1488b1966],
21	.	.	O	.	_	0	SENT_49	[p2l1375t1940r1488b1966],

1	The	DT	O	the	det	5	SENT_50	[p2l1499t1940r1551b1966],
2	two	CD	NUMBER	two	num	5	SENT_50	[p2l1561t1945r1612b1966],
3	major	JJ	O	major	amod	5	SENT_50	[p2l1625t1943r1705b1973],
4	intracellular	JJ	O	intracellular	amod	5	SENT_50	[p2l1716t1940r1880b1966],
5	pathways	NNS	O	pathway	nsubj	11	SENT_50	[p2l1891t1940r2018b1973],
6	activated	VBN	O	activate	partmod	5	SENT_50	[p2l120t1982r244b2007],
7	by	IN	O	by	_	0	SENT_50	[p2l258t1982r286b2015],
8	EGFR	NN	ORGANIZATION	egfr	agent	6	SENT_50	[p2l299t1984r372b2007],
9	are	VBP	O	be	cop	11	SENT_50	[p2l384t1991r425b2007],
10	the	DT	O	the	det	11	SENT_50	[p2l435t1982r478b2007],
11	RAS	NN	O	ra	_	0	SENT_50	[p2l492t1984r816b2007],
12	.	.	O	.	_	0	SENT_50	[p2l492t1984r816b2007],

1	—	NN	O	—	_	0	SENT_51	[p2l492t1984r816b2007],
2	.	.	O	.	_	0	SENT_51	[p2l492t1984r816b2007],

1	RAF	NN	O	raf	_	0	SENT_52	[p2l492t1984r816b2007],
2	.	.	O	.	_	0	SENT_52	[p2l492t1984r816b2007],

1	—	NN	O	—	_	0	SENT_53	[p2l492t1984r816b2007],
2	.	.	O	.	_	0	SENT_53	[p2l492t1984r816b2007],

1	MEK	NN	O	mek	_	0	SENT_54	[p2l492t1984r816b2007],
2	.	.	O	.	_	0	SENT_54	[p2l492t1984r816b2007],

1	—	NN	O	—	_	0	SENT_55	[p2l492t1984r816b2007],
2	.	.	O	.	_	0	SENT_55	[p2l492t1984r816b2007],

1	MAPK	NN	ORGANIZATION	mapk	nn	2	SENT_56	[p2l492t1984r816b2007],
2	pathway	NN	O	pathway	_	0	SENT_56	[p2l828t1982r947b2015],
3	,	,	O	,	_	0	SENT_56	[p2l828t1982r947b2015],
4	which	WDT	O	which	nsubj	5	SENT_56	[p2l958t1982r1038b2007],
5	controls	VBZ	O	control	dep	2	SENT_56	[p2l1051t1982r1163b2007],
6	gene	NN	O	gene	nn	7	SENT_56	[p2l1175t1991r1240b2015],
7	transcription	NN	O	transcription	dobj	5	SENT_56	[p2l1250t1984r1437b2015],
8	,	,	O	,	_	0	SENT_56	[p2l1250t1984r1437b2015],
9	cell-cycle	JJ	O	cell-cycle	amod	10	SENT_56	[p2l1449t1982r1575b2015],
10	progression	NN	O	progression	dobj	5	SENT_56	[p2l1588t1984r1749b2015],
11	from	IN	O	from	_	0	SENT_56	[p2l1761t1982r1826b2007],
12	the	DT	O	the	det	14	SENT_56	[p2l1838t1982r1881b2007],
13	G1	NN	O	g1	nn	14	SENT_56	[p2l1893t1984r1928b2007],
14	phase	NN	O	phase	prep_from	10	SENT_56	[p2l1942t1982r2022b2015],
15	to	TO	O	to	_	0	SENT_56	[p2l119t2028r146b2049],
16	the	DT	O	the	det	18	SENT_56	[p2l156t2024r200b2049],
17	S	NN	O	s	nn	18	SENT_56	[p2l212t2026r226b2049],
18	phase	NN	O	phase	prep_to	14	SENT_56	[p2l239t2024r327b2056],
19	,	,	O	,	_	0	SENT_56	[p2l239t2024r327b2056],
20	and	CC	O	and	_	0	SENT_56	[p2l340t2024r388b2049],
21	cell	NN	O	cell	nn	22	SENT_56	[p2l401t2024r445b2049],
22	proliferation	NN	O	proliferation	prep_to	14	SENT_56	[p2l459t2023r636b2056],
23	,	,	O	,	_	0	SENT_56	[p2l459t2023r636b2056],
24	and	CC	O	and	_	0	SENT_56	[p2l649t2024r698b2049],
25	the	DT	O	the	det	28	SENT_56	[p2l709t2024r753b2049],
26	P	NN	O	p	nn	28	SENT_56	[p2l766t2024r892b2049],
27	|	CD	NUMBER	|	num	28	SENT_56	[p2l766t2024r892b2049],
28	3K	NN	O	3k	dobj	5	SENT_56	[p2l766t2024r892b2049],
29	.	.	O	.	_	0	SENT_56	[p2l766t2024r892b2049],

1	—	NN	O	—	_	0	SENT_57	[p2l766t2024r892b2049],
2	.	.	O	.	_	0	SENT_57	[p2l766t2024r892b2049],

1	Akt	NN	O	akt	nn	2	SENT_58	[p2l766t2024r892b2049],
2	pathway	NN	O	pathway	_	0	SENT_58	[p2l904t2024r1023b2057],
3	,	,	O	,	_	0	SENT_58	[p2l904t2024r1023b2057],
4	which	WDT	O	which	nsubj	5	SENT_58	[p2l1034t2024r1114b2049],
5	activates	VBZ	O	activate	dep	2	SENT_58	[p2l1127t2026r1248b2049],
6	a	DT	O	a	det	7	SENT_58	[p2l1260t2032r1273b2049],
7	cascade	NN	O	cascade	nsubj	11	SENT_58	[p2l1285t2024r1395b2049],
8	ofanti-apoptotic	JJ	O	ofanti-apoptotic	amod	11	SENT_58	[p2l1406t2023r1638b2056],
9	and	CC	O	and	_	0	SENT_58	[p2l1649t2024r1698b2049],
10	prosurvival	JJ	O	prosurvival	amod	11	SENT_58	[p2l1712t2024r1863b2056],
11	signals	NNS	O	signal	xcomp	5	SENT_58	[p2l1876t2024r1979b2057],
12	.	.	O	.	_	0	SENT_58	[p2l1876t2024r1979b2057],

1	bFGF	NN	O	bfgf	nsubj	2	SENT_59	[p2l121t2065r194b2091],
2	denotes	VBZ	O	denote	_	0	SENT_59	[p2l205t2065r315b2091],
3	basic	JJ	O	basic	amod	6	SENT_59	[p2l328t2065r397b2091],
4	fibroblast	NN	O	fibroblast	nn	6	SENT_59	[p2l407t2065r541b2091],
5	growth	NN	O	growth	nn	6	SENT_59	[p2l552t2065r648b2099],
6	factor	NN	O	factor	nsubj	26	SENT_59	[p2l660t2065r746b2095],
7	,	,	O	,	_	0	SENT_59	[p2l660t2065r746b2095],
8	HB-EGF	NN	O	hb-egf	nn	10	SENT_59	[p2l761t2067r872b2091],
9	heparin-binding	JJ	O	heparin-binding	amod	10	SENT_59	[p2l884t2065r1106b2099],
10	EGF	NN	ORGANIZATION	egf	appos	6	SENT_59	[p2l1118t2067r1177b2095],
11	,	,	O	,	_	0	SENT_59	[p2l1118t2067r1177b2095],
12	MAPK	NN	O	mapk	appos	6	SENT_59	[p2l1192t2067r1276b2090],
13	mitogen-activated	JJ	O	mitogen-activated	amod	15	SENT_59	[p2l1288t2065r1537b2099],
14	protein	NN	O	protein	nn	15	SENT_59	[p2l1551t2068r1647b2098],
15	kinase	NN	O	kinase	dep	12	SENT_59	[p2l1661t2065r1754b2095],
16	,	,	O	,	_	0	SENT_59	[p2l1661t2065r1754b2095],
17	P	NN	O	p	nn	18	SENT_59	[p2l1769t2068r1783b2090],
18	phosphate	NN	O	phosphate	appos	6	SENT_59	[p2l1796t2065r1948b2098],
19	,	,	O	,	_	0	SENT_59	[p2l1796t2065r1948b2098],
20	P	NN	O	p	nn	23	SENT_59	[p2l1963t2067r2023b2090],
21	|	CD	NUMBER	|	num	23	SENT_59	[p2l1963t2067r2023b2090],
22	3K	NN	O	3k	nn	23	SENT_59	[p2l1963t2067r2023b2090],
23	phosphatidylinositol	NN	O	phosphatidylinositol	appos	6	SENT_59	[p2l121t2107r403b2140],
24	3,4,5-kinase	NN	O	3,4,5-kinase	dep	23	SENT_59	[p2l416t2107r588b2137],
25	,	,	O	,	_	0	SENT_59	[p2l416t2107r588b2137],
26	TGFoz	NN	O	tgfoz	xcomp	2	SENT_59	[p2l600t2109r677b2132],
27	transforming	VBG	O	transform	partmod	26	SENT_59	[p2l688t2107r870b2140],
28	growth	NN	O	growth	dobj	27	SENT_59	[p2l881t2107r976b2140],
29	factor	NN	O	factor	dep	28	SENT_59	[p2l989t2107r1070b2132],
30	a	DT	O	a	dep	29	SENT_59	[p2l1080t2117r1106b2137],
31	,	,	O	,	_	0	SENT_59	[p2l1080t2117r1106b2137],
32	and	CC	O	and	_	0	SENT_59	[p2l1119t2107r1168b2132],
33	VEGF	NN	O	vegf	nn	37	SENT_59	[p2l1179t2109r1256b2132],
34	vascular	JJ	O	vascular	amod	37	SENT_59	[p2l1267t2107r1381b2132],
35	endothelial	JJ	O	endothelial	amod	37	SENT_59	[p2l1391t2107r1544b2132],
36	growth	NN	O	growth	nn	37	SENT_59	[p2l1557t2107r1652b2140],
37	factor	NN	O	factor	conj_and	28	SENT_59	[p2l1665t2107r1751b2132],
38	.	.	O	.	_	0	SENT_59	[p2l1665t2107r1751b2132],

1	For	IN	O	for	_	0	SENT_60	[p2l1766t2109r1809b2132],
2	more	JJR	O	more	amod	4	SENT_60	[p2l1820t2116r1891b2132],
3	detailed	JJ	O	detailed	amod	4	SENT_60	[p2l1902t2107r2011b2132],
4	information	NN	O	information	prep_for	6	SENT_60	[p2l121t2148r291b2178],
5	,	,	O	,	_	0	SENT_60	[p2l121t2148r291b2178],
6	see	VB	O	see	_	0	SENT_60	[p2l305t2157r349b2174],
7	Figure	NNP	O	Figure	nsubj	14	SENT_60	[p2l362t2151r446b2182],
8	1	CD	NUMBER	1	num	7	SENT_60	[p2l460t2151r471b2173],
9	in	IN	O	in	_	0	SENT_60	[p2l485t2151r506b2173],
10	the	DT	O	the	det	13	SENT_60	[p2l518t2149r562b2174],
11	Supplementary	NNP	O	Supplementary	nn	13	SENT_60	[p2l573t2149r786b2182],
12	Appendix	NNP	O	Appendix	nn	13	SENT_60	[p2l795t2149r927b2181],
13	(	NN	O	(	prep_in	7	SENT_60	[p2l941t2149r1069b2182],
14	available	JJ	O	available	xcomp	6	SENT_60	[p2l941t2149r1069b2182],
15	with	IN	O	with	_	0	SENT_60	[p2l1079t2149r1136b2174],
16	the	DT	O	the	det	20	SENT_60	[p2l1148t2149r1192b2174],
17	full	JJ	O	full	amod	20	SENT_60	[p2l1202t2148r1243b2174],
18	text	NN	O	text	nn	20	SENT_60	[p2l1255t2153r1306b2174],
19	ofthis	NN	O	ofthi	nn	20	SENT_60	[p2l1317t2148r1403b2174],
20	article	NN	O	article	prep_with	14	SENT_60	[p2l1415t2149r1500b2174],
21	at	IN	O	at	_	0	SENT_60	[p2l1511t2153r1536b2174],
22	www.nejm.org	NN	O	www.nejm.org	prep_at	20	SENT_60	[p2l1545t2151r1767b2182],
23	)	CD	NUMBER	)	num	22	SENT_60	[p2l1545t2151r1767b2182],
24	.	.	O	.	_	0	SENT_60	[p2l1545t2151r1767b2182],

1	exclusively	RB	O	exclusively	advmod	6	SENT_61	[p2l94t2295r265b2335],
2	and	CC	O	and	nsubj	6	SENT_61	[p2l282t2295r342b2326],
3	are	VBP	O	be	cop	6	SENT_61	[p2l361t2306r410b2326],
4	therefore	RB	O	therefore	advmod	6	SENT_61	[p2l429t2295r576b2326],
5	highly	RB	O	highly	advmod	6	SENT_61	[p2l595t2295r699b2335],
6	selective	JJ	O	selective	_	0	SENT_61	[p2l717t2295r852b2327],
7	for	IN	O	for	mark	8	SENT_61	[p2l871t2295r918b2326],
8	are	VBP	O	be	ccomp	6	SENT_61	[p2l956t2306r1007b2327],
9	now	RB	DATE	now	advmod	8	SENT_61	[p2l1034t2306r1107b2327],
10	in	IN	O	in	_	0	SENT_61	[p2l1132t2296r1165b2326],
11	early	JJ	O	early	amod	12	SENT_61	[p2l1193t2296r1274b2335],
12	stages	NNS	O	stage	prep_in	8	SENT_61	[p2l1293t2302r1397b2335],
13	of	IN	O	of	_	0	SENT_61	[p2l1425t2295r1464b2327],
14	clinical	JJ	O	clinical	amod	16	SENT_61	[p2l1485t2296r1609b2327],
15	developthis	NN	O	developthi	nn	16	SENT_61	[p2l1637t2296r1779b2335, p2l94t2345r154b2376],
16	receptor	NN	O	receptor	prep_of	12	SENT_61	[p2l169t2351r311b2384],
17	.	.	O	.	_	0	SENT_61	[p2l169t2351r311b2384],

1	In	IN	O	in	_	0	SENT_62	[p2l327t2348r361b2375],
2	addition	NN	O	addition	prep_in	25	SENT_62	[p2l375t2345r519b2382],
3	,	,	O	,	_	0	SENT_62	[p2l375t2345r519b2382],
4	various	JJ	O	various	amod	7	SENT_62	[p2l534t2345r652b2376],
5	small	JJ	O	small	amod	7	SENT_62	[p2l668t2345r916b2376],
6	—	NN	O	—	nn	7	SENT_62	[p2l668t2345r916b2376],
7	molecule	NN	O	molecule	nsubj	25	SENT_62	[p2l668t2345r916b2376],
8	ment	NN	O	ment	nn	10	SENT_62	[p2l956t2347r1122b2376],
9	.4	CD	NUMBER	.4	num	10	SENT_62	[p2l956t2347r1122b2376],
10	v5	NN	O	v5	dep	7	SENT_62	[p2l956t2347r1122b2376],
11	=	JJ	O	=	amod	15	SENT_62	[p2l956t2347r1122b2376],
12	12	CD	NUMBER	12	tmod	11	SENT_62	[p2l956t2347r1122b2376],
13	The	DT	O	the	det	15	SENT_62	[p2l1143t2345r1204b2376],
14	mechanism	NN	O	mechanism	nn	15	SENT_62	[p2l1227t2345r1418b2376],
15	(	NN	O	(	dep	7	SENT_62	[p2l1442t2348r1486b2381],
16	or	CC	O	or	_	0	SENT_62	[p2l1442t2348r1486b2381],
17	mechanisms	NNS	O	mechanism	dep	7	SENT_62	[p2l1507t2345r1723b2381],
18	)	CD	NUMBER	)	num	17	SENT_62	[p2l1507t2345r1723b2381],
19	of	IN	O	of	_	0	SENT_62	[p2l1748t2345r1786b2376],
20	EGFR	NN	ORGANIZATION	egfr	nn	23	SENT_62	[p2l93t2397r191b2427],
21	tyrosine	NN	O	tyrosine	nn	23	SENT_62	[p2l201t2395r332b2433],
22	kinase	NN	O	kinase	nn	23	SENT_62	[p2l346t2394r452b2425],
23	inhibitors	NNS	O	inhibitor	prep_of	17	SENT_62	[p2l466t2394r626b2425],
24	can	MD	O	can	aux	25	SENT_62	[p2l641t2404r698b2425],
25	block	VB	O	block	_	0	SENT_62	[p2l712t2394r802b2425],
26	differ	VB	O	differ	dep	25	SENT_62	[p2l814t2394r916b2425],
27	—	CD	NUMBER	—	num	28	SENT_62	[p2l814t2394r916b2425],
28	action	NN	O	action	dobj	25	SENT_62	[p2l956t2395r1065b2432],
29	,	,	O	,	_	0	SENT_62	[p2l956t2395r1065b2432],
30	pharmacologic	JJ	O	pharmacologic	amod	31	SENT_62	[p2l1087t2395r1333b2434],
31	effects	NNS	O	effect	dobj	25	SENT_62	[p2l1353t2394r1469b2432],
32	,	,	O	,	_	0	SENT_62	[p2l1353t2394r1469b2432],
33	and	CC	O	and	_	0	SENT_62	[p2l1491t2395r1552b2425],
34	spectrum	NN	O	spectrum	dobj	25	SENT_62	[p2l1573t2401r1727b2434],
35	of	IN	O	of	_	0	SENT_62	[p2l1748t2394r1787b2425],
36	ent	JJ	O	ent	amod	41	SENT_62	[p2l94t2450r145b2474],
37	growth	NN	O	growth	nn	41	SENT_62	[p2l162t2443r282b2483],
38	factor	NN	O	factor	nn	41	SENT_62	[p2l302t2443r397b2474],
39	receptor	NN	O	receptor	nn	41	SENT_62	[p2l415t2450r550b2483],
40	tyrosine	NN	O	tyrosine	nn	41	SENT_62	[p2l569t2444r700b2483],
41	kinases	NNS	O	kinase	prep_of	34	SENT_62	[p2l719t2443r851b2481],
42	,	,	O	,	_	0	SENT_62	[p2l719t2443r851b2481],
43	in	IN	O	in	_	0	SENT_62	[p2l872t2444r916b2474],
44	-	:	O	-	_	0	SENT_62	[p2l872t2444r916b2474],
45	activity	NN	O	activity	prep_in	25	SENT_62	[p2l956t2444r1073b2483],
46	of	IN	O	of	_	0	SENT_62	[p2l1088t2443r1127b2475],
47	anti-EGFR	JJ	O	anti-egfr	amod	49	SENT_62	[p2l1135t2444r1309b2477],
48	monoclonal	JJ	O	monoclonal	amod	49	SENT_62	[p2l1320t2444r1516b2475],
49	antibodies	NNS	O	antibody	prep_of	45	SENT_62	[p2l1531t2444r1702b2475],
50	and	CC	O	and	_	0	SENT_62	[p2l1719t2444r1780b2475],
51	eluding	VBG	O	elude	amod	53	SENT_62	[p2l94t2493r216b2533],
52	other	JJ	O	other	amod	53	SENT_62	[p2l227t2493r313b2524],
53	members	NNS	O	member	conj_and	45	SENT_62	[p2l324t2493r475b2524],
54	of	IN	O	of	_	0	SENT_62	[p2l488t2493r526b2524],
55	the	DT	O	the	det	57	SENT_62	[p2l531t2493r581b2524],
56	EGFR	NN	ORGANIZATION	egfr	nn	57	SENT_62	[p2l592t2496r691b2526],
57	family	NN	O	family	prep_of	53	SENT_62	[p2l698t2493r807b2533],
58	,	,	O	,	_	0	SENT_62	[p2l698t2493r807b2533],
59	or	CC	O	or	_	0	SENT_62	[p2l821t2503r855b2524],
60	the	DT	O	the	det	72	SENT_62	[p2l866t2493r916b2524],
61	small	JJ	O	small	amod	67	SENT_62	[p2l957t2494r1206b2525],
62	—	NN	O	—	nn	67	SENT_62	[p2l957t2494r1206b2525],
63	molecule	NN	O	molecule	nn	67	SENT_62	[p2l957t2494r1206b2525],
64	EGFR	NN	ORGANIZATION	egfr	nn	67	SENT_62	[p2l1225t2496r1324b2527],
65	tyrosine	NN	O	tyrosine	nn	67	SENT_62	[p2l1340t2494r1472b2533],
66	kinase	NN	O	kinase	nn	67	SENT_62	[p2l1492t2494r1598b2525],
67	inhibitors	NNS	O	inhibitor	nn	72	SENT_62	[p2l1619t2494r1779b2525],
68	vascular	JJ	O	vascular	amod	69	SENT_62	[p2l92t2543r228b2575],
69	endothelial	JJ	O	endothelial	amod	67	SENT_62	[p2l241t2543r425b2574],
70	growth	NN	O	growth	nn	72	SENT_62	[p2l439t2543r559b2583],
71	factor	NN	O	factor	nn	72	SENT_62	[p2l574t2543r669b2574],
72	receptor	NN	O	receptor	conj_or	45	SENT_62	[p2l682t2550r824b2583],
73	.	.	O	.	_	0	SENT_62	[p2l682t2550r824b2583],

1	Vari	SYM	PERSON	vari	dep	3	SENT_63	[p2l839t2544r916b2574],
2	-	:	O	-	_	0	SENT_63	[p2l839t2544r916b2574],
3	have	VBP	O	have	_	0	SENT_63	[p2l956t2544r1029b2575],
4	differences	NNS	O	difference	dobj	3	SENT_63	[p2l1044t2543r1225b2575],
5	that	WDT	O	that	nsubj	8	SENT_63	[p2l1241t2544r1307b2575],
6	may	MD	O	may	aux	8	SENT_63	[p2l1320t2554r1389b2583],
7	be	VB	O	be	cop	8	SENT_63	[p2l1403t2544r1441b2575],
8	relevant	JJ	O	relevant	rcmod	4	SENT_63	[p2l1456t2544r1585b2575],
9	for	IN	O	for	_	0	SENT_63	[p2l1599t2543r1646b2575],
10	clinical	JJ	O	clinical	amod	17	SENT_63	[p2l1661t2544r1780b2575],
11	ous	JJ	O	ous	amod	17	SENT_63	[p2l94t2603r149b2624],
12	irreversible	JJ	O	irreversible	amod	17	SENT_63	[p2l169t2593r349b2624],
13	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_63	[p2l368t2595r466b2626],
14	tyrosine	NN	O	tyrosine	nn	17	SENT_63	[p2l481t2593r612b2632],
15	kinase	NN	O	kinase	nn	17	SENT_63	[p2l631t2593r737b2624],
16	inhibitors	NNS	O	inhibitor	nn	17	SENT_63	[p2l756t2593r916b2624],
17	activity	NN	O	activity	prep_for	8	SENT_63	[p2l956t2594r1073b2633],
18	(	CD	NUMBER	(	num	19	SENT_63	[p2l1088t2593r1186b2629],
19	Table	NNP	O	Table	tmod	8	SENT_63	[p2l1088t2593r1186b2629],
20	1	CD	NUMBER	1	num	19	SENT_63	[p2l1201t2596r1219b2624],
21	and	CC	O	and	_	0	SENT_63	[p2l1233t2593r1294b2624],
22	Fig	NN	O	fig	tmod	8	SENT_63	[p2l1307t2594r1365b2633],
23	.	.	O	.	_	0	SENT_63	[p2l1307t2594r1365b2633],

1	2	CD	NUMBER	2	_	0	SENT_64	[p2l1381t2595r1400b2624],
2	and	CC	O	and	_	0	SENT_64	[p2l1414t2593r1475b2624],
3	3	CD	NUMBER	3	conj_and	1	SENT_64	[p2l1489t2595r1555b2629],
4	)	NN	O	)	dep	1	SENT_64	[p2l1489t2595r1555b2629],
5	.13	CD	NUMBER	.13	dep	1	SENT_64	[p2l1489t2595r1555b2629],

1	N	NN	O	n	nn	3	SENT_65	[p2l572t2718r585b2734],
2	ENGLJ	NN	O	englj	nn	3	SENT_65	[p2l600t2718r678b2740],
3	MED	NN	O	med	_	0	SENT_65	[p2l693t2718r745b2733],
4	358	CD	NUMBER	358	num	6	SENT_65	[p2l755t2712r824b2740],
5	;	:	O	;	_	0	SENT_65	[p2l755t2712r824b2740],
6	i1	CD	NUMBER	i1	dep	3	SENT_65	[p2l755t2712r824b2740],
7	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	8	SENT_65	[p2l859t2718r1061b2740],
8	MARCH	NNP	DATE	MARCH	dep	3	SENT_65	[p2l1097t2718r1183b2734],
9	13,2008	CD	DATE	13,2008	number	10	SENT_65	[p2l1197t2712r1303b2740],
10	1161	CD	DATE	1161	dep	8	SENT_65	[p2l1990t2708r2067b2730],

1	The	DT	O	the	det	4	SENT_66	[p2l752t2776r803b2799],
2	New	NNP	O	New	nn	4	SENT_66	[p2l812t2776r874b2799],
3	England	NNP	O	England	nn	4	SENT_66	[p2l883t2776r994b2806],
4	Journal	NNP	O	Journal	_	0	SENT_66	[p2l1002t2776r1100b2799],
5	of	IN	O	of	_	0	SENT_66	[p2l1110t2776r1139b2799],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_66	[p2l1145t2776r1271b2799],

1	Downloaded	VBN	O	download	_	0	SENT_67	[p2l194t2816r364b2839],
2	from	IN	O	from	_	0	SENT_67	[p2l373t2816r437b2839],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_67	[p2l446t2816r564b2846],
4	at	IN	O	at	_	0	SENT_67	[p2l574t2819r597b2839],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_67	[p2l606t2816r789b2840],
6	on	IN	O	on	_	0	SENT_67	[p2l798t2823r830b2839],
7	January	NNP	DATE	January	prep_on	1	SENT_67	[p2l839t2816r942b2846],
8	5	CD	DATE	5	num	7	SENT_67	[p2l952t2816r974b2844],
9	,	,	DATE	,	_	0	SENT_67	[p2l952t2816r974b2844],
10	2014	CD	DATE	2014	num	7	SENT_67	[p2l985t2816r1057b2840],
11	.	.	O	.	_	0	SENT_67	[p2l985t2816r1057b2840],

1	For	IN	O	for	_	0	SENT_68	[p2l1068t2816r1114b2839],
2	personal	JJ	O	personal	amod	3	SENT_68	[p2l1122t2816r1235b2846],
3	use	NN	O	use	pobj	1	SENT_68	[p2l1244t2823r1287b2839],
4	only	RB	O	only	advmod	3	SENT_68	[p2l1297t2816r1362b2846],
5	.	.	O	.	_	0	SENT_68	[p2l1297t2816r1362b2846],

1	No	DT	O	no	det	3	SENT_69	[p2l1372t2816r1412b2839],
2	other	JJ	O	other	amod	3	SENT_69	[p2l1422t2816r1490b2839],
3	uses	NNS	O	use	_	0	SENT_69	[p2l1499t2823r1555b2839],
4	without	IN	O	without	_	0	SENT_69	[p2l1565t2816r1666b2839],
5	permission	NN	O	permission	prep_without	3	SENT_69	[p2l1674t2816r1827b2846],
6	.	.	O	.	_	0	SENT_69	[p2l1674t2816r1827b2846],

1	Copyright	NN	O	copyright	_	0	SENT_70	[p2l544t2857r679b2888],
2	©	CD	NUMBER	©	num	6	SENT_70	[p2l688t2857r711b2881],
3	2008	CD	DATE	2008	num	6	SENT_70	[p2l721t2857r786b2881],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_70	[p2l796t2857r987b2881],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_70	[p2l997t2857r1105b2881],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_70	[p2l1115t2857r1221b2888],
7	.	.	O	.	_	0	SENT_70	[p2l1115t2857r1221b2888],

1	All	DT	O	all	det	2	SENT_71	[p2l1231t2857r1273b2881],
2	rights	NNS	O	rights	nsubj	3	SENT_71	[p2l1282t2857r1357b2888],
3	reserved	VBN	O	reserve	_	0	SENT_71	[p2l1366t2857r1485b2881],
4	.	.	O	.	_	0	SENT_71	[p2l1366t2857r1485b2881],

1	The	DT	O	the	det	4	SENT_72	[p2l814t2900r860b2921],
2	NEW	NNP	O	NEW	nn	4	SENT_72	[p2l878t2902r964b2921],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_72	[p2l983t2902r1171b2921],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_72	[p2l1190t2902r1370b2928],
5	of	IN	O	of	_	0	SENT_72	[p2l1389t2900r1418b2927],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_72	[p2l1429t2902r1628b2921],

1	Table	NNP	O	Table	_	0	SENT_73	[p3l117t71r191b96],
2	1	CD	NUMBER	1	dep	1	SENT_73	[p3l201t74r222b96],
3	.	.	O	.	_	0	SENT_73	[p3l201t74r222b96],

1	Functional	JJ	O	functional	amod	4	SENT_74	[p3l234t71r376b96],
2	and	CC	O	and	_	0	SENT_74	[p3l387t71r436b96],
3	Pharmacologic	JJ	O	pharmacologic	conj_and	1	SENT_74	[p3l448t71r649b104],
4	Characteristics	NNS	O	characteristic	_	0	SENT_74	[p3l658t71r861b96],
5	of	IN	O	of	_	0	SENT_74	[p3l870t71r902b96],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_74	[p3l907t73r982b96],
7	Inhibitors	NNS	O	inhibitor	prep_of	4	SENT_74	[p3l993t71r1149b96],
8	.	.	O	.	_	0	SENT_74	[p3l993t71r1149b96],

1	‘	SYM	O	‘	dep	3	SENT_75	[p3l993t71r1149b96],
2	-	:	O	-	_	0	SENT_75	[p3l993t71r1149b96],
3	"	``	O	"	_	0	SENT_75	[p3l993t71r1149b96],
4	‘	IN	O	‘	prep	3	SENT_75	[p3l993t71r1149b96],

1	Characteristic	JJ	O	characteristic	amod	2	SENT_76	[p3l117t146r306b172],
2	Route	NN	O	route	_	0	SENT_76	[p3l120t206r197b229],
3	of	IN	O	of	_	0	SENT_76	[p3l207t204r236b229],
4	administration	NN	O	administration	nn	7	SENT_76	[p3l242t204r442b229],
5	Structure	NN	O	structure	nn	7	SENT_76	[p3l118t264r243b287],
6	Target	NN	O	target	nn	7	SENT_76	[p3l117t322r204b353],
7	selectivity	NN	O	selectivity	prep_of	2	SENT_76	[p3l214t319r346b352],

1	Mechanism	NN	O	mechanism	nn	2	SENT_77	[p3l120t527r277b552],
2	ofinterference	NN	O	ofinterference	_	0	SENT_77	[p3l289t527r485b552],
3	with	IN	O	with	_	0	SENT_77	[p3l167t565r223b590],
4	EG	NN	O	eg	nn	6	SENT_77	[p3l236t567r272b590],
5	FR	NN	O	fr	nn	6	SENT_77	[p3l278t567r310b589],
6	activation	NN	O	activation	prep_with	2	SENT_77	[p3l321t567r451b590],

1	Cellular	JJ	MISC	cellular	amod	2	SENT_78	[p3l118t772r222b798],
2	effects	NNS	O	effect	_	0	SENT_78	[p3l230t772r318b798],
3	of	IN	O	of	_	0	SENT_78	[p3l328t772r358b797],
4	EG	NN	O	eg	nn	5	SENT_78	[p3l365t774r401b798],
5	FR	NN	O	fr	prep_of	2	SENT_78	[p3l407t775r439b797],

1	inhibition	NN	O	inhibition	_	0	SENT_79	[p3l169t810r297b835],

1	Induction	NN	O	induction	_	0	SENT_80	[p3l120t980r248b1005],
2	of	IN	O	of	_	0	SENT_80	[p3l259t980r289b1005],
3	EGFR	NN	ORGANIZATION	egfr	nn	4	SENT_80	[p3l296t982r370b1005],
4	internalization	NN	O	internalization	prep_of	1	SENT_80	[p3l381t980r532b1005, p3l167t1020r227b1047],
5	,	,	O	,	_	0	SENT_80	[p3l381t980r532b1005, p3l167t1020r227b1047],
6	down-regulation	NN	O	down-regulation	prep_of	1	SENT_80	[p3l238t1017r469b1051],
7	,	,	O	,	_	0	SENT_80	[p3l238t1017r469b1051],
8	and	CC	O	and	_	0	SENT_80	[p3l168t1055r216b1080],
9	degradation	NN	O	degradation	nn	10	SENT_80	[p3l228t1055r390b1088],
10	Inhibition	NN	O	inhibition	prep_of	1	SENT_80	[p3l120t1113r249b1138],
11	of	IN	O	of	_	0	SENT_80	[p3l260t1112r290b1138],
12	EGFR-dependent	JJ	O	egfr-dependent	amod	14	SENT_80	[p3l297t1113r529b1145],
13	intracellular	JJ	O	intracellular	amod	14	SENT_80	[p3l169t1150r330b1175],
14	signaling	NN	O	signaling	prep_of	1	SENT_80	[p3l339t1150r463b1183],

1	Activity	NN	O	activity	_	0	SENT_81	[p3l117t1210r216b1241],
2	against	IN	O	against	_	0	SENT_81	[p3l226t1210r324b1241],
3	mutant	JJ	O	mutant	amod	4	SENT_81	[p3l335t1213r433b1233],
4	EGFR	NN	ORGANIZATION	egfr	prep_against	1	SENT_81	[p3l445t1210r518b1233],

1	proteins	NNS	O	protein	_	0	SENT_82	[p3l169t1248r279b1278],

1	Activation	NN	O	activation	_	0	SENT_83	[p3l117t1680r253b1703],
2	of	IN	O	of	_	0	SENT_83	[p3l264t1678r294b1703],
3	host	NN	O	host	prep_of	1	SENT_83	[p3l300t1678r358b1703],
4	immune	JJ	O	immune	amod	5	SENT_83	[p3l369t1680r482b1703],
5	response	NN	O	response	dep	1	SENT_83	[p3l169t1724r292b1748],

1	Blocking	VBG	O	block	_	0	SENT_84	[p3l751t146r867b179],
2	Monoclonal	JJ	O	monoclonal	amod	3	SENT_84	[p3l879t146r1038b172],
3	Antibodies	NNS	O	antibody	dobj	1	SENT_84	[p3l1049t146r1196b172],

1	Intravenous	JJ	O	intravenous	amod	2	SENT_85	[p3l625t206r785b229],
2	(	NN	O	(	nsubj	14	SENT_85	[p3l798t204r929b237],
3	generally	RB	O	generally	amod	2	SENT_85	[p3l798t204r929b237],
4	once	RB	DATE	once	advmod	6	SENT_85	[p3l938t213r1003b229],
5	a	DT	DURATION	a	det	6	SENT_85	[p3l1013t213r1025b229],
6	week	NN	DURATION	week	tmod	3	SENT_85	[p3l1035t204r1103b229],
7	or	CC	O	or	_	0	SENT_85	[p3l1113t213r1140b229],
8	every	DT	SET	every	det	10	SENT_85	[p3l1149t213r1219b237],
9	2	CD	SET	2	num	10	SENT_85	[p3l1228t206r1242b229],
10	wk	NN	SET	wk	conj_or	2	SENT_85	[p3l1251t204r1297b237],
11	)	CD	NUMBER	)	num	13	SENT_85	[p3l1251t204r1297b237],
12	Recombinant	JJ	O	recombinant	amod	13	SENT_85	[p3l625t262r805b287],
13	immunoglobulins	NNS	O	immunoglobulin	dep	10	SENT_85	[p3l816t262r1058b295],
14	(	VBP	O	(	_	0	SENT_85	[p3l1072t262r1251b295],
15	150	CD	NUMBER	150	number	16	SENT_85	[p3l1072t262r1251b295],
16	—	CD	NUMBER	—	num	17	SENT_85	[p3l1072t262r1251b295],
17	180kD	NN	O	180kd	dobj	14	SENT_85	[p3l1072t262r1251b295],
18	)	CD	NUMBER	)	npadvmod	20	SENT_85	[p3l1072t262r1251b295],
19	Exclusively	RB	O	exclusively	advmod	18	SENT_85	[p3l625t319r769b352],
20	specific	JJ	O	specific	amod	17	SENT_85	[p3l779t319r880b352],
21	for	IN	O	for	_	0	SENT_85	[p3l889t319r927b345],
22	EC	NNP	ORGANIZATION	EC	nn	23	SENT_85	[p3l938t321r974b345],
23	FR	NN	O	fr	prep_for	14	SENT_85	[p3l980t322r1012b344],

1	Bind	VB	O	bind	_	0	SENT_86	[p3l625t527r683b552],
2	extracellular	JJ	O	extracellular	amod	3	SENT_86	[p3l695t527r859b552],
3	portion	NN	O	portion	dobj	1	SENT_86	[p3l870t529r966b560],
4	of	IN	O	of	_	0	SENT_86	[p3l978t527r1007b552],
5	receptor	NN	O	receptor	prep_of	3	SENT_86	[p3l1014t532r1132b560],
6	,	,	O	,	_	0	SENT_86	[p3l1014t532r1132b560],
7	preventing	VBG	O	prevent	partmod	1	SENT_86	[p3l1145t529r1289b560],
8	ligand	NN	O	ligand	nn	9	SENT_86	[p3l674t565r754b598],
9	binding	NN	O	binding	dobj	7	SENT_86	[p3l767t565r869b598],
10	and	CC	O	and	_	0	SENT_86	[p3l879t565r927b590],
11	receptor	NN	O	receptor	nn	12	SENT_86	[p3l940t569r1052b597],
12	dimerization	NN	O	dimerization	conj_and	9	SENT_86	[p3l1061t565r1232b590],
13	by	IN	O	by	_	0	SENT_86	[p3l1245t565r1274b597],
14	occluding	VBG	O	occlude	amod	16	SENT_86	[p3l673t602r806b635],
15	ligand	NN	O	ligand	nn	16	SENT_86	[p3l817t602r897b635],
16	region	NN	O	region	prep_by	9	SENT_86	[p3l910t604r992b635],
17	(	CD	NUMBER	(	num	19	SENT_86	[p3l1007t602r1165b635],
18	cetuximab	NN	O	cetuximab	nn	19	SENT_86	[p3l1007t602r1165b635],
19	)	NN	O	)	nsubj	1	SENT_86	[p3l1007t602r1165b635],

1	Inhibit	VB	O	inhibit	_	0	SENT_87	[p3l625t772r712b798],
2	cancer-cell	NN	O	cancer-cell	nn	3	SENT_87	[p3l721t772r863b798],
3	proliferation	NN	O	proliferation	dobj	1	SENT_87	[p3l876t772r1041b805],
4	(	CD	NUMBER	(	num	5	SENT_87	[p3l1055t774r1101b805],
5	G1	NN	O	g1	nsubj	1	SENT_87	[p3l1055t774r1101b805],
6	phase	NN	O	phase	nn	8	SENT_87	[p3l1114t772r1193b805],
7	arrest	NN	O	arrest	nn	8	SENT_87	[p3l1203t774r1299b805],
8	)	NN	O	)	nsubj	26	SENT_87	[p3l1203t774r1299b805],
9	,	,	O	,	_	0	SENT_87	[p3l1203t774r1299b805],
10	angiogenic	JJ	O	angiogenic	amod	17	SENT_87	[p3l673t812r822b843],
11	growth	NN	O	growth	nn	17	SENT_87	[p3l832t810r924b843],
12	factor	NN	O	factor	nn	17	SENT_87	[p3l935t810r1014b835],
13	production	NN	O	production	nn	17	SENT_87	[p3l1024t810r1171b843],
14	(	CD	NUMBER	(	num	17	SENT_87	[p3l1186t812r1252b843],
15	VEG	NN	O	veg	nn	17	SENT_87	[p3l1186t812r1252b843],
16	F	NN	O	f	nn	17	SENT_87	[p3l1258t812r1280b843],
17	)	NN	O	)	nsubj	26	SENT_87	[p3l1258t812r1280b843],
18	and	CC	O	and	_	0	SENT_87	[p3l673t847r721b873],
19	tumor-induced	JJ	O	tumor-induced	amod	20	SENT_87	[p3l732t847r935b873],
20	angiogenesis	NN	O	angiogenesis	conj_and	8	SENT_87	[p3l946t850r1132b881],
21	,	,	O	,	_	0	SENT_87	[p3l946t850r1132b881],
22	and	CC	O	and	_	0	SENT_87	[p3l1144t847r1192b873],
23	cancercell	NN	O	cancercell	nn	24	SENT_87	[p3l1203t856r1301b873, p3l673t885r716b910],
24	invasion	NN	O	invasion	nsubj	26	SENT_87	[p3l728t887r848b914],
25	;	:	O	;	_	0	SENT_87	[p3l728t887r848b914],
26	potentiate	VB	O	potentiate	rcmod	5	SENT_87	[p3l861t887r997b918],
27	antitumor	NN	O	antitumor	nn	28	SENT_87	[p3l1008t887r1144b910],
28	activity	NN	O	activity	dobj	26	SENT_87	[p3l1154t887r1248b918],
29	of	IN	O	of	_	0	SENT_87	[p3l1257t885r1287b910],
30	cytotoxic	JJ	O	cytotoxic	amod	31	SENT_87	[p3l673t925r792b955],
31	drugs	NNS	O	drug	prep_of	28	SENT_87	[p3l802t922r878b956],
32	and	CC	O	and	_	0	SENT_87	[p3l889t922r937b948],
33	radiotherapy	NN	O	radiotherapy	prep_of	28	SENT_87	[p3l949t922r1120b955],

1	Yes	UH	O	yes	_	0	SENT_88	[p3l622t982r669b1005],

1	Yes	UH	O	yes	_	0	SENT_89	[p3l622t1115r669b1138],

1	Probably	RB	O	probably	advmod	16	SENT_90	[p3l625t1208r741b1241],
2	yes	RB	O	yes	nsubj	16	SENT_90	[p3l750t1217r800b1241],
3	,	,	O	,	_	0	SENT_90	[p3l750t1217r800b1241],
4	for	IN	O	for	_	0	SENT_90	[p3l810t1208r848b1233],
5	mutations	NNS	O	mutation	prep_for	2	SENT_90	[p3l858t1210r996b1233],
6	of	IN	O	of	_	0	SENT_90	[p3l1007t1208r1036b1233],
7	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_90	[p3l1044t1210r1118b1233],
8	tyrosine	NN	O	tyrosine	nn	10	SENT_90	[p3l1127t1210r1235b1241],
9	kinase	NN	O	kinase	nn	10	SENT_90	[p3l674t1245r759b1271],
10	domain	NN	O	domain	prep_of	5	SENT_90	[p3l769t1245r880b1275],
11	,	,	O	,	_	0	SENT_90	[p3l769t1245r880b1275],
12	since	IN	O	since	_	0	SENT_90	[p3l892t1248r961b1271],
13	anti-EGFR	JJ	O	anti-egfr	amod	15	SENT_90	[p3l971t1247r1109b1271],
14	monoclonal	JJ	O	monoclonal	amod	15	SENT_90	[p3l1120t1245r1279b1271],
15	antibodies	NNS	O	antibody	prep_since	2	SENT_90	[p3l673t1283r815b1308],
16	bind	VBP	O	bind	_	0	SENT_90	[p3l827t1283r884b1308],
17	to	TO	O	to	_	0	SENT_90	[p3l894t1288r921b1308],
18	EG	NNP	O	EG	nn	21	SENT_90	[p3l933t1285r968b1308],
19	FR	NN	O	fr	nn	21	SENT_90	[p3l975t1285r1007b1308],
20	extracellular	JJ	O	extracellular	amod	21	SENT_90	[p3l1017t1283r1182b1308],
21	domain	NN	O	domain	prep_to	16	SENT_90	[p3l1191t1283r1302b1313],
22	;	:	O	;	_	0	SENT_90	[p3l1191t1283r1302b1313],
23	not	RB	O	not	dep	24	SENT_90	[p3l674t1325r717b1346],
24	completely	RB	O	completely	advmod	25	SENT_90	[p3l727t1320r875b1353],
25	known	VBN	O	know	parataxis	16	SENT_90	[p3l886t1320r972b1346],
26	for	IN	O	for	_	0	SENT_90	[p3l983t1320r1021b1346],
27	mutations	NNS	O	mutation	prep_for	25	SENT_90	[p3l1031t1323r1169b1346],
28	of	IN	O	of	_	0	SENT_90	[p3l1180t1320r1209b1346],
29	EGFR	NN	ORGANIZATION	egfr	nn	31	SENT_90	[p3l1217t1322r1291b1346],
30	extracellular	JJ	O	extracellular	amod	31	SENT_90	[p3l673t1358r838b1383],
31	domain	NN	O	domain	prep_of	27	SENT_90	[p3l847t1358r949b1383],

1	Yes	UH	O	yes	dep	7	SENT_91	[p3l622t1680r669b1703],
2	—	CD	NUMBER	—	num	4	SENT_91	[p3l678t1694r712b1696],
3	antibody-dependent	JJ	O	antibody-dependent	amod	4	SENT_91	[p3l721t1678r995b1711],
4	cytotoxicity	NN	O	cytotoxicity	nsubj	7	SENT_91	[p3l1005t1680r1156b1711],
5	may	MD	O	may	aux	7	SENT_91	[p3l1167t1687r1221b1711],
6	significantly	RB	O	significantly	advmod	7	SENT_91	[p3l1231t1678r1321b1711, p3l673t1716r752b1749],
7	contribute	VB	O	contribute	_	0	SENT_91	[p3l761t1716r901b1741],
8	to	TO	O	to	_	0	SENT_91	[p3l910t1720r937b1741],
9	anticancer	JJ	O	anticancer	amod	10	SENT_91	[p3l947t1718r1089b1741],
10	activity	NN	O	activity	prep_to	7	SENT_91	[p3l1098t1718r1192b1748],
11	of	IN	O	of	_	0	SENT_91	[p3l1202t1715r1231b1741],
12	some	DT	O	some	det	15	SENT_91	[p3l1237t1724r1311b1741],
13	anti-EGFR	JJ	O	anti-egfr	amod	15	SENT_91	[p3l673t1755r811b1778],
14	monoclonal	JJ	O	monoclonal	amod	15	SENT_91	[p3l822t1753r982b1778],
15	antibodies	NNS	O	antibody	prep_of	10	SENT_91	[p3l994t1753r1143b1783],
16	,	,	O	,	_	0	SENT_91	[p3l994t1753r1143b1783],
17	such	JJ	O	such	_	0	SENT_91	[p3l1155t1753r1216b1778],
18	as	IN	O	as	_	0	SENT_91	[p3l1228t1762r1255b1778],
19	cetuximab	NN	O	cetuximab	prep_such_as	10	SENT_91	[p3l1266t1762r1303b1778, p3l672t1791r790b1820],
20	;	:	O	;	_	0	SENT_91	[p3l1266t1762r1303b1778, p3l672t1791r790b1820],
21	however	RB	O	however	advmod	28	SENT_91	[p3l802t1791r921b1820],
22	,	,	O	,	_	0	SENT_91	[p3l802t1791r921b1820],
23	no	DT	O	no	det	25	SENT_91	[p3l933t1799r966b1816],
24	antibody-dependent	JJ	O	antibody-dependent	amod	25	SENT_91	[p3l976t1791r1250b1824],
25	cytotoxicity	NN	O	cytotoxicity	nsubjpass	28	SENT_91	[p3l1260t1799r1295b1823, p3l672t1830r796b1861],
26	has	VBZ	O	have	aux	28	SENT_91	[p3l806t1828r851b1853],
27	been	VBN	O	be	auxpass	28	SENT_91	[p3l863t1828r925b1853],
28	reported	VBN	O	report	parataxis	7	SENT_91	[p3l938t1828r1051b1861],
29	for	IN	O	for	_	0	SENT_91	[p3l1061t1828r1099b1853],
30	panitumumab	NN	O	panitumumab	prep_for	28	SENT_91	[p3l1110t1828r1302b1861],

1	Small-Molecule	JJ	O	small-molecule	amod	4	SENT_92	[p3l1412t146r1625b172],
2	Tyrosine	NN	O	tyrosine	nn	4	SENT_92	[p3l1634t147r1752b179],
3	Kinase	NN	O	kinase	nn	4	SENT_92	[p3l1763t147r1852b172],
4	Inhibitors	NNS	O	inhibitor	nsubj	14	SENT_92	[p3l1865t146r1994b172],
5	Oral	JJ	O	oral	amod	6	SENT_92	[p3l1367t204r1423b229],
6	(	NN	O	(	dep	4	SENT_92	[p3l1438t204r1568b237],
7	generally	RB	O	generally	advmod	10	SENT_92	[p3l1438t204r1568b237],
8	daily	JJ	SET	daily	amod	10	SENT_92	[p3l1577t204r1639b237],
9	continuous	JJ	O	continuous	amod	10	SENT_92	[p3l1649t206r1802b229],
10	dosing	NN	O	dosing	dep	4	SENT_92	[p3l1813t204r1914b237],
11	)	CD	NUMBER	)	num	13	SENT_92	[p3l1813t204r1914b237],
12	Low-molecular-weight	JJ	O	low-molecular-weight	amod	13	SENT_92	[p3l1369t262r1668b295],
13	compounds	NNS	O	compound	dep	10	SENT_92	[p3l1678t262r1841b295],
14	(	VBP	O	(	_	0	SENT_92	[p3l1854t263r1978b295],
15	400	CD	NUMBER	400	number	16	SENT_92	[p3l1854t263r1978b295],
16	—	CD	NUMBER	—	nsubj	18	SENT_92	[p3l1854t263r1978b295],
17	600	CD	NUMBER	600	num	18	SENT_92	[p3l1854t263r1978b295],
18	kD	NN	O	kd	ccomp	14	SENT_92	[p3l1989t262r2034b295],
19	)	CD	NUMBER	)	dobj	18	SENT_92	[p3l1989t262r2034b295],
20	Relatively	RB	O	relatively	advmod	21	SENT_92	[p3l1369t319r1495b352],
21	specific	JJ	O	specific	amod	19	SENT_92	[p3l1504t319r1606b352],
22	for	IN	O	for	_	0	SENT_92	[p3l1615t319r1653b345],
23	EGFR	NN	ORGANIZATION	egfr	prep_for	18	SENT_92	[p3l1664t321r1745b349],
24	;	:	O	;	_	0	SENT_92	[p3l1664t321r1745b349],
25	may	MD	O	may	aux	26	SENT_92	[p3l1758t328r1812b352],
26	inhibit	VB	O	inhibit	parataxis	14	SENT_92	[p3l1823t319r1909b345],
27	only	RB	O	only	advmod	28	SENT_92	[p3l1918t319r1974b352],
28	one	CD	NUMBER	one	dobj	26	SENT_92	[p3l1983t328r2033b345],
29	or	CC	O	or	_	0	SENT_92	[p3l1416t366r1444b382],
30	all	DT	O	all	det	31	SENT_92	[p3l1454t357r1481b382],
31	EGFR	NN	ORGANIZATION	egfr	dobj	26	SENT_92	[p3l1495t359r1569b382],
32	family	NN	O	family	nn	33	SENT_92	[p3l1578t357r1661b390],
33	receptors	NNS	O	receptor	nsubj	26	SENT_92	[p3l1671t362r1805b390],
34	;	:	O	;	_	0	SENT_92	[p3l1671t362r1805b390],
35	some	DT	O	some	det	40	SENT_92	[p3l1816t366r1890b382],
36	EG	NN	O	eg	nn	40	SENT_92	[p3l1902t359r1937b382],
37	FR	NN	O	fr	nn	40	SENT_92	[p3l1944t359r1976b382],
38	tyrosine	NN	O	tyrosine	nn	40	SENT_92	[p3l1415t397r1524b427],
39	kinase	NN	O	kinase	nn	40	SENT_92	[p3l1535t394r1620b420],
40	inhibitors	NNS	O	inhibitor	nsubj	42	SENT_92	[p3l1631t394r1759b420],
41	also	RB	O	also	advmod	42	SENT_92	[p3l1770t394r1824b420],
42	inhibit	VBP	O	inhibit	parataxis	14	SENT_92	[p3l1835t394r1921b420],
43	other	JJ	O	other	amod	46	SENT_92	[p3l1930t394r2002b420],
44	growth	NN	O	growth	nn	46	SENT_92	[p3l1417t432r1509b465],
45	factor	NN	O	factor	nn	46	SENT_92	[p3l1520t432r1599b457],
46	receptors	NNS	O	receptor	nsubj	47	SENT_92	[p3l1609t437r1734b465],
47	(	VBP	O	(	ccomp	42	SENT_92	[p3l1748t434r1811b465],
48	e.g.	FW	O	e.g.	dobj	47	SENT_92	[p3l1748t434r1811b465],
49	,	,	O	,	_	0	SENT_92	[p3l1748t434r1811b465],
50	dual	JJ	O	dual	amod	51	SENT_92	[p3l1823t432r1879b457],
51	inhibitors	NNS	O	inhibitor	conj_and	48	SENT_92	[p3l1891t432r2020b457],
52	of	IN	O	of	_	0	SENT_92	[p3l1416t469r1446b495],
53	EGFR	NN	ORGANIZATION	egfr	prep_of	51	SENT_92	[p3l1454t471r1528b495],
54	and	CC	O	and	_	0	SENT_92	[p3l1538t469r1586b495],
55	VEGFR	NN	O	vegfr	nn	57	SENT_92	[p3l1596t471r1702b502],
56	)	CD	NUMBER	)	num	57	SENT_92	[p3l1596t471r1702b502],
57	Bind	NN	O	bind	conj_and	48	SENT_92	[p3l1369t527r1427b552],
58	intracellular	JJ	O	intracellular	amod	59	SENT_92	[p3l1439t527r1600b552],
59	portion	NN	O	portion	dep	57	SENT_92	[p3l1611t529r1707b560],
60	of	IN	O	of	_	0	SENT_92	[p3l1719t527r1748b552],
61	receptor	NN	O	receptor	prep_of	59	SENT_92	[p3l1755t532r1867b560],
62	within	IN	O	within	_	0	SENT_92	[p3l1875t527r1957b552],
63	tyrosine	NN	O	tyrosine	nn	65	SENT_92	[p3l1968t532r2028b560, p3l1417t567r1471b590],
64	kinase	NN	O	kinase	nn	65	SENT_92	[p3l1482t565r1567b590],
65	domain	NN	O	domain	prep_within	47	SENT_92	[p3l1577t565r1688b594],
66	,	,	O	,	_	0	SENT_92	[p3l1577t565r1688b594],
67	generally	RB	O	generally	advmod	47	SENT_92	[p3l1699t565r1821b598],
68	by	IN	O	by	_	0	SENT_92	[p3l1831t565r1860b597],
69	competing	VBG	O	compete	prepc_by	47	SENT_92	[p3l1869t567r2015b598],
70	with	IN	O	with	_	0	SENT_92	[p3l1416t602r1471b627],
71	ATP	NN	ORGANIZATION	atp	prep_with	69	SENT_92	[p3l1482t604r1537b627],
72	and	CC	O	and	_	0	SENT_92	[p3l1547t602r1595b627],
73	inhibiting	VBG	O	inhibit	conj_and	69	SENT_92	[p3l1608t602r1737b635],
74	receptor	NN	O	receptor	nn	75	SENT_92	[p3l1748t607r1860b635],
75	autophosphorylation	NN	O	autophosphorylation	dobj	73	SENT_92	[p3l1869t602r2006b635, p3l1418t640r1578b673],
76	;	:	O	;	_	0	SENT_92	[p3l1869t602r2006b635, p3l1418t640r1578b673],
77	most	JJS	O	most	nsubj	79	SENT_92	[p3l1591t644r1659b665],
78	are	VBP	O	be	cop	79	SENT_92	[p3l1669t648r1709b665],
79	reversible	JJ	O	reversible	parataxis	14	SENT_92	[p3l1720t640r1857b669],
80	;	:	O	;	_	0	SENT_92	[p3l1720t640r1857b669],
81	irreversible	JJ	O	irreversible	amod	85	SENT_92	[p3l1869t640r2018b665],
82	EGFR	NN	ORGANIZATION	egfr	nn	85	SENT_92	[p3l1419t679r1493b702],
83	tyrosine	NN	O	tyrosine	nn	85	SENT_92	[p3l1502t679r1610b710],
84	kinase	NN	O	kinase	nn	85	SENT_92	[p3l1621t677r1706b702],
85	inhibitors	NNS	O	inhibitor	nsubj	86	SENT_92	[p3l1717t677r1845b702],
86	are	VBP	O	be	parataxis	14	SENT_92	[p3l1856t686r1897b702],
87	in	IN	O	in	_	0	SENT_92	[p3l1908t679r1929b702],
88	clinical	JJ	O	clinical	amod	89	SENT_92	[p3l1941t677r2033b702],
89	development	NN	O	development	prep_in	86	SENT_92	[p3l1416t715r1595b747],
90	Inhibit	VB	O	inhibit	ccomp	86	SENT_92	[p3l1369t772r1455b798],
91	cancer-cell	JJ	O	cancer-cell	amod	92	SENT_92	[p3l1465t772r1607b798],
92	proliferation	NN	O	proliferation	dobj	90	SENT_92	[p3l1620t772r1785b805],
93	(	CD	NUMBER	(	num	94	SENT_92	[p3l1799t774r1902b805],
94	GO	NN	O	go	dep	92	SENT_92	[p3l1799t774r1902b805],
95	.	.	O	.	_	0	SENT_92	[p3l1799t774r1902b805],

1	—	NN	O	—	_	0	SENT_93	[p3l1799t774r1902b805],
2	.	.	O	.	_	0	SENT_93	[p3l1799t774r1902b805],

1	G1	NN	O	g1	nn	2	SENT_94	[p3l1799t774r1902b805],
2	phase	NN	O	phase	_	0	SENT_94	[p3l1915t772r1993b805],
3	arrest	NN	O	arrest	nn	4	SENT_94	[p3l1417t812r1513b843],
4	)	NN	O	)	nsubj	21	SENT_94	[p3l1417t812r1513b843],
5	,	,	O	,	_	0	SENT_94	[p3l1417t812r1513b843],
6	angiogenic	JJ	O	angiogenic	amod	12	SENT_94	[p3l1524t812r1673b843],
7	growth	NN	O	growth	nn	12	SENT_94	[p3l1683t810r1775b843],
8	factor	NN	O	factor	nn	12	SENT_94	[p3l1786t810r1864b835],
9	production	NN	O	production	nn	12	SENT_94	[p3l1875t810r2022b843],
10	(	CD	NUMBER	(	num	12	SENT_94	[p3l1419t849r1512b880],
11	VEGF	NN	O	vegf	nn	12	SENT_94	[p3l1419t849r1512b880],
12	)	NN	O	)	conj_and	4	SENT_94	[p3l1419t849r1512b880],
13	and	CC	O	and	_	0	SENT_94	[p3l1525t847r1572b873],
14	tumor-induced	JJ	O	tumor-induced	amod	15	SENT_94	[p3l1582t847r1781b873],
15	angiogenesis	NN	O	angiogenesis	conj_and	4	SENT_94	[p3l1792t850r1974b881],
16	,	,	O	,	_	0	SENT_94	[p3l1792t850r1974b881],
17	and	CC	O	and	_	0	SENT_94	[p3l1985t847r2032b873],
18	cancer-cell	NN	O	cancer-cell	nn	19	SENT_94	[p3l1416t885r1559b910],
19	invasion	NN	O	invasion	conj_and	4	SENT_94	[p3l1571t887r1692b915],
20	;	:	O	;	_	0	SENT_94	[p3l1571t887r1692b915],
21	potentiate	VB	O	potentiate	rcmod	2	SENT_94	[p3l1704t887r1841b918],
22	antitumor	NN	O	antitumor	nn	23	SENT_94	[p3l1851t887r1988b910],
23	activity	NN	O	activity	dobj	21	SENT_94	[p3l1997t894r2034b910, p3l1416t925r1480b955],
24	of	IN	O	of	_	0	SENT_94	[p3l1490t922r1519b948],
25	cytotoxic	JJ	O	cytotoxic	amod	26	SENT_94	[p3l1525t925r1644b955],
26	drugs	NNS	O	drug	prep_of	23	SENT_94	[p3l1653t922r1729b956],
27	and	CC	O	and	_	0	SENT_94	[p3l1740t922r1788b948],
28	radiotherapy	NN	O	radiotherapy	prep_of	23	SENT_94	[p3l1801t922r1972b955],
29	No	DT	O	no	det	30	SENT_94	[p3l1369t982r1407b1005],
30	(	NN	O	(	dep	2	SENT_94	[p3l1420t980r1548b1013],
31	although	IN	O	although	mark	39	SENT_94	[p3l1420t980r1548b1013],
32	irreversible	JJ	O	irreversible	amod	37	SENT_94	[p3l1561t980r1710b1005],
33	EG	NN	O	eg	nn	37	SENT_94	[p3l1722t982r1757b1005],
34	FR	NN	O	fr	nn	37	SENT_94	[p3l1764t982r1796b1005],
35	tyrosine	NN	O	tyrosine	nn	37	SENT_94	[p3l1805t982r1914b1013],
36	kinase	NN	O	kinase	nn	37	SENT_94	[p3l1925t980r2009b1005],
37	inhibitors	NNS	O	inhibitor	nsubj	39	SENT_94	[p3l1418t1018r1546b1043],
38	can	MD	O	can	aux	39	SENT_94	[p3l1557t1026r1602b1043],
39	cause	VB	O	cause	dep	30	SENT_94	[p3l1613t1026r1690b1043],
40	EGFR	NN	ORGANIZATION	egfr	nn	41	SENT_94	[p3l1703t1019r1776b1043],
41	degradation	NN	O	degradation	dobj	39	SENT_94	[p3l1786t1017r1949b1051],
42	and	CC	O	and	_	0	SENT_94	[p3l1417t1055r1465b1080],
43	subsequent	JJ	O	subsequent	amod	45	SENT_94	[p3l1477t1055r1635b1088],
44	EGFR	NN	ORGANIZATION	egfr	nn	45	SENT_94	[p3l1647t1057r1721b1080],
45	down-regulation	NN	O	down-regulation	dobj	39	SENT_94	[p3l1731t1055r1963b1088],
46	)	CD	NUMBER	)	dep	45	SENT_94	[p3l1731t1055r1963b1088],

1	Yes	UH	O	yes	_	0	SENT_95	[p3l1366t1115r1412b1138],

1	Yes	UH	O	yes	_	0	SENT_96	[p3l1366t1210r1420b1237],
2	,	,	O	,	_	0	SENT_96	[p3l1366t1210r1420b1237],
3	for	IN	O	for	dep	1	SENT_96	[p3l1431t1208r1469b1233],
4	most	JJS	O	most	amod	5	SENT_96	[p3l1479t1213r1547b1233],
5	mutations	NNS	O	mutation	pobj	3	SENT_96	[p3l1558t1210r1695b1233],
6	of	IN	O	of	_	0	SENT_96	[p3l1706t1208r1736b1233],
7	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_96	[p3l1743t1210r1817b1233],
8	tyrosine	NN	O	tyrosine	nn	12	SENT_96	[p3l1826t1210r1935b1241],
9	kinase	NN	O	kinase	nn	12	SENT_96	[p3l1946t1208r2030b1233],
10	domain	NN	O	domain	nn	12	SENT_96	[p3l1416t1245r1519b1271],
11	(	NN	O	(	nn	12	SENT_96	[p3l1533t1247r1666b1278],
12	mutation	NN	O	mutation	prep_of	1	SENT_96	[p3l1533t1247r1666b1278],
13	in	IN	O	in	_	0	SENT_96	[p3l1678t1248r1700b1270],
14	codons	NNS	O	codon	prep_in	12	SENT_96	[p3l1711t1245r1810b1271],
15	746-750	CD	NUMBER	746-750	num	14	SENT_96	[p3l1822t1247r1935b1271],
16	in	IN	O	in	_	0	SENT_96	[p3l1418t1285r1439b1308],
17	exon	NN	O	exon	prep_in	14	SENT_96	[p3l1451t1292r1512b1308],
18	19	CD	NUMBER	19	num	17	SENT_96	[p3l1525t1285r1554b1308],
19	and	CC	O	and	_	0	SENT_96	[p3l1565t1283r1613b1308],
20	L858R	NN	O	l858r	conj_and	14	SENT_96	[p3l1626t1284r1708b1308],
21	in	IN	O	in	_	0	SENT_96	[p3l1719t1285r1740b1308],
22	exon	NN	O	exon	nn	24	SENT_96	[p3l1752t1292r1813b1308],
23	21	CD	NUMBER	21	num	24	SENT_96	[p3l1825t1285r1875b1316],
24	)	NN	O	)	prep_in	20	SENT_96	[p3l1825t1285r1875b1316],
25	,	,	O	,	_	0	SENT_96	[p3l1825t1285r1875b1316],
26	since	IN	O	since	_	0	SENT_96	[p3l1887t1285r1956b1308],
27	these	DT	O	these	det	28	SENT_96	[p3l1965t1283r2038b1308],
28	EGFR	NN	ORGANIZATION	egfr	prep_since	12	SENT_96	[p3l1419t1322r1493b1346],
29	mutant	JJ	O	mutant	amod	30	SENT_96	[p3l1504t1325r1602b1346],
30	proteins	NNS	O	protein	nsubj	31	SENT_96	[p3l1613t1323r1723b1353],
31	bind	VBP	O	bind	rcmod	28	SENT_96	[p3l1735t1320r1792b1346],
32	with	IN	O	with	_	0	SENT_96	[p3l1802t1320r1858b1346],
33	higherafﬁnity	NN	O	higherafﬁnity	prep_with	31	SENT_96	[p3l1871t1320r2034b1354, p3l1418t1360r1447b1391],
34	small-molecule	JJ	O	small-molecule	amod	38	SENT_96	[p3l1457t1358r1664b1383],
35	EGFR	NN	ORGANIZATION	egfr	nn	38	SENT_96	[p3l1676t1360r1750b1383],
36	tyrosine	NN	O	tyrosine	nn	38	SENT_96	[p3l1759t1360r1868b1391],
37	kinase	NN	O	kinase	nn	38	SENT_96	[p3l1879t1358r1964b1383],
38	inhibitors	NNS	O	inhibitor	dep	33	SENT_96	[p3l1418t1395r1554b1425],
39	,	,	O	,	_	0	SENT_96	[p3l1418t1395r1554b1425],
40	such	JJ	O	such	_	0	SENT_96	[p3l1566t1395r1627b1421],
41	as	IN	O	as	_	0	SENT_96	[p3l1639t1404r1666b1421],
42	erlotinib	NN	O	erlotinib	prep_such_as	33	SENT_96	[p3l1677t1395r1790b1421],
43	or	CC	O	or	_	0	SENT_96	[p3l1800t1404r1828b1421],
44	geﬁtinib	NN	O	geﬁtinib	conj_or	42	SENT_96	[p3l1837t1395r1954b1429],
45	;	:	O	;	_	0	SENT_96	[p3l1837t1395r1954b1429],
46	no	DT	O	no	amod	33	SENT_96	[p3l1418t1442r1457b1463],
47	,	,	O	,	_	0	SENT_96	[p3l1418t1442r1457b1463],
48	for	IN	O	for	amod	33	SENT_96	[p3l1468t1433r1506b1458],
49	geﬁtinib	NN	O	geﬁtinib	pobj	48	SENT_96	[p3l1515t1433r1634b1466],
50	-	:	O	-	_	0	SENT_96	[p3l1515t1433r1634b1466],
51	or	CC	O	or	_	0	SENT_96	[p3l1644t1442r1672b1458],
52	erlotinib-acquired	JJ	O	erlotinib-acquired	amod	54	SENT_96	[p3l1681t1433r1921b1466],
53	EGFRresistance	NN	O	egfrresistance	nn	54	SENT_96	[p3l1934t1435r2018b1458, p3l1418t1473r1554b1496],
54	mutation	NN	O	mutation	conj_or	46	SENT_96	[p3l1565t1473r1687b1496],
55	(	CD	NUMBER	(	num	56	SENT_96	[p3l1701t1472r1803b1503],
56	T790M	NN	O	t790m	dep	54	SENT_96	[p3l1701t1472r1803b1503],
57	in	IN	O	in	_	0	SENT_96	[p3l1817t1473r1838b1495],
58	exon	NN	O	exon	nn	60	SENT_96	[p3l1850t1479r1911b1496],
59	20	CD	NUMBER	20	num	60	SENT_96	[p3l1923t1472r1973b1503],
60	)	NN	O	)	prep_in	33	SENT_96	[p3l1923t1472r1973b1503],
61	,	,	O	,	_	0	SENT_96	[p3l1923t1472r1973b1503],
62	although	IN	O	although	mark	77	SENT_96	[p3l1984t1470r2015b1496, p3l1415t1508r1512b1541],
63	several	JJ	O	several	amod	68	SENT_96	[p3l1524t1508r1615b1533],
64	new-generation	NN	O	new-generation	nn	68	SENT_96	[p3l1628t1510r1836b1541],
65	EGFR	NN	ORGANIZATION	egfr	nn	68	SENT_96	[p3l1850t1510r1924b1533],
66	tyrosine	NN	O	tyrosine	nn	68	SENT_96	[p3l1933t1510r2041b1541],
67	kinase	NN	O	kinase	nn	68	SENT_96	[p3l1418t1545r1502b1571],
68	inhibitors	NNS	O	inhibitor	nsubj	77	SENT_96	[p3l1513t1545r1642b1571],
69	that	WDT	O	that	nsubj	71	SENT_96	[p3l1651t1545r1705b1571],
70	are	VBP	O	be	cop	71	SENT_96	[p3l1715t1554r1755b1571],
71	active	JJ	O	active	rcmod	68	SENT_96	[p3l1765t1548r1843b1571],
72	against	IN	O	against	_	0	SENT_96	[p3l1853t1548r1951b1579],
73	mutant	JJ	O	mutant	amod	76	SENT_96	[p3l1962t1554r2013b1571, p3l1415t1588r1469b1608],
74	EG	NN	O	eg	nn	76	SENT_96	[p3l1481t1585r1516b1608],
75	FR	NN	O	fr	nn	76	SENT_96	[p3l1523t1585r1555b1608],
76	proteins	NNS	O	protein	prep_against	71	SENT_96	[p3l1566t1585r1676b1616],
77	are	VBP	O	be	advcl	31	SENT_96	[p3l1688t1592r1728b1608],
78	in	IN	O	in	_	0	SENT_96	[p3l1739t1585r1760b1608],
79	early	JJ	O	early	amod	81	SENT_96	[p3l1772t1583r1834b1616],
80	clinical	JJ	O	clinical	amod	81	SENT_96	[p3l1844t1583r1936b1608],
81	development	NN	O	development	prep_in	77	SENT_96	[p3l1947t1583r2026b1608, p3l1416t1625r1523b1653],
82	No	DT	O	no	dep	81	SENT_96	[p3l1369t1680r1407b1703],

1	*	JJ	O	*	amod	2	SENT_97	[p3l91t1915r106b1930],
2	EGFR	NN	ORGANIZATION	egfr	nsubj	3	SENT_97	[p3l119t1915r193b1938],
3	denotes	VBZ	O	denote	_	0	SENT_97	[p3l204t1913r311b1938],
4	epidermal	JJ	O	epidermal	amod	7	SENT_97	[p3l324t1913r459b1946],
5	growth	NN	O	growth	nn	7	SENT_97	[p3l472t1913r564b1946],
6	factor	NN	O	factor	nn	7	SENT_97	[p3l576t1913r655b1938],
7	receptor	NN	O	receptor	dobj	3	SENT_97	[p3l667t1918r785b1946],
8	,	,	O	,	_	0	SENT_97	[p3l667t1918r785b1946],
9	VEGF	NN	O	vegf	nn	13	SENT_97	[p3l797t1915r874b1938],
10	vascular	JJ	O	vascular	amod	13	SENT_97	[p3l885t1913r998b1938],
11	endothelial	JJ	O	endothelial	amod	13	SENT_97	[p3l1008t1913r1158b1938],
12	growth	NN	O	growth	nn	13	SENT_97	[p3l1171t1913r1264b1946],
13	factor	NN	O	factor	dobj	3	SENT_97	[p3l1276t1913r1361b1943],
14	,	,	O	,	_	0	SENT_97	[p3l1276t1913r1361b1943],
15	and	CC	O	and	_	0	SENT_97	[p3l1374t1913r1422b1938],
16	VEGFR	NNP	O	VEGFR	nn	18	SENT_97	[p3l1434t1915r1530b1938],
17	VEGF	NN	O	vegf	nn	18	SENT_97	[p3l1541t1915r1618b1938],
18	receptor	NN	O	receptor	conj_and	7	SENT_97	[p3l1631t1918r1749b1946],
19	.	.	O	.	_	0	SENT_97	[p3l1631t1918r1749b1946],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_98	[p3l256t2252r797b2311],
2	EFFICACY	NN	O	efficacy	_	0	SENT_98	[p3l850t2252r1375b2311],
3	OF	IN	O	of	_	0	SENT_98	[p3l1423t2252r1553b2311],
4	EGFR	NN	O	egfr	prep_of	2	SENT_98	[p3l1608t2252r1895b2311],

1	ANTAGONISTS	NNS	O	antagonist	_	0	SENT_99	[p3l54t2358r855b2418],
2	IN	IN	O	in	_	0	SENT_99	[p3l912t2359r1036b2418],
3	HUMAN	NNP	O	HUMAN	nn	4	SENT_99	[p3l1095t2359r1520b2419],
4	CANCERS	NNS	O	cancer	prep_in	1	SENT_99	[p3l1576t2359r2085b2418],

1	More	JJR	O	more	mwe	2	SENT_100	[p3l8t2585r227b2656],
2	than	IN	O	than	quantmod	3	SENT_100	[p3l278t2578r471b2656],
3	10	CD	NUMBER	10	num	5	SENT_100	[p3l524t2583r616b2656],
4	EGFR-targeting	JJ	O	egfr-targeting	amod	5	SENT_100	[p3l666t2579r1328b2679],
5	agents	NNS	O	agent	nsubj	6	SENT_100	[p3l1375t2594r1645b2679],
6	are	VBP	O	be	_	0	SENT_100	[p3l1696t2604r1824b2656],
7	in	IN	O	in	_	0	SENT_100	[p3l1873t2579r1956b2655],
8	advanced	JJ	O	advanced	amod	10	SENT_100	[p3l2006t2578r2133b2656, p3l6t2706r298b2785],
9	clinical	JJ	O	clinical	amod	10	SENT_100	[p3l341t2706r647b2784],
10	development	NN	O	development	prep_in	6	SENT_100	[p3l690t2706r1228b2806],
11	for	IN	O	for	_	0	SENT_100	[p3l1265t2705r1387b2784],
12	the	DT	O	the	det	13	SENT_100	[p3l1427t2706r1557b2784],
13	treatment	NN	O	treatment	prep_for	10	SENT_100	[p3l1601t2723r2015b2784],
14	of	IN	O	of	_	0	SENT_100	[p3l2054t2705r2153b2784],
15	various	JJ	O	various	amod	18	SENT_100	[p3l6t2835r310b2913],
16	human	JJ	O	human	amod	18	SENT_100	[p3l377t2834r677b2912],
17	cancer	NN	O	cancer	nn	18	SENT_100	[p3l743t2859r1019b2911],
18	types	NNS	O	type	prep_of	13	SENT_100	[p3l1081t2839r1638b2933],
19	.5	CD	NUMBER	.5	num	20	SENT_100	[p3l1081t2839r1638b2933],
20	’	NN	O	’	nsubj	30	SENT_100	[p3l1081t2839r1638b2933],
21	1	CD	NUMBER	1	num	23	SENT_100	[p3l1081t2839r1638b2933],
22	°	CD	NUMBER	°	num	23	SENT_100	[p3l1081t2839r1638b2933],
23	»	NN	O	»	dep	20	SENT_100	[p3l1081t2839r1638b2933],
24	11	CD	NUMBER	11	number	25	SENT_100	[p3l1081t2839r1638b2933],
25	’12	CD	NUMBER	’12	dep	20	SENT_100	[p3l1081t2839r1638b2933],
26	Two	CD	NUMBER	two	num	29	SENT_100	[p3l1700t2839r1874b2913],
27	antiEGFR	JJ	O	antiegfr	amod	29	SENT_100	[p3l1940t2835r2133b2911, p3l10t2967r263b3044],
28	monoclonal	JJ	O	monoclonal	amod	29	SENT_100	[p3l287t2962r791b3039],
29	antibodies	NNS	O	antibody	dep	25	SENT_100	[p3l826t2962r1267b3039],
30	(	VBP	O	(	rcmod	18	SENT_100	[p3l1309t2962r1776b3052],
31	cetuximab	NN	O	cetuximab	nn	34	SENT_100	[p3l1309t2962r1776b3052],
32	and	CC	O	and	_	0	SENT_100	[p3l1813t2962r1969b3039],
33	panitumumab	NN	O	panitumumab	nn	34	SENT_100	[p3l2003t2987r2132b3061, p3l11t3090r534b3180],
34	)	NN	O	)	nsubj	44	SENT_100	[p3l2003t2987r2132b3061, p3l11t3090r534b3180],
35	and	CC	O	and	_	0	SENT_100	[p3l592t3090r748b3167],
36	two	CD	NUMBER	two	num	43	SENT_100	[p3l802t3106r957b3168],
37	small-molecule	JJ	O	small-molecule	amod	43	SENT_100	[p3l1014t3090r1677b3185],
38	,	,	O	,	_	0	SENT_100	[p3l1014t3090r1677b3185],
39	reversible	JJ	O	reversible	amod	43	SENT_100	[p3l1736t3090r2134b3168],
40	EGFR	NN	ORGANIZATION	egfr	nn	43	SENT_100	[p3l10t3222r262b3300],
41	tyrosine	NN	O	tyrosine	nn	43	SENT_100	[p3l284t3218r623b3317],
42	kinase	NN	O	kinase	nn	43	SENT_100	[p3l655t3217r928b3296],
43	inhibitors	NNS	O	inhibitor	conj_and	34	SENT_100	[p3l959t3217r1372b3295],
44	(	VBP	O	(	ccomp	30	SENT_100	[p3l1411t3216r1804b3318],
45	geﬁtinib	NN	O	geﬁtinib	nsubjpass	51	SENT_100	[p3l1411t3216r1804b3318],
46	and	CC	O	and	_	0	SENT_100	[p3l1837t3217r1993b3295],
47	erlotinib	NN	O	erlotinib	nsubjpass	51	SENT_100	[p3l2025t3243r2132b3295, p3l10t3345r312b3435],
48	)	CD	NUMBER	)	num	47	SENT_100	[p3l2025t3243r2132b3295, p3l10t3345r312b3435],
49	have	VBP	O	have	aux	51	SENT_100	[p3l366t3345r553b3424],
50	been	VBN	O	be	auxpass	51	SENT_100	[p3l602t3345r800b3422],
51	approved	VBN	O	approve	ccomp	44	SENT_100	[p3l847t3345r1229b3444],
52	in	IN	O	in	_	0	SENT_100	[p3l1277t3346r1359b3421],
53	several	JJ	O	several	amod	54	SENT_100	[p3l1409t3345r1694b3424],
54	countries	NNS	O	country	prep_in	51	SENT_100	[p3l1742t3346r2131b3424],
55	for	IN	O	for	_	0	SENT_100	[p3l11t3473r132b3552],
56	the	DT	O	the	det	57	SENT_100	[p3l193t3474r324b3552],
57	treatment	NN	O	treatment	prep_for	54	SENT_100	[p3l388t3490r802b3552],
58	of	IN	O	of	_	0	SENT_100	[p3l862t3473r961b3552],
59	metastatic	JJ	O	metastatic	amod	61	SENT_100	[p3l1006t3475r1443b3552],
60	non	JJ	O	non	amod	61	SENT_100	[p3l1506t3474r2135b3552],
61	—	NN	O	—	prep_of	57	SENT_100	[p3l1506t3474r2135b3552],
62	small	JJ	O	small	amod	66	SENT_100	[p3l1506t3474r2135b3552],
63	—	NN	O	—	nn	66	SENT_100	[p3l1506t3474r2135b3552],
64	cell	NN	O	cell	nn	66	SENT_100	[p3l1506t3474r2135b3552],
65	lung	NN	O	lung	nn	66	SENT_100	[p3l6t3602r198b3704],
66	cancer	NN	O	cancer	dep	51	SENT_100	[p3l227t3628r522b3699],
67	,	,	O	,	_	0	SENT_100	[p3l227t3628r522b3699],
68	colorectal	JJ	O	colorectal	amod	69	SENT_100	[p3l560t3602r975b3682],
69	cancer	NN	O	cancer	appos	66	SENT_100	[p3l1007t3628r1301b3699],
70	,	,	O	,	_	0	SENT_100	[p3l1007t3628r1301b3699],
71	squamous	JJ	O	squamous	amod	74	SENT_100	[p3l1340t3602r1957b3703],
72	—	NN	O	—	nn	74	SENT_100	[p3l1340t3602r1957b3703],
73	cell	NN	O	cell	nn	74	SENT_100	[p3l1340t3602r1957b3703],
74	carcinoma	NN	O	carcinoma	appos	66	SENT_100	[p3l1989t3628r2148b3681, p4l8t22r324b101],

1	of	IN	O	of	_	0	SENT_101	[p4l355t20r454b101],
2	the	DT	O	the	det	3	SENT_101	[p4l468t21r600b101],
3	head	NN	O	head	pobj	1	SENT_101	[p4l632t21r833b101],
4	and	CC	O	and	_	0	SENT_101	[p4l864t21r1021b101],
5	neck	NN	O	neck	pobj	1	SENT_101	[p4l1053t21r1271b118],
6	,	,	O	,	_	0	SENT_101	[p4l1053t21r1271b118],
7	and	CC	O	and	_	0	SENT_101	[p4l1308t21r1465b101],
8	pancreatic	JJ	O	pancreatic	amod	9	SENT_101	[p4l1495t22r1937b122],
9	cancer	NN	O	cancer	dep	17	SENT_101	[p4l1969t47r2148b100, p4l8t176r134b228],
10	(	CD	NUMBER	(	num	11	SENT_101	[p4l163t150r418b241],
11	Table	NNP	O	Table	dep	9	SENT_101	[p4l163t150r418b241],
12	2	CD	NUMBER	2	num	11	SENT_101	[p4l446t155r718b241],
13	)	CD	NUMBER	)	num	14	SENT_101	[p4l446t155r718b241],
14	.2	NN	NUMBER	.2	dep	17	SENT_101	[p4l446t155r718b241],
15	°	CD	NUMBER	°	number	16	SENT_101	[p4l446t155r718b241],
16	'24	CD	NUMBER	'24	num	17	SENT_101	[p4l446t155r718b241],
17	(	NN	O	(	dep	34	SENT_101	[p4l750t156r920b241],
18	For	IN	O	for	_	0	SENT_101	[p4l750t156r920b241],
19	relevant	JJ	O	relevant	amod	21	SENT_101	[p4l945t150r1281b229],
20	clinical	JJ	O	clinical	amod	21	SENT_101	[p4l1304t150r1613b228],
21	studies	NNS	O	study	prep_for	17	SENT_101	[p4l1641t150r1937b229],
22	supporting	VBG	O	support	dep	34	SENT_101	[p4l1969t176r2148b250, p4l6t280r329b381],
23	the	DT	O	the	det	24	SENT_101	[p4l376t279r507b358],
24	use	NN	O	use	dobj	22	SENT_101	[p4l557t306r696b359],
25	of	IN	O	of	_	0	SENT_101	[p4l747t278r847b359],
26	anti-EGFR	JJ	O	anti-egfr	amod	27	SENT_101	[p4l877t280r1327b363],
27	drugs	NNS	O	drug	prep_of	24	SENT_101	[p4l1367t279r1608b381],
28	in	IN	O	in	_	0	SENT_101	[p4l1659t280r1742b357],
29	the	DT	O	the	det	32	SENT_101	[p4l1792t279r1924b358],
30	first	JJ	ORDINAL	first	amod	32	SENT_101	[p4l1973t278r2154b358],
31	three	CD	NUMBER	three	num	32	SENT_101	[p4l7t408r225b487],
32	conditions	NNS	O	condition	prep_in	22	SENT_101	[p4l255t408r725b504],
33	,	,	O	,	_	0	SENT_101	[p4l255t408r725b504],
34	see	VBP	O	see	conj_and	1	SENT_101	[p4l761t434r890b486],
35	Tables	NNS	O	table	dobj	34	SENT_101	[p4l915t408r1184b487],
36	1	CD	NUMBER	1	dep	35	SENT_101	[p4l1219t414r1286b504],
37	,	,	O	,	_	0	SENT_101	[p4l1219t414r1286b504],
38	2	CD	NUMBER	2	num	36	SENT_101	[p4l1319t414r1390b504],
39	,	,	O	,	_	0	SENT_101	[p4l1319t414r1390b504],
40	and	CC	NUMBER	and	_	0	SENT_101	[p4l1424t408r1581b487],
41	3	CD	NUMBER	3	conj_and	36	SENT_101	[p4l1611t414r1654b487],
42	in	IN	O	in	_	0	SENT_101	[p4l1686t409r1769b486],
43	the	DT	O	the	det	45	SENT_101	[p4l1798t408r1930b486],
44	Supplementary	NNP	O	Supplementary	nn	45	SENT_101	[p4l1961t414r2148b508, p4l6t538r490b639],
45	Appendix	NNP	O	Appendix	prep_in	36	SENT_101	[p4l522t538r955b639],
46	,	,	O	,	_	0	SENT_101	[p4l522t538r955b639],
47	available	JJ	O	available	rcmod	36	SENT_101	[p4l1001t538r1367b618],
48	with	IN	O	with	dep	47	SENT_101	[p4l1403t538r1597b618],
49	the	DT	O	the	det	51	SENT_101	[p4l1637t538r1769b617],
50	full	JJ	O	full	amod	51	SENT_101	[p4l1809t537r1955b618],
51	text	NN	O	text	pobj	48	SENT_101	[p4l1995t555r2154b617],
52	of	IN	O	of	_	0	SENT_101	[p4l8t666r108b747],
53	this	DT	O	this	det	54	SENT_101	[p4l122t667r280b746],
54	article	NN	O	article	prep_of	51	SENT_101	[p4l314t667r578b746],
55	at	IN	O	at	_	0	SENT_101	[p4l610t684r689b746],
56	www.nejm.org	NN	O	www.nejm.org	prep_at	54	SENT_101	[p4l712t668r1394b769],
57	.	.	O	.	_	0	SENT_101	[p4l712t668r1394b769],
58	)	SYM	O	)	dep	35	SENT_101	[p4l712t668r1394b769],

1	NON	NNP	O	NON	_	0	SENT_102	[p4l14t944r745b995],
2	.	.	O	.	_	0	SENT_102	[p4l14t944r745b995],

1	—	NN	O	—	_	0	SENT_103	[p4l14t944r745b995],
2	.	.	O	.	_	0	SENT_103	[p4l14t944r745b995],

1	SMALL-CELL	NN	O	small-cell	nn	2	SENT_104	[p4l14t944r745b995],
2	LUNG	NN	O	lung	_	0	SENT_104	[p4l782t944r997b995],
3	CANCER	NNP	O	CANCER	dep	2	SENT_104	[p4l1035t944r1352b995],

1	Phase	NN	O	phase	nsubj	4	SENT_105	[p4l6t1043r254b1122],
2	1	CD	NUMBER	1	num	3	SENT_105	[p4l288t1049r333b1121],
3	trials	NNS	O	trial	dep	1	SENT_105	[p4l366t1043r587b1122],
4	showed	VBD	O	show	_	0	SENT_105	[p4l622t1043r947b1123],
5	that	IN	O	that	complm	9	SENT_105	[p4l979t1043r1153b1122],
6	gefitinib	NN	O	gefitinib	nsubj	9	SENT_105	[p4l1179t1042r1554b1145],
7	and	CC	O	and	_	0	SENT_105	[p4l1586t1043r1745b1123],
8	erlotinib	NN	O	erlotinib	nsubj	9	SENT_105	[p4l1777t1043r2147b1123],
9	have	VBP	O	have	ccomp	4	SENT_105	[p4l7t1171r199b1250],
10	important	JJ	O	important	amod	12	SENT_105	[p4l243t1172r687b1271],
11	clinical	JJ	O	clinical	amod	12	SENT_105	[p4l727t1171r1044b1249],
12	activity	NN	O	activity	dobj	9	SENT_105	[p4l1087t1172r1399b1271],
13	in	IN	O	in	_	0	SENT_105	[p4l1439t1172r1523b1249],
14	patients	NNS	O	patient	prep_in	12	SENT_105	[p4l1565t1172r1910b1271],
15	with	IN	O	with	prep	9	SENT_105	[p4l1952t1171r2149b1251],

1	1162	CD	DATE	1162	num	4	SENT_106	[p4l149t1346r225b1368],
2	N	NN	O	n	nn	4	SENT_106	[p4l914t1357r927b1372],
3	ENGLJ	NN	O	englj	nn	4	SENT_106	[p4l942t1357r1020b1379],
4	MED	NN	O	med	_	0	SENT_106	[p4l1035t1357r1086b1372],
5	358	CD	NUMBER	358	num	7	SENT_106	[p4l1097t1351r1165b1379],
6	;	:	O	;	_	0	SENT_106	[p4l1097t1351r1165b1379],
7	11	CD	NUMBER	11	dep	4	SENT_106	[p4l1097t1351r1165b1379],
8	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	9	SENT_106	[p4l1201t1357r1402b1379],
9	MARCH	NNP	DATE	MARCH	dep	4	SENT_106	[p4l1439t1357r1524b1372],
10	13	CD	DATE	13	num	9	SENT_106	[p4l1538t1357r1570b1379],
11	,	,	DATE	,	_	0	SENT_106	[p4l1538t1357r1570b1379],
12	2008	CD	DATE	2008	num	9	SENT_106	[p4l1581t1351r1644b1373],

1	The	DT	O	the	det	4	SENT_107	[p4l935t1390r986b1414],
2	New	NNP	O	New	nn	4	SENT_107	[p4l995t1391r1057b1414],
3	England	NNP	O	England	nn	4	SENT_107	[p4l1066t1390r1177b1421],
4	Journal	NNP	O	Journal	_	0	SENT_107	[p4l1186t1390r1283b1414],
5	of	IN	O	of	_	0	SENT_107	[p4l1293t1390r1322b1414],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_107	[p4l1329t1390r1454b1414],

1	Downloaded	VBN	O	download	_	0	SENT_108	[p4l377t1431r547b1454],
2	from	IN	O	from	_	0	SENT_108	[p4l556t1431r621b1454],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_108	[p4l629t1431r748b1461],
4	at	IN	O	at	_	0	SENT_108	[p4l758t1435r781b1454],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_108	[p4l789t1431r972b1454],
6	on	IN	O	on	_	0	SENT_108	[p4l981t1438r1014b1454],
7	January	NNP	DATE	January	prep_on	1	SENT_108	[p4l1022t1431r1125b1461],
8	5	CD	DATE	5	num	7	SENT_108	[p4l1135t1431r1158b1458],
9	,	,	DATE	,	_	0	SENT_108	[p4l1135t1431r1158b1458],
10	2014	CD	DATE	2014	num	7	SENT_108	[p4l1168t1431r1240b1454],
11	.	.	O	.	_	0	SENT_108	[p4l1168t1431r1240b1454],

1	For	IN	O	for	_	0	SENT_109	[p4l1251t1431r1298b1454],
2	personal	JJ	O	personal	amod	3	SENT_109	[p4l1306t1431r1418b1461],
3	use	NN	O	use	pobj	1	SENT_109	[p4l1427t1438r1471b1454],
4	only	RB	O	only	advmod	3	SENT_109	[p4l1480t1431r1545b1461],
5	.	.	O	.	_	0	SENT_109	[p4l1480t1431r1545b1461],

1	No	DT	O	no	det	3	SENT_110	[p4l1556t1431r1595b1454],
2	other	JJ	O	other	amod	3	SENT_110	[p4l1605t1431r1673b1454],
3	uses	NNS	O	use	_	0	SENT_110	[p4l1682t1438r1738b1454],
4	without	IN	O	without	_	0	SENT_110	[p4l1748t1431r1849b1454],
5	permission	NN	O	permission	prep_without	3	SENT_110	[p4l1857t1431r2010b1461],
6	.	.	O	.	_	0	SENT_110	[p4l1857t1431r2010b1461],

1	Copyright	NN	O	copyright	_	0	SENT_111	[p4l728t1472r862b1503],
2	©	CD	NUMBER	©	num	6	SENT_111	[p4l871t1472r895b1496],
3	2008	CD	DATE	2008	num	6	SENT_111	[p4l905t1472r969b1496],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_111	[p4l979t1472r1170b1496],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_111	[p4l1180t1472r1288b1496],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_111	[p4l1299t1472r1404b1503],
7	.	.	O	.	_	0	SENT_111	[p4l1299t1472r1404b1503],

1	All	DT	O	all	det	2	SENT_112	[p4l1415t1472r1456b1496],
2	rights	NNS	O	rights	nsubj	3	SENT_112	[p4l1465t1472r1540b1503],
3	reserved	VBN	O	reserve	_	0	SENT_112	[p4l1550t1472r1668b1496],
4	.	.	O	.	_	0	SENT_112	[p4l1550t1472r1668b1496],

1	DRUG	NN	O	drug	_	0	SENT_113	[p4l807t1515r899b1534],
2	TH	NN	O	th	nn	3	SENT_113	[p4l911t1515r955b1534],
3	ERAPY	NN	O	erapy	dep	1	SENT_113	[p4l961t1515r1064b1534],

1	Table	NNP	O	Table	_	0	SENT_114	[p4l117t1636r191b1661],
2	2	CD	NUMBER	2	dep	1	SENT_114	[p4l200t1639r223b1661],
3	.	.	O	.	_	0	SENT_114	[p4l200t1639r223b1661],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_115	[p4l234t1638r310b1661],
2	Inhibitors	NNS	O	inhibitor	nsubj	4	SENT_115	[p4l321t1636r451b1661],
3	Currently	RB	DATE	currently	advmod	4	SENT_115	[p4l460t1636r587b1669],
4	Approved	VBN	O	approve	_	0	SENT_115	[p4l594t1636r726b1669],
5	for	IN	O	for	_	0	SENT_115	[p4l735t1636r774b1661],
6	Cancer	NNP	O	Cancer	nn	7	SENT_115	[p4l781t1638r877b1661],
7	Treatment	NN	O	treatment	prep_for	4	SENT_115	[p4l884t1638r1052b1661],
8	.	.	O	.	_	0	SENT_115	[p4l884t1638r1052b1661],

1	‘	SYM	O	‘	dep	3	SENT_116	[p4l884t1638r1052b1661],
2	-	:	O	-	_	0	SENT_116	[p4l884t1638r1052b1661],
3	"	``	O	"	_	0	SENT_116	[p4l884t1638r1052b1661],
4	‘	IN	O	‘	prep	3	SENT_116	[p4l884t1638r1052b1661],

1	Drug	NN	O	drug	nsubj	5	SENT_117	[p4l119t1714r187b1744],
2	Molecular	JJ	O	molecular	amod	3	SENT_117	[p4l471t1711r607b1737],
3	Properties	NNPS	O	Properties	nsubj	4	SENT_117	[p4l618t1712r755b1744],
4	Approved	VBD	O	approve	rcmod	1	SENT_117	[p4l1367t1711r1498b1744],
5	Uses	VBZ	O	use	_	0	SENT_117	[p4l1512t1714r1577b1737],
6	Erlotinib	NNP	O	Erlotinib	nn	9	SENT_117	[p4l120t1769r233b1794],
7	Reversible	JJ	O	reversible	amod	9	SENT_117	[p4l376t1769r513b1794],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_117	[p4l525t1771r599b1794],
9	tyrosine	NN	O	tyrosine	dobj	5	SENT_117	[p4l608t1771r717b1802],
10	kinase	NN	O	kinase	nn	11	SENT_117	[p4l728t1769r812b1794],
11	Erlotinib	NN	O	erlotinib	nsubjpass	14	SENT_117	[p4l905t1769r1018b1794],
12	has	VBZ	O	have	aux	14	SENT_117	[p4l1030t1769r1074b1794],
13	been	VBN	O	be	auxpass	14	SENT_117	[p4l1086t1769r1148b1794],
14	approved	VBN	O	approve	rcmod	9	SENT_117	[p4l1160t1769r1286b1802],
15	by	IN	O	by	_	0	SENT_117	[p4l1298t1769r1326b1802],
16	several	JJ	O	several	amod	18	SENT_117	[p4l1336t1769r1428b1794],
17	regulatory	JJ	O	regulatory	amod	18	SENT_117	[p4l1441t1769r1577b1802],
18	agencies	NNS	O	agency	agent	14	SENT_117	[p4l1586t1771r1703b1802],
19	worldwide	RB	O	worldwide	advmod	14	SENT_117	[p4l1713t1769r1860b1799],
20	,	,	O	,	_	0	SENT_117	[p4l1713t1769r1860b1799],
21	including	VBG	O	include	_	0	SENT_117	[p4l1872t1769r1998b1802],
22	inhibitor	NN	O	inhibitor	nn	24	SENT_117	[p4l425t1807r541b1832],
23	(	NN	O	(	nn	24	SENT_117	[p4l552t1807r822b1839],
24	quinazo	NN	O	quinazo	prep_including	5	SENT_117	[p4l552t1807r822b1839],
25	|	CD	NUMBER	|	num	26	SENT_117	[p4l552t1807r822b1839],
26	ine-deriva	NN	O	ine-deriva	dep	45	SENT_117	[p4l552t1807r822b1839],
27	-	:	O	-	_	0	SENT_117	[p4l552t1807r822b1839],
28	the	DT	O	the	det	29	SENT_117	[p4l952t1807r995b1832],
29	FDA	NNP	ORGANIZATION	FDA	dep	26	SENT_117	[p4l1007t1808r1064b1831],
30	and	CC	O	and	_	0	SENT_117	[p4l1074t1807r1122b1832],
31	the	DT	O	the	det	33	SENT_117	[p4l1132t1807r1175b1832],
32	EM	NNP	O	EM	nn	33	SENT_117	[p4l1187t1809r1227b1831],
33	EA	NN	O	ea	dep	26	SENT_117	[p4l1234t1808r1268b1831],
34	in	IN	O	in	_	0	SENT_117	[p4l1279t1809r1300b1831],
35	the	DT	O	the	det	37	SENT_117	[p4l1311t1807r1353b1832],
36	European	NNP	ORGANIZATION	European	nn	37	SENT_117	[p4l1365t1809r1492b1839],
37	Union	NNP	ORGANIZATION	Union	prep_in	33	SENT_117	[p4l1505t1809r1594b1836],
38	,	,	O	,	_	0	SENT_117	[p4l1505t1809r1594b1836],
39	as	IN	O	as	_	0	SENT_117	[p4l1606t1815r1633b1832],
40	monotherapy	NN	O	monotherapy	nn	41	SENT_117	[p4l1645t1807r1827b1840],
41	forthe	NN	O	forthe	prep_as	26	SENT_117	[p4l1836t1806r1924b1832],
42	treattive	JJ	O	treattive	amod	43	SENT_117	[p4l1933t1811r2004b1832, p4l423t1846r471b1869],
43	molecule	NN	O	molecule	dep	45	SENT_117	[p4l482t1844r614b1877],
44	)	CD	NUMBER	)	num	45	SENT_117	[p4l482t1844r614b1877],
45	ment	NN	O	ment	dep	24	SENT_117	[p4l955t1849r1024b1869],
46	of	IN	O	of	_	0	SENT_117	[p4l1033t1844r1063b1869],
47	non	JJ	O	non	amod	53	SENT_117	[p4l1070t1844r1266b1869],
48	—	JJ	O	—	amod	53	SENT_117	[p4l1070t1844r1266b1869],
49	small	JJ	O	small	amod	53	SENT_117	[p4l1070t1844r1266b1869],
50	—	NN	O	—	nn	53	SENT_117	[p4l1070t1844r1266b1869],
51	cell	NN	O	cell	nn	53	SENT_117	[p4l1070t1844r1266b1869],
52	lung	NN	O	lung	nn	53	SENT_117	[p4l1279t1844r1337b1877],
53	cancer	NN	O	cancer	prep_of	45	SENT_117	[p4l1346t1853r1435b1869],
54	that	WDT	O	that	nsubj	56	SENT_117	[p4l1443t1844r1497b1869],
55	is	VBZ	O	be	cop	56	SENT_117	[p4l1508t1846r1527b1869],
56	refractory	JJ	O	refractory	rcmod	24	SENT_117	[p4l1539t1844r1667b1877],
57	to	TO	O	to	_	0	SENT_117	[p4l1675t1849r1702b1869],
58	platinum-based	JJ	O	platinum-based	amod	59	SENT_117	[p4l1713t1844r1924b1877],
59	chemotherapy	NN	O	chemotherapy	prep_to	56	SENT_117	[p4l1936t1844r2037b1869, p4l952t1882r1061b1914],
60	.	.	O	.	_	0	SENT_117	[p4l1936t1844r2037b1869, p4l952t1882r1061b1914],

1	More	RBR	O	more	advmod	2	SENT_118	[p4l1074t1884r1144b1907],
2	recently	RB	DATE	recently	advmod	7	SENT_118	[p4l1155t1882r1266b1914],
3	,	,	O	,	_	0	SENT_118	[p4l1155t1882r1266b1914],
4	erlotinib	NN	O	erlotinib	nsubjpass	7	SENT_118	[p4l1277t1882r1390b1907],
5	has	VBZ	O	have	aux	7	SENT_118	[p4l1401t1882r1445b1907],
6	been	VBN	O	be	auxpass	7	SENT_118	[p4l1457t1882r1519b1907],
7	approved	VBN	O	approve	_	0	SENT_118	[p4l1531t1882r1657b1914],
8	by	IN	O	by	_	0	SENT_118	[p4l1669t1882r1698b1915],
9	the	DT	O	the	det	10	SENT_118	[p4l1706t1882r1749b1907],
10	FDA	NNP	ORGANIZATION	FDA	agent	7	SENT_118	[p4l1761t1883r1818b1906],
11	and	CC	O	and	_	0	SENT_118	[p4l1828t1882r1876b1907],
12	the	DT	O	the	det	14	SENT_118	[p4l1886t1882r1929b1907],
13	EM	NNP	O	EM	nn	14	SENT_118	[p4l1941t1884r1981b1906],
14	EA	NN	O	ea	conj_and	10	SENT_118	[p4l1988t1883r2022b1906],
15	for	IN	O	for	_	0	SENT_118	[p4l953t1919r991b1944],
16	use	NN	O	use	prep_for	7	SENT_118	[p4l1001t1928r1046b1944],
17	in	IN	O	in	_	0	SENT_118	[p4l1057t1921r1078b1944],
18	combination	NN	O	combination	prep_in	16	SENT_118	[p4l1090t1919r1261b1944],
19	with	IN	O	with	_	0	SENT_118	[p4l1272t1919r1328b1944],
20	gemcitabine	NN	O	gemcitabine	prep_with	7	SENT_118	[p4l1339t1919r1507b1952],
21	as	IN	O	as	_	0	SENT_118	[p4l1517t1928r1544b1944],
22	first	JJ	ORDINAL	first	amod	25	SENT_118	[p4l1554t1919r1666b1944],
23	—	NN	O	—	nn	25	SENT_118	[p4l1554t1919r1666b1944],
24	line	NN	O	line	nn	25	SENT_118	[p4l1554t1919r1666b1944],
25	treatment	NN	O	treatment	prep_as	20	SENT_118	[p4l1675t1924r1810b1944],
26	for	IN	O	for	_	0	SENT_118	[p4l1819t1919r1857b1944],
27	advanced	JJ	O	advanced	amod	29	SENT_118	[p4l1866t1919r1993b1944],
28	pancreatic	JJ	O	pancreatic	amod	29	SENT_118	[p4l955t1959r1095b1989],
29	cancer	NN	O	cancer	prep_for	25	SENT_118	[p4l1104t1965r1200b1982],
30	.	.	O	.	_	0	SENT_118	[p4l1104t1965r1200b1982],

1	Reversible	JJ	O	reversible	amod	5	SENT_119	[p4l376t2014r513b2039],
2	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_119	[p4l525t2016r599b2039],
3	tyrosine	NN	O	tyrosine	nn	5	SENT_119	[p4l608t2017r717b2047],
4	kinase	NN	O	kinase	nn	5	SENT_119	[p4l728t2014r813b2039],
5	Geﬁtinib	NNP	O	Geﬁtinib	nsubjpass	8	SENT_119	[p4l903t2014r1020b2039],
6	has	VBZ	O	have	aux	8	SENT_119	[p4l1032t2014r1076b2039],
7	been	VBN	O	be	auxpass	8	SENT_119	[p4l1088t2014r1150b2039],
8	approved	VBN	O	approve	_	0	SENT_119	[p4l1162t2014r1287b2047],
9	in	IN	O	in	_	0	SENT_119	[p4l1300t2017r1321b2039],
10	various	JJ	O	various	amod	11	SENT_119	[p4l1332t2017r1431b2039],
11	countries	NNS	O	country	prep_in	8	SENT_119	[p4l1442t2017r1568b2039],
12	for	IN	O	for	_	0	SENT_119	[p4l1578t2014r1616b2039],
13	use	NN	O	use	prep_for	11	SENT_119	[p4l1626t2023r1671b2039],
14	as	IN	O	as	_	0	SENT_119	[p4l1681t2023r1709b2039],
15	third-line	JJ	O	third-line	amod	16	SENT_119	[p4l1718t2014r1842b2039],
16	treatment	NN	O	treatment	prep_as	8	SENT_119	[p4l1851t2019r1986b2039],
17	of	IN	O	of	_	0	SENT_119	[p4l1996t2014r2025b2039],
18	inhibitor	NN	O	inhibitor	nn	20	SENT_119	[p4l425t2052r540b2077],
19	(	NN	O	(	nn	20	SENT_119	[p4l552t2052r822b2085],
20	quinazoline-deriva	NN	O	quinazoline-deriva	prep_of	16	SENT_119	[p4l552t2052r822b2085],
21	-	:	O	-	_	0	SENT_119	[p4l552t2052r822b2085],
22	non	JJ	O	non	amod	28	SENT_119	[p4l955t2052r1151b2077],
23	—	JJ	O	—	amod	28	SENT_119	[p4l955t2052r1151b2077],
24	small	JJ	O	small	amod	28	SENT_119	[p4l955t2052r1151b2077],
25	—	NN	O	—	nn	28	SENT_119	[p4l955t2052r1151b2077],
26	cell	NN	O	cell	nn	28	SENT_119	[p4l955t2052r1151b2077],
27	lung	NN	O	lung	nn	28	SENT_119	[p4l1164t2052r1222b2085],
28	cancer	NN	O	cancer	dep	20	SENT_119	[p4l1231t2061r1320b2077],
29	that	WDT	O	that	nsubj	31	SENT_119	[p4l1328t2052r1382b2077],
30	is	VBZ	O	be	cop	31	SENT_119	[p4l1393t2054r1412b2077],
31	refractory	JJ	O	refractory	rcmod	28	SENT_119	[p4l1424t2051r1552b2085],
32	to	TO	O	to	_	0	SENT_119	[p4l1560t2057r1587b2077],
33	platinum-based	JJ	O	platinum-based	amod	36	SENT_119	[p4l1598t2052r1809b2085],
34	and	CC	O	and	_	0	SENT_119	[p4l1821t2052r1869b2077],
35	docetaxe	JJ	O	docetaxe	amod	36	SENT_119	[p4l1880t2052r2017b2077, p4l423t2092r471b2114],
36	|	NN	O	|	prep_to	31	SENT_119	[p4l1880t2052r2017b2077, p4l423t2092r471b2114],
37	tive	JJ	O	tive	amod	39	SENT_119	[p4l1880t2052r2017b2077, p4l423t2092r471b2114],
38	molecule	NN	O	molecule	nn	39	SENT_119	[p4l482t2089r614b2122],
39	)	NN	O	)	dep	36	SENT_119	[p4l482t2089r614b2122],
40	based	VBN	O	base	partmod	39	SENT_119	[p4l955t2089r1032b2114],
41	chemotherapy	NN	O	chemotherapy	nn	42	SENT_119	[p4l1043t2089r1238b2122],
42	regimens	NNS	O	regimen	dobj	40	SENT_119	[p4l1249t2092r1382b2122],
43	.	.	O	.	_	0	SENT_119	[p4l1249t2092r1382b2122],

1	After	IN	O	after	_	0	SENT_120	[p4l1392t2089r1458b2114],
2	an	DT	O	a	det	5	SENT_120	[p4l1467t2098r1497b2114],
3	accelerated	VBN	O	accelerate	amod	5	SENT_120	[p4l1509t2089r1661b2114],
4	approval	NN	O	approval	nn	5	SENT_120	[p4l1672t2089r1788b2122],
5	process	NN	O	process	prep_after	9	SENT_120	[p4l1801t2098r1912b2122],
6	,	,	O	,	_	0	SENT_120	[p4l1801t2098r1912b2122],
7	it	PRP	O	it	nsubjpass	9	SENT_120	[p4l1924t2092r1940b2114],
8	was	VBD	O	be	auxpass	9	SENT_120	[p4l1948t2098r1999b2114],
9	approved	VBN	O	approve	_	0	SENT_120	[p4l954t2127r1079b2160],
10	by	IN	O	by	_	0	SENT_120	[p4l1092t2127r1120b2160],
11	the	DT	O	the	det	12	SENT_120	[p4l1128t2127r1171b2152],
12	FDA	NNP	ORGANIZATION	FDA	agent	9	SENT_120	[p4l1183t2128r1240b2152],
13	in	IN	O	in	_	0	SENT_120	[p4l1251t2129r1272b2152],
14	May	NNP	DATE	May	prep_in	9	SENT_120	[p4l1286t2129r1341b2160],
15	2003	CD	DATE	2003	num	14	SENT_120	[p4l1350t2128r1413b2152],
16	but	CC	O	but	_	0	SENT_120	[p4l1426t2127r1469b2152],
17	has	VBZ	O	have	aux	19	SENT_120	[p4l1479t2127r1524b2152],
18	been	VBN	O	be	auxpass	19	SENT_120	[p4l1536t2127r1598b2152],
19	withheld	VBN	O	withhold	conj_but	9	SENT_120	[p4l1608t2127r1724b2152],
20	from	IN	O	from	_	0	SENT_120	[p4l1735t2126r1798b2152],
21	the	DT	O	the	det	23	SENT_120	[p4l1809t2127r1851b2152],
22	U.S.	NNP	LOCATION	U.S.	nn	23	SENT_120	[p4l1863t2129r1916b2152],
23	market	NN	O	market	prep_from	19	SENT_120	[p4l1928t2127r2021b2152],
24	sincejune	JJ	O	sincejune	amod	23	SENT_120	[p4l954t2167r1092b2197],
25	2005	CD	DATE	2005	tmod	24	SENT_120	[p4l1102t2166r1174b2194],
26	,	,	O	,	_	0	SENT_120	[p4l1102t2166r1174b2194],
27	as	IN	O	as	mark	35	SENT_120	[p4l1185t2173r1213b2189],
28	a	DT	O	a	det	31	SENT_120	[p4l1224t2173r1237b2189],
29	result	NN	O	result	nn	31	SENT_120	[p4l1249t2164r1324b2189],
30	ofthe	NN	O	ofthe	nn	31	SENT_120	[p4l1333t2164r1410b2189],
31	release	NN	O	release	nsubj	35	SENT_120	[p4l1421t2164r1514b2189],
32	of	IN	O	of	_	0	SENT_120	[p4l1524t2164r1554b2189],
33	preliminary	JJ	O	preliminary	amod	34	SENT_120	[p4l1561t2164r1714b2197],
34	results	NNS	O	result	prep_of	31	SENT_120	[p4l1725t2164r1813b2189],
35	ofthe	VBP	O	ofthe	advcl	19	SENT_120	[p4l1824t2164r1901b2189],
36	ISEL	NN	O	isel	nn	37	SENT_120	[p4l1913t2166r1971b2189],
37	trial	NN	O	trial	dobj	35	SENT_120	[p4l1980t2164r2039b2194],
38	,	,	O	,	_	0	SENT_120	[p4l1980t2164r2039b2194],
39	which	WDT	O	which	nsubj	40	SENT_120	[p4l952t2202r1031b2227],
40	assessed	VBD	O	assess	rcmod	37	SENT_120	[p4l1042t2202r1163b2227],
41	its	PRP$	O	its	poss	42	SENT_120	[p4l1176t2204r1205b2227],
42	use	NN	O	use	dobj	40	SENT_120	[p4l1217t2211r1262b2227],
43	in	IN	O	in	_	0	SENT_120	[p4l1273t2204r1295b2227],
44	patients	NNS	O	patient	prep_in	40	SENT_120	[p4l1308t2204r1415b2235],
45	with	IN	O	with	_	0	SENT_120	[p4l1424t2202r1480b2227],
46	non	JJ	O	non	amod	52	SENT_120	[p4l1493t2202r1689b2227],
47	—	JJ	O	—	amod	52	SENT_120	[p4l1493t2202r1689b2227],
48	small	JJ	O	small	amod	52	SENT_120	[p4l1493t2202r1689b2227],
49	—	NN	O	—	nn	52	SENT_120	[p4l1493t2202r1689b2227],
50	cell	NN	O	cell	nn	52	SENT_120	[p4l1493t2202r1689b2227],
51	lung	NN	O	lung	nn	52	SENT_120	[p4l1702t2202r1760b2235],
52	cancer	NN	O	cancer	prep_with	40	SENT_120	[p4l1770t2211r1859b2227],
53	that	WDT	O	that	nsubj	55	SENT_120	[p4l1867t2202r1921b2227],
54	was	VBD	O	be	cop	55	SENT_120	[p4l1929t2211r1980b2227],
55	refractory	JJ	O	refractory	rcmod	52	SENT_120	[p4l1992t2211r2025b2227, p4l953t2239r1056b2272],
56	to	TO	O	to	_	0	SENT_120	[p4l1064t2244r1091b2264],
57	previous	JJ	O	previous	amod	59	SENT_120	[p4l1102t2242r1217b2272],
58	platinum-based	JJ	O	platinum-based	amod	59	SENT_120	[p4l1229t2239r1440b2272],
59	chemotherapy	NN	O	chemotherapy	prep_to	55	SENT_120	[p4l1451t2239r1653b2272],
60	.	.	O	.	_	0	SENT_120	[p4l1451t2239r1653b2272],

1	Geﬁtinib	NNP	O	Geﬁtinib	nsubjpass	5	SENT_121	[p4l1664t2239r1781b2264],
2	has	VBZ	O	have	aux	5	SENT_121	[p4l1793t2239r1837b2264],
3	never	RB	O	never	neg	5	SENT_121	[p4l1849t2248r1922b2264],
4	been	VBN	O	be	auxpass	5	SENT_121	[p4l1932t2239r1994b2264],
5	approved	VBN	O	approve	_	0	SENT_121	[p4l954t2277r1079b2310],
6	in	IN	O	in	_	0	SENT_121	[p4l1092t2279r1113b2302],
7	the	DT	O	the	det	9	SENT_121	[p4l1124t2277r1166b2302],
8	European	NNP	ORGANIZATION	European	nn	9	SENT_121	[p4l1178t2279r1305b2310],
9	Union	NNP	ORGANIZATION	Union	prep_in	5	SENT_121	[p4l1318t2279r1399b2302],
10	but	CC	O	but	_	0	SENT_121	[p4l1411t2277r1454b2302],
11	is	VBZ	O	be	conj_but	5	SENT_121	[p4l1465t2279r1484b2302],
12	currently	RB	DATE	currently	advmod	11	SENT_121	[p4l1495t2277r1614b2310],
13	on	IN	O	on	_	0	SENT_121	[p4l1623t2286r1656b2302],
14	the	DT	O	the	det	16	SENT_121	[p4l1666t2277r1709b2302],
15	market	NN	O	market	nn	16	SENT_121	[p4l1720t2277r1813b2302],
16	injapan	NN	O	injapan	prep_on	11	SENT_121	[p4l1824t2279r1940b2310],
17	,	,	O	,	_	0	SENT_121	[p4l1824t2279r1940b2310],
18	Korea	NNP	LOCATION	Korea	prep_on	11	SENT_121	[p4l1953t2279r2035b2306],
19	,	,	O	,	_	0	SENT_121	[p4l1953t2279r2035b2306],
20	China	NNP	LOCATION	China	prep_on	11	SENT_121	[p4l953t2314r1038b2344],
21	,	,	O	,	_	0	SENT_121	[p4l953t2314r1038b2344],
22	and	CC	O	and	_	0	SENT_121	[p4l1050t2314r1098b2339],
23	several	JJ	O	several	amod	26	SENT_121	[p4l1110t2314r1202b2339],
24	other	JJ	O	other	amod	26	SENT_121	[p4l1213t2314r1285b2339],
25	Asian	JJ	LOCATION	asian	amod	26	SENT_121	[p4l1293t2316r1367b2339],
26	countries	NNS	O	country	prep_on	11	SENT_121	[p4l1379t2317r1513b2339],
27	.	.	O	.	_	0	SENT_121	[p4l1379t2317r1513b2339],

1	It	PRP	O	it	nsubj	6	SENT_122	[p4l1526t2317r1542b2339],
2	is	VBZ	O	be	cop	6	SENT_122	[p4l1553t2317r1572b2339],
3	currently	RB	DATE	currently	advmod	6	SENT_122	[p4l1583t2314r1702b2347],
4	an	DT	O	a	det	6	SENT_122	[p4l1712t2323r1742b2339],
5	investigational	JJ	O	investigational	amod	6	SENT_122	[p4l1754t2314r1951b2347],
6	drug	NN	O	drug	_	0	SENT_122	[p4l1962t2314r2025b2347],
7	in	IN	O	in	_	0	SENT_122	[p4l954t2354r976b2377],
8	the	DT	O	the	det	10	SENT_122	[p4l986t2352r1029b2377],
9	United	NNP	LOCATION	United	nn	10	SENT_122	[p4l1041t2352r1129b2377],
10	States	NNPS	LOCATION	States	prep_in	6	SENT_122	[p4l1141t2354r1222b2377],
11	and	CC	O	and	_	0	SENT_122	[p4l1233t2352r1281b2377],
12	the	DT	O	the	det	14	SENT_122	[p4l1292t2352r1334b2377],
13	European	NNP	ORGANIZATION	European	nn	14	SENT_122	[p4l1346t2354r1473b2385],
14	Union	NNP	ORGANIZATION	Union	prep_in	6	SENT_122	[p4l1486t2354r1575b2377],
15	.	.	O	.	_	0	SENT_122	[p4l1486t2354r1575b2377],

1	Cetuximab	NNP	O	Cetuximab	nn	2	SENT_123	[p4l118t2409r263b2435],
2	Human	NNP	O	Human	_	0	SENT_123	[p4l376t2412r589b2435],
3	—	CD	NUMBER	—	num	6	SENT_123	[p4l376t2412r589b2435],
4	mouse	NN	O	mouse	nn	6	SENT_123	[p4l376t2412r589b2435],
5	chimeric	JJ	O	chimeric	amod	6	SENT_123	[p4l599t2409r717b2435],
6	mono	NN	O	mono	nsubjpass	11	SENT_123	[p4l727t2418r815b2435],
7	-	:	O	-	_	0	SENT_123	[p4l727t2418r815b2435],
8	Cetuximab	NNP	O	Cetuximab	nsubjpass	11	SENT_123	[p4l903t2409r1048b2435],
9	has	VBZ	O	have	aux	11	SENT_123	[p4l1060t2409r1104b2435],
10	been	VBN	O	be	auxpass	11	SENT_123	[p4l1116t2409r1178b2435],
11	approved	VBN	O	approve	rcmod	2	SENT_123	[p4l1190t2409r1316b2442],
12	by	IN	O	by	_	0	SENT_123	[p4l1328t2409r1356b2442],
13	several	JJ	O	several	amod	15	SENT_123	[p4l1366t2409r1458b2435],
14	regulatory	JJ	O	regulatory	amod	15	SENT_123	[p4l1471t2409r1607b2443],
15	agencies	NNS	O	agency	agent	11	SENT_123	[p4l1616t2412r1733b2443],
16	worldwide	RB	O	worldwide	advmod	11	SENT_123	[p4l1743t2409r1890b2439],
17	,	,	O	,	_	0	SENT_123	[p4l1743t2409r1890b2439],
18	including	VBG	O	include	_	0	SENT_123	[p4l1902t2409r2028b2443],
19	clonal	JJ	O	clonal	amod	20	SENT_123	[p4l424t2447r503b2472],
20	antibody	NN	O	antibody	prep_including	11	SENT_123	[p4l515t2447r632b2480],
21	(	CD	NUMBER	(	num	22	SENT_123	[p4l644t2449r717b2480],
22	|	NN	O	|	dep	27	SENT_123	[p4l644t2449r717b2480],
23	gG1	NN	O	gg1	dep	22	SENT_123	[p4l644t2449r717b2480],
24	subtype	NN	O	subtype	dep	27	SENT_123	[p4l729t2447r844b2480],
25	)	CD	NUMBER	)	num	24	SENT_123	[p4l729t2447r844b2480],
26	the	DT	O	the	det	27	SENT_123	[p4l952t2447r995b2472],
27	FDA	NNP	ORGANIZATION	FDA	dep	38	SENT_123	[p4l1007t2449r1064b2472],
28	and	CC	O	and	_	0	SENT_123	[p4l1074t2447r1122b2472],
29	the	DT	O	the	det	31	SENT_123	[p4l1132t2447r1175b2472],
30	EM	NNP	O	EM	nn	31	SENT_123	[p4l1187t2449r1227b2472],
31	EA	NN	O	ea	dep	38	SENT_123	[p4l1234t2449r1275b2477],
32	,	,	O	,	_	0	SENT_123	[p4l1234t2449r1275b2477],
33	for	IN	O	for	dep	35	SENT_123	[p4l1285t2447r1323b2472],
34	the	DT	O	the	det	35	SENT_123	[p4l1331t2447r1374b2472],
35	treatment	NN	O	treatment	dep	38	SENT_123	[p4l1383t2452r1518b2472],
36	ofadvanced	JJ	O	ofadvanced	amod	38	SENT_123	[p4l1527t2447r1690b2472],
37	colorectal	JJ	O	colorectal	amod	38	SENT_123	[p4l1701t2447r1831b2472],
38	cancer	NN	O	cancer	dep	2	SENT_123	[p4l1843t2456r1932b2472],
39	that	WDT	O	that	nsubj	41	SENT_123	[p4l1940t2447r1994b2472],
40	is	VBZ	O	be	cop	41	SENT_123	[p4l2004t2449r2023b2472],
41	refractory	JJ	O	refractory	rcmod	38	SENT_123	[p4l955t2484r1083b2517],
42	to	TO	O	to	_	0	SENT_123	[p4l1091t2489r1118b2510],
43	irinotecan-based	JJ	O	irinotecan-based	amod	45	SENT_123	[p4l1129t2484r1354b2510],
44	chemotherapy	NN	O	chemotherapy	nn	45	SENT_123	[p4l1365t2484r1561b2517],
45	(	NN	O	(	prep_to	41	SENT_123	[p4l1573t2484r1655b2517],
46	alone	RB	O	alone	dep	45	SENT_123	[p4l1573t2484r1655b2517],
47	or	CC	O	or	_	0	SENT_123	[p4l1665t2493r1693b2510],
48	in	IN	O	in	conj_or	46	SENT_123	[p4l1703t2487r1724b2509],
49	combination	NN	O	combination	pobj	48	SENT_123	[p4l1736t2484r1907b2510],
50	with	IN	O	with	_	0	SENT_123	[p4l1918t2484r1974b2510],
51	irinotecan	NN	O	irinotecan	prep_with	41	SENT_123	[p4l1986t2487r2020b2509, p4l955t2527r1060b2547],
52	in	IN	O	in	_	0	SENT_123	[p4l1073t2524r1094b2547],
53	the	DT	O	the	det	55	SENT_123	[p4l1105t2522r1147b2547],
54	United	NNP	LOCATION	United	nn	55	SENT_123	[p4l1159t2522r1247b2547],
55	States	NNPS	LOCATION	States	prep_in	51	SENT_123	[p4l1259t2524r1341b2547],
56	but	CC	O	but	_	0	SENT_123	[p4l1353t2522r1396b2547],
57	only	RB	O	only	_	0	SENT_123	[p4l1405t2522r1461b2555],
58	in	IN	O	in	_	0	SENT_123	[p4l1471t2524r1493b2547],
59	combination	NN	O	combination	prep_in	41	SENT_123	[p4l1504t2522r1676b2547],
60	with	IN	O	with	_	0	SENT_123	[p4l1686t2522r1742b2547],
61	irinotecan	NN	O	irinotecan	prep_with	59	SENT_123	[p4l1755t2524r1888b2547],
62	in	IN	O	in	_	0	SENT_123	[p4l1901t2524r1922b2547],
63	the	DT	O	the	det	66	SENT_123	[p4l1933t2522r1976b2547],
64	European	NNP	ORGANIZATION	European	nn	66	SENT_123	[p4l955t2562r1082b2592],
65	Union	NNP	ORGANIZATION	Union	nn	66	SENT_123	[p4l1095t2561r1197b2592],
66	)	NN	O	)	prep_in	61	SENT_123	[p4l1095t2561r1197b2592],
67	.	.	O	.	_	0	SENT_123	[p4l1095t2561r1197b2592],

1	Cetuximab	NNP	O	Cetuximab	nsubjpass	8	SENT_124	[p4l1208t2559r1353b2585],
2	in	IN	O	in	_	0	SENT_124	[p4l1364t2562r1386b2584],
3	combination	NN	O	combination	prep_in	1	SENT_124	[p4l1397t2559r1568b2585],
4	with	IN	O	with	_	0	SENT_124	[p4l1579t2559r1635b2585],
5	radiotherapy	NN	O	radiotherapy	prep_with	3	SENT_124	[p4l1648t2559r1818b2592],
6	is	VBZ	O	be	auxpass	8	SENT_124	[p4l1829t2562r1848b2585],
7	also	RB	O	also	advmod	8	SENT_124	[p4l1859t2559r1913b2585],
8	approved	VBN	O	approve	_	0	SENT_124	[p4l1923t2568r1964b2592, p4l955t2597r1045b2630],
9	for	IN	O	for	mark	13	SENT_124	[p4l1056t2597r1094b2622],
10	the	DT	O	the	det	11	SENT_124	[p4l1102t2597r1144b2622],
11	treatment	NN	O	treatment	nsubj	13	SENT_124	[p4l1153t2602r1288b2622],
12	oflocally	RB	O	oflocally	advmod	13	SENT_124	[p4l1298t2597r1417b2630],
13	advanced	VBD	O	advance	advcl	8	SENT_124	[p4l1427t2597r1554b2622],
14	squamous-cell	JJ	O	squamous-cell	amod	16	SENT_124	[p4l1566t2597r1762b2630],
15	carcinoma	NN	O	carcinoma	nn	16	SENT_124	[p4l1774t2599r1916b2622],
16	ofthe	NN	O	ofthe	dobj	13	SENT_124	[p4l1926t2597r2003b2622],
17	head	NN	O	head	advmod	13	SENT_124	[p4l954t2634r1017b2660],
18	and	CC	O	and	_	0	SENT_124	[p4l1029t2634r1077b2660],
19	neck	NN	O	neck	advmod	13	SENT_124	[p4l1089t2634r1157b2660],
20	.	.	O	.	_	0	SENT_124	[p4l1089t2634r1157b2660],

1	Panitumumab	NNP	O	Panitumumab	nn	5	SENT_125	[p4l120t2692r313b2717],
2	Fully	RB	O	fully	advmod	5	SENT_125	[p4l376t2692r437b2725],
3	human	JJ	O	human	amod	5	SENT_125	[p4l448t2692r541b2717],
4	monoclonal	JJ	O	monoclonal	amod	5	SENT_125	[p4l554t2692r713b2717],
5	antibody	NN	O	antibody	nsubjpass	9	SENT_125	[p4l725t2692r843b2725],
6	Panitumumab	NNP	LOCATION	Panitumumab	dep	5	SENT_125	[p4l905t2692r1098b2717],
7	has	VBZ	O	have	aux	9	SENT_125	[p4l1109t2692r1154b2717],
8	been	VBN	O	be	auxpass	9	SENT_125	[p4l1166t2692r1228b2717],
9	approved	VBN	O	approve	_	0	SENT_125	[p4l1239t2692r1365b2725],
10	by	IN	O	by	_	0	SENT_125	[p4l1378t2692r1406b2725],
11	several	JJ	O	several	amod	13	SENT_125	[p4l1416t2692r1507b2717],
12	regulatory	JJ	O	regulatory	amod	13	SENT_125	[p4l1520t2692r1656b2725],
13	agencies	NNS	O	agency	agent	9	SENT_125	[p4l1665t2694r1782b2725],
14	worldwide	RB	O	worldwide	advmod	13	SENT_125	[p4l1792t2692r1939b2722],
15	,	,	O	,	_	0	SENT_125	[p4l1792t2692r1939b2722],
16	includ	NN	O	includ	nn	19	SENT_125	[p4l1951t2692r2042b2717, p4l427t2731r519b2763],
17	(	CD	NUMBER	(	num	19	SENT_125	[p4l1951t2692r2042b2717, p4l427t2731r519b2763],
18	|	NN	O	|	nn	19	SENT_125	[p4l1951t2692r2042b2717, p4l427t2731r519b2763],
19	gG2	NN	O	gg2	appos	13	SENT_125	[p4l1951t2692r2042b2717, p4l427t2731r519b2763],
20	:	:	O	:	_	0	SENT_125	[p4l1951t2692r2042b2717, p4l427t2731r519b2763],
21	<	JJR	O	<	amod	22	SENT_125	[p4l1951t2692r2042b2717, p4l427t2731r519b2763],
22	subtype	NN	O	subtype	dep	19	SENT_125	[p4l530t2729r645b2762],
23	)	CD	NUMBER	)	dep	22	SENT_125	[p4l530t2729r645b2762],
24	ing	VBG	O	ing	xcomp	9	SENT_125	[p4l954t2732r995b2763],
25	the	DT	O	the	det	26	SENT_125	[p4l1003t2729r1046b2755],
26	FDA	NNP	ORGANIZATION	FDA	dobj	24	SENT_125	[p4l1058t2731r1122b2759],
27	,	,	O	,	_	0	SENT_125	[p4l1058t2731r1122b2759],
28	as	IN	O	as	_	0	SENT_125	[p4l1133t2738r1161b2755],
29	monotherapy	NN	O	monotherapy	prep_as	9	SENT_125	[p4l1173t2729r1355b2762],
30	for	IN	O	for	_	0	SENT_125	[p4l1363t2729r1401b2755],
31	third-line	JJ	O	third-line	amod	34	SENT_125	[p4l1409t2729r1532b2755],
32	treatment	NN	O	treatment	nn	34	SENT_125	[p4l1541t2734r1676b2755],
33	ofcolorectal	JJ	O	ofcolorectal	amod	34	SENT_125	[p4l1686t2729r1851b2755],
34	cancer	NN	O	cancer	prep_for	29	SENT_125	[p4l1863t2738r1952b2755],
35	that	WDT	O	that	nsubj	37	SENT_125	[p4l1960t2729r2013b2755],
36	is	VBZ	O	be	cop	37	SENT_125	[p4l954t2769r973b2792],
37	refractory	JJ	O	refractory	rcmod	34	SENT_125	[p4l986t2767r1114b2800],
38	to	TO	O	to	_	0	SENT_125	[p4l1122t2772r1148b2792],
39	ﬂuoropyrimidines	NNS	O	ﬂuoropyrimidines	prep_to	37	SENT_125	[p4l1158t2767r1408b2800],
40	,	,	O	,	_	0	SENT_125	[p4l1158t2767r1408b2800],
41	oxaliplatin	NN	O	oxaliplatin	prep_to	37	SENT_125	[p4l1419t2767r1566b2800],
42	,	,	O	,	_	0	SENT_125	[p4l1419t2767r1566b2800],
43	or	CC	O	or	_	0	SENT_125	[p4l1578t2776r1605b2792],
44	irinotecan	NN	O	irinotecan	prep_to	37	SENT_125	[p4l1615t2769r1758b2792],
45	.	.	O	.	_	0	SENT_125	[p4l1615t2769r1758b2792],

1	In	IN	O	in	_	0	SENT_126	[p4l1771t2769r1793b2792],
2	December	NNP	DATE	December	prep_in	7	SENT_126	[p4l1807t2767r1946b2792],
3	2007	CD	DATE	2007	num	2	SENT_126	[p4l1955t2769r2026b2797],
4	,	,	O	,	_	0	SENT_126	[p4l1955t2769r2026b2797],
5	panitumumab	NN	O	panitumumab	nsubjpass	7	SENT_126	[p4l955t2804r1148b2837],
6	was	VBD	O	be	auxpass	7	SENT_126	[p4l1157t2813r1208b2830],
7	approved	VBN	O	approve	_	0	SENT_126	[p4l1219t2804r1344b2837],
8	by	IN	O	by	_	0	SENT_126	[p4l1357t2804r1385b2837],
9	the	DT	O	the	det	11	SENT_126	[p4l1394t2804r1436b2830],
10	EM	NNP	O	EM	nn	11	SENT_126	[p4l1448t2807r1489b2829],
11	EA	NN	O	ea	agent	7	SENT_126	[p4l1496t2806r1530b2829],
12	for	IN	O	for	_	0	SENT_126	[p4l1538t2804r1576b2830],
13	use	NN	O	use	prep_for	11	SENT_126	[p4l1586t2813r1631b2830],
14	in	IN	O	in	_	0	SENT_126	[p4l1643t2807r1664b2829],
15	patients	NNS	O	patient	prep_in	7	SENT_126	[p4l1677t2807r1784b2837],
16	with	IN	O	with	_	0	SENT_126	[p4l1794t2804r1850b2830],
17	colorectal	JJ	O	colorectal	amod	18	SENT_126	[p4l1861t2804r1992b2830],
18	cancer	NN	O	cancer	prep_with	15	SENT_126	[p4l953t2851r1043b2867],
19	who	WP	O	who	nsubj	20	SENT_126	[p4l1050t2842r1107b2867],
20	carry	VBP	O	carry	rcmod	15	SENT_126	[p4l1117t2851r1182b2875],
21	a	DT	O	a	det	26	SENT_126	[p4l1192t2851r1205b2867],
22	normal	JJ	O	normal	amod	26	SENT_126	[p4l1217t2842r1319b2872],
23	,	,	O	,	_	0	SENT_126	[p4l1217t2842r1319b2872],
24	wild-type	JJ	O	wild-type	amod	26	SENT_126	[p4l1330t2842r1451b2875],
25	K-RAS	NN	O	k-ra	nn	26	SENT_126	[p4l1463t2844r1546b2867],
26	gene	NN	O	gene	dobj	20	SENT_126	[p4l1555t2851r1626b2875],
27	.	.	O	.	_	0	SENT_126	[p4l1555t2851r1626b2875],

1	*	JJ	O	*	amod	2	SENT_127	[p4l91t2929r106b2944],
2	EGFR	NN	ORGANIZATION	egfr	nsubj	3	SENT_127	[p4l119t2929r193b2952],
3	denotes	VBZ	O	denote	_	0	SENT_127	[p4l204t2927r311b2952],
4	epidermal	JJ	O	epidermal	amod	10	SENT_127	[p4l324t2927r459b2960],
5	growth	NN	O	growth	nn	10	SENT_127	[p4l472t2927r564b2960],
6	factor	NN	O	factor	nn	10	SENT_127	[p4l577t2927r655b2952],
7	receptor	NN	O	receptor	nn	10	SENT_127	[p4l667t2932r785b2960],
8	,	,	O	,	_	0	SENT_127	[p4l667t2932r785b2960],
9	EM	NNP	ORGANIZATION	EM	dep	10	SENT_127	[p4l800t2929r841b2952],
10	EA	NN	ORGANIZATION	ea	dobj	3	SENT_127	[p4l848t2929r882b2952],
11	European	JJ	ORGANIZATION	european	amod	10	SENT_127	[p4l894t2929r1021b2960],
12	Medicines	NNP	ORGANIZATION	Medicines	nn	14	SENT_127	[p4l1037t2927r1174b2952],
13	Evaluation	NN	ORGANIZATION	evaluation	nn	14	SENT_127	[p4l1189t2927r1328b2952],
14	Agency	NNP	ORGANIZATION	Agency	dep	10	SENT_127	[p4l1340t2929r1444b2960],
15	,	,	O	,	_	0	SENT_127	[p4l1340t2929r1444b2960],
16	FDA	NNP	ORGANIZATION	FDA	nn	17	SENT_127	[p4l1459t2929r1516b2952],
17	Food	NNP	ORGANIZATION	Food	dobj	3	SENT_127	[p4l1529t2927r1594b2952],
18	and	CC	ORGANIZATION	and	_	0	SENT_127	[p4l1608t2927r1656b2952],
19	Drug	NNP	ORGANIZATION	Drug	nn	20	SENT_127	[p4l1671t2929r1737b2960],
20	Administration	NNP	ORGANIZATION	Administration	conj_and	10	SENT_127	[p4l1747t2927r1960b2956],
21	,	,	O	,	_	0	SENT_127	[p4l1747t2927r1960b2956],
22	and	CC	O	and	_	0	SENT_127	[p4l1973t2927r2021b2952],
23	ISEL	NNP	O	ISEL	nn	26	SENT_127	[p4l119t2966r177b2989],
24	Iressa	NNP	O	Iressa	nn	26	SENT_127	[p4l190t2966r268b2989],
25	Survival	NNP	O	Survival	nn	26	SENT_127	[p4l280t2964r385b2989],
26	Evaluation	NN	O	evaluation	dobj	3	SENT_127	[p4l400t2964r539b2989],
27	in	IN	O	in	_	0	SENT_127	[p4l553t2966r575b2989],
28	Lung	NN	O	lung	nn	29	SENT_127	[p4l590t2966r656b2997],
29	Cancer	NN	O	cancer	prep_in	26	SENT_127	[p4l667t2966r767b2989],
30	.	.	O	.	_	0	SENT_127	[p4l667t2966r767b2989],

1	metastatic	JJ	O	metastatic	dep	26	SENT_128	[p4l11t3113r481b3208],
2	,	,	O	,	_	0	SENT_128	[p4l11t3113r481b3208],
3	chemorefractory	JJ	O	chemorefractory	amod	5	SENT_128	[p4l523t3111r1235b3212],
4	non	JJ	O	non	amod	5	SENT_128	[p4l1267t3112r1910b3191],
5	—	NN	O	—	dep	13	SENT_128	[p4l1267t3112r1910b3191],
6	small	JJ	O	small	amod	9	SENT_128	[p4l1267t3112r1910b3191],
7	—	NN	O	—	nn	9	SENT_128	[p4l1267t3112r1910b3191],
8	cell	NN	O	cell	nn	9	SENT_128	[p4l1267t3112r1910b3191],
9	lung	NN	O	lung	dep	5	SENT_128	[p4l1943t3112r2137b3213],
10	cancer	NN	O	cancer	dep	13	SENT_128	[p4l12t3246r483b3318],
11	.25	CD	NUMBER	.25	num	10	SENT_128	[p4l12t3246r483b3318],
12	'29	CD	NUMBER	'29	number	13	SENT_128	[p4l12t3246r483b3318],
13	Dose-dependent	JJ	O	dose-dependent	dep	26	SENT_128	[p4l528t3240r1235b3339],
14	and	CC	O	and	_	0	SENT_128	[p4l1275t3240r1433b3318],
15	reversible	JJ	O	reversible	amod	16	SENT_128	[p4l1478t3240r1885b3319],
16	diarrhea	NN	O	diarrhea	dep	26	SENT_128	[p4l1931t3240r2132b3318, p4l11t3368r197b3447],
17	and	CC	O	and	_	0	SENT_128	[p4l243t3368r401b3447],
18	acneiform	NN	O	acneiform	dep	26	SENT_128	[p4l448t3367r884b3447],
19	rashes	NNS	O	rash	nsubj	26	SENT_128	[p4l933t3368r1203b3446],
20	have	VBP	O	have	aux	26	SENT_128	[p4l1253t3368r1443b3447],
21	been	VBN	O	be	cop	26	SENT_128	[p4l1492t3368r1693b3447],
22	the	DT	O	the	det	26	SENT_128	[p4l1742t3368r1874b3447],
23	most	RBS	O	most	advmod	26	SENT_128	[p4l1922t3385r2139b3447],
24	prominent	JJ	O	prominent	amod	26	SENT_128	[p4l9t3496r469b3595],
25	side	NN	O	side	nn	26	SENT_128	[p4l493t3495r658b3574],
26	effects	NNS	O	effect	dep	29	SENT_128	[p4l688t3494r968b3573],
27	(	CD	NUMBER	(	num	28	SENT_128	[p4l1004t3496r1475b3586],
28	maximum	NN	O	maximum	nsubj	29	SENT_128	[p4l1004t3496r1475b3586],
29	tolerated	VBD	O	tolerate	_	0	SENT_128	[p4l1504t3495r1881b3574],
30	dose	NN	O	dose	dobj	29	SENT_128	[p4l1911t3495r2128b3591],
31	,	,	O	,	_	0	SENT_128	[p4l1911t3495r2128b3591],
32	750	CD	NUMBER	750	num	33	SENT_128	[p4l12t3630r161b3703],
33	mg	NN	O	mg	conj_and	30	SENT_128	[p4l196t3650r335b3725],
34	per	IN	O	per	_	0	SENT_128	[p4l364t3650r504b3724],
35	day	NN	DURATION	day	prep_per	33	SENT_128	[p4l536t3624r682b3724],
36	for	IN	O	for	_	0	SENT_128	[p4l712t3623r835b3703],
37	gefitinib	NN	O	gefitinib	prep_for	35	SENT_128	[p4l866t3623r1238b3725],
38	and	CC	O	and	_	0	SENT_128	[p4l1272t3624r1430b3703],
39	150	CD	NUMBER	150	num	40	SENT_128	[p4l1468t3630r1617b3703],
40	mg	NN	O	mg	conj_and	30	SENT_128	[p4l1651t3650r1790b3725],
41	per	IN	O	per	_	0	SENT_128	[p4l1819t3650r1960b3724],
42	day	NN	DURATION	day	prep_per	40	SENT_128	[p4l1992t3624r2138b3724],
43	for	IN	O	for	_	0	SENT_128	[p5l11t20r134b100],
44	erlotinib	JJ	O	erlotinib	amod	45	SENT_128	[p5l190t21r607b112],
45	)	NN	O	)	prep_for	29	SENT_128	[p5l190t21r607b112],
46	.	.	O	.	_	0	SENT_128	[p5l190t21r607b112],

1	The	DT	O	the	det	3	SENT_129	[p5l667t21r828b100],
2	histologic	JJ	O	histologic	amod	3	SENT_129	[p5l886t21r1311b122],
3	characteristics	NNS	O	characteristic	nsubj	22	SENT_129	[p5l1370t21r1991b99],
4	of	IN	O	of	_	0	SENT_129	[p5l2051t20r2152b100],
5	the	DT	O	the	det	7	SENT_129	[p5l12t148r144b226],
6	rash	JJ	O	rash	amod	7	SENT_129	[p5l174t148r356b226],
7	(	NN	O	(	prep_of	3	SENT_129	[p5l391t155r459b239],
8	a	DT	O	a	det	10	SENT_129	[p5l391t155r459b239],
9	neutrophilic	JJ	O	neutrophilic	amod	10	SENT_129	[p5l487t148r1016b248],
10	inﬁltrate	NN	O	inﬁltrate	dep	7	SENT_129	[p5l1044t147r1427b226],
11	in	IN	O	in	_	0	SENT_129	[p5l1457t149r1540b226],
12	perifollicular	JJ	O	perifollicular	amod	13	SENT_129	[p5l1568t147r2136b248],
13	areas	NNS	O	area	prep_in	10	SENT_129	[p5l11t302r232b354],
14	within	IN	O	within	_	0	SENT_129	[p5l279t276r564b356],
15	the	DT	O	the	det	17	SENT_129	[p5l614t276r747b354],
16	basal	JJ	O	basal	amod	17	SENT_129	[p5l799t276r1020b355],
17	layer	NN	O	layer	prep_within	13	SENT_129	[p5l1068t276r1271b376],
18	of	IN	O	of	_	0	SENT_129	[p5l1319t275r1418b355],
19	the	DT	O	the	det	21	SENT_129	[p5l1450t276r1583b354],
20	skin	NN	O	skin	nn	21	SENT_129	[p5l1635t276r1840b367],
21	)	NN	O	)	prep_of	17	SENT_129	[p5l1635t276r1840b367],
22	differ	VBP	O	differ	_	0	SENT_129	[p5l1897t275r2137b355],
23	from	IN	O	from	_	0	SENT_129	[p5l11t403r221b483],
24	those	DT	O	those	prep_from	22	SENT_129	[p5l255t404r486b483],
25	seen	VBN	O	see	partmod	24	SENT_129	[p5l521t430r709b482],
26	in	IN	O	in	_	0	SENT_129	[p5l741t405r824b482],
27	typical	JJ	O	typical	amod	28	SENT_129	[p5l858t404r1145b504],
28	acne	NN	O	acne	prep_in	25	SENT_129	[p5l1177t430r1367b482],
29	and	CC	O	and	_	0	SENT_129	[p5l1400t404r1557b483],
30	are	VBP	O	be	cop	31	SENT_129	[p5l1589t430r1719b482],
31	common	JJ	O	common	conj_and	22	SENT_129	[p5l1752t430r2134b483],
32	to	TO	O	to	_	0	SENT_129	[p5l12t550r93b612],
33	all	DT	O	all	det	35	SENT_129	[p5l130t533r234b611],
34	EGFR	NN	O	egfr	nn	35	SENT_129	[p5l269t533r901b634],
35	—	NN	O	—	prep_to	31	SENT_129	[p5l269t533r901b634],
36	targeted	VBN	O	target	partmod	35	SENT_129	[p5l269t533r901b634],
37	drugs	NNS	O	drug	dobj	36	SENT_129	[p5l937t533r1205b634],
38	,	,	O	,	_	0	SENT_129	[p5l937t533r1205b634],
39	including	VBG	O	include	_	0	SENT_129	[p5l1246t533r1657b634],
40	anti	JJ	O	anti	prep_including	37	SENT_129	[p5l1689t534r2144b616],
41	.	.	O	.	_	0	SENT_129	[p5l1689t534r2144b616],

1	—	NN	O	—	_	0	SENT_130	[p5l1689t534r2144b616],
2	.	.	O	.	_	0	SENT_130	[p5l1689t534r2144b616],

1	EGFR	NN	ORGANIZATION	egfr	nn	3	SENT_131	[p5l1689t534r2144b616],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_131	[p5l11t661r524b740],
3	antibodies	NNS	O	antibody	nsubj	23	SENT_131	[p5l567t661r1120b740],
4	.3	NN	NUMBER	.3	nn	7	SENT_131	[p5l567t661r1120b740],
5	°	CD	NUMBER	°	num	7	SENT_131	[p5l567t661r1120b740],
6	Skin	NN	O	skin	nn	7	SENT_131	[p5l1166t661r1353b740],
7	toxicity	NN	O	toxicity	dep	3	SENT_131	[p5l1397t662r1715b761],
8	is	VBZ	O	be	auxpass	10	SENT_131	[p5l1753t662r1818b739],
9	generally	RB	O	generally	advmod	10	SENT_131	[p5l1864t687r2132b762, p5l11t788r163b888],
10	observed	VBN	O	observe	_	0	SENT_131	[p5l198t788r578b867],
11	within	IN	O	within	_	0	SENT_131	[p5l612t788r897b868],
12	2	CD	DURATION	2	number	14	SENT_131	[p5l936t794r983b866],
13	to	TO	DURATION	to	dep	14	SENT_131	[p5l1023t805r1105b867],
14	3	CD	DURATION	3	num	15	SENT_131	[p5l1146t794r1189b867],
15	weeks	NNS	NUMBER	week	prep_within	10	SENT_131	[p5l1227t788r1488b868],
16	after	IN	O	after	_	0	SENT_131	[p5l1529t787r1730b866],
17	the	DT	O	the	det	18	SENT_131	[p5l1767t788r1899b866],
18	start	NN	O	start	prep_after	10	SENT_131	[p5l1940t805r2139b866],
19	of	IN	O	of	_	0	SENT_131	[p5l12t916r112b996],
20	treatment	NN	O	treatment	prep_of	18	SENT_131	[p5l138t934r562b995],
21	and	CC	O	and	_	0	SENT_131	[p5l588t917r746b996],
22	gradually	RB	O	gradually	advmod	23	SENT_131	[p5l790t917r1195b1018],
23	resolves	VBZ	O	resolve	conj_and	10	SENT_131	[p5l1236t917r1572b996],
24	in	IN	O	in	_	0	SENT_131	[p5l1618t918r1702b995],
25	most	JJS	O	most	amod	26	SENT_131	[p5l1747t934r1963b996],
26	patients	NNS	O	patient	prep_in	23	SENT_131	[p5l2001t943r2132b1017, p5l12t1045r273b1139],
27	,	,	O	,	_	0	SENT_131	[p5l2001t943r2132b1017, p5l12t1045r273b1139],
28	even	RB	O	even	rcmod	26	SENT_131	[p5l312t1070r501b1123],
29	when	WRB	O	when	advmod	30	SENT_131	[p5l529t1044r763b1123],
30	anti	JJ	O	anti	dep	28	SENT_131	[p5l796t1045r1251b1127],
31	.	.	O	.	_	0	SENT_131	[p5l796t1045r1251b1127],

1	—	NN	O	—	_	0	SENT_132	[p5l796t1045r1251b1127],
2	.	.	O	.	_	0	SENT_132	[p5l796t1045r1251b1127],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_133	[p5l796t1045r1251b1127],
2	treatment	NN	O	treatment	nsubjpass	4	SENT_133	[p5l1274t1060r1698b1121],
3	is	VBZ	O	be	auxpass	4	SENT_133	[p5l1725t1045r1791b1121],
4	continued	VBN	O	continue	_	0	SENT_133	[p5l1827t1045r2132b1122, p5l11t1172r186b1251],
5	.	.	O	.	_	0	SENT_133	[p5l1827t1045r2132b1122, p5l11t1172r186b1251],

1	The	DT	O	the	det	2	SENT_134	[p5l241t1172r402b1250],
2	maximum	NN	O	maximum	nsubj	3	SENT_134	[p5l454t1173r900b1251],
3	tolerated	VBD	O	tolerate	_	0	SENT_134	[p5l953t1172r1330b1251],
4	dose	NN	O	dose	dobj	3	SENT_134	[p5l1383t1172r1577b1251],
5	of	IN	O	of	_	0	SENT_134	[p5l1631t1171r1730b1251],
6	erlotinib	NN	O	erlotinib	prep_of	4	SENT_134	[p5l1765t1172r2132b1251],

1	(	NN	O	(	nn	3	SENT_135	[p5l16t1306r194b1391],
2	150	CD	NUMBER	150	num	3	SENT_135	[p5l16t1306r194b1391],
3	mg	NN	O	mg	nsubjpass	14	SENT_135	[p5l227t1326r366b1401],
4	per	IN	O	per	_	0	SENT_135	[p5l394t1326r533b1400],
5	day	NN	DURATION	day	prep_per	3	SENT_135	[p5l563t1300r756b1400],
6	)	CD	NUMBER	)	num	5	SENT_135	[p5l563t1300r756b1400],
7	,	,	O	,	_	0	SENT_135	[p5l563t1300r756b1400],
8	based	VBN	O	base	partmod	3	SENT_135	[p5l795t1300r1039b1379],
9	on	IN	O	on	_	0	SENT_135	[p5l1072t1326r1178b1379],
10	side	JJ	O	side	amod	11	SENT_135	[p5l1212t1300r1376b1379],
11	effects	NNS	O	effect	prep_on	8	SENT_135	[p5l1410t1299r1715b1396],
12	,	,	O	,	_	0	SENT_135	[p5l1410t1299r1715b1396],
13	was	VBD	O	be	auxpass	14	SENT_135	[p5l1749t1326r1911b1379],
14	chosen	VBN	O	choose	_	0	SENT_135	[p5l1947t1300r2132b1379, p5l12t1454r153b1506],
15	for	IN	O	for	_	0	SENT_135	[p5l189t1427r312b1507],
16	further	JJ	O	further	amod	17	SENT_135	[p5l345t1427r653b1507],
17	study	NN	O	study	prep_for	14	SENT_135	[p5l687t1428r929b1528],
18	,	,	O	,	_	0	SENT_135	[p5l687t1428r929b1528],
19	whereas	IN	O	whereas	mark	30	SENT_135	[p5l965t1428r1317b1507],
20	for	IN	O	for	_	0	SENT_135	[p5l1355t1427r1478b1507],
21	gefitinib	NN	O	gefitinib	prep_for	30	SENT_135	[p5l1510t1427r1903b1529],
22	,	,	O	,	_	0	SENT_135	[p5l1510t1427r1903b1529],
23	relatively	RB	O	relatively	advmod	24	SENT_135	[p5l1944t1428r2132b1506, p5l12t1556r235b1656],
24	low	JJ	O	low	amod	25	SENT_135	[p5l256t1556r411b1635],
25	doses	NNS	O	dose	appos	21	SENT_135	[p5l434t1556r671b1635],
26	(	CD	NUMBER	(	num	27	SENT_135	[p5l704t1557r1072b1656],
27	patients	NNS	O	patient	nsubjpass	30	SENT_135	[p5l704t1557r1072b1656],
28	were	VBD	O	be	auxpass	30	SENT_135	[p5l1096t1582r1297b1635],
29	randomly	RB	O	randomly	advmod	30	SENT_135	[p5l1324t1556r1739b1656],
30	assigned	VBN	O	assign	advcl	14	SENT_135	[p5l1760t1556r2133b1657],
31	to	TO	O	to	aux	32	SENT_135	[p5l12t1701r93b1763],
32	receive	VB	O	receive	xcomp	30	SENT_135	[p5l133t1685r422b1763],
33	250	CD	NUMBER	250	num	34	SENT_135	[p5l462t1690r613b1763],
34	mg	NN	O	mg	dobj	32	SENT_135	[p5l653t1710r792b1785],
35	or	CC	O	or	_	0	SENT_135	[p5l829t1710r918b1763],
36	500	CD	NUMBER	500	num	37	SENT_135	[p5l955t1690r1107b1763],
37	mg	NN	O	mg	nsubjpass	49	SENT_135	[p5l1147t1710r1286b1785],
38	per	IN	O	per	_	0	SENT_135	[p5l1320t1710r1460b1784],
39	day	NN	DURATION	day	prep_per	37	SENT_135	[p5l1497t1684r1690b1784],
40	)	CD	NUMBER	)	num	39	SENT_135	[p5l1497t1684r1690b1784],
41	,	,	O	,	_	0	SENT_135	[p5l1497t1684r1690b1784],
42	given	VBN	O	give	partmod	37	SENT_135	[p5l1734t1685r1961b1785],
43	the	DT	O	the	det	44	SENT_135	[p5l2001t1684r2133b1762],
44	maximum	NN	O	maximum	nsubj	45	SENT_135	[p5l11t1812r457b1890],
45	tolerated	VBD	O	tolerate	ccomp	42	SENT_135	[p5l492t1811r869b1889],
46	doses	NNS	O	dose	dobj	45	SENT_135	[p5l904t1811r1165b1906],
47	,	,	O	,	_	0	SENT_135	[p5l904t1811r1165b1906],
48	were	VBD	O	be	auxpass	49	SENT_135	[p5l1201t1837r1403b1890],
49	chosen	VBN	O	choose	advcl	14	SENT_135	[p5l1439t1811r1760b1889],
50	.	.	O	.	_	0	SENT_135	[p5l1439t1811r1760b1889],

1	Gefitinib	NNP	O	Gefitinib	nsubj	5	SENT_136	[p5l140t1938r533b2018],
2	was	VBD	O	be	cop	5	SENT_136	[p5l577t1965r740b2018],
3	the	DT	O	the	det	5	SENT_136	[p5l790t1939r923b2017],
4	first	JJ	ORDINAL	first	amod	5	SENT_136	[p5l970t1938r1154b2017],
5	anti	JJ	O	anti	_	0	SENT_136	[p5l1196t1940r1650b2022],
6	.	.	O	.	_	0	SENT_136	[p5l1196t1940r1650b2022],

1	—	NN	O	—	_	0	SENT_137	[p5l1196t1940r1650b2022],
2	.	.	O	.	_	0	SENT_137	[p5l1196t1940r1650b2022],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_138	[p5l1196t1940r1650b2022],
2	agent	NN	O	agent	nsubj	67	SENT_138	[p5l1686t1956r1923b2040],
3	that	WDT	O	that	nsubjpass	5	SENT_138	[p5l1966t1939r2138b2017],
4	was	VBD	O	be	auxpass	5	SENT_138	[p5l7t2093r169b2146],
5	shown	VBN	O	show	rcmod	2	SENT_138	[p5l210t2067r515b2162],
6	,	,	O	,	_	0	SENT_138	[p5l210t2067r515b2162],
7	in	IN	O	in	_	0	SENT_138	[p5l557t2068r640b2144],
8	two	CD	NUMBER	two	num	12	SENT_138	[p5l678t2084r835b2146],
9	randomized	JJ	O	randomized	amod	12	SENT_138	[p5l874t2067r1395b2145],
10	phase	NN	O	phase	nn	12	SENT_138	[p5l1430t2067r1679b2166],
11	2	CD	NUMBER	2	num	12	SENT_138	[p5l1716t2073r1763b2144],
12	studies	NNS	O	study	prep_in	5	SENT_138	[p5l1803t2067r2128b2162],
13	,	,	O	,	_	0	SENT_138	[p5l1803t2067r2128b2162],
14	to	TO	O	to	aux	15	SENT_138	[p5l12t2212r93b2273],
15	have	VB	O	have	prep_in	5	SENT_138	[p5l128t2195r318b2274],
16	clinically	RB	O	clinically	advmod	17	SENT_138	[p5l354t2195r745b2294],
17	important	JJ	O	important	acomp	15	SENT_138	[p5l773t2196r1215b2294],
18	antitumor	NN	O	antitumor	nn	19	SENT_138	[p5l1243t2196r1681b2274],
19	activity	NN	O	activity	dep	17	SENT_138	[p5l1712t2196r2021b2294],
20	in	IN	O	in	_	0	SENT_138	[p5l2050t2196r2134b2272],
21	patients	NNS	O	patient	prep_in	19	SENT_138	[p5l7t2324r350b2423],
22	with	IN	O	with	_	0	SENT_138	[p5l407t2323r603b2402],
23	non	JJ	O	non	amod	29	SENT_138	[p5l662t2323r1306b2402],
24	—	JJ	O	—	amod	29	SENT_138	[p5l662t2323r1306b2402],
25	small	JJ	O	small	amod	29	SENT_138	[p5l662t2323r1306b2402],
26	—	NN	O	—	nn	29	SENT_138	[p5l662t2323r1306b2402],
27	cell	NN	O	cell	nn	29	SENT_138	[p5l662t2323r1306b2402],
28	lung	NN	O	lung	nn	29	SENT_138	[p5l1365t2323r1558b2424],
29	cancer	NN	O	cancer	prep_with	15	SENT_138	[p5l1616t2349r1897b2401],
30	who	WP	O	who	nsubj	33	SENT_138	[p5l1950t2323r2133b2402],
31	had	VBD	O	have	aux	33	SENT_138	[p5l9t2451r165b2529],
32	not	RB	O	not	neg	33	SENT_138	[p5l210t2467r353b2529],
33	had	VBN	O	have	rcmod	29	SENT_138	[p5l392t2451r549b2529],
34	a	DT	O	a	det	35	SENT_138	[p5l592t2477r637b2528],
35	response	NN	O	response	dobj	33	SENT_138	[p5l680t2477r1062b2550],
36	to	TO	O	to	_	0	SENT_138	[p5l1094t2468r1175b2529],
37	one	CD	NUMBER	one	num	41	SENT_138	[p5l1222t2477r1373b2529],
38	or	CC	O	or	_	0	SENT_138	[p5l1419t2477r1507b2529],
39	more	JJR	O	more	conj_or	37	SENT_138	[p5l1549t2477r1769b2529],
40	chemotherapy	NN	O	chemotherapy	nn	41	SENT_138	[p5l1814t2451r2133b2529, p5l10t2579r332b2679],
41	regimens	NNS	O	regimen	prep_to	33	SENT_138	[p5l361t2580r785b2680],
42	,	,	O	,	_	0	SENT_138	[p5l361t2580r785b2680],
43	including	VBG	O	include	_	0	SENT_138	[p5l825t2579r1236b2680],
44	platinum	NN	O	platinum	nn	45	SENT_138	[p5l1266t2579r1943b2679],
45	—	NN	O	—	prep_including	15	SENT_138	[p5l1266t2579r1943b2679],
46	based	VBN	O	base	partmod	45	SENT_138	[p5l1266t2579r1943b2679],
47	and	CC	O	and	_	0	SENT_138	[p5l1977t2579r2135b2658],
48	docetaxel	NN	O	docetaxel	nn	49	SENT_138	[p5l10t2706r697b2785],
49	—	NN	O	—	prep_in	5	SENT_138	[p5l10t2706r697b2785],
50	based	VBN	O	base	partmod	49	SENT_138	[p5l10t2706r697b2785],
51	therapies	NNS	O	therapy	nn	52	SENT_138	[p5l738t2706r1332b2806],
52	.3	NN	NUMBER	.3	dobj	50	SENT_138	[p5l738t2706r1332b2806],
53	°	CD	NUMBER	°	number	54	SENT_138	[p5l738t2706r1332b2806],
54	'32	CD	NUMBER	'32	dep	52	SENT_138	[p5l738t2706r1332b2806],
55	The	DT	O	the	det	57	SENT_138	[p5l1369t2706r1530b2784],
56	two	CD	NUMBER	two	num	57	SENT_138	[p5l1572t2723r1729b2786],
57	doses	NNS	O	dose	dep	62	SENT_138	[p5l1772t2706r2009b2785],
58	of	IN	O	of	_	0	SENT_138	[p5l2053t2705r2153b2785],
59	gefitinib	NN	O	gefitinib	prep_of	57	SENT_138	[p5l8t2834r381b2936],
60	(	NN	O	(	dep	62	SENT_138	[p5l423t2841r603b2926],
61	250	CD	NUMBER	250	num	60	SENT_138	[p5l423t2841r603b2926],
62	mg	NN	O	mg	dep	52	SENT_138	[p5l640t2861r779b2936],
63	and	CC	O	and	_	0	SENT_138	[p5l811t2835r969b2914],
64	500	CD	NUMBER	500	num	66	SENT_138	[p5l1007t2841r1159b2914],
65	mg	NN	O	mg	nn	66	SENT_138	[p5l1196t2842r1361b2936],
66	)	NN	O	)	dep	52	SENT_138	[p5l1196t2842r1361b2936],
67	had	VBD	O	have	_	0	SENT_138	[p5l1403t2835r1560b2914],
68	similar	JJ	O	similar	amod	70	SENT_138	[p5l1597t2835r1904b2913],
69	antitumor	NN	O	antitumor	nn	70	SENT_138	[p5l1936t2836r2133b2913, p5l10t2980r277b3042],
70	activity	NN	O	activity	dobj	67	SENT_138	[p5l333t2964r656b3063],
71	,	,	O	,	_	0	SENT_138	[p5l333t2964r656b3063],
72	but	CC	O	but	_	0	SENT_138	[p5l721t2963r861b3042],
73	toxicity	NN	O	toxicity	nsubj	75	SENT_138	[p5l915t2964r1233b3063],
74	was	VBD	O	be	cop	75	SENT_138	[p5l1283t2989r1446b3042],
75	greater	JJR	O	greater	conj_but	67	SENT_138	[p5l1507t2980r1812b3064],
76	at	IN	O	at	_	0	SENT_138	[p5l1868t2980r1947b3041],
77	the	DT	O	the	det	79	SENT_138	[p5l2001t2963r2134b3041],
78	higher	JJR	O	higher	amod	79	SENT_138	[p5l9t3091r290b3192],
79	dose	NN	O	dose	prep_at	75	SENT_138	[p5l336t3091r553b3170],
80	.	.	O	.	_	0	SENT_138	[p5l336t3091r553b3170],

1	Therefore	RB	O	therefore	advmod	7	SENT_139	[p5l603t3090r1044b3187],
2	,	,	O	,	_	0	SENT_139	[p5l603t3090r1044b3187],
3	the	DT	O	the	det	5	SENT_139	[p5l1099t3091r1231b3170],
4	lower	JJR	O	lower	amod	5	SENT_139	[p5l1278t3091r1516b3170],
5	dose	NN	O	dose	nsubjpass	7	SENT_139	[p5l1562t3091r1757b3170],
6	was	VBD	O	be	auxpass	7	SENT_139	[p5l1800t3117r1963b3170],
7	selected	VBN	O	select	_	0	SENT_139	[p5l2015t3117r2133b3170, p5l7t3219r259b3298],
8	for	IN	O	for	_	0	SENT_139	[p5l315t3218r438b3298],
9	further	JJ	O	further	amod	11	SENT_139	[p5l490t3218r799b3298],
10	clinical	JJ	O	clinical	amod	11	SENT_139	[p5l852t3219r1166b3297],
11	studies	NNS	O	study	prep_for	7	SENT_139	[p5l1222t3219r1547b3298],
12	.	.	O	.	_	0	SENT_139	[p5l1222t3219r1547b3298],

1	These	DT	O	these	det	2	SENT_140	[p5l1604t3219r1856b3297],
2	trials	NNS	O	trial	nsubj	3	SENT_140	[p5l1912t3219r2131b3297],
3	led	VBD	O	lead	_	0	SENT_140	[p5l7t3347r133b3426],
4	the	DT	O	the	det	8	SENT_140	[p5l175t3347r307b3425],
5	Food	NNP	ORGANIZATION	Food	nn	8	SENT_140	[p5l347t3347r562b3426],
6	and	CC	ORGANIZATION	and	_	0	SENT_140	[p5l602t3347r760b3426],
7	Drug	NNP	ORGANIZATION	Drug	nn	8	SENT_140	[p5l799t3353r1021b3448],
8	Administration	NNP	ORGANIZATION	Administration	nsubj	10	SENT_140	[p5l1055t3347r1722b3426],
9	(	CD	NUMBER	(	num	10	SENT_140	[p5l1768t3353r2005b3438],
10	FDA	NNP	ORGANIZATION	FDA	xcomp	3	SENT_140	[p5l1768t3353r2005b3438],
11	)	CD	NUMBER	)	num	10	SENT_140	[p5l1768t3353r2005b3438],
12	in	IN	O	in	_	0	SENT_140	[p5l2051t3348r2134b3425],
13	May	NNP	DATE	May	prep_in	10	SENT_140	[p5l6t3483r187b3575],
14	2003	CD	DATE	2003	num	13	SENT_140	[p5l259t3481r461b3554],
15	to	TO	O	to	aux	16	SENT_140	[p5l542t3492r624b3554],
16	approve	VB	O	approve	infmod	10	SENT_140	[p5l701t3501r1035b3575],
17	gefitinib	NN	O	gefitinib	dobj	16	SENT_140	[p5l1112t3474r1484b3576],
18	as	IN	O	as	_	0	SENT_140	[p5l1562t3501r1648b3553],
19	third	JJ	ORDINAL	third	amod	22	SENT_140	[p5l1728t3475r2134b3554],
20	—	NN	O	—	nn	22	SENT_140	[p5l1728t3475r2134b3554],
21	line	NN	O	line	nn	22	SENT_140	[p5l1728t3475r2134b3554],
22	therapy	NN	O	therapy	prep_as	16	SENT_140	[p5l10t3602r332b3702],
23	for	IN	O	for	_	0	SENT_140	[p5l392t3601r516b3681],
24	patients	NNS	O	patient	prep_for	22	SENT_140	[p5l577t3603r919b3702],
25	with	IN	O	with	_	0	SENT_140	[p5l982t3602r1178b3682],
26	locally	RB	O	locally	advmod	27	SENT_140	[p5l1242t3602r1525b3702],
27	advanced	VBN	O	advance	amod	48	SENT_140	[p5l1586t3602r1983b3682],
28	or	CC	O	or	_	0	SENT_140	[p5l2049t3628r2138b3681],
29	metastatic	JJ	O	metastatic	amod	31	SENT_140	[p6l9t23r457b100],
30	non	JJ	O	non	amod	31	SENT_140	[p6l495t22r1139b101],
31	—	NN	O	—	conj_or	27	SENT_140	[p6l495t22r1139b101],
32	small	JJ	O	small	amod	36	SENT_140	[p6l495t22r1139b101],
33	—	NN	O	—	nn	36	SENT_140	[p6l495t22r1139b101],
34	cell	NN	O	cell	nn	36	SENT_140	[p6l495t22r1139b101],
35	lung	NN	O	lung	nn	36	SENT_140	[p6l1176t22r1370b123],
36	cancer	NN	O	cancer	nsubj	43	SENT_140	[p6l1407t48r1688b101],
37	after	IN	O	after	_	0	SENT_140	[p6l1724t21r1927b101],
38	failure	NN	O	failure	prep_after	36	SENT_140	[p6l1963t21r2133b100, p6l9t175r144b229],
39	of	IN	O	of	_	0	SENT_140	[p6l183t148r283b228],
40	both	DT	O	both	det	42	SENT_140	[p6l303t149r501b228],
41	platinum	NN	O	platinum	nn	42	SENT_140	[p6l537t149r1214b249],
42	—	NN	O	—	prep_of	38	SENT_140	[p6l537t149r1214b249],
43	based	VBN	O	base	rcmod	31	SENT_140	[p6l537t149r1214b249],
44	and	CC	O	and	_	0	SENT_140	[p6l1251t149r1409b228],
45	docetaXel	NN	O	docetaxel	nn	46	SENT_140	[p6l1447t149r2134b228],
46	—	NN	O	—	conj_or	27	SENT_140	[p6l1447t149r2134b228],
47	based	VBN	O	base	partmod	46	SENT_140	[p6l1447t149r2134b228],
48	chemotherapies	NNS	O	chemotherapy	prep_with	16	SENT_140	[p6l10t278r714b377],
49	.	.	O	.	_	0	SENT_140	[p6l10t278r714b377],

1	However	RB	O	however	advmod	25	SENT_141	[p6l138t413r532b501],
2	,	,	O	,	_	0	SENT_141	[p6l138t413r532b501],
3	a	DT	O	a	det	5	SENT_141	[p6l603t432r647b483],
4	placebo	NN	O	placebo	nn	5	SENT_141	[p6l709t406r1542b505],
5	—	NN	O	—	nsubj	25	SENT_141	[p6l709t406r1542b505],
6	controlled	VBN	O	control	partmod	5	SENT_141	[p6l709t406r1542b505],
7	,	,	O	,	_	0	SENT_141	[p6l709t406r1542b505],
8	randomized	VBN	O	randomize	dep	6	SENT_141	[p6l1613t406r2135b484],
9	phase	NN	O	phase	nn	11	SENT_141	[p6l7t534r257b633],
10	3	CD	NUMBER	3	num	11	SENT_141	[p6l309t540r353b613],
11	trial	NN	O	trial	dobj	6	SENT_141	[p6l409t534r587b612],
12	(	IN	O	(	_	0	SENT_141	[p6l643t534r801b624],
13	the	DT	O	the	det	16	SENT_141	[p6l643t534r801b624],
14	Iressa	NNP	O	Iressa	nn	16	SENT_141	[p6l852t541r1105b612],
15	Survival	NNP	O	Survival	nn	16	SENT_141	[p6l1158t534r1498b613],
16	Evaluation	NN	O	evaluation	prep_(	6	SENT_141	[p6l1548t534r1999b613],
17	in	IN	O	in	_	0	SENT_141	[p6l2051t535r2134b611],
18	Lung	NN	O	lung	nn	19	SENT_141	[p6l7t670r227b763],
19	Cancer	NN	O	cancer	prep_in	16	SENT_141	[p6l285t668r585b741],
20	[	CD	NUMBER	[	num	19	SENT_141	[p6l652t668r894b753],
21	ISEL	NN	O	isel	nn	24	SENT_141	[p6l652t668r894b753],
22	]	CD	NUMBER	]	num	24	SENT_141	[p6l652t668r894b753],
23	trial	NN	O	trial	nn	24	SENT_141	[p6l964t662r1170b753],
24	)	NN	O	)	dep	5	SENT_141	[p6l964t662r1170b753],
25	failed	VBD	O	fail	_	0	SENT_141	[p6l1237t661r1477b741],
26	to	TO	O	to	aux	27	SENT_141	[p6l1538t679r1620b741],
27	show	VB	O	show	xcomp	25	SENT_141	[p6l1684t662r1909b741],
28	that	IN	O	that	complm	31	SENT_141	[p6l1967t662r2139b740],
29	gefitinib	NN	O	gefitinib	nsubj	31	SENT_141	[p6l8t789r381b891],
30	was	VBD	O	be	cop	31	SENT_141	[p6l432t816r594b869],
31	effective	JJ	O	effective	ccomp	27	SENT_141	[p6l652t789r1010b869],
32	in	IN	O	in	_	0	SENT_141	[p6l1064t791r1147b868],
33	improving	VBG	O	improve	prepc_in	31	SENT_141	[p6l1201t791r1650b891],
34	survival	NN	O	survival	dobj	33	SENT_141	[p6l1702t790r2133b869],
35	.33	CD	NUMBER	.33	num	34	SENT_141	[p6l1702t790r2133b869],
36	Neither	CC	O	neither	preconj	38	SENT_141	[p6l7t918r331b997],
37	median	JJ	O	median	amod	38	SENT_141	[p6l372t918r696b997],
38	survival	NN	O	survival	nsubj	47	SENT_141	[p6l741t918r1073b997],
39	nor	CC	O	nor	_	0	SENT_141	[p6l1117t944r1264b997],
40	the	DT	O	the	det	41	SENT_141	[p6l1305t918r1438b997],
41	rate	NN	O	rate	conj_nor	38	SENT_141	[p6l1482t935r1643b996],
42	of	IN	O	of	_	0	SENT_141	[p6l1675t917r1776b997],
43	survival	NN	O	survival	prep_of	41	SENT_141	[p6l1803t918r2135b997],
44	at	IN	O	at	_	0	SENT_141	[p6l8t1063r87b1124],
45	1	CD	DURATION	1	num	46	SENT_141	[p6l127t1052r171b1124],
46	year	NN	NUMBER	year	prep_at	43	SENT_141	[p6l209t1072r389b1146],
47	differed	VBD	O	differ	rcmod	34	SENT_141	[p6l428t1045r768b1125],
48	significantly	RB	O	significantly	advmod	47	SENT_141	[p6l811t1045r1355b1147],
49	between	IN	O	between	_	0	SENT_141	[p6l1392t1046r1750b1125],
50	patients	NNS	O	patient	prep_between	47	SENT_141	[p6l1790t1047r2132b1146],
51	receiving	VBG	O	receive	partmod	50	SENT_141	[p6l9t1175r399b1275],
52	gefitinib	NN	O	gefitinib	dobj	51	SENT_141	[p6l448t1173r820b1275],
53	and	CC	O	and	_	0	SENT_141	[p6l873t1174r1030b1253],
54	those	DT	O	those	nsubj	55	SENT_141	[p6l1082t1174r1314b1253],
55	receiving	VBG	O	receive	rcmod	34	SENT_141	[p6l1366t1175r1757b1275],
56	placebo	NN	O	placebo	dobj	55	SENT_141	[p6l1804t1174r2133b1274],
57	in	IN	O	in	_	0	SENT_141	[p6l8t1303r91b1379],
58	either	CC	O	either	preconj	62	SENT_141	[p6l140t1302r387b1380],
59	the	DT	O	the	det	62	SENT_141	[p6l432t1302r566b1380],
60	overall	JJ	O	overall	amod	62	SENT_141	[p6l614t1302r900b1381],
61	study	NN	O	study	nn	62	SENT_141	[p6l949t1302r1179b1401],
62	population	NN	O	population	prep_in	55	SENT_141	[p6l1220t1302r1692b1401],
63	or	CC	O	or	_	0	SENT_141	[p6l1727t1328r1816b1380],
64	a	DT	O	a	det	65	SENT_141	[p6l1860t1328r1904b1379],
65	subgroup	NN	O	subgroup	conj_or	62	SENT_141	[p6l1952t1302r2133b1381, p6l8t1456r261b1531],
66	With	IN	O	with	_	0	SENT_141	[p6l316t1430r511b1509],
67	a	DT	O	a	det	68	SENT_141	[p6l568t1456r612b1508],
68	history	NN	O	history	prep_with	47	SENT_141	[p6l668t1430r972b1530],
69	of	IN	O	of	_	0	SENT_141	[p6l1026t1429r1126b1509],
70	adenocarcinoma	NN	O	adenocarcinoma	prep_of	68	SENT_141	[p6l1164t1430r1902b1509],
71	.	.	O	.	_	0	SENT_141	[p6l1164t1430r1902b1509],

1	PreENGLJ	NN	O	preenglj	_	0	SENT_142	[p6l1964t1437r2133b1508, p6l550t1617r628b1639],

1	MED	NN	O	med	_	0	SENT_143	[p6l643t1617r695b1632],
2	358	CD	NUMBER	358	num	1	SENT_143	[p6l705t1611r773b1639],
3	;	:	O	;	_	0	SENT_143	[p6l705t1611r773b1639],
4	11	CD	NUMBER	11	num	5	SENT_143	[p6l705t1611r773b1639],
5	WWW	NNP	O	WWW	dep	1	SENT_143	[p6l809t1617r916b1633],
6	,	,	O	,	_	0	SENT_143	[p6l809t1617r916b1633],
7	NE	NN	O	ne	nn	9	SENT_143	[p6l809t1617r916b1633],
8	M.ORG	NNP	O	M.ORG	nn	9	SENT_143	[p6l931t1617r1010b1633],
9	MARCH	NNP	DATE	MARCH	appos	5	SENT_143	[p6l1047t1617r1132b1632],
10	13	CD	DATE	13	num	9	SENT_143	[p6l1147t1617r1178b1639],
11	,	,	DATE	,	_	0	SENT_143	[p6l1147t1617r1178b1639],
12	2008	CD	DATE	2008	num	13	SENT_143	[p6l1189t1611r1252b1633],
13	1163	CD	DATE	1163	appos	5	SENT_143	[p6l1940t1606r2015b1630],

1	The	DT	O	the	det	4	SENT_144	[p6l702t1650r753b1674],
2	New	NNP	O	New	nn	4	SENT_144	[p6l762t1651r824b1674],
3	Englan	NNP	O	Englan	nn	4	SENT_144	[p6l833t1650r927b1681],
4	oumal	NN	O	oumal	_	0	SENT_144	[p6l966t1650r1050b1674],
5	of	IN	O	of	_	0	SENT_144	[p6l1059t1650r1088b1674],
6	Medicine	NN	MISC	medicine	prep_of	4	SENT_144	[p6l1095t1650r1220b1674],

1	Downloaded	VBN	O	download	_	0	SENT_145	[p6l144t1691r314b1714],
2	from	IN	O	from	_	0	SENT_145	[p6l323t1691r387b1714],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_145	[p6l396t1691r514b1721],
4	at	IN	O	at	_	0	SENT_145	[p6l524t1695r547b1714],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_145	[p6l556t1691r738b1714],
6	on	IN	O	on	_	0	SENT_145	[p6l748t1698r780b1714],
7	January	NNP	DATE	January	prep_on	1	SENT_145	[p6l789t1691r892b1721],
8	5	CD	DATE	5	num	7	SENT_145	[p6l902t1691r924b1719],
9	,	,	DATE	,	_	0	SENT_145	[p6l902t1691r924b1719],
10	2014	CD	DATE	2014	num	7	SENT_145	[p6l935t1691r1007b1714],
11	.	.	O	.	_	0	SENT_145	[p6l935t1691r1007b1714],

1	For	IN	O	for	_	0	SENT_146	[p6l1018t1691r1064b1714],
2	personal	JJ	O	personal	amod	3	SENT_146	[p6l1072t1691r1185b1721],
3	use	NN	O	use	pobj	1	SENT_146	[p6l1194t1698r1237b1714],
4	only	RB	O	only	advmod	3	SENT_146	[p6l1247t1691r1312b1721],
5	.	.	O	.	_	0	SENT_146	[p6l1247t1691r1312b1721],

1	No	DT	O	no	det	3	SENT_147	[p6l1322t1691r1362b1714],
2	other	JJ	O	other	amod	3	SENT_147	[p6l1372t1691r1440b1714],
3	uses	NNS	O	use	_	0	SENT_147	[p6l1448t1698r1504b1714],
4	without	IN	O	without	_	0	SENT_147	[p6l1514t1691r1616b1714],
5	permission	NN	O	permission	prep_without	3	SENT_147	[p6l1624t1691r1776b1721],
6	.	.	O	.	_	0	SENT_147	[p6l1624t1691r1776b1721],

1	Copyright	NN	O	copyright	_	0	SENT_148	[p6l494t1732r629b1763],
2	©	CD	NUMBER	©	num	6	SENT_148	[p6l638t1732r661b1756],
3	2008	CD	DATE	2008	num	6	SENT_148	[p6l671t1732r736b1756],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_148	[p6l746t1732r937b1756],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_148	[p6l947t1732r1055b1756],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_148	[p6l1065t1732r1170b1763],
7	.	.	O	.	_	0	SENT_148	[p6l1065t1732r1170b1763],

1	All	DT	O	all	det	2	SENT_149	[p6l1181t1732r1223b1756],
2	rights	NNS	O	rights	nsubj	3	SENT_149	[p6l1232t1732r1306b1763],
3	reserved	VBN	O	reserve	_	0	SENT_149	[p6l1316t1732r1435b1756],
4	.	.	O	.	_	0	SENT_149	[p6l1316t1732r1435b1756],

1	The	DT	O	the	det	4	SENT_150	[p6l673t1838r718b1859],
2	NEW	NNP	O	NEW	nn	4	SENT_150	[p6l737t1840r822b1859],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_150	[p6l841t1840r1029b1859],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_150	[p6l1048t1840r1227b1866],
5	of	IN	O	of	_	0	SENT_150	[p6l1247t1838r1275b1865],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_150	[p6l1287t1840r1486b1859],

1	Receptor-speciﬁc	NN	O	receptor-speciﬁc	_	0	SENT_151	[p7l712t104r1159b168],
2	a	DT	O	a	dep	1	SENT_151	[p7l467t143r696b337],
3	/	:	O	/	punct	4	SENT_151	[p7l467t143r696b337],
4	ligand	NN	O	ligand	dep	1	SENT_151	[p7l855t182r1010b246],

1	%	NN	O	%	_	0	SENT_152	[p7l31t427r237b475],
2	(	CD	NUMBER	(	num	3	SENT_152	[p7l31t427r237b475],
3	p	NN	O	p	dep	1	SENT_152	[p7l31t427r237b475],
4	+	CC	O	+	_	0	SENT_152	[p7l31t427r237b475],
5	&	CC	O	&	_	0	SENT_152	[p7l257t433r267b448],
6	(	NN	O	(	dep	1	SENT_152	[p7l257t433r267b448],
7	p	NN	O	p	dep	6	SENT_152	[p7l257t433r267b448],
8	+	CC	O	+	_	0	SENT_152	[p7l257t433r267b448],
9	P	NN	O	p	conj_+	3	SENT_152	[p7l303t379r417b526],
10	&	CC	O	&	_	0	SENT_152	[p7l303t379r417b526],
11	(	NN	O	(	nn	12	SENT_152	[p7l303t379r417b526],
12	p	NN	O	p	conj_+	6	SENT_152	[p7l303t379r417b526],
13	+	CC	O	+	_	0	SENT_152	[p7l303t379r417b526],
14	Anti-EGFR	JJ	O	anti-egfr	amod	18	SENT_152	[p7l614t468r889b513],
15	monoclonal	JJ	O	monoclonal	amod	18	SENT_152	[p7l599t541r906b590],
16	antibody	NN	O	antibody	nn	18	SENT_152	[p7l641t618r867b682],
17	Cell	NN	O	cell	nn	18	SENT_152	[p7l1064t585r1156b633],
18	membrane	NN	O	membrane	conj_+	6	SENT_152	[p7l1182t585r1465b634],

1	=	JJ	O	=	nsubj	8	SENT_153	[p7l1893t1416r1908b1427],
2	=	JJ	O	=	amod	3	SENT_153	[p7l1893t1416r1908b1427],
3	ia	NN	O	ia	dep	1	SENT_153	[p7l1893t1416r1908b1427],
4	'	''	O	'	_	0	SENT_153	[p7l1943t1414r1946b1417],
5	«	CD	NUMBER	«	dep	3	SENT_153	[p7l1881t1432r1897b1443],
6	ii	LS	O	ii	dep	8	SENT_153	[p7l1881t1432r1897b1443],
7	'	''	DATE	'	_	0	SENT_153	[p7l1905t1428r1932b1443],
8	21	CD	DATE	21	_	0	SENT_153	[p7l1905t1428r1932b1443],
9	:	:	O	:	_	0	SENT_153	[p7l1905t1428r1932b1443],
10	“	CD	NUMBER	“	dep	8	SENT_153	[p7l1905t1428r1932b1443],
11	.	.	O	.	_	0	SENT_153	[p7l1961t1428r1976b1443],
12	'	''	O	'	_	0	SENT_153	[p7l1961t1428r1976b1443],

1	.	.	O	.	_	0	SENT_154	[p7l1989t1440r1992b1443],

1	,	,	O	,	_	0	SENT_155	[p7l429t1496r436b1507],
2	4	CD	NUMBER	4	dep	5	SENT_155	[p7l457t1468r480b1523],
3	$	$	MONEY	$	dep	2	SENT_155	[p7l457t1468r480b1523],
4	(	CD	MONEY	(	num	3	SENT_155	[p7l457t1468r480b1523],
5	p	NN	O	p	_	0	SENT_155	[p7l457t1468r480b1523],
6	+	CC	O	+	_	0	SENT_155	[p7l457t1468r480b1523],
7	ofcancer-cell	NN	O	ofcancer-cell	nn	8	SENT_155	[p7l509t1453r874b1503],
8	proliferation	NN	O	proliferation	conj_+	5	SENT_155	[p7l900t1454r1218b1517],
9	and	CC	O	and	_	0	SENT_155	[p7l1241t1454r1334b1503],
10	invasion	NN	O	invasion	nn	17	SENT_155	[p7l1360t1471r1591b1512],
11	,	,	O	,	_	0	SENT_155	[p7l1360t1471r1591b1512],
12	metastasis	NN	O	metastasis	dep	17	SENT_155	[p7l1616t1464r1910b1512],
13	,	,	O	,	_	0	SENT_155	[p7l1616t1464r1910b1512],
14	Q	NNP	O	Q	dep	17	SENT_155	[p7l2007t1468r2142b1523],
15	"	``	O	"	punct	17	SENT_155	[p7l2007t1468r2142b1523],
16	(	NN	O	(	nn	17	SENT_155	[p7l2007t1468r2142b1523],
17	p	NN	O	p	conj_and	5	SENT_155	[p7l2007t1468r2142b1523],
18	+	CC	O	+	rcmod	17	SENT_155	[p7l2007t1468r2142b1523],

1	and	CC	O	and	dep	3	SENT_156	[p7l599t1531r691b1580],
2	tumor-induced	JJ	O	tumor-induced	amod	3	SENT_156	[p7l713t1531r1103b1580],
3	neoangiogenesis	NN	O	neoangiogenesis	_	0	SENT_156	[p7l1129t1536r1569b1595],

1	o	NN	O	o	_	0	SENT_157	[p7l93t1668r100b1683],
2	(	CD	NUMBER	(	num	3	SENT_157	[p7l93t1668r100b1683],
3	p	NN	O	p	dep	1	SENT_157	[p7l93t1668r100b1683],
4	+	CC	O	+	_	0	SENT_157	[p7l93t1668r100b1683],
5	[	NN	O	[	nn	8	SENT_157	[p7l125t1648r141b1693],
6	3	CD	NUMBER	3	num	8	SENT_157	[p7l125t1648r141b1693],
7	(	NN	O	(	nn	8	SENT_157	[p7l125t1648r141b1693],
8	p	NN	O	p	conj_+	3	SENT_157	[p7l125t1648r141b1693],
9	+	CC	O	+	_	0	SENT_157	[p7l125t1648r141b1693],
10	1	CD	NUMBER	1	num	12	SENT_157	[p7l161t1636r180b1654],
11	(	NN	O	(	nn	12	SENT_157	[p7l161t1636r180b1654],
12	p	NN	O	p	conj_+	3	SENT_157	[p7l161t1636r180b1654],
13	+	CC	O	+	_	0	SENT_157	[p7l161t1636r180b1654],
14	llnduction	NN	O	llnduction	conj_+	3	SENT_157	[p7l206t1636r464b1708],
15	of	IN	O	of	_	0	SENT_157	[p7l487t1658r545b1708],
16	cancer-cell	JJ	O	cancer-cell	amod	18	SENT_157	[p7l556t1659r830b1708],
17	cycle	NN	O	cycle	nn	18	SENT_157	[p7l853t1659r978b1723],
18	arrest	NN	O	arrest	prep_of	14	SENT_157	[p7l999t1668r1147b1708],
19	and	CC	O	and	_	0	SENT_157	[p7l1167t1659r1259b1708],
20	potentiation	NN	O	potentiation	conj_and	8	SENT_157	[p7l1285t1663r1601b1722],
21	of	IN	O	of	_	0	SENT_157	[p7l1624t1658r1681b1708],
22	antitumor	NN	O	antitumor	nn	23	SENT_157	[p7l1693t1663r1957b1708],
23	activity	NN	O	activity	prep_of	20	SENT_157	[p7l510t1740r692b1800],
24	of	IN	O	of	_	0	SENT_157	[p7l711t1735r768b1785],
25	cytotoxic	JJ	O	cytotoxic	amod	26	SENT_157	[p7l779t1740r1009b1800],
26	drugs	NNS	O	drug	prep_of	23	SENT_157	[p7l1028t1736r1175b1800],
27	and	CC	O	and	_	0	SENT_157	[p7l1197t1736r1289b1785],
28	radiotherapy	NN	O	radiotherapy	prep_of	23	SENT_157	[p7l1316t1736r1645b1800],

1	Figure	NN	O	figure	_	0	SENT_158	[p7l64t1906r227b1967],
2	2	CD	NUMBER	2	dep	1	SENT_158	[p7l246t1909r293b1953],
3	.	.	O	.	_	0	SENT_158	[p7l246t1909r293b1953],

1	Mechanisms	NNS	O	mechanism	_	0	SENT_159	[p7l319t1904r655b1953],
2	ofAction	NN	O	ofaction	nn	4	SENT_159	[p7l676t1904r916b1953],
3	ofAnti-EGFR	NN	O	ofanti-egfr	nn	4	SENT_159	[p7l938t1904r1286b1953],
4	Drugs	NNS	O	drug	dep	1	SENT_159	[p7l1310t1909r1469b1968],
5	in	IN	O	in	_	0	SENT_159	[p7l1492t1906r1536b1952],
6	Cancer	NN	O	cancer	nn	7	SENT_159	[p7l1558t1908r1745b1953],
7	Cells	NNS	O	cell	prep_in	4	SENT_159	[p7l1763t1904r1906b1953],
8	.	.	O	.	_	0	SENT_159	[p7l1763t1904r1906b1953],

1	Anti-EGFR	JJ	O	anti-egfr	amod	3	SENT_160	[p7l59t2004r338b2049],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_160	[p7l362t2001r675b2049],
3	antibodies	NNS	O	antibody	nsubj	4	SENT_160	[p7l700t2000r978b2049],
4	bind	VBP	O	bind	_	0	SENT_160	[p7l1004t2001r1115b2049],
5	to	TO	O	to	_	0	SENT_160	[p7l1138t2010r1189b2049],
6	the	DT	O	the	det	8	SENT_160	[p7l1210t2001r1293b2049],
7	extracellular	JJ	O	extracellular	amod	8	SENT_160	[p7l1315t2001r1641b2049],
8	domain	NN	O	domain	prep_to	4	SENT_160	[p7l1661t2001r1860b2049],
9	of	IN	O	of	_	0	SENT_160	[p7l1885t2000r1942b2049],
10	EGFR	NN	ORGANIZATION	egfr	prep_of	8	SENT_160	[p7l1959t2004r2100b2049],
11	and	CC	O	and	_	0	SENT_160	[p7l62t2081r155b2129],
12	block	NN	O	block	nn	14	SENT_160	[p7l182t2081r321b2129],
13	ligand	NN	O	ligand	nn	14	SENT_160	[p7l344t2081r500b2145],
14	binding	NN	O	binding	conj_and	10	SENT_160	[p7l528t2081r727b2145],
15	and	CC	O	and	_	0	SENT_160	[p7l748t2081r841b2129],
16	receptor	NN	O	receptor	nn	17	SENT_160	[p7l869t2090r1090b2144],
17	activation	NN	O	activation	conj_and	10	SENT_160	[p7l1111t2085r1385b2129],
18	.	.	O	.	_	0	SENT_160	[p7l1111t2085r1385b2129],

1	Small-molecule	JJ	O	small-molecule	amod	5	SENT_161	[p7l1410t2081r1824b2129],
2	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_161	[p7l1850t2085r1991b2129],
3	tyrosine	NN	O	tyrosine	nn	5	SENT_161	[p7l2012t2090r2076b2144, p7l64t2166r223b2210],
4	kinase	NN	O	kinase	nn	5	SENT_161	[p7l248t2161r412b2210],
5	inhibitors	NNS	O	inhibitor	nsubj	6	SENT_161	[p7l436t2161r686b2210],
6	(	VBP	O	(	_	0	SENT_161	[p7l716t2165r868b2224],
7	TK	NN	O	tk	nn	8	SENT_161	[p7l716t2165r868b2224],
8	|	NN	O	|	nsubj	10	SENT_161	[p7l716t2165r868b2224],
9	s	VBZ	O	s	cop	10	SENT_161	[p7l716t2165r868b2224],
10	)	CD	NUMBER	)	ccomp	6	SENT_161	[p7l716t2165r868b2224],
11	compete	VBP	O	compete	rcmod	10	SENT_161	[p7l896t2171r1127b2224],
12	with	IN	O	with	_	0	SENT_161	[p7l1148t2161r1257b2210],
13	ATP	NN	ORGANIZATION	atp	prep_with	11	SENT_161	[p7l1280t2164r1385b2209],
14	to	TO	O	to	aux	15	SENT_161	[p7l1404t2171r1456b2210],
15	bind	VB	O	bind	xcomp	11	SENT_161	[p7l1481t2161r1592b2210],
16	to	TO	O	to	_	0	SENT_161	[p7l1615t2171r1666b2210],
17	the	DT	O	the	det	21	SENT_161	[p7l1686t2161r1770b2210],
18	intracellular	JJ	O	intracellular	amod	21	SENT_161	[p7l1794t2161r2109b2210],
19	EGFR	NN	ORGANIZATION	egfr	nn	21	SENT_161	[p7l65t2245r206b2290],
20	tyrosine	NN	O	tyrosine	nn	21	SENT_161	[p7l226t2246r440b2305],
21	kinase	NN	O	kinase	prep_to	15	SENT_161	[p7l464t2241r628b2290],
22	catalytic	JJ	O	catalytic	amod	23	SENT_161	[p7l650t2241r870b2305],
23	domain	NN	O	domain	dep	21	SENT_161	[p7l891t2241r1090b2290],
24	and	CC	O	and	_	0	SENT_161	[p7l1116t2241r1209b2290],
25	thus	RB	O	thus	advmod	26	SENT_161	[p7l1232t2241r1347b2290],
26	block	VBP	O	block	rcmod	10	SENT_161	[p7l1373t2241r1512b2290],
27	EGFR	NN	ORGANIZATION	egfr	nn	28	SENT_161	[p7l1537t2245r1678b2290],
28	autophosphorylation	NN	O	autophosphorylation	dobj	26	SENT_161	[p7l1700t2241r2094b2304, p7l59t2322r234b2385],
29	and	CC	O	and	_	0	SENT_161	[p7l259t2322r352b2370],
30	downstream	JJ	O	downstream	amod	31	SENT_161	[p7l378t2322r707b2370],
31	signaling	NN	O	signaling	dobj	26	SENT_161	[p7l733t2322r985b2385],
32	.	.	O	.	_	0	SENT_161	[p7l733t2322r985b2385],

1	As	IN	O	as	_	0	SENT_162	[p7l1007t2325r1072b2370],
2	a	DT	O	a	det	4	SENT_162	[p7l1096t2339r1121b2370],
3	consequence	NN	O	consequence	nn	4	SENT_162	[p7l1144t2339r1493b2385],
4	oftreatment	NN	O	oftreatment	prep_as	17	SENT_162	[p7l1516t2321r1849b2370],
5	with	IN	O	with	_	0	SENT_162	[p7l1868t2322r1978b2370],
6	these	DT	O	these	det	7	SENT_162	[p7l59t2402r203b2451],
7	drugs	NNS	O	drug	prep_with	4	SENT_162	[p7l224t2402r390b2466],
8	,	,	O	,	_	0	SENT_162	[p7l224t2402r390b2466],
9	key	JJ	O	key	amod	12	SENT_162	[p7l417t2402r497b2466],
10	EGFR-dependent	JJ	O	egfr-dependent	amod	12	SENT_162	[p7l522t2402r976b2465],
11	intracellular	JJ	O	intracellular	amod	12	SENT_162	[p7l999t2402r1314b2451],
12	signals	NNS	O	signal	nsubjpass	17	SENT_162	[p7l1336t2402r1517b2466],
13	in	IN	O	in	_	0	SENT_162	[p7l1542t2407r1584b2450],
14	cancer	NN	O	cancer	nn	15	SENT_162	[p7l1609t2419r1784b2451],
15	cells	NNS	O	cell	prep_in	12	SENT_162	[p7l1804t2402r1918b2451],
16	are	VBP	O	be	auxpass	17	SENT_162	[p7l1942t2419r2020b2451],
17	affected	VBN	O	affect	_	0	SENT_162	[p7l2043t2401r2104b2451, p7l60t2482r239b2531],
18	.	.	O	.	_	0	SENT_162	[p7l2043t2401r2104b2451, p7l60t2482r239b2531],

1	There	EX	O	there	expl	2	SENT_163	[p7l261t2482r413b2531],
2	is	VBZ	O	be	_	0	SENT_163	[p7l437t2487r474b2531],
3	inhibition	NN	O	inhibition	nsubj	2	SENT_163	[p7l499t2482r749b2531],
4	ofcancer-cell	JJ	O	ofcancer-cell	amod	7	SENT_163	[p7l774t2482r1125b2531],
5	proliferation	NN	O	proliferation	nn	7	SENT_163	[p7l1152t2482r1476b2545],
6	(	NN	O	(	nn	7	SENT_163	[p7l1507t2482r1763b2546],
7	blockade	NN	O	blockade	dep	3	SENT_163	[p7l1507t2482r1763b2546],
8	of	IN	O	of	_	0	SENT_163	[p7l1785t2482r1843b2531],
9	cell-cycle	JJ	O	cell-cycle	amod	10	SENT_163	[p7l1856t2482r2097b2546],
10	progression	NN	O	progression	prep_of	7	SENT_163	[p7l64t2567r374b2626],
11	and	CC	O	and	_	0	SENT_163	[p7l400t2563r494b2611],
12	G1	NN	O	g1	nn	13	SENT_163	[p7l519t2566r587b2611],
13	arrest	NN	O	arrest	conj_and	10	SENT_163	[p7l613t2572r764b2611],
14	through	IN	O	through	_	0	SENT_163	[p7l783t2563r993b2626],
15	an	DT	O	a	det	16	SENT_163	[p7l1018t2579r1076b2611],
16	increase	NN	O	increase	prep_through	10	SENT_163	[p7l1103t2567r1321b2611],
17	in	IN	O	in	_	0	SENT_163	[p7l1345t2567r1386b2610],
18	the	DT	O	the	det	22	SENT_163	[p7l1409t2563r1493b2611],
19	p27l	NN	O	p27l	nn	22	SENT_163	[p7l1518t2550r1691b2626],
20	‘	CD	NUMBER	‘	num	22	SENT_163	[p7l1518t2550r1691b2626],
21	lP1	NN	O	lp1	nn	22	SENT_163	[p7l1518t2550r1691b2626],
22	inhibitor	NN	O	inhibitor	prep_in	16	SENT_163	[p7l1716t2563r1941b2611],
23	ofcyclin-dependent	JJ	O	ofcyclin-dependent	amod	25	SENT_163	[p7l1961t2562r2102b2626, p7l61t2643r466b2706],
24	kinases	NNS	O	kinase	nn	25	SENT_163	[p7l490t2643r717b2706],
25	)	NN	O	)	dep	22	SENT_163	[p7l490t2643r717b2706],
26	;	:	O	;	_	0	SENT_163	[p7l490t2643r717b2706],
27	inhibition	NN	O	inhibition	nn	29	SENT_163	[p7l744t2643r993b2691],
28	oftumor-induced	JJ	O	oftumor-induced	amod	29	SENT_163	[p7l1018t2642r1483b2691],
29	angiogenesis	NN	O	angiogenesis	dep	22	SENT_163	[p7l1508t2648r1856b2707],
30	by	IN	O	by	_	0	SENT_163	[p7l1882t2643r1936b2707],
31	blockade	NN	O	blockade	prep_by	29	SENT_163	[p7l63t2723r298b2771],
32	of	IN	O	of	_	0	SENT_163	[p7l321t2723r378b2771],
33	cancer-cell	NN	O	cancer-cell	nn	34	SENT_163	[p7l391t2723r671b2772],
34	production	NN	O	production	prep_of	31	SENT_163	[p7l698t2723r990b2786],
35	of	IN	O	of	_	0	SENT_163	[p7l1014t2723r1072b2771],
36	angiogenic	JJ	O	angiogenic	amod	37	SENT_163	[p7l1085t2728r1376b2787],
37	factors	NNS	O	factor	prep_of	34	SENT_163	[p7l1396t2723r1595b2780],
38	,	,	O	,	_	0	SENT_163	[p7l1396t2723r1595b2780],
39	including	VBG	O	include	_	0	SENT_163	[p7l1621t2723r1866b2787],
40	transforming	VBG	O	transform	prepc_including	3	SENT_163	[p7l1886t2732r2038b2771, p7l60t2803r272b2867],
41	growth	NN	O	growth	dep	42	SENT_163	[p7l294t2804r477b2867],
42	factor	NN	O	factor	dep	40	SENT_163	[p7l500t2803r657b2852],
43	a	DT	O	a	dep	42	SENT_163	[p7l676t2822r726b2860],
44	,	,	O	,	_	0	SENT_163	[p7l676t2822r726b2860],
45	vascular	JJ	O	vascular	amod	48	SENT_163	[p7l749t2804r969b2852],
46	endothelial	JJ	O	endothelial	amod	48	SENT_163	[p7l989t2804r1283b2852],
47	growth	NN	O	growth	nn	48	SENT_163	[p7l1309t2804r1492b2867],
48	factor	NN	O	factor	conj_and	42	SENT_163	[p7l1515t2803r1681b2860],
49	,	,	O	,	_	0	SENT_163	[p7l1515t2803r1681b2860],
50	interleukin-8	NN	O	interleukin-8	conj_and	42	SENT_163	[p7l1708t2804r2059b2860],
51	,	,	O	,	_	0	SENT_163	[p7l1708t2804r2059b2860],
52	and	CC	O	and	_	0	SENT_163	[p7l62t2884r155b2932],
53	basic	JJ	O	basic	amod	56	SENT_163	[p7l182t2884r315b2932],
54	fibroblast	NN	O	fibroblast	nn	56	SENT_163	[p7l334t2883r592b2932],
55	growth	NN	O	growth	nn	56	SENT_163	[p7l614t2884r797b2948],
56	factor	NN	O	factor	conj_and	42	SENT_163	[p7l821t2883r991b2941],
57	;	:	O	;	_	0	SENT_163	[p7l821t2883r991b2941],
58	inhibition	NN	O	inhibition	dep	56	SENT_163	[p7l1017t2884r1267b2932],
59	of	IN	O	of	_	0	SENT_163	[p7l1292t2883r1349b2932],
60	cancer-cell	JJ	O	cancer-cell	amod	61	SENT_163	[p7l1362t2884r1643b2932],
61	invasion	NN	O	invasion	prep_of	58	SENT_163	[p7l1669t2888r1885b2932],
62	and	CC	O	and	_	0	SENT_163	[p7l1911t2884r2004b2932],
63	metastasis	NN	O	metastasis	prep_of	58	SENT_163	[p7l64t2968r364b3021],
64	;	:	O	;	_	0	SENT_163	[p7l64t2968r364b3021],
65	and	CC	O	and	_	0	SENT_163	[p7l389t2964r482b3012],
66	potentiation	NN	O	potentiation	dep	85	SENT_163	[p7l509t2968r831b3027],
67	of	IN	O	of	_	0	SENT_163	[p7l856t2964r914b3012],
68	antitumor	NN	O	antitumor	nn	69	SENT_163	[p7l927t2968r1194b3012],
69	activity	NN	O	activity	prep_of	66	SENT_163	[p7l1215t2968r1404b3028],
70	of	IN	O	of	_	0	SENT_163	[p7l1425t2964r1482b3012],
71	cytotoxic	JJ	O	cytotoxic	amod	72	SENT_163	[p7l1495t2968r1732b3028],
72	drugs	NNS	O	drug	prep_of	69	SENT_163	[p7l1753t2964r1902b3028],
73	and	CC	O	and	_	0	SENT_163	[p7l1926t2964r2019b3012],
74	radiotherapy	NN	O	radiotherapy	nn	75	SENT_163	[p7l64t3043r716b3108],
75	.5	NN	NUMBER	.5	conj_and	72	SENT_163	[p7l64t3043r716b3108],
76	'	''	O	'	_	0	SENT_163	[p7l64t3043r716b3108],
77	9	CD	NUMBER	9	dep	66	SENT_163	[p7l64t3043r716b3108],
78	'	''	O	'	_	0	SENT_163	[p7l64t3043r716b3108],
79	“	NN	O	“	dep	66	SENT_163	[p7l64t3043r716b3108],
80	'	''	O	'	_	0	SENT_163	[p7l64t3043r716b3108],
81	1	CD	NUMBER	1	number	82	SENT_163	[p7l64t3043r716b3108],
82	°	CD	NUMBER	°	num	83	SENT_163	[p7l64t3043r716b3108],
83	9	CD	NUMBER	9	dep	79	SENT_163	[p7l64t3043r716b3108],
84	'	''	O	'	_	0	SENT_163	[p7l64t3043r716b3108],
85	”	NN	O	”	conj_and	42	SENT_163	[p7l64t3043r716b3108],
86	2	CD	NUMBER	2	num	85	SENT_163	[p7l64t3043r716b3108],

1	planned	VBN	O	plan	amod	3	SENT_164	[p7l562t3273r824b3347],
2	subgroup	NN	O	subgroup	nn	3	SENT_164	[p7l854t3273r1155b3348],
3	analysis	NN	O	analysis	nsubj	4	SENT_164	[p7l1185t3273r1439b3347],
4	showed	VBD	O	show	_	0	SENT_164	[p7l1470t3273r1711b3332],
5	a	DT	O	a	det	8	SENT_164	[p7l1740t3292r1773b3331],
6	significant	JJ	O	significant	amod	8	SENT_164	[p7l1802t3272r2152b3348],
7	survival	NN	O	survival	nn	8	SENT_164	[p7l564t3368r812b3427],
8	benefit	NN	O	benefit	dobj	4	SENT_164	[p7l845t3367r1073b3427],
9	only	RB	O	only	advmod	4	SENT_164	[p7l1101t3368r1239b3442],
10	in	IN	O	in	_	0	SENT_164	[p7l1267t3369r1329b3426],
11	patients	NNS	O	patient	prep_in	4	SENT_164	[p7l1360t3369r1615b3442],
12	of	IN	O	of	_	0	SENT_164	[p7l1649t3367r1724b3427],
13	Asian	JJ	MISC	asian	amod	14	SENT_164	[p7l1740t3369r1922b3426],
14	origin	NN	O	origin	prep_of	11	SENT_164	[p7l1955t3369r2148b3443],
15	and	CC	O	and	_	0	SENT_164	[p7l563t3464r681b3522],
16	in	IN	O	in	_	0	SENT_164	[p7l722t3465r785b3521],
17	those	DT	O	those	conj_and	11	SENT_164	[p7l827t3464r1001b3522],
18	who	WP	O	who	nsubj	21	SENT_164	[p7l1040t3464r1177b3523],
19	had	VBD	O	have	aux	21	SENT_164	[p7l1220t3464r1336b3522],
20	never	RB	O	never	neg	21	SENT_164	[p7l1379t3483r1550b3523],
21	smoked	VBN	O	smoke	rcmod	17	SENT_164	[p7l1592t3464r1857b3523],
22	.	.	O	.	_	0	SENT_164	[p7l1592t3464r1857b3523],

1	In	IN	O	in	_	0	SENT_165	[p7l1903t3469r1969b3521],
2	June	NNP	DATE	June	pobj	1	SENT_165	[p7l2004t3469r2148b3531],
3	2005	CD	DATE	2005	num	2	SENT_165	[p7l563t3562r733b3629],
4	,	,	O	,	_	0	SENT_165	[p7l563t3562r733b3629],
5	on	IN	O	on	_	0	SENT_165	[p7l768t3577r847b3617],
6	the	DT	O	the	det	7	SENT_165	[p7l877t3558r977b3616],
7	basis	NN	O	basis	prep_on	2	SENT_165	[p7l1007t3558r1166b3617],
8	of	IN	O	of	_	0	SENT_165	[p7l1198t3557r1273b3617],
9	the	DT	O	the	det	10	SENT_165	[p7l1289t3558r1388b3616],
10	lack	NN	O	lack	prep_of	7	SENT_165	[p7l1418t3558r1549b3617],
11	of	IN	O	of	_	0	SENT_165	[p7l1577t3557r1651b3617],
12	a	DT	O	a	det	14	SENT_165	[p7l1667t3577r1701b3616],
13	survival	NN	O	survival	nn	14	SENT_165	[p7l1731t3558r1979b3617],
14	benefit	NN	O	benefit	prep_of	10	SENT_165	[p7l2009t3558r2147b3617, p8l564t18r673b77],

1	in	IN	O	in	_	0	SENT_166	[p8l696t20r758b76],
2	the	DT	O	the	det	4	SENT_166	[p8l786t19r886b77],
3	ISEL	NNP	ORGANIZATION	ISEL	nn	4	SENT_166	[p8l912t24r1055b78],
4	study	NN	O	study	prep_in	8	SENT_166	[p8l1083t19r1263b93],
5	,	,	O	,	_	0	SENT_166	[p8l1083t19r1263b93],
6	the	DT	O	the	det	7	SENT_166	[p8l1296t19r1395b77],
7	FDA	NNP	ORGANIZATION	FDA	nsubj	8	SENT_166	[p8l1422t24r1560b77],
8	restricted	VBD	O	restrict	_	0	SENT_166	[p8l1585t19r1888b78],
9	the	DT	O	the	det	10	SENT_166	[p8l1917t19r2015b77],
10	use	NN	O	use	dobj	8	SENT_166	[p8l2043t38r2148b78],
11	of	IN	O	of	_	0	SENT_166	[p8l564t113r639b173],
12	gefitinib	NN	O	gefitinib	prep_of	10	SENT_166	[p8l651t113r928b189],
13	to	TO	O	to	_	0	SENT_166	[p8l956t126r1017b173],
14	patients	NNS	O	patient	prep_to	8	SENT_166	[p8l1043t115r1298b188],
15	participating	VBG	O	participate	dep	14	SENT_166	[p8l1325t115r1744b189],
16	in	IN	O	in	_	0	SENT_166	[p8l1767t115r1830b171],
17	a	DT	O	a	det	19	SENT_166	[p8l1855t134r1889b172],
18	clinical	JJ	O	clinical	amod	19	SENT_166	[p8l1915t114r2148b172],
19	trial	NN	O	trial	prep_in	15	SENT_166	[p8l564t209r697b267],
20	or	CC	O	or	_	0	SENT_166	[p8l744t228r810b268],
21	continuing	VBG	O	continue	dep	14	SENT_166	[p8l854t210r1208b284],
22	to	TO	O	to	aux	23	SENT_166	[p8l1252t221r1313b268],
23	benefit	VB	O	benefit	xcomp	21	SENT_166	[p8l1361t208r1589b268],
24	from	IN	O	from	_	0	SENT_166	[p8l1632t208r1789b268],
25	treatment	NN	O	treatment	prep_from	23	SENT_166	[p8l1836t221r2152b267],
26	already	RB	O	already	advmod	27	SENT_166	[p8l563t304r796b378],
27	initiated	VBN	O	initiate	partmod	25	SENT_166	[p8l815t304r1101b363],
28	.	.	O	.	_	0	SENT_166	[p8l815t304r1101b363],

1	Currently	RB	DATE	currently	advmod	5	SENT_167	[p8l1129t304r1442b378],
2	,	,	O	,	_	0	SENT_167	[p8l1129t304r1442b378],
3	gefitinib	NN	O	gefitinib	nsubj	15	SENT_167	[p8l1470t303r1747b379],
4	is	VBZ	O	be	auxpass	5	SENT_167	[p8l1771t305r1820b362],
5	marketed	VBN	O	market	_	0	SENT_167	[p8l1845t304r2148b363],
6	in	IN	O	in	_	0	SENT_167	[p8l563t401r625b458],
7	several	JJ	O	several	amod	8	SENT_167	[p8l667t400r884b459],
8	countries	NNS	O	country	prep_in	5	SENT_167	[p8l925t401r1222b459],
9	in	IN	O	in	_	0	SENT_167	[p8l1264t401r1326b458],
10	eastern	JJ	O	eastern	amod	11	SENT_167	[p8l1367t412r1598b458],
11	Asia	NNP	LOCATION	Asia	prep_in	8	SENT_167	[p8l1636t401r1775b458],
12	but	CC	O	but	_	0	SENT_167	[p8l1814t400r1919b459],
13	is	VBZ	O	be	cop	15	SENT_167	[p8l1954t401r2004b458],
14	not	RB	O	not	neg	15	SENT_167	[p8l2046t412r2152b459],
15	available	JJ	O	available	conj_but	5	SENT_167	[p8l563t495r840b554],
16	in	IN	O	in	_	0	SENT_167	[p8l879t496r941b552],
17	the	DT	O	the	det	19	SENT_167	[p8l981t495r1079b553],
18	United	NNP	LOCATION	United	nn	19	SENT_167	[p8l1118t495r1333b554],
19	States	NNPS	LOCATION	States	prep_in	15	SENT_167	[p8l1374t500r1559b554],
20	or	CC	O	or	_	0	SENT_167	[p8l1600t514r1666b554],
21	the	DT	O	the	det	23	SENT_167	[p8l1703t495r1802b553],
22	European	NNP	ORGANIZATION	European	nn	23	SENT_167	[p8l1840t501r2148b569],
23	Union	NNP	ORGANIZATION	Union	prep_in	15	SENT_167	[p8l563t592r777b650],
24	.	.	O	.	_	0	SENT_167	[p8l563t592r777b650],

1	More	RBR	O	more	advmod	2	SENT_168	[p8l658t692r823b745],
2	recently	RB	DATE	recently	advmod	9	SENT_168	[p8l851t686r1114b760],
3	,	,	O	,	_	0	SENT_168	[p8l851t686r1114b760],
4	two	CD	NUMBER	two	num	6	SENT_168	[p8l1146t698r1263b745],
5	randomized	JJ	O	randomized	amod	6	SENT_168	[p8l1292t686r1680b745],
6	phase	NN	O	phase	nsubj	9	SENT_168	[p8l1707t686r1892b760],
7	3	CD	NUMBER	3	num	8	SENT_168	[p8l1921t691r1953b745],
8	trials	NNS	O	trial	dep	6	SENT_168	[p8l1983t686r2147b744],
9	evaluated	VBD	O	evaluate	_	0	SENT_168	[p8l564t781r864b840],
10	the	DT	O	the	det	11	SENT_168	[p8l909t781r1008b839],
11	effectiveness	NN	O	effectiveness	dobj	9	SENT_168	[p8l1053t780r1462b840],
12	of	IN	O	of	_	0	SENT_168	[p8l1509t780r1583b840],
13	gefitinib	NN	O	gefitinib	nn	14	SENT_168	[p8l1614t780r1891b856],
14	monotherapy	NN	O	monotherapy	prep_of	11	SENT_168	[p8l1937t800r2147b840, p8l564t876r804b950],
15	as	IN	O	as	_	0	SENT_168	[p8l831t895r895b934],
16	compared	VBN	O	compare	prepc_as	9	SENT_168	[p8l929t876r1247b950],
17	With	IN	O	with	pcomp	16	SENT_168	[p8l1274t876r1420b935],
18	that	DT	O	that	pobj	17	SENT_168	[p8l1452t876r1580b934],
19	of	IN	O	of	_	0	SENT_168	[p8l1608t875r1682b935],
20	standard	JJ	O	standard	amod	23	SENT_168	[p8l1701t876r1984b935],
21	chemotherapy	NN	O	chemotherapy	nn	23	SENT_168	[p8l2015t876r2147b934, p8l563t971r909b1045],
22	(	NN	O	(	nn	23	SENT_168	[p8l946t971r1289b1039],
23	docetaxel	NN	O	docetaxel	prep_of	18	SENT_168	[p8l946t971r1289b1039],
24	)	RB	O	)	advmod	23	SENT_168	[p8l946t971r1289b1039],
25	as	IN	O	as	_	0	SENT_168	[p8l1329t990r1393b1029],
26	second-line	JJ	O	second-line	amod	27	SENT_168	[p8l1433t971r1799b1030],
27	treatment	NN	O	treatment	prep_as	23	SENT_168	[p8l1836t983r2152b1029],
28	for	IN	O	for	_	0	SENT_168	[p8l564t1065r655b1125],
29	chemotherapy-refractory	JJ	O	chemotherapy-refractory	amod	34	SENT_168	[p8l681t1065r1477b1140],
30	non	JJ	O	non	amod	34	SENT_168	[p8l1501t1066r1981b1125],
31	—	NN	O	—	nn	34	SENT_168	[p8l1501t1066r1981b1125],
32	small-cell	NN	O	small-cell	nn	34	SENT_168	[p8l1501t1066r1981b1125],
33	lung	NN	O	lung	nn	34	SENT_168	[p8l2006t1066r2151b1141],
34	cancer	NN	O	cancer	prep_for	27	SENT_168	[p8l564t1180r787b1220],
35	.	.	O	.	_	0	SENT_168	[p8l564t1180r787b1220],

1	The	DT	O	the	det	3	SENT_169	[p8l832t1161r952b1219],
2	V-15-32	JJ	O	v-15-32	amod	3	SENT_169	[p8l993t1166r1230b1220],
3	trial	NN	O	trial	nsubj	9	SENT_169	[p8l1275t1161r1425b1232],
4	,	,	O	,	_	0	SENT_169	[p8l1275t1161r1425b1232],
5	conducted	VBN	O	conduct	partmod	3	SENT_169	[p8l1473t1161r1803b1220],
6	in	IN	O	in	_	0	SENT_169	[p8l1846t1162r1908b1218],
7	Japan	NNP	LOCATION	Japan	prep_in	5	SENT_169	[p8l1945t1167r2144b1235],
8	,	,	O	,	_	0	SENT_169	[p8l1945t1167r2144b1235],
9	failed	VBD	O	fail	_	0	SENT_169	[p8l564t1255r742b1315],
10	to	TO	O	to	aux	11	SENT_169	[p8l773t1268r834b1315],
11	demonstrate	VB	O	demonstrate	xcomp	9	SENT_169	[p8l866t1256r1267b1315],
12	the	DT	O	the	det	13	SENT_169	[p8l1298t1256r1397b1314],
13	noninferiority	NN	O	noninferiority	dobj	11	SENT_169	[p8l1428t1255r1881b1330],
14	of	IN	O	of	_	0	SENT_169	[p8l1909t1255r1984b1315],
15	gefitinib	NN	O	gefitinib	prep_of	13	SENT_169	[p8l2000t1255r2147b1331, p8l11t1525r213b1604],

1	in	IN	O	in	_	0	SENT_170	[p8l252t1526r335b1603],
2	terms	NNS	O	term	prep_in	26	SENT_170	[p8l375t1542r618b1603],
3	of	IN	O	of	_	0	SENT_170	[p8l660t1524r760b1604],
4	overall	JJ	O	overall	amod	5	SENT_170	[p8l781t1525r1066b1604],
5	survival	NN	O	survival	prep_of	2	SENT_170	[p8l1106t1525r1460b1621],
6	,	,	O	,	_	0	SENT_170	[p8l1106t1525r1460b1621],
7	which	WDT	O	which	nsubj	12	SENT_170	[p8l1500t1525r1763b1604],
8	was	VBD	O	be	cop	12	SENT_170	[p8l1797t1551r1960b1604],
9	the	DT	O	the	det	12	SENT_170	[p8l2001t1525r2134b1603],
10	primary	JJ	O	primary	amod	12	SENT_170	[p8l10t1655r360b1754],
11	end	NN	O	end	nn	12	SENT_170	[p8l398t1654r551b1733],
12	point	NN	O	point	rcmod	5	SENT_170	[p8l592t1655r923b1754],
13	.34	CD	NUMBER	.34	num	12	SENT_170	[p8l592t1655r923b1754],
14	However	RB	O	however	advmod	12	SENT_170	[p8l964t1662r1358b1750],
15	,	,	O	,	_	0	SENT_170	[p8l964t1662r1358b1750],
16	in	IN	O	in	_	0	SENT_170	[p8l1406t1655r1489b1731],
17	a	DT	O	a	det	20	SENT_170	[p8l1531t1680r1575b1732],
18	large	JJ	O	large	amod	20	SENT_170	[p8l1615t1654r1829b1755],
19	multicenter	JJ	O	multicenter	amod	20	SENT_170	[p8l1872t1654r2133b1733, p8l12t1798r275b1859],
20	trial	NN	O	trial	prep_in	12	SENT_170	[p8l329t1782r529b1877],
21	,	,	O	,	_	0	SENT_170	[p8l329t1782r529b1877],
22	this	DT	O	this	det	24	SENT_170	[p8l593t1782r752b1859],
23	end	NN	O	end	nn	24	SENT_170	[p8l812t1782r965b1860],
24	point	NN	O	point	nsubjpass	26	SENT_170	[p8l1020t1783r1250b1881],
25	was	VBD	O	be	auxpass	26	SENT_170	[p8l1298t1808r1460b1861],
26	achieved	VBN	O	achieve	_	0	SENT_170	[p8l1518t1782r1886b1861],
27	with	IN	O	with	_	0	SENT_170	[p8l1939t1782r2134b1861],
28	gefitinib	NN	O	gefitinib	prep_with	26	SENT_170	[p8l11t1909r382b2011],
29	after	IN	O	after	_	0	SENT_170	[p8l484t1909r686b1988],
30	platinum	NN	O	platinum	nn	31	SENT_170	[p8l783t1910r1458b2010],
31	—	NN	O	—	prep_after	26	SENT_170	[p8l783t1910r1458b2010],
32	based	VBN	O	base	partmod	31	SENT_170	[p8l783t1910r1458b2010],
33	therapy	NN	O	therapy	nsubj	35	SENT_170	[p8l1559t1910r1881b2010],
34	had	VBD	O	have	aux	35	SENT_170	[p8l1977t1910r2134b1989],
35	failed	VBN	O	fail	ccomp	32	SENT_170	[p8l11t2036r348b2116],
36	.35	CD	NUMBER	.35	dobj	35	SENT_170	[p8l11t2036r348b2116],
37	In	IN	O	in	_	0	SENT_170	[p8l402t2045r490b2115],
38	addition	NN	O	addition	prep_in	45	SENT_170	[p8l542t2037r921b2133],
39	,	,	O	,	_	0	SENT_170	[p8l542t2037r921b2133],
40	the	DT	O	the	det	44	SENT_170	[p8l980t2037r1113b2115],
41	side	NN	O	side	nn	44	SENT_170	[p8l1167t2036r1615b2116],
42	—	NN	O	—	nn	44	SENT_170	[p8l1167t2036r1615b2116],
43	effect	NN	O	effect	nn	44	SENT_170	[p8l1167t2036r1615b2116],
44	profile	NN	O	profile	nsubj	45	SENT_170	[p8l1660t2036r1948b2137],
45	appeared	VBD	O	appear	rcmod	36	SENT_170	[p8l2001t2063r2133b2137, p8l10t2166r300b2266],
46	to	TO	O	to	aux	47	SENT_170	[p8l341t2183r422b2245],
47	favor	VB	O	favor	xcomp	45	SENT_170	[p8l463t2165r676b2245],
48	gef1tinib	NN	O	gef1tinib	dobj	47	SENT_170	[p8l713t2165r1180b2267],
49	.35	CD	NUMBER	.35	num	48	SENT_170	[p8l713t2165r1180b2267],

1	In	IN	O	in	_	0	SENT_171	[p8l139t2301r227b2371],
2	a	DT	O	a	det	5	SENT_171	[p8l273t2319r317b2371],
3	phase	NN	O	phase	nn	5	SENT_171	[p8l359t2293r608b2393],
4	2	CD	NUMBER	2	num	5	SENT_171	[p8l654t2300r700b2371],
5	study	NN	O	study	prep_in	25	SENT_171	[p8l749t2293r992b2393],
6	,	,	O	,	_	0	SENT_171	[p8l749t2293r992b2393],
7	the	DT	O	the	det	9	SENT_171	[p8l1043t2293r1175b2371],
8	antitumor	NN	O	antitumor	nn	9	SENT_171	[p8l1221t2294r1659b2373],
9	activity	NN	O	activity	appos	5	SENT_171	[p8l1701t2294r2010b2393],
10	of	IN	O	of	_	0	SENT_171	[p8l2052t2292r2152b2372],
11	erlotinib	NN	O	erlotinib	prep_of	9	SENT_171	[p8l12t2422r379b2501],
12	as	IN	O	as	_	0	SENT_171	[p8l425t2448r511b2500],
13	a	DT	O	a	det	15	SENT_171	[p8l559t2448r603b2500],
14	single	JJ	O	single	amod	15	SENT_171	[p8l650t2422r901b2523],
15	agent	NN	O	agent	prep_as	11	SENT_171	[p8l948t2439r1184b2523],
16	in	IN	O	in	_	0	SENT_171	[p8l1224t2423r1308b2499],
17	heavily	RB	O	heavily	advmod	18	SENT_171	[p8l1354t2422r1654b2522],
18	pretreated	JJ	O	pretreated	amod	21	SENT_171	[p8l1694t2422r2134b2522],
19	non	JJ	O	non	amod	21	SENT_171	[p8l11t2550r654b2629],
20	—	NN	O	—	nn	21	SENT_171	[p8l11t2550r654b2629],
21	small-cell	NN	O	small-cell	prep_in	15	SENT_171	[p8l11t2550r654b2629],
22	lung	NN	O	lung	nn	23	SENT_171	[p8l701t2550r895b2651],
23	cancer	NN	O	cancer	nsubj	25	SENT_171	[p8l943t2576r1223b2628],
24	was	VBD	O	be	cop	25	SENT_171	[p8l1265t2576r1428b2629],
25	similar	JJ	O	similar	_	0	SENT_171	[p8l1481t2550r1787b2628],
26	to	TO	O	to	_	0	SENT_171	[p8l1834t2567r1915b2629],
27	that	DT	O	that	prep_to	25	SENT_171	[p8l1967t2550r2139b2628],
28	of	IN	O	of	_	0	SENT_171	[p8l12t2677r112b2757],
29	gefitinib	NN	O	gefitinib	prep_of	27	SENT_171	[p8l162t2677r634b2779],
30	.	.	O	.	_	0	SENT_171	[p8l162t2677r634b2779],

1	-	:	O	-	_	0	SENT_172	[p8l162t2677r634b2779],
2	‘	CD	NUMBER	‘	_	0	SENT_172	[p8l162t2677r634b2779],
3	$	$	MONEY	$	amod	2	SENT_172	[p8l162t2677r634b2779],
4	6	CD	MONEY	6	number	3	SENT_172	[p8l162t2677r634b2779],
5	More	RBR	O	more	advmod	6	SENT_172	[p8l700t2686r922b2757],
6	important	JJ	O	important	amod	2	SENT_172	[p8l990t2679r1452b2778],
7	,	,	O	,	_	0	SENT_172	[p8l990t2679r1452b2778],
8	in	IN	O	in	_	0	SENT_172	[p8l1526t2679r1609b2756],
9	the	DT	O	the	det	12	SENT_172	[p8l1678t2678r1811b2756],
10	BR	NN	O	br	nn	12	SENT_172	[p8l1878t2684r2134b2761],
11	.21	CD	NUMBER	.21	num	12	SENT_172	[p8l1878t2684r2134b2761],
12	trial	NN	O	trial	prep_in	2	SENT_172	[p8l11t2806r211b2901],
13	,	,	O	,	_	0	SENT_172	[p8l11t2806r211b2901],
14	a	DT	O	a	det	15	SENT_172	[p8l261t2832r306b2883],
15	phase	NN	O	phase	appos	2	SENT_172	[p8l346t2806r596b2905],
16	3	CD	NUMBER	3	dep	15	SENT_172	[p8l642t2812r710b2901],
17	,	,	O	,	_	0	SENT_172	[p8l642t2812r710b2901],
18	randomized	VBN	O	randomize	dep	2	SENT_172	[p8l760t2806r1304b2901],
19	,	,	O	,	_	0	SENT_172	[p8l760t2806r1304b2901],
20	double	JJ	O	double	amod	27	SENT_172	[p8l1354t2806r1924b2901],
21	—	RB	O	—	advmod	20	SENT_172	[p8l1354t2806r1924b2901],
22	blind	JJ	O	blind	amod	27	SENT_172	[p8l1354t2806r1924b2901],
23	,	,	O	,	_	0	SENT_172	[p8l1354t2806r1924b2901],
24	placebo	NN	O	placebo	dep	27	SENT_172	[p8l1972t2806r2133b2905, p8l12t2934r688b3013],
25	—	NN	O	—	nn	27	SENT_172	[p8l1972t2806r2133b2905, p8l12t2934r688b3013],
26	controlled	JJ	O	controlled	amod	27	SENT_172	[p8l1972t2806r2133b2905, p8l12t2934r688b3013],
27	study	NN	O	study	nsubj	28	SENT_172	[p8l763t2934r992b3034],
28	involving	VBG	O	involve	dep	18	SENT_172	[p8l1060t2934r1457b3035],
29	patients	NNS	O	patient	dobj	28	SENT_172	[p8l1526t2935r1867b3034],
30	with	IN	O	with	_	0	SENT_172	[p8l1939t2934r2134b3013],
31	pretreated	JJ	O	pretreated	amod	36	SENT_172	[p8l10t3062r450b3162],
32	non	JJ	O	non	amod	36	SENT_172	[p8l494t3062r1137b3141],
33	—	NN	O	—	nn	36	SENT_172	[p8l494t3062r1137b3141],
34	small-cell	NN	O	small-cell	nn	36	SENT_172	[p8l494t3062r1137b3141],
35	lung	NN	O	lung	nn	36	SENT_172	[p8l1180t3062r1374b3163],
36	cancer	NN	O	cancer	prep_with	28	SENT_172	[p8l1416t3088r1714b3158],
37	,	,	O	,	_	0	SENT_172	[p8l1416t3088r1714b3158],
38	erlotinib	NN	O	erlotinib	nsubj	39	SENT_172	[p8l1766t3062r2132b3141],
39	increased	VBD	O	increase	parataxis	18	SENT_172	[p8l10t3190r419b3268],
40	median	JJ	O	median	amod	41	SENT_172	[p8l480t3190r803b3268],
41	survival	NN	O	survival	dobj	39	SENT_172	[p8l866t3190r1198b3269],
42	by	IN	O	by	_	0	SENT_172	[p8l1260t3190r1357b3289],
43	approximately	RB	O	approximately	quantmod	44	SENT_172	[p8l1412t3190r2029b3289],
44	2	CD	DURATION	2	num	45	SENT_172	[p8l2086t3196r2133b3267],
45	months	NNS	NUMBER	month	prep_by	39	SENT_172	[p8l11t3318r338b3396],
46	as	IN	O	as	mark	59	SENT_172	[p8l393t3344r478b3395],
47	compared	VBN	O	compare	_	0	SENT_172	[p8l535t3318r961b3417],
48	with	IN	O	with	prepc_compared_with	59	SENT_172	[p8l1011t3318r1206b3397],
49	placebo	NN	O	placebo	nn	51	SENT_172	[p8l1258t3318r1587b3417],
50	(	CD	NUMBER	(	num	51	SENT_172	[p8l1647t3318r1905b3408],
51	Table	NNP	O	Table	pobj	59	SENT_172	[p8l1647t3318r1905b3408],
52	3	CD	NUMBER	3	number	53	SENT_172	[p8l1959t3324r2134b3408],
53	)	CD	NUMBER	)	dep	51	SENT_172	[p8l1959t3324r2134b3408],
54	.37	CD	NUMBER	.37	num	55	SENT_172	[p8l1959t3324r2134b3408],
55	Responses	NNS	O	response	nsubj	59	SENT_172	[p8l10t3453r463b3546],
56	were	VBD	O	be	cop	59	SENT_172	[p8l514t3472r716b3525],
57	significantly	RB	O	significantly	advmod	59	SENT_172	[p8l772t3445r1315b3547],
58	more	RBR	O	more	advmod	59	SENT_172	[p8l1364t3472r1583b3525],
59	frequent	JJ	O	frequent	advcl	39	SENT_172	[p8l1638t3445r2002b3546],
60	in	IN	O	in	_	0	SENT_172	[p8l2051t3447r2134b3524],
61	Women	NNS	O	woman	prep_in	59	SENT_172	[p8l7t3599r346b3669],
62	,	,	O	,	_	0	SENT_172	[p8l7t3599r346b3669],
63	in	IN	O	in	_	0	SENT_172	[p8l404t3575r487b3651],
64	patients	NNS	O	patient	prep_in	18	SENT_172	[p8l540t3575r881b3673],
65	with	IN	O	with	_	0	SENT_172	[p8l932t3574r1127b3653],
66	adenocarcinoma	NN	O	adenocarcinoma	prep_with	64	SENT_172	[p8l1181t3574r1918b3669],
67	,	,	O	,	_	0	SENT_172	[p8l1181t3574r1918b3669],
68	and	CC	O	and	_	0	SENT_172	[p8l1976t3574r2134b3652],
69	in	IN	O	in	_	0	SENT_172	[p8l10t3703r94b3780],
70	patients	NNS	O	patient	prep_in	64	SENT_172	[p8l134t3703r476b3802],
71	with	IN	O	with	_	0	SENT_172	[p8l515t3702r710b3781],
72	no	DT	O	no	det	73	SENT_172	[p8l752t3728r857b3781],
73	history	NN	O	history	prep_with	70	SENT_172	[p8l900t3702r1205b3802],
74	of	IN	O	of	_	0	SENT_172	[p8l1242t3701r1343b3781],
75	smoking	NN	O	smoking	prep_of	73	SENT_172	[p8l1367t3702r1763b3803],
76	.	.	O	.	_	0	SENT_172	[p8l1367t3702r1763b3803],

1	However	RB	O	however	_	0	SENT_173	[p8l1810t3710r2133b3781, p9l12t47r111b117],
2	,	,	O	,	_	0	SENT_173	[p8l1810t3710r2133b3781, p9l12t47r111b117],

1	a	DT	O	a	det	4	SENT_174	[p9l150t47r194b99],
2	signiﬁcant	JJ	O	signiﬁcant	amod	4	SENT_174	[p9l228t20r697b122],
3	survival	NN	O	survival	nn	4	SENT_174	[p9l727t21r1059b100],
4	advantage	NN	O	advantage	nsubjpass	6	SENT_174	[p9l1092t21r1523b122],
5	was	VBD	O	be	auxpass	6	SENT_174	[p9l1553t47r1716b100],
6	observed	VBN	O	observe	_	0	SENT_174	[p9l1753t21r2134b100],
7	in	IN	O	in	_	0	SENT_174	[p9l10t150r94b227],
8	all	DT	O	all	det	10	SENT_174	[p9l157t149r262b227],
9	patient	NN	O	patient	nn	10	SENT_174	[p9l323t150r626b249],
10	subgroups	NNS	O	subgroup	prep_in	6	SENT_174	[p9l686t149r1132b250],
11	after	IN	O	after	_	0	SENT_174	[p9l1197t148r1400b227],
12	treatment	NN	O	treatment	prep_after	6	SENT_174	[p9l1461t166r1885b227],
13	with	IN	O	with	_	0	SENT_174	[p9l1939t149r2134b228],
14	erlotinib	NN	O	erlotinib	prep_with	12	SENT_174	[p9l12t276r379b355],
15	as	IN	O	as	prep	6	SENT_174	[p9l425t302r510b354],
16	compared	VBN	O	compare	_	0	SENT_174	[p9l559t276r985b376],
17	with	IN	O	with	prepc_compared_with	6	SENT_174	[p9l1026t276r1221b356],
18	placebo	NN	O	placebo	pobj	6	SENT_174	[p9l1265t276r1616b376],
19	.	.	O	.	_	0	SENT_174	[p9l1265t276r1616b376],

1	Quality	JJ	O	quality	amod	4	SENT_175	[p9l1668t275r2132b376, p9l10t403r146b482],
2	—	NN	O	—	nn	4	SENT_175	[p9l1668t275r2132b376, p9l10t403r146b482],
3	oflife	NN	O	oflife	nn	4	SENT_175	[p9l1668t275r2132b376, p9l10t403r146b482],
4	analysis	NN	O	analysis	nsubj	5	SENT_175	[p9l197t404r536b504],
5	supported	VBD	O	support	_	0	SENT_175	[p9l590t404r1023b504],
6	the	DT	O	the	det	8	SENT_175	[p9l1074t404r1206b482],
7	palliative	JJ	O	palliative	amod	8	SENT_175	[p9l1256t404r1649b504],
8	benefit	NN	O	benefit	dobj	5	SENT_175	[p9l1701t403r2006b483],
9	of	IN	O	of	_	0	SENT_175	[p9l2052t403r2152b483],
10	erlotinib	NN	O	erlotinib	prep_of	8	SENT_175	[p9l12t533r379b612],
11	in	IN	O	in	_	0	SENT_175	[p9l442t534r525b611],
12	extending	VBG	O	extend	prepc_in	5	SENT_175	[p9l588t533r1016b634],
13	the	DT	O	the	det	14	SENT_175	[p9l1076t533r1209b611],
14	time	NN	O	time	iobj	12	SENT_175	[p9l1272t534r1464b611],
15	during	IN	O	during	_	0	SENT_175	[p9l1528t533r1816b634],
16	which	WDT	O	which	rel	19	SENT_175	[p9l1871t533r2134b612],
17	patients	NNS	O	patient	nsubj	19	SENT_175	[p9l10t662r351b761],
18	were	VBD	O	be	cop	19	SENT_175	[p9l381t687r583b740],
19	free	JJ	O	free	dep	25	SENT_175	[p9l616t660r779b739],
20	of	IN	O	of	_	0	SENT_175	[p9l812t660r912b740],
21	symptoms	NNS	O	symptom	prep_of	19	SENT_175	[p9l928t678r1371b761],
22	(	JJ	O	(	dep	23	SENT_175	[p9l1411t661r1721b762],
23	cough	NN	O	cough	amod	21	SENT_175	[p9l1411t661r1721b762],
24	,	,	O	,	_	0	SENT_175	[p9l1411t661r1721b762],
25	dyspnea	NN	O	dyspnea	dobj	12	SENT_175	[p9l1761t661r2129b761],
26	,	,	O	,	_	0	SENT_175	[p9l1761t661r2129b761],
27	and	CC	O	and	_	0	SENT_175	[p9l10t788r168b867],
28	pain	NN	O	pain	dobj	12	SENT_175	[p9l211t789r402b888],
29	.33	CD	NUMBER	.33	num	28	SENT_175	[p9l438t794r530b867],
30	On	IN	O	on	_	0	SENT_175	[p9l576t795r702b867],
31	the	DT	O	the	det	32	SENT_175	[p9l748t788r880b866],
32	basis	NN	O	basis	prep_on	39	SENT_175	[p9l926t788r1136b867],
33	of	IN	O	of	_	0	SENT_175	[p9l1184t787r1284b867],
34	these	DT	O	these	det	35	SENT_175	[p9l1312t788r1534b866],
35	results	NNS	O	result	prep_of	32	SENT_175	[p9l1580t788r1887b884],
36	,	,	O	,	_	0	SENT_175	[p9l1580t788r1887b884],
37	erlotinib	NN	O	erlotinib	nsubjpass	39	SENT_175	[p9l1937t788r2133b867, p9l11t917r213b995],
38	was	VBD	O	be	auxpass	39	SENT_175	[p9l273t943r436b996],
39	approved	VBN	O	approve	rcmod	28	SENT_175	[p9l500t917r890b1016],
40	by	IN	O	by	_	0	SENT_175	[p9l953t917r1050b1016],
41	the	DT	O	the	det	42	SENT_175	[p9l1110t917r1242b994],
42	FDA	NNP	ORGANIZATION	FDA	agent	39	SENT_175	[p9l1304t923r1489b994],
43	in	IN	O	in	_	0	SENT_175	[p9l1548t918r1632b994],
44	November	NNP	DATE	November	prep_in	42	SENT_175	[p9l1692t917r2136b996],
45	2004	CD	DATE	2004	num	44	SENT_175	[p9l11t1051r220b1123],
46	and	CC	O	and	_	0	SENT_175	[p9l259t1045r416b1123],
47	by	IN	O	by	_	0	SENT_175	[p9l456t1045r553b1144],
48	the	DT	O	the	det	51	SENT_175	[p9l588t1045r720b1123],
49	European	JJ	ORGANIZATION	european	amod	51	SENT_175	[p9l758t1052r1170b1144],
50	Medicines	NNP	ORGANIZATION	Medicines	nn	51	SENT_175	[p9l1207t1045r1644b1123],
51	Evaluation	NN	ORGANIZATION	evaluation	agent	39	SENT_175	[p9l1683t1045r2134b1124],
52	Agency	NNP	ORGANIZATION	Agency	dep	39	SENT_175	[p9l7t1181r322b1274],
53	(	CD	NUMBER	(	num	52	SENT_175	[p9l358t1180r678b1264],
54	EMEA	NNP	ORGANIZATION	EMEA	dep	39	SENT_175	[p9l358t1180r678b1264],
55	)	CD	NUMBER	)	num	54	SENT_175	[p9l358t1180r678b1264],
56	in	IN	O	in	_	0	SENT_175	[p9l718t1174r801b1251],
57	October	NNP	DATE	October	prep_in	39	SENT_175	[p9l837t1173r1183b1252],
58	2005	CD	DATE	2005	num	57	SENT_175	[p9l1215t1180r1418b1252],
59	for	IN	O	for	_	0	SENT_175	[p9l1456t1172r1579b1252],
60	second	JJ	ORDINAL	second	amod	61	SENT_175	[p9l1613t1173r1940b1252],
61	—	NN	O	—	prep_for	39	SENT_175	[p9l1613t1173r1940b1252],
62	and	CC	O	and	_	0	SENT_175	[p9l1976t1173r2134b1252],
63	third	JJ	ORDINAL	third	amod	66	SENT_175	[p9l11t1300r418b1379],
64	—	NN	O	—	nn	66	SENT_175	[p9l11t1300r418b1379],
65	line	NN	O	line	nn	66	SENT_175	[p9l11t1300r418b1379],
66	treatment	NN	O	treatment	dep	70	SENT_175	[p9l476t1317r900b1378],
67	of	IN	O	of	_	0	SENT_175	[p9l953t1299r1053b1379],
68	chemotherapy	NN	O	chemotherapy	prep_of	66	SENT_175	[p9l1093t1300r2129b1400],
69	—	CD	NUMBER	—	num	68	SENT_175	[p9l1093t1300r2129b1400],
70	resistant	JJ	O	resistant	conj_and	39	SENT_175	[p9l1093t1300r2129b1400],
71	,	,	O	,	_	0	SENT_175	[p9l1093t1300r2129b1400],
72	advanced	JJ	O	advanced	amod	74	SENT_175	[p9l10t1429r399b1508],
73	non	JJ	O	non	amod	74	SENT_175	[p9l439t1429r1068b1508],
74	—	NN	O	—	iobj	12	SENT_175	[p9l439t1429r1068b1508],
75	small	JJ	O	small	amod	79	SENT_175	[p9l439t1429r1068b1508],
76	—	NN	O	—	nn	79	SENT_175	[p9l439t1429r1068b1508],
77	cell	NN	O	cell	nn	79	SENT_175	[p9l439t1429r1068b1508],
78	lung	NN	O	lung	nn	79	SENT_175	[p9l1106t1429r1296b1530],
79	cancer	NN	O	cancer	dobj	12	SENT_175	[p9l1335t1455r1627b1508],
80	.	.	O	.	_	0	SENT_175	[p9l1335t1455r1627b1508],

1	Several	JJ	O	several	amod	2	SENT_176	[p9l1675t1429r1967b1508],
2	hypotheses	NNS	O	hypothesis	nsubjpass	5	SENT_176	[p9l2007t1429r2133b1529, p9l10t1556r381b1656],
3	have	VBP	O	have	aux	5	SENT_176	[p9l425t1556r611b1636],
4	been	VBN	O	be	auxpass	5	SENT_176	[p9l653t1556r851b1635],
5	proposed	VBN	O	propose	_	0	SENT_176	[p9l891t1556r1285b1656],
6	as	IN	O	as	_	0	SENT_176	[p9l1326t1582r1410b1634],
7	to	TO	O	to	prepc_as_to	5	SENT_176	[p9l1454t1573r1534b1635],
8	Why	WRB	O	why	advmod	12	SENT_176	[p9l1572t1556r1748b1656],
9	the	DT	O	the	det	10	SENT_176	[p9l1785t1556r1916b1634],
10	efficacy	NN	O	efficacy	nsubj	12	SENT_176	[p9l1958t1555r2133b1634, p9l12t1711r193b1785],
11	seems	VBZ	O	seem	cop	12	SENT_176	[p9l225t1711r480b1763],
12	different	JJ	O	different	pcomp	5	SENT_176	[p9l518t1684r886b1764],
13	for	IN	O	for	_	0	SENT_176	[p9l915t1684r1036b1764],
14	gefitinib	NN	O	gefitinib	prep_for	12	SENT_176	[p9l1068t1684r1431b1786],
15	and	CC	O	and	_	0	SENT_176	[p9l1467t1685r1623b1764],
16	erlotinib	NN	O	erlotinib	prep_for	12	SENT_176	[p9l1659t1685r2016b1764],
17	in	IN	O	in	_	0	SENT_176	[p9l2052t1686r2134b1763],
18	the	DT	O	the	det	21	SENT_176	[p9l11t1813r144b1890],
19	similar	JJ	O	similar	amod	21	SENT_176	[p9l181t1813r487b1890],
20	BR	NN	O	br	nn	21	SENT_176	[p9l519t1819r774b1896],
21	.21	NN	NUMBER	.21	prep_in	14	SENT_176	[p9l519t1819r774b1896],
22	and	CC	O	and	_	0	SENT_176	[p9l810t1813r968b1891],
23	ISEL	NN	O	isel	nn	24	SENT_176	[p9l1002t1819r1193b1891],
24	phase	NN	O	phase	conj_and	14	SENT_176	[p9l1225t1813r1475b1912],
25	3	CD	NUMBER	3	num	26	SENT_176	[p9l1512t1819r1555b1892],
26	studies	NNS	O	study	dep	24	SENT_176	[p9l1596t1813r1920b1892],
27	.	.	O	.	_	0	SENT_176	[p9l1596t1813r1920b1892],

1	One	CD	NUMBER	one	num	3	SENT_177	[p9l1962t1819r2134b1891],
2	possible	JJ	O	possible	amod	3	SENT_177	[p9l10t1941r352b2041],
3	explanation	NN	O	explanation	nsubj	5	SENT_177	[p9l386t1941r881b2041],
4	is	VBZ	O	be	cop	5	SENT_177	[p9l914t1942r979b2019],
5	dosing	NN	O	dosing	_	0	SENT_177	[p9l1015t1941r1318b2042],
6	:	:	O	:	_	0	SENT_177	[p9l1015t1941r1318b2042],
7	erlotinib	NN	O	erlotinib	nsubjpass	9	SENT_177	[p9l1357t1941r1715b2020],
8	was	VBD	O	be	auxpass	9	SENT_177	[p9l1745t1967r1905b2020],
9	used	VBN	O	use	parataxis	5	SENT_177	[p9l1940t1941r2134b2020],
10	at	IN	O	at	_	0	SENT_177	[p9l10t2086r88b2147],
11	the	DT	O	the	det	12	SENT_177	[p9l114t2069r245b2147],
12	maximum	NN	O	maximum	prep_at	9	SENT_177	[p9l275t2070r715b2148],
13	tolerated	VBD	O	tolerate	partmod	12	SENT_177	[p9l746t2069r1114b2148],
14	dose	NN	O	dose	dobj	13	SENT_177	[p9l1145t2069r1358b2165],
15	,	,	O	,	_	0	SENT_177	[p9l1145t2069r1358b2165],
16	Whereas	IN	O	whereas	mark	19	SENT_177	[p9l1389t2069r1735b2148],
17	gefitinib	NN	O	gefitinib	nsubjpass	19	SENT_177	[p9l1767t2068r2132b2170],
18	was	VBD	O	be	auxpass	19	SENT_177	[p9l6t2223r169b2276],
19	provided	VBN	O	provide	dep	5	SENT_177	[p9l210t2197r584b2296],
20	at	IN	O	at	_	0	SENT_177	[p9l623t2213r702b2274],
21	a	DT	O	a	det	24	SENT_177	[p9l735t2223r780b2274],
22	much	RB	O	much	advmod	23	SENT_177	[p9l817t2197r1056b2276],
23	lower	JJR	O	lower	amod	24	SENT_177	[p9l1095t2197r1332b2276],
24	dose	NN	O	dose	prep_at	19	SENT_177	[p9l1370t2197r1664b2275],
25	.	.	O	.	_	0	SENT_177	[p9l1370t2197r1664b2275],

1	”	NN	O	”	_	0	SENT_178	[p9l1370t2197r1664b2275],

1	On	IN	O	on	_	0	SENT_179	[p9l140t2331r266b2403],
2	the	DT	O	the	det	3	SENT_179	[p9l314t2324r446b2402],
3	basis	NN	O	basis	pobj	1	SENT_179	[p9l495t2324r706b2403],
4	of	IN	O	of	_	0	SENT_179	[p9l755t2323r855b2403],
5	preclinical	JJ	O	preclinical	amod	6	SENT_179	[p9l882t2324r1338b2424],
6	data	NNS	O	datum	prep_of	3	SENT_179	[p9l1385t2324r1568b2403],
7	demonstrating	VBG	O	demonstrate	partmod	6	SENT_179	[p9l1614t2324r2133b2403, p9l10t2454r149b2554],
8	that	IN	O	that	complm	9	SENT_179	[p9l193t2453r365b2531],
9	anti	JJ	O	anti	dep	7	SENT_179	[p9l406t2454r860b2536],
10	.	.	O	.	_	0	SENT_179	[p9l406t2454r860b2536],

1	—	NN	O	—	_	0	SENT_180	[p9l406t2454r860b2536],
2	.	.	O	.	_	0	SENT_180	[p9l406t2454r860b2536],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_181	[p9l406t2454r860b2536],
2	drugs	NNS	O	drug	nsubj	3	SENT_181	[p9l896t2453r1140b2554],
3	potentiate	VBP	O	potentiate	_	0	SENT_181	[p9l1186t2454r1622b2553],
4	the	DT	O	the	det	8	SENT_181	[p9l1668t2453r1801b2531],
5	antitu	JJ	O	antitu	amod	8	SENT_181	[p9l1846t2454r2133b2532],
6	—	NN	O	—	nn	8	SENT_181	[p9l1846t2454r2133b2532],
7	mor	NN	O	mor	nn	8	SENT_181	[p9l11t2607r189b2660],
8	activity	NN	O	activity	dobj	3	SENT_181	[p9l238t2582r556b2681],
9	of	IN	O	of	_	0	SENT_181	[p9l604t2580r705b2660],
10	cytotoxic	JJ	O	cytotoxic	amod	11	SENT_181	[p9l740t2582r1136b2681],
11	drugs	NNS	O	drug	prep_of	8	SENT_181	[p9l1189t2581r1462b2682],
12	,	,	O	,	_	0	SENT_181	[p9l1189t2581r1462b2682],
13	four	CD	NUMBER	four	num	14	SENT_181	[p9l1520t2580r1703b2660],
14	phase	NN	O	phase	appos	11	SENT_181	[p9l1751t2581r2005b2681],
15	3	CD	NUMBER	3	dep	14	SENT_181	[p9l2059t2588r2128b2677],
16	,	,	O	,	_	0	SENT_181	[p9l2059t2588r2128b2677],
17	double	JJ	O	double	advmod	14	SENT_181	[p9l12t2709r594b2804],
18	—	RB	O	—	advmod	19	SENT_181	[p9l12t2709r594b2804],
19	blind	JJ	O	blind	amod	14	SENT_181	[p9l12t2709r594b2804],
20	,	,	O	,	_	0	SENT_181	[p9l12t2709r594b2804],
21	placebo-controlled	JJ	O	placebo-controlled	amod	25	SENT_181	[p9l672t2709r1524b2808],
22	,	,	O	,	_	0	SENT_181	[p9l672t2709r1524b2808],
23	randomized	JJ	O	randomized	amod	25	SENT_181	[p9l1603t2709r2134b2787],
24	clinical	JJ	O	clinical	amod	25	SENT_181	[p9l12t2837r329b2915],
25	trials	NNS	O	trial	appos	14	SENT_181	[p9l363t2837r582b2915],
26	examined	VBD	O	examine	rcmod	25	SENT_181	[p9l619t2837r1039b2916],
27	the	DT	O	the	det	28	SENT_181	[p9l1073t2837r1206b2915],
28	combination	NN	O	combination	dobj	26	SENT_181	[p9l1241t2837r1787b2916],
29	of	IN	O	of	_	0	SENT_181	[p9l1822t2836r1922b2916],
30	erlotinib	NN	O	erlotinib	prep_of	28	SENT_181	[p9l1938t2837r2133b2916, p9l11t2965r213b3044],

1	or	CC	O	or	dep	2	SENT_182	[p9l250t2991r338b3044],
2	gefitinib	NN	O	gefitinib	_	0	SENT_182	[p9l369t2964r740b3066],
3	with	IN	O	with	_	0	SENT_182	[p9l772t2965r967b3044],
4	chemotherapy	NN	O	chemotherapy	prep_with	2	SENT_182	[p9l1002t2965r1613b3065],
5	as	IN	O	as	_	0	SENT_182	[p9l1642t2991r1727b3043],
6	first	JJ	ORDINAL	first	amod	9	SENT_182	[p9l1764t2964r2134b3043],
7	—	NN	O	—	nn	9	SENT_182	[p9l1764t2964r2134b3043],
8	line	NN	O	line	nn	9	SENT_182	[p9l1764t2964r2134b3043],
9	treatment	NN	O	treatment	prep_as	2	SENT_182	[p9l11t3110r444b3171],
10	for	IN	O	for	_	0	SENT_182	[p9l486t3092r611b3172],
11	non	JJ	O	non	amod	17	SENT_182	[p9l656t3093r1312b3172],
12	—	JJ	O	—	amod	17	SENT_182	[p9l656t3093r1312b3172],
13	small	JJ	O	small	amod	17	SENT_182	[p9l656t3093r1312b3172],
14	—	NN	O	—	nn	17	SENT_182	[p9l656t3093r1312b3172],
15	cell	NN	O	cell	nn	17	SENT_182	[p9l656t3093r1312b3172],
16	lung	NN	O	lung	nn	17	SENT_182	[p9l1358t3093r1555b3194],
17	cancer	NN	O	cancer	prep_for	9	SENT_182	[p9l1599t3119r1904b3172],
18	.	.	O	.	_	0	SENT_182	[p9l1599t3119r1904b3172],

1	Two	CD	NUMBER	two	num	4	SENT_183	[p9l1954t3100r2133b3172],
2	standard	JJ	O	standard	amod	4	SENT_183	[p9l12t3221r391b3300],
3	platinum	NN	O	platinum	nn	4	SENT_183	[p9l461t3221r1160b3321],
4	—	NN	O	—	nsubj	5	SENT_183	[p9l461t3221r1160b3321],
5	based	VBN	O	base	partmod	12	SENT_183	[p9l461t3221r1160b3321],
6	,	,	O	,	_	0	SENT_183	[p9l461t3221r1160b3321],
7	dual	JJ	O	dual	amod	10	SENT_183	[p9l1238t3221r1664b3322],
8	—	NN	O	—	nn	10	SENT_183	[p9l1238t3221r1664b3322],
9	drug	NN	O	drug	nn	10	SENT_183	[p9l1238t3221r1664b3322],
10	regimens	NNS	O	regimen	nsubjpass	12	SENT_183	[p9l1733t3222r2131b3322],
11	Were	VBD	O	be	auxpass	12	SENT_183	[p9l6t3375r208b3428],
12	used	VBN	O	use	_	0	SENT_183	[p9l245t3349r442b3428],
13	in	IN	O	in	_	0	SENT_183	[p9l477t3350r561b3427],
14	combination	NN	O	combination	prep_in	12	SENT_183	[p9l598t3349r1144b3428],
15	with	IN	O	with	_	0	SENT_183	[p9l1176t3349r1371b3428],
16	erlotinib	NN	O	erlotinib	prep_with	14	SENT_183	[p9l1408t3349r1775b3428],
17	or	CC	O	or	_	0	SENT_183	[p9l1814t3375r1903b3428],
18	gefitinib	NN	O	gefitinib	prep_with	14	SENT_183	[p9l1936t3348r2133b3450, p9l11t3477r426b3556],
19	.4	CD	NUMBER	.4	num	18	SENT_183	[p9l1936t3348r2133b3450, p9l11t3477r426b3556],
20	°	NN	O	°	tmod	12	SENT_183	[p9l1936t3348r2133b3450, p9l11t3477r426b3556],
21	'43	CD	NUMBER	'43	num	20	SENT_183	[p9l1936t3348r2133b3450, p9l11t3477r426b3556],
22	Neither	CC	O	neither	preconj	25	SENT_183	[p9l487t3477r818b3556],
23	a	DT	O	a	det	25	SENT_183	[p9l876t3503r920b3555],
24	survival	NN	O	survival	nn	25	SENT_183	[p9l982t3477r1322b3556],
25	advantage	NN	O	advantage	nsubjpass	40	SENT_183	[p9l1383t3477r1822b3578],
26	nor	CC	O	nor	_	0	SENT_183	[p9l1884t3503r2033b3556],
27	a	DT	O	a	det	28	SENT_183	[p9l2091t3503r2135b3555],
28	benefit	NN	O	benefit	conj_nor	25	SENT_183	[p9l11t3603r317b3683],
29	with	IN	O	with	_	0	SENT_183	[p9l343t3604r538b3683],
30	respect	NN	O	respect	_	0	SENT_183	[p9l575t3621r883b3704],
31	to	TO	O	to	_	0	SENT_183	[p9l915t3621r996b3683],
32	the	DT	O	the	det	34	SENT_183	[p9l1034t3604r1167b3682],
33	response	NN	O	response	nn	34	SENT_183	[p9l1203t3630r1584b3704],
34	rate	NN	O	rate	prep_with_respect_to	28	SENT_183	[p9l1621t3621r1780b3682],
35	or	CC	O	or	_	0	SENT_183	[p9l1818t3630r1907b3683],
36	time	NN	O	time	conj_nor	25	SENT_183	[p9l1940t3605r2133b3682],
37	to	TO	O	to	_	0	SENT_183	[p10l11t39r94b101],
38	progression	NN	O	progression	prep_to	36	SENT_183	[p10l149t23r671b123],
39	was	VBD	O	be	auxpass	40	SENT_183	[p10l722t48r886b101],
40	seen	VBN	O	see	rcmod	20	SENT_183	[p10l945t48r1137b100],
41	with	IN	O	with	_	0	SENT_183	[p10l1188t22r1386b101],
42	the	DT	O	the	det	43	SENT_183	[p10l1442t22r1576b100],
43	addition	NN	O	addition	prep_with	40	SENT_183	[p10l1632t22r1996b101],
44	of	IN	O	of	_	0	SENT_183	[p10l2052t21r2152b101],
45	gefitinib	NN	O	gefitinib	prep_of	43	SENT_183	[p10l11t149r391b251],
46	or	CC	O	or	_	0	SENT_183	[p10l430t176r520b229],
47	erlotinib	NN	O	erlotinib	prep_of	43	SENT_183	[p10l555t150r930b229],
48	to	TO	O	to	_	0	SENT_183	[p10l969t167r1051b229],
49	chemotherapy	NN	O	chemotherapy	prep_to	40	SENT_183	[p10l1091t150r1713b250],
50	in	IN	O	in	_	0	SENT_183	[p10l1745t151r1829b228],
51	any	DT	O	any	prep_in	40	SENT_183	[p10l1866t176r2019b250],
52	of	IN	O	of	_	0	SENT_183	[p10l2052t149r2153b229],
53	these	DT	O	these	det	54	SENT_183	[p10l11t278r235b355],
54	trials	NNS	O	trial	prep_of	51	SENT_183	[p10l269t278r512b356],
55	.	.	O	.	_	0	SENT_183	[p10l269t278r512b356],

1	One	CD	NUMBER	one	num	3	SENT_184	[p10l550t284r722b356],
2	possible	JJ	O	possible	amod	3	SENT_184	[p10l754t278r1104b377],
3	reason	NN	O	reason	nsubj	18	SENT_184	[p10l1137t303r1422b356],
4	that	IN	O	that	complm	7	SENT_184	[p10l1455t278r1627b355],
5	these	DT	O	these	det	6	SENT_184	[p10l1655t278r1878b355],
6	trials	NNS	O	trial	nsubj	7	SENT_184	[p10l1913t278r2131b355],
7	failed	VBD	O	fail	ccomp	3	SENT_184	[p10l11t405r256b485],
8	to	TO	O	to	aux	9	SENT_184	[p10l318t423r401b485],
9	demonstrate	VB	O	demonstrate	xcomp	7	SENT_184	[p10l465t406r1014b485],
10	any	DT	O	any	det	11	SENT_184	[p10l1075t432r1228b506],
11	advantage	NN	O	advantage	dobj	9	SENT_184	[p10l1284t406r1724b507],
12	of	IN	O	of	_	0	SENT_184	[p10l1787t405r1888b485],
13	gefi	FW	O	gefi	nn	14	SENT_184	[p10l1931t405r2132b507],
14	—	FW	O	—	amod	15	SENT_184	[p10l1931t405r2132b507],
15	tinib	NN	O	tinib	prep_of	11	SENT_184	[p10l11t534r217b612],
16	or	CC	O	or	_	0	SENT_184	[p10l256t560r346b612],
17	erlotinib	NN	O	erlotinib	prep_of	11	SENT_184	[p10l380t534r756b612],
18	is	VBZ	O	be	_	0	SENT_184	[p10l793t535r860b611],
19	that	IN	O	that	complm	22	SENT_184	[p10l899t534r1075b611],
20	they	PRP	O	they	nsubjpass	22	SENT_184	[p10l1107t534r1293b633],
21	were	VBD	O	be	auxpass	22	SENT_184	[p10l1321t560r1526b613],
22	conducted	VBN	O	conduct	ccomp	18	SENT_184	[p10l1563t534r2014b613],
23	in	IN	O	in	prep	22	SENT_184	[p10l2050t535r2134b611],

1	1164	CD	DATE	1164	num	2	SENT_185	[p10l149t708r225b730],
2	N	NN	O	n	_	0	SENT_185	[p10l914t718r927b734],
3	EN	IN	O	en	_	0	SENT_185	[p10l942t718r970b734],
4	L	NN	O	l	nn	5	SENT_185	[p10l996t718r1006b733],
5	MED	NN	O	med	prep_en	2	SENT_185	[p10l1035t718r1086b733],
6	358	CD	NUMBER	358	num	5	SENT_185	[p10l1097t712r1165b740],
7	;	:	O	;	_	0	SENT_185	[p10l1097t712r1165b740],
8	11	CD	NUMBER	11	dep	2	SENT_185	[p10l1097t712r1165b740],
9	WWW	NNP	O	WWW	nn	12	SENT_185	[p10l1201t718r1402b740],
10	,	,	O	,	_	0	SENT_185	[p10l1201t718r1402b740],
11	NEJM.ORG	NNP	O	NEJM.ORG	appos	12	SENT_185	[p10l1201t718r1402b740],
12	MARCH	NNP	DATE	MARCH	dep	8	SENT_185	[p10l1439t718r1524b734],
13	13,2008	CD	DATE	13,2008	num	12	SENT_185	[p10l1538t712r1644b740],

1	Th	NN	O	th	nn	2	SENT_186	[p10l935t751r972b774],
2	w	NN	O	w	_	0	SENT_186	[p10l1035t758r1057b774],
3	England	NNP	O	England	nn	4	SENT_186	[p10l1067t751r1177b781],
4	Journal	NNP	O	Journal	dep	2	SENT_186	[p10l1186t751r1283b774],
5	of	IN	O	of	_	0	SENT_186	[p10l1293t751r1322b774],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_186	[p10l1329t751r1454b774],

1	Downloaded	VBN	O	download	_	0	SENT_187	[p10l377t791r547b814],
2	from	IN	O	from	_	0	SENT_187	[p10l556t791r621b814],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_187	[p10l629t791r748b821],
4	at	IN	O	at	_	0	SENT_187	[p10l758t795r781b814],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_187	[p10l789t791r972b814],
6	on	IN	O	on	_	0	SENT_187	[p10l981t798r1014b814],
7	Janu	NNP	DATE	Janu	prep_on	1	SENT_187	[p10l1022t791r1083b814],
8	5	CD	DATE	5	num	7	SENT_187	[p10l1135t791r1158b818],
9	,	,	DATE	,	_	0	SENT_187	[p10l1135t791r1158b818],
10	2014	CD	DATE	2014	num	7	SENT_187	[p10l1168t791r1241b814],
11	.	.	O	.	_	0	SENT_187	[p10l1168t791r1241b814],

1	For	IN	O	for	_	0	SENT_188	[p10l1251t791r1298b814],
2	personal	JJ	O	personal	amod	3	SENT_188	[p10l1306t791r1418b821],
3	use	NN	O	use	pobj	1	SENT_188	[p10l1427t798r1471b814],
4	only	RB	O	only	advmod	3	SENT_188	[p10l1480t791r1545b821],
5	.	.	O	.	_	0	SENT_188	[p10l1480t791r1545b821],

1	No	DT	O	no	det	3	SENT_189	[p10l1556t791r1595b814],
2	other	JJ	O	other	amod	3	SENT_189	[p10l1605t791r1673b814],
3	uses	NNS	O	use	_	0	SENT_189	[p10l1682t798r1738b814],
4	without	IN	O	without	_	0	SENT_189	[p10l1748t791r1849b814],
5	permission	NN	O	permission	prep_without	3	SENT_189	[p10l1857t791r2010b821],
6	.	.	O	.	_	0	SENT_189	[p10l1857t791r2010b821],

1	Copyright	NN	O	copyright	nn	5	SENT_190	[p10l728t832r862b863],
2	©	CD	NUMBER	©	num	5	SENT_190	[p10l871t832r895b856],
3	2008	CD	DATE	2008	num	5	SENT_190	[p10l905t832r969b856],
4	Massa	NNP	PERSON	Massa	nn	5	SENT_190	[p10l979t833r1064b856],
5	etts	NNP	O	etts	_	0	SENT_190	[p10l1126t836r1170b856],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_190	[p10l1180t832r1289b856],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_190	[p10l1299t832r1404b863],
8	.	.	O	.	_	0	SENT_190	[p10l1299t832r1404b863],

1	All	DT	O	all	det	2	SENT_191	[p10l1415t832r1456b856],
2	rights	NNS	O	rights	nsubj	3	SENT_191	[p10l1465t832r1540b863],
3	reserved	VBN	O	reserve	_	0	SENT_191	[p10l1550t832r1668b856],
4	.	.	O	.	_	0	SENT_191	[p10l1550t832r1668b856],

1	DRUG	NN	O	drug	nn	2	SENT_192	[p10l808t876r900b895],
2	THERAPY	NN	O	therapy	_	0	SENT_192	[p10l912t876r1066b895],

1	Immune	JJ	O	immune	amod	2	SENT_193	[p10l256t1073r370b1096],
2	effector	NN	O	effector	_	0	SENT_193	[p10l234t1110r337b1136],
3	cell	NN	O	cell	nn	4	SENT_193	[p10l346t1111r389b1136],
4	Endocytosis	NN	O	endocytosis	dep	2	SENT_193	[p10l1438t1115r1599b1148],

1	A	DT	O	a	det	2	SENT_194	[p10l600t1319r614b1337],
2	Activation	NN	O	activation	_	0	SENT_194	[p10l706t1311r842b1334],
3	of	IN	O	of	_	0	SENT_194	[p10l854t1309r884b1334],
4	l	NN	O	l	prep_of	2	SENT_194	[p10l602t1322r617b1377],
5	‘	CD	NUMBER	‘	num	4	SENT_194	[p10l602t1322r617b1377],
6	antibody-dependent	JJ	O	antibody-dependent	dep	2	SENT_194	[p10l652t1349r933b1382],
7	,	,	O	,	_	0	SENT_194	[p10l652t1349r933b1382],
8	I	PRP	O	I	appos	6	SENT_194	[p10l599t1378r606b1393],

1	.	.	O	.	_	0	SENT_195	[p10l544t1411r550b1414],

1	_	NN	O	_	_	0	SENT_196	[p10l580t1402r590b1422],
2	cell-mediated	JJ	O	cell-mediated	amod	3	SENT_196	[p10l621t1389r803b1414],
3	cytotoxicity	NN	O	cytotoxicity	dep	1	SENT_196	[p10l815t1391r966b1422],

1	Anti-EG	JJ	O	anti-eg	amod	2	SENT_197	[p10l248t1420r353b1444],
2	FR	NN	O	fr	_	0	SENT_197	[p10l359t1421r391b1444],
3	"	''	O	"	punct	2	SENT_197	[p10l576t1423r584b1425],
4	monoclonal	JJ	O	monoclonal	amod	5	SENT_197	[p10l241t1459r400b1484],
5	antibody	NN	O	antibody	dep	2	SENT_197	[p10l262t1499r380b1532],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_198	[p10l451t1540r525b1563],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_199	[p10l1622t2026r1696b2050],
2	degradation	NN	O	degradation	_	0	SENT_199	[p10l1576t2064r1738b2098],

1	Figure	NNP	O	Figure	_	0	SENT_200	[p10l121t2207r206b2238],
2	3	CD	NUMBER	3	dep	1	SENT_200	[p10l217t2208r239b2231],
3	.	.	O	.	_	0	SENT_200	[p10l217t2208r239b2231],

1	Mechanisms	NNS	O	mechanism	nn	3	SENT_201	[p10l252t2206r427b2231],
2	ofAction	NN	O	ofaction	nn	3	SENT_201	[p10l438t2205r562b2231],
3	ofAnti-EGFR	NN	O	ofanti-egfr	_	0	SENT_201	[p10l574t2205r754b2231],
4	Monoclonal	JJ	O	monoclonal	amod	5	SENT_201	[p10l767t2206r928b2231],
5	Antibodies	NNS	O	antibody	dep	3	SENT_201	[p10l939t2206r1088b2231],
6	in	IN	O	in	_	0	SENT_201	[p10l1100t2206r1123b2231],
7	Cancer	NN	O	cancer	nn	8	SENT_201	[p10l1134t2208r1231b2231],
8	Cells	NNS	O	cell	prep_in	5	SENT_201	[p10l1240t2206r1315b2231],
9	.	.	O	.	_	0	SENT_201	[p10l1240t2206r1315b2231],

1	The	DT	O	the	det	2	SENT_202	[p10l118t2256r170b2281],
2	mechanisms	NNS	O	mechanism	nsubj	20	SENT_202	[p10l183t2256r357b2281],
3	of	IN	O	of	_	0	SENT_202	[p10l369t2255r399b2281],
4	action	NN	O	action	prep_of	2	SENT_202	[p10l406t2258r489b2281],
5	and	CC	O	and	_	0	SENT_202	[p10l503t2256r551b2281],
6	pharmacologic	JJ	O	pharmacologic	amod	7	SENT_202	[p10l565t2256r771b2289],
7	effects	NNS	O	effect	conj_and	2	SENT_202	[p10l782t2255r874b2281],
8	ofanti-EGFR	JJ	O	ofanti-egfr	amod	10	SENT_202	[p10l886t2255r1062b2281],
9	monoclonal	JJ	O	monoclonal	amod	10	SENT_202	[p10l1075t2256r1237b2281],
10	antibodies	NNS	O	antibody	dep	7	SENT_202	[p10l1251t2256r1395b2281],
11	and	CC	O	and	_	0	SENT_202	[p10l1407t2256r1456b2281],
12	small-molecule	JJ	O	small-molecule	amod	16	SENT_202	[p10l1469t2256r1681b2281],
13	EGFR	NN	ORGANIZATION	egfr	nn	16	SENT_202	[p10l1695t2258r1768b2281],
14	tyrosine	NN	O	tyrosine	nn	16	SENT_202	[p10l1778t2258r1889b2289],
15	kinase	NN	O	kinase	nn	16	SENT_202	[p10l1902t2256r1987b2281],
16	inhibitors	NNS	O	inhibitor	conj_and	10	SENT_202	[p10l2000t2258r2033b2281, p10l121t2297r224b2323],
17	do	VBP	O	do	aux	20	SENT_202	[p10l236t2297r270b2323],
18	not	RB	O	not	neg	20	SENT_202	[p10l283t2302r327b2323],
19	completely	RB	O	completely	advmod	20	SENT_202	[p10l338t2297r489b2330],
20	overlap	VB	O	overlap	_	0	SENT_202	[p10l500t2297r608b2330],
21	,	,	O	,	_	0	SENT_202	[p10l500t2297r608b2330],
22	and	CC	O	and	_	0	SENT_202	[p10l621t2297r669b2323],
23	some	DT	O	some	det	25	SENT_202	[p10l683t2306r757b2323],
24	ofthe	NN	O	ofthe	nn	25	SENT_202	[p10l769t2297r848b2323],
25	differences	NNS	O	difference	nsubj	31	SENT_202	[p10l859t2297r1011b2323],
26	between	IN	O	between	_	0	SENT_202	[p10l1025t2297r1140b2323],
27	them	PRP	O	they	prep_between	25	SENT_202	[p10l1151t2297r1222b2323],
28	may	MD	O	may	aux	31	SENT_202	[p10l1236t2306r1291b2330],
29	be	VB	O	be	cop	31	SENT_202	[p10l1303t2297r1334b2323],
30	clinically	RB	O	clinically	advmod	31	SENT_202	[p10l1345t2297r1463b2330],
31	relevant	JJ	O	relevant	conj_and	20	SENT_202	[p10l1475t2297r1584b2323],
32	(	IN	O	(	_	0	SENT_202	[p10l1598t2299r1651b2330],
33	see	VB	O	see	prepc_(	31	SENT_202	[p10l1598t2299r1651b2330],
34	Table	NNP	O	Table	nsubj	36	SENT_202	[p10l1661t2297r1734b2323],
35	1	CD	NUMBER	1	num	36	SENT_202	[p10l1748t2299r1777b2330],
36	)	CD	NUMBER	)	xcomp	33	SENT_202	[p10l1748t2299r1777b2330],
37	.	.	O	.	_	0	SENT_202	[p10l1748t2299r1777b2330],

1	In	IN	O	in	_	0	SENT_203	[p10l1792t2300r1814b2322],
2	particular	JJ	O	particular	prep_in	19	SENT_203	[p10l1828t2297r1966b2330],
3	,	,	O	,	_	0	SENT_203	[p10l1828t2297r1966b2330],
4	the	DT	O	the	det	9	SENT_203	[p10l1977t2297r2021b2323],
5	anti-EG	JJ	O	anti-eg	amod	9	SENT_203	[p10l120t2341r220b2364],
6	FR	NN	O	fr	nn	9	SENT_203	[p10l227t2341r259b2364],
7	monoclonal	JJ	O	monoclonal	amod	9	SENT_203	[p10l272t2339r434b2364],
8	antibody	NN	O	antibody	nn	9	SENT_203	[p10l447t2339r567b2372],
9	cetuximab	NN	O	cetuximab	nsubj	19	SENT_203	[p10l578t2339r727b2369],
10	,	,	O	,	_	0	SENT_203	[p10l578t2339r727b2369],
11	which	WDT	O	which	nsubj	16	SENT_203	[p10l739t2339r819b2364],
12	is	VBZ	O	be	cop	16	SENT_203	[p10l832t2341r851b2364],
13	an	DT	O	a	det	16	SENT_203	[p10l864t2348r894b2364],
14	|	JJ	O	|	amod	16	SENT_203	[p10l909t2341r970b2372],
15	gG1	NN	O	gg1	nn	16	SENT_203	[p10l909t2341r970b2372],
16	immunoglobulin	NN	O	immunoglobulin	rcmod	9	SENT_203	[p10l984t2339r1222b2372],
17	,	,	O	,	_	0	SENT_203	[p10l984t2339r1222b2372],
18	could	MD	O	could	aux	19	SENT_203	[p10l1235t2339r1309b2364],
19	elicit	VB	O	elicit	_	0	SENT_203	[p10l1322t2339r1386b2364],
20	host	NN	O	host	dobj	19	SENT_203	[p10l1398t2339r1457b2364],
21	antitumor	JJ	O	antitumor	amod	23	SENT_203	[p10l1469t2341r1607b2364],
22	immune	JJ	O	immune	amod	23	SENT_203	[p10l1619t2341r1733b2364],
23	responses	NNS	O	response	tmod	19	SENT_203	[p10l1746t2348r1893b2372],
24	,	,	O	,	_	0	SENT_203	[p10l1746t2348r1893b2372],
25	including	VBG	O	include	_	0	SENT_203	[p10l1907t2339r2034b2372],
26	antibody-dependent	JJ	O	antibody-dependent	prep_including	23	SENT_203	[p10l120t2381r409b2414],
27	,	,	O	,	_	0	SENT_203	[p10l120t2381r409b2414],
28	cell	NN	O	cell	nn	30	SENT_203	[p10l422t2381r466b2406],
29	mediated	JJ	O	mediated	amod	30	SENT_203	[p10l480t2381r607b2406],
30	cytotoxicity	NN	O	cytotoxicity	appos	26	SENT_203	[p10l620t2383r777b2414],
31	(	CD	NUMBER	(	num	32	SENT_203	[p10l791t2381r874b2414],
32	Panel	NN	O	panel	dep	30	SENT_203	[p10l791t2381r874b2414],
33	A	DT	O	a	det	34	SENT_203	[p10l886t2382r923b2414],
34	)	NN	O	)	dep	23	SENT_203	[p10l886t2382r923b2414],
35	.	.	O	.	_	0	SENT_203	[p10l886t2382r923b2414],

1	Furthermore	RB	O	furthermore	advmod	7	SENT_204	[p10l938t2381r1119b2410],
2	,	,	O	,	_	0	SENT_204	[p10l938t2381r1119b2410],
3	anti-EGFR	JJ	O	anti-egfr	amod	5	SENT_204	[p10l1132t2383r1271b2406],
4	monoclonal	JJ	O	monoclonal	amod	5	SENT_204	[p10l1284t2381r1446b2406],
5	antibodies	NNS	O	antibody	nsubj	7	SENT_204	[p10l1459t2381r1604b2406],
6	can	MD	O	can	aux	7	SENT_204	[p10l1616t2390r1662b2406],
7	induce	VB	O	induce	_	0	SENT_204	[p10l1676t2381r1766b2406],
8	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_204	[p10l1780t2383r1853b2406],
9	cellular	JJ	O	cellular	amod	10	SENT_204	[p10l1864t2381r1964b2406],
10	internalization	NN	O	internalization	dobj	7	SENT_204	[p10l1976t2383r2008b2406, p10l119t2422r292b2448],
11	and	CC	O	and	_	0	SENT_204	[p10l305t2422r354b2448],
12	down-regulation	NN	O	down-regulation	conj_and	10	SENT_204	[p10l366t2422r602b2456],
13	,	,	O	,	_	0	SENT_204	[p10l366t2422r602b2456],
14	thereby	RB	O	thereby	advmod	15	SENT_204	[p10l614t2422r717b2455],
15	enhancing	VBG	O	enhance	partmod	7	SENT_204	[p10l728t2422r872b2456],
16	receptor	NN	O	receptor	nn	17	SENT_204	[p10l884t2427r999b2455],
17	degradation	NN	O	degradation	nsubj	21	SENT_204	[p10l1009t2422r1175b2456],
18	(	CD	NUMBER	(	num	21	SENT_204	[p10l1190t2422r1274b2455],
19	Panel	NN	O	panel	nn	21	SENT_204	[p10l1190t2422r1274b2455],
20	B	NN	O	b	nn	21	SENT_204	[p10l1289t2424r1322b2455],
21	)	NN	O	)	xcomp	15	SENT_204	[p10l1289t2424r1322b2455],
22	.	.	O	.	_	0	SENT_204	[p10l1289t2424r1322b2455],

1	These	DT	O	these	det	3	SENT_205	[p10l1333t2422r1416b2448],
2	two	CD	NUMBER	two	num	3	SENT_205	[p10l1427t2427r1477b2448],
3	mechanisms	NNS	O	mechanism	nsubj	5	SENT_205	[p10l1490t2422r1665b2448],
4	could	MD	O	could	aux	5	SENT_205	[p10l1677t2422r1751b2448],
5	make	VB	O	make	_	0	SENT_205	[p10l1765t2422r1836b2448],
6	an	DT	O	a	det	8	SENT_205	[p10l1848t2431r1878b2448],
7	important	JJ	O	important	amod	8	SENT_205	[p10l1892t2425r2031b2455],
8	contribution	NN	O	contribution	dobj	5	SENT_205	[p10l120t2464r289b2489],
9	to	TO	O	to	_	0	SENT_205	[p10l301t2469r328b2489],
10	antitumor	NN	O	antitumor	nn	11	SENT_205	[p10l340t2466r479b2489],
11	activity	NN	O	activity	prep_to	5	SENT_205	[p10l489t2466r593b2497],
12	.	.	O	.	_	0	SENT_205	[p10l489t2466r593b2497],

1	unselected	JJ	O	unselected	amod	2	SENT_206	[p10l10t2730r480b2809],
2	patients	NNS	O	patient	_	0	SENT_206	[p10l545t2731r897b2830],
3	with	IN	O	with	_	0	SENT_206	[p10l961t2730r1161b2809],
4	non	JJ	O	non	amod	10	SENT_206	[p10l1228t2730r1889b2809],
5	—	JJ	O	—	amod	10	SENT_206	[p10l1228t2730r1889b2809],
6	small	JJ	O	small	amod	10	SENT_206	[p10l1228t2730r1889b2809],
7	—	NN	O	—	nn	10	SENT_206	[p10l1228t2730r1889b2809],
8	cell	NN	O	cell	nn	10	SENT_206	[p10l1228t2730r1889b2809],
9	lung	NN	O	lung	nn	10	SENT_206	[p10l1955t2730r2153b2831],
10	cancer	NN	O	cancer	prep_with	2	SENT_206	[p10l11t2863r399b2938],
11	.	.	O	.	_	0	SENT_206	[p10l11t2863r399b2938],

1	“	NN	O	“	dep	19	SENT_207	[p10l11t2863r399b2938],
2	Since	IN	O	since	dep	19	SENT_207	[p10l434t2859r658b2938],
3	only	RB	O	only	advmod	5	SENT_207	[p10l692t2858r877b2959],
4	a	DT	O	a	det	5	SENT_207	[p10l906t2885r950b2937],
5	subgroup	NN	O	subgroup	nsubj	19	SENT_207	[p10l984t2858r1390b2960],
6	of	IN	O	of	_	0	SENT_207	[p10l1426t2857r1526b2938],
7	EGFR	NN	ORGANIZATION	egfr	npadvmod	9	SENT_207	[p10l1540t2859r2149b2959],
8	—	CD	NUMBER	—	num	7	SENT_207	[p10l1540t2859r2149b2959],
9	positive	JJ	O	positive	amod	10	SENT_207	[p10l1540t2859r2149b2959],
10	patients	NNS	O	patient	prep_of	5	SENT_207	[p10l8t2988r360b3087],
11	with	IN	O	with	_	0	SENT_207	[p10l409t2987r610b3066],
12	non	JJ	O	non	amod	18	SENT_207	[p10l660t2987r1322b3066],
13	—	JJ	O	—	amod	18	SENT_207	[p10l660t2987r1322b3066],
14	small	JJ	O	small	amod	18	SENT_207	[p10l660t2987r1322b3066],
15	—	NN	O	—	nn	18	SENT_207	[p10l660t2987r1322b3066],
16	cell	NN	O	cell	nn	18	SENT_207	[p10l660t2987r1322b3066],
17	lung	NN	O	lung	nn	18	SENT_207	[p10l1371t2987r1569b3088],
18	cancer	NN	O	cancer	prep_with	10	SENT_207	[p10l1618t3013r1906b3065],
19	have	VBP	O	have	advcl	37	SENT_207	[p10l1955t2987r2149b3066],
20	tumors	NNS	O	tumor	dobj	19	SENT_207	[p10l11t3132r326b3194],
21	that	WDT	O	that	nsubj	23	SENT_207	[p10l376t3115r553b3193],
22	are	VBP	O	be	cop	23	SENT_207	[p10l596t3141r728b3193],
23	dependent	JJ	O	dependent	rcmod	20	SENT_207	[p10l777t3115r1239b3215],
24	on	IN	O	on	_	0	SENT_207	[p10l1283t3141r1390b3194],
25	the	DT	O	the	det	27	SENT_207	[p10l1439t3115r1574b3193],
26	EGFR	NN	ORGANIZATION	egfr	nn	27	SENT_207	[p10l1621t3121r1882b3198],
27	pathway	NN	O	pathway	prep_on	23	SENT_207	[p10l1918t3115r2148b3215, p10l6t3270r188b3343],
28	,	,	O	,	_	0	SENT_207	[p10l1918t3115r2148b3215, p10l6t3270r188b3343],
29	few	JJ	O	few	amod	30	SENT_207	[p10l230t3242r386b3323],
30	patients	NNS	O	patient	nsubj	37	SENT_207	[p10l417t3244r761b3343],
31	with	IN	O	with	_	0	SENT_207	[p10l795t3243r992b3322],
32	this	DT	O	this	det	33	SENT_207	[p10l1029t3243r1190b3321],
33	type	NN	O	type	prep_with	30	SENT_207	[p10l1229t3260r1412b3343],
34	of	IN	O	of	_	0	SENT_207	[p10l1450t3242r1550b3322],
35	cancer	NN	O	cancer	prep_of	33	SENT_207	[p10l1570t3269r1853b3321],
36	would	MD	O	would	aux	37	SENT_207	[p10l1881t3243r2149b3323],
37	have	VB	O	have	_	0	SENT_207	[p10l10t3373r201b3453],
38	a	DT	O	a	det	40	SENT_207	[p10l250t3400r295b3452],
39	clinical	JJ	O	clinical	amod	40	SENT_207	[p10l344t3373r660b3452],
40	benefit	NN	O	benefit	dobj	37	SENT_207	[p10l709t3372r1017b3453],
41	from	IN	O	from	_	0	SENT_207	[p10l1060t3372r1273b3453],
42	the	DT	O	the	det	43	SENT_207	[p10l1323t3373r1456b3452],
43	addition	NN	O	addition	prep_from	40	SENT_207	[p10l1505t3373r1864b3453],
44	of	IN	O	of	_	0	SENT_207	[p10l1915t3372r2016b3453],
45	an	DT	O	a	det	47	SENT_207	[p10l2046t3399r2150b3452],
46	anti-EGFR	JJ	O	anti-egfr	amod	47	SENT_207	[p10l10t3503r468b3585],
47	drug	NN	O	drug	prep_of	43	SENT_207	[p10l501t3502r707b3603],
48	to	TO	O	to	_	0	SENT_207	[p10l748t3519r829b3581],
49	chemotherapy	NN	O	chemotherapy	prep_to	37	SENT_207	[p10l876t3502r1587b3602],
50	.	.	O	.	_	0	SENT_207	[p10l876t3502r1587b3602],

1	“	NN	O	“	npadvmod	9	SENT_208	[p10l876t3502r1587b3602],
2	In	IN	O	in	_	0	SENT_208	[p10l1628t3509r1719b3579],
3	addition	NN	O	addition	prep_in	9	SENT_208	[p10l1761t3502r2144b3598],
4	,	,	O	,	_	0	SENT_208	[p10l1761t3502r2144b3598],
5	a	DT	O	a	det	8	SENT_208	[p10l10t3656r54b3708],
6	retrospective	JJ	O	retrospective	amod	8	SENT_208	[p10l132t3631r702b3730],
7	subgroup	NN	O	subgroup	nn	8	SENT_208	[p10l783t3630r1197b3731],
8	analysis	NN	O	analysis	nsubj	9	SENT_208	[p10l1277t3630r1628b3730],
9	suggested	VBD	O	suggest	_	0	SENT_208	[p10l1710t3630r2149b3731],
10	that	IN	O	that	advmod	9	SENT_208	[p11l11t20r187b98],
11	the	DT	O	the	det	12	SENT_208	[p11l218t20r353b98],
12	addition	NN	O	addition	pobj	10	SENT_208	[p11l388t20r755b99],
13	of	IN	O	of	_	0	SENT_208	[p11l791t19r893b99],
14	erlotinib	NN	O	erlotinib	prep_of	10	SENT_208	[p11l911t20r1288b99],
15	to	TO	O	to	_	0	SENT_208	[p11l1326t37r1409b99],
16	carboplatin	NN	O	carboplatin	prep_to	10	SENT_208	[p11l1446t20r1954b120],
17	and	CC	O	and	_	0	SENT_208	[p11l1989t20r2150b99],
18	paclitaxel	NN	O	paclitaxel	conj_and	16	SENT_208	[p11l8t149r433b250],
19	significantly	RB	O	significantly	advmod	20	SENT_208	[p11l470t148r1030b251],
20	prolonged	JJ	O	prolonged	amod	21	SENT_208	[p11l1073t149r1524b251],
21	survival	NN	O	survival	dobj	9	SENT_208	[p11l1574t149r1916b229],
22	only	RB	O	only	advmod	9	SENT_208	[p11l1965t149r2154b250],
23	in	IN	O	in	_	0	SENT_208	[p11l10t279r95b356],
24	the	DT	O	the	det	25	SENT_208	[p11l166t278r301b357],
25	subgroup	NN	O	subgroup	prep_in	9	SENT_208	[p11l373t278r786b380],
26	of	IN	O	of	_	0	SENT_208	[p11l859t277r961b358],
27	patients	NNS	O	patient	prep_of	25	SENT_208	[p11l1011t279r1362b379],
28	who	WP	O	who	nsubj	31	SENT_208	[p11l1430t278r1617b358],
29	had	VBD	O	have	aux	31	SENT_208	[p11l1688t278r1847b358],
30	never	RB	O	never	neg	31	SENT_208	[p11l1918t304r2153b358],
31	smoked	VBN	O	smoke	rcmod	27	SENT_208	[p11l12t408r449b487],
32	.	.	O	.	_	0	SENT_208	[p11l12t408r449b487],

1	“	NN	O	“	_	0	SENT_209	[p11l12t408r449b487],

1	Cetuximab	JJ	O	cetuximab	amod	2	SENT_210	[p11l140t536r598b615],
2	treatment	NN	O	treatment	nsubjpass	4	SENT_210	[p11l647t553r1057b614],
3	is	VBZ	O	be	auxpass	4	SENT_210	[p11l1098t537r1162b614],
4	said	VBN	O	say	_	0	SENT_210	[p11l1212t536r1378b615],
5	to	TO	O	to	aux	6	SENT_210	[p11l1426t553r1505b615],
6	have	VB	O	have	xcomp	4	SENT_210	[p11l1553t536r1738b615],
7	relatively	RB	O	relatively	advmod	8	SENT_210	[p11l1786t536r2154b636],
8	few	JJ	O	few	amod	10	SENT_210	[p11l10t665r161b746],
9	side	JJ	O	side	amod	10	SENT_210	[p11l193t666r352b746],
10	effects	NNS	O	effect	dobj	6	SENT_210	[p11l387t665r680b746],
11	.	.	O	.	_	0	SENT_210	[p11l387t665r680b746],

1	The	DT	O	the	det	5	SENT_211	[p11l715t666r872b745],
2	most	RBS	O	most	advmod	3	SENT_211	[p11l907t683r1118b746],
3	common	JJ	O	common	amod	5	SENT_211	[p11l1147t692r1521b746],
4	adverse	JJ	O	adverse	amod	5	SENT_211	[p11l1553t666r1858b746],
5	events	NNS	O	event	nsubj	6	SENT_211	[p11l1892t683r2146b746],
6	include	VBP	O	include	_	0	SENT_211	[p11l10t795r309b875],
7	skin	NN	O	skin	nn	8	SENT_211	[p11l363t795r538b875],
8	toxicity	NN	O	toxicity	dobj	6	SENT_211	[p11l592t796r897b896],
9	(	CD	NUMBER	(	num	10	SENT_211	[p11l949t794r1344b897],
10	flushing	NN	O	flushing	nsubj	40	SENT_211	[p11l949t794r1344b897],
11	,	,	O	,	_	0	SENT_211	[p11l949t794r1344b897],
12	an	DT	O	a	det	14	SENT_211	[p11l1401t821r1503b874],
13	acnelike	JJ	O	acnelike	amod	14	SENT_211	[p11l1554t795r1893b875],
14	rash	NN	O	rash	appos	10	SENT_211	[p11l1946t795r2144b892],
15	,	,	O	,	_	0	SENT_211	[p11l1946t795r2144b892],
16	and	CC	O	and	_	0	SENT_211	[p11l10t925r164b1005],
17	folliculitis	NN	O	folliculitis	nn	18	SENT_211	[p11l193t924r656b1022],
18	)	NN	O	)	conj_and	10	SENT_211	[p11l193t924r656b1022],
19	,	,	O	,	_	0	SENT_211	[p11l193t924r656b1022],
20	fever	NN	O	fever	conj_and	10	SENT_211	[p11l691t924r889b1005],
21	and	CC	O	and	_	0	SENT_211	[p11l915t925r1070b1005],
22	chills	NNS	O	chill	conj_and	10	SENT_211	[p11l1099t925r1342b1022],
23	,	,	O	,	_	0	SENT_211	[p11l1099t925r1342b1022],
24	asthenia	NN	O	asthenia	appos	20	SENT_211	[p11l1376t925r1747b1022],
25	,	,	O	,	_	0	SENT_211	[p11l1376t925r1747b1022],
26	transient	JJ	O	transient	amod	27	SENT_211	[p11l1783t926r2154b1004],
27	elevations	NNS	O	elevation	conj_and	10	SENT_211	[p11l11t1055r417b1135],
28	in	IN	O	in	_	0	SENT_211	[p11l486t1056r568b1133],
29	aminotransferase	NN	O	aminotransferase	nn	30	SENT_211	[p11l634t1054r1364b1135],
30	levels	NNS	O	level	prep_in	27	SENT_211	[p11l1430t1055r1674b1152],
31	,	,	O	,	_	0	SENT_211	[p11l1430t1055r1674b1152],
32	and	CC	O	and	_	0	SENT_211	[p11l1746t1055r1901b1135],
33	nausea	NN	O	nausea	conj_and	10	SENT_211	[p11l1967t1081r2148b1135, p11l12t1188r235b1262],
34	.45	CD	NUMBER	.45	num	33	SENT_211	[p11l1967t1081r2148b1135, p11l12t1188r235b1262],
35	Approximately	RB	O	approximately	quantmod	36	SENT_211	[p11l285t1183r901b1283],
36	1.5	CD	PERCENT	1.5	num	37	SENT_211	[p11l950t1188r1153b1263],
37	%	NN	PERCENT	%	dep	33	SENT_211	[p11l950t1188r1153b1263],
38	of	IN	O	of	_	0	SENT_211	[p11l1203t1182r1301b1262],
39	patients	NNS	O	patient	prep_of	37	SENT_211	[p11l1331t1184r1660b1283],
40	have	VBP	O	have	rcmod	8	SENT_211	[p11l1713t1183r1897b1262],
41	infusion	NN	O	infusion	nn	42	SENT_211	[p11l1947t1182r2148b1263, p11l12t1313r182b1391],
42	reactions	NNS	O	reaction	dobj	40	SENT_211	[p11l219t1313r617b1408],
43	,	,	O	,	_	0	SENT_211	[p11l219t1313r617b1408],
44	Which	WDT	O	which	nsubj	45	SENT_211	[p11l655t1312r911b1391],
45	include	VBP	O	include	rcmod	42	SENT_211	[p11l947t1312r1247b1391],
46	allergic	JJ	O	allergic	amod	47	SENT_211	[p11l1283t1312r1587b1413],
47	reactions	NNS	O	reaction	dobj	45	SENT_211	[p11l1624t1313r1999b1391],
48	requiring	VBG	O	require	partmod	47	SENT_211	[p11l2039t1338r2148b1390, p11l12t1441r321b1542],
49	discontinuation	NN	O	discontinuation	dobj	48	SENT_211	[p11l362t1440r1017b1520],
50	of	IN	O	of	_	0	SENT_211	[p11l1062t1439r1160b1520],
51	therapy	NN	O	therapy	prep_of	49	SENT_211	[p11l1186t1440r1512b1541],
52	;	:	O	;	_	0	SENT_211	[p11l1186t1440r1512b1541],
53	this	DT	O	this	det	54	SENT_211	[p11l1561t1440r1715b1519],
54	rate	NN	O	rate	nsubj	55	SENT_211	[p11l1761t1457r1915b1519],
55	is	VBZ	O	be	parataxis	6	SENT_211	[p11l1959t1441r2023b1519],
56	in	IN	O	in	_	0	SENT_211	[p11l2068t1441r2149b1518],
57	keeping	VBG	O	keep	prepc_in	55	SENT_211	[p11l11t1569r341b1671],
58	with	IN	O	with	_	0	SENT_211	[p11l369t1569r558b1649],
59	the	DT	O	the	det	60	SENT_211	[p11l594t1569r724b1648],
60	use	NN	O	use	prep_with	57	SENT_211	[p11l759t1596r896b1649],
61	of	IN	O	of	_	0	SENT_211	[p11l934t1568r1032b1649],
62	a	DT	O	a	det	66	SENT_211	[p11l1048t1596r1093b1648],
63	chimeric	JJ	O	chimeric	amod	66	SENT_211	[p11l1127t1569r1489b1648],
64	human	JJ	O	human	amod	66	SENT_211	[p11l1524t1569r2150b1649],
65	—	NN	O	—	nn	66	SENT_211	[p11l1524t1569r2150b1649],
66	mouse	NN	O	mouse	prep_of	60	SENT_211	[p11l1524t1569r2150b1649],
67	monoclonal	JJ	O	monoclonal	amod	68	SENT_211	[p11l11t1698r508b1777],
68	antibody	NN	O	antibody	dobj	57	SENT_211	[p11l546t1698r925b1798],
69	.	.	O	.	_	0	SENT_211	[p11l546t1698r925b1798],

1	Whereas	IN	O	whereas	mark	5	SENT_212	[p11l966t1698r1328b1776],
2	cetuximab	NN	O	cetuximab	nsubj	5	SENT_212	[p11l1369t1698r1806b1777],
3	is	VBZ	O	be	cop	5	SENT_212	[p11l1846t1699r1910b1776],
4	marginally	RB	O	marginally	advmod	5	SENT_212	[p11l1951t1724r2148b1776, p11l11t1827r297b1928],
5	active	JJ	O	active	advcl	22	SENT_212	[p11l337t1828r568b1906],
6	as	IN	O	as	_	0	SENT_212	[p11l612t1853r696b1905],
7	a	DT	O	a	det	9	SENT_212	[p11l741t1853r786b1905],
8	single	JJ	O	single	amod	9	SENT_212	[p11l831t1827r1073b1928],
9	agent	NN	O	agent	prep_as	5	SENT_212	[p11l1117t1844r1346b1928],
10	in	IN	O	in	_	0	SENT_212	[p11l1385t1828r1467b1904],
11	advanced	JJ	O	advanced	amod	12	SENT_212	[p11l1511t1827r1895b1906],
12	nonsmall	JJ	O	nonsmall	amod	16	SENT_212	[p11l1938t1853r2153b1906, p11l13t1955r414b2033],
13	—	NN	O	—	nn	16	SENT_212	[p11l1938t1853r2153b1906, p11l13t1955r414b2033],
14	cell	NN	O	cell	nn	16	SENT_212	[p11l1938t1853r2153b1906, p11l13t1955r414b2033],
15	lung	NN	O	lung	nn	16	SENT_212	[p11l455t1955r643b2056],
16	cancer	NN	O	cancer	prep_in	9	SENT_212	[p11l683t1981r970b2051],
17	,	,	O	,	_	0	SENT_212	[p11l683t1981r970b2051],
18	most	JJS	O	most	amod	19	SENT_212	[p11l1018t1972r1229b2034],
19	phase	NN	O	phase	nsubj	22	SENT_212	[p11l1265t1955r1507b2055],
20	2	CD	NUMBER	2	num	21	SENT_212	[p11l1550t1961r1597b2032],
21	studies	NNS	O	study	dep	19	SENT_212	[p11l1641t1955r1930b2034],
22	suggest	VBP	O	suggest	_	0	SENT_212	[p11l1976t1981r2148b2056, p11l11t2100r182b2184],
23	that	IN	O	that	complm	34	SENT_212	[p11l247t2083r414b2161],
24	adding	VBG	O	add	csubj	34	SENT_212	[p11l480t2083r769b2184],
25	cetuximab	NN	O	cetuximab	dobj	24	SENT_212	[p11l837t2083r1275b2162],
26	to	TO	O	to	_	0	SENT_212	[p11l1347t2100r1427b2162],
27	platinum-based	JJ	O	platinum-based	amod	28	SENT_212	[p11l1498t2083r2150b2183],
28	therapies	NNS	O	therapy	prep_to	24	SENT_212	[p11l12t2211r387b2312],
29	is	VBZ	O	be	cop	34	SENT_212	[p11l428t2212r492b2290],
30	of	IN	O	of	_	0	SENT_212	[p11l535t2210r634b2291],
31	clinical	JJ	O	clinical	amod	32	SENT_212	[p11l655t2211r956b2290],
32	benef1t	NN	O	benef1t	prep_of	34	SENT_212	[p11l996t2210r1484b2291],
33	.46	CD	NUMBER	.46	number	34	SENT_212	[p11l996t2210r1484b2291],
34	‘	CD	NUMBER	‘	ccomp	22	SENT_212	[p11l996t2210r1484b2291],
35	5	CD	NUMBER	5	num	36	SENT_212	[p11l996t2210r1484b2291],
36	°	NN	O	°	dep	34	SENT_212	[p11l996t2210r1484b2291],
37	A	DT	O	a	dep	38	SENT_212	[p11l1521t2219r1588b2289],
38	large	JJ	O	large	amod	34	SENT_212	[p11l1623t2211r1852b2313],
39	,	,	O	,	_	0	SENT_212	[p11l1623t2211r1852b2313],
40	multicenter	JJ	O	multicenter	amod	34	SENT_212	[p11l1897t2211r2148b2291, p11l12t2357r281b2436],
41	,	,	O	,	_	0	SENT_212	[p11l1897t2211r2148b2291, p11l12t2357r281b2436],
42	randomized	VBN	O	randomize	partmod	34	SENT_212	[p11l321t2340r848b2436],
43	,	,	O	,	_	0	SENT_212	[p11l321t2340r848b2436],
44	phase	NN	O	phase	nn	46	SENT_212	[p11l887t2340r1128b2440],
45	3	CD	NUMBER	3	num	46	SENT_212	[p11l1164t2346r1208b2419],
46	study	NN	O	study	appos	34	SENT_212	[p11l1247t2340r1470b2440],
47	in	IN	O	in	_	0	SENT_212	[p11l1499t2341r1580b2418],
48	which	WDT	O	which	rel	66	SENT_212	[p11l1611t2340r1866b2419],
49	cetuX	NN	O	cetux	nsubjpass	66	SENT_212	[p11l1902t2357r2148b2419],
50	—	CD	NUMBER	—	num	51	SENT_212	[p11l1902t2357r2148b2419],
51	imab	NN	O	imab	nsubjpass	53	SENT_212	[p11l11t2469r228b2548],
52	was	VBD	O	be	auxpass	53	SENT_212	[p11l297t2495r461b2548],
53	added	VBN	O	add	rcmod	49	SENT_212	[p11l533t2469r790b2548],
54	to	TO	O	to	_	0	SENT_212	[p11l862t2486r943b2548],
55	standard	JJ	O	standard	amod	59	SENT_212	[p11l1018t2469r1399b2548],
56	platinum-based	JJ	O	platinum-based	amod	59	SENT_212	[p11l1469t2469r2149b2569],
57	chemotherapy	NN	O	chemotherapy	nn	59	SENT_212	[p11l12t2598r627b2698],
58	(	NN	O	(	nn	59	SENT_212	[p11l705t2598r1099b2698],
59	cisplatin	NN	O	cisplatin	prep_to	53	SENT_212	[p11l705t2598r1099b2698],
60	and	CC	O	and	_	0	SENT_212	[p11l1175t2598r1334b2677],
61	Vinorelbine	NN	O	vinorelbine	nn	62	SENT_212	[p11l1407t2598r1921b2689],
62	)	NN	O	)	conj_and	59	SENT_212	[p11l1407t2598r1921b2689],
63	has	VBZ	O	have	aux	66	SENT_212	[p11l2003t2598r2148b2676],
64	recently	RB	DATE	recently	advmod	66	SENT_212	[p11l11t2727r353b2827],
65	been	VBN	O	be	auxpass	66	SENT_212	[p11l381t2727r583b2806],
66	completed	VBN	O	complete	rcmod	46	SENT_212	[p11l615t2727r1064b2827],
67	(	CD	NUMBER	(	num	68	SENT_212	[p11l1099t2727r1892b2828],
68	ClinicalTrials	NNS	O	clinicaltrial	dobj	66	SENT_212	[p11l1099t2727r1892b2828],
69	.	.	O	.	_	0	SENT_212	[p11l1099t2727r1892b2828],

1	gov	NN	O	gov	nn	2	SENT_213	[p11l1099t2727r1892b2828],
2	number	NN	O	number	_	0	SENT_213	[p11l1920t2753r2148b2806, p11l12t2855r168b2951],
3	,	,	O	,	_	0	SENT_213	[p11l1920t2753r2148b2806, p11l12t2855r168b2951],
4	NCTOO148798	NN	O	nctoo148798	nn	5	SENT_213	[p11l223t2861r866b2946],
5	)	NN	O	)	appos	2	SENT_213	[p11l223t2861r866b2946],
6	.	.	O	.	_	0	SENT_213	[p11l223t2861r866b2946],

1	A	DT	O	a	det	21	SENT_214	[p11l915t2863r982b2932],
2	more	JJR	O	more	amod	4	SENT_214	[p11l1027t2881r1241b2934],
3	thorough	JJ	O	thorough	amod	4	SENT_214	[p11l1289t2855r1677b2956],
4	evaluation	NN	O	evaluation	nn	21	SENT_214	[p11l1725t2855r2149b2934],
5	of	IN	O	of	_	0	SENT_214	[p11l12t2983r110b3064],
6	the	DT	O	the	det	7	SENT_214	[p11l140t2984r270b3063],
7	role	NN	O	role	prep_of	4	SENT_214	[p11l317t2984r471b3064],
8	of	IN	O	of	_	0	SENT_214	[p11l520t2983r619b3064],
9	cetuximab	NN	O	cetuximab	prep_of	7	SENT_214	[p11l649t2984r1086b3064],
10	in	IN	O	in	_	0	SENT_214	[p11l1135t2985r1217b3062],
11	the	DT	O	the	det	12	SENT_214	[p11l1265t2984r1394b3063],
12	treatment	NN	O	treatment	prep_in	4	SENT_214	[p11l1443t3001r1853b3063],
13	of	IN	O	of	_	0	SENT_214	[p11l1897t2983r1995b3064],
14	advanced	JJ	O	advanced	amod	16	SENT_214	[p11l2023t2984r2148b3064, p11l7t3113r295b3192],
15	non	JJ	O	non	amod	16	SENT_214	[p11l333t3113r952b3192],
16	—	NN	O	—	prep_of	12	SENT_214	[p11l333t3113r952b3192],
17	small	JJ	O	small	amod	21	SENT_214	[p11l333t3113r952b3192],
18	—	NN	O	—	nn	21	SENT_214	[p11l333t3113r952b3192],
19	cell	NN	O	cell	nn	21	SENT_214	[p11l333t3113r952b3192],
20	lung	NN	O	lung	nn	21	SENT_214	[p11l988t3113r1176b3214],
21	cancer	NN	O	cancer	nsubj	22	SENT_214	[p11l1212t3139r1483b3191],
22	awaits	VBZ	O	await	_	0	SENT_214	[p11l1517t3114r1778b3192],
23	publication	NN	O	publication	dobj	22	SENT_214	[p11l1816t3113r2148b3213, p11l12t3243r176b3322],
24	of	IN	O	of	_	0	SENT_214	[p11l212t3241r310b3322],
25	the	DT	O	the	det	26	SENT_214	[p11l328t3242r457b3321],
26	results	NNS	O	result	prep_of	23	SENT_214	[p11l493t3242r765b3322],
27	of	IN	O	of	_	0	SENT_214	[p11l803t3241r901b3322],
28	this	DT	O	this	det	29	SENT_214	[p11l919t3242r1073b3321],
29	trial	NN	O	trial	prep_of	26	SENT_214	[p11l1112t3242r1302b3322],
30	.	.	O	.	_	0	SENT_214	[p11l1112t3242r1302b3322],

1	COLORECTAL	JJ	O	colorectal	amod	3	SENT_215	[p11l12t3517r527b3568],
2	CANCER	NNP	O	CANCER	nn	3	SENT_215	[p11l561t3517r877b3568],
3	Cetuximab	NNP	PERSON	Cetuximab	nsubjpass	6	SENT_215	[p11l11t3616r478b3695],
4	has	VBZ	O	have	aux	6	SENT_215	[p11l506t3616r649b3694],
5	been	VBN	O	be	auxpass	6	SENT_215	[p11l679t3616r878b3695],
6	evaluated	VBN	O	evaluate	_	0	SENT_215	[p11l906t3616r1303b3695],
7	in	IN	O	in	prep	6	SENT_215	[p11l1329t3617r1412b3693],
8	both	CC	O	both	prep	6	SENT_215	[p11l1440t3616r1636b3695],
9	chemotherapy-refractory	JJ	O	chemotherapy-refractory	dep	8	SENT_215	[p11l1664t3616r2148b3695, p12l11t30r611b131],

1	and	CC	O	and	dep	4	SENT_216	[p12l650t31r809b110],
2	untreated	JJ	O	untreated	amod	4	SENT_216	[p12l854t31r1269b111],
3	metastatic	JJ	O	metastatic	amod	4	SENT_216	[p12l1313t32r1763b109],
4	colorecENGLJ	NN	O	colorecenglj	_	0	SENT_216	[p12l1808t31r2148b110, p12l550t216r628b238],

1	MED	NN	O	med	_	0	SENT_217	[p12l643t216r695b231],
2	358	CD	NUMBER	358	num	1	SENT_217	[p12l705t210r773b238],
3	;	:	O	;	_	0	SENT_217	[p12l705t210r773b238],
4	11	CD	NUMBER	11	num	5	SENT_217	[p12l705t210r773b238],
5	WWW	NNP	O	WWW	dep	1	SENT_217	[p12l809t216r917b232],
6	.	.	O	.	_	0	SENT_217	[p12l809t216r917b232],

1	NE	NNS	O	ne	_	0	SENT_218	[p12l809t216r917b232],
2	M.ORG	NNP	O	M.ORG	nn	3	SENT_218	[p12l931t216r1010b232],
3	MARCH	NNP	DATE	MARCH	dep	1	SENT_218	[p12l1047t216r1133b232],
4	13	CD	DATE	13	num	3	SENT_218	[p12l1147t216r1178b238],
5	,	,	DATE	,	_	0	SENT_218	[p12l1147t216r1178b238],
6	2008	CD	DATE	2008	num	3	SENT_218	[p12l1189t210r1253b232],
7	1165	CD	DATE	1165	dep	1	SENT_218	[p12l1940t206r2015b229],

1	The	DT	O	the	det	4	SENT_219	[p12l702t249r753b272],
2	New	NNP	O	New	nn	4	SENT_219	[p12l762t249r824b272],
3	Englan	NNP	O	Englan	nn	4	SENT_219	[p12l833t249r927b279],
4	ournal	NN	O	ournal	_	0	SENT_219	[p12l966t249r1050b272],
5	of	IN	O	of	_	0	SENT_219	[p12l1060t249r1089b272],
6	Medicine	NN	MISC	medicine	prep_of	4	SENT_219	[p12l1095t249r1220b272],

1	Downloaded	VBN	O	download	_	0	SENT_220	[p12l144t289r314b312],
2	from	IN	O	from	_	0	SENT_220	[p12l323t289r387b312],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_220	[p12l396t289r514b319],
4	at	IN	O	at	_	0	SENT_220	[p12l524t293r547b312],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_220	[p12l556t289r738b312],
6	on	IN	O	on	_	0	SENT_220	[p12l748t296r780b312],
7	January	NNP	DATE	January	prep_on	1	SENT_220	[p12l789t289r892b319],
8	5	CD	DATE	5	num	7	SENT_220	[p12l902t289r924b317],
9	,	,	DATE	,	_	0	SENT_220	[p12l902t289r924b317],
10	2014	CD	DATE	2014	num	7	SENT_220	[p12l935t289r1007b312],
11	.	.	O	.	_	0	SENT_220	[p12l935t289r1007b312],

1	For	IN	O	for	_	0	SENT_221	[p12l1018t289r1064b312],
2	personal	JJ	O	personal	amod	3	SENT_221	[p12l1072t289r1185b319],
3	use	NN	O	use	pobj	1	SENT_221	[p12l1194t296r1237b312],
4	only	RB	O	only	advmod	3	SENT_221	[p12l1247t289r1312b319],
5	.	.	O	.	_	0	SENT_221	[p12l1247t289r1312b319],

1	No	DT	O	no	det	3	SENT_222	[p12l1323t289r1362b312],
2	other	JJ	O	other	amod	3	SENT_222	[p12l1372t289r1440b312],
3	uses	NNS	O	use	_	0	SENT_222	[p12l1449t296r1505b312],
4	without	IN	O	without	_	0	SENT_222	[p12l1515t289r1616b312],
5	permission	NN	O	permission	prep_without	3	SENT_222	[p12l1624t289r1777b319],
6	.	.	O	.	_	0	SENT_222	[p12l1624t289r1777b319],

1	Copyright	NN	O	copyright	_	0	SENT_223	[p12l494t330r629b361],
2	©	CD	NUMBER	©	num	6	SENT_223	[p12l638t330r661b354],
3	2008	CD	DATE	2008	num	6	SENT_223	[p12l671t330r736b354],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_223	[p12l746t330r937b354],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_223	[p12l947t330r1055b354],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_223	[p12l1065t330r1170b361],
7	.	.	O	.	_	0	SENT_223	[p12l1065t330r1170b361],

1	All	DT	O	all	det	2	SENT_224	[p12l1181t330r1223b354],
2	rights	NNS	O	rights	nsubj	3	SENT_224	[p12l1232t330r1307b361],
3	reserved	VBN	O	reserve	_	0	SENT_224	[p12l1316t330r1435b354],
4	.	.	O	.	_	0	SENT_224	[p12l1316t330r1435b354],

1	The	DT	O	the	det	4	SENT_225	[p12l673t373r718b394],
2	NEW	NNP	O	NEW	nn	4	SENT_225	[p12l737t375r822b394],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_225	[p12l841t375r1029b394],
4	IOURNAL	NNP	O	IOURNAL	_	0	SENT_225	[p12l1048t375r1228b401],
5	of	IN	O	of	_	0	SENT_225	[p12l1247t373r1276b400],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_225	[p12l1288t375r1487b394],

1	Table	NNP	O	Table	_	0	SENT_226	[p12l263t503r337b528],
2	3	CD	NUMBER	3	dep	1	SENT_226	[p12l346t506r368b528],
3	.	.	O	.	_	0	SENT_226	[p12l346t506r368b528],

1	Efficacy	NN	O	efficacy	_	0	SENT_227	[p12l380t503r483b536],
2	of	IN	O	of	_	0	SENT_227	[p12l491t503r523b528],
3	Erlotinib	NNP	O	Erlotinib	prep_of	1	SENT_227	[p12l528t503r641b529],
4	in	IN	O	in	_	0	SENT_227	[p12l651t504r674b528],
5	Chemotherapy-Refractory	NNP	O	Chemotherapy-Refractory	nn	6	SENT_227	[p12l684t503r1035b536],
6	Non	NNP	O	Non	prep_in	1	SENT_227	[p12l1046t503r1256b528],
7	.	.	O	.	_	0	SENT_227	[p12l1046t503r1256b528],

1	—	NN	O	—	_	0	SENT_228	[p12l1046t503r1256b528],
2	.	.	O	.	_	0	SENT_228	[p12l1046t503r1256b528],

1	Sma	NN	O	sma	_	0	SENT_229	[p12l1046t503r1256b528],
2	|	CD	NUMBER	|	amod	1	SENT_229	[p12l1046t503r1256b528],
3	|	SYM	O	|	dep	5	SENT_229	[p12l1046t503r1256b528],
4	-	:	O	-	_	0	SENT_229	[p12l1046t503r1256b528],
5	Cell	NN	O	cell	dep	1	SENT_229	[p12l1046t503r1256b528],
6	Lung	NN	O	lung	dep	7	SENT_229	[p12l1269t506r1336b536],
7	Cancer	NN	O	cancer	dep	5	SENT_229	[p12l1344t505r1464b528],
8	.	.	O	.	_	0	SENT_229	[p12l1344t505r1464b528],

1	‘	SYM	O	‘	dep	3	SENT_230	[p12l1344t505r1464b528],
2	-	:	O	-	_	0	SENT_230	[p12l1344t505r1464b528],
3	"	``	O	"	_	0	SENT_230	[p12l1344t505r1464b528],
4	‘	IN	O	‘	prep	3	SENT_230	[p12l1344t505r1464b528],

1	Placebo	NNP	O	Placebo	nn	4	SENT_231	[p12l1004t578r1108b604],
2	Erlotinib	NNP	O	Erlotinib	nn	4	SENT_231	[p12l1208t578r1321b604],
3	Hazard	NNP	O	Hazard	nn	4	SENT_231	[p12l1421t578r1517b604],
4	Ratio	NNP	O	Ratio	_	0	SENT_231	[p12l1530t579r1598b604],

1	Variable	JJ	O	variable	amod	3	SENT_232	[p12l263t616r374b641],
2	(	NN	O	(	nn	3	SENT_232	[p12l996t618r1027b649],
3	N	NN	O	n	_	0	SENT_232	[p12l996t618r1027b649],
4	=	JJ	O	=	amod	3	SENT_232	[p12l1034t618r1114b649],
5	243	CD	NUMBER	243	number	6	SENT_232	[p12l1034t618r1114b649],
6	)	CD	NUMBER	)	num	8	SENT_232	[p12l1034t618r1114b649],
7	(	NN	O	(	nn	8	SENT_232	[p12l1205t618r1235b649],
8	N	NN	O	n	npadvmod	9	SENT_232	[p12l1205t618r1235b649],
9	=	JJ	O	=	dep	3	SENT_232	[p12l1243t618r1323b649],
10	488	CD	NUMBER	488	number	11	SENT_232	[p12l1243t618r1323b649],
11	)	CD	NUMBER	)	num	12	SENT_232	[p12l1243t618r1323b649],
12	(	NN	O	(	dep	18	SENT_232	[p12l1450t617r1518b649],
13	95	CD	PERCENT	95	num	14	SENT_232	[p12l1450t617r1518b649],
14	%	NN	PERCENT	%	dep	12	SENT_232	[p12l1450t617r1518b649],
15	Cl	NN	O	cl	dep	18	SENT_232	[p12l1529t618r1567b649],
16	)	CD	NUMBER	)	num	15	SENT_232	[p12l1529t618r1567b649],
17	P	NN	O	p	nn	18	SENT_232	[p12l1734t618r1750b641],
18	Value	NN	O	value	dep	23	SENT_232	[p12l1759t616r1835b641],
19	Overall	JJ	O	overall	amod	21	SENT_232	[p12l264t674r359b699],
20	response	NN	O	response	nn	21	SENT_232	[p12l372t682r495b706],
21	rate	NN	O	rate	dep	18	SENT_232	[p12l506t678r556b699],
22	(	CD	PERCENT	(	num	23	SENT_232	[p12l568t675r634b707],
23	%	NN	PERCENT	%	dep	89	SENT_232	[p12l568t675r634b707],
24	)	CD	NUMBER	)	num	25	SENT_232	[p12l568t675r634b707],
25	‘	NN	O	‘	dep	23	SENT_232	[p12l568t675r634b707],
26	i	FW	O	i	nn	87	SENT_232	[p12l568t675r634b707],
27	'	''	O	'	_	0	SENT_232	[p12l568t675r634b707],
28	<	JJR	O	<	amod	87	SENT_232	[p12l1013t676r1045b698],
29	1	CD	NUMBER	1	number	30	SENT_232	[p12l1013t676r1045b698],
30	9	CD	NUMBER	9	npadvmod	31	SENT_232	[p12l1240t676r1254b699],
31	<	JJR	O	<	dep	28	SENT_232	[p12l1732t675r1821b699],
32	0.001	CD	NUMBER	0.001	num	38	SENT_232	[p12l1732t675r1821b699],
33	Median	JJ	O	median	amod	38	SENT_232	[p12l266t731r365b756],
34	progression-free	JJ	O	progression-free	amod	38	SENT_232	[p12l378t731r601b764],
35	survival	NN	O	survival	nn	38	SENT_232	[p12l611t731r713b756],
36	(	CD	NUMBER	(	num	38	SENT_232	[p12l727t733r789b764],
37	mo	NN	DURATION	mo	nn	38	SENT_232	[p12l727t733r789b764],
38	)	NN	O	)	dep	46	SENT_232	[p12l727t733r789b764],
39	1.8	CD	NUMBER	1.8	number	40	SENT_232	[p12l1033t733r1070b757],
40	2.2	CD	NUMBER	2.2	dep	38	SENT_232	[p12l1240t734r1279b756],
41	0.61	CD	NUMBER	0.61	dep	40	SENT_232	[p12l1402t733r1457b756],
42	(	NN	O	(	dep	46	SENT_232	[p12l1471t733r1621b764],
43	0.51	CD	NUMBER	0.51	num	42	SENT_232	[p12l1471t733r1621b764],
44	—	CD	NUMBER	—	num	46	SENT_232	[p12l1471t733r1621b764],
45	0.74	CD	NUMBER	0.74	num	46	SENT_232	[p12l1471t733r1621b764],
46	)	NN	O	)	dep	54	SENT_232	[p12l1471t733r1621b764],
47	<	JJR	O	<	dep	46	SENT_232	[p12l1732t733r1821b756],
48	0.001	CD	NUMBER	0.001	num	54	SENT_232	[p12l1732t733r1821b756],
49	Median	JJ	O	median	amod	54	SENT_232	[p12l266t789r365b814],
50	overall	JJ	O	overall	amod	54	SENT_232	[p12l377t789r464b814],
51	survival	NN	O	survival	nn	54	SENT_232	[p12l476t789r578b814],
52	(	CD	NUMBER	(	num	54	SENT_232	[p12l593t791r655b822],
53	mo	NN	DURATION	mo	nn	54	SENT_232	[p12l593t791r655b822],
54	)	NN	O	)	dep	66	SENT_232	[p12l593t791r655b822],
55	4.7	CD	NUMBER	4.7	number	56	SENT_232	[p12l1031t791r1071b814],
56	6.7	CD	NUMBER	6.7	dep	54	SENT_232	[p12l1240t791r1279b814],
57	0.70	CD	NUMBER	0.70	num	58	SENT_232	[p12l1402t790r1459b814],
58	(	NN	O	(	dep	56	SENT_232	[p12l1471t790r1621b822],
59	0.58	CD	NUMBER	0.58	number	60	SENT_232	[p12l1471t790r1621b822],
60	—	CD	NUMBER	—	num	65	SENT_232	[p12l1471t790r1621b822],
61	0.85	CD	NUMBER	0.85	num	65	SENT_232	[p12l1471t790r1621b822],
62	)	NN	O	)	nn	65	SENT_232	[p12l1471t790r1621b822],
63	0.001	CD	NUMBER	0.001	number	64	SENT_232	[p12l1750t790r1821b814],
64	*	CD	NUMBER	*	num	65	SENT_232	[p12l237t876r252b890],
65	Patients	NNS	O	patient	npadvmod	66	SENT_232	[p12l264t876r369b899],
66	with	IN	O	with	dep	77	SENT_232	[p12l379t874r434b899],
67	metastatic	JJ	O	metastatic	amod	73	SENT_232	[p12l448t876r593b903],
68	,	,	O	,	_	0	SENT_232	[p12l448t876r593b903],
69	platinum-refractory	JJ	O	platinum-refractory	amod	73	SENT_232	[p12l606t873r868b907],
70	,	,	O	,	_	0	SENT_232	[p12l606t873r868b907],
71	non	JJ	O	non	amod	73	SENT_232	[p12l882t874r1074b899],
72	—	NN	O	—	nn	73	SENT_232	[p12l882t874r1074b899],
73	small-cell	NN	O	small-cell	pobj	66	SENT_232	[p12l882t874r1074b899],
74	lung	NN	O	lung	nn	75	SENT_232	[p12l1087t874r1144b907],
75	cancer	NN	O	cancer	nsubjpass	77	SENT_232	[p12l1154t883r1242b899],
76	were	VBD	O	be	auxpass	77	SENT_232	[p12l1251t883r1313b899],
77	treated	VBN	O	treat	ccomp	28	SENT_232	[p12l1323t874r1415b899],
78	either	CC	O	either	dep	77	SENT_232	[p12l1427t874r1503b899],
79	with	IN	O	with	_	0	SENT_232	[p12l1512t874r1567b899],
80	erlotinib	NN	O	erlotinib	prep_with	77	SENT_232	[p12l1579t874r1689b899],
81	alone	RB	O	alone	advmod	84	SENT_232	[p12l1701t874r1772b899],
82	o	NN	O	o	nn	84	SENT_232	[p12l1827t875r1842b899],
83	mg	NN	O	mg	nn	84	SENT_232	[p12l1854t883r1895b907],
84	t	NN	O	t	dep	80	SENT_232	[p12l643t911r667b937],
85	'	''	O	'	_	0	SENT_232	[p12l643t911r667b937],
86	|	JJ	O	|	amod	80	SENT_232	[p12l643t911r667b937],
87	disease	NN	O	disease	nsubj	89	SENT_232	[p12l680t911r781b937],
88	also	RB	O	also	advmod	87	SENT_232	[p12l1513t911r1567b937],
89	re	VBD	O	re	ccomp	9	SENT_232	[p12l766t957r789b973],
90	val	NN	O	val	dobj	89	SENT_232	[p12l1501t948r1545b973],
91	.	.	O	.	_	0	SENT_232	[p12l1501t948r1545b973],

1	per	IN	O	per	_	0	SENT_233	[p12l264t920r306b945],
2	day	NN	DURATION	day	pobj	1	SENT_233	[p12l317t911r371b945],
3	)	CD	NUMBER	)	num	2	SENT_233	[p12l317t911r371b945],
4	or	CC	O	or	_	0	SENT_233	[p12l385t920r413b937],
5	with	IN	O	with	conj_or	1	SENT_233	[p12l422t911r478b937],
6	placebo	NN	O	placebo	nn	7	SENT_233	[p12l493t911r596b945],
7	un	NN	O	un	pobj	5	SENT_233	[p12l609t920r640b937],
8	I	PRP	O	I	dep	7	SENT_233	[p12l656t921r659b936],
9	progression	NN	O	progression	dep	1	SENT_233	[p12l794t914r962b945],
10	.	.	O	.	_	0	SENT_233	[p12l794t914r962b945],

1	Approximately	RB	O	approximately	quantmod	2	SENT_234	[p12l974t911r1171b945],
2	half	DT	O	half	num	4	SENT_234	[p12l1183t911r1235b937],
3	ofthe	NN	O	ofthe	nn	4	SENT_234	[p12l1242t911r1320b937],
4	patients	NNS	O	patient	nsubj	6	SENT_234	[p12l1333t914r1440b945],
5	had	VBD	O	have	aux	6	SENT_234	[p12l1453t911r1500b937],
6	received	VBN	O	receive	_	0	SENT_234	[p12l1580t911r1689b937],
7	a	DT	O	a	det	9	SENT_234	[p12l1702t920r1715b937],
8	se	FW	O	se	nn	9	SENT_234	[p12l1727t920r1755b937],
9	n	NN	O	n	dobj	6	SENT_234	[p12l1791t920r1804b936],
10	-	:	O	-	_	0	SENT_234	[p12l1826t911r1883b937],
11	line	NN	O	line	nn	12	SENT_234	[p12l1826t911r1883b937],
12	treatment	NN	O	treatment	dep	9	SENT_234	[p12l261t953r396b973],
13	before	IN	O	before	_	0	SENT_234	[p12l409t948r492b973],
14	study	NN	O	study	nn	15	SENT_234	[p12l504t948r577b981],
15	entry	NN	O	entry	prep_before	12	SENT_234	[p12l587t953r661b981],
16	.	.	O	.	_	0	SENT_234	[p12l587t953r661b981],

1	D	NN	O	d	nn	2	SENT_235	[p12l676t951r695b973],
2	ta	NN	O	ta	nsubj	9	SENT_235	[p12l712t953r737b973],
3	from	IN	O	from	_	0	SENT_235	[p12l800t948r864b973],
4	Shepherd	NNP	O	Shepherd	prep_from	2	SENT_235	[p12l877t948r1005b981],
5	et	FW	O	et	nn	6	SENT_235	[p12l1018t953r1042b973],
6	al.	FW	O	al.	dep	4	SENT_235	[p12l1053t948r1107b973],
7	37	CD	NUMBER	37	num	8	SENT_235	[p12l1053t948r1107b973],
8	Cl	NN	O	cl	dep	6	SENT_235	[p12l1119t950r1145b973],
9	denotes	VBZ	O	denote	_	0	SENT_235	[p12l1158t948r1266b973],
10	conﬁdence	NN	O	conﬁdence	nn	13	SENT_235	[p12l1278t948r1426b973],
11	inter	NN	O	inter	nn	13	SENT_235	[p12l1439t951r1500b973],
12	rate	NN	O	rate	nn	13	SENT_235	[p12l560t990r610b1010],
13	includ	NN	O	includ	dobj	9	SENT_235	[p12l622t985r703b1010],
14	d	NN	O	d	prep	9	SENT_235	[p12l722t985r736b1010],
15	a	DT	O	a	dep	16	SENT_235	[p12l698t957r711b973],
16	a	DT	O	a	dep	14	SENT_235	[p12l749t957r762b973],

1	1	CD	NUMBER	1	num	2	SENT_236	[p12l238t987r253b1018],
2	‘	CD	NUMBER	‘	nsubj	10	SENT_236	[p12l238t987r253b1018],
3	The	DT	O	the	det	5	SENT_236	[p12l261t985r312b1010],
4	overall	JJ	O	overall	amod	5	SENT_236	[p12l323t985r411b1010],
5	response	NN	O	response	dep	2	SENT_236	[p12l425t994r548b1018],
6	e	SYM	O	e	dep	10	SENT_236	[p12l706t994r720b1010],
7	complete	JJ	O	complete	amod	10	SENT_236	[p12l749t985r875b1018],
8	and	CC	O	and	_	0	SENT_236	[p12l887t985r935b1010],
9	partial	JJ	O	partial	amod	10	SENT_236	[p12l949t985r1032b1018],
10	responses	NNS	O	response	_	0	SENT_236	[p12l1046t994r1191b1018],
11	.	.	O	.	_	0	SENT_236	[p12l1046t994r1191b1018],

1	tal	JJ	O	tal	amod	2	SENT_237	[p12l12t1118r119b1197],
2	cancer	NN	O	cancer	_	0	SENT_237	[p12l161t1144r453b1197],
3	.	.	O	.	_	0	SENT_237	[p12l161t1144r453b1197],

1	In	IN	O	in	_	0	SENT_238	[p12l499t1126r587b1196],
2	phase	NN	O	phase	nn	4	SENT_238	[p12l627t1118r871b1219],
3	2	CD	NUMBER	2	num	4	SENT_238	[p12l913t1124r960b1196],
4	studies	NNS	O	study	prep_in	9	SENT_238	[p12l1005t1118r1322b1214],
5	,	,	O	,	_	0	SENT_238	[p12l1005t1118r1322b1214],
6	cetuximab	JJ	O	cetuximab	amod	7	SENT_238	[p12l1369t1118r1813b1197],
7	monotherapy	NN	O	monotherapy	nsubjpass	9	SENT_238	[p12l1855t1144r2133b1197, p12l12t1246r327b1347],
8	was	VBD	O	be	auxpass	9	SENT_238	[p12l350t1273r510b1325],
9	associated	VBN	O	associate	_	0	SENT_238	[p12l542t1246r977b1325],
10	with	IN	O	with	_	0	SENT_238	[p12l1004t1246r1195b1325],
11	response	NN	O	response	nn	12	SENT_238	[p12l1226t1272r1599b1347],
12	rates	NNS	O	rate	prep_with	9	SENT_238	[p12l1630t1263r1828b1325],
13	of	IN	O	of	_	0	SENT_238	[p12l1862t1246r1961b1325],
14	9	CD	NUMBER	9	number	16	SENT_238	[p12l1974t1252r2020b1325],
15	to	TO	O	to	dep	16	SENT_238	[p12l2052t1263r2133b1325],
16	12	CD	PERCENT	12	num	17	SENT_238	[p12l15t1379r224b1453],
17	%	NN	PERCENT	%	prep_of	12	SENT_238	[p12l15t1379r224b1453],
18	.	.	O	.	_	0	SENT_238	[p12l15t1379r224b1453],

1	Response	NN	O	response	nn	2	SENT_239	[p12l264t1381r674b1475],
2	rates	NNS	O	rate	nsubjpass	8	SENT_239	[p12l710t1391r912b1453],
3	of	IN	O	of	_	0	SENT_239	[p12l951t1374r1051b1453],
4	approximately	RB	O	approximately	quantmod	5	SENT_239	[p12l1067t1374r1683b1475],
5	20	CD	PERCENT	20	num	6	SENT_239	[p12l1714t1380r1902b1453],
6	%	NN	PERCENT	%	prep_of	2	SENT_239	[p12l1714t1380r1902b1453],
7	were	VBD	O	be	auxpass	8	SENT_239	[p12l1932t1400r2134b1453],
8	achieved	VBN	O	achieve	_	0	SENT_239	[p12l11t1503r379b1582],
9	when	WRB	O	when	advmod	12	SENT_239	[p12l412t1503r646b1582],
10	cetuximab	NN	O	cetuximab	nsubjpass	12	SENT_239	[p12l684t1503r1136b1582],
11	was	VBD	O	be	auxpass	12	SENT_239	[p12l1171t1530r1333b1582],
12	used	VBN	O	use	advcl	8	SENT_239	[p12l1373t1503r1570b1582],
13	in	IN	O	in	_	0	SENT_239	[p12l1607t1504r1690b1581],
14	combina	NN	O	combina	prep_in	12	SENT_239	[p12l1729t1503r2133b1582],
15	—	CD	NUMBER	—	num	14	SENT_239	[p12l1729t1503r2133b1582],

1	tion	NN	O	tion	nsubj	27	SENT_240	[p12l12t1632r181b1710],
2	with	IN	O	with	_	0	SENT_240	[p12l211t1631r406b1711],
3	irinotecan	NN	O	irinotecan	prep_with	1	SENT_240	[p12l439t1632r879b1710],
4	in	IN	O	in	_	0	SENT_240	[p12l912t1632r995b1709],
5	patients	NNS	O	patient	prep_in	3	SENT_240	[p12l1027t1632r1369b1732],
6	who	WP	O	who	nsubj	9	SENT_240	[p12l1400t1631r1583b1711],
7	had	VBD	O	have	aux	9	SENT_240	[p12l1618t1631r1774b1710],
8	not	RB	O	not	neg	9	SENT_240	[p12l1807t1648r1950b1710],
9	had	VBN	O	have	rcmod	5	SENT_240	[p12l1978t1631r2134b1710],
10	a	DT	O	a	det	11	SENT_240	[p12l11t1786r56b1838],
11	response	NN	O	response	dobj	9	SENT_240	[p12l86t1785r452b1860],
12	to	TO	O	to	_	0	SENT_240	[p12l484t1776r564b1838],
13	previous	JJ	O	previous	amod	14	SENT_240	[p12l596t1760r944b1860],
14	therapy	NN	O	therapy	prep_to	9	SENT_240	[p12l978t1759r1287b1860],
15	with	IN	O	with	_	0	SENT_240	[p12l1310t1759r1498b1838],
16	irinotecan	NN	O	irinotecan	prep_with	9	SENT_240	[p12l1530t1760r2133b1838],
17	.51	CD	NUMBER	.51	number	18	SENT_240	[p12l1530t1760r2133b1838],
18	'53	CD	NUMBER	'53	dep	16	SENT_240	[p12l1530t1760r2133b1838],
19	A	DT	O	a	det	20	SENT_240	[p12l8t1895r74b1965],
20	multicenter	NN	O	multicenter	dep	18	SENT_240	[p12l116t1887r630b1983],
21	,	,	O	,	_	0	SENT_240	[p12l116t1887r630b1983],
22	randomized	VBN	O	randomize	dep	9	SENT_240	[p12l681t1887r1225b1983],
23	,	,	O	,	_	0	SENT_240	[p12l681t1887r1225b1983],
24	phase	NN	O	phase	nn	26	SENT_240	[p12l1274t1887r1523b1988],
25	2	CD	NUMBER	2	num	26	SENT_240	[p12l1568t1893r1614b1965],
26	trial	NN	O	trial	dobj	9	SENT_240	[p12l1661t1887r1839b1966],
27	evaluated	VBD	O	evaluate	dep	61	SENT_240	[p12l1884t1887r2133b1966, p12l11t2015r189b2094],
28	the	DT	O	the	det	29	SENT_240	[p12l220t2015r352b2094],
29	activity	NN	O	activity	dobj	27	SENT_240	[p12l382t2016r692b2116],
30	of	IN	O	of	_	0	SENT_240	[p12l718t2015r817b2094],
31	cetuximab	NN	O	cetuximab	prep_of	29	SENT_240	[p12l830t2015r1281b2094],
32	given	VBN	O	give	prep	27	SENT_240	[p12l1312t2016r1538b2116],
33	alone	RB	O	alone	dep	32	SENT_240	[p12l1568t2015r1797b2094],
34	or	CC	O	or	_	0	SENT_240	[p12l1828t2041r1917b2094],
35	with	IN	O	with	prep	27	SENT_240	[p12l1939t2015r2134b2094],
36	irinotecan	NN	O	irinotecan	pobj	35	SENT_240	[p12l11t2144r452b2222],
37	in	IN	O	in	_	0	SENT_240	[p12l511t2144r594b2221],
38	patients	NNS	O	patient	prep_in	36	SENT_240	[p12l652t2144r993b2244],
39	who	WP	O	who	nsubj	42	SENT_240	[p12l1049t2143r1232b2222],
40	had	VBD	O	have	aux	42	SENT_240	[p12l1293t2143r1449b2222],
41	not	RB	O	not	neg	42	SENT_240	[p12l1507t2160r1650b2222],
42	had	VBN	O	have	rcmod	38	SENT_240	[p12l1704t2143r1860b2222],
43	a	DT	O	a	det	44	SENT_240	[p12l1918t2170r1963b2222],
44	response	NN	O	response	dobj	42	SENT_240	[p12l2020t2169r2133b2222, p12l13t2297r308b2372],
45	to	TO	O	to	_	0	SENT_240	[p12l371t2288r452b2350],
46	irinotecan	NN	O	irinotecan	nn	47	SENT_240	[p12l515t2272r956b2350],
47	monotherapy	NN	O	monotherapy	prep_to	42	SENT_240	[p12l1018t2271r1592b2372],
48	(	CD	NUMBER	(	num	49	SENT_240	[p12l1636t2271r1894b2363],
49	Table	NNP	O	Table	dep	47	SENT_240	[p12l1636t2271r1894b2363],
50	4	CD	NUMBER	4	num	49	SENT_240	[p12l1955t2277r2135b2363],
51	)	CD	NUMBER	)	number	52	SENT_240	[p12l1955t2277r2135b2363],
52	.54	CD	NUMBER	.54	dep	49	SENT_240	[p12l1955t2277r2135b2363],
53	The	DT	O	the	det	57	SENT_240	[p12l8t2399r169b2478],
54	cetuXimab	NN	O	cetuximab	nn	57	SENT_240	[p12l208t2399r1162b2478],
55	—	NN	O	—	nn	57	SENT_240	[p12l208t2399r1162b2478],
56	irinotecan	NN	O	irinotecan	nn	57	SENT_240	[p12l208t2399r1162b2478],
57	combination	NN	O	combination	dep	52	SENT_240	[p12l1200t2399r1746b2478],
58	was	VBD	O	be	cop	61	SENT_240	[p12l1779t2426r1942b2478],
59	significantly	RB	O	significantly	advmod	61	SENT_240	[p12l1983t2400r2133b2500, p12l12t2527r430b2628],
60	more	RBR	O	more	advmod	61	SENT_240	[p12l465t2553r684b2606],
61	effective	JJ	O	effective	_	0	SENT_240	[p12l725t2527r1083b2606],
62	than	IN	O	than	_	0	SENT_240	[p12l1123t2527r1319b2606],
63	cetuximab	JJ	O	cetuximab	amod	64	SENT_240	[p12l1359t2527r1810b2606],
64	monotherapy	NN	O	monotherapy	prep_than	61	SENT_240	[p12l1851t2553r2133b2606, p12l12t2655r334b2756],
65	in	IN	O	in	_	0	SENT_240	[p12l364t2656r448b2733],
66	terms	NNS	O	term	prep_in	61	SENT_240	[p12l484t2672r727b2734],
67	of	IN	O	of	_	0	SENT_240	[p12l765t2655r865b2734],
68	the	DT	O	the	det	69	SENT_240	[p12l883t2655r1016b2734],
69	response	NN	O	response	prep_of	66	SENT_240	[p12l1052t2681r1432b2756],
70	rate	NN	O	rate	amod	69	SENT_240	[p12l1468t2672r1627b2734],
71	and	CC	O	and	_	0	SENT_240	[p12l1663t2655r1821b2734],
72	rate	NN	O	rate	amod	69	SENT_240	[p12l1856t2672r2016b2734],
73	of	IN	O	of	_	0	SENT_240	[p12l2053t2655r2152b2734],
74	progression	NN	O	progression	prep_of	69	SENT_240	[p12l11t2783r719b2884],
75	—	CD	NUMBER	—	num	77	SENT_240	[p12l11t2783r719b2884],
76	free	JJ	O	free	amod	77	SENT_240	[p12l11t2783r719b2884],
77	survival	NN	O	survival	nsubj	61	SENT_240	[p12l770t2783r1124b2862],
78	.	.	O	.	_	0	SENT_240	[p12l770t2783r1124b2862],

1	However	RB	O	however	advmod	7	SENT_241	[p12l1178t2791r1573b2879],
2	,	,	O	,	_	0	SENT_241	[p12l1178t2791r1573b2879],
3	the	DT	O	the	det	5	SENT_241	[p12l1628t2783r1761b2862],
4	median	JJ	O	median	amod	5	SENT_241	[p12l1811t2783r2134b2862],
5	survival	NN	O	survival	nsubj	7	SENT_241	[p12l13t2911r345b2990],
6	was	VBD	O	be	cop	7	SENT_241	[p12l395t2938r558b2990],
7	similar	JJ	O	similar	_	0	SENT_241	[p12l616t2911r922b2990],
8	with	IN	O	with	_	0	SENT_241	[p12l969t2911r1165b2990],
9	the	DT	O	the	det	11	SENT_241	[p12l1221t2911r1353b2990],
10	two	CD	NUMBER	two	num	11	SENT_241	[p12l1409t2928r1566b2990],
11	approaches	NNS	O	approach	prep_with	7	SENT_241	[p12l1622t2911r2129b3012],
12	,	,	O	,	_	0	SENT_241	[p12l1622t2911r2129b3012],
13	mainly	RB	O	mainly	advmod	7	SENT_241	[p12l12t3039r312b3140],
14	because	IN	O	because	_	0	SENT_241	[p12l342t3039r678b3118],
15	of	IN	O	of	_	0	SENT_241	[p12l713t3039r813b3118],
16	the	DT	O	the	det	17	SENT_241	[p12l829t3039r962b3118],
17	crossover	NN	O	crossover	prep_because_of	7	SENT_241	[p12l997t3065r1400b3118],
18	of	IN	O	of	_	0	SENT_241	[p12l1432t3039r1532b3118],
19	patients	NNS	O	patient	prep_of	17	SENT_241	[p12l1547t3040r1888b3140],
20	from	IN	O	from	_	0	SENT_241	[p12l1924t3039r2134b3118],
21	cetuximab	JJ	O	cetuximab	amod	22	SENT_241	[p12l12t3167r464b3246],
22	monotherapy	NN	O	monotherapy	prep_from	7	SENT_241	[p12l550t3167r1123b3268],
23	to	TO	O	to	_	0	SENT_241	[p12l1204t3184r1285b3246],
24	the	DT	O	the	det	26	SENT_241	[p12l1370t3167r1503b3246],
25	combination	NN	O	combination	nn	26	SENT_241	[p12l1588t3167r2134b3246],
26	group	NN	O	group	prep_to	7	SENT_241	[p12l12t3321r264b3396],
27	on	IN	O	on	_	0	SENT_241	[p12l298t3321r404b3374],
28	treatment	NN	O	treatment	nn	29	SENT_241	[p12l436t3312r861b3374],
29	failure	NN	O	failure	prep_on	26	SENT_241	[p12l888t3295r1188b3374],
30	.	.	O	.	_	0	SENT_241	[p12l888t3295r1188b3374],

1	On	IN	O	on	_	0	SENT_242	[p12l1226t3301r1352b3374],
2	the	DT	O	the	det	3	SENT_242	[p12l1384t3295r1517b3374],
3	basis	NN	O	basis	prep_on	10	SENT_242	[p12l1551t3295r1761b3374],
4	of	IN	O	of	_	0	SENT_242	[p12l1797t3295r1897b3374],
5	these	DT	O	these	det	6	SENT_242	[p12l1911t3295r2134b3374],
6	results	NNS	O	result	prep_of	3	SENT_242	[p12l12t3423r319b3519],
7	,	,	O	,	_	0	SENT_242	[p12l12t3423r319b3519],
8	cetuximab	NN	O	cetuximab	nsubjpass	10	SENT_242	[p12l371t3423r822b3502],
9	was	VBD	O	be	auxpass	10	SENT_242	[p12l865t3450r1027b3503],
10	approved	VBN	O	approve	_	0	SENT_242	[p12l1074t3423r1463b3524],
11	by	IN	O	by	_	0	SENT_242	[p12l1509t3423r1607b3524],
12	the	DT	O	the	det	13	SENT_242	[p12l1648t3423r1780b3502],
13	FDA	NNP	ORGANIZATION	FDA	agent	10	SENT_242	[p12l1824t3430r2009b3501],
14	in	IN	O	in	_	0	SENT_242	[p12l2051t3424r2134b3501],
15	February	NNP	DATE	February	prep_in	13	SENT_242	[p12l11t3551r397b3652],
16	2004	CD	DATE	2004	num	15	SENT_242	[p12l422t3557r631b3630],
17	for	IN	O	for	_	0	SENT_242	[p12l661t3551r785b3630],
18	use	NN	O	use	prep_for	10	SENT_242	[p12l812t3578r952b3630],
19	in	IN	O	in	_	0	SENT_242	[p12l982t3552r1065b3629],
20	patients	NNS	O	patient	prep_in	18	SENT_242	[p12l1094t3552r1435b3652],
21	with	IN	O	with	_	0	SENT_242	[p12l1463t3551r1658b3630],
22	metastatic	JJ	O	metastatic	amod	24	SENT_242	[p12l1689t3552r2135b3630],
23	colorectal	JJ	O	colorectal	amod	24	SENT_242	[p12l12t3678r433b3756],
24	cancer	NN	O	cancer	prep_with	20	SENT_242	[p12l467t3704r767b3773],
25	,	,	O	,	_	0	SENT_242	[p12l467t3704r767b3773],
26	either	CC	O	either	dep	10	SENT_242	[p12l807t3678r1054b3756],
27	in	IN	O	in	conj	10	SENT_242	[p12l1085t3679r1168b3755],
28	combination	NN	O	combination	pobj	27	SENT_242	[p12l1204t3678r1750b3756],
29	with	IN	O	with	dep	10	SENT_242	[p12l1779t3678r1975b3757],
30	irinotecan	NN	O	irinotecan	pobj	29	SENT_242	[p12l2009t3679r2133b3755, p13l12t40r353b102],

1	(	NN	O	(	_	0	SENT_243	[p13l390t23r539b114],
2	for	IN	O	for	_	0	SENT_243	[p13l390t23r539b114],
3	patients	NNS	O	patient	prep_for	1	SENT_243	[p13l566t24r907b124],
4	who	WP	O	who	nsubj	7	SENT_243	[p13l937t23r1119b103],
5	do	VBP	O	do	aux	7	SENT_243	[p13l1153t23r1256b102],
6	not	RB	O	not	neg	7	SENT_243	[p13l1289t40r1431b102],
7	have	VB	O	have	rcmod	3	SENT_243	[p13l1458t23r1648b102],
8	a	DT	O	a	det	9	SENT_243	[p13l1679t50r1723b102],
9	response	NN	O	response	dobj	7	SENT_243	[p13l1753t49r2134b124],
10	to	TO	O	to	_	0	SENT_243	[p13l12t168r92b230],
11	irinotecan	NN	O	irinotecan	prep_to	9	SENT_243	[p13l119t152r550b230],
12	alone	RB	O	alone	advmod	13	SENT_243	[p13l575t151r825b243],
13	)	RB	O	)	amod	17	SENT_243	[p13l575t151r825b243],
14	or	CC	O	or	_	0	SENT_243	[p13l856t177r944b230],
15	as	RB	O	as	advmod	16	SENT_243	[p13l965t178r1049b230],
16	monotherapy	JJ	O	monotherapy	conj_or	13	SENT_243	[p13l1077t151r1640b252],
17	(	NN	O	(	dep	1	SENT_243	[p13l1666t152r1775b243],
18	in	IN	O	in	_	0	SENT_243	[p13l1666t152r1775b243],
19	patients	NNS	O	patient	prep_in	17	SENT_243	[p13l1799t152r2133b252],
20	who	WP	O	who	nsubj	23	SENT_243	[p13l7t280r190b359],
21	can	MD	O	can	aux	23	SENT_243	[p13l236t297r535b359],
22	not	RB	O	not	neg	23	SENT_243	[p13l236t297r535b359],
23	tolerate	VB	O	tolerate	rcmod	19	SENT_243	[p13l574t280r894b359],
24	irinotecan	JJ	O	irinotecan	amod	25	SENT_243	[p13l938t281r1430b372],
25	)	NN	O	)	dobj	23	SENT_243	[p13l938t281r1430b372],
26	.	.	O	.	_	0	SENT_243	[p13l938t281r1430b372],

1	The	DT	O	the	det	2	SENT_244	[p13l1476t280r1636b359],
2	EMEA	NNP	ORGANIZATION	EMEA	nsubj	4	SENT_244	[p13l1679t288r1947b359],
3	has	VBZ	O	have	aux	4	SENT_244	[p13l1988t280r2132b359],
4	approved	VBN	O	approve	_	0	SENT_244	[p13l11t408r401b509],
5	cetuximab	NN	O	cetuximab	dobj	4	SENT_244	[p13l457t408r909b487],
6	only	RB	O	only	advmod	5	SENT_244	[p13l967t408r1151b509],
7	in	IN	O	in	_	0	SENT_244	[p13l1201t409r1285b486],
8	combination	NN	O	combination	prep_in	5	SENT_244	[p13l1342t408r1888b487],
9	with	IN	O	with	_	0	SENT_244	[p13l1939t408r2134b487],
10	irinotecan	NN	O	irinotecan	prep_with	4	SENT_244	[p13l11t537r475b614],
11	.	.	O	.	_	0	SENT_244	[p13l11t537r475b614],

1	A	DT	O	a	det	2	SENT_245	[p13l137t671r203b741],
2	multicenter	NN	O	multicenter	nsubj	9	SENT_245	[p13l245t663r760b759],
3	,	,	O	,	_	0	SENT_245	[p13l245t663r760b759],
4	randomized	VBN	O	randomize	partmod	9	SENT_245	[p13l811t663r1355b759],
5	,	,	O	,	_	0	SENT_245	[p13l811t663r1355b759],
6	phase	NN	O	phase	nsubj	9	SENT_245	[p13l1404t663r1653b764],
7	3	CD	NUMBER	3	num	8	SENT_245	[p13l1699t669r1743b742],
8	trial	NN	O	trial	dep	6	SENT_245	[p13l1792t663r1970b742],
9	examined	VBD	O	examine	_	0	SENT_245	[p13l2015t690r2133b742, p13l11t791r335b870],
10	the	DT	O	the	det	11	SENT_245	[p13l382t791r515b870],
11	combination	NN	O	combination	dobj	9	SENT_245	[p13l563t791r1110b870],
12	of	IN	O	of	_	0	SENT_245	[p13l1157t791r1257b870],
13	cetuximab	NN	O	cetuximab	prep_of	11	SENT_245	[p13l1286t791r1738b870],
14	plus	CC	O	plus	_	0	SENT_245	[p13l1785t791r1960b892],
15	irinotecan	NN	O	irinotecan	dobj	9	SENT_245	[p13l2009t792r2133b869, p13l12t937r353b999],
16	as	IN	O	as	_	0	SENT_245	[p13l401t947r487b999],
17	second	JJ	ORDINAL	second	amod	20	SENT_245	[p13l539t920r1029b999],
18	—	NN	O	—	nn	20	SENT_245	[p13l539t920r1029b999],
19	line	NN	O	line	nn	20	SENT_245	[p13l539t920r1029b999],
20	treatment	NN	O	treatment	prep_as	15	SENT_245	[p13l1078t937r1502b999],
21	for	IN	O	for	_	0	SENT_245	[p13l1545t920r1668b999],
22	colorectal	JJ	O	colorectal	amod	23	SENT_245	[p13l1715t920r2135b999],
23	cancer	NN	O	cancer	prep_for	20	SENT_245	[p13l12t1074r293b1127],
24	in	IN	O	in	_	0	SENT_245	[p13l336t1049r419b1126],
25	patients	NNS	O	patient	prep_in	9	SENT_245	[p13l463t1049r804b1149],
26	who	WP	O	who	nsubj	29	SENT_245	[p13l848t1048r1031b1128],
27	had	VBD	O	have	aux	29	SENT_245	[p13l1078t1048r1234b1127],
28	not	RB	O	not	neg	29	SENT_245	[p13l1280t1065r1422b1127],
29	had	VBN	O	have	rcmod	25	SENT_245	[p13l1463t1048r1619b1127],
30	a	DT	O	a	det	31	SENT_245	[p13l1664t1075r1709b1127],
31	response	NN	O	response	dobj	29	SENT_245	[p13l1753t1074r2134b1149],
32	to	TO	O	to	_	0	SENT_245	[p13l12t1193r94b1255],
33	an	DT	O	a	det	35	SENT_245	[p13l127t1202r230b1255],
34	oXaliplatin	NN	O	oxaliplatin	nn	35	SENT_245	[p13l263t1176r1004b1277],
35	—	NN	O	—	prep_to	29	SENT_245	[p13l263t1176r1004b1277],
36	based	VBN	O	base	partmod	35	SENT_245	[p13l263t1176r1004b1277],
37	regimen	NN	O	regimen	dobj	36	SENT_245	[p13l1036t1177r1415b1277],
38	.	.	O	.	_	0	SENT_245	[p13l1036t1177r1415b1277],

1	Cetuximab	NNP	O	Cetuximab	nsubj	6	SENT_246	[p13l1453t1176r1924b1255],
2	plus	CC	O	plus	prep	1	SENT_246	[p13l1957t1176r2132b1277],
3	irinotecan	NN	O	irinotecan	dep	2	SENT_246	[p13l11t1305r452b1383],
4	was	VBD	O	be	cop	6	SENT_246	[p13l491t1331r653b1383],
5	significantly	RB	O	significantly	advmod	6	SENT_246	[p13l700t1304r1243b1405],
6	better	JJR	O	better	ccomp	33	SENT_246	[p13l1282t1304r1534b1383],
7	than	IN	O	than	_	0	SENT_246	[p13l1574t1304r1770b1383],
8	irinotecan	NN	O	irinotecan	prep_than	6	SENT_246	[p13l1813t1305r2133b1383, p13l12t1459r162b1512],
9	alone	RB	O	alone	advmod	6	SENT_246	[p13l205t1433r435b1512],
10	in	IN	O	in	_	0	SENT_246	[p13l479t1434r562b1511],
11	improving	VBG	O	improve	prepc_in	6	SENT_246	[p13l605t1434r1054b1534],
12	response	NN	O	response	nn	13	SENT_246	[p13l1094t1459r1475b1534],
13	rates	NNS	O	rate	dobj	11	SENT_246	[p13l1519t1450r1746b1529],
14	,	,	O	,	_	0	SENT_246	[p13l1519t1450r1746b1529],
15	increasing	VBG	O	increase	prepc_in	6	SENT_246	[p13l1795t1434r2133b1512, p13l11t1562r150b1662],
16	progression	NN	O	progression	iobj	15	SENT_246	[p13l183t1561r891b1662],
17	—	CD	NUMBER	—	num	19	SENT_246	[p13l183t1561r891b1662],
18	free	JJ	O	free	amod	19	SENT_246	[p13l183t1561r891b1662],
19	survival	NN	O	survival	dobj	15	SENT_246	[p13l929t1561r1284b1657],
20	,	,	O	,	_	0	SENT_246	[p13l929t1561r1284b1657],
21	and	CC	O	and	_	0	SENT_246	[p13l1325t1561r1483b1640],
22	improving	VBG	O	improve	prepc_in	6	SENT_246	[p13l1519t1562r1968b1662],
23	the	DT	O	the	det	24	SENT_246	[p13l2001t1561r2134b1640],
24	quality	NN	O	quality	dobj	22	SENT_246	[p13l12t1689r310b1790],
25	of	IN	O	of	_	0	SENT_246	[p13l362t1689r462b1768],
26	life	NN	O	life	prep_of	24	SENT_246	[p13l498t1689r729b1768],
27	.55	CD	NUMBER	.55	num	26	SENT_246	[p13l498t1689r729b1768],
28	However	RB	O	however	advmod	22	SENT_246	[p13l786t1697r1181b1785],
29	,	,	O	,	_	0	SENT_246	[p13l786t1697r1181b1785],
30	no	DT	O	no	det	31	SENT_246	[p13l1242t1715r1347b1768],
31	differences	NNS	O	difference	nsubjpass	33	SENT_246	[p13l1405t1689r1879b1768],
32	were	VBD	O	be	auxpass	33	SENT_246	[p13l1933t1716r2134b1769],
33	seen	VBN	O	see	_	0	SENT_246	[p13l13t1843r202b1896],
34	in	IN	O	in	_	0	SENT_246	[p13l235t1818r318b1895],
35	overall	JJ	O	overall	amod	36	SENT_246	[p13l353t1817r638b1896],
36	survival	NN	O	survival	prep_in	33	SENT_246	[p13l673t1817r1027b1913],
37	,	,	O	,	_	0	SENT_246	[p13l673t1817r1027b1913],
38	probably	RB	O	probably	advmod	33	SENT_246	[p13l1066t1817r1443b1918],
39	because	IN	O	because	mark	44	SENT_246	[p13l1472t1817r1809b1896],
40	almost	RB	O	almost	advmod	43	SENT_246	[p13l1842t1817r2139b1896],
41	half	PDT	O	half	predet	43	SENT_246	[p13l12t1945r198b2024],
42	the	DT	O	the	det	43	SENT_246	[p13l254t1945r386b2024],
43	patients	NNS	O	patient	nsubj	44	SENT_246	[p13l460t1946r800b2046],
44	crossed	VBD	O	cross	advcl	33	SENT_246	[p13l878t1945r1200b2024],
45	over	IN	O	over	prep	44	SENT_246	[p13l1275t1971r1453b2024],
46	to	TO	O	to	pcomp	45	SENT_246	[p13l1524t1962r1605b2024],
47	cetuximab	JJ	O	cetuximab	amod	48	SENT_246	[p13l1681t1945r2133b2024],
48	treatment	NN	O	treatment	pobj	46	SENT_246	[p13l12t2091r436b2153],
49	after	IN	O	after	_	0	SENT_246	[p13l479t2074r680b2153],
50	the	DT	O	the	det	51	SENT_246	[p13l726t2074r858b2153],
51	failure	NN	O	failure	prep_after	44	SENT_246	[p13l907t2074r1184b2153],
52	of	IN	O	of	_	0	SENT_246	[p13l1233t2074r1333b2153],
53	irinotecan	JJ	O	irinotecan	amod	54	SENT_246	[p13l1361t2075r1803b2153],
54	monotherapy	NN	O	monotherapy	prep_of	51	SENT_246	[p13l1851t2100r2133b2153, p13l12t2202r332b2303],
55	.	.	O	.	_	0	SENT_246	[p13l1851t2100r2133b2153, p13l12t2202r332b2303],

1	Recently	RB	DATE	recently	advmod	57	SENT_247	[p13l367t2202r732b2303],
2	,	,	O	,	_	0	SENT_247	[p13l367t2202r732b2303],
3	a	DT	O	a	det	5	SENT_247	[p13l769t2229r813b2281],
4	randomized	JJ	O	randomized	amod	5	SENT_247	[p13l843t2202r1344b2281],
5	phase	NN	O	phase	nsubj	57	SENT_247	[p13l1374t2202r1614b2303],
6	3	CD	NUMBER	3	num	7	SENT_247	[p13l1646t2208r1690b2281],
7	trial	NN	O	trial	nsubj	35	SENT_247	[p13l1725t2202r1894b2281],
8	comparing	VBG	O	compare	partmod	7	SENT_247	[p13l1926t2228r2133b2281, p13l11t2331r286b2431],
9	the	DT	O	the	det	10	SENT_247	[p13l314t2330r446b2409],
10	use	NN	O	use	dobj	8	SENT_247	[p13l479t2357r620b2409],
11	of	IN	O	of	_	0	SENT_247	[p13l653t2330r754b2409],
12	cetuximab	NN	O	cetuximab	prep_of	10	SENT_247	[p13l769t2330r1220b2409],
13	with	IN	O	with	_	0	SENT_247	[p13l1250t2330r1445b2409],
14	best	JJS	O	best	dep	15	SENT_247	[p13l1479t2330r1656b2409],
15	supportive	JJ	O	supportive	amod	16	SENT_247	[p13l1685t2331r2134b2431],
16	care	NN	O	care	prep_with	8	SENT_247	[p13l12t2484r185b2537],
17	for	IN	O	for	_	0	SENT_247	[p13l224t2458r346b2537],
18	patients	NNS	O	patient	prep_for	16	SENT_247	[p13l380t2459r716b2559],
19	in	IN	O	in	_	0	SENT_247	[p13l756t2459r839b2536],
20	whom	WP	O	whom	rel	34	SENT_247	[p13l873t2458r1142b2537],
21	all	DT	O	all	det	23	SENT_247	[p13l1180t2458r1283b2537],
22	available	JJ	O	available	amod	23	SENT_247	[p13l1321t2458r1686b2537],
23	drugs	NNS	O	drug	nsubj	34	SENT_247	[p13l1726t2458r1990b2559],
24	,	,	O	,	_	0	SENT_247	[p13l1726t2458r1990b2559],
25	including	VBG	O	include	_	0	SENT_247	[p13l2033t2459r2147b2536, p13l12t2586r330b2687],
26	fluoropyrimidines	NNS	O	fluoropyrimidine	prep_including	23	SENT_247	[p13l363t2586r1160b2687],
27	,	,	O	,	_	0	SENT_247	[p13l363t2586r1160b2687],
28	oxaliplatin	NN	O	oxaliplatin	prep_including	23	SENT_247	[p13l1202t2586r1677b2687],
29	,	,	O	,	_	0	SENT_247	[p13l1202t2586r1677b2687],
30	and	CC	O	and	_	0	SENT_247	[p13l1718t2586r1874b2665],
31	irinotecan	NN	O	irinotecan	prep_including	23	SENT_247	[p13l1910t2587r2147b2665, p13l12t2731r255b2810],
32	,	,	O	,	_	0	SENT_247	[p13l1910t2587r2147b2665, p13l12t2731r255b2810],
33	had	VBD	O	have	aux	34	SENT_247	[p13l294t2714r447b2793],
34	failed	VBN	O	fail	rcmod	18	SENT_247	[p13l479t2714r709b2793],
35	showed	VBD	O	show	rcmod	5	SENT_247	[p13l743t2714r1057b2794],
36	that	IN	O	that	complm	38	SENT_247	[p13l1090t2714r1256b2793],
37	cetuximab	NN	O	cetuximab	nsubj	38	SENT_247	[p13l1284t2714r1721b2794],
38	increased	VBD	O	increase	ccomp	35	SENT_247	[p13l1754t2714r2148b2793],
39	progression	NN	O	progression	iobj	38	SENT_247	[p13l11t2843r723b2944],
40	—	CD	NUMBER	—	num	42	SENT_247	[p13l11t2843r723b2944],
41	free	JJ	O	free	amod	42	SENT_247	[p13l11t2843r723b2944],
42	survival	NN	O	survival	dobj	38	SENT_247	[p13l788t2843r1144b2939],
43	,	,	O	,	_	0	SENT_247	[p13l788t2843r1144b2939],
44	overall	JJ	O	overall	amod	45	SENT_247	[p13l1214t2843r1501b2922],
45	survival	NN	O	survival	conj_and	42	SENT_247	[p13l1565t2843r1922b2939],
46	,	,	O	,	_	0	SENT_247	[p13l1565t2843r1922b2939],
47	and	CC	O	and	_	0	SENT_247	[p13l1989t2843r2148b2922],
48	quality	NN	O	quality	conj_and	42	SENT_247	[p13l12t2971r299b3072],
49	of	IN	O	of	_	0	SENT_247	[p13l328t2971r427b3050],
50	life	NN	O	life	nn	52	SENT_247	[p13l439t2971r569b3050],
51	(	CD	NUMBER	(	num	52	SENT_247	[p13l607t2971r856b3063],
52	Table	NNP	O	Table	prep_of	48	SENT_247	[p13l607t2971r856b3063],
53	4	CD	NUMBER	4	number	54	SENT_247	[p13l887t2975r1059b3063],
54	)	CD	NUMBER	)	dep	52	SENT_247	[p13l887t2975r1059b3063],
55	.56	CD	NUMBER	.56	num	56	SENT_247	[p13l887t2975r1059b3063],
56	Cetuximab	NN	O	cetuximab	dep	54	SENT_247	[p13l1092t2971r1549b3050],
57	appears	VBZ	O	appear	_	0	SENT_247	[p13l1583t2997r1904b3072],
58	to	TO	O	to	aux	62	SENT_247	[p13l1939t2988r2018b3050],
59	be	VB	O	be	cop	62	SENT_247	[p13l2053t2971r2148b3050],
60	the	DT	O	the	det	62	SENT_247	[p13l12t3099r146b3178],
61	only	JJ	O	only	amod	62	SENT_247	[p13l180t3099r364b3200],
62	drug	NN	O	drug	xcomp	57	SENT_247	[p13l394t3099r599b3200],
63	that	WDT	O	that	nsubj	64	SENT_247	[p13l629t3099r802b3178],
64	does	VBZ	O	do	rcmod	62	SENT_247	[p13l831t3099r1025b3178],
65	so	RB	O	so	advmod	64	SENT_247	[p13l1062t3125r1152b3178],
66	with	IN	O	with	_	0	SENT_247	[p13l1183t3099r1379b3178],
67	colorectal	JJ	O	colorectal	amod	68	SENT_247	[p13l1413t3099r1836b3178],
68	cancer	NN	O	cancer	prep_with	64	SENT_247	[p13l1869t3125r2152b3178],
69	who	WP	O	who	nsubj	71	SENT_247	[p13l7t3227r187b3306],
70	have	VBP	O	have	aux	71	SENT_247	[p13l220t3227r404b3306],
71	had	VBN	O	have	rcmod	68	SENT_247	[p13l437t3227r590b3306],
72	unsuccessful	JJ	O	unsuccessful	amod	73	SENT_247	[p13l621t3227r1156b3306],
73	courses	NNS	O	course	dobj	71	SENT_247	[p13l1188t3253r1499b3306],
74	of	IN	O	of	_	0	SENT_247	[p13l1534t3227r1633b3306],
75	all	DT	O	all	det	78	SENT_247	[p13l1645t3227r1746b3306],
76	currently	RB	DATE	currently	advmod	77	SENT_247	[p13l1778t3227r2152b3328],
77	available	JJ	O	available	amod	78	SENT_247	[p13l11t3355r385b3434],
78	chemotherapies	NNS	O	chemotherapy	prep_of	73	SENT_247	[p13l426t3355r1134b3456],
79	.	.	O	.	_	0	SENT_247	[p13l426t3355r1134b3456],

1	Phase	NN	O	phase	nsubj	4	SENT_248	[p13l140t3484r388b3563],
2	2	CD	NUMBER	2	num	3	SENT_248	[p13l443t3490r490b3562],
3	studies5758	NN	O	studies5758	dep	1	SENT_248	[p13l548t3484r1013b3563],
4	indicate	VBP	O	indicate	_	0	SENT_248	[p13l1069t3484r1412b3563],
5	that	IN	O	that	complm	7	SENT_248	[p13l1468t3484r1642b3563],
6	cetuximab	NN	O	cetuximab	nsubj	7	SENT_248	[p13l1692t3484r2147b3563],
7	combined	VBN	O	combine	ccomp	4	SENT_248	[p13l12t3612r440b3691],
8	with	IN	O	with	_	0	SENT_248	[p13l479t3612r676b3692],
9	both	DT	O	both	det	10	SENT_248	[p13l720t3612r919b3691],
10	irinotecan	NN	O	irinotecan	prep_with	7	SENT_248	[p13l962t3613r1406b3691],
11	and	CC	O	and	_	0	SENT_248	[p13l1449t3612r1608b3691],
12	oXaliplatin	NN	O	oxaliplatin	conj_and	10	SENT_248	[p13l1652t3612r2147b3713],
13	—	CD	NUMBER	—	num	12	SENT_248	[p13l1652t3612r2147b3713],

1	based	VBN	O	base	amod	2	SENT_249	[p14l12t20r259b99],
2	chemotherapies	NNS	O	chemotherapy	nsubj	4	SENT_249	[p14l319t20r1002b121],
3	may	MD	O	may	aux	4	SENT_249	[p14l1064t46r1243b121],
4	have	VB	O	have	_	0	SENT_249	[p14l1299t20r1490b99],
5	a	DT	O	a	det	6	SENT_249	[p14l1549t47r1594b99],
6	role	NN	O	role	dobj	4	SENT_249	[p14l1652t20r1812b99],
7	in	IN	O	in	_	0	SENT_249	[p14l1871t21r1955b98],
8	the	DT	O	the	det	12	SENT_249	[p14l2015t20r2148b99],
9	first	JJ	ORDINAL	first	amod	12	SENT_249	[p14l12t149r384b228],
10	—	NN	O	—	nn	12	SENT_249	[p14l12t149r384b228],
11	line	NN	O	line	nn	12	SENT_249	[p14l12t149r384b228],
12	treatment	NN	O	treatment	prep_in	6	SENT_249	[p14l425t166r852b228],
13	of	IN	O	of	_	0	SENT_249	[p14l888t149r989b228],
14	metastatic	JJ	O	metastatic	amod	16	SENT_249	[p14l1011t150r1461b228],
15	colorectal	JJ	O	colorectal	amod	16	SENT_249	[p14l1501t149r1925b228],
16	cancer	NN	O	cancer	prep_of	12	SENT_249	[p14l1965t175r2147b228, p14l12t304r158b373],
17	,	,	O	,	_	0	SENT_249	[p14l1965t175r2147b228, p14l12t304r158b373],

1	with	IN	O	with	_	0	SENT_250	[p14l212t277r408b357],
2	a	DT	O	a	det	8	SENT_250	[p14l460t304r504b356],
3	10	CD	NUMBER	10	number	5	SENT_250	[p14l558t283r651b356],
4	to	TO	O	to	dep	5	SENT_250	[p14l705t294r787b356],
5	20	CD	PERCENT	20	dep	6	SENT_250	[p14l840t283r1030b356],
6	%	NN	PERCENT	%	dep	8	SENT_250	[p14l840t283r1030b356],
7	absolute	JJ	O	absolute	amod	8	SENT_250	[p14l1080t277r1439b356],
8	increase	NN	O	increase	prep_with	12	SENT_250	[p14l1491t278r1845b356],
9	in	IN	O	in	_	0	SENT_250	[p14l1897t278r1980b355],
10	response	NN	O	response	prep_in	8	SENT_250	[p14l2033t303r2147b356, p14l13t432r310b507],
11	rates	NNS	O	rate	nsubj	12	SENT_250	[p14l348t423r552b485],
12	reported	VBD	O	report	_	0	SENT_250	[p14l592t406r985b507],
13	.	.	O	.	_	0	SENT_250	[p14l592t406r985b507],

1	Such	PDT	O	such	predet	3	SENT_251	[p14l1031t406r1234b485],
2	a	DT	O	a	det	3	SENT_251	[p14l1272t433r1317b485],
3	response	NN	O	response	nsubj	7	SENT_251	[p14l1353t432r1736b507],
4	could	MD	O	could	aux	7	SENT_251	[p14l1776t406r2012b485],
5	be	VB	O	be	cop	7	SENT_251	[p14l2050t406r2148b485],
6	clinically	RB	O	clinically	advmod	7	SENT_251	[p14l12t534r406b635],
7	relevant	JJ	O	relevant	_	0	SENT_251	[p14l451t534r814b630],
8	,	,	O	,	_	0	SENT_251	[p14l451t534r814b630],
9	particularly	RB	O	particularly	advmod	7	SENT_251	[p14l867t534r1373b635],
10	for	IN	O	for	_	0	SENT_251	[p14l1417t534r1540b613],
11	the	DT	O	the	det	12	SENT_251	[p14l1587t534r1721b613],
12	management	NN	O	management	prep_for	7	SENT_251	[p14l1770t560r2147b635, p14l12t679r234b741],
13	of	IN	O	of	_	0	SENT_251	[p14l278t662r379b741],
14	metastatic	JJ	O	metastatic	amod	15	SENT_251	[p14l409t663r859b741],
15	disease	NN	O	disease	prep_of	12	SENT_251	[p14l907t662r1220b741],
16	limited	VBN	O	limit	partmod	15	SENT_251	[p14l1267t662r1578b741],
17	to	TO	O	to	_	0	SENT_251	[p14l1626t679r1708b741],
18	the	DT	O	the	det	19	SENT_251	[p14l1758t662r1892b741],
19	liver	NN	O	liver	prep_to	16	SENT_251	[p14l1940t662r2143b758],
20	,	,	O	,	_	0	SENT_251	[p14l1940t662r2143b758],
21	since	IN	O	since	_	0	SENT_251	[p14l13t793r229b871],
22	reductions	NNS	O	reduction	prep_since	16	SENT_251	[p14l272t792r726b871],
23	in	IN	O	in	_	0	SENT_251	[p14l770t793r854b870],
24	the	DT	O	the	det	25	SENT_251	[p14l896t792r1030b871],
25	number	NN	O	number	prep_in	22	SENT_251	[p14l1073t792r1412b871],
26	and	CC	O	and	_	0	SENT_251	[p14l1451t792r1609b871],
27	size	NN	O	size	prep_in	22	SENT_251	[p14l1654t793r1816b871],
28	of	IN	O	of	_	0	SENT_251	[p14l1859t792r1960b871],
29	metastases	NNS	O	metastase	prep_of	25	SENT_251	[p14l1984t818r2147b871, p14l12t937r352b999],

1	after	IN	O	after	mark	7	SENT_252	[p14l399t920r602b999],
2	administration	NN	O	administration	nsubj	7	SENT_252	[p14l643t920r1294b999],
3	of	IN	O	of	_	0	SENT_252	[p14l1339t920r1439b999],
4	the	DT	O	the	det	5	SENT_252	[p14l1466t920r1600b999],
5	drug	NN	O	drug	prep_of	2	SENT_252	[p14l1645t920r1851b1021],
6	might	MD	O	might	aux	7	SENT_252	[p14l1892t920r2153b1021],
7	present	VB	DATE	present	_	0	SENT_252	[p14l11t1065r332b1149],
8	the	DT	O	the	det	9	SENT_252	[p14l377t1048r510b1127],
9	opportunity	NN	O	opportunity	dobj	7	SENT_252	[p14l561t1049r1082b1149],
10	for	IN	O	for	_	0	SENT_252	[p14l1127t1048r1251b1127],
11	potentially	RB	O	potentially	advmod	12	SENT_252	[p14l1296t1048r1764b1149],
12	curative	JJ	O	curative	amod	13	SENT_252	[p14l1810t1049r2148b1128],
13	surgery	NN	O	surgery	prep_for	9	SENT_252	[p14l13t1202r351b1277],
14	.	.	O	.	_	0	SENT_252	[p14l13t1202r351b1277],

1	Recently	RB	DATE	recently	advmod	11	SENT_253	[p14l426t1176r811b1277],
2	,	,	O	,	_	0	SENT_253	[p14l426t1176r811b1277],
3	a	DT	O	a	det	4	SENT_253	[p14l887t1203r931b1255],
4	multicenter	NN	O	multicenter	nsubj	11	SENT_253	[p14l1000t1176r1518b1272],
5	,	,	O	,	_	0	SENT_253	[p14l1000t1176r1518b1272],
6	randomized	VBN	O	randomize	partmod	4	SENT_253	[p14l1595t1176r2142b1272],
7	,	,	O	,	_	0	SENT_253	[p14l1595t1176r2142b1272],
8	phase	NN	O	phase	nn	10	SENT_253	[p14l11t1304r260b1405],
9	3	CD	NUMBER	3	num	10	SENT_253	[p14l307t1310r351b1383],
10	study	NN	O	study	dobj	6	SENT_253	[p14l401t1304r632b1405],
11	evaluated	VBD	O	evaluate	_	0	SENT_253	[p14l673t1304r1078b1383],
12	the	DT	O	the	det	13	SENT_253	[p14l1123t1304r1257b1383],
13	combination	NN	O	combination	dobj	11	SENT_253	[p14l1303t1304r1853b1383],
14	of	IN	O	of	_	0	SENT_253	[p14l1898t1304r1999b1383],
15	cetuximab	NN	O	cetuximab	prep_of	13	SENT_253	[p14l2026t1331r2147b1383, p14l12t1432r374b1511],
16	with	IN	O	with	_	0	SENT_253	[p14l407t1432r603b1512],
17	a	DT	O	a	det	20	SENT_253	[p14l638t1459r683b1511],
18	standard	JJ	O	standard	amod	20	SENT_253	[p14l718t1432r1100b1511],
19	chemotherapeutic	JJ	O	chemotherapeutic	amod	20	SENT_253	[p14l1136t1432r1916b1533],
20	regimen	NN	O	regimen	prep_with	11	SENT_253	[p14l1950t1433r2147b1533, p14l12t1586r198b1639],
21	of	IN	O	of	_	0	SENT_253	[p14l248t1560r349b1639],
22	fluorouracil	NN	O	fluorouracil	prep_of	20	SENT_253	[p14l379t1560r916b1656],
23	,	,	O	,	_	0	SENT_253	[p14l379t1560r916b1656],
24	leucovorin	NN	O	leucovorin	prep_of	20	SENT_253	[p14l969t1560r1444b1656],
25	,	,	O	,	_	0	SENT_253	[p14l969t1560r1444b1656],
26	and	CC	O	and	_	0	SENT_253	[p14l1497t1560r1656b1639],
27	irinotecan	NN	O	irinotecan	prep_of	20	SENT_253	[p14l1704t1561r2148b1639],
28	(	CD	NUMBER	(	num	29	SENT_253	[p14l17t1695r444b1781],
29	FOLFIRI	NNP	O	FOLFIRI	dep	22	SENT_253	[p14l17t1695r444b1781],
30	)	CD	NUMBER	)	num	29	SENT_253	[p14l17t1695r444b1781],
31	in	IN	O	in	_	0	SENT_253	[p14l527t1690r611b1767],
32	previously	RB	DATE	previously	advmod	33	SENT_253	[p14l689t1689r1131b1790],
33	untreated	JJ	O	untreated	amod	36	SENT_253	[p14l1205t1689r1621b1768],
34	metastatic	JJ	O	metastatic	amod	36	SENT_253	[p14l1699t1690r2149b1768],
35	colorectal	JJ	O	colorectal	amod	36	SENT_253	[p14l12t1817r436b1896],
36	cancer	NN	O	cancer	prep_in	11	SENT_253	[p14l482t1843r783b1896],
37	.	.	O	.	_	0	SENT_253	[p14l482t1843r783b1896],

1	Cetuximab	NNP	O	Cetuximab	nsubj	16	SENT_254	[p14l835t1817r1310b1896],
2	plus	CC	O	plus	_	0	SENT_254	[p14l1357t1817r1533b1918],
3	FOLFIRI	NNP	O	FOLFIRI	conj_plus	1	SENT_254	[p14l1580t1823r1949b1901],
4	significantly	RB	O	significantly	advmod	5	SENT_254	[p14l1996t1818r2147b1918, p14l12t1945r433b2046],
5	increased	VBD	O	increase	_	0	SENT_254	[p14l491t1945r902b2024],
6	response	NN	O	response	nn	7	SENT_254	[p14l965t1971r1348b2046],
7	rates	NNS	O	rate	dobj	5	SENT_254	[p14l1411t1962r1640b2041],
8	,	,	O	,	_	0	SENT_254	[p14l1411t1962r1640b2041],
9	prolonged	JJ	O	prolonged	amod	10	SENT_254	[p14l1707t1945r2148b2046],
10	progression	NN	O	progression	appos	7	SENT_254	[p14l11t2073r723b2174],
11	—	CD	NUMBER	—	num	13	SENT_254	[p14l11t2073r723b2174],
12	free	JJ	O	free	amod	13	SENT_254	[p14l11t2073r723b2174],
13	survival	NN	O	survival	dep	10	SENT_254	[p14l814t2073r1171b2169],
14	,	,	O	,	_	0	SENT_254	[p14l814t2073r1171b2169],
15	and	CC	O	and	_	0	SENT_254	[p14l1266t2073r1425b2152],
16	increased	VBD	O	increase	conj_and	5	SENT_254	[p14l1513t2073r1925b2152],
17	the	DT	O	the	det	18	SENT_254	[p14l2014t2073r2148b2152],
18	number	NN	O	number	dobj	16	SENT_254	[p14l12t2201r352b2280],
19	of	IN	O	of	_	0	SENT_254	[p14l403t2201r503b2280],
20	patients	NNS	O	patient	prep_of	18	SENT_254	[p14l535t2202r880b2302],
21	who	WP	O	who	nsubj	23	SENT_254	[p14l930t2201r1114b2280],
22	could	MD	O	could	aux	23	SENT_254	[p14l1169t2201r1404b2280],
23	undergo	VB	O	undergo	rcmod	20	SENT_254	[p14l1457t2201r1816b2302],
24	potentially	RB	O	potentially	advmod	25	SENT_254	[p14l1868t2218r2147b2302, p14l12t2329r230b2430],
25	curative	JJ	O	curative	amod	27	SENT_254	[p14l269t2330r607b2408],
26	surgical	JJ	O	surgical	amod	27	SENT_254	[p14l652t2329r995b2430],
27	removal	NN	O	removal	dobj	23	SENT_254	[p14l1038t2329r1382b2408],
28	of	IN	O	of	_	0	SENT_254	[p14l1426t2329r1526b2408],
29	liver	NN	O	liver	nn	30	SENT_254	[p14l1549t2329r1735b2408],
30	metasta	NN	O	metasta	prep_of	27	SENT_254	[p14l1774t2346r2147b2408],
31	—	CD	NUMBER	—	num	32	SENT_254	[p14l1774t2346r2147b2408],
32	sis	NN	O	si	dobj	5	SENT_254	[p14l13t2458r120b2536],
33	by	IN	O	by	_	0	SENT_254	[p14l163t2457r260b2558],
34	a	DT	O	a	det	35	SENT_254	[p14l295t2484r340b2536],
35	factor	NN	O	factor	prep_by	32	SENT_254	[p14l378t2457r630b2536],
36	of	IN	O	of	_	0	SENT_254	[p14l668t2457r768b2536],
37	approximately	RB	O	approximately	quantmod	39	SENT_254	[p14l788t2457r1409b2558],
38	three	CD	NUMBER	three	number	39	SENT_254	[p14l1444t2457r1765b2536],
39	.59	CD	NUMBER	.59	prep_of	35	SENT_254	[p14l1444t2457r1765b2536],

1	Another	DT	O	another	det	3	SENT_255	[p14l138t2585r496b2664],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_255	[p14l542t2585r1058b2664],
3	agent	NN	O	agent	nsubj	5	SENT_255	[p14l1105t2602r1343b2686],
4	is	VBZ	O	be	cop	5	SENT_255	[p14l1386t2586r1452b2664],
5	panitumumab	NN	O	panitumumab	_	0	SENT_255	[p14l1501t2585r2142b2686],
6	,	,	O	,	_	0	SENT_255	[p14l1501t2585r2142b2686],
7	a	DT	O	a	det	9	SENT_255	[p14l11t2740r56b2792],
8	fully	RB	O	fully	advmod	9	SENT_255	[p14l86t2713r283b2814],
9	human	JJ	O	human	appos	5	SENT_255	[p14l310t2713r616b2792],
10	anti	JJ	O	anti	amod	9	SENT_255	[p14l647t2714r1104b2797],
11	.	.	O	.	_	0	SENT_255	[p14l647t2714r1104b2797],

1	—	NN	O	—	_	0	SENT_256	[p14l647t2714r1104b2797],
2	.	.	O	.	_	0	SENT_256	[p14l647t2714r1104b2797],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_257	[p14l647t2714r1104b2797],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_257	[p14l1126t2713r1642b2792],
3	antibody	NN	O	antibody	dep	1	SENT_257	[p14l1672t2713r2148b2814],
4	.	.	O	.	_	0	SENT_257	[p14l1672t2713r2148b2814],

1	”	RB	O	”	advmod	16	SENT_258	[p14l1672t2713r2148b2814],
2	As	IN	O	as	_	0	SENT_258	[p14l8t2849r115b2920],
3	seen	VBN	O	see	prepc_as	16	SENT_258	[p14l162t2867r351b2920],
4	with	IN	O	with	_	0	SENT_258	[p14l391t2841r587b2920],
5	cetuximab	NN	O	cetuximab	prep_with	3	SENT_258	[p14l631t2841r1108b2937],
6	,	,	O	,	_	0	SENT_258	[p14l631t2841r1108b2937],
7	skin	NN	O	skin	nn	8	SENT_258	[p14l1159t2841r1340b2921],
8	toxicity	NN	O	toxicity	nsubj	16	SENT_258	[p14l1384t2842r1704b2942],
9	and	CC	O	and	_	0	SENT_258	[p14l1742t2841r1901b2920],
10	diarrhea	NN	O	diarrhea	nsubj	16	SENT_258	[p14l1945t2841r2147b2920, p14l12t2970r199b3049],
11	are	VBP	O	be	cop	16	SENT_258	[p14l246t2996r376b3049],
12	the	DT	O	the	det	16	SENT_258	[p14l425t2970r559b3049],
13	most	RBS	O	most	advmod	14	SENT_258	[p14l608t2987r825b3049],
14	common	JJ	O	common	amod	16	SENT_258	[p14l870t2996r1254b3049],
15	side	NN	O	side	nn	16	SENT_258	[p14l1304t2970r1469b3049],
16	effects	NNS	O	effect	_	0	SENT_258	[p14l1519t2970r1802b3049],
17	of	IN	O	of	_	0	SENT_258	[p14l1854t2970r1955b3049],
18	this	DT	O	this	det	19	SENT_258	[p14l1985t2970r2145b3049],
19	agent	NN	O	agent	prep_of	16	SENT_258	[p14l11t3115r270b3199],
20	.	.	O	.	_	0	SENT_258	[p14l11t3115r270b3199],

1	A	DT	O	a	det	6	SENT_259	[p14l312t3106r378b3176],
2	randomized	JJ	O	randomized	amod	6	SENT_259	[p14l416t3098r939b3177],
3	phase	NN	O	phase	nn	6	SENT_259	[p14l978t3098r1228b3199],
4	3	CD	NUMBER	3	num	6	SENT_259	[p14l1270t3104r1313b3177],
5	clinical	JJ	O	clinical	amod	6	SENT_259	[p14l1358t3098r1673b3177],
6	trial	NN	O	trial	_	0	SENT_259	[p14l1713t3098r1892b3177],
7	compared	VBN	O	compare	prep	6	SENT_259	[p14l1932t3124r2147b3177, p14l11t3226r255b3327],
8	the	DT	O	the	det	9	SENT_259	[p14l315t3226r448b3305],
9	use	NN	O	use	npadvmod	12	SENT_259	[p14l508t3253r649b3305],
10	of	IN	O	of	_	0	SENT_259	[p14l709t3226r810b3305],
11	panitumumab	NN	LOCATION	panitumumab	prep_of	9	SENT_259	[p14l849t3226r1468b3327],
12	with	IN	O	with	pcomp	7	SENT_259	[p14l1525t3226r1721b3306],
13	the	DT	O	the	det	16	SENT_259	[p14l1781t3226r1914b3305],
14	best	JJS	O	best	dep	15	SENT_259	[p14l1975t3226r2153b3305],
15	supportive	JJ	O	supportive	amod	16	SENT_259	[p14l13t3355r465b3455],
16	care	NN	O	care	pobj	12	SENT_259	[p14l513t3381r689b3433],
17	in	IN	O	in	_	0	SENT_259	[p14l735t3355r819b3432],
18	patients	NNS	O	patient	prep_in	6	SENT_259	[p14l864t3355r1208b3455],
19	with	IN	O	with	_	0	SENT_259	[p14l1252t3354r1448b3433],
20	colorectal	JJ	O	colorectal	amod	21	SENT_259	[p14l1496t3354r1918b3433],
21	cancer	NN	O	cancer	prep_with	6	SENT_259	[p14l1966t3380r2147b3433, p14l12t3508r140b3561],
22	Who	WP	O	who	nsubjpass	26	SENT_259	[p14l177t3482r360b3561],
23	had	VBD	O	have	aux	26	SENT_259	[p14l406t3482r563b3561],
24	previously	RB	DATE	previously	advmod	26	SENT_259	[p14l605t3482r1047b3583],
25	been	VBN	O	be	auxpass	26	SENT_259	[p14l1087t3482r1290b3561],
26	treated	VBN	O	treat	rcmod	21	SENT_259	[p14l1334t3482r1634b3561],
27	unsuccessfully	RB	O	unsuccessfully	advmod	26	SENT_259	[p14l1678t3508r2147b3561, p14l12t3610r209b3711],
28	with	IN	O	with	_	0	SENT_259	[p14l256t3610r453b3689],
29	a	DT	O	a	det	30	SENT_259	[p14l509t3637r554b3689],
30	fluoropyrimidine	NN	O	fluoropyrimidine	prep_with	26	SENT_259	[p14l608t3610r1379b3711],
31	,	,	O	,	_	0	SENT_259	[p14l608t3610r1379b3711],
32	oxaliplatin	NN	O	oxaliplatin	conj_and	30	SENT_259	[p14l1442t3610r1928b3711],
33	,	,	O	,	_	0	SENT_259	[p14l1442t3610r1928b3711],
34	and	CC	O	and	_	0	SENT_259	[p14l1989t3610r2148b3689],
35	irinotecan	NN	O	irinotecan	conj_and	30	SENT_259	[p15l11t21r478b99],
36	.	.	O	.	_	0	SENT_259	[p15l11t21r478b99],

1	A	DT	O	a	det	5	SENT_260	[p15l533t28r599b98],
2	10	CD	PERCENT	10	number	3	SENT_260	[p15l652t26r834b99],
3	%	NN	PERCENT	%	amod	5	SENT_260	[p15l652t26r834b99],
4	response	NN	O	response	nn	5	SENT_260	[p15l887t46r1269b121],
5	rate	NN	O	rate	nsubjpass	7	SENT_260	[p15l1322t37r1483b99],
6	was	VBD	O	be	auxpass	7	SENT_260	[p15l1532t47r1695b100],
7	reported	VBN	O	report	_	0	SENT_260	[p15l1750t20r2142b121],
8	,	,	O	,	_	0	SENT_260	[p15l1750t20r2142b121],

1	1166	CD	DATE	1166	num	4	SENT_261	[p15l149t196r225b218],
2	N	NN	O	n	nn	4	SENT_261	[p15l914t207r927b222],
3	ENGLJ	NN	O	englj	nn	4	SENT_261	[p15l942t207r1020b229],
4	MED	NN	O	med	_	0	SENT_261	[p15l1035t207r1086b222],
5	358	CD	NUMBER	358	num	7	SENT_261	[p15l1097t201r1165b229],
6	;	:	O	;	_	0	SENT_261	[p15l1097t201r1165b229],
7	11	CD	NUMBER	11	dep	4	SENT_261	[p15l1097t201r1165b229],
8	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	9	SENT_261	[p15l1201t207r1402b229],
9	MARCH	NNP	DATE	MARCH	dep	7	SENT_261	[p15l1439t207r1524b222],
10	13,2008	CD	DATE	13,2008	dep	4	SENT_261	[p15l1538t201r1644b229],

1	The	DT	O	the	det	4	SENT_262	[p15l935t240r986b264],
2	New	NNP	O	New	nn	4	SENT_262	[p15l995t241r1057b264],
3	England	NNP	O	England	nn	4	SENT_262	[p15l1066t240r1177b271],
4	Journal	NNP	O	Journal	_	0	SENT_262	[p15l1186t240r1283b264],
5	of	IN	O	of	_	0	SENT_262	[p15l1293t240r1322b264],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_262	[p15l1329t240r1454b264],

1	Downloaded	VBN	O	download	_	0	SENT_263	[p15l377t281r547b304],
2	from	IN	O	from	_	0	SENT_263	[p15l556t281r621b304],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_263	[p15l629t281r748b311],
4	at	IN	O	at	_	0	SENT_263	[p15l758t285r781b304],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_263	[p15l789t281r972b304],
6	on	IN	O	on	_	0	SENT_263	[p15l981t288r1014b304],
7	January	NNP	DATE	January	prep_on	1	SENT_263	[p15l1022t281r1125b311],
8	5	CD	DATE	5	num	7	SENT_263	[p15l1135t281r1158b308],
9	,	,	DATE	,	_	0	SENT_263	[p15l1135t281r1158b308],
10	2014	CD	DATE	2014	num	7	SENT_263	[p15l1168t281r1241b304],
11	.	.	O	.	_	0	SENT_263	[p15l1168t281r1241b304],

1	For	IN	O	for	_	0	SENT_264	[p15l1251t281r1298b304],
2	personal	JJ	O	personal	amod	3	SENT_264	[p15l1306t281r1418b311],
3	use	NN	O	use	pobj	1	SENT_264	[p15l1427t288r1471b304],
4	only	RB	O	only	advmod	3	SENT_264	[p15l1480t281r1545b311],
5	.	.	O	.	_	0	SENT_264	[p15l1480t281r1545b311],

1	No	DT	O	no	det	3	SENT_265	[p15l1556t281r1595b304],
2	other	JJ	O	other	amod	3	SENT_265	[p15l1605t281r1673b304],
3	uses	NNS	O	use	_	0	SENT_265	[p15l1682t288r1738b304],
4	without	IN	O	without	_	0	SENT_265	[p15l1748t281r1849b304],
5	permission	NN	O	permission	prep_without	3	SENT_265	[p15l1857t281r2010b311],
6	.	.	O	.	_	0	SENT_265	[p15l1857t281r2010b311],

1	Copyright	NN	O	copyright	_	0	SENT_266	[p15l728t322r862b353],
2	©	CD	NUMBER	©	num	6	SENT_266	[p15l871t322r895b346],
3	2008	CD	DATE	2008	num	6	SENT_266	[p15l905t322r969b346],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_266	[p15l979t322r1170b346],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_266	[p15l1180t322r1288b346],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_266	[p15l1299t322r1404b353],
7	.	.	O	.	_	0	SENT_266	[p15l1299t322r1404b353],

1	All	DT	O	all	det	2	SENT_267	[p15l1415t322r1456b346],
2	rights	NNS	O	rights	nsubj	3	SENT_267	[p15l1465t322r1540b353],
3	reserved	VBN	O	reserve	_	0	SENT_267	[p15l1550t322r1668b346],
4	.	.	O	.	_	0	SENT_267	[p15l1550t322r1668b346],

1	DRUG	NN	O	drug	nn	2	SENT_268	[p15l951t428r1043b447],
2	THERAPY	NN	O	therapy	_	0	SENT_268	[p15l1056t428r1209b447],

1	together	RB	O	together	advmod	2	SENT_269	[p15l11t643r376b745],
2	with	IN	O	with	_	0	SENT_269	[p15l409t643r606b723],
3	a	DT	O	a	det	5	SENT_269	[p15l646t670r690b722],
4	signiﬁcant	JJ	O	signiﬁcant	amod	5	SENT_269	[p15l731t642r1202b745],
5	reduction	NN	O	reduction	pobj	2	SENT_269	[p15l1237t643r1650b723],
6	in	IN	O	in	_	0	SENT_269	[p15l1690t644r1773b721],
7	the	DT	O	the	det	8	SENT_269	[p15l1815t643r1949b722],
8	risk	NN	O	risk	prep_in	5	SENT_269	[p15l1989t643r2154b723],
9	of	IN	O	of	_	0	SENT_269	[p15l11t771r111b852],
10	tumor	NN	O	tumor	nn	11	SENT_269	[p15l138t789r408b852],
11	progression	NN	O	progression	prep_of	8	SENT_269	[p15l448t773r1068b874],
12	.	.	O	.	_	0	SENT_269	[p15l448t773r1068b874],

1	“	NN	O	“	ccomp	7	SENT_270	[p15l448t773r1068b874],
2	However	RB	O	however	advmod	1	SENT_270	[p15l1112t780r1510b869],
3	,	,	O	,	_	0	SENT_270	[p15l1112t780r1510b869],
4	no	DT	O	no	det	5	SENT_270	[p15l1561t798r1667b852],
5	difference	NN	O	difference	nsubjpass	7	SENT_270	[p15l1713t771r2149b852],
6	was	VBD	O	be	auxpass	7	SENT_270	[p15l6t927r170b980],
7	observed	VBN	O	observe	_	0	SENT_270	[p15l231t901r615b980],
8	in	IN	O	in	_	0	SENT_270	[p15l673t902r756b979],
9	overall	JJ	O	overall	amod	10	SENT_270	[p15l816t901r1103b981],
10	survival	NN	O	survival	prep_in	7	SENT_270	[p15l1162t901r1520b997],
11	,	,	O	,	_	0	SENT_270	[p15l1162t901r1520b997],
12	probably	RB	O	probably	advmod	7	SENT_270	[p15l1582t901r1962b1001],
13	because	IN	O	because	_	0	SENT_270	[p15l2017t901r2148b980, p15l11t1055r246b1109],
14	of	IN	O	of	_	0	SENT_270	[p15l312t1028r413b1108],
15	the	DT	O	the	det	17	SENT_270	[p15l460t1029r594b1107],
16	preplanned	JJ	O	preplanned	amod	17	SENT_270	[p15l658t1029r1152b1129],
17	crossover	NN	O	crossover	prep_because_of	7	SENT_270	[p15l1218t1055r1624b1108],
18	to	TO	O	to	aux	19	SENT_270	[p15l1687t1046r1769b1108],
19	panitu	VB	O	panitu	infmod	17	SENT_270	[p15l1835t1030r2148b1129],
20	—	NN	O	—	nn	21	SENT_270	[p15l1835t1030r2148b1129],
21	mumab	NN	O	mumab	dobj	19	SENT_270	[p15l10t1158r341b1237],
22	in	IN	O	in	_	0	SENT_270	[p15l406t1159r490b1236],
23	the	DT	O	the	det	25	SENT_270	[p15l556t1158r689b1236],
24	treatment	NN	O	treatment	nn	25	SENT_270	[p15l755t1175r1182b1236],
25	group	NN	O	group	prep_in	19	SENT_270	[p15l1241t1184r1495b1259],
26	receiving	VBG	O	receive	partmod	25	SENT_270	[p15l1561t1159r1954b1259],
27	the	DT	O	the	det	30	SENT_270	[p15l2016t1158r2149b1236],
28	best	JJS	O	best	dep	29	SENT_270	[p15l11t1285r189b1364],
29	supportive	JJ	O	supportive	amod	30	SENT_270	[p15l236t1286r689b1385],
30	care	NN	O	care	dobj	26	SENT_270	[p15l740t1311r940b1364],
31	.	.	O	.	_	0	SENT_270	[p15l740t1311r940b1364],

1	On	IN	O	on	_	0	SENT_271	[p15l995t1291r1123b1364],
2	the	DT	O	the	det	3	SENT_271	[p15l1175t1285r1308b1363],
3	basis	NN	O	basis	prep_on	10	SENT_271	[p15l1359t1285r1572b1364],
4	of	IN	O	of	_	0	SENT_271	[p15l1626t1284r1726b1364],
5	these	DT	O	these	det	6	SENT_271	[p15l1759t1285r1984b1363],
6	results	NNS	O	result	prep_of	3	SENT_271	[p15l2034t1311r2148b1363, p15l11t1414r235b1510],
7	,	,	O	,	_	0	SENT_271	[p15l2034t1311r2148b1363, p15l11t1414r235b1510],
8	panitumumab	NN	LOCATION	panitumumab	nsubjpass	10	SENT_271	[p15l274t1414r893b1514],
9	was	VBD	O	be	auxpass	10	SENT_271	[p15l925t1440r1088b1493],
10	approved	VBN	O	approve	_	0	SENT_271	[p15l1124t1414r1517b1514],
11	by	IN	O	by	_	0	SENT_271	[p15l1553t1414r1651b1514],
12	the	DT	O	the	det	13	SENT_271	[p15l1681t1414r1815b1492],
13	FDA	NNP	ORGANIZATION	FDA	agent	10	SENT_271	[p15l1848t1420r2034b1492],
14	in	IN	O	in	_	0	SENT_271	[p15l2065t1415r2149b1492],
15	September	NNP	DATE	September	prep_in	13	SENT_271	[p15l12t1542r472b1642],
16	2006	CD	DATE	2006	num	15	SENT_271	[p15l523t1548r733b1621],
17	as	IN	O	as	_	0	SENT_271	[p15l788t1568r874b1620],
18	monotherapy	NN	O	monotherapy	prep_as	10	SENT_271	[p15l930t1542r1509b1642],
19	for	IN	O	for	_	0	SENT_271	[p15l1559t1541r1682b1621],
20	the	DT	O	the	det	21	SENT_271	[p15l1735t1542r1868b1620],
21	treatment	NN	O	treatment	prep_for	18	SENT_271	[p15l1924t1559r2148b1620, p15l10t1689r233b1751],
22	of	IN	O	of	_	0	SENT_271	[p15l284t1671r385b1752],
23	metastatic	JJ	O	metastatic	amod	25	SENT_271	[p15l422t1673r872b1751],
24	colorectal	JJ	O	colorectal	amod	25	SENT_271	[p15l928t1672r1352b1752],
25	cancer	NN	O	cancer	prep_of	21	SENT_271	[p15l1407t1698r1690b1751],
26	with	IN	O	with	_	0	SENT_271	[p15l1738t1672r1935b1752],
27	disease	NN	O	disease	nn	28	SENT_271	[p15l1991t1672r2148b1752, p15l11t1828r192b1880],
28	progression	NN	O	progression	prep_with	10	SENT_271	[p15l248t1802r763b1903],
29	after	IN	O	after	_	0	SENT_271	[p15l820t1800r1023b1880],
30	chemotherapy	NN	O	chemotherapy	nn	31	SENT_271	[p15l1078t1801r1694b1902],
31	regimens	NNS	O	regimen	prep_after	10	SENT_271	[p15l1746t1802r2147b1903],
32	consisting	VBG	O	consist	partmod	31	SENT_271	[p15l11t1931r460b2032],
33	of	IN	O	of	_	0	SENT_271	[p15l538t1929r638b2010],
34	a	DT	O	a	det	35	SENT_271	[p15l675t1957r720b2009],
35	fluoropyrimidine	NN	O	fluoropyrimidine	prep_of	32	SENT_271	[p15l799t1929r1570b2031],
36	,	,	O	,	_	0	SENT_271	[p15l799t1929r1570b2031],
37	oxaliplatin	NN	O	oxaliplatin	prep_of	32	SENT_271	[p15l1657t1930r2144b2031],
38	,	,	O	,	_	0	SENT_271	[p15l1657t1930r2144b2031],
39	and	CC	O	and	_	0	SENT_271	[p15l10t2060r169b2139],
40	irinotecan	NN	O	irinotecan	prep_of	32	SENT_271	[p15l207t2061r676b2139],
41	.	.	O	.	_	0	SENT_271	[p15l207t2061r676b2139],

1	SQUAMOUS-CELL	NNP	O	SQUAMOUS-CELL	nn	2	SENT_272	[p15l10t2334r703b2400],
2	CARCINOMA	NNP	O	CARCINOMA	nsubj	24	SENT_272	[p15l736t2334r1230b2385],
3	OF	IN	O	of	_	0	SENT_272	[p15l1262t2334r1365b2385],
4	THE	DT	O	the	det	5	SENT_272	[p15l1396t2335r1550b2383],
5	HEAD	NN	O	head	prep_of	2	SENT_272	[p15l1591t2335r1806b2383],
6	AND	CC	O	and	_	0	SENT_272	[p15l9t2420r179b2469],
7	NECK	NN	O	neck	conj_and	5	SENT_272	[p15l220t2419r423b2470],
8	The	DT	O	the	det	9	SENT_272	[p15l6t2529r169b2607],
9	combination	NN	O	combination	nsubjpass	16	SENT_272	[p15l206t2529r757b2608],
10	of	IN	O	of	_	0	SENT_272	[p15l795t2528r895b2608],
11	cetuximab	NN	O	cetuximab	prep_of	9	SENT_272	[p15l915t2529r1369b2609],
12	and	CC	O	and	_	0	SENT_272	[p15l1407t2529r1566b2608],
13	radiotherapy	NN	O	radiotherapy	prep_of	9	SENT_272	[p15l1603t2529r2154b2629],
14	was	VBD	O	be	auxpass	16	SENT_272	[p15l6t2684r169b2737],
15	initially	RB	O	initially	advmod	16	SENT_272	[p15l227t2658r563b2758],
16	tested	VBN	O	test	rcmod	7	SENT_272	[p15l614t2658r870b2737],
17	in	IN	O	in	_	0	SENT_272	[p15l925t2659r1009b2736],
18	patients	NNS	O	patient	prep_in	16	SENT_272	[p15l1063t2659r1407b2758],
19	with	IN	O	with	_	0	SENT_272	[p15l1460t2658r1656b2737],
20	previously	RB	DATE	previously	advmod	21	SENT_272	[p15l1710t2658r2153b2758],
21	untreated	JJ	O	untreated	prep_with	18	SENT_272	[p15l10t2787r448b2883],
22	,	,	O	,	_	0	SENT_272	[p15l10t2787r448b2883],
23	locally	RB	O	locally	advmod	16	SENT_272	[p15l491t2787r776b2887],
24	advanced	VBD	O	advance	_	0	SENT_272	[p15l808t2787r1207b2866],
25	squamous	JJ	O	squamous	amod	28	SENT_272	[p15l1246t2787r1875b2887],
26	—	NN	O	—	nn	28	SENT_272	[p15l1246t2787r1875b2887],
27	cell	NN	O	cell	nn	28	SENT_272	[p15l1246t2787r1875b2887],
28	carcinoma	NN	O	carcinoma	dobj	24	SENT_272	[p15l1912t2788r2148b2865, p15l10t2943r256b2997],
29	of	IN	O	of	_	0	SENT_272	[p15l305t2916r406b2997],
30	the	DT	O	the	det	31	SENT_272	[p15l439t2917r572b2997],
31	head	NN	O	head	prep_of	28	SENT_272	[p15l622t2917r827b2997],
32	and	CC	O	and	_	0	SENT_272	[p15l876t2917r1035b2997],
33	neck	NN	O	neck	prep_of	28	SENT_272	[p15l1085t2917r1308b2997],
34	.	.	O	.	_	0	SENT_272	[p15l1085t2917r1308b2997],

1	In	IN	O	in	_	0	SENT_273	[p15l1363t2925r1452b2996],
2	a	DT	O	a	prep_in	14	SENT_273	[p15l1502t2944r1547b2996],
3	randomized	VBN	O	randomize	partmod	2	SENT_273	[p15l1596t2917r2144b3014],
4	,	,	O	,	_	0	SENT_273	[p15l1596t2917r2144b3014],
5	multicenter	NN	O	multicenter	nn	10	SENT_273	[p15l10t3046r529b3142],
6	,	,	O	,	_	0	SENT_273	[p15l10t3046r529b3142],
7	phase	NN	O	phase	dep	10	SENT_273	[p15l574t3046r825b3146],
8	3	CD	NUMBER	3	num	10	SENT_273	[p15l868t3052r912b3125],
9	clinical	JJ	O	clinical	amod	10	SENT_273	[p15l958t3046r1274b3124],
10	trial	NN	O	trial	nsubjpass	14	SENT_273	[p15l1315t3046r1517b3142],
11	,	,	O	,	_	0	SENT_273	[p15l1315t3046r1517b3142],
12	patients	NNS	O	patient	nsubjpass	14	SENT_273	[p15l1562t3047r1906b3146],
13	were	VBD	O	be	auxpass	14	SENT_273	[p15l1946t3072r2149b3125],
14	treated	VBN	O	treat	conj_or	14	SENT_273	[p15l11t3175r311b3254],
15	with	IN	O	with	_	0	SENT_273	[p15l355t3175r551b3254],
16	radiotherapy	NN	O	radiotherapy	prep_with	14	SENT_273	[p15l600t3175r1151b3275],
17	alone	RB	O	alone	advmod	14	SENT_273	[p15l1194t3175r1426b3254],
18	or	CC	O	or	_	0	SENT_273	[p15l1475t3201r1565b3254],
19	in	IN	O	in	_	0	SENT_273	[p15l1609t3176r1693b3253],
20	combination	NN	O	combination	prep_in	14	SENT_273	[p15l1742t3175r2148b3254, p15l11t3305r181b3383],
21	with	IN	O	with	_	0	SENT_273	[p15l219t3304r416b3384],
22	cetuximab	NN	O	cetuximab	nn	24	SENT_273	[p15l459t3304r914b3383],
23	(	CD	NUMBER	(	num	24	SENT_273	[p15l963t3304r1223b3395],
24	Table	NNP	O	Table	prep_with	20	SENT_273	[p15l963t3304r1223b3395],
25	5	CD	NUMBER	5	number	26	SENT_273	[p15l1267t3308r1542b3395],
26	)	CD	NUMBER	)	num	24	SENT_273	[p15l1267t3308r1542b3395],
27	.61	CD	NUMBER	.61	number	28	SENT_273	[p15l1267t3308r1542b3395],
28	’52	CD	NUMBER	’52	num	29	SENT_273	[p15l1267t3308r1542b3395],
29	Radiotherapy	NN	O	radiotherapy	nsubj	33	SENT_273	[p15l1571t3304r2154b3404],
30	plus	CC	O	plus	prep	29	SENT_273	[p15l9t3433r186b3534],
31	cetuximab	NN	O	cetuximab	dep	30	SENT_273	[p15l227t3433r682b3513],
32	significantly	RB	O	significantly	advmod	33	SENT_273	[p15l725t3432r1272b3535],
33	prolonged	VBD	O	prolong	dep	14	SENT_273	[p15l1305t3433r1747b3535],
34	progression-free	JJ	O	progression-free	amod	35	SENT_273	[p15l1784t3459r2148b3535, p15l12t3561r387b3642],
35	survival	NN	O	survival	dobj	33	SENT_273	[p15l432t3562r789b3659],
36	,	,	O	,	_	0	SENT_273	[p15l432t3562r789b3659],
37	duration	NN	O	duration	conj_and	35	SENT_273	[p15l839t3562r1208b3642],
38	of	IN	O	of	_	0	SENT_273	[p15l1253t3561r1353b3642],
39	locoregional	JJ	O	locoregional	amod	40	SENT_273	[p15l1377t3562r1920b3664],
40	control	NN	O	control	prep_of	37	SENT_273	[p15l1964t3588r2148b3642, p15l11t3691r184b3787],
41	,	,	O	,	_	0	SENT_273	[p15l1964t3588r2148b3642, p15l11t3691r184b3787],
42	and	CC	O	and	_	0	SENT_273	[p15l227t3691r386b3770],
43	overall	JJ	O	overall	amod	44	SENT_273	[p15l425t3691r712b3771],
44	survival	NN	O	survival	conj_and	35	SENT_273	[p15l752t3691r1109b3770],
45	.	.	O	.	_	0	SENT_273	[p15l752t3691r1109b3770],

1	A	DT	O	a	det	3	SENT_274	[p15l1149t3699r1215b3769],
2	randomized	JJ	O	randomized	amod	3	SENT_274	[p15l1250t3691r1776b3770],
3	phase	NN	O	phase	_	0	SENT_274	[p15l1812t3691r2063b3791],
4	3	CD	NUMBER	3	dep	3	SENT_274	[p15l2102t3697r2146b3770],

1	trial	NN	O	trial	nsubj	26	SENT_275	[p16l11t21r189b99],
2	of	IN	O	of	_	0	SENT_275	[p16l249t20r349b100],
3	cisplatin	NN	O	cisplatin	prep_of	1	SENT_275	[p16l391t21r760b121],
4	plus	CC	O	plus	prep	3	SENT_275	[p16l817t21r994b121],
5	cetuximab	NN	O	cetuximab	nn	20	SENT_275	[p16l1057t21r1512b100],
6	as	IN	O	as	dep	20	SENT_275	[p16l1572t47r1658b99],
7	compared	VBN	O	compare	_	0	SENT_275	[p16l1720t21r2150b121],
8	with	IN	O	with	prepc_compared_with	6	SENT_275	[p16l6t150r202b229],
9	placebo	NN	O	placebo	pobj	6	SENT_275	[p16l237t150r569b250],
10	in	IN	O	in	_	0	SENT_275	[p16l606t151r690b228],
11	patients	NNS	O	patient	prep_in	9	SENT_275	[p16l724t151r1068b250],
12	with	IN	O	with	_	0	SENT_275	[p16l1102t150r1299b229],
13	previously	RB	DATE	previously	advmod	14	SENT_275	[p16l1334t150r1777b250],
14	untreated	JJ	O	untreated	amod	19	SENT_275	[p16l1808t167r2148b229, p16l11t278r131b374],
15	,	,	O	,	_	0	SENT_275	[p16l1808t167r2148b229, p16l11t278r131b374],
16	metastatic	JJ	O	metastatic	amod	17	SENT_275	[p16l189t279r639b356],
17	squamous	JJ	O	squamous	amod	19	SENT_275	[p16l692t278r1321b378],
18	—	NN	O	—	nn	19	SENT_275	[p16l692t278r1321b378],
19	cell	NN	O	cell	prep_with	11	SENT_275	[p16l692t278r1321b378],
20	carcinoma	NN	O	carcinoma	dep	4	SENT_275	[p16l1374t279r1830b357],
21	of	IN	O	of	_	0	SENT_275	[p16l1881t277r1981b357],
22	the	DT	O	the	det	23	SENT_275	[p16l2015t278r2149b356],
23	head	NN	O	head	prep_of	20	SENT_275	[p16l10t407r214b487],
24	and	CC	O	and	_	0	SENT_275	[p16l252t407r411b487],
25	neck	NN	O	neck	conj_and	23	SENT_275	[p16l449t407r653b487],
26	showed	VBD	O	show	_	0	SENT_275	[p16l688t407r1014b487],
27	a	DT	O	a	det	31	SENT_275	[p16l1051t434r1096b486],
28	significantly	RB	O	significantly	advmod	29	SENT_275	[p16l1134t406r1682b509],
29	higher	JJR	O	higher	amod	31	SENT_275	[p16l1716t407r1998b509],
30	response	NN	O	response	nn	31	SENT_275	[p16l2034t433r2148b486, p16l11t562r308b636],
31	rate	NN	O	rate	dobj	26	SENT_275	[p16l354t553r516b614],
32	in	IN	O	in	_	0	SENT_275	[p16l561t537r645b614],
33	the	DT	O	the	det	34	SENT_275	[p16l691t536r824b615],
34	group	NN	O	group	prep_in	26	SENT_275	[p16l870t562r1125b637],
35	that	WDT	O	that	nsubj	36	SENT_275	[p16l1172t536r1346b614],
36	received	VBD	O	receive	rcmod	34	SENT_275	[p16l1387t536r1734b615],
37	cisplatin	NN	O	cisplatin	dobj	36	SENT_275	[p16l1781t536r2150b636],
38	plus	CC	O	plus	prep	37	SENT_275	[p16l9t664r186b765],
39	cetuximab	NN	O	cetuximab	dep	38	SENT_275	[p16l219t664r773b744],
40	.	.	O	.	_	0	SENT_275	[p16l219t664r773b744],

1	“	NN	O	“	ccomp	11	SENT_276	[p16l219t664r773b744],
2	However	RB	O	however	advmod	1	SENT_276	[p16l805t672r1204b761],
3	,	,	O	,	_	0	SENT_276	[p16l805t672r1204b761],
4	no	DT	O	no	det	6	SENT_276	[p16l1240t690r1345b744],
5	significant	JJ	O	significant	amod	6	SENT_276	[p16l1379t663r1851b766],
6	difference	NN	O	difference	nsubjpass	11	SENT_276	[p16l1877t663r2148b744, p16l11t819r201b871],
7	in	IN	O	in	_	0	SENT_276	[p16l254t794r338b871],
8	overall	JJ	O	overall	amod	9	SENT_276	[p16l391t793r678b872],
9	survival	NN	O	survival	prep_in	6	SENT_276	[p16l733t793r1067b872],
10	was	VBD	O	be	auxpass	11	SENT_276	[p16l1115t819r1278b872],
11	observed	VBN	O	observe	_	0	SENT_276	[p16l1334t793r1741b889],
12	,	,	O	,	_	0	SENT_276	[p16l1334t793r1741b889],
13	possibly	RB	O	possibly	advmod	11	SENT_276	[p16l1798t793r2154b893],
14	because	IN	O	because	_	0	SENT_276	[p16l11t921r349b1000],
15	of	IN	O	of	_	0	SENT_276	[p16l399t920r500b1000],
16	the	DT	O	the	det	20	SENT_276	[p16l530t921r664b999],
17	relatively	RB	O	relatively	advmod	18	SENT_276	[p16l712t921r1101b1021],
18	small	JJ	O	small	amod	20	SENT_276	[p16l1146t921r1382b999],
19	study	NN	O	study	nn	20	SENT_276	[p16l1431t921r1663b1021],
20	sample	NN	O	sample	prep_because_of	11	SENT_276	[p16l1708t921r2036b1021],
21	.	.	O	.	_	0	SENT_276	[p16l1708t921r2036b1021],

1	A	DT	O	a	det	3	SENT_277	[p16l2086t929r2153b999],
2	recent	JJ	O	recent	amod	3	SENT_277	[p16l10t1067r277b1128],
3	larger	JJR	O	larger	nsubj	11	SENT_277	[p16l320t1050r595b1151],
4	,	,	O	,	_	0	SENT_277	[p16l320t1050r595b1151],
5	randomized	VBN	O	randomize	partmod	11	SENT_277	[p16l651t1050r1199b1146],
6	,	,	O	,	_	0	SENT_277	[p16l651t1050r1199b1146],
7	multicenter	JJ	O	multicenter	amod	8	SENT_277	[p16l1254t1050r1755b1129],
8	phase	NN	O	phase	nsubj	11	SENT_277	[p16l1800t1050r2050b1150],
9	3	CD	NUMBER	3	num	10	SENT_277	[p16l2102t1056r2146b1129],
10	trial	NN	O	trial	dep	8	SENT_277	[p16l11t1179r190b1258],
11	showed	VBD	O	show	_	0	SENT_277	[p16l240t1179r566b1259],
12	that	IN	O	that	complm	23	SENT_277	[p16l616t1179r789b1258],
13	the	DT	O	the	det	14	SENT_277	[p16l834t1179r968b1258],
14	addition	NN	O	addition	nsubj	23	SENT_277	[p16l1017t1179r1377b1259],
15	of	IN	O	of	_	0	SENT_277	[p16l1427t1178r1528b1259],
16	cetuximab	NN	O	cetuximab	prep_of	14	SENT_277	[p16l1560t1179r2015b1259],
17	to	TO	O	to	_	0	SENT_277	[p16l2067t1196r2149b1259],
18	platinum	NN	O	platinum	nn	19	SENT_277	[p16l8t1307r438b1407],
19	—	NN	O	—	prep_to	16	SENT_277	[p16l8t1307r438b1407],
20	and	CC	O	and	_	0	SENT_277	[p16l486t1307r645b1386],
21	fluorouracil	NN	O	fluorouracil	nn	22	SENT_277	[p16l692t1306r1491b1387],
22	—	NN	O	—	prep_to	16	SENT_277	[p16l692t1306r1491b1387],
23	based	VBN	O	base	ccomp	11	SENT_277	[p16l692t1306r1491b1387],
24	chemotherapy	NN	O	chemotherapy	dobj	23	SENT_277	[p16l1539t1307r2154b1407],
25	in	IN	O	in	_	0	SENT_277	[p16l10t1438r93b1516],
26	the	DT	O	the	det	28	SENT_277	[p16l138t1437r273b1516],
27	first-line	JJ	O	first-line	amod	28	SENT_277	[p16l317t1436r690b1516],
28	treatment	NN	O	treatment	prep_in	24	SENT_277	[p16l735t1454r1162b1516],
29	of	IN	O	of	_	0	SENT_277	[p16l1203t1436r1304b1517],
30	recurrent	JJ	O	recurrent	prep_of	28	SENT_277	[p16l1329t1454r1733b1517],
31	or	CC	O	or	_	0	SENT_277	[p16l1773t1463r1862b1517],
32	metastatic	JJ	O	metastatic	conj_or	30	SENT_277	[p16l1904t1454r2148b1517, p16l11t1566r242b1643],

1	squamous	JJ	O	squamous	amod	4	SENT_278	[p16l283t1565r912b1665],
2	—	NN	O	—	nn	4	SENT_278	[p16l283t1565r912b1665],
3	cell	NN	O	cell	nn	4	SENT_278	[p16l283t1565r912b1665],
4	carcinoma	NN	O	carcinoma	nsubj	12	SENT_278	[p16l953t1566r1409b1644],
5	of	IN	O	of	_	0	SENT_278	[p16l1449t1564r1550b1644],
6	the	DT	O	the	det	7	SENT_278	[p16l1573t1565r1707b1643],
7	head	NN	O	head	prep_of	4	SENT_278	[p16l1747t1565r1951b1644],
8	and	CC	O	and	_	0	SENT_278	[p16l1991t1565r2150b1644],
9	neck	NN	O	neck	prep_of	4	SENT_278	[p16l10t1694r214b1774],
10	may	MD	O	may	aux	12	SENT_278	[p16l249t1720r429b1795],
11	be	VB	O	be	cop	12	SENT_278	[p16l464t1694r561b1774],
12	helpful	JJ	O	helpful	ccomp	24	SENT_278	[p16l600t1693r929b1795],
13	,	,	O	,	_	0	SENT_278	[p16l600t1693r929b1795],
14	since	IN	O	since	_	0	SENT_278	[p16l976t1695r1192b1773],
15	progression	NN	O	progression	nn	18	SENT_278	[p16l1230t1693r1944b1796],
16	—	CD	NUMBER	—	num	18	SENT_278	[p16l1230t1693r1944b1796],
17	free	JJ	O	free	amod	18	SENT_278	[p16l1230t1693r1944b1796],
18	survival	NN	O	survival	prep_since	24	SENT_278	[p16l1985t1720r2148b1774, p16l6t1823r202b1903],
19	and	CC	O	and	_	0	SENT_278	[p16l241t1823r400b1903],
20	overall	JJ	O	overall	amod	21	SENT_278	[p16l442t1823r729b1903],
21	survival	NN	O	survival	conj_and	18	SENT_278	[p16l771t1823r1105b1903],
22	were	VBD	O	be	cop	24	SENT_278	[p16l1141t1849r1344b1903],
23	significantly	RB	O	significantly	advmod	24	SENT_278	[p16l1387t1822r1934b1925],
24	prolonged	JJ	O	prolonged	_	0	SENT_278	[p16l1968t1849r2148b1924, p16l9t1952r302b2053],
25	(	CD	NUMBER	(	num	28	SENT_278	[p16l347t1952r607b2043],
26	Table	NNP	O	Table	dep	27	SENT_278	[p16l347t1952r607b2043],
27	5	CD	NUMBER	5	amod	28	SENT_278	[p16l649t1956r829b2043],
28	)	NN	O	)	nsubj	24	SENT_278	[p16l649t1956r829b2043],
29	.	.	O	.	_	0	SENT_278	[p16l649t1956r829b2043],

1	”	NN	O	”	nsubj	7	SENT_279	[p16l649t1956r829b2043],
2	This	DT	O	this	det	5	SENT_279	[p16l867t1952r1055b2030],
3	phase	NN	O	phase	nn	5	SENT_279	[p16l1097t1952r1347b2052],
4	3	CD	NUMBER	3	num	5	SENT_279	[p16l1388t1958r1432b2031],
5	study	NN	O	study	dep	1	SENT_279	[p16l1478t1952r1709b2052],
6	is	VBZ	O	be	cop	7	SENT_279	[p16l1744t1953r1810b2030],
7	unique	JJ	O	unique	_	0	SENT_279	[p16l1852t1953r2149b2052],
8	in	IN	O	in	_	0	SENT_279	[p16l10t2081r93b2158],
9	showing	VBG	O	show	prepc_in	7	SENT_279	[p16l144t2080r515b2182],
10	a	DT	O	a	det	12	SENT_279	[p16l559t2107r604b2159],
11	survival	NN	O	survival	nn	12	SENT_279	[p16l653t2080r987b2160],
12	benefit	NN	O	benefit	dobj	9	SENT_279	[p16l1036t2079r1344b2160],
13	for	IN	O	for	_	0	SENT_279	[p16l1387t2079r1512b2160],
14	a	DT	O	a	det	16	SENT_279	[p16l1557t2107r1602b2159],
15	novel	JJ	O	novel	amod	16	SENT_279	[p16l1648t2080r1875b2160],
16	treatment	NN	O	treatment	prep_for	12	SENT_279	[p16l1924t2097r2148b2159, p16l10t2226r232b2287],
17	as	IN	O	as	amod	16	SENT_279	[p16l269t2235r355b2287],
18	compared	VBN	O	compare	_	0	SENT_279	[p16l400t2209r829b2309],
19	with	IN	O	with	prepc_compared_with	9	SENT_279	[p16l867t2209r1063b2288],
20	platinum	NN	O	platinum	nn	21	SENT_279	[p16l1103t2209r1785b2309],
21	—	NN	O	—	pobj	9	SENT_279	[p16l1103t2209r1785b2309],
22	based	VBN	O	base	partmod	21	SENT_279	[p16l1103t2209r1785b2309],
23	chemotherapy	NN	O	chemotherapy	dobj	22	SENT_279	[p16l1827t2209r2148b2288, p16l11t2337r335b2437],
24	in	IN	O	in	_	0	SENT_279	[p16l365t2338r448b2415],
25	the	DT	O	the	det	26	SENT_279	[p16l484t2337r617b2415],
26	treatment	NN	O	treatment	prep_in	22	SENT_279	[p16l653t2354r1080b2415],
27	of	IN	O	of	_	0	SENT_279	[p16l1111t2336r1211b2416],
28	this	DT	O	this	det	29	SENT_279	[p16l1228t2337r1389b2415],
29	disease	NN	O	disease	prep_of	26	SENT_279	[p16l1427t2337r1763b2416],
30	.	.	O	.	_	0	SENT_279	[p16l1427t2337r1763b2416],

1	Several	JJ	O	several	amod	2	SENT_280	[p16l142t2466r443b2545],
2	phase	NN	O	phase	nsubj	5	SENT_280	[p16l489t2466r740b2566],
3	2	CD	NUMBER	2	num	4	SENT_280	[p16l789t2472r836b2544],
4	studies	NNS	O	study	dep	2	SENT_280	[p16l886t2466r1188b2545],
5	evaluated	VBD	O	evaluate	_	0	SENT_280	[p16l1239t2466r1644b2545],
6	cetuximab	NN	O	cetuximab	dobj	5	SENT_280	[p16l1692t2466r2148b2545],
7	alone	RB	O	alone	dep	6	SENT_280	[p16l10t2595r232b2674],
8	or	CC	O	or	_	0	SENT_280	[p16l266t2621r353b2674],
9	in	IN	O	in	dep	6	SENT_280	[p16l382t2596r463b2673],
10	combination	NN	O	combination	pobj	9	SENT_280	[p16l496t2595r1024b2674],
11	with	IN	O	with	_	0	SENT_280	[p16l1053t2595r1243b2675],
12	cisplatin	NN	O	cisplatin	prep_with	5	SENT_280	[p16l1276t2595r1627b2695],
13	in	IN	O	in	_	0	SENT_280	[p16l1659t2596r1741b2673],
14	the	DT	O	the	det	15	SENT_280	[p16l1773t2595r1902b2673],
15	treatment	NN	O	treatment	prep_in	12	SENT_280	[p16l1935t2612r2148b2673, p16l10t2740r226b2801],
16	of	IN	O	of	_	0	SENT_280	[p16l285t2722r383b2802],
17	platinum	NN	O	platinum	npadvmod	19	SENT_280	[p16l426t2723r1198b2823],
18	—	CD	NUMBER	—	num	17	SENT_280	[p16l426t2723r1198b2823],
19	resistant	JJ	O	resistant	amod	23	SENT_280	[p16l426t2723r1198b2823],
20	squamous	JJ	O	squamous	amod	23	SENT_280	[p16l1257t2723r1860b2823],
21	—	NN	O	—	nn	23	SENT_280	[p16l1257t2723r1860b2823],
22	cell	NN	O	cell	nn	23	SENT_280	[p16l1257t2723r1860b2823],
23	carcinoma	NN	O	carcinoma	prep_of	15	SENT_280	[p16l1924t2724r2148b2801, p16l10t2879r249b2933],
24	of	IN	O	of	_	0	SENT_280	[p16l285t2852r383b2933],
25	the	DT	O	the	det	26	SENT_280	[p16l402t2853r531b2932],
26	head	NN	O	head	prep_of	23	SENT_280	[p16l569t2853r766b2933],
27	and	CC	O	and	_	0	SENT_280	[p16l802t2853r957b2933],
28	neck	NN	O	neck	prep_of	23	SENT_280	[p16l993t2853r1207b2950],
29	,	,	O	,	_	0	SENT_280	[p16l993t2853r1207b2950],
30	a	DT	O	a	det	31	SENT_280	[p16l1249t2880r1293b2932],
31	cancer	NN	O	cancer	appos	26	SENT_280	[p16l1330t2879r1602b2932],
32	in	IN	O	in	_	0	SENT_280	[p16l1635t2854r1716b2932],
33	which	WDT	O	which	rel	39	SENT_280	[p16l1749t2853r2005b2933],
34	no	DT	O	no	det	36	SENT_280	[p16l2042t2879r2148b2933],
35	specific	JJ	O	specific	amod	36	SENT_280	[p16l11t2980r344b3081],
36	therapy	NN	O	therapy	nsubj	39	SENT_280	[p16l378t2981r702b3081],
37	has	VBZ	O	have	aux	39	SENT_280	[p16l731t2981r876b3059],
38	been	VBN	O	be	cop	39	SENT_280	[p16l913t2981r1116b3060],
39	effective	JJ	O	effective	rcmod	31	SENT_280	[p16l1151t2980r1535b3077],
40	;	:	O	;	_	0	SENT_280	[p16l1151t2980r1535b3077],
41	such	JJ	O	such	amod	42	SENT_280	[p16l1575t2981r1771b3060],
42	patients	NNS	O	patient	nsubj	43	SENT_280	[p16l1803t2982r2148b3081],
43	have	VBP	O	have	parataxis	5	SENT_280	[p16l10t3109r201b3188],
44	a	DT	O	a	det	48	SENT_280	[p16l262t3135r307b3187],
45	very	RB	O	very	advmod	46	SENT_280	[p16l362t3135r542b3209],
46	short	JJ	O	short	amod	48	SENT_280	[p16l600t3109r825b3188],
47	life	NN	O	life	nn	48	SENT_280	[p16l881t3108r1018b3187],
48	expectancy	NN	O	expectancy	dobj	43	SENT_280	[p16l1080t3126r1574b3209],
49	.	.	O	.	_	0	SENT_280	[p16l1080t3126r1574b3209],

1	The	DT	O	the	det	4	SENT_281	[p16l1638t3109r1799b3187],
2	overall	JJ	O	overall	amod	4	SENT_281	[p16l1862t3109r2149b3189],
3	response	NN	O	response	nn	4	SENT_281	[p16l10t3264r394b3338],
4	rate	NN	O	rate	nsubj	12	SENT_281	[p16l436t3255r597b3316],
5	with	IN	O	with	_	0	SENT_281	[p16l634t3238r831b3317],
6	cetuximab	JJ	O	cetuximab	amod	7	SENT_281	[p16l874t3238r1329b3317],
7	monotherapy	NN	O	monotherapy	prep_with	4	SENT_281	[p16l1372t3238r1950b3338],
8	was	VBD	O	be	cop	12	SENT_281	[p16l1983t3264r2147b3318],
9	10	CD	NUMBER	10	number	11	SENT_281	[p16l14t3372r107b3445],
10	to	TO	O	to	dep	11	SENT_281	[p16l167t3383r248b3445],
11	13	CD	PERCENT	13	num	12	SENT_281	[p16l311t3372r520b3462],
12	%	NN	PERCENT	%	_	0	SENT_281	[p16l311t3372r520b3462],
13	,	,	O	,	_	0	SENT_281	[p16l311t3372r520b3462],
14	with	IN	O	with	_	0	SENT_281	[p16l579t3366r776b3446],
15	a	DT	O	a	det	19	SENT_281	[p16l833t3392r877b3444],
16	disease	NN	O	disease	nn	19	SENT_281	[p16l935t3366r1598b3445],
17	—	NN	O	—	nn	19	SENT_281	[p16l935t3366r1598b3445],
18	control	NN	O	control	nn	19	SENT_281	[p16l935t3366r1598b3445],
19	rate	NN	O	rate	prep_with	12	SENT_281	[p16l1656t3383r1817b3444],
20	of	IN	O	of	_	0	SENT_281	[p16l1876t3365r1976b3445],
21	apmm	NN	O	apmm	prep_of	19	SENT_281	[p16l2015t3392r2148b3466, p17l2030t1109r2082b1218],
22	.	.	O	.	_	0	SENT_281	[p16l2015t3392r2148b3466, p17l2030t1109r2082b1218],

1	_	NN	O	_	nn	2	SENT_282	[p16l2015t3392r2148b3466, p17l2030t1109r2082b1218],
2	m	NN	O	m	_	0	SENT_282	[p16l2015t3392r2148b3466, p17l2030t1109r2082b1218],

1	E	NN	O	e	nn	4	SENT_283	[p17l2040t1242r2082b1291],
2	_	CD	NUMBER	_	num	4	SENT_283	[p17l2030t1312r2096b1498],
3	mv	NN	O	mv	nn	4	SENT_283	[p17l2030t1312r2096b1498],
4	_	NN	O	_	_	0	SENT_283	[p17l2030t1312r2096b1498],
5	:	:	O	:	_	0	SENT_283	[p17l2030t1312r2096b1498],
6	oa	NN	O	oa	nn	7	SENT_283	[p17l2030t1312r2096b1498],
7	Eo	NN	O	eo	dep	4	SENT_283	[p17l2030t1515r2082b1645],
8	:	:	O	:	_	0	SENT_283	[p17l2030t1515r2082b1645],
9	Em	NNP	O	Em	nn	10	SENT_283	[p17l2049t1667r2082b1749],
10	Sam	NNP	PERSON	Sam	dep	7	SENT_283	[p17l2035t1774r2082b1898],
11	.	.	O	.	_	0	SENT_283	[p17l2035t1774r2082b1898],

1	.23	NN	NUMBER	.23	nn	2	SENT_284	[p17l2049t1928r2082b2055],
2	m	NN	O	m	_	0	SENT_284	[p17l2035t2079r2097b2373],
3	>	JJR	O	>	dep	2	SENT_284	[p17l2035t2079r2097b2373],
4	_	CD	NUMBER	_	num	5	SENT_284	[p17l2035t2079r2097b2373],
5	toQQ	NN	O	toqq	dep	3	SENT_284	[p17l2035t2079r2097b2373],
6	:	:	O	:	_	0	SENT_284	[p17l2035t2079r2097b2373],
7	m	NN	O	m	nn	9	SENT_284	[p17l2035t2079r2097b2373],
8	H.	NN	PERSON	h.	nn	9	SENT_284	[p17l2030t2397r2082b2509],
9	mmn	NN	PERSON	mmn	dep	3	SENT_284	[p17l2030t2397r2082b2509],
10	_	CD	NUMBER	_	number	11	SENT_284	[p17l2030t2397r2082b2509],
11	_	CD	NUMBER	_	num	12	SENT_284	[p17l2030t2539r2082b2761],
12	um	NN	O	um	npadvmod	13	SENT_284	[p17l2030t2539r2082b2761],
13	>	JJR	O	>	amod	9	SENT_284	[p17l2030t2539r2082b2761],
14	_	CD	NUMBER	_	num	15	SENT_284	[p17l2030t2539r2082b2761],
15	mu2	NN	O	mu2	dep	2	SENT_284	[p17l2030t2539r2082b2761],
16	H.	NN	O	h.	nn	18	SENT_284	[p17l2030t2786r2082b2895],
17	mc	NN	O	mc	nn	18	SENT_284	[p17l2030t2786r2082b2895],
18	_	NN	O	_	dep	15	SENT_284	[p17l2030t2786r2082b2895],
19	.	.	O	.	_	0	SENT_284	[p17l2030t2786r2082b2895],

1	.	.	O	.	_	0	SENT_285	[p17l2030t2786r2082b2895],

1	n	NN	O	n	nn	2	SENT_286	[p17l2049t2917r2098b3078],
2	_	NN	O	_	_	0	SENT_286	[p17l2049t2917r2098b3078],
3	:	:	O	:	_	0	SENT_286	[p17l2049t2917r2098b3078],
4	o_w	NN	O	o_w	dep	2	SENT_286	[p17l2049t2917r2098b3078],
5	2	CD	NUMBER	2	dep	4	SENT_286	[p17l2030t3102r2082b3189],
6	:	:	O	:	_	0	SENT_286	[p17l2030t3102r2082b3189],
7	E	NN	O	e	dep	4	SENT_286	[p17l2035t3213r2081b3257],
8	:	:	O	:	_	0	SENT_286	[p17l2035t3286r2098b3612],
9	o_mm2wo	NN	O	o_mm2wo	dep	7	SENT_286	[p17l2035t3286r2098b3612],
10	.	.	O	.	_	0	SENT_286	[p17l2035t3286r2098b3612],

1	n	NN	O	n	_	0	SENT_287	[p17l2035t3286r2098b3612],
2	_	SYM	O	_	dep	4	SENT_287	[p17l2035t3286r2098b3612],
3	Eﬁm	FW	O	eﬁm	nn	4	SENT_287	[p17l2030t3636r2082b3760],
4	_	FW	O	_	rcmod	1	SENT_287	[p17l2030t3787r2082b3834],
5	um	FW	O	um	dep	1	SENT_287	[p17l2030t3787r2082b3834],
6	mmmmmﬁ	FW	O	mmmmmﬁ	rcmod	5	SENT_287	[p17l1954t155r2005b361],
7	E	NN	O	e	dep	6	SENT_287	[p17l1954t387r2005b504],
8	:	:	O	:	_	0	SENT_287	[p17l1954t387r2005b504],
9	:	:	O	:	_	0	SENT_287	[p17l1954t387r2005b504],
10	2.8	CD	NUMBER	2.8	num	11	SENT_287	[p17l1972t531r2005b643],
11	m	NN	O	m	dep	12	SENT_287	[p17l1959t667r2021b961],
12	>	JJR	O	>	dep	5	SENT_287	[p17l1959t667r2021b961],
13	_	CD	NUMBER	_	num	15	SENT_287	[p17l1959t667r2021b961],
14	ton_n	NN	O	ton_n	nn	15	SENT_287	[p17l1959t667r2021b961],
15	_	NN	O	_	dep	12	SENT_287	[p17l1959t667r2021b961],
16	:	:	O	:	_	0	SENT_287	[p17l1959t667r2021b961],
17	m	NN	O	m	dep	5	SENT_287	[p17l1959t667r2021b961],
18	“	CD	NUMBER	“	num	17	SENT_287	[p17l1954t984r2005b1097],
19	mug	NN	O	mug	dep	17	SENT_287	[p17l1954t984r2005b1097],
20	5:3	CD	NUMBER	5:3	num	19	SENT_287	[p17l1954t1126r2005b1240],
21	.	.	O	.	_	0	SENT_287	[p17l1972t1260r2005b1316],

1	o	NN	O	o	nn	5	SENT_288	[p17l1972t1260r2005b1316],
2	CBoE	NN	MISC	cboe	nn	5	SENT_288	[p17l1958t1346r2021b1522],
3	Emscm	NN	MISC	emscm	nn	5	SENT_288	[p17l1972t1548r2021b1732],
4	.3	NN	NUMBER	.3	nn	5	SENT_288	[p17l1972t1755r2021b1841],
5	wr	NN	O	wr	_	0	SENT_288	[p17l1972t1866r2021b1952],
6	:	:	O	:	_	0	SENT_288	[p17l1972t1866r2021b1952],
7	OmN	NN	O	omn	dep	5	SENT_288	[p17l1953t1977r2005b2149],
8	.	.	O	.	_	0	SENT_288	[p17l1953t1977r2005b2149],

1	.	.	O	.	_	0	SENT_289	[p17l1953t1977r2005b2149],

1	_	NN	O	_	nn	4	SENT_290	[p17l1953t1977r2005b2149],
2	O	NN	O	o	nn	4	SENT_290	[p17l1953t1977r2005b2149],
3	momou	NN	O	momou	nn	4	SENT_290	[p17l1954t2175r2005b2333],
4	m	NN	O	m	nsubj	39	SENT_290	[p17l1959t2358r2005b2683],
5	:	:	O	:	_	0	SENT_290	[p17l1959t2358r2005b2683],
6	o	NN	O	o	dep	4	SENT_290	[p17l1959t2358r2005b2683],
7	:	:	O	:	_	0	SENT_290	[p17l1959t2358r2005b2683],
8	m	NN	O	m	dep	6	SENT_290	[p17l1959t2358r2005b2683],
9	>	JJR	O	>	amod	10	SENT_290	[p17l1959t2358r2005b2683],
10	m	NN	O	m	dep	8	SENT_290	[p17l1959t2358r2005b2683],
11	:	:	O	:	_	0	SENT_290	[p17l1959t2358r2005b2683],
12	:	:	O	:	_	0	SENT_290	[p17l1959t2358r2005b2683],
13	_	CD	NUMBER	_	dep	10	SENT_290	[p17l1959t2358r2005b2683],
14	>	JJR	O	>	dep	21	SENT_290	[p17l1954t2707r2021b2890],
15	_	CD	NUMBER	_	num	16	SENT_290	[p17l1954t2707r2021b2890],
16	v_oo	NN	O	v_oo	dep	14	SENT_290	[p17l1954t2707r2021b2890],
17	>>	CD	NUMBER	>>	num	18	SENT_290	[p17l1954t2707r2021b2890],
18	E	NN	O	e	dep	21	SENT_290	[p17l1954t2910r2021b2967],
19	nm	NN	O	nm	nn	21	SENT_290	[p17l1953t2996r2005b3228],
20	>>	NN	O	>>	nn	21	SENT_290	[p17l1953t2996r2005b3228],
21	o	NN	O	o	dep	23	SENT_290	[p17l1953t2996r2005b3228],
22	__	CD	NUMBER	__	dep	21	SENT_290	[p17l1953t2996r2005b3228],
23	o.	NN	O	o.	dep	25	SENT_290	[p17l1953t2996r2005b3228],
24	_	CD	NUMBER	_	num	23	SENT_290	[p17l1953t2996r2005b3228],
25	o_BoE	NN	O	o_boe	dep	10	SENT_290	[p17l1964t3253r2014b3425],
26	22	CD	NUMBER	22	num	25	SENT_290	[p17l1972t3451r2021b3635],
27	;	:	O	;	_	0	SENT_290	[p17l1972t3451r2021b3635],
28	:	:	O	:	_	0	SENT_290	[p17l1972t3451r2021b3635],
29	.3	NN	NUMBER	.3	nn	30	SENT_290	[p17l1972t3658r2021b3744],
30	mg	NN	O	mg	dep	6	SENT_290	[p17l1972t3769r2021b3834],
31	53	CD	NUMBER	53	rcmod	30	SENT_290	[p17l1877t169r1929b283],
32	>	JJR	O	>	amod	34	SENT_290	[p17l1877t169r1929b283],
33	Esta	NN	O	esta	nn	34	SENT_290	[p17l1877t302r1929b460],
34	vmpmm	NN	O	vmpmm	dep	31	SENT_290	[p17l1877t487r1929b679],
35	:	:	O	:	_	0	SENT_290	[p17l1877t487r1929b679],
36	225	CD	NUMBER	225	dep	31	SENT_290	[p17l1896t700r1929b830],
37	:	:	O	:	_	0	SENT_290	[p17l1877t854r1944b1136],
38	:	:	O	:	_	0	SENT_290	[p17l1877t854r1944b1136],
39	m_n	VB	O	m_n	_	0	SENT_290	[p17l1877t854r1944b1136],
40	___	CD	NUMBER	___	num	42	SENT_290	[p17l1877t854r1944b1136],
41	m.	JJ	NUMBER	m.	amod	42	SENT_290	[p17l1877t854r1944b1136],
42	xo	NN	O	xo	dobj	39	SENT_290	[p17l1877t854r1944b1136],
43	_	NN	O	_	nn	44	SENT_290	[p17l1877t1162r1929b1259],
44	u	NN	O	u	dep	42	SENT_290	[p17l1877t1162r1929b1259],
45	:	:	O	:	_	0	SENT_290	[p17l1877t1162r1929b1259],
46	m	NN	O	m	dep	42	SENT_290	[p17l1877t1162r1929b1259],
47	.	.	O	.	_	0	SENT_290	[p17l1882t1286r1938b1576],

1	:	:	O	:	_	0	SENT_291	[p17l1882t1286r1938b1576],
2	muBo	NN	O	mubo	_	0	SENT_291	[p17l1882t1286r1938b1576],
3	:	:	O	:	_	0	SENT_291	[p17l1882t1286r1938b1576],
4	E	NN	O	e	dep	2	SENT_291	[p17l1882t1286r1938b1576],
5	.	.	O	.	_	0	SENT_291	[p17l1877t1605r1938b1939],

1	__	NN	O	__	_	0	SENT_292	[p17l1877t1605r1938b1939],
2	um	NN	O	um	dep	1	SENT_292	[p17l1877t1605r1938b1939],
3	.	.	O	.	_	0	SENT_292	[p17l1877t1605r1938b1939],

1	_	NN	O	_	_	0	SENT_293	[p17l1877t1605r1938b1939],
2	:	:	O	:	_	0	SENT_293	[p17l1877t1605r1938b1939],
3	o.	NN	O	o.	nn	4	SENT_293	[p17l1877t1605r1938b1939],
4	o	NN	O	o	dep	1	SENT_293	[p17l1877t1605r1938b1939],
5	:	:	O	:	_	0	SENT_293	[p17l1877t1605r1938b1939],
6	¢	CD	NUMBER	¢	number	7	SENT_293	[p17l1877t1605r1938b1939],
7	8	CD	NUMBER	8	dep	4	SENT_293	[p17l1887t1961r1929b2015],
8	.	.	O	.	_	0	SENT_293	[p17l1887t1961r1929b2015],

1	>	JJR	O	>	_	0	SENT_294	[p17l1877t2035r1944b2296],
2	.	.	O	.	_	0	SENT_294	[p17l1877t2035r1944b2296],

1	_	SYM	O	_	dep	5	SENT_295	[p17l1877t2035r1944b2296],
2	8um	FW	O	8um	nn	5	SENT_295	[p17l1877t2035r1944b2296],
3	¢	FW	O	¢	nn	5	SENT_295	[p17l1877t2035r1944b2296],
4	m.	FW	O	m.	nn	5	SENT_295	[p17l1877t2035r1944b2296],
5	_	FW	O	_	dep	8	SENT_295	[p17l1877t2035r1944b2296],
6	mm	NN	O	mm	dep	5	SENT_295	[p17l1896t2324r1929b2428],
7	;	:	O	;	_	0	SENT_295	[p17l1896t2324r1929b2428],
8	:2	CD	NUMBER	:2	_	0	SENT_295	[p17l1877t2448r1929b2558],
9	:	:	O	:	_	0	SENT_295	[p17l1877t2448r1929b2558],
10	Eucmu	NNP	LOCATION	Eucmu	dep	8	SENT_295	[p17l1896t2577r1929b2759],
11	_	CD	NUMBER	_	num	13	SENT_295	[p17l1877t2785r1929b3051],
12	Su2o_ou	NN	O	su2o_ou	nn	13	SENT_295	[p17l1877t2785r1929b3051],
13	u	NN	O	u	dep	10	SENT_295	[p17l1882t3073r1929b3361],
14	:	:	O	:	_	0	SENT_295	[p17l1882t3073r1929b3361],
15	_	CD	NUMBER	_	num	17	SENT_295	[p17l1882t3073r1929b3361],
16	Bm3mE	NN	O	bm3me	nn	17	SENT_295	[p17l1882t3073r1929b3361],
17	_	NN	O	_	dep	13	SENT_295	[p17l1877t3391r1929b3505],
18	.	.	O	.	_	0	SENT_295	[p17l1877t3391r1929b3505],

1	_	NN	O	_	nsubj	6	SENT_296	[p17l1877t3391r1929b3505],
2	:	:	O	:	_	0	SENT_296	[p17l1877t3391r1929b3505],
3	>>	CD	NUMBER	>>	dep	1	SENT_296	[p17l1877t3391r1929b3505],
4	mEo	NNP	O	mEo	dep	3	SENT_296	[p17l1882t3528r1929b3745],
5	:	:	O	:	_	0	SENT_296	[p17l1882t3528r1929b3745],
6	mn	VB	O	mn	_	0	SENT_296	[p17l1882t3528r1929b3745],
7	_	NN	O	_	dobj	6	SENT_296	[p17l1882t3528r1929b3745],
8	.	.	O	.	_	0	SENT_296	[p17l1877t3775r1929b3833],

1	_	NN	O	_	_	0	SENT_297	[p17l1877t3775r1929b3833],
2	m	NN	O	m	nn	3	SENT_297	[p17l1877t3775r1929b3833],
3	womcogmo	NN	O	womcogmo	dep	1	SENT_297	[p17l1819t3398r1868b3693],
4	.	.	O	.	_	0	SENT_297	[p17l1819t3398r1868b3693],

1	_	NN	O	_	nn	2	SENT_298	[p17l1801t3723r1852b3834],
2	m_t	NN	O	m_t	dep	8	SENT_298	[p17l1801t3723r1852b3834],
3	_	CD	NUMBER	_	num	8	SENT_298	[p17l1801t3723r1852b3834],
4	E.	NNP	O	E.	nn	8	SENT_298	[p17l1723t1636r1776b1748],
5	_	NNP	O	_	nn	8	SENT_298	[p17l1723t1636r1776b1748],
6	m.	NN	O	m.	nn	8	SENT_298	[p17l1723t1636r1776b1748],
7	B	NN	O	b	nn	8	SENT_298	[p17l1734t1771r1776b1820],
8	E	NN	O	e	_	0	SENT_298	[p17l1724t1846r1792b2205],
9	£	CD	NUMBER	£	num	10	SENT_298	[p17l1724t1846r1792b2205],
10	w	NN	O	w	dep	8	SENT_298	[p17l1724t1846r1792b2205],
11	:	:	O	:	_	0	SENT_298	[p17l1724t1846r1792b2205],
12	_	CD	NUMBER	_	num	13	SENT_298	[p17l1724t1846r1792b2205],
13	E5	NN	O	e5	dep	14	SENT_298	[p17l1724t1846r1792b2205],
14	E9	NN	O	e9	parataxis	8	SENT_298	[p17l1724t2232r1776b2362],
15	...	:	O	...	_	0	SENT_298	[p17l1724t2232r1776b2362],
16	Em	NNP	ORGANIZATION	Em	nn	17	SENT_298	[p17l1743t2384r1776b2465],
17	Ema	NNP	ORGANIZATION	Ema	dep	19	SENT_298	[p17l1729t2491r1776b2615],
18	5:3	CD	NUMBER	5:3	num	19	SENT_298	[p17l1734t2645r1791b2795],
19	>	JJR	O	>	parataxis	8	SENT_298	[p17l1724t2817r1791b2965],
20	_	CD	NUMBER	_	num	22	SENT_298	[p17l1724t2817r1791b2965],
21	u3m	NN	O	u3m	nn	22	SENT_298	[p17l1724t2817r1791b2965],
22	m	NN	O	m	dep	19	SENT_298	[p17l1724t2990r1776b3160],
23	:	:	O	:	_	0	SENT_298	[p17l1724t2990r1776b3160],
24	£	CD	NUMBER	£	dep	30	SENT_298	[p17l1724t2990r1776b3160],
25	on	IN	O	on	_	0	SENT_298	[p17l1724t2990r1776b3160],
26	_	CD	MONEY	_	num	27	SENT_298	[p17l1724t2990r1776b3160],
27	\	CD	MONEY	\	prep_on	24	SENT_298	[p17l1724t3185r1792b3393],
28	€	CD	MONEY	€	num	30	SENT_298	[p17l1724t3185r1792b3393],
29	Em	NNP	O	Em	nn	30	SENT_298	[p17l1724t3185r1792b3393],
30	_	NN	O	_	parataxis	8	SENT_298	[p17l1724t3185r1792b3393],
31	.	.	O	.	_	0	SENT_298	[p17l1724t3185r1792b3393],

1	_	NN	O	_	_	0	SENT_299	[p17l1724t3185r1792b3393],
2	.	.	O	.	_	0	SENT_299	[p17l1724t3185r1792b3393],

1	.	.	O	.	_	0	SENT_300	[p17l1724t3185r1792b3393],

1	_	NN	O	_	nsubj	4	SENT_301	[p17l1724t3417r1791b3834],
2	oommn	SYM	O	oommn	dep	4	SENT_301	[p17l1724t3417r1791b3834],
3	-	:	O	-	_	0	SENT_301	[p17l1724t3417r1791b3834],
4	:	:	O	:	_	0	SENT_301	[p17l1724t3417r1791b3834],
5	:	:	O	:	_	0	SENT_301	[p17l1724t3417r1791b3834],
6	m_a	FW	O	m_a	nn	10	SENT_301	[p17l1724t3417r1791b3834],
7	__	FW	O	__	nn	10	SENT_301	[p17l1724t3417r1791b3834],
8	§	FW	O	§	nn	10	SENT_301	[p17l1724t3417r1791b3834],
9	_	FW	O	_	nn	10	SENT_301	[p17l1648t96r1699b318],
10	um	FW	O	um	dep	15	SENT_301	[p17l1648t96r1699b318],
11	>	JJR	O	>	dep	10	SENT_301	[p17l1648t96r1699b318],
12	_	CD	NUMBER	_	num	13	SENT_301	[p17l1648t96r1699b318],
13	mu2	NN	O	mu2	dep	15	SENT_301	[p17l1648t96r1699b318],
14	o.u.	NN	O	o.u.	nn	15	SENT_301	[p17l1648t345r1699b454],
15	_	NN	O	_	dep	19	SENT_301	[p17l1648t345r1699b454],
16	m	NN	O	m	nn	17	SENT_301	[p17l1648t345r1699b454],
17	cm	NN	O	cm	dep	15	SENT_301	[p17l1648t481r1699b576],
18	;	:	O	;	_	0	SENT_301	[p17l1648t481r1699b576],
19	m.	NN	O	m.	dep	4	SENT_301	[p17l1653t604r1715b822],
20	.	.	O	.	_	0	SENT_301	[p17l1653t604r1715b822],

1	:	:	O	:	_	0	SENT_302	[p17l1653t604r1715b822],
2	m	NN	O	m	_	0	SENT_302	[p17l1653t604r1715b822],
3	:	:	O	:	_	0	SENT_302	[p17l1653t604r1715b822],
4	mn	VB	O	mn	dep	13	SENT_302	[p17l1653t604r1715b822],
5	_	NN	O	_	nn	7	SENT_302	[p17l1653t604r1715b822],
6	mc_Co	NN	O	mc_co	nn	7	SENT_302	[p17l1647t849r1699b1007],
7	mP_f	NN	O	mp_f	nsubj	9	SENT_302	[p17l1648t1032r1699b1192],
8	9,3	CD	NUMBER	9,3	num	9	SENT_302	[p17l1658t1214r1699b1313],
9	>	JJR	O	>	xcomp	4	SENT_302	[p17l1648t1333r1715b1737],
10	_	CD	NUMBER	_	num	11	SENT_302	[p17l1648t1333r1715b1737],
11	BmE_xo	NN	O	bme_xo	dep	9	SENT_302	[p17l1648t1333r1715b1737],
12	:	:	O	:	_	0	SENT_302	[p17l1648t1333r1715b1737],
13	E	NN	O	e	dep	2	SENT_302	[p17l1648t1333r1715b1737],
14	<	JJR	O	<	dep	13	SENT_302	[p17l1648t1333r1715b1737],
15	.	.	O	.	_	0	SENT_302	[p17l1653t1760r1715b2103],

1	:	:	O	:	_	0	SENT_303	[p17l1653t1760r1715b2103],
2	o_mm2woE	NN	O	o_mm2woe	nn	3	SENT_303	[p17l1653t1760r1715b2103],
3	ommmmﬁ	NN	O	ommmmﬁ	nsubj	4	SENT_303	[p17l1648t2130r1699b2335],
4	Es	NNS	O	e	_	0	SENT_303	[p17l1648t2362r1699b2479],
5	:	:	O	:	_	0	SENT_303	[p17l1648t2362r1699b2479],
6	:	:	O	:	_	0	SENT_303	[p17l1653t2508r1699b2781],
7	mu8	NN	O	mu8	dobj	4	SENT_303	[p17l1653t2508r1699b2781],
8	.	.	O	.	_	0	SENT_303	[p17l1653t2508r1699b2781],

1	o	NN	O	o	nsubj	7	SENT_304	[p17l1653t2508r1699b2781],
2	:	:	O	:	_	0	SENT_304	[p17l1653t2508r1699b2781],
3	_	CD	NUMBER	_	dep	1	SENT_304	[p17l1653t2508r1699b2781],
4	:	:	O	:	_	0	SENT_304	[p17l1653t2508r1699b2781],
5	m	NN	O	m	dep	3	SENT_304	[p17l1648t2808r1715b2919],
6	:	:	O	:	_	0	SENT_304	[p17l1648t2808r1715b2919],
7	_	VB	O	_	_	0	SENT_304	[p17l1648t2808r1715b2919],
8	a	DT	O	a	det	14	SENT_304	[p17l1648t2808r1715b2919],
9	§	JJ	O	§	amod	14	SENT_304	[p17l1648t2951r1715b3151],
10	_	NN	O	_	nn	14	SENT_304	[p17l1648t2951r1715b3151],
11	v_mm	NN	O	v_mm	nn	14	SENT_304	[p17l1648t2951r1715b3151],
12	>>	CD	NUMBER	>>	num	14	SENT_304	[p17l1648t2951r1715b3151],
13	BEE	NN	O	bee	nn	14	SENT_304	[p17l1658t3171r1699b3330],
14	Emscm	NN	O	emscm	nsubj	16	SENT_304	[p17l1666t3357r1715b3541],
15	.8	CD	NUMBER	.8	num	16	SENT_304	[p17l1666t3563r1715b3649],
16	wc	NN	O	wc	xcomp	7	SENT_304	[p17l1666t3674r1716b3760],
17	:	:	O	:	_	0	SENT_304	[p17l1666t3674r1716b3760],
18	om	SYM	O	om	dep	20	SENT_304	[p17l1651t3786r1699b3834],
19	-	:	O	-	_	0	SENT_304	[p17l1571t104r1638b258],
20	_	NN	O	_	dep	16	SENT_304	[p17l1571t104r1638b258],
21	umo_v	NN	O	umo_v	nn	22	SENT_304	[p17l1571t104r1638b258],
22	n_mE_x	NN	O	n_me_x	dep	16	SENT_304	[p17l1571t288r1623b572],
23	:	:	O	:	_	0	SENT_304	[p17l1571t288r1623b572],
24	.	.	O	.	_	0	SENT_304	[p17l1571t288r1623b572],

1	.	.	O	.	_	0	SENT_305	[p17l1571t288r1623b572],

1	mu	NN	O	mu	_	0	SENT_306	[p17l1571t288r1623b572],
2	53	CD	NUMBER	53	num	3	SENT_306	[p17l1571t599r1623b713],
3	>	JJR	O	>	dep	1	SENT_306	[p17l1571t599r1623b713],
4	.	.	O	.	_	0	SENT_306	[p17l1590t732r1623b788],

1	o	NN	O	o	nn	2	SENT_307	[p17l1590t732r1623b788],
2	C33	NN	O	c33	_	0	SENT_307	[p17l1576t817r1638b994],
3	:	:	O	:	_	0	SENT_307	[p17l1576t817r1638b994],
4	m	NN	O	m	dep	2	SENT_307	[p17l1590t1021r1638b1204],
5	:	:	O	:	_	0	SENT_307	[p17l1590t1021r1638b1204],
6	m	NN	O	m	dep	4	SENT_307	[p17l1590t1021r1638b1204],
7	:	:	O	:	_	0	SENT_307	[p17l1590t1021r1638b1204],
8	_	CD	NUMBER	_	num	10	SENT_307	[p17l1590t1021r1638b1204],
9	um	NN	O	um	nn	10	SENT_307	[p17l1590t1021r1638b1204],
10	.3	NN	NUMBER	.3	dep	6	SENT_307	[p17l1590t1227r1638b1313],
11	we	PRP	O	we	nsubj	12	SENT_307	[p17l1590t1338r1639b1424],
12	omm	VBP	O	omm	rcmod	10	SENT_307	[p17l1575t1449r1623b1547],
13	.6	CD	NUMBER	.6	num	15	SENT_307	[p17l1571t1561r1623b1621],
14	mmmot	NN	O	mmmot	nn	15	SENT_307	[p17l1571t1646r1623b1806],
15	m	NN	O	m	dobj	12	SENT_307	[p17l1576t1831r1623b2155],
16	:	:	O	:	_	0	SENT_307	[p17l1576t1831r1623b2155],
17	o	NN	O	o	dep	2	SENT_307	[p17l1576t1831r1623b2155],
18	:	:	O	:	_	0	SENT_307	[p17l1576t1831r1623b2155],
19	m	NN	O	m	dep	17	SENT_307	[p17l1576t1831r1623b2155],
20	>	JJR	O	>	amod	21	SENT_307	[p17l1576t1831r1623b2155],
21	m	NN	O	m	dep	19	SENT_307	[p17l1576t1831r1623b2155],
22	:	:	O	:	_	0	SENT_307	[p17l1576t1831r1623b2155],
23	:	:	O	:	_	0	SENT_307	[p17l1576t1831r1623b2155],
24	_	CD	NUMBER	_	num	25	SENT_307	[p17l1576t1831r1623b2155],
25	>	JJR	O	>	dep	2	SENT_307	[p17l1571t2179r1638b2362],
26	_	CD	NUMBER	_	num	27	SENT_307	[p17l1571t2179r1638b2362],
27	v_mm	NN	O	v_mm	dep	25	SENT_307	[p17l1571t2179r1638b2362],
28	>>	CD	NUMBER	>>	num	29	SENT_307	[p17l1571t2179r1638b2362],
29	E	NN	O	e	dep	25	SENT_307	[p17l1571t2382r1638b2439],
30	_	CD	NUMBER	_	num	33	SENT_307	[p17l1571t2468r1623b2700],
31	om	NN	O	om	nn	33	SENT_307	[p17l1571t2468r1623b2700],
32	>>	NN	O	>>	nn	33	SENT_307	[p17l1571t2468r1623b2700],
33	o	NN	O	o	dep	29	SENT_307	[p17l1571t2468r1623b2700],
34	__	CD	MONEY	__	num	35	SENT_307	[p17l1571t2468r1623b2700],
35	£	NN	MONEY	£	dep	29	SENT_307	[p17l1571t2468r1623b2700],
36	.	.	O	.	_	0	SENT_307	[p17l1590t2725r1632b2853],

1	m2m	NN	O	m2m	_	0	SENT_308	[p17l1590t2725r1632b2853],
2	oumt	NN	O	oumt	nn	3	SENT_308	[p17l1571t2878r1638b3229],
3	_	NN	O	_	dep	1	SENT_308	[p17l1571t2878r1638b3229],
4	.	.	O	.	_	0	SENT_308	[p17l1571t2878r1638b3229],

1	_	NN	O	_	nn	2	SENT_309	[p17l1571t2878r1638b3229],
2	m	NN	O	m	_	0	SENT_309	[p17l1571t2878r1638b3229],
3	-	:	O	-	_	0	SENT_309	[p17l1571t2878r1638b3229],
4	>	JJR	O	>	amod	6	SENT_309	[p17l1571t2878r1638b3229],
5	_	NN	O	_	nn	6	SENT_309	[p17l1571t2878r1638b3229],
6	uon	NN	O	uon	dep	2	SENT_309	[p17l1571t2878r1638b3229],
7	_	CD	NUMBER	_	num	9	SENT_309	[p17l1571t2878r1638b3229],
8	mo	NN	DURATION	mo	nn	9	SENT_309	[p17l1571t3245r1623b3306],
9	BEE	NN	O	bee	dep	6	SENT_309	[p17l1581t3327r1623b3487],
10	2	CD	NUMBER	2	number	11	SENT_309	[p17l1590t3513r1638b3697],
11	§	CD	NUMBER	§	num	12	SENT_309	[p17l1590t3513r1638b3697],
12	_	NN	O	_	dep	9	SENT_309	[p17l1590t3513r1638b3697],
13	.	.	O	.	_	0	SENT_309	[p17l1590t3513r1638b3697],

1	.	.	O	.	_	0	SENT_310	[p17l1590t3513r1638b3697],

1	m	NN	O	m	_	0	SENT_311	[p17l1590t3513r1638b3697],
2	.	.	O	.	_	0	SENT_311	[p17l1590t3720r1638b3806],

1	_	NN	O	_	nn	6	SENT_312	[p17l1590t3720r1638b3806],
2	ma	NN	O	ma	nn	6	SENT_312	[p17l1590t3720r1638b3806],
3	W	NN	O	w	nn	6	SENT_312	[p17l1590t3831r1631b3834],
4	-8	CD	NUMBER	-8	num	6	SENT_312	[p17l1513t95r1546b170],
5	_	NN	O	_	nn	6	SENT_312	[p17l1495t197r1546b311],
6	t	NN	O	t	_	0	SENT_312	[p17l1495t197r1546b311],
7	_	CD	NUMBER	_	number	8	SENT_312	[p17l1495t197r1546b311],
8	>>	CD	NUMBER	>>	num	9	SENT_312	[p17l1495t197r1546b311],
9	BEE	NN	O	bee	dep	6	SENT_312	[p17l1495t330r1546b488],
10	_	CD	NUMBER	_	num	11	SENT_312	[p17l1495t515r1546b707],
11	uBmm	NN	O	ubmm	dep	6	SENT_312	[p17l1495t515r1546b707],
12	:	:	O	:	_	0	SENT_312	[p17l1495t515r1546b707],
13	28	CD	NUMBER	28	num	14	SENT_312	[p17l1513t728r1546b857],
14	>	JJR	O	>	dep	11	SENT_312	[p17l1513t728r1546b857],
15	Bucmu	NNP	O	Bucmu	dep	14	SENT_312	[p17l1513t877r1546b1059],
16	_	CD	NUMBER	_	num	15	SENT_312	[p17l1495t1085r1546b1351],
17	3u2o_ou	CD	NUMBER	3u2o_ou	num	19	SENT_312	[p17l1495t1085r1546b1351],
18	boBm	NN	O	bobm	nn	19	SENT_312	[p17l1494t1373r1562b1936],
19	¢	NN	O	¢	dep	14	SENT_312	[p17l1494t1373r1562b1936],
20	2	CD	NUMBER	2	dep	19	SENT_312	[p17l1494t1373r1562b1936],
21	-	:	O	-	_	0	SENT_312	[p17l1494t1373r1562b1936],
22	:	:	O	:	_	0	SENT_312	[p17l1494t1373r1562b1936],
23	mu3o	NN	O	mu3o	dep	6	SENT_312	[p17l1494t1373r1562b1936],
24	:	:	O	:	_	0	SENT_312	[p17l1494t1373r1562b1936],
25	___	CD	NUMBER	___	dep	23	SENT_312	[p17l1494t1373r1562b1936],
26	.	.	O	.	_	0	SENT_312	[p17l1500t1965r1555b2266],

1	u	NN	O	u	nsubj	10	SENT_313	[p17l1500t1965r1555b2266],
2	:	:	O	:	_	0	SENT_313	[p17l1500t1965r1555b2266],
3	Sm3mE	NN	O	sm3me	dep	1	SENT_313	[p17l1500t1965r1555b2266],
4	53	CD	NUMBER	53	num	6	SENT_313	[p17l1495t2295r1546b2409],
5	>	JJR	O	>	amod	6	SENT_313	[p17l1495t2295r1546b2409],
6	B	NN	O	b	dep	3	SENT_313	[p17l1500t2432r1546b2649],
7	:	:	O	:	_	0	SENT_313	[p17l1500t2432r1546b2649],
8	m	NN	O	m	dep	3	SENT_313	[p17l1500t2432r1546b2649],
9	:	:	O	:	_	0	SENT_313	[p17l1500t2432r1546b2649],
10	mn	VB	O	mn	_	0	SENT_313	[p17l1500t2432r1546b2649],
11	_	NN	O	_	dobj	10	SENT_313	[p17l1500t2432r1546b2649],
12	.	.	O	.	_	0	SENT_313	[p17l1495t2680r1546b2801],

1	_	NNP	O	_	_	0	SENT_314	[p17l1495t2680r1546b2801],
2	m.	NNP	O	m.	dep	1	SENT_314	[p17l1495t2680r1546b2801],
3	_	NNP	O	_	dep	2	SENT_314	[p17l1495t2680r1546b2801],
4	:	:	O	:	_	0	SENT_314	[p17l1495t2680r1546b2801],
5	.	.	O	.	_	0	SENT_314	[p17l1495t2680r1546b2801],

1	N	NN	O	n	nn	6	SENT_315	[p17l1500t2824r1545b2851],
2	mmmsq	NN	O	mmmsq	nn	6	SENT_315	[p17l1495t2875r1562b3036],
3	voN_Eo_u	NN	O	von_eo_u	nn	6	SENT_315	[p17l1495t3065r1546b3394],
4	:2	CD	NUMBER	:2	num	6	SENT_315	[p17l1495t3065r1546b3394],
5	m	NN	O	m	nn	6	SENT_315	[p17l1513t3421r1546b3447],
6	mm	NN	O	mm	_	0	SENT_315	[p17l1513t3473r1546b3577],
7	;	:	O	;	_	0	SENT_315	[p17l1513t3473r1546b3577],
8	:2	CD	NUMBER	:2	dep	6	SENT_315	[p17l1495t3601r1546b3705],
9	:	:	O	:	_	0	SENT_315	[p17l1495t3601r1546b3705],
10	E7	NN	O	e7	dep	8	SENT_315	[p17l1499t3732r1562b3834],
11	.	.	O	.	_	0	SENT_315	[p17l1418t1659r1470b1821],

1	m	NN	O	m	_	0	SENT_316	[p17l1418t1659r1470b1821],
2	:	:	O	:	_	0	SENT_316	[p17l1418t1659r1470b1821],
3	o_m	NN	O	o_m	nn	4	SENT_316	[p17l1418t1659r1470b1821],
4	n_mE_x3mu	NN	O	n_me_x3mu	dep	1	SENT_316	[p17l1418t1846r1470b2131],
5	5:3	CD	NUMBER	5:3	num	6	SENT_316	[p17l1418t2157r1470b2271],
6	>	JJR	O	>	dep	4	SENT_316	[p17l1418t2291r1485b2486],
7	__	CD	NUMBER	__	num	8	SENT_316	[p17l1418t2291r1485b2486],
8	mE	NN	O	me	dep	4	SENT_316	[p17l1418t2291r1485b2486],
9	:	:	O	:	_	0	SENT_316	[p17l1418t2291r1485b2486],
10	_	CD	NUMBER	_	number	11	SENT_316	[p17l1418t2291r1485b2486],
11	_	CD	NUMBER	_	dep	1	SENT_316	[p17l1418t2515r1470b2707],
12	o8	NN	O	o8	dep	11	SENT_316	[p17l1418t2515r1470b2707],
13	.	.	O	.	_	0	SENT_316	[p17l1418t2515r1470b2707],

1	mm	NN	O	mm	_	0	SENT_317	[p17l1418t2515r1470b2707],
2	:	:	O	:	_	0	SENT_317	[p17l1418t2515r1470b2707],
3	Anxuomv	NNP	O	Anxuomv	nn	6	SENT_317	[p17l1421t2735r1485b2893],
4	ﬂcosmq	NN	O	ﬂcosmq	nn	6	SENT_317	[p17l1423t2924r1485b3142],
5	mm	NN	O	mm	nn	6	SENT_317	[p17l1423t3169r1470b3231],
6	E	NN	O	e	dep	1	SENT_317	[p17l1423t3258r1469b3302],
7	__	NN	O	__	nn	8	SENT_317	[p17l1423t3331r1486b3656],
8	o	NN	O	o	nsubj	9	SENT_317	[p17l1423t3331r1486b3656],
9	_	VBD	O	_	rcmod	6	SENT_317	[p17l1423t3331r1486b3656],
10	$	$	MONEY	$	num	13	SENT_317	[p17l1423t3331r1486b3656],
11	2woa	CD	MONEY	2woa	number	10	SENT_317	[p17l1423t3331r1486b3656],
12	_	CD	MONEY	_	number	10	SENT_317	[p17l1423t3331r1486b3656],
13	Eta	NN	O	eta	dobj	9	SENT_317	[p17l1418t3681r1470b3805],
14	_	IN	O	_	prep	9	SENT_317	[p17l1418t3832r1469b3834],

1	Ar	NN	O	ar	_	0	SENT_318	[p17l1352t3751r1393b3834],
2	:	:	O	:	_	0	SENT_318	[p17l1352t3751r1393b3834],

1	mood	NN	O	mood	_	0	SENT_319	[p17l1172t210r1220b355],
2	§	NN	O	§	dep	1	SENT_319	[p17l1172t567r1236b872],
3	.	.	O	.	_	0	SENT_319	[p17l1172t567r1236b872],

1	o	NN	O	o	_	0	SENT_320	[p17l1172t567r1236b872],
2	:	:	O	:	_	0	SENT_320	[p17l1172t567r1236b872],
3	$	$	MONEY	$	dep	1	SENT_320	[p17l1172t567r1236b872],
4	.	.	MONEY	.	_	0	SENT_320	[p17l1172t567r1236b872],

1	e	LS	O	e	dep	2	SENT_321	[p17l1172t567r1236b872],
2	Rd	NN	O	rd	_	0	SENT_321	[p17l1172t899r1220b1013],
3	:3	CD	NUMBER	:3	number	4	SENT_321	[p17l1173t1193r1220b1306],
4	3	CD	NUMBER	3	dobj	2	SENT_321	[p17l1173t1737r1220b1818],
5	.	.	O	.	_	0	SENT_321	[p17l1173t1737r1220b1818],

1	Sodv	NNP	O	Sodv	_	0	SENT_322	[p17l1063t210r1111b393],
2	$	$	MONEY	$	dep	4	SENT_322	[p17l1063t567r1127b872],
3	0-39	CD	MONEY	0-39	num	4	SENT_322	[p17l1063t567r1127b872],
4	mod	NN	O	mod	dep	1	SENT_322	[p17l1063t899r1111b1013],
5	3	CD	NUMBER	3	number	6	SENT_322	[p17l1064t1227r1111b1303],
6	3	CD	NUMBER	3	dep	4	SENT_322	[p17l1063t1738r1111b1813],

1	So	RB	O	so	_	0	SENT_323	[p17l954t210r1002b393],
2	.	.	O	.	_	0	SENT_323	[p17l954t210r1002b393],

1	ov	NN	O	ov	nn	4	SENT_324	[p17l954t210r1002b393],
2	m	NN	O	m	nn	4	SENT_324	[p17l954t1279r1002b1307],
3	o	NN	O	o	nn	4	SENT_324	[p17l954t1787r1002b1817],
4	mz	NN	O	mz	_	0	SENT_324	[p17l736t2230r783b2307],
5	:	:	O	:	_	0	SENT_324	[p17l736t2517r800b2823],
6	~	NN	O	~	dep	4	SENT_324	[p17l736t2517r800b2823],
7	.	.	O	.	_	0	SENT_324	[p17l736t2517r800b2823],

1	T$	NN	MISC	t$	_	0	SENT_325	[p17l736t2517r800b2823],
2	.	.	O	.	_	0	SENT_325	[p17l736t2517r800b2823],

1	e	LS	O	e	dep	2	SENT_326	[p17l736t2517r800b2823],
2	Rd	NN	O	rd	_	0	SENT_326	[p17l736t2852r784b2964],
3	3	CD	NUMBER	3	npadvmod	4	SENT_326	[p17l736t3267r784b3347],
4	So	RB	O	so	advmod	2	SENT_326	[p17l627t2182r674b2365],
5	.	.	O	.	_	0	SENT_326	[p17l627t2182r674b2365],

1	ov	NN	O	ov	_	0	SENT_327	[p17l627t2182r674b2365],
2	:	:	O	:	_	0	SENT_327	[p17l627t2517r690b2822],
3	:	:	O	:	_	0	SENT_327	[p17l627t2517r690b2822],
4	.	.	O	.	_	0	SENT_327	[p17l627t2517r690b2822],

1	o	NN	O	o	_	0	SENT_328	[p17l627t2517r690b2822],
2	:	:	O	:	_	0	SENT_328	[p17l627t2517r690b2822],
3	$	$	MONEY	$	dep	1	SENT_328	[p17l627t2517r690b2822],
4	.	.	MONEY	.	_	0	SENT_328	[p17l627t2517r690b2822],

1	e	LS	O	e	dep	2	SENT_329	[p17l627t2517r690b2822],
2	vno	FW	O	vno	_	0	SENT_329	[p17l627t2849r674b2964],
3	3	CD	NUMBER	3	nsubj	2	SENT_329	[p17l628t3270r674b3348],

1	Bod	NNP	PERSON	Bod	_	0	SENT_330	[p17l518t2179r566b2327],
2	mam	NN	O	mam	dep	1	SENT_330	[p17l519t3267r566b3381],

1	2	CD	NUMBER	2	number	2	SENT_331	[p17l292t198r344b354],
2	__	CD	NUMBER	__	dep	3	SENT_331	[p17l292t198r344b354],
3	~	NN	O	~	dep	5	SENT_331	[p17l292t198r344b354],
4	>	JJR	O	>	amod	5	SENT_331	[p17l292t198r344b354],
5	n	NN	O	n	nsubj	11	SENT_331	[p17l297t374r342b405],
6	_	VBG	O	_	partmod	5	SENT_331	[p17l297t374r342b405],
7	3	CD	NUMBER	3	num	9	SENT_331	[p17l296t667r359b744],
8	X3	NN	O	x3	nn	9	SENT_331	[p17l295t766r359b905],
9	Ea	NN	O	ea	dobj	6	SENT_331	[p17l295t1147r359b1309],
10	"	''	O	"	punct	6	SENT_331	[p17l295t1147r359b1309],
11	2	LS	NUMBER	2	_	0	SENT_331	[p17l297t1326r359b1387],
12	.	.	O	.	_	0	SENT_331	[p17l297t1326r359b1387],

1	ﬁﬁu	NN	O	ﬁﬁu	_	0	SENT_332	[p17l295t1575r359b1738],
2	2	CD	NUMBER	2	dep	1	SENT_332	[p17l297t1754r359b1815],
3	.	.	O	.	_	0	SENT_332	[p17l297t1754r359b1815],

1	28	CD	NUMBER	28	number	2	SENT_333	[p17l296t1839r343b1966],
2	2	CD	NUMBER	2	num	4	SENT_333	[p17l292t2164r344b2320],
3	__	NN	O	__	nn	4	SENT_333	[p17l292t2164r344b2320],
4	~	NN	O	~	_	0	SENT_333	[p17l292t2164r344b2320],
5	>	JJR	O	>	amod	6	SENT_333	[p17l292t2164r344b2320],
6	n	NN	O	n	dep	4	SENT_333	[p17l297t2339r342b2371],
7	_	VBG	O	_	partmod	6	SENT_333	[p17l297t2339r342b2371],
8	3	CD	NUMBER	3	num	9	SENT_333	[p17l296t2618r359b2694],
9	xmm	NN	O	xmm	dobj	7	SENT_333	[p17l295t2717r359b2856],
10	.	.	O	.	_	0	SENT_333	[p17l295t2717r359b2856],

1	33	CD	NUMBER	33	_	0	SENT_334	[p17l295t3035r359b3198],
2	"	``	O	"	punct	3	SENT_334	[p17l295t3035r359b3198],
3	z.	NN	O	z.	dep	1	SENT_334	[p17l297t3214r359b3275],
4	=	JJ	O	=	amod	6	SENT_334	[p17l293t3303r343b3578],
5	83o	CD	NUMBER	83o	tmod	4	SENT_334	[p17l293t3303r343b3578],
6	_	NN	O	_	dep	3	SENT_334	[p17l293t3303r343b3578],
7	.	.	O	.	_	0	SENT_334	[p17l293t3303r343b3578],

1	_	NN	O	_	_	0	SENT_335	[p17l293t3303r343b3578],
2	.	.	O	.	_	0	SENT_335	[p17l293t3303r343b3578],

1	_	NN	O	_	_	0	SENT_336	[p17l293t3303r343b3578],
2	.	.	O	.	_	0	SENT_336	[p17l297t3736r359b3834],

1	_	NN	O	_	_	0	SENT_337	[p17l297t3736r359b3834],
2	.	.	O	.	_	0	SENT_337	[p17l297t3736r359b3834],

1	:	:	O	:	_	0	SENT_338	[p17l297t3736r359b3834],
2	_	NN	O	_	nn	3	SENT_338	[p17l297t3736r359b3834],
3	osmm	NN	O	osmm	_	0	SENT_338	[p17l217t603r266b741],
4	_	CD	NUMBER	_	num	5	SENT_338	[p17l216t770r266b966],
5	u.	NN	O	u.	dep	3	SENT_338	[p17l216t770r266b966],
6	_	JJ	O	_	amod	8	SENT_338	[p17l216t770r266b966],
7	mNa	NN	O	mna	nn	8	SENT_338	[p17l216t770r266b966],
8	_	NN	O	_	dep	5	SENT_338	[p17l216t770r266b966],
9	.	.	O	.	_	0	SENT_338	[p17l216t770r266b966],

1	_	NN	O	_	_	0	SENT_339	[p17l216t770r266b966],
2	n_aE_x	NN	O	n_ae_x	nn	3	SENT_339	[p17l216t1117r267b1417],
3	_	NN	O	_	dep	1	SENT_339	[p17l216t1117r267b1417],
4	.	.	O	.	_	0	SENT_339	[p17l216t1117r267b1417],

1	:	:	O	:	_	0	SENT_340	[p17l216t1117r267b1417],
2	.	.	O	.	_	0	SENT_340	[p17l216t1117r267b1417],

1	mU	NN	O	mu	nn	2	SENT_341	[p17l216t1117r267b1417],
2	o	NN	O	o	dep	3	SENT_341	[p17l217t1545r282b1849],
3	>	JJR	O	>	_	0	SENT_341	[p17l217t1545r282b1849],
4	_	CD	NUMBER	_	num	6	SENT_341	[p17l217t1545r282b1849],
5	tOQn	NN	O	toqn	nn	6	SENT_341	[p17l217t1545r282b1849],
6	_	NN	O	_	dep	3	SENT_341	[p17l217t1545r282b1849],
7	:	:	O	:	_	0	SENT_341	[p17l217t1545r282b1849],
8	W	NNP	O	W	dep	3	SENT_341	[p17l217t1545r282b1849],
9	“	CD	NUMBER	“	num	8	SENT_341	[p17l220t1869r266b1987],
10	mum	JJ	O	mum	amod	14	SENT_341	[p17l220t1869r266b1987],
11	o_ua	NN	O	o_ua	nn	14	SENT_341	[p17l217t2554r266b2692],
12	~	NN	O	~	nn	14	SENT_341	[p17l217t2554r266b2692],
13	_	NN	O	_	nn	14	SENT_341	[p17l217t2554r266b2692],
14	m	NN	O	m	dep	8	SENT_341	[p17l216t2720r266b2916],
15	:	:	O	:	_	0	SENT_341	[p17l216t2720r266b2916],
16	NNmT	NNP	O	NNmT	dep	3	SENT_341	[p17l216t2720r266b2916],
17	_	NNP	O	_	nn	18	SENT_341	[p17l216t2720r266b2916],
18	ms.	NNP	O	ms.	dep	16	SENT_341	[p17l216t3089r282b3202],
19	.	.	O	.	_	0	SENT_341	[p17l216t3089r282b3202],

1	.	.	O	.	_	0	SENT_342	[p17l216t3089r282b3202],

1	n	NN	O	n	nn	4	SENT_343	[p17l216t3226r267b3527],
2	_	CD	NUMBER	_	num	4	SENT_343	[p17l216t3226r267b3527],
3	~	NN	O	~	nn	4	SENT_343	[p17l216t3226r267b3527],
4	E_x3mU	NN	O	e_x3mu	_	0	SENT_343	[p17l216t3226r267b3527],
5	ANS	NN	O	an	dep	4	SENT_343	[p17l216t3726r267b3834],
6	.	.	O	.	_	0	SENT_343	[p17l216t3726r267b3834],

1	.....	NN	O	.....	_	0	SENT_344	[p17l65t3092r113b3336],
2	.	.	O	.	_	0	SENT_344	[p17l65t3092r113b3336],

1	.	.	O	.	_	0	SENT_345	[p17l65t3092r113b3336],

1	_	NN	O	_	nn	2	SENT_346	[p17l65t3092r113b3336],
2	mu	NN	O	mu	_	0	SENT_346	[p17l65t3092r113b3336],
3	:	:	O	:	_	0	SENT_346	[p17l65t3092r113b3336],
4	aU	NNP	O	aU	nn	6	SENT_346	[p17l65t3092r113b3336],
5	_	NNP	O	_	nn	6	SENT_346	[p17l62t3357r113b3634],
6	a.	NNP	O	a.	dep	2	SENT_346	[p17l62t3357r113b3634],
7	.	.	O	.	_	0	SENT_346	[p17l62t3357r113b3634],

1	.	.	O	.	_	0	SENT_347	[p17l62t3357r113b3634],

1	um	NN	O	um	_	0	SENT_348	[p17l62t3357r113b3634],
2	.	.	O	.	_	0	SENT_348	[p17l62t3357r113b3634],

1	_	NN	O	_	_	0	SENT_349	[p17l62t3357r113b3634],
2	o_oU	NN	O	o_ou	nn	3	SENT_349	[p17l62t3357r113b3634],
3	E039	NN	O	e039	dep	1	SENT_349	[p17l71t3651r129b3834],

1	§	NN	O	§	_	0	SENT_350	[p18l2030t6r2082b166],
2	>	JJR	O	>	amod	5	SENT_350	[p18l2030t6r2082b166],
3	o	NN	O	o	nn	5	SENT_350	[p18l2030t6r2082b166],
4	__	NN	O	__	nn	5	SENT_350	[p18l2030t6r2082b166],
5	m	NN	O	m	dep	1	SENT_350	[p18l2030t6r2082b166],
6	Ho	NNP	O	Ho	dep	1	SENT_350	[p18l2040t189r2082b276],
7	:	:	O	:	_	0	SENT_350	[p18l2040t189r2082b276],
8	mm	NN	O	mm	dep	1	SENT_350	[p18l2049t304r2082b408],
9	;	:	O	;	_	0	SENT_350	[p18l2049t304r2082b408],
10	n_mE_x3mu	NN	O	n_me_x3mu	dep	8	SENT_350	[p18l2030t430r2082b715],
11	8	CD	NUMBER	8	num	10	SENT_350	[p18l2040t739r2082b793],
12	.	.	O	.	_	0	SENT_350	[p18l2034t812r2082b1092],

1	o	NN	O	o	_	0	SENT_351	[p18l2034t812r2082b1092],
2	>	JJR	O	>	amod	4	SENT_351	[p18l2034t812r2082b1092],
3	o.u.	NN	O	o.u.	nn	4	SENT_351	[p18l2034t812r2082b1092],
4	mo_U	NN	O	mo_u	dep	1	SENT_351	[p18l2034t812r2082b1092],
5	.	.	O	.	_	0	SENT_351	[p18l2035t1118r2098b1461],

1	:	:	O	:	_	0	SENT_352	[p18l2035t1118r2098b1461],
2	o	NN	O	o	nn	3	SENT_352	[p18l2035t1118r2098b1461],
3	_	NN	O	_	_	0	SENT_352	[p18l2035t1118r2098b1461],
4	.	.	O	.	_	0	SENT_352	[p18l2035t1118r2098b1461],

1	u.	NN	O	u.	_	0	SENT_353	[p18l2035t1118r2098b1461],
2	m2wo	NN	O	m2wo	dep	1	SENT_353	[p18l2035t1118r2098b1461],
3	.	.	O	.	_	0	SENT_353	[p18l2035t1118r2098b1461],

1	a	DT	O	a	det	2	SENT_354	[p18l2035t1118r2098b1461],
2	L	NN	O	l	dep	3	SENT_354	[p18l1972t6r2004b26],
3	oov	NN	O	oov	_	0	SENT_354	[p18l1953t52r2005b224],
4	...	:	O	...	_	0	SENT_354	[p18l1953t52r2005b224],
5	o	NN	O	o	dep	7	SENT_354	[p18l1953t52r2005b224],
6	omov	NN	O	omov	nn	7	SENT_354	[p18l1954t248r2005b378],
7	w	NN	O	w	parataxis	3	SENT_354	[p18l1954t400r2021b604],
8	:	:	O	:	_	0	SENT_354	[p18l1954t400r2021b604],
9	_	CD	NUMBER	_	num	12	SENT_354	[p18l1954t400r2021b604],
10	umo	NN	O	umo	nn	12	SENT_354	[p18l1954t400r2021b604],
11	_	NN	O	_	nn	12	SENT_354	[p18l1954t400r2021b604],
12	m	NN	O	m	dep	14	SENT_354	[p18l1958t632r2021b977],
13	:	:	O	:	_	0	SENT_354	[p18l1958t632r2021b977],
14	o	NN	O	o	parataxis	3	SENT_354	[p18l1958t632r2021b977],
15	:	:	O	:	_	0	SENT_354	[p18l1958t632r2021b977],
16	m	NN	O	m	dep	14	SENT_354	[p18l1958t632r2021b977],
17	>	JJR	O	>	amod	18	SENT_354	[p18l1958t632r2021b977],
18	m	NN	O	m	dep	16	SENT_354	[p18l1958t632r2021b977],
19	:	:	O	:	_	0	SENT_354	[p18l1958t632r2021b977],
20	:	:	O	:	_	0	SENT_354	[p18l1958t632r2021b977],
21	_	CD	NUMBER	_	num	24	SENT_354	[p18l1958t632r2021b977],
22	V	NN	O	v	nn	24	SENT_354	[p18l1958t632r2021b977],
23	oco_m	NN	O	oco_m	nn	24	SENT_354	[p18l1954t1006r2005b1155],
24	n_mE_x3mu	NN	O	n_me_x3mu	dep	28	SENT_354	[p18l1954t1179r2005b1464],
25	E.	NNP	O	E.	nn	28	SENT_354	[p18l1882t13r1929b69],
26	m	NN	O	m	nn	28	SENT_354	[p18l1882t94r1928b119],
27	mmmsg	NN	O	mmmsg	nn	28	SENT_354	[p18l1877t143r1944b303],
28	_	NN	O	_	parataxis	3	SENT_354	[p18l1877t333r1929b661],
29	umN_Eo_u	NN	O	umn_eo_u	dep	28	SENT_354	[p18l1877t333r1929b661],
30	:	:	O	:	_	0	SENT_354	[p18l1877t333r1929b661],
31	m	NN	O	m	dep	36	SENT_354	[p18l1877t333r1929b661],
32	;	:	O	;	_	0	SENT_354	[p18l1877t333r1929b661],
33	m	NN	O	m	nn	36	SENT_354	[p18l1896t689r1929b715],
34	33	CD	NUMBER	33	num	36	SENT_354	[p18l1896t741r1929b845],
35	_	NN	O	_	nn	36	SENT_354	[p18l1877t869r1929b972],
36	m	NN	O	m	parataxis	3	SENT_354	[p18l1877t869r1929b972],
37	_	CD	NUMBER	_	dep	36	SENT_354	[p18l1877t869r1929b972],
38	:	:	O	:	_	0	SENT_354	[p18l1877t869r1929b972],
39	D.Ou-U	JJ	O	d.ou-u	amod	42	SENT_354	[p18l1881t994r1929b1336],
40	_	NN	O	_	nn	42	SENT_354	[p18l1881t994r1929b1336],
41	UZ	NN	O	uz	nn	42	SENT_354	[p18l1881t994r1929b1336],
42	m	NN	O	m	dep	36	SENT_354	[p18l1877t1364r1943b1514],
43	;	:	O	;	_	0	SENT_354	[p18l1877t1364r1943b1514],
44	.	.	O	.	_	0	SENT_354	[p18l1877t1364r1943b1514],

1	_	NN	O	_	_	0	SENT_355	[p18l1877t1364r1943b1514],
2	.	.	O	.	_	0	SENT_355	[p18l1877t1364r1943b1514],

1	_	NN	O	_	nn	2	SENT_356	[p18l1877t1364r1943b1514],
2	r	NN	O	r	_	0	SENT_356	[p18l1877t1364r1943b1514],
3	3	CD	NUMBER	3	num	6	SENT_356	[p18l1819t6r1868b63],
4	vcm	NN	O	vcm	nn	6	SENT_356	[p18l1801t92r1852b189],
5	3m_QEou	NN	O	3m_qeou	nn	6	SENT_356	[p18l1801t214r1868b471],
6	vmv	NN	O	vmv	dep	2	SENT_356	[p18l1801t497r1852b730],
7	:	:	O	:	_	0	SENT_356	[p18l1801t497r1852b730],
8	_	CD	NUMBER	_	num	9	SENT_356	[p18l1801t497r1852b730],
9	u	NN	O	u	dep	2	SENT_356	[p18l1801t497r1852b730],
10	:	:	O	:	_	0	SENT_356	[p18l1801t497r1852b730],
11	_	CD	NUMBER	_	num	13	SENT_356	[p18l1801t497r1852b730],
12	BS	NN	O	b	nn	13	SENT_356	[p18l1811t755r1852b856],
13	mm	NN	O	mm	dep	9	SENT_356	[p18l1819t882r1868b1132],
14	:	:	O	:	_	0	SENT_356	[p18l1819t882r1868b1132],
15	on_m2	CD	NUMBER	on_m2	num	17	SENT_356	[p18l1819t882r1868b1132],
16	__	CD	NUMBER	__	num	17	SENT_356	[p18l1801t1162r1852b1340],
17	2m	NN	O	2m	dep	2	SENT_356	[p18l1801t1162r1852b1340],
18	>	JJR	O	>	amod	21	SENT_356	[p18l1801t1162r1852b1340],
19	o	NN	O	o	nn	21	SENT_356	[p18l1801t1162r1852b1340],
20	mr	NN	O	mr	nn	21	SENT_356	[p18l1801t1364r1852b1466],
21	_	NN	O	_	dep	17	SENT_356	[p18l1801t1364r1852b1466],
22	.	.	O	.	_	0	SENT_356	[p18l1801t1364r1852b1466],

1	_	NN	O	_	_	0	SENT_357	[p18l1801t1364r1852b1466],
2	.	.	O	.	_	0	SENT_357	[p18l1801t1364r1852b1466],

1	@	SYM	O	@	_	0	SENT_358	[p18l1801t1493r1868b1515],

1	8	CD	NUMBER	8	num	2	SENT_359	[p18l1743t6r1776b57],
2	cm	NN	O	cm	_	0	SENT_359	[p18l1743t83r1776b144],
3	53	CD	NUMBER	53	num	5	SENT_359	[p18l1724t171r1776b285],
4	>	JJR	O	>	amod	5	SENT_359	[p18l1724t171r1776b285],
5	mmmmmﬁ	NN	O	mmmmmﬁ	dep	2	SENT_359	[p18l1724t306r1776b512],
6	u	NN	O	u	nn	7	SENT_359	[p18l1729t535r1776b823],
7	_	NN	O	_	dep	5	SENT_359	[p18l1729t535r1776b823],
8	.	.	O	.	_	0	SENT_359	[p18l1729t535r1776b823],

1	.	.	O	.	_	0	SENT_360	[p18l1729t535r1776b823],

1	$	$	MONEY	$	_	0	SENT_361	[p18l1729t535r1776b823],
2	m3mE	JJ	MONEY	m3me	dep	1	SENT_361	[p18l1729t535r1776b823],
3	.	.	O	.	_	0	SENT_361	[p18l1724t847r1776b924],

1	o	NN	O	o	_	0	SENT_362	[p18l1724t847r1776b924],
2	»	NN	O	»	dep	1	SENT_362	[p18l1724t847r1776b924],
3	.	.	O	.	_	0	SENT_362	[p18l1724t847r1776b924],

1	EmE	NNP	O	EmE	_	0	SENT_363	[p18l1724t945r1776b1292],
2	.	.	O	.	_	0	SENT_363	[p18l1724t945r1776b1292],

1	.	.	O	.	_	0	SENT_364	[p18l1724t945r1776b1292],

1	m2Co	NN	O	m2co	nn	2	SENT_365	[p18l1724t945r1776b1292],
2	cc	NN	O	cc	_	0	SENT_365	[p18l1724t1316r1776b1410],
3	:	:	O	:	_	0	SENT_365	[p18l1724t1316r1776b1410],
4	m	NN	O	m	nn	5	SENT_365	[p18l1743t1437r1776b1463],
5	mm	NN	O	mm	dep	2	SENT_365	[p18l1653t6r1699b56],
6	3	CD	NUMBER	3	number	8	SENT_365	[p18l1648t78r1715b135],
7	_	NN	O	_	dep	8	SENT_365	[p18l1647t164r1699b396],
8	um	NN	O	um	amod	5	SENT_365	[p18l1647t164r1699b396],
9	>>	NN	O	>>	prep	5	SENT_365	[p18l1647t164r1699b396],
10	o	NN	O	o	nn	12	SENT_365	[p18l1647t164r1699b396],
11	__	CD	NUMBER	__	num	12	SENT_365	[p18l1647t164r1699b396],
12	o.	NN	O	o.	dep	9	SENT_365	[p18l1647t164r1699b396],
13	_	CD	NUMBER	_	num	12	SENT_365	[p18l1647t164r1699b396],
14	BEE	NN	O	bee	nn	17	SENT_365	[p18l1658t416r1699b576],
15	2.2.3	CD	NUMBER	2.2.3	num	17	SENT_365	[p18l1666t602r1715b786],
16	.3	NN	NUMBER	.3	nn	17	SENT_365	[p18l1666t808r1715b894],
17	mc	NN	O	mc	dep	5	SENT_365	[p18l1666t920r1715b1005],
18	:	:	O	:	_	0	SENT_365	[p18l1666t920r1715b1005],
19	oovmo	NN	O	oovmo	nn	21	SENT_365	[p18l1647t1031r1699b1203],
20	wmov	NN	O	wmov	nn	21	SENT_365	[p18l1648t1226r1699b1357],
21	m	NN	O	m	dep	5	SENT_365	[p18l1653t1379r1715b1461],
22	:	:	O	:	_	0	SENT_365	[p18l1653t1379r1715b1461],
23	_	CD	NUMBER	_	dep	21	SENT_365	[p18l1653t1379r1715b1461],
24	we	PRP	O	we	nsubj	25	SENT_365	[p18l1590t6r1639b88],
25	oow	VBP	O	oow	rcmod	23	SENT_365	[p18l1575t114r1623b213],
26	mo	NN	DURATION	mo	nn	28	SENT_365	[p18l1571t226r1623b286],
27	mmo_o	NN	O	mmo_o	nn	28	SENT_365	[p18l1571t309r1623b440],
28	w	NN	O	w	dobj	25	SENT_365	[p18l1571t462r1639b666],
29	:	:	O	:	_	0	SENT_365	[p18l1571t462r1639b666],
30	__	CD	NUMBER	__	num	33	SENT_365	[p18l1571t462r1639b666],
31	omo	NN	O	omo	nn	33	SENT_365	[p18l1571t462r1639b666],
32	_	NN	O	_	nn	33	SENT_365	[p18l1571t462r1639b666],
33	m	NN	O	m	dep	2	SENT_365	[p18l1576t694r1638b1039],
34	:	:	O	:	_	0	SENT_365	[p18l1576t694r1638b1039],
35	o	NN	O	o	dep	33	SENT_365	[p18l1576t694r1638b1039],
36	:	:	O	:	_	0	SENT_365	[p18l1576t694r1638b1039],
37	m	NN	O	m	dep	33	SENT_365	[p18l1576t694r1638b1039],
38	>	JJR	O	>	amod	39	SENT_365	[p18l1576t694r1638b1039],
39	m	NN	O	m	dep	37	SENT_365	[p18l1576t694r1638b1039],
40	:	:	O	:	_	0	SENT_365	[p18l1576t694r1638b1039],
41	:	:	O	:	_	0	SENT_365	[p18l1576t694r1638b1039],
42	_	CD	NUMBER	_	dep	33	SENT_365	[p18l1576t694r1638b1039],
43	v	LS	O	v	prep	42	SENT_365	[p18l1576t694r1638b1039],
44	m	NN	O	m	dep	43	SENT_365	[p18l1571t1068r1623b1216],
45	:	:	O	:	_	0	SENT_365	[p18l1571t1068r1623b1216],
46	o_m	NN	O	o_m	nn	47	SENT_365	[p18l1571t1068r1623b1216],
47	n_mE_x_3	NN	O	n_me_x_3	dep	33	SENT_365	[p18l1571t1241r1623b1466],
48	_	CD	NUMBER	_	num	49	SENT_365	[p18l1499t6r1562b129],
49	Om_V	NN	O	om_v	tmod	47	SENT_365	[p18l1499t6r1562b129],
50	\	CD	MONEY	\	num	51	SENT_365	[p18l1495t157r1562b407],
51	€	NN	MONEY	€	npadvmod	52	SENT_365	[p18l1495t157r1562b407],
52	on	IN	O	on	advmod	49	SENT_365	[p18l1495t157r1562b407],
53	:	:	O	:	_	0	SENT_365	[p18l1495t157r1562b407],
54	E	NN	O	e	dep	33	SENT_365	[p18l1495t157r1562b407],
55	<	JJR	O	<	amod	60	SENT_365	[p18l1495t157r1562b407],
56	n_mE_x3wU	CD	NUMBER	n_me_x3wu	number	57	SENT_365	[p18l1495t429r1546b724],
57	53	CD	NUMBER	53	num	58	SENT_365	[p18l1495t751r1546b865],
58	>	JJR	O	>	npadvmod	59	SENT_365	[p18l1495t751r1546b865],
59	>	JJR	O	>	amod	60	SENT_365	[p18l1495t885r1562b1151],
60	mo_ou	NN	O	mo_ou	dep	54	SENT_365	[p18l1495t885r1562b1151],
61	:	:	O	:	_	0	SENT_365	[p18l1495t885r1562b1151],
62	O	NN	O	o	nn	67	SENT_365	[p18l1495t885r1562b1151],
63	_	NN	O	_	nn	67	SENT_365	[p18l1495t1178r1546b1336],
64	m	NN	O	m	nn	67	SENT_365	[p18l1495t1178r1546b1336],
65	>>	CD	NUMBER	>>	num	67	SENT_365	[p18l1495t1178r1546b1336],
66	om	NN	O	om	nn	67	SENT_365	[p18l1495t1178r1546b1336],
67	_	NN	O	_	dep	33	SENT_365	[p18l1495t1178r1546b1336],
68	or	CC	O	or	_	0	SENT_365	[p18l1495t1364r1562b1514],
69	_	NN	O	_	dep	33	SENT_365	[p18l1495t1364r1562b1514],
70	.	.	O	.	_	0	SENT_365	[p18l1495t1364r1562b1514],

1	_	NN	O	_	_	0	SENT_366	[p18l1495t1364r1562b1514],
2	.	.	O	.	_	0	SENT_366	[p18l1495t1364r1562b1514],

1	nw	NN	O	nw	nn	7	SENT_367	[p18l1495t1364r1562b1514],
2	vm	NN	O	vm	nn	7	SENT_367	[p18l1418t6r1470b211],
3	>>	NN	O	>>	nn	7	SENT_367	[p18l1418t6r1470b211],
4	o	NN	O	o	nn	7	SENT_367	[p18l1418t6r1470b211],
5	__	NN	O	__	nn	7	SENT_367	[p18l1418t6r1470b211],
6	m	NN	O	m	nn	7	SENT_367	[p18l1418t6r1470b211],
7	mm	NN	O	mm	_	0	SENT_367	[p18l1437t236r1470b340],
8	;	:	O	;	_	0	SENT_367	[p18l1437t236r1470b340],
9	_	NN	O	_	dep	7	SENT_367	[p18l1423t365r1470b637],
10	.	.	O	.	_	0	SENT_367	[p18l1423t365r1470b637],

1	_	NN	O	_	nn	2	SENT_368	[p18l1423t365r1470b637],
2	muBo	NN	O	mubo	_	0	SENT_368	[p18l1423t365r1470b637],
3	:	:	O	:	_	0	SENT_368	[p18l1423t365r1470b637],
4	:	:	O	:	_	0	SENT_368	[p18l1423t365r1470b637],
5	_	NN	O	_	nn	6	SENT_368	[p18l1423t365r1470b637],
6	m	NN	O	m	dep	2	SENT_368	[p18l1418t664r1485b775],
7	:	:	O	:	_	0	SENT_368	[p18l1418t664r1485b775],
8	_	VB	O	_	dep	2	SENT_368	[p18l1418t664r1485b775],
9	a	DT	O	a	det	13	SENT_368	[p18l1418t664r1485b775],
10	n_mE_x3mu	NN	O	n_me_x3mu	nn	13	SENT_368	[p18l1418t802r1470b1087],
11	B	NN	O	b	nn	13	SENT_368	[p18l1428t1111r1470b1164],
12	_	NN	O	_	nn	13	SENT_368	[p18l1423t1184r1470b1463],
13	m	NN	O	m	nsubj	14	SENT_368	[p18l1423t1184r1470b1463],
14	>	JJR	O	>	xcomp	8	SENT_368	[p18l1423t1184r1470b1463],
15	o.u.	CD	NUMBER	o.u.	num	17	SENT_368	[p18l1423t1184r1470b1463],
16	mo.	NN	O	mo.	nn	17	SENT_368	[p18l1423t1184r1470b1463],
17	u	NN	O	u	nsubj	8	SENT_368	[p18l1423t1184r1470b1463],
18	.	.	O	.	_	0	SENT_368	[p18l1423t1482r1486b1514],

1	_	NN	O	_	_	0	SENT_369	[p18l1423t1482r1486b1514],
2	.	.	O	.	_	0	SENT_369	[p18l1423t1482r1486b1514],

1	8	CD	NUMBER	8	num	2	SENT_370	[p18l1341t6r1409b224],
2	_	NN	O	_	_	0	SENT_370	[p18l1341t6r1409b224],
3	...	:	O	...	_	0	SENT_370	[p18l1341t6r1409b224],
4	_	CD	NUMBER	_	num	6	SENT_370	[p18l1341t6r1409b224],
5	cw_m	NN	O	cw_m	nn	6	SENT_370	[p18l1341t6r1409b224],
6	#o	NN	O	#o	dep	2	SENT_370	[p18l1352t248r1393b335],
7	:	:	O	:	_	0	SENT_370	[p18l1352t248r1393b335],
8	m2	NN	O	m2	nn	9	SENT_370	[p18l1346t363r1393b440],
9	ccm	NN	O	ccm	dep	6	SENT_370	[p18l1342t471r1393b569],
10	.	.	O	.	_	0	SENT_370	[p18l1342t596r1402b812],

1	_	NN	O	_	nn	2	SENT_371	[p18l1342t596r1402b812],
2	m	NN	O	m	dep	3	SENT_371	[p18l1342t596r1402b812],
3	>	JJR	O	>	_	0	SENT_371	[p18l1342t596r1402b812],
4	.	.	O	.	_	0	SENT_371	[p18l1342t596r1402b812],

1	_	NN	O	_	nn	2	SENT_372	[p18l1342t596r1402b812],
2	B	NN	O	b	_	0	SENT_372	[p18l1342t596r1402b812],
3	:	:	O	:	_	0	SENT_372	[p18l1342t596r1402b812],
4	_	CD	NUMBER	_	num	6	SENT_372	[p18l1342t596r1402b812],
5	oucmnmcou	NN	O	oucmnmcou	nn	6	SENT_372	[p18l1341t838r1393b1140],
6	m3o	NN	O	m3o	dep	2	SENT_372	[p18l1342t1165r1393b1384],
7	:	:	O	:	_	0	SENT_372	[p18l1342t1165r1393b1384],
8	m_u	FW	O	m_u	nn	10	SENT_372	[p18l1342t1165r1393b1384],
9	_	FW	O	_	nn	10	SENT_372	[p18l1346t1412r1393b1463],
10	U	NN	O	u	dep	6	SENT_372	[p18l1346t1412r1393b1463],
11	.	.	O	.	_	0	SENT_372	[p18l1347t1485r1376b1516],

1	,	,	O	,	_	0	SENT_373	[p18l1347t1485r1376b1516],
2	_	NN	O	_	_	0	SENT_373	[p18l1347t1485r1376b1516],
3	.	.	O	.	_	0	SENT_373	[p18l1347t1485r1376b1516],

1	.	.	O	.	_	0	SENT_374	[p18l1347t1485r1376b1516],

1	AOEV	NN	ORGANIZATION	aoev	nn	3	SENT_375	[p18l1173t664r1236b791],
2	_	NN	O	_	nn	3	SENT_375	[p18l1169t820r1220b1027],
3	m	NN	O	m	_	0	SENT_375	[p18l1169t820r1220b1027],
4	>	JJR	O	>	dep	3	SENT_375	[p18l1169t820r1220b1027],
5	_	CD	NUMBER	_	num	7	SENT_375	[p18l1169t820r1220b1027],
6	>	JJR	O	>	amod	7	SENT_375	[p18l1169t820r1220b1027],
7	Sm	NN	O	sm	dep	4	SENT_375	[p18l1169t820r1220b1027],
8	__	NN	O	__	nn	9	SENT_375	[p18l1169t1052r1220b1231],
9	m	NN	O	m	dep	3	SENT_375	[p18l1169t1052r1220b1231],
10	$	$	MONEY	$	amod	9	SENT_375	[p18l1169t1052r1220b1231],
11	>	JJR	MONEY	>	dep	10	SENT_375	[p18l1169t1052r1220b1231],
12	o	NN	O	o	dep	10	SENT_375	[p18l1169t1052r1220b1231],
13	:	:	O	:	_	0	SENT_375	[p18l1169t1254r1220b1456],
14	m_Um	NN	O	m_um	dep	15	SENT_375	[p18l1169t1254r1220b1456],
15	_	NN	O	_	amod	16	SENT_375	[p18l1169t1254r1220b1456],
16	>	JJR	O	>	dep	9	SENT_375	[p18l1169t1254r1220b1456],
17	_	CD	NUMBER	_	num	20	SENT_375	[p18l1169t1254r1220b1456],
18	A95	NN	O	a95	nn	20	SENT_375	[p18l1064t390r1127b516],
19	_	NN	O	_	nn	20	SENT_375	[p18l1059t546r1111b752],
20	m	NN	O	m	dep	16	SENT_375	[p18l1059t546r1111b752],
21	>	JJR	O	>	dep	3	SENT_375	[p18l1059t546r1111b752],
22	_	CD	NUMBER	_	num	23	SENT_375	[p18l1059t546r1111b752],
23	>	JJR	O	>	dep	21	SENT_375	[p18l1059t546r1111b752],
24	.	.	O	.	_	0	SENT_375	[p18l1059t546r1111b752],

1	:	:	O	:	_	0	SENT_376	[p18l1059t546r1111b752],
2	m	NN	O	m	nn	3	SENT_376	[p18l1059t546r1111b752],
3	mm	NN	O	mm	nsubj	7	SENT_376	[p18l1059t774r1127b1228],
4	¢	SYM	O	¢	dep	7	SENT_376	[p18l1059t774r1127b1228],
5	-	:	O	-	_	0	SENT_376	[p18l1059t774r1127b1228],
6	:	:	O	:	_	0	SENT_376	[p18l1059t774r1127b1228],
7	o_mm2wo	NN	O	o_mm2wo	_	0	SENT_376	[p18l1059t774r1127b1228],
8	.	.	O	.	_	0	SENT_376	[p18l1059t774r1127b1228],

1	n	NN	O	n	_	0	SENT_377	[p18l1059t774r1127b1228],
2	_	CD	NUMBER	_	num	1	SENT_377	[p18l1059t774r1127b1228],
3	:	:	O	:	_	0	SENT_377	[p18l1060t1254r1111b1456],
4	m	NN	O	m	nn	7	SENT_377	[p18l1060t1254r1111b1456],
5	__	CD	NUMBER	__	num	7	SENT_377	[p18l1060t1254r1111b1456],
6	um	NN	O	um	nn	7	SENT_377	[p18l1060t1254r1111b1456],
7	_	NN	O	_	dep	11	SENT_377	[p18l1060t1254r1111b1456],
8	>	JJR	O	>	dep	7	SENT_377	[p18l1060t1254r1111b1456],
9	_	CD	NUMBER	_	num	10	SENT_377	[p18l1060t1254r1111b1456],
10	fﬁv	NN	O	fﬁv	dep	11	SENT_377	[p18l950t717r1018b840],
11	B2	NN	O	b2	dep	14	SENT_377	[p18l960t866r1002b966],
12	mm	NN	O	mm	dep	11	SENT_377	[p18l969t990r1017b1240],
13	:	:	O	:	_	0	SENT_377	[p18l969t990r1017b1240],
14	on	IN	O	on	dep	1	SENT_377	[p18l969t990r1017b1240],
15	_	NN	O	_	pobj	14	SENT_377	[p18l969t990r1017b1240],
16	.	.	O	.	_	0	SENT_377	[p18l969t990r1017b1240],

1	u.	NN	O	u.	_	0	SENT_378	[p18l969t990r1017b1240],
2	2	CD	NUMBER	2	number	3	SENT_378	[p18l969t990r1017b1240],
3	__	CD	NUMBER	__	num	5	SENT_378	[p18l950t1267r1002b1460],
4	m.	NN	NUMBER	m.	nn	5	SENT_378	[p18l950t1267r1002b1460],
5	m	NN	O	m	dep	1	SENT_378	[p18l950t1267r1002b1460],
6	>	JJR	O	>	amod	8	SENT_378	[p18l950t1267r1002b1460],
7	O	NN	O	o	nn	8	SENT_378	[p18l950t1267r1002b1460],
8	__	NN	O	__	dep	5	SENT_378	[p18l841t947r908b1097],
9	.	.	O	.	_	0	SENT_378	[p18l841t947r908b1097],

1	_	NN	O	_	nsubj	3	SENT_379	[p18l841t947r908b1097],
2	~	CD	NUMBER	~	dep	3	SENT_379	[p18l841t947r908b1097],
3	_	NN	O	_	_	0	SENT_379	[p18l841t947r908b1097],
4	:	:	O	:	_	0	SENT_379	[p18l841t947r908b1097],
5	:	:	O	:	_	0	SENT_379	[p18l845t1115r893b1457],
6	.	.	O	.	_	0	SENT_379	[p18l845t1115r893b1457],

1	ou-u_uz	JJ	O	ou-u_uz	amod	3	SENT_380	[p18l845t1115r893b1457],
2	m.o	NN	O	m.o	nn	3	SENT_380	[p18l737t26r784b104],
3	A95	NN	O	a95	_	0	SENT_380	[p18l737t664r800b790],
4	_	NN	O	_	nn	5	SENT_380	[p18l732t820r783b1027],
5	m	NN	O	m	dep	3	SENT_380	[p18l732t820r783b1027],
6	>	JJR	O	>	rcmod	5	SENT_380	[p18l732t820r783b1027],
7	_	CD	NUMBER	_	npadvmod	8	SENT_380	[p18l732t820r783b1027],
8	>	JJR	O	>	dep	6	SENT_380	[p18l732t820r783b1027],
9	:	:	O	:	_	0	SENT_380	[p18l732t820r783b1027],
10	.	.	O	.	_	0	SENT_380	[p18l732t820r783b1027],

1	_	NN	O	_	nn	4	SENT_381	[p18l732t820r783b1027],
2	m	NN	O	m	nn	4	SENT_381	[p18l732t820r783b1027],
3	__	NN	O	__	nn	4	SENT_381	[p18l732t1052r783b1231],
4	m	NN	O	m	nsubj	7	SENT_381	[p18l732t1052r783b1231],
5	$	$	MONEY	$	amod	4	SENT_381	[p18l732t1052r783b1231],
6	>	JJR	MONEY	>	dep	5	SENT_381	[p18l732t1052r783b1231],
7	o	NN	O	o	_	0	SENT_381	[p18l732t1052r783b1231],
8	:	:	O	:	_	0	SENT_381	[p18l732t1254r783b1456],
9	m_vm	VB	O	m_vm	ccomp	7	SENT_381	[p18l732t1254r783b1456],
10	_	NN	O	_	nsubj	11	SENT_381	[p18l732t1254r783b1456],
11	>	JJR	O	>	xcomp	9	SENT_381	[p18l732t1254r783b1456],
12	_	CD	NUMBER	_	num	14	SENT_381	[p18l732t1254r783b1456],
13	ma	NN	O	ma	nn	14	SENT_381	[p18l628t29r674b101],
14	A95	NN	O	a95	dep	9	SENT_381	[p18l628t530r690b656],
15	coﬁmﬂwoa	NN	O	coﬁmﬂwoa	prep	14	SENT_381	[p18l628t686r691b1011],
16	8	CD	NUMBER	8	dep	15	SENT_381	[p18l633t1035r674b1089],
17	.	.	O	.	_	0	SENT_381	[p18l633t1035r674b1089],

1	2	CD	NUMBER	2	_	0	SENT_382	[p18l628t1108r674b1232],
2	:	:	O	:	_	0	SENT_382	[p18l628t1108r674b1232],
3	:	:	O	:	_	0	SENT_382	[p18l628t1108r674b1232],
4	:	:	O	:	_	0	SENT_382	[p18l623t1254r674b1456],
5	m_vm	VB	O	m_vm	dep	1	SENT_382	[p18l623t1254r674b1456],
6	_	NN	O	_	amod	11	SENT_382	[p18l623t1254r674b1456],
7	>	JJR	O	>	dep	6	SENT_382	[p18l623t1254r674b1456],
8	_	CD	NUMBER	_	number	10	SENT_382	[p18l623t1254r674b1456],
9	w.	NN	O	w.	dep	10	SENT_382	[p18l518t26r566b135],
10	oH	NN	O	oh	amod	11	SENT_382	[p18l518t26r566b135],
11	fnxov	NN	O	fnxov	nsubj	20	SENT_382	[p18l514t717r581b840],
12	BS	NN	O	b	nn	13	SENT_382	[p18l524t866r565b966],
13	mmcogmme	NN	O	mmcogmme	npadvmod	17	SENT_382	[p18l532t990r581b1240],
14	__	CD	NUMBER	__	number	16	SENT_382	[p18l515t1266r565b1460],
15	m.	NN	NUMBER	m.	dep	16	SENT_382	[p18l515t1266r565b1460],
16	m	NN	O	m	amod	13	SENT_382	[p18l515t1266r565b1460],
17	>	JJR	PERCENT	>	amod	11	SENT_382	[p18l515t1266r565b1460],
18	O	CD	PERCENT	o	number	19	SENT_382	[p18l515t1266r565b1460],
19	%	NN	PERCENT	%	amod	11	SENT_382	[p18l405t1111r472b1256],
20	_	NN	O	_	ccomp	5	SENT_382	[p18l405t1111r472b1256],
21	=	JJ	O	=	amod	24	SENT_382	[p18l405t1111r472b1256],
22	n	NN	O	n	nn	24	SENT_382	[p18l410t1273r456b1314],
23	_	VBG	O	_	amod	24	SENT_382	[p18l410t1273r456b1314],
24	zom	NN	O	zom	dobj	20	SENT_382	[p18l409t1326r456b1458],
25	:	:	O	:	_	0	SENT_382	[p18l297t6r342b62],
26	u	NN	O	u	dep	24	SENT_382	[p18l318t76r335b111],
27	2	CD	NUMBER	2	num	26	SENT_382	[p18l297t127r359b188],
28	.	.	O	.	_	0	SENT_382	[p18l297t127r359b188],

1	...	:	O	...	_	0	SENT_383	[p18l292t1237r344b1463],
2	_	NN	O	_	_	0	SENT_383	[p18l292t1237r344b1463],
3	.	.	O	.	_	0	SENT_383	[p18l292t1237r344b1463],

1	_	NN	O	_	nn	2	SENT_384	[p18l292t1237r344b1463],
2	~	NN	O	~	nsubj	3	SENT_384	[p18l292t1237r344b1463],
3	_	VBD	O	_	_	0	SENT_384	[p18l292t1237r344b1463],
4	a	DT	O	a	det	5	SENT_384	[p18l292t1237r344b1463],
5	>	JJR	O	>	dobj	3	SENT_384	[p18l292t1237r344b1463],

1	__	NN	O	__	nn	2	SENT_385	[p18l217t6r266b198],
2	x3mU	NN	O	x3mu	_	0	SENT_385	[p18l217t6r266b198],

1	_	NN	O	_	_	0	SENT_386	[p18l61t6r129b538],
2	.	.	O	.	_	0	SENT_386	[p18l61t6r129b538],

1	.6	NN	NUMBER	.6	_	0	SENT_387	[p18l61t6r129b538],
2	m	NN	O	m	nn	3	SENT_387	[p18l61t6r129b538],
3	_	NN	O	_	dep	1	SENT_387	[p18l61t6r129b538],
4	.	.	O	.	_	0	SENT_387	[p18l61t6r129b538],

1	EEmﬁoEm	NN	O	eemﬁoem	_	0	SENT_388	[p18l61t6r129b538],
2	;	:	O	;	_	0	SENT_388	[p18l61t6r129b538],
3	U	NNP	O	U	dep	1	SENT_388	[p18l61t6r129b538],
4	:	:	O	:	_	0	SENT_388	[p18l63t559r112b606],
5	_	CD	NUMBER	_	num	6	SENT_388	[p18l63t559r112b606],
6	n_mE_x3mU	NN	O	n_me_x3mu	dep	3	SENT_388	[p18l61t626r113b997],
7	.	.	O	.	_	0	SENT_388	[p18l61t626r113b997],

1	+	CC	O	+	cc	2	SENT_389	[p18l61t626r113b997],
2	o	NN	O	o	_	0	SENT_389	[p18l61t626r113b997],
3	»	CD	NUMBER	»	num	5	SENT_389	[p18l61t1014r129b1223],
4	uau	NN	O	uau	nn	5	SENT_389	[p18l61t1014r129b1223],
5	_	NN	O	_	dep	2	SENT_389	[p18l61t1014r129b1223],
6	.	.	O	.	_	0	SENT_389	[p18l61t1014r129b1223],

1	¢	NN	O	¢	_	0	SENT_390	[p18l61t1014r129b1223],
2	m	NN	O	m	nn	3	SENT_390	[p18l61t1014r129b1223],
3	_	NN	O	_	dep	1	SENT_390	[p18l61t1014r129b1223],
4	.	.	O	.	_	0	SENT_390	[p18l67t1248r113b1295],

1	v	LS	O	v	dep	2	SENT_391	[p18l67t1248r113b1295],
2	w_n_m	NN	O	w_n_m	_	0	SENT_391	[p18l62t1312r113b1463],
3	.	.	O	.	_	0	SENT_391	[p18l62t1312r113b1463],

1	_	NN	O	_	_	0	SENT_392	[p18l62t1312r113b1463],
2	.	.	O	.	_	0	SENT_392	[p18l62t1312r113b1463],

1	N	NN	O	n	nn	3	SENT_393	[p18l522t1604r535b1619],
2	ENGLJ	NN	O	englj	nn	3	SENT_393	[p18l550t1604r628b1626],
3	MED	NN	O	med	_	0	SENT_393	[p18l643t1604r695b1619],
4	358	CD	NUMBER	358	dep	3	SENT_393	[p18l705t1598r773b1626],
5	;	:	O	;	_	0	SENT_393	[p18l705t1598r773b1626],
6	11	CD	NUMBER	11	num	7	SENT_393	[p18l705t1598r773b1626],
7	WWW	NNP	O	WWW	dep	3	SENT_393	[p18l809t1604r1010b1626],
8	,	,	O	,	_	0	SENT_393	[p18l809t1604r1010b1626],
9	NEJM.ORG	NNP	O	NEJM.ORG	nn	10	SENT_393	[p18l809t1604r1010b1626],
10	MARCH	NNP	DATE	MARCH	appos	7	SENT_393	[p18l1047t1604r1132b1619],
11	13	CD	DATE	13	num	10	SENT_393	[p18l1147t1604r1178b1626],
12	,	,	DATE	,	_	0	SENT_393	[p18l1147t1604r1178b1626],
13	2008	CD	DATE	2008	num	10	SENT_393	[p18l1189t1598r1252b1620],
14	The	DT	O	the	det	17	SENT_393	[p18l702t1637r753b1661],
15	New	NNP	O	New	nn	17	SENT_393	[p18l762t1638r824b1661],
16	England	NNP	O	England	nn	17	SENT_393	[p18l833t1637r944b1668],
17	Journal	NNP	O	Journal	dep	3	SENT_393	[p18l952t1637r1050b1661],
18	of	IN	O	of	_	0	SENT_393	[p18l1059t1637r1088b1661],
19	Medicine	NNP	O	Medicine	prep_of	17	SENT_393	[p18l1095t1637r1220b1661],

1	Downloaded	VBN	O	download	_	0	SENT_394	[p18l144t1678r314b1701],
2	from	IN	O	from	_	0	SENT_394	[p18l323t1678r387b1701],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_394	[p18l396t1678r514b1708],
4	at	IN	O	at	_	0	SENT_394	[p18l524t1682r547b1701],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_394	[p18l556t1678r738b1701],
6	on	IN	O	on	_	0	SENT_394	[p18l748t1685r780b1701],
7	January	NNP	DATE	January	prep_on	1	SENT_394	[p18l789t1678r892b1708],
8	5	CD	DATE	5	num	7	SENT_394	[p18l902t1678r924b1706],
9	,	,	DATE	,	_	0	SENT_394	[p18l902t1678r924b1706],
10	2014	CD	DATE	2014	num	7	SENT_394	[p18l935t1678r1007b1701],
11	.	.	O	.	_	0	SENT_394	[p18l935t1678r1007b1701],

1	For	IN	O	for	_	0	SENT_395	[p18l1018t1678r1064b1701],
2	personal	JJ	O	personal	amod	3	SENT_395	[p18l1072t1678r1184b1708],
3	use	NN	O	use	pobj	1	SENT_395	[p18l1194t1685r1237b1701],
4	only	RB	O	only	advmod	3	SENT_395	[p18l1247t1678r1312b1708],
5	.	.	O	.	_	0	SENT_395	[p18l1247t1678r1312b1708],

1	No	DT	O	no	det	3	SENT_396	[p18l1322t1678r1362b1701],
2	other	JJ	O	other	amod	3	SENT_396	[p18l1372t1678r1440b1701],
3	uses	NNS	O	use	_	0	SENT_396	[p18l1448t1685r1504b1701],
4	without	IN	O	without	_	0	SENT_396	[p18l1515t1678r1616b1701],
5	permission	NN	O	permission	prep_without	3	SENT_396	[p18l1624t1678r1776b1708],
6	.	.	O	.	_	0	SENT_396	[p18l1624t1678r1776b1708],

1	Copyright	NN	O	copyright	_	0	SENT_397	[p18l494t1719r629b1750],
2	©	CD	NUMBER	©	num	6	SENT_397	[p18l638t1719r661b1743],
3	2008	CD	DATE	2008	num	6	SENT_397	[p18l671t1719r736b1743],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_397	[p18l746t1719r937b1743],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_397	[p18l947t1719r1055b1743],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_397	[p18l1065t1719r1170b1750],
7	.	.	O	.	_	0	SENT_397	[p18l1065t1719r1170b1750],

1	All	DT	O	all	det	2	SENT_398	[p18l1181t1719r1223b1743],
2	rights	NNS	O	rights	nsubj	3	SENT_398	[p18l1232t1719r1306b1750],
3	reserved	VBN	O	reserve	_	0	SENT_398	[p18l1316t1719r1435b1743],
4	.	.	O	.	_	0	SENT_398	[p18l1316t1719r1435b1743],

1	The	DT	O	the	det	4	SENT_399	[p18l673t1825r718b1846],
2	NEW	NNP	O	NEW	nn	4	SENT_399	[p18l737t1827r822b1846],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_399	[p18l841t1827r1029b1846],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_399	[p18l1048t1827r1227b1853],
5	of	IN	O	of	_	0	SENT_399	[p18l1247t1825r1275b1852],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_399	[p18l1287t1827r1486b1846],

1	S.	NNP	O	S.	nn	4	SENT_400	[p19l2031t979r2083b1088],
2	_	NNP	O	_	nn	4	SENT_400	[p19l2031t979r2083b1088],
3	m	NN	O	m	nn	4	SENT_400	[p19l2031t979r2083b1088],
4	E	NN	O	e	_	0	SENT_400	[p19l2042t1111r2083b1160],
5	:	:	O	:	_	0	SENT_400	[p19l2033t1186r2084b1486],
6	mv_6E	NN	O	mv_6e	dep	4	SENT_400	[p19l2033t1186r2084b1486],
7	.	.	O	.	_	0	SENT_400	[p19l2033t1186r2084b1486],

1	o	NN	O	o	dep	2	SENT_401	[p19l2033t1186r2084b1486],
2	>	JJR	O	>	_	0	SENT_401	[p19l2033t1186r2084b1486],
3	:6	CD	NUMBER	:6	dep	2	SENT_401	[p19l2032t1511r2083b1638],
4	...	:	O	...	_	0	SENT_401	[p19l2032t1511r2083b1638],
5	En	IN	O	en	_	0	SENT_401	[p19l2050t1660r2083b1741],
6	Ema	NN	O	ema	prep_en	3	SENT_401	[p19l2037t1766r2083b1887],
7	.	.	O	.	_	0	SENT_401	[p19l2033t1917r2083b2078],

1	o	NN	O	o	_	0	SENT_402	[p19l2033t1917r2083b2078],
2	:	:	O	:	_	0	SENT_402	[p19l2033t1917r2083b2078],
3	o_m	NN	O	o_m	dep	1	SENT_402	[p19l2033t1917r2083b2078],
4	.	.	O	.	_	0	SENT_402	[p19l2033t2100r2099b2493],

1	€	NN	MONEY	€	nn	3	SENT_403	[p19l2033t2100r2099b2493],
2	_	CD	MONEY	_	num	3	SENT_403	[p19l2033t2100r2099b2493],
3	m.	NN	MONEY	m.	_	0	SENT_403	[p19l2033t2100r2099b2493],
4	_	CD	NUMBER	_	num	5	SENT_403	[p19l2033t2100r2099b2493],
5	m.	NN	NUMBER	m.	dep	3	SENT_403	[p19l2033t2100r2099b2493],
6	...	:	O	...	_	0	SENT_403	[p19l2033t2100r2099b2493],
7	oEmo_u	NN	O	oemo_u	nn	8	SENT_403	[p19l2033t2100r2099b2493],
8	vo	NN	O	vo	dep	9	SENT_403	[p19l2033t2519r2083b2738],
9	>	JJR	O	>	dep	3	SENT_403	[p19l2033t2519r2083b2738],
10	_	CD	NUMBER	_	num	11	SENT_403	[p19l2033t2519r2083b2738],
11	mum	NN	O	mum	dep	9	SENT_403	[p19l2033t2519r2083b2738],
12	.	.	O	.	_	0	SENT_403	[p19l2033t2519r2083b2738],

1	.	.	O	.	_	0	SENT_404	[p19l2033t2763r2083b2870],

1	o.	NN	O	o.	_	0	SENT_405	[p19l2033t2763r2083b2870],
2	.	.	O	.	_	0	SENT_405	[p19l2033t2763r2083b2870],

1	.	.	O	.	_	0	SENT_406	[p19l2033t2763r2083b2870],

1	0020	CD	DATE	0020	num	2	SENT_407	[p19l2050t2892r2099b3051],
2	o.	NN	O	o.	_	0	SENT_407	[p19l2033t3074r2083b3160],
3	...	:	O	...	_	0	SENT_407	[p19l2033t3074r2083b3160],
4	E	NN	O	e	dep	2	SENT_407	[p19l2037t3184r2082b3227],
5	:	:	O	:	_	0	SENT_407	[p19l2037t3256r2099b3576],
6	o_mmm	NN	O	o_mmm	dep	4	SENT_407	[p19l2037t3256r2099b3576],
7	.	.	O	.	_	0	SENT_407	[p19l2037t3256r2099b3576],

1	mo3	NN	O	mo3	nn	6	SENT_408	[p19l2037t3256r2099b3576],
2	Eta	NN	O	eta	nn	6	SENT_408	[p19l2032t3600r2083b3722],
3	Um	NN	O	um	nn	6	SENT_408	[p19l2033t3749r2083b3834],
4	)	CD	NUMBER	)	num	6	SENT_408	[p19l2033t3749r2083b3834],
5	mmmmm	NN	O	mmmmm	nn	6	SENT_408	[p19l1958t175r2008b377],
6	__	NN	O	__	_	0	SENT_408	[p19l1958t175r2008b377],
7	o	NN	O	o	nn	8	SENT_408	[p19l1958t175r2008b377],
8	E2	NN	O	e2	dep	6	SENT_408	[p19l1958t403r2008b519],
9	:	:	O	:	_	0	SENT_408	[p19l1958t403r2008b519],
10	CSEE	NNP	ORGANIZATION	CSEE	dep	6	SENT_408	[p19l1962t551r2023b725],
11	203.3	CD	NUMBER	203.3	number	12	SENT_408	[p19l1975t750r2023b932],
12	30	CD	NUMBER	30	dep	10	SENT_408	[p19l1975t954r2023b1039],
13	.	.	O	.	_	0	SENT_408	[p19l1975t954r2023b1039],

1	we	PRP	O	we	_	0	SENT_409	[p19l1975t1064r2024b1148],
2	:	:	O	:	_	0	SENT_409	[p19l1975t1064r2024b1148],
3	omm	NN	O	omm	dep	1	SENT_409	[p19l1961t1173r2008b1269],
4	.6	CD	NUMBER	.6	num	6	SENT_409	[p19l1957t1283r2008b1343],
5	mmmot	NN	O	mmmot	nn	6	SENT_409	[p19l1958t1368r2008b1525],
6	m	NN	O	m	dep	3	SENT_409	[p19l1962t1549r2008b1869],
7	:	:	O	:	_	0	SENT_409	[p19l1962t1549r2008b1869],
8	o	NN	O	o	dep	3	SENT_409	[p19l1962t1549r2008b1869],
9	:	:	O	:	_	0	SENT_409	[p19l1962t1549r2008b1869],
10	m	NN	O	m	dep	8	SENT_409	[p19l1962t1549r2008b1869],
11	>	JJR	O	>	amod	12	SENT_409	[p19l1962t1549r2008b1869],
12	m	NN	O	m	dep	10	SENT_409	[p19l1962t1549r2008b1869],
13	:	:	O	:	_	0	SENT_409	[p19l1962t1549r2008b1869],
14	.	.	O	.	_	0	SENT_409	[p19l1962t1549r2008b1869],

1	:	:	O	:	_	0	SENT_410	[p19l1962t1549r2008b1869],
2	_	NN	O	_	dep	7	SENT_410	[p19l1962t1549r2008b1869],
3	>	JJR	O	>	dep	2	SENT_410	[p19l1958t1892r2024b2073],
4	_	CD	NUMBER	_	num	5	SENT_410	[p19l1958t1892r2024b2073],
5	v_oo	NN	O	v_oo	dep	7	SENT_410	[p19l1958t1892r2024b2073],
6	>>	CD	NUMBER	>>	num	7	SENT_410	[p19l1958t1892r2024b2073],
7	.3	NN	NUMBER	.3	dep	11	SENT_410	[p19l1958t2092r2023b2149],
8	.0	CD	NUMBER	.0	num	9	SENT_410	[p19l1957t2178r2008b2406],
9	o26	NN	O	o26	dep	7	SENT_410	[p19l1957t2178r2008b2406],
10	__	CD	NUMBER	__	num	11	SENT_410	[p19l1957t2178r2008b2406],
11	o.	NN	O	o.	dep	12	SENT_410	[p19l1957t2178r2008b2406],
12	_	NN	O	_	_	0	SENT_410	[p19l1957t2178r2008b2406],
13	.	.	O	.	_	0	SENT_410	[p19l1967t2430r2017b2600],

1	.8	NN	NUMBER	.8	_	0	SENT_411	[p19l1967t2430r2017b2600],
2	.	.	O	.	_	0	SENT_411	[p19l1967t2430r2017b2600],

1	wE	NN	O	we	_	0	SENT_412	[p19l1967t2430r2017b2600],
2	22.0	CD	NUMBER	22.0	dep	1	SENT_412	[p19l1975t2626r2023b2807],
3	.	.	O	.	_	0	SENT_412	[p19l1975t2626r2023b2807],

1	50	CD	NUMBER	50	_	0	SENT_413	[p19l1975t2829r2023b2914],
2	.	.	O	.	_	0	SENT_413	[p19l1975t2829r2023b2914],

1	me	PRP	O	I	_	0	SENT_414	[p19l1975t2939r2024b3023],
2	:	:	O	:	_	0	SENT_414	[p19l1975t2939r2024b3023],
3	cow	NN	O	cow	dep	1	SENT_414	[p19l1961t3048r2008b3146],
4	.6	CD	NUMBER	.6	num	6	SENT_414	[p19l1957t3159r2008b3218],
5	omov	NN	O	omov	nn	6	SENT_414	[p19l1958t3241r2008b3370],
6	w	NN	O	w	dep	3	SENT_414	[p19l1958t3392r2024b3592],
7	:	:	O	:	_	0	SENT_414	[p19l1958t3392r2024b3592],
8	__	CD	NUMBER	__	num	11	SENT_414	[p19l1958t3392r2024b3592],
9	omo	NN	O	omo	nn	11	SENT_414	[p19l1958t3392r2024b3592],
10	_	NN	O	_	nn	11	SENT_414	[p19l1958t3392r2024b3592],
11	m	NN	O	m	dep	1	SENT_414	[p19l1975t3620r2008b3834],
12	:	:	O	:	_	0	SENT_414	[p19l1975t3620r2008b3834],
13	o	NN	O	o	dep	11	SENT_414	[p19l1975t3620r2008b3834],
14	:	:	O	:	_	0	SENT_414	[p19l1975t3620r2008b3834],
15	m	NN	O	m	dep	1	SENT_414	[p19l1975t3620r2008b3834],
16	>	JJR	O	>	amod	17	SENT_414	[p19l1975t3620r2008b3834],
17	m	NN	O	m	dep	15	SENT_414	[p19l1975t3620r2008b3834],
18	6	CD	NUMBER	6	dep	15	SENT_414	[p19l1900t137r1932b192],
19	.	.	O	.	_	0	SENT_414	[p19l1882t214r1948b606],

1	aSm	NNP	O	aSm	_	0	SENT_415	[p19l1882t214r1948b606],
2	:	:	O	:	_	0	SENT_415	[p19l1882t214r1948b606],
3	.	.	O	.	_	0	SENT_415	[p19l1882t214r1948b606],

1	o.	NN	O	o.	_	0	SENT_416	[p19l1882t214r1948b606],
2	oEm	NN	O	oem	dep	1	SENT_416	[p19l1882t214r1948b606],
3	.	.	O	.	_	0	SENT_416	[p19l1882t214r1948b606],

1	.	.	O	.	_	0	SENT_417	[p19l1882t214r1948b606],

1	u	FW	O	u	_	0	SENT_418	[p19l1882t214r1948b606],
2	__	FW	O	__	nn	3	SENT_418	[p19l1881t633r1948b1225],
3	um.	FW	O	um.	dep	1	SENT_418	[p19l1881t633r1948b1225],
4	:	:	O	:	_	0	SENT_418	[p19l1881t633r1948b1225],
5	o.	NN	O	o.	nn	6	SENT_418	[p19l1881t633r1948b1225],
6	o	NN	O	o	dep	3	SENT_418	[p19l1881t633r1948b1225],
7	:	:	O	:	_	0	SENT_418	[p19l1881t633r1948b1225],
8	rTE	NNP	O	rTE	dep	6	SENT_418	[p19l1881t633r1948b1225],
9	:	:	O	:	_	0	SENT_418	[p19l1881t633r1948b1225],
10	:	:	O	:	_	0	SENT_418	[p19l1881t633r1948b1225],
11	:	:	O	:	_	0	SENT_418	[p19l1881t633r1948b1225],
12	m_Q	NN	O	m_q	dep	1	SENT_418	[p19l1881t633r1948b1225],
13	5:3	CD	NUMBER	5:3	number	14	SENT_418	[p19l1882t1254r1932b1366],
14	68.02	CD	NUMBER	68.02	dep	12	SENT_418	[p19l1882t1390r1932b1579],
15	.	.	O	.	_	0	SENT_418	[p19l1882t1390r1932b1579],

1	.	.	O	.	_	0	SENT_419	[p19l1882t1390r1932b1579],

1	203	CD	NUMBER	203	num	2	SENT_420	[p19l1900t1601r1932b1728],
2	v_uo	NN	O	v_uo	_	0	SENT_420	[p19l1882t1748r1932b1870],
3	:	:	O	:	_	0	SENT_420	[p19l1882t1748r1932b1870],
4	6:0	CD	NUMBER	6:0	number	5	SENT_420	[p19l1882t1898r1932b1995],
5	602	CD	NUMBER	602	dep	2	SENT_420	[p19l1882t2022r1932b2147],
6	.	.	O	.	_	0	SENT_420	[p19l1882t2022r1932b2147],

1	m	NN	O	m	_	0	SENT_421	[p19l1881t2172r1932b2329],
2	_	NN	O	_	dep	1	SENT_421	[p19l1881t2172r1932b2329],
3	.	.	O	.	_	0	SENT_421	[p19l1881t2172r1932b2329],

1	_	NN	O	_	_	0	SENT_422	[p19l1881t2172r1932b2329],
2	...	:	O	...	_	0	SENT_422	[p19l1881t2172r1932b2329],
3	_	CD	NUMBER	_	num	4	SENT_422	[p19l1881t2172r1932b2329],
4	o	NN	O	o	dep	5	SENT_422	[p19l1881t2172r1932b2329],
5	mEo	NNP	O	mEo	dep	1	SENT_422	[p19l1887t2353r1932b2639],
6	:	:	O	:	_	0	SENT_422	[p19l1887t2353r1932b2639],
7	_	CD	NUMBER	_	num	8	SENT_422	[p19l1887t2353r1932b2639],
8	u.	NN	O	u.	dep	5	SENT_422	[p19l1887t2353r1932b2639],
9	mu	NN	O	mu	nn	11	SENT_422	[p19l1887t2353r1932b2639],
10	__	NN	O	__	nn	11	SENT_422	[p19l1882t2665r1948b3059],
11	mu-m	NN	O	mu-m	dep	8	SENT_422	[p19l1882t2665r1948b3059],
12	:	:	O	:	_	0	SENT_422	[p19l1882t2665r1948b3059],
13	o	NN	O	o	dep	8	SENT_422	[p19l1882t2665r1948b3059],
14	:	:	O	:	_	0	SENT_422	[p19l1882t2665r1948b3059],
15	.	.	O	.	_	0	SENT_422	[p19l1882t2665r1948b3059],

1	_	NN	O	_	nn	2	SENT_423	[p19l1882t2665r1948b3059],
2	m	NN	O	m	_	0	SENT_423	[p19l1882t2665r1948b3059],
3	:	:	O	:	_	0	SENT_423	[p19l1882t2665r1948b3059],
4	.	.	O	.	_	0	SENT_423	[p19l1882t2665r1948b3059],

1	um	NN	O	um	_	0	SENT_424	[p19l1882t2665r1948b3059],
2	u	NN	O	u	nn	3	SENT_424	[p19l1887t3082r1932b3366],
3	_	NN	O	_	dep	1	SENT_424	[p19l1887t3082r1932b3366],
4	.	.	O	.	_	0	SENT_424	[p19l1887t3082r1932b3366],

1	.	.	O	.	_	0	SENT_425	[p19l1887t3082r1932b3366],

1	Bm_BoE	NN	O	bm_boe	_	0	SENT_426	[p19l1887t3082r1932b3366],
2	53	CD	NUMBER	53	num	4	SENT_426	[p19l1882t3395r1932b3508],
3	>	JJR	O	>	amod	4	SENT_426	[p19l1882t3395r1932b3508],
4	m.	NN	O	m.	dep	1	SENT_426	[p19l1887t3531r1932b3745],
5	.	.	O	.	_	0	SENT_426	[p19l1887t3531r1932b3745],

1	:	:	O	:	_	0	SENT_427	[p19l1887t3531r1932b3745],
2	m	NN	O	m	nn	3	SENT_427	[p19l1887t3531r1932b3745],
3	_	NN	O	_	_	0	SENT_427	[p19l1887t3531r1932b3745],
4	.	.	O	.	_	0	SENT_427	[p19l1887t3531r1932b3745],

1	.	.	O	.	_	0	SENT_428	[p19l1887t3531r1932b3745],

1	mn	NN	O	mn	nn	4	SENT_429	[p19l1887t3531r1932b3745],
2	_	NN	O	_	nn	4	SENT_429	[p19l1887t3531r1932b3745],
3	.2	NN	NUMBER	.2	nn	4	SENT_429	[p19l1900t3774r1932b3834],
4	.3	NN	NUMBER	.3	_	0	SENT_429	[p19l1824t102r1857b177],
5	3.0	CD	NUMBER	3.0	dep	4	SENT_429	[p19l1807t201r1872b311],
6	.	.	O	.	_	0	SENT_429	[p19l1807t201r1872b311],

1	.	.	O	.	_	0	SENT_430	[p19l1807t335r1873b728],

1	Em	NNP	O	Em	_	0	SENT_431	[p19l1807t335r1873b728],
2	.	.	O	.	_	0	SENT_431	[p19l1807t335r1873b728],

1	m	NN	O	m	nn	3	SENT_432	[p19l1807t335r1873b728],
2	£	CD	NUMBER	£	num	3	SENT_432	[p19l1807t335r1873b728],
3	oEmo_u	NN	O	oemo_u	_	0	SENT_432	[p19l1807t335r1873b728],
4	6	CD	NUMBER	6	number	5	SENT_432	[p19l1824t749r1857b804],
5	96.0	CD	NUMBER	96.0	num	3	SENT_432	[p19l1807t828r1857b974],
6	.	.	O	.	_	0	SENT_432	[p19l1807t996r1873b1389],

1	Em	NNP	O	Em	_	0	SENT_433	[p19l1807t996r1873b1389],
2	.	.	O	.	_	0	SENT_433	[p19l1807t996r1873b1389],

1	m	NN	O	m	_	0	SENT_434	[p19l1807t996r1873b1389],
2	;	:	O	;	_	0	SENT_434	[p19l1807t996r1873b1389],
3	o.	NNP	O	o.	nn	5	SENT_434	[p19l1807t996r1873b1389],
4	oEm	NNP	O	oEm	nn	5	SENT_434	[p19l1807t996r1873b1389],
5	_	NNP	O	_	dep	1	SENT_434	[p19l1807t996r1873b1389],
6	.	.	O	.	_	0	SENT_434	[p19l1807t996r1873b1389],

1	_	NN	O	_	nn	2	SENT_435	[p19l1807t996r1873b1389],
2	u	NN	O	u	_	0	SENT_435	[p19l1807t996r1873b1389],
3	.6	CD	NUMBER	.6	num	4	SENT_435	[p19l1806t1402r1857b1461],
4	_	NN	O	_	dep	2	SENT_435	[p19l1807t1488r1857b1590],
5	m	NN	O	m	rcmod	4	SENT_435	[p19l1807t1488r1857b1590],
6	_	CD	NUMBER	_	dep	5	SENT_435	[p19l1807t1488r1857b1590],
7	:	:	O	:	_	0	SENT_435	[p19l1807t1488r1857b1590],
8	.	.	O	.	_	0	SENT_435	[p19l1807t1488r1857b1590],

1	m	NN	O	m	_	0	SENT_436	[p19l1811t1615r1857b1639],
2	022	CD	NUMBER	022	num	1	SENT_436	[p19l1807t1663r1872b1821],
3	...	:	O	...	_	0	SENT_436	[p19l1807t1663r1872b1821],
4	.	.	O	.	_	0	SENT_436	[p19l1807t1850r1857b2174],

1	omN_Eot	NNP	O	omN_Eot	_	0	SENT_437	[p19l1807t1850r1857b2174],
2	:	:	O	:	_	0	SENT_437	[p19l1807t1850r1857b2174],
3	m.	NN	O	m.	nn	5	SENT_437	[p19l1807t1850r1857b2174],
4	o	NN	O	o	nn	5	SENT_437	[p19l1824t2201r1857b2226],
5	mm	NN	O	mm	dep	1	SENT_437	[p19l1824t2252r1857b2354],
6	;	:	O	;	_	0	SENT_437	[p19l1824t2252r1857b2354],
7	_	NN	O	_	nn	8	SENT_437	[p19l1807t2378r1857b2480],
8	m	NN	O	m	dep	5	SENT_437	[p19l1807t2378r1857b2480],
9	_	CD	NUMBER	_	dep	8	SENT_437	[p19l1807t2378r1857b2480],
10	:	:	O	:	_	0	SENT_437	[p19l1807t2378r1857b2480],
11	m	NN	O	m	dep	8	SENT_437	[p19l1811t2507r1873b2820],
12	__	CD	NUMBER	__	num	11	SENT_437	[p19l1811t2507r1873b2820],
13	>	JJR	O	>	amod	15	SENT_437	[p19l1811t2507r1873b2820],
14	_	NN	O	_	nn	15	SENT_437	[p19l1811t2507r1873b2820],
15	m	NN	O	m	dep	11	SENT_437	[p19l1811t2507r1873b2820],
16	_	CD	NUMBER	_	num	17	SENT_437	[p19l1811t2507r1873b2820],
17	~	NN	O	~	dep	11	SENT_437	[p19l1811t2507r1873b2820],
18	:	:	O	:	_	0	SENT_437	[p19l1811t2507r1873b2820],
19	.	.	O	.	_	0	SENT_437	[p19l1811t2507r1873b2820],

1	xm	NN	O	xm	_	0	SENT_438	[p19l1811t2507r1873b2820],
2	_	NN	O	_	dep	1	SENT_438	[p19l1811t2507r1873b2820],
3	.	.	O	.	_	0	SENT_438	[p19l1811t2507r1873b2820],

1	.3200	CD	NUMBER	.3200	_	0	SENT_439	[p19l1811t2847r1857b3037],
2	v.	CC	O	v.	cc	1	SENT_439	[p19l1807t3059r1857b3194],
3	82	CD	NUMBER	82	number	4	SENT_439	[p19l1807t3059r1857b3194],
4	.050	CD	NUMBER	.050	dep	1	SENT_439	[p19l1807t3224r1857b3320],
5	E81	NN	O	e81	nn	7	SENT_439	[p19l1807t3347r1857b3486],
6	u	NN	O	u	nn	7	SENT_439	[p19l1811t3513r1857b3797],
7	_	NN	O	_	dep	4	SENT_439	[p19l1811t3513r1857b3797],
8	.	.	O	.	_	0	SENT_439	[p19l1811t3513r1857b3797],

1	.	.	O	.	_	0	SENT_440	[p19l1811t3513r1857b3797],

1	m.	NN	O	m.	_	0	SENT_441	[p19l1811t3513r1857b3797],
2	.	.	O	.	_	0	SENT_441	[p19l1811t3513r1857b3797],

1	mm	NN	O	mm	_	0	SENT_442	[p19l1811t3513r1857b3797],
2	.	.	O	.	_	0	SENT_442	[p19l1811t3513r1857b3797],

1	.	.	O	.	_	0	SENT_443	[p19l1811t3513r1857b3797],

1	m	NN	O	m	nsubj	4	SENT_444	[p19l1811t3513r1857b3797],
2	_	SYM	O	_	dep	4	SENT_444	[p19l1811t3513r1857b3797],
3	>	JJR	O	>	amod	4	SENT_444	[p19l1811t3513r1857b3797],
4	_	NN	O	_	_	0	SENT_444	[p19l1811t3513r1857b3797],
5	.	.	O	.	_	0	SENT_444	[p19l1824t3822r1837b3834],

1	.	.	O	.	_	0	SENT_445	[p19l1749t3372r1797b3663],

1	mmm	NN	O	mmm	_	0	SENT_446	[p19l1749t3372r1797b3663],
2	:	:	O	:	_	0	SENT_446	[p19l1749t3372r1797b3663],
3	on	IN	O	on	prep	1	SENT_446	[p19l1749t3372r1797b3663],
4	.	.	O	.	_	0	SENT_446	[p19l1749t3372r1797b3663],

1	mm	NN	O	mm	_	0	SENT_447	[p19l1749t3372r1797b3663],
2	.	.	O	.	_	0	SENT_447	[p19l1749t3372r1797b3663],

1	_	NN	O	_	_	0	SENT_448	[p19l1731t3692r1781b3834],
2	m_tm	NN	O	m_tm	dep	1	SENT_448	[p19l1731t3692r1781b3834],
3	.	.	O	.	_	0	SENT_448	[p19l1731t3692r1781b3834],

1	.	.	O	.	_	0	SENT_449	[p19l1656t2532r1722b2912],

1	¢	NN	O	¢	_	0	SENT_450	[p19l1656t2532r1722b2912],
2	Em	NN	O	em	dep	1	SENT_450	[p19l1656t2532r1722b2912],
3	.	.	O	.	_	0	SENT_450	[p19l1656t2532r1722b2912],

1	oo_o	NN	O	oo_o	_	0	SENT_451	[p19l1656t2532r1722b2912],
2	.	.	O	.	_	0	SENT_451	[p19l1656t2532r1722b2912],

1	o	NN	O	o	_	0	SENT_452	[p19l1656t2532r1722b2912],
2	_	NN	O	_	dep	1	SENT_452	[p19l1656t2532r1722b2912],
3	.	.	O	.	_	0	SENT_452	[p19l1656t2532r1722b2912],

1	om	NN	O	om	_	0	SENT_453	[p19l1656t2532r1722b2912],
2	.	.	O	.	_	0	SENT_453	[p19l1656t2532r1722b2912],

1	.6	CD	NUMBER	.6	_	0	SENT_454	[p19l1655t2928r1706b2988],
2	:	:	O	:	_	0	SENT_454	[p19l1656t3014r1706b3242],
3	o	NN	O	o	nn	4	SENT_454	[p19l1656t3014r1706b3242],
4	_	NN	O	_	dep	1	SENT_454	[p19l1656t3014r1706b3242],
5	.	.	O	.	_	0	SENT_454	[p19l1656t3014r1706b3242],

1	.	.	O	.	_	0	SENT_455	[p19l1656t3014r1706b3242],

1	m.	NN	O	m.	_	0	SENT_456	[p19l1656t3014r1706b3242],
2	:	:	O	:	_	0	SENT_456	[p19l1656t3014r1706b3242],
3	w	NN	O	w	dep	1	SENT_456	[p19l1656t3014r1706b3242],
4	2	CD	NUMBER	2	num	3	SENT_456	[p19l1656t3265r1706b3351],
5	...	:	O	...	_	0	SENT_456	[p19l1656t3265r1706b3351],
6	.	.	O	.	_	0	SENT_456	[p19l1655t3370r1706b3446],

1	.	.	O	.	_	0	SENT_457	[p19l1655t3370r1706b3446],

1	O.	NNP	O	O.	_	0	SENT_458	[p19l1655t3370r1706b3446],
2	.	.	O	.	_	0	SENT_458	[p19l1655t3370r1706b3446],

1	_	NN	O	_	_	0	SENT_459	[p19l1655t3370r1706b3446],
2	.	.	O	.	_	0	SENT_459	[p19l1665t3465r1706b3623],

1	_	NN	O	_	_	0	SENT_460	[p19l1665t3465r1706b3623],
2	m.	NN	O	m.	dep	1	SENT_460	[p19l1665t3465r1706b3623],
3	.	.	O	.	_	0	SENT_460	[p19l1665t3465r1706b3623],

1	.	.	O	.	_	0	SENT_461	[p19l1665t3465r1706b3623],

1	®	NN	O	®	_	0	SENT_462	[p19l1665t3465r1706b3623],
2	E	NN	O	e	prep	1	SENT_462	[p19l1665t3465r1706b3623],
3	22	CD	NUMBER	22	dep	2	SENT_462	[p19l1673t3649r1722b3830],
4	....	SYM	O	....	dep	1	SENT_462	[p19l1673t3649r1722b3830],
5	-	:	O	-	_	0	SENT_462	[p19l1580t168r1631b254],
6	_	NN	O	_	dep	1	SENT_462	[p19l1580t168r1631b254],
7	£	CD	MONEY	£	num	6	SENT_462	[p19l1580t168r1631b254],
8	.020	CD	MONEY	.020	num	9	SENT_462	[p19l1598t278r1640b405],
9	mum.	NNS	O	mum.	dep	6	SENT_462	[p19l1580t429r1647b775],
10	:	:	O	:	_	0	SENT_462	[p19l1580t429r1647b775],
11	:	:	O	:	_	0	SENT_462	[p19l1580t429r1647b775],
12	m	NN	O	m	dep	1	SENT_462	[p19l1580t429r1647b775],
13	-	:	O	-	_	0	SENT_462	[p19l1580t429r1647b775],
14	.	.	O	.	_	0	SENT_462	[p19l1580t429r1647b775],

1	€	NN	O	€	_	0	SENT_463	[p19l1580t429r1647b775],
2	on	IN	O	on	_	0	SENT_463	[p19l1580t429r1647b775],
3	_	NN	O	_	prep_on	1	SENT_463	[p19l1580t429r1647b775],
4	.6	CD	NUMBER	.6	number	5	SENT_463	[p19l1580t791r1631b851],
5	.638	CD	NUMBER	.638	dep	1	SENT_463	[p19l1590t872r1631b1029],
6	203.0	CD	NUMBER	203.0	num	8	SENT_463	[p19l1598t1055r1646b1236],
7	...	:	O	...	_	0	SENT_463	[p19l1598t1055r1646b1236],
8	.60	CD	NUMBER	.60	dep	5	SENT_463	[p19l1598t1258r1646b1344],
9	.	.	O	.	_	0	SENT_463	[p19l1598t1258r1646b1344],

1	ms.	NN	O	ms.	nn	2	SENT_464	[p19l1598t1368r1647b1453],
2	oov	NN	O	oov	_	0	SENT_464	[p19l1580t1478r1631b1647],
3	.6	CD	NUMBER	.6	num	5	SENT_464	[p19l1580t1478r1631b1647],
4	30.0	CD	NUMBER	30.0	num	5	SENT_464	[p19l1581t1671r1631b1799],
5	w	NN	O	w	dep	2	SENT_464	[p19l1581t1821r1647b2022],
6	:	:	O	:	_	0	SENT_464	[p19l1581t1821r1647b2022],
7	__	CD	NUMBER	__	num	10	SENT_464	[p19l1581t1821r1647b2022],
8	umo	NN	O	umo	nn	10	SENT_464	[p19l1581t1821r1647b2022],
9	_	NN	O	_	nn	10	SENT_464	[p19l1581t1821r1647b2022],
10	m	NN	O	m	dep	2	SENT_464	[p19l1585t2049r1647b2389],
11	:	:	O	:	_	0	SENT_464	[p19l1585t2049r1647b2389],
12	o	NN	O	o	dep	10	SENT_464	[p19l1585t2049r1647b2389],
13	:	:	O	:	_	0	SENT_464	[p19l1585t2049r1647b2389],
14	o	NN	O	o	dep	2	SENT_464	[p19l1585t2049r1647b2389],
15	>	JJR	O	>	amod	16	SENT_464	[p19l1585t2049r1647b2389],
16	m	NN	O	m	dep	14	SENT_464	[p19l1585t2049r1647b2389],
17	:	:	O	:	_	0	SENT_464	[p19l1585t2049r1647b2389],
18	:	:	O	:	_	0	SENT_464	[p19l1585t2049r1647b2389],
19	_	NN	O	_	dep	16	SENT_464	[p19l1585t2049r1647b2389],
20	.	.	O	.	_	0	SENT_464	[p19l1585t2049r1647b2389],

1	n.	NN	O	n.	nn	3	SENT_465	[p19l1581t2419r1631b2699],
2	mE_x3ou	NN	O	me_x3ou	nn	3	SENT_465	[p19l1581t2419r1631b2699],
3	m	NN	O	m	_	0	SENT_465	[p19l1581t2724r1646b2833],
4	:	:	O	:	_	0	SENT_465	[p19l1581t2724r1646b2833],
5	_	CD	NUMBER	_	num	7	SENT_465	[p19l1581t2724r1646b2833],
6	o	NN	O	o	nn	7	SENT_465	[p19l1581t2724r1646b2833],
7	_	NN	O	_	dep	3	SENT_465	[p19l1581t2724r1646b2833],
8	.	.	O	.	_	0	SENT_465	[p19l1581t2858r1647b3201],

1	€	NN	O	€	dep	9	SENT_466	[p19l1581t2858r1647b3201],
2	m.	SYM	O	m.	dep	4	SENT_466	[p19l1581t2858r1647b3201],
3	m0_6	CD	NUMBER	m0_6	number	4	SENT_466	[p19l1581t2858r1647b3201],
4	_	CD	NUMBER	_	dep	1	SENT_466	[p19l1581t2858r1647b3201],
5	.0	CD	NUMBER	.0	num	6	SENT_466	[p19l1581t2858r1647b3201],
6	m.	NN	NUMBER	m.	dep	4	SENT_466	[p19l1581t2858r1647b3201],
7	_	NN	O	_	dep	9	SENT_466	[p19l1581t2858r1647b3201],
8	5.3	CD	NUMBER	5.3	num	7	SENT_466	[p19l1581t3230r1631b3342],
9	6	CD	NUMBER	6	dep	12	SENT_466	[p19l1598t3361r1631b3417],
10	o	NN	O	o	dep	9	SENT_466	[p19l1581t3440r1631b3586],
11	:	:	O	:	_	0	SENT_466	[p19l1581t3440r1631b3586],
12	o_m	NN	O	o_m	_	0	SENT_466	[p19l1581t3440r1631b3586],
13	20.0.60	CD	NUMBER	20.0.60	num	12	SENT_466	[p19l1581t3608r1647b3834],
14	?	.	O	?	_	0	SENT_466	[p19l1581t3608r1647b3834],

1	m.	NN	O	m.	nn	2	SENT_467	[p19l1510t143r1555b428],
2	Eo	NN	O	eo	_	0	SENT_467	[p19l1510t143r1555b428],
3	:	:	O	:	_	0	SENT_467	[p19l1510t143r1555b428],
4	_	CD	NUMBER	_	num	5	SENT_467	[p19l1510t143r1555b428],
5	u	NN	O	u	dep	2	SENT_467	[p19l1510t143r1555b428],
6	:8	CD	NUMBER	:8	num	8	SENT_467	[p19l1510t143r1555b428],
7	__	NN	O	__	nn	8	SENT_467	[p19l1505t455r1571b849],
8	mu	NN	O	mu	dep	5	SENT_467	[p19l1505t455r1571b849],
9	-	:	O	-	_	0	SENT_467	[p19l1505t455r1571b849],
10	.	.	O	.	_	0	SENT_467	[p19l1505t455r1571b849],

1	n.	NN	O	n.	_	0	SENT_468	[p19l1505t455r1571b849],
2	:	:	O	:	_	0	SENT_468	[p19l1505t455r1571b849],
3	oEm	NN	O	oem	dep	1	SENT_468	[p19l1505t455r1571b849],
4	:	:	O	:	_	0	SENT_468	[p19l1505t455r1571b849],
5	.	.	O	.	_	0	SENT_468	[p19l1505t455r1571b849],

1	om	NN	O	om	_	0	SENT_469	[p19l1505t455r1571b849],
2	60020300	CD	NUMBER	60020300	num	3	SENT_469	[p19l1505t876r1555b1132],
3	>	JJR	O	>	dep	1	SENT_469	[p19l1505t1154r1571b1321],
4	__	CD	NUMBER	__	num	5	SENT_469	[p19l1505t1154r1571b1321],
5	muo	NN	O	muo	dep	3	SENT_469	[p19l1505t1154r1571b1321],
6	_	CD	NUMBER	_	number	7	SENT_469	[p19l1505t1154r1571b1321],
7	_	CD	NUMBER	_	dep	1	SENT_469	[p19l1505t1349r1555b1462],
8	...	:	O	...	_	0	SENT_469	[p19l1505t1349r1555b1462],
9	_	CD	NUMBER	_	number	10	SENT_469	[p19l1505t1349r1555b1462],
10	>>	CD	NUMBER	>>	dep	7	SENT_469	[p19l1505t1349r1555b1462],
11	3:02.00	CD	TIME	3:02.00	dep	10	SENT_469	[p19l1510t1485r1555b1699],
12	.	.	O	.	_	0	SENT_469	[p19l1510t1485r1555b1699],

1	.	.	O	.	_	0	SENT_470	[p19l1505t1728r1555b1946],

1	.	.	O	.	_	0	SENT_471	[p19l1505t1728r1555b1946],

1	ummmm	NN	O	ummmm	_	0	SENT_472	[p19l1505t1728r1555b1946],
2	:	:	O	:	_	0	SENT_472	[p19l1505t1728r1555b1946],
3	.	.	O	.	_	0	SENT_472	[p19l1505t1728r1555b1946],

1	.	.	O	.	_	0	SENT_473	[p19l1505t1972r1555b2227],

1	.	.	O	.	_	0	SENT_474	[p19l1505t1972r1555b2227],

1	mu	NN	O	mu	_	0	SENT_475	[p19l1505t1972r1555b2227],
2	:	:	O	:	_	0	SENT_475	[p19l1505t1972r1555b2227],
3	m	NN	O	m	dep	1	SENT_475	[p19l1505t1972r1555b2227],
4	>	JJR	O	>	amod	5	SENT_475	[p19l1505t1972r1555b2227],
5	vm	NN	O	vm	dep	6	SENT_475	[p19l1505t1972r1555b2227],
6	>	JJR	O	>	dep	3	SENT_475	[p19l1505t2250r1571b2416],
7	__	CD	NUMBER	__	num	8	SENT_475	[p19l1505t2250r1571b2416],
8	muo	NN	O	muo	dep	3	SENT_475	[p19l1505t2250r1571b2416],
9	_	CD	NUMBER	_	num	12	SENT_475	[p19l1505t2250r1571b2416],
10	E	NN	O	e	nn	12	SENT_475	[p19l1510t2445r1555b2488],
11	n_mE_x3mu	NN	O	n_me_x3mu	nn	12	SENT_475	[p19l1505t2514r1555b2794],
12	m	NN	O	m	dep	8	SENT_475	[p19l1505t2819r1571b2929],
13	:	:	O	:	_	0	SENT_475	[p19l1505t2819r1571b2929],
14	_	CD	NUMBER	_	dep	1	SENT_475	[p19l1505t2819r1571b2929],
15	Q	NNP	O	Q	dep	14	SENT_475	[p19l1505t2819r1571b2929],
16	.	.	O	.	_	0	SENT_475	[p19l1505t2953r1571b3296],

1	am	VBP	O	be	_	0	SENT_476	[p19l1505t2953r1571b3296],
2	.	.	O	.	_	0	SENT_476	[p19l1505t2953r1571b3296],

1	m	NN	O	m	_	0	SENT_477	[p19l1505t2953r1571b3296],
2	_	NN	O	_	dep	1	SENT_477	[p19l1505t2953r1571b3296],
3	.	.	O	.	_	0	SENT_477	[p19l1505t2953r1571b3296],

1	_	NN	O	_	_	0	SENT_478	[p19l1505t2953r1571b3296],
2	.	.	O	.	_	0	SENT_478	[p19l1505t2953r1571b3296],

1	.	.	O	.	_	0	SENT_479	[p19l1505t2953r1571b3296],

1	o	NN	O	o	_	0	SENT_480	[p19l1505t2953r1571b3296],
2	_	NN	O	_	dep	1	SENT_480	[p19l1505t2953r1571b3296],
3	.	.	O	.	_	0	SENT_480	[p19l1505t2953r1571b3296],

1	om	NN	O	om	_	0	SENT_481	[p19l1505t2953r1571b3296],
2	.	.	O	.	_	0	SENT_481	[p19l1505t2953r1571b3296],

1	6	CD	NUMBER	6	num	2	SENT_482	[p19l1523t3320r1555b3376],
2	m	NN	O	m	_	0	SENT_482	[p19l1505t3399r1555b3545],
3	:	:	O	:	_	0	SENT_482	[p19l1505t3399r1555b3545],
4	o_m	NN	O	o_m	dep	2	SENT_482	[p19l1505t3399r1555b3545],
5	.	.	O	.	_	0	SENT_482	[p19l1505t3567r1571b3834],

1	€	NN	O	€	nn	3	SENT_483	[p19l1505t3567r1571b3834],
2	m.	NN	O	m.	nn	3	SENT_483	[p19l1505t3567r1571b3834],
3	m	NN	O	m	_	0	SENT_483	[p19l1505t3567r1571b3834],
4	_	CD	NUMBER	_	dep	3	SENT_483	[p19l1505t3567r1571b3834],
5	...	:	O	...	_	0	SENT_483	[p19l1505t3567r1571b3834],
6	o	NN	O	o	nn	7	SENT_483	[p19l1505t3567r1571b3834],
7	__	NN	O	__	dep	3	SENT_483	[p19l1505t3567r1571b3834],
8	.	.	O	.	_	0	SENT_483	[p19l1262t230r1310b343],

1	_	NN	O	_	_	0	SENT_484	[p19l1262t230r1310b343],
2	.	.	O	.	_	0	SENT_484	[p19l1262t230r1310b343],

1	o.o	NN	O	o.o	_	0	SENT_485	[p19l1262t230r1310b343],
2	.	.	O	.	_	0	SENT_485	[p19l1262t514r1325b815],

1	oo	NN	O	oo	_	0	SENT_486	[p19l1262t514r1325b815],
2	.	.	O	.	_	0	SENT_486	[p19l1262t514r1325b815],

1	o	NN	O	o	_	0	SENT_487	[p19l1262t514r1325b815],
2	-	:	O	-	_	0	SENT_487	[p19l1262t514r1325b815],
3	.	.	O	.	_	0	SENT_487	[p19l1262t514r1325b815],

1	.	.	O	.	_	0	SENT_488	[p19l1262t514r1325b815],

1	o.o.	NN	O	o.o.	_	0	SENT_489	[p19l1262t514r1325b815],
2	oo	NN	O	oo	dep	1	SENT_489	[p19l1262t840r1310b954],
3	.	.	O	.	_	0	SENT_489	[p19l1262t840r1310b954],

1	o	NN	O	o	_	0	SENT_490	[p19l1262t840r1310b954],
2	oo	NN	O	oo	dep	1	SENT_490	[p19l1262t1254r1310b1360],
3	.	.	O	.	_	0	SENT_490	[p19l1262t1254r1310b1360],

1	E	NN	O	e	_	0	SENT_491	[p19l1264t1771r1309b1847],
2	So	RB	O	so	dep	1	SENT_491	[p19l1155t199r1202b379],
3	.	.	O	.	_	0	SENT_491	[p19l1155t199r1202b379],

1	ov	NN	O	ov	_	0	SENT_492	[p19l1155t199r1202b379],
2	5.0-3	CD	NUMBER	5.0-3	number	3	SENT_492	[p19l1155t514r1217b815],
3	.0	CD	NUMBER	.0	num	1	SENT_492	[p19l1155t514r1217b815],
4	.	.	O	.	_	0	SENT_492	[p19l1155t514r1217b815],

1	.	.	O	.	_	0	SENT_493	[p19l1155t842r1202b954],

1	:	:	O	:	_	0	SENT_494	[p19l1155t842r1202b954],
2	...	:	O	...	_	0	SENT_494	[p19l1155t842r1202b954],
3	o	NN	O	o	nn	5	SENT_494	[p19l1155t842r1202b954],
4	o.o	NN	O	o.o	nn	5	SENT_494	[p19l1156t1252r1202b1330],
5	o.	NN	O	o.	dep	1	SENT_494	[p19l1156t1775r1202b1849],
6	...	:	O	...	_	0	SENT_494	[p19l1156t1775r1202b1849],

1	80.0	CD	NUMBER	80.0	num	2	SENT_495	[p19l1047t199r1095b343],
2	0.2	CD	NUMBER	0.2	_	0	SENT_495	[p19l1048t1252r1095b1363],
3	0.2	CD	NUMBER	0.2	num	6	SENT_495	[p19l1048t1774r1095b1879],
4	mo.	NN	O	mo.	nn	6	SENT_495	[p19l832t2202r880b2348],
5	ov	NN	O	ov	nn	6	SENT_495	[p19l832t2202r880b2348],
6	ooo	NN	O	ooo	dep	2	SENT_495	[p19l725t2165r772b2348],
7	.	.	O	.	_	0	SENT_495	[p19l725t2165r772b2348],

1	ov	NN	O	ov	_	0	SENT_496	[p19l725t2165r772b2348],
2	moo	NN	O	moo	dep	1	SENT_496	[p19l617t2168r665b2348],
3	.	.	O	.	_	0	SENT_496	[p19l617t2168r665b2348],

1	ov	NN	O	ov	_	0	SENT_497	[p19l617t2168r665b2348],
2	No.	NN	O	no.	nn	3	SENT_497	[p19l510t2199r557b2311],
3	o	NN	O	o	dep	1	SENT_497	[p19l510t2199r557b2311],

1	2	LS	NUMBER	2	_	0	SENT_498	[p19l287t179r338b333],
2	.	.	O	.	_	0	SENT_498	[p19l287t179r338b333],

1	_	NN	O	_	nsubj	3	SENT_499	[p19l287t179r338b333],
2	~	SYM	O	~	dep	3	SENT_499	[p19l287t179r338b333],
3	>	JJR	O	>	_	0	SENT_499	[p19l287t179r338b333],
4	.	.	O	.	_	0	SENT_499	[p19l292t352r337b383],

1	_	NN	O	_	_	0	SENT_500	[p19l292t352r337b383],
2	5	CD	NUMBER	5	num	1	SENT_500	[p19l291t625r354b700],
3	$	$	MONEY	$	dep	1	SENT_500	[p19l290t722r354b859],
4	oo	CD	MONEY	oo	num	3	SENT_500	[p19l290t722r354b859],
5	.	.	O	.	_	0	SENT_500	[p19l290t722r354b859],

1	#	#	MONEY	#	dep	2	SENT_501	[p19l292t1014r354b1175],
2	2	CD	MONEY	2	_	0	SENT_501	[p19l292t1014r354b1175],
3	“	NN	O	“	dep	2	SENT_501	[p19l292t1014r354b1175],
4	2	CD	NUMBER	2	num	3	SENT_501	[p19l292t1190r354b1250],
5	.	.	O	.	_	0	SENT_501	[p19l292t1190r354b1250],

1	n	NN	O	n	nn	4	SENT_502	[p19l287t1275r338b1571],
2	_	CD	NUMBER	_	num	4	SENT_502	[p19l287t1275r338b1571],
3	~	NN	O	~	nn	4	SENT_502	[p19l287t1275r338b1571],
4	s_x30u	NN	O	s_x30u	_	0	SENT_502	[p19l287t1275r338b1571],
5	.02	CD	NUMBER	.02	dep	4	SENT_502	[p19l291t1696r354b1856],
6	"	``	O	"	punct	5	SENT_502	[p19l291t1696r354b1856],
7	2	LS	NUMBER	2	dep	5	SENT_502	[p19l292t1872r354b1933],
8	.	.	O	.	_	0	SENT_502	[p19l292t1872r354b1933],

1	2	CD	NUMBER	2	num	2	SENT_503	[p19l287t2146r338b2300],
2	__	NN	O	__	dep	7	SENT_503	[p19l287t2146r338b2300],
3	0	CD	NUMBER	0	dep	2	SENT_503	[p19l287t2146r338b2300],
4	>	JJR	O	>	amod	5	SENT_503	[p19l287t2146r338b2300],
5	n	NN	O	n	dep	7	SENT_503	[p19l292t2318r337b2350],
6	_	CD	NUMBER	_	num	7	SENT_503	[p19l292t2318r337b2350],
7	osmm	NN	O	osmm	dep	15	SENT_503	[p19l213t562r262b698],
8	t.	NN	O	t.	nn	11	SENT_503	[p19l212t725r262b919],
9	_	CD	NUMBER	_	num	11	SENT_503	[p19l212t725r262b919],
10	mNmI	NN	O	mnmus	nn	11	SENT_503	[p19l212t725r262b919],
11	m	NN	O	m	dep	7	SENT_503	[p19l212t1021r277b1134],
12	:	:	O	:	_	0	SENT_503	[p19l212t1021r277b1134],
13	_	CD	NUMBER	_	num	15	SENT_503	[p19l212t1021r277b1134],
14	n	NN	O	n	nn	15	SENT_503	[p19l212t1021r277b1134],
15	_	NN	O	_	_	0	SENT_503	[p19l212t1021r277b1134],
16	.	.	O	.	_	0	SENT_503	[p19l212t1156r278b1562],

1	€	NN	MONEY	€	_	0	SENT_504	[p19l212t1156r278b1562],
2	§	CD	MONEY	§	num	3	SENT_504	[p19l212t1156r278b1562],
3	__	NN	O	__	dep	1	SENT_504	[p19l212t1156r278b1562],
4	.	.	O	.	_	0	SENT_504	[p19l212t1156r278b1562],

1	.	.	O	.	_	0	SENT_505	[p19l212t1156r278b1562],

1	=	JJ	O	=	amod	3	SENT_506	[p19l212t1156r278b1562],
2	=	JJ	O	=	amod	3	SENT_506	[p19l212t1156r278b1562],
3	oEm	NN	O	oem	_	0	SENT_506	[p19l212t1156r278b1562],
4	_	NN	O	_	dep	3	SENT_506	[p19l212t1156r278b1562],
5	.	.	O	.	_	0	SENT_506	[p19l212t1156r278b1562],

1	U	NNP	O	U	_	0	SENT_507	[p19l212t1156r278b1562],
2	.	.	O	.	_	0	SENT_507	[p19l212t1611r278b2017],

1	€	NN	O	€	nn	4	SENT_508	[p19l212t1611r278b2017],
2	m.	NN	O	m.	nn	4	SENT_508	[p19l212t1611r278b2017],
3	_	NN	O	_	nn	4	SENT_508	[p19l212t1611r278b2017],
4	m	NN	O	m	_	0	SENT_508	[p19l212t1611r278b2017],
5	£	CD	NUMBER	£	num	6	SENT_508	[p19l212t1611r278b2017],
6	oEm	NN	O	oem	dep	4	SENT_508	[p19l212t1611r278b2017],
7	.	.	O	.	_	0	SENT_508	[p19l212t1611r278b2017],

1	.	.	O	.	_	0	SENT_509	[p19l212t1611r278b2017],

1	U	NNP	O	U	_	0	SENT_510	[p19l212t1611r278b2017],
2	5.0-3	CD	NUMBER	5.0-3	dep	1	SENT_510	[p19l832t2608r895b2859],
3	.	.	O	.	_	0	SENT_510	[p19l832t2608r895b2859],

1	:	:	O	:	_	0	SENT_511	[p19l832t2885r880b2998],
2	o	NN	O	o	_	0	SENT_511	[p19l832t2885r880b2998],
3	o.o.	NNS	O	o.o.	dep	2	SENT_511	[p19l832t3277r880b3392],
4	.	.	O	.	_	0	SENT_511	[p19l832t3277r880b3392],

1	o.	NN	O	o.	_	0	SENT_512	[p19l833t3793r879b3833],
2	200.0130	CD	NUMBER	200.0130	dep	1	SENT_512	[p19l725t2558r787b2859],
3	.	.	O	.	_	0	SENT_512	[p19l725t2558r787b2859],

1	2.0	CD	NUMBER	2.0	num	2	SENT_513	[p19l725t2884r772b2998],
2	o	NN	O	o	_	0	SENT_513	[p19l726t3281r772b3387],
3	:	:	O	:	_	0	SENT_513	[p19l726t3281r772b3387],
4	o.	VB	O	o.	dep	2	SENT_513	[p19l726t3790r772b3833],
5	30.0-3	CD	NUMBER	30.0-3	num	6	SENT_513	[p19l617t2558r680b2859],
6	.0	CD	NUMBER	.0	dobj	4	SENT_513	[p19l617t2558r680b2859],
7	.	.	O	.	_	0	SENT_513	[p19l617t2558r680b2859],

1	oo	NN	O	oo	_	0	SENT_514	[p19l617t2886r665b2998],
2	.	.	O	.	_	0	SENT_514	[p19l617t2886r665b2998],

1	o	NN	O	o	_	0	SENT_515	[p19l617t2886r665b2998],
2	...	:	O	...	_	0	SENT_515	[p19l619t3279r664b3391],
3	E	NN	O	e	nn	4	SENT_515	[p19l619t3279r664b3391],
4	o.	NN	O	o.	dep	1	SENT_515	[p19l619t3790r665b3833],
5	200.0130	CD	NUMBER	200.0130	dep	4	SENT_515	[p19l510t2558r573b2859],
6	.	.	O	.	_	0	SENT_515	[p19l510t2558r573b2859],

1	3.0	CD	NUMBER	3.0	num	2	SENT_516	[p19l510t2885r557b2998],
2	3	CD	NUMBER	3	_	0	SENT_516	[p19l511t3329r557b3388],
3	.	.	O	.	_	0	SENT_516	[p19l291t2660r354b2736],

1	_	NN	O	_	_	0	SENT_517	[p19l291t2660r354b2736],
2	u	FW	O	u	dep	1	SENT_517	[p19l291t2660r354b2736],
3	$	$	MONEY	$	dep	2	SENT_517	[p19l290t2758r354b2895],
4	oo	CD	MONEY	oo	num	3	SENT_517	[p19l290t2758r354b2895],
5	.	.	O	.	_	0	SENT_517	[p19l290t2758r354b2895],

1	fun	NN	O	fun	_	0	SENT_518	[p19l292t3050r354b3210],
2	2	CD	NUMBER	2	dep	1	SENT_518	[p19l292t3226r354b3286],
3	.	.	O	.	_	0	SENT_518	[p19l292t3226r354b3286],

1	n_0E_x	NN	O	n_0e_x	_	0	SENT_519	[p19l287t3311r338b3607],
2	_	CD	NUMBER	_	number	3	SENT_519	[p19l287t3311r338b3607],
3	:8	CD	NUMBER	:8	dep	1	SENT_519	[p19l287t3311r338b3607],
4	Ea	NNP	O	Ea	nn	5	SENT_519	[p19l292t3715r354b3830],
5	cram	NN	O	cram	dep	3	SENT_519	[p19l213t2597r262b2733],
6	.	.	O	.	_	0	SENT_519	[p19l213t2597r262b2733],

1	_	NN	O	_	nn	2	SENT_520	[p19l212t2761r262b2954],
2	u.	NN	O	u.	_	0	SENT_520	[p19l212t2761r262b2954],
3	_	JJ	O	_	amod	5	SENT_520	[p19l212t2761r262b2954],
4	mNaI	NN	O	mnaus	nn	5	SENT_520	[p19l212t2761r262b2954],
5	m	NN	O	m	dep	2	SENT_520	[p19l212t3077r277b3190],
6	:	:	O	:	_	0	SENT_520	[p19l212t3077r277b3190],
7	_	CD	NUMBER	_	num	8	SENT_520	[p19l212t3077r277b3190],
8	n	NN	O	n	dep	2	SENT_520	[p19l212t3077r277b3190],
9	_	NN	O	_	dep	8	SENT_520	[p19l212t3077r277b3190],
10	.	.	O	.	_	0	SENT_520	[p19l212t3212r278b3572],

1	€	NN	O	€	_	0	SENT_521	[p19l212t3212r278b3572],
2	2m	NN	O	2m	nn	3	SENT_521	[p19l212t3212r278b3572],
3	_	NN	O	_	dep	1	SENT_521	[p19l212t3212r278b3572],
4	.	.	O	.	_	0	SENT_521	[p19l212t3212r278b3572],

1	_	NN	O	_	_	0	SENT_522	[p19l212t3212r278b3572],
2	0	CD	NUMBER	0	dep	1	SENT_522	[p19l212t3212r278b3572],
3	.	.	O	.	_	0	SENT_522	[p19l212t3212r278b3572],

1	o	NN	O	o	nn	4	SENT_523	[p19l212t3212r278b3572],
2	__	CD	NUMBER	__	num	4	SENT_523	[p19l212t3212r278b3572],
3	um	NN	O	um	nn	4	SENT_523	[p19l212t3212r278b3572],
4	~	NN	O	~	_	0	SENT_523	[p19l212t3212r278b3572],
5	_	NN	O	_	dep	4	SENT_523	[p19l212t3212r278b3572],
6	.	.	O	.	_	0	SENT_523	[p19l212t3650r278b3833],

1	€	NN	O	€	nn	2	SENT_524	[p19l212t3650r278b3833],
2	m.	NN	O	m.	_	0	SENT_524	[p19l212t3650r278b3833],
3	_	CD	NUMBER	_	num	5	SENT_524	[p19l212t3650r278b3833],
4	o	NN	O	o	nn	5	SENT_524	[p19l212t3650r278b3833],
5	_	NN	O	_	dep	2	SENT_524	[p19l212t3650r278b3833],
6	.	.	O	.	_	0	SENT_524	[p19l212t3650r278b3833],

1	.....	NN	O	.....	_	0	SENT_525	[p19l61t2921r111b3107],
2	.	.	O	.	_	0	SENT_525	[p19l61t2921r111b3107],

1	v_uoz	NN	O	v_uoz	nn	2	SENT_526	[p19l61t2921r111b3107],
2	_	NN	O	_	_	0	SENT_526	[p19l61t3133r111b3231],
3	u	FW	O	u	nn	4	SENT_526	[p19l61t3133r111b3231],
4	_	FW	O	_	dep	2	SENT_526	[p19l61t3133r111b3231],
5	.	.	O	.	_	0	SENT_526	[p19l61t3133r111b3231],

1	_	NN	O	_	nn	3	SENT_527	[p19l61t3133r111b3231],
2	a	DT	O	a	det	3	SENT_527	[p19l61t3133r111b3231],
3	vac	NN	O	vac	_	0	SENT_527	[p19l61t3252r111b3393],
4	...	:	O	...	_	0	SENT_527	[p19l61t3252r111b3393],
5	m	NN	O	m	nn	6	SENT_527	[p19l60t3415r111b3571],
6	_	NN	O	_	dep	3	SENT_527	[p19l60t3415r111b3571],
7	.	.	O	.	_	0	SENT_527	[p19l60t3415r111b3571],

1	__	NN	O	__	_	0	SENT_528	[p19l60t3415r111b3571],
2	...	:	O	...	_	0	SENT_528	[p19l60t3415r111b3571],
3	_	CD	NUMBER	_	num	4	SENT_528	[p19l60t3415r111b3571],
4	o	NN	O	o	dep	5	SENT_528	[p19l60t3415r111b3571],
5	aEo	NN	O	aeo	dep	1	SENT_528	[p19l62t3590r111b3834],
6	:	:	O	:	_	0	SENT_528	[p19l62t3590r111b3834],
7	_	CD	NUMBER	_	num	8	SENT_528	[p19l62t3590r111b3834],
8	u.	NN	O	u.	dep	5	SENT_528	[p19l62t3590r111b3834],
9	:	:	O	:	_	0	SENT_528	[p19l62t3590r111b3834],

1	ofthe	NN	O	ofthe	_	0	SENT_529	[p20l1580t1248r1631b1404],
2	head	NN	O	head	advmod	6	SENT_529	[p20l1581t1097r1631b1223],
3	and	CC	O	and	_	0	SENT_529	[p20l1581t974r1631b1070],
4	neck	NN	O	neck	advmod	6	SENT_529	[p20l1581t823r1631b945],
5	were	VBD	O	be	auxpass	6	SENT_529	[p20l1598t676r1631b804],
6	treated	VBN	O	treat	dep	1	SENT_529	[p20l1581t466r1631b655],
7	either	CC	O	either	dep	6	SENT_529	[p20l1581t284r1631b440],
8	with	IN	O	with	_	0	SENT_529	[p20l1581t152r1631b265],
9	radi	NN	O	radus	prep_with	6	SENT_529	[p20l1581t6r1631b123],
10	<	JJR	O	<	amod	9	SENT_529	[p20l1581t6r1631b123],

1	lowed	VBN	O	low	_	0	SENT_530	[p20l1656t1248r1706b1402],
2	by	IN	O	by	_	0	SENT_530	[p20l1656t1163r1722b1219],
3	weekly	JJ	SET	weekly	amod	5	SENT_530	[p20l1656t963r1722b1143],
4	intravenous	JJ	O	intravenous	amod	5	SENT_530	[p20l1660t620r1706b939],
5	doses	NNS	O	dose	prep_by	1	SENT_530	[p20l1656t438r1706b595],
6	of	IN	O	of	_	0	SENT_530	[p20l1655t354r1706b413],
7	250	CD	NUMBER	250	num	8	SENT_530	[p20l1659t244r1706b340],
8	mg	NN	O	mg	prep_of	5	SENT_530	[p20l1674t134r1722b218],
9	per	IN	O	per	_	0	SENT_530	[p20l1673t24r1722b109],
10	Ii	NN	O	ii	prep_per	8	SENT_530	[p20l1736t1423r1797b1453],
11	:	:	O	:	_	0	SENT_530	[p20l1736t1423r1797b1453],
12	The	DT	O	the	det	15	SENT_530	[p20l1731t1306r1781b1407],
13	overall	JJ	O	overall	amod	15	SENT_530	[p20l1731t1107r1782b1282],
14	response	NN	O	response	nn	15	SENT_530	[p20l1749t831r1797b1078],
15	rate	NN	O	rate	nsubj	16	SENT_530	[p20l1741t706r1781b805],
16	includes	VBZ	O	include	dep	5	SENT_530	[p20l1731t457r1782b681],
17	complete	JJ	O	complete	acomp	16	SENT_530	[p20l1731t178r1797b432],
18	and	CC	O	and	_	0	SENT_530	[p20l1731t59r1781b154],
19	p	NN	O	p	conj_and	5	SENT_530	[p20l1749t6r1797b30],
20	§	CD	NUMBER	§	num	19	SENT_530	[p20l1806t1434r1873b1454],
21	The	DT	O	the	det	22	SENT_530	[p20l1807t1306r1857b1407],
22	Erbitux	NN	MISC	erbitux	dep	19	SENT_530	[p20l1807t1091r1857b1278],
23	in	IN	O	in	_	0	SENT_530	[p20l1811t1025r1856b1067],
24	First-Line	NNP	O	First-Line	nn	25	SENT_530	[p20l1811t742r1857b994],
25	Treatment	NN	O	treatment	prep_in	22	SENT_530	[p20l1811t434r1857b721],
26	of	IN	O	of	_	0	SENT_530	[p20l1806t352r1857b412],
27	Recurrent	JJ	O	recurrent	amod	28	SENT_530	[p20l1811t73r1857b334],
28	OI	NN	O	ous	prep_of	22	SENT_530	[p20l1824t6r1857b50],

1	tuximab	RB	O	tuximab	_	0	SENT_531	[p20l1882t1185r1932b1406],
2	as	IN	O	as	mark	20	SENT_531	[p20l1900t1106r1932b1161],
3	first-line	JJ	O	first-line	amod	4	SENT_531	[p20l1881t859r1932b1082],
4	treatment	NN	O	treatment	nsubj	20	SENT_531	[p20l1892t566r1932b837],
5	in	IN	O	in	_	0	SENT_531	[p20l1887t499r1932b542],
6	metastatic	JJ	O	metastatic	amod	7	SENT_531	[p20l1887t185r1932b470],
7	diseas	NNS	O	disea	prep_in	4	SENT_531	[p20l1882t6r1932b164],
8	with	IN	O	with	_	0	SENT_531	[p20l1958t1294r2008b1407],
9	the	DT	O	the	det	11	SENT_531	[p20l1958t1185r2008b1270],
10	same	JJ	O	same	amod	11	SENT_531	[p20l1975t1016r2008b1160],
11	chemotherapy	NN	O	chemotherapy	prep_with	7	SENT_531	[p20l1958t600r2024b993],
12	plus	CC	O	plus	prep	11	SENT_531	[p20l1958t467r2023b576],
13	cetuximab	JJ	O	cetuximab	amod	17	SENT_531	[p20l1958t161r2008b442],
14	(	NN	O	(	nn	17	SENT_531	[p20l1962t6r2023b132],
15	intrz	NN	O	intrz	nn	17	SENT_531	[p20l1962t6r2023b132],
16	progression	NN	O	progression	nn	17	SENT_531	[p20l2037t1081r2099b1402],
17	Crossover	NN	O	crossover	dep	12	SENT_531	[p20l2037t762r2083b1037],
18	to	TO	O	to	_	0	SENT_531	[p20l2042t690r2083b743],
19	cetuximab	NN	O	cetuximab	prep_to	17	SENT_531	[p20l2033t386r2083b666],
20	was	VBD	O	be	dep	1	SENT_531	[p20l2050t262r2083b364],
21	not	RB	O	not	neg	20	SENT_531	[p20l2042t148r2083b234],
22	allov	IN	O	allov	prep	20	SENT_531	[p20l2033t6r2083b125],

1	U	NNP	O	U	_	0	SENT_532	[p20l65t6r111b59],

1	T	NN	O	t	nn	2	SENT_533	[p20l61t95r111b138],
2	)	NN	O	)	_	0	SENT_533	[p20l61t95r111b138],
3	H	NN	O	h	nn	5	SENT_533	[p20l65t140r111b196],
4	’	CD	NUMBER	’	num	5	SENT_533	[p20l65t140r111b196],
5	U	NNP	O	U	dep	2	SENT_533	[p20l77t200r111b226],
6	!	.	O	!	_	0	SENT_533	[p20l77t200r111b226],

1	3	CD	NUMBER	3	num	3	SENT_534	[p20l78t232r111b260],
2	O	NN	O	o	nn	3	SENT_534	[p20l78t266r111b298],
3	E	NN	O	e	_	0	SENT_534	[p20l78t303r111b350],
4	to	TO	O	to	_	0	SENT_534	[p20l78t357r111b385],
5	3	CD	NUMBER	3	num	8	SENT_534	[p20l78t391r111b419],
6	U	NNP	O	U	nn	8	SENT_534	[p20l78t426r126b456],
7	‘	CD	NUMBER	‘	num	8	SENT_534	[p20l78t426r126b456],
8	U	NNP	O	U	prep_to	3	SENT_534	[p20l65t460r111b492],
9	)	CD	NUMBER	)	num	10	SENT_534	[p20l65t460r111b492],
10	E	NN	O	e	dep	8	SENT_534	[p20l62t513r111b559],
11	.	.	O	.	_	0	SENT_534	[p20l61t579r112b608],

1	o	NN	O	o	_	0	SENT_535	[p20l61t579r112b608],
2	as	IN	O	as	dep	1	SENT_535	[p20l78t614r111b642],
3	.	.	O	.	_	0	SENT_535	[p20l62t648r111b713],

1	§	CD	NUMBER	§	_	0	SENT_536	[p20l62t648r111b713],
2	x	CC	O	x	_	0	SENT_536	[p20l78t717r111b747],
3	3	CD	NUMBER	3	num	4	SENT_536	[p20l69t751r111b805],
4	cu	NN	O	cu	conj_x	1	SENT_536	[p20l78t805r111b834],
5	U	NNP	O	U	nn	6	SENT_536	[p20l65t837r111b875],
6	L.O	NNP	O	L.O	dep	4	SENT_536	[p20l60t882r111b911, p20l78t912r111b944],
7	>	JJR	O	>	amod	9	SENT_536	[p20l78t961r127b990],
8	~	NN	O	~	nn	9	SENT_536	[p20l78t961r127b990],
9	u	NN	O	u	dep	4	SENT_536	[p20l78t991r111b1019],
10	as	IN	O	as	_	0	SENT_536	[p20l78t1022r111b1050],
11	2	CD	NUMBER	2	prep_as	1	SENT_536	[p20l78t1053r111b1094],
12	El	NNP	O	El	dep	11	SENT_536	[p20l60t1085r111b1137],
13	:	:	O	:	_	0	SENT_536	[p20l60t1085r111b1137],
14	u.	VB	O	u.	dep	1	SENT_536	[p20l65t1139r111b1167],
15	|	JJ	O	|	amod	16	SENT_536	[p20l65t1139r111b1167],
16	L6	NN	O	l6	dobj	14	SENT_536	[p20l66t1191r111b1236],
17	2	CD	NUMBER	2	nsubj	14	SENT_536	[p20l61t1255r111b1297],
18	.	.	O	.	_	0	SENT_536	[p20l61t1303r111b1332],

1	o	NN	O	o	_	0	SENT_537	[p20l61t1303r111b1332],
2	<	JJR	O	<	dep	1	SENT_537	[p20l78t1338r111b1366],
3	5	CD	NUMBER	5	num	4	SENT_537	[p20l78t1338r111b1366],
4	IStudy	NN	O	istudy	dep	1	SENT_537	[p20l66t1368r110b1404, p20l287t1247r354b1403],

1	BonneretaLT	NNP	O	BonneretaLT	nn	4	SENT_538	[p20l399t1020r465b1399],
2	Overall	JJ	O	overall	amod	4	SENT_538	[p20l506t1210r557b1401],
3	response	NN	O	response	nn	4	SENT_538	[p20l524t937r572b1184],
4	rate	NN	O	rate	dep	18	SENT_538	[p20l516t815r557b914],
5	(	CD	PERCENT	(	num	6	SENT_538	[p20l509t657r573b789],
6	%	NN	PERCENT	%	dep	4	SENT_538	[p20l509t657r573b789],
7	)	CD	NUMBER	)	dep	6	SENT_538	[p20l509t657r573b789],
8	:	:	O	:	_	0	SENT_538	[p20l509t657r573b789],
9	i	FW	O	i	dep	6	SENT_538	[p20l509t657r573b789],
10	:	:	O	:	_	0	SENT_538	[p20l509t657r573b789],
11	Median	JJ	O	median	amod	13	SENT_538	[p20l614t1198r665b1397],
12	locoregional	JJ	O	locoregional	amod	13	SENT_538	[p20l614t840r681b1172],
13	control	NN	O	control	dep	9	SENT_538	[p20l614t628r665b817],
14	Median	JJ	O	median	amod	15	SENT_538	[p20l721t1198r772b1397],
15	progression	NN	O	progression	dep	18	SENT_538	[p20l721t725r788b1172],
16	—	CD	NUMBER	—	num	18	SENT_538	[p20l721t725r788b1172],
17	free	JJ	O	free	amod	18	SENT_538	[p20l721t725r788b1172],
18	survival	NN	O	survival	dep	24	SENT_538	[p20l721t499r772b703],
19	(	CD	NUMBER	(	num	20	SENT_538	[p20l726t345r787b470],
20	mo	NN	DURATION	mo	dep	18	SENT_538	[p20l726t345r787b470],
21	)	CD	NUMBER	)	num	24	SENT_538	[p20l726t345r787b470],
22	Median	JJ	O	median	amod	24	SENT_538	[p20l829t1198r880b1397],
23	overall	JJ	O	overall	amod	24	SENT_538	[p20l829t998r880b1174],
24	survival	NN	O	survival	dep	29	SENT_538	[p20l829t770r880b974],
25	(	CD	NUMBER	(	num	26	SENT_538	[p20l833t616r895b741],
26	mo	NN	DURATION	mo	dep	24	SENT_538	[p20l833t616r895b741],
27	)	CD	NUMBER	)	num	29	SENT_538	[p20l833t616r895b741],
28	EXTREME	JJ	O	extreme	amod	29	SENT_538	[p20l941t1125r986b1398],
29	trialﬁ	NN	O	trialﬁ	dep	34	SENT_538	[p20l937t968r1004b1108],
30	Overall	JJ	O	overall	amod	32	SENT_538	[p20l1044t1210r1094b1401],
31	response	NN	O	response	nn	32	SENT_538	[p20l1062t937r1110b1184],
32	rate	NN	O	rate	dep	29	SENT_538	[p20l1054t815r1094b914],
33	(	CD	PERCENT	(	num	34	SENT_538	[p20l1046t657r1110b789],
34	%	NN	PERCENT	%	dep	35	SENT_538	[p20l1046t657r1110b789],
35	)	CD	NUMBER	)	_	0	SENT_538	[p20l1046t657r1110b789],
36	:	:	O	:	_	0	SENT_538	[p20l1046t657r1110b789],
37	i2	CD	NUMBER	i2	num	39	SENT_538	[p20l1046t657r1110b789],
38	Median	JJ	O	median	amod	39	SENT_538	[p20l1152t1198r1202b1397],
39	progression	NN	O	progression	dep	48	SENT_538	[p20l1151t725r1218b1172],
40	—	CD	NUMBER	—	num	42	SENT_538	[p20l1151t725r1218b1172],
41	free	JJ	O	free	amod	42	SENT_538	[p20l1151t725r1218b1172],
42	survival	NN	O	survival	dep	39	SENT_538	[p20l1152t499r1202b703],
43	(	CD	NUMBER	(	num	44	SENT_538	[p20l1156t345r1217b470],
44	mo	NN	DURATION	mo	dep	48	SENT_538	[p20l1156t345r1217b470],
45	)	CD	NUMBER	)	num	48	SENT_538	[p20l1156t345r1217b470],
46	Median	JJ	O	median	amod	48	SENT_538	[p20l1259t1198r1309b1397],
47	overall	JJ	O	overall	amod	48	SENT_538	[p20l1259t999r1310b1175],
48	survival	NN	O	survival	dep	51	SENT_538	[p20l1259t770r1310b974],
49	(	CD	NUMBER	(	num	50	SENT_538	[p20l1263t616r1325b741],
50	mo	NN	DURATION	mo	dep	48	SENT_538	[p20l1263t616r1325b741],
51	)	NN	O	)	dep	35	SENT_538	[p20l1263t616r1325b741],

1	7	CD	NUMBER	7	nsubj	4	SENT_539	[p20l1434t1426r1464b1456],
2	"	``	O	"	punct	3	SENT_539	[p20l1434t1426r1464b1456],
3	CI	NN	O	ci	dep	1	SENT_539	[p20l1434t1353r1480b1404],
4	denotes	VBZ	O	denote	_	0	SENT_539	[p20l1430t1110r1480b1325],
5	confidence	NN	O	confidence	nn	6	SENT_539	[p20l1429t787r1480b1085],
6	interval	NN	O	interval	dobj	4	SENT_539	[p20l1430t548r1480b762],
7	.	.	O	.	_	0	SENT_539	[p20l1430t548r1480b762],

1	1	CD	NUMBER	1	dep	9	SENT_540	[p20l1510t1423r1571b1454],
2	'	''	O	'	_	0	SENT_540	[p20l1510t1423r1571b1454],
3	This	DT	O	this	det	5	SENT_540	[p20l1505t1292r1555b1407],
4	study	NN	O	study	nn	5	SENT_540	[p20l1503t1073r1571b1266],
5	“	NN	O	“	nsubj	9	SENT_540	[p20l1503t1073r1571b1266],
6	was	VBD	O	be	cop	9	SENT_540	[p20l1523t948r1555b1051],
7	a	DT	O	a	det	9	SENT_540	[p20l1523t897r1555b923],
8	randomized	JJ	O	randomized	amod	9	SENT_540	[p20l1505t546r1555b870],
9	phase	NN	O	phase	_	0	SENT_540	[p20l1505t359r1571b517],
10	3	CD	NUMBER	3	num	11	SENT_540	[p20l1509t311r1555b335],
11	trial	NN	O	trial	nsubjpass	25	SENT_540	[p20l1505t184r1555b286],
12	of	IN	O	of	_	0	SENT_540	[p20l1505t99r1555b158],
13	rad	NN	O	rad	prep_of	11	SENT_540	[p20l1505t6r1555b82],
14	proximately	RB	O	proximately	amod	13	SENT_540	[p20l11t1651r526b1750],
15	40	CD	NUMBER	40	tmod	14	SENT_540	[p20l565t1657r668b1729],
16	to	TO	O	to	_	0	SENT_540	[p20l714t1668r795b1729],
17	46	CD	NUMBER	46	number	18	SENT_540	[p20l840t1655r1233b1730],
18	°	CD	NUMBER	°	prep_to	14	SENT_540	[p20l840t1655r1233b1730],
19	/	:	O	/	punct	20	SENT_540	[p20l840t1655r1233b1730],
20	o.	NN	O	o.	dep	18	SENT_540	[p20l840t1655r1233b1730],
21	64	CD	NUMBER	64	number	22	SENT_540	[p20l840t1655r1233b1730],
22	'67	CD	NUMBER	'67	dep	20	SENT_540	[p20l840t1655r1233b1730],
23	Cetuximab	NNP	O	Cetuximab	dep	22	SENT_540	[p20l1277t1651r1749b1730],
24	was	VBD	O	be	auxpass	25	SENT_540	[p20l1791t1677r1954b1730],
25	approved	VBN	O	approve	rcmod	9	SENT_540	[p20l2001t1677r2133b1750, p20l11t1778r300b1878],
26	by	IN	O	by	_	0	SENT_540	[p20l346t1778r443b1878],
27	the	DT	O	the	det	28	SENT_540	[p20l485t1778r617b1856],
28	FDA	NNP	ORGANIZATION	FDA	agent	25	SENT_540	[p20l662t1785r847b1856],
29	in	IN	O	in	_	0	SENT_540	[p20l889t1779r972b1856],
30	February	NNP	DATE	February	prep_in	28	SENT_540	[p20l1017t1778r1403b1878],
31	2006	CD	DATE	2006	num	30	SENT_540	[p20l1444t1784r1652b1857],
32	for	IN	O	for	_	0	SENT_540	[p20l1699t1777r1822b1857],
33	use	NN	O	use	prep_for	25	SENT_540	[p20l1865t1804r2005b1858],
34	in	IN	O	in	_	0	SENT_540	[p20l2051t1779r2134b1856],
35	combination	NN	O	combination	prep_in	33	SENT_540	[p20l12t1907r559b1985],
36	with	IN	O	with	_	0	SENT_540	[p20l599t1907r794b1986],
37	radiotherapy	NN	O	radiotherapy	prep_with	35	SENT_540	[p20l839t1907r1386b2006],
38	to	TO	O	to	aux	39	SENT_540	[p20l1426t1924r1507b1985],
39	treat	VB	O	treat	xcomp	25	SENT_540	[p20l1554t1923r1753b1985],
40	patients	NNS	O	patient	dobj	39	SENT_540	[p20l1791t1908r2132b2006],
41	with	IN	O	with	prep	40	SENT_540	[p20l7t2035r203b2114],
42	locally	RB	O	locally	advmod	43	SENT_540	[p20l255t2035r537b2134],
43	advanced	VBN	O	advance	dep	41	SENT_540	[p20l586t2035r1004b2130],
44	,	,	O	,	_	0	SENT_540	[p20l586t2035r1004b2130],
45	unresectable	JJ	O	unresectable	amod	47	SENT_540	[p20l1063t2035r1607b2114],
46	squamouscell	NN	O	squamouscell	nn	47	SENT_540	[p20l1662t2061r2133b2134, p20l12t2163r158b2241],
47	carcinoma	NN	O	carcinoma	appos	40	SENT_540	[p20l195t2164r648b2242],
48	of	IN	O	of	_	0	SENT_540	[p20l684t2162r785b2242],
49	the	DT	O	the	det	50	SENT_540	[p20l804t2163r936b2241],
50	head	NN	O	head	prep_of	47	SENT_540	[p20l973t2163r1176b2242],
51	and	CC	O	and	_	0	SENT_540	[p20l1212t2163r1369b2242],
52	neck	NN	O	neck	prep_of	47	SENT_540	[p20l1406t2163r1627b2242],
53	.	.	O	.	_	0	SENT_540	[p20l1406t2163r1627b2242],

1	It	PRP	O	it	nsubjpass	4	SENT_541	[p20l1668t2171r1733b2241],
2	was	VBD	O	be	auxpass	4	SENT_541	[p20l1760t2189r1923b2242],
3	also	RB	O	also	advmod	4	SENT_541	[p20l1961t2163r2133b2242],
4	approved	VBN	O	approve	_	0	SENT_541	[p20l11t2290r401b2390],
5	as	IN	O	as	_	0	SENT_541	[p20l440t2316r526b2368],
6	monotherapy	NN	O	monotherapy	prep_as	4	SENT_541	[p20l568t2290r1142b2390],
7	for	IN	O	for	_	0	SENT_541	[p20l1177t2289r1300b2369],
8	metastatic	JJ	O	metastatic	amod	9	SENT_541	[p20l1337t2291r1784b2368],
9	disease	NN	O	disease	prep_for	6	SENT_541	[p20l1824t2290r2134b2369],
10	in	IN	O	in	_	0	SENT_541	[p20l11t2420r95b2496],
11	patients	NNS	O	patient	prep_in	4	SENT_541	[p20l132t2420r473b2518],
12	who	WP	O	who	nsubj	15	SENT_541	[p20l510t2419r692b2498],
13	have	VBP	O	have	aux	15	SENT_541	[p20l733t2419r923b2498],
14	not	RB	O	not	neg	15	SENT_541	[p20l961t2436r1105b2497],
15	had	VBN	O	have	rcmod	11	SENT_541	[p20l1138t2419r1295b2497],
16	a	DT	O	a	det	17	SENT_541	[p20l1333t2445r1377b2496],
17	response	NN	O	response	dobj	15	SENT_541	[p20l1414t2445r1795b2518],
18	to	TO	O	to	_	0	SENT_541	[p20l1835t2436r1916b2497],
19	chemotherapy	NN	O	chemotherapy	prep_to	15	SENT_541	[p20l1957t2419r2133b2497, p20l12t2547r488b2646],
20	.	.	O	.	_	0	SENT_541	[p20l1957t2419r2133b2497, p20l12t2547r488b2646],

1	In	IN	O	in	_	0	SENT_542	[p20l535t2554r624b2624],
2	March	NNP	DATE	March	prep_in	7	SENT_542	[p20l664t2547r940b2625],
3	2006	CD	DATE	2006	num	2	SENT_542	[p20l983t2553r1214b2642],
4	,	,	O	,	_	0	SENT_542	[p20l983t2553r1214b2642],
5	the	DT	O	the	det	6	SENT_542	[p20l1263t2547r1396b2625],
6	EMEA	NNP	ORGANIZATION	EMEA	nsubj	7	SENT_542	[p20l1438t2554r1706b2625],
7	approved	VBD	O	approve	_	0	SENT_542	[p20l1745t2547r2134b2646],
8	cetuximab	NN	O	cetuximab	dobj	7	SENT_542	[p20l12t2674r464b2754],
9	in	IN	O	in	_	0	SENT_542	[p20l502t2675r585b2752],
10	combination	NN	O	combination	prep_in	7	SENT_542	[p20l623t2674r1169b2753],
11	with	IN	O	with	_	0	SENT_542	[p20l1202t2674r1398b2754],
12	radiotherapy	NN	O	radiotherapy	prep_with	7	SENT_542	[p20l1435t2674r1982b2774],
13	for	IN	O	for	_	0	SENT_542	[p20l2014t2673r2137b2753],
14	the	DT	O	the	det	15	SENT_542	[p20l12t2802r145b2880],
15	treatment	NN	O	treatment	prep_for	7	SENT_542	[p20l185t2819r609b2880],
16	of	IN	O	of	_	0	SENT_542	[p20l644t2801r744b2881],
17	locally	RB	O	locally	advmod	18	SENT_542	[p20l764t2802r1047b2902],
18	advanced	VBN	O	advance	amod	19	SENT_542	[p20l1081t2802r1476b2882],
19	disease	NN	O	disease	prep_of	15	SENT_542	[p20l1517t2802r1850b2881],
20	.	.	O	.	_	0	SENT_542	[p20l1517t2802r1850b2881],

1	PANCREATIC	JJ	O	pancreatic	amod	2	SENT_543	[p20l17t3077r502b3127],
2	CANCER	NNP	O	CANCER	_	0	SENT_543	[p20l535t3077r849b3127],

1	A	DT	O	a	dep	184	SENT_544	[p20l8t3184r74b3254],
2	single	JJ	O	single	dep	184	SENT_544	[p20l117t3176r648b3277],
3	—	NN	O	—	dep	184	SENT_544	[p20l117t3176r648b3277],
4	group	NN	O	group	dep	184	SENT_544	[p20l117t3176r648b3277],
5	phase	NN	O	phase	dep	184	SENT_544	[p20l693t3176r937b3276],
6	2	CD	NUMBER	2	dep	184	SENT_544	[p20l982t3182r1029b3254],
7	study	NN	O	study	dep	184	SENT_544	[p20l1076t3176r1301b3276],
8	suggested	VBD	O	suggest	dep	184	SENT_544	[p20l1343t3176r1761b3277],
9	that	IN	O	that	dep	184	SENT_544	[p20l1805t3176r1974b3254],
10	cetuximab	NN	O	cetuximab	dep	184	SENT_544	[p20l2015t3202r2133b3254, p20l12t3304r365b3383],
11	was	VBD	O	be	dep	184	SENT_544	[p20l408t3330r568b3383],
12	promising	JJ	O	promising	dep	184	SENT_544	[p20l616t3305r1055b3405],
13	when	WRB	O	when	dep	184	SENT_544	[p20l1093t3304r1323b3383],
14	used	VBN	O	use	dep	184	SENT_544	[p20l1369t3304r1563b3383],
15	in	IN	O	in	dep	184	SENT_544	[p20l1608t3305r1690b3382],
16	combination	NN	O	combination	dep	184	SENT_544	[p20l1737t3304r2133b3383, p20l12t3433r181b3511],
17	with	IN	O	with	dep	184	SENT_544	[p20l227t3432r423b3511],
18	gemcitabine	NN	O	gemcitabine	dep	184	SENT_544	[p20l472t3432r998b3533],
19	for	IN	O	for	dep	184	SENT_544	[p20l1049t3431r1172b3511],
20	the	DT	O	the	dep	184	SENT_544	[p20l1219t3432r1352b3510],
21	treatment	NN	O	treatment	dep	184	SENT_544	[p20l1404t3449r1827b3510],
22	of	IN	O	of	dep	184	SENT_544	[p20l1873t3431r1973b3511],
23	advanced	JJ	O	advanced	dep	184	SENT_544	[p20l2004t3432r2133b3511, p20l7t3560r304b3639],
24	pancreatic	JJ	O	pancreatic	dep	184	SENT_544	[p20l372t3561r818b3659],
25	cancer	NN	O	cancer	dep	184	SENT_544	[p20l888t3564r1265b3638],
26	.68	CD	NUMBER	.68	dep	184	SENT_544	[p20l888t3564r1265b3638],
27	However	RB	O	however	dep	184	SENT_544	[p20l1334t3567r1729b3655],
28	,	,	O	,	_	0	SENT_544	[p20l1334t3567r1729b3655],
29	a	DT	O	a	dep	184	SENT_544	[p20l1803t3586r1848b3637],
30	more	RBR	O	more	dep	184	SENT_544	[p20l1915t3586r2134b3638],
31	recent	JJ	O	recent	dep	184	SENT_544	[p20l12t3704r271b3765],
32	randomized	JJ	O	randomized	dep	184	SENT_544	[p20l299t3687r810b3766],
33	phase	NN	O	phase	dep	184	SENT_544	[p20l841t3687r1086b3787],
34	3	CD	NUMBER	3	dep	184	SENT_544	[p20l1120t3693r1164b3766],
35	study	NN	O	study	dep	184	SENT_544	[p20l1202t3687r1428b3787],
36	failed	VBD	O	fail	dep	184	SENT_544	[p20l1457t3686r1690b3766],
37	to	TO	O	to	dep	184	SENT_544	[p20l1724t3704r1804b3766],
38	show	VB	O	show	dep	184	SENT_544	[p20l1841t3687r2062b3767],
39	a	DT	O	a	dep	184	SENT_544	[p20l2091t3713r2135b3765],
40	significant	JJ	O	significant	dep	184	SENT_544	[p21l13t21r470b123],
41	survival	NN	O	survival	dep	184	SENT_544	[p21l502t22r826b101],
42	advantage	NN	O	advantage	dep	184	SENT_544	[p21l861t22r1283b123],
43	with	IN	O	with	dep	184	SENT_544	[p21l1315t22r1506b101],
44	this	DT	O	this	dep	184	SENT_544	[p21l1543t22r1698b100],
45	combination	NN	O	combination	dep	184	SENT_544	[p21l1737t22r2133b101, p21l12t151r179b229],
46	as	IN	O	as	dep	184	SENT_544	[p21l216t176r300b228],
47	compared	VBN	O	compare	dep	184	SENT_544	[p21l342t150r761b250],
48	with	IN	O	with	dep	184	SENT_544	[p21l795t150r987b229],
49	standard	JJ	O	standard	dep	184	SENT_544	[p21l1027t150r1399b229],
50	treatment	NN	O	treatment	dep	184	SENT_544	[p21l1437t167r1853b228],
51	(	NN	O	(	dep	184	SENT_544	[p21l1891t157r2133b251, p21l12t278r343b356],
52	gemcitabine	NN	O	gemcitabine	dep	184	SENT_544	[p21l1891t157r2133b251, p21l12t278r343b356],
53	monotherapy	NN	O	monotherapy	dep	184	SENT_544	[p21l373t278r1058b377],
54	)	CD	NUMBER	)	dep	184	SENT_544	[p21l373t278r1058b377],
55	.69	CD	NUMBER	.69	dep	184	SENT_544	[p21l373t278r1058b377],
56	In	IN	O	in	dep	184	SENT_544	[p21l1089t286r1176b355],
57	contrast	NN	O	contrast	dep	184	SENT_544	[p21l1208t294r1572b373],
58	,	,	O	,	_	0	SENT_544	[p21l1208t294r1572b373],
59	another	DT	O	another	dep	184	SENT_544	[p21l1607t278r1936b356],
60	randomized	VBN	O	randomize	dep	184	SENT_544	[p21l1963t304r2133b355, p21l12t406r381b484],
61	phase	NN	O	phase	dep	184	SENT_544	[p21l456t406r700b505],
62	3	CD	NUMBER	3	dep	184	SENT_544	[p21l777t412r821b485],
63	trial	NN	O	trial	dep	184	SENT_544	[p21l901t406r1096b501],
64	,	,	O	,	_	0	SENT_544	[p21l901t406r1096b501],
65	which	WDT	O	which	dep	184	SENT_544	[p21l1173t406r1431b485],
66	compared	VBD	O	compare	dep	184	SENT_544	[p21l1508t406r1927b505],
67	the	DT	O	the	dep	184	SENT_544	[p21l2003t406r2134b484],
68	combination	NN	O	combination	dep	184	SENT_544	[p21l12t534r548b613],
69	of	IN	O	of	dep	184	SENT_544	[p21l602t533r701b613],
70	erlotinib	NN	O	erlotinib	dep	184	SENT_544	[p21l736t534r1094b613],
71	(	NN	O	(	dep	184	SENT_544	[p21l1154t540r1328b625],
72	100	CD	NUMBER	100	dep	184	SENT_544	[p21l1154t540r1328b625],
73	mg	NN	O	mg	dep	184	SENT_544	[p21l1382t560r1519b635],
74	per	IN	O	per	dep	184	SENT_544	[p21l1568t560r1705b634],
75	day	NN	DURATION	day	dep	184	SENT_544	[p21l1756t534r1921b634],
76	)	CD	NUMBER	)	dep	184	SENT_544	[p21l1756t534r1921b634],
77	and	CC	O	and	dep	184	SENT_544	[p21l1979t534r2134b613],
78	gemcitabine	NN	O	gemcitabine	dep	184	SENT_544	[p21l12t662r527b763],
79	with	IN	O	with	dep	184	SENT_544	[p21l581t662r773b741],
80	gemcitabine	NN	O	gemcitabine	dep	184	SENT_544	[p21l831t662r1346b763],
81	alone	RB	O	alone	dep	184	SENT_544	[p21l1404t662r1651b758],
82	,	,	O	,	_	0	SENT_544	[p21l1404t662r1651b758],
83	showed	VBD	O	show	dep	184	SENT_544	[p21l1717t662r2034b741],
84	a	DT	O	a	dep	184	SENT_544	[p21l2091t688r2136b740],
85	signiﬁcant	JJ	O	signiﬁcant	dep	184	SENT_544	[p21l13t789r470b891],
86	improvement	NN	O	improvement	dep	184	SENT_544	[p21l501t791r1063b890],
87	in	IN	O	in	dep	184	SENT_544	[p21l1093t791r1175b868],
88	response	NN	O	response	dep	184	SENT_544	[p21l1210t816r1583b890],
89	and	CC	O	and	dep	184	SENT_544	[p21l1618t790r1774b869],
90	survival	NN	O	survival	dep	184	SENT_544	[p21l1810t790r2134b869],
91	rates	NNS	O	rate	dep	184	SENT_544	[p21l12t934r210b995],
92	(	VBP	O	(	dep	184	SENT_544	[p21l243t917r562b1008],
93	hazard	NN	O	hazard	dep	184	SENT_544	[p21l243t917r562b1008],
94	ratio	NN	O	ratio	dep	184	SENT_544	[p21l587t918r780b996],
95	for	IN	O	for	dep	184	SENT_544	[p21l807t916r928b996],
96	death	NN	O	death	dep	184	SENT_544	[p21l951t917r1206b1013],
97	,	,	O	,	_	0	SENT_544	[p21l951t917r1206b1013],
98	0.82	CD	NUMBER	0.82	dep	184	SENT_544	[p21l1237t923r1435b1013],
99	;	:	O	;	_	0	SENT_544	[p21l1237t923r1435b1013],
100	95	CD	PERCENT	95	dep	184	SENT_544	[p21l1465t922r1647b996],
101	%	NN	PERCENT	%	dep	184	SENT_544	[p21l1465t922r1647b996],
102	confidence	NN	O	confidence	dep	184	SENT_544	[p21l1672t916r2134b996],
103	interval	NN	O	interval	dep	184	SENT_544	[p21l11t1046r351b1141],
104	,	,	O	,	_	0	SENT_544	[p21l11t1046r351b1141],
105	0.69	CD	NUMBER	0.69	dep	184	SENT_544	[p21l390t1052r562b1124],
106	to	TO	O	to	dep	184	SENT_544	[p21l596t1063r677b1124],
107	0.99	CD	NUMBER	0.99	dep	184	SENT_544	[p21l711t1052r907b1140],
108	;	:	O	;	_	0	SENT_544	[p21l711t1052r907b1140],
109	P	NN	O	p	dep	184	SENT_544	[p21l942t1052r1276b1140],
110	=	JJ	O	=	dep	184	SENT_544	[p21l942t1052r1276b1140],
111	0.04	CD	NUMBER	0.04	dep	184	SENT_544	[p21l942t1052r1276b1140],
112	;	:	O	;	_	0	SENT_544	[p21l942t1052r1276b1140],
113	1-year	JJ	DURATION	1-year	dep	184	SENT_544	[p21l1316t1052r1563b1145],
114	survival	NN	O	survival	dep	184	SENT_544	[p21l1593t1046r1917b1125],
115	rate	NN	O	rate	dep	184	SENT_544	[p21l1949t1062r2129b1141],
116	,	,	O	,	_	0	SENT_544	[p21l1949t1062r2129b1141],
117	23	CD	PERCENT	23	dep	184	SENT_544	[p21l12t1178r196b1252],
118	%	NN	PERCENT	%	dep	184	SENT_544	[p21l12t1178r196b1252],
119	vs.	CC	O	vs.	dep	184	SENT_544	[p21l247t1199r353b1252],
120	17	CD	PERCENT	17	dep	184	SENT_544	[p21l418t1178r620b1268],
121	%	NN	PERCENT	%	dep	184	SENT_544	[p21l418t1178r620b1268],
122	,	,	O	,	_	0	SENT_544	[p21l418t1178r620b1268],
123	P	NN	O	p	dep	184	SENT_544	[p21l679t1179r1035b1268],
124	=	JJ	O	=	dep	184	SENT_544	[p21l679t1179r1035b1268],
125	0.02	CD	NUMBER	0.02	dep	184	SENT_544	[p21l679t1179r1035b1268],
126	)	NN	O	)	dep	184	SENT_544	[p21l679t1179r1035b1268],
127	,	,	O	,	_	0	SENT_544	[p21l679t1179r1035b1268],
128	and	CC	O	and	dep	184	SENT_544	[p21l1097t1173r1252b1251],
129	both	CC	O	both	dep	184	SENT_544	[p21l1308t1173r1502b1251],
130	the	DT	O	the	dep	184	SENT_544	[p21l1559t1173r1689b1250],
131	FDA	NNP	ORGANIZATION	FDA	dep	184	SENT_544	[p21l1744t1179r1926b1250],
132	and	CC	O	and	dep	184	SENT_544	[p21l1979t1173r2134b1251],
133	EMEA	NNP	ORGANIZATION	EMEA	dep	184	SENT_544	[p21l11t1309r275b1379],
134	have	VBP	O	have	dep	184	SENT_544	[p21l323t1301r509b1380],
135	approved	VBN	O	approve	dep	184	SENT_544	[p21l560t1301r942b1401],
136	this	DT	O	this	dep	184	SENT_544	[p21l994t1301r1150b1379],
137	regimen	NN	O	regimen	dep	184	SENT_544	[p21l1204t1302r1554b1402],
138	for	IN	O	for	dep	184	SENT_544	[p21l1605t1300r1725b1380],
139	first-line	JJ	O	first-line	dep	184	SENT_544	[p21l1774t1300r2134b1379],
140	treatment	NN	O	treatment	dep	184	SENT_544	[p21l12t1446r428b1507],
141	of	IN	O	of	dep	184	SENT_544	[p21l455t1428r554b1508],
142	pancreatic	JJ	O	pancreatic	dep	184	SENT_544	[p21l565t1430r1002b1529],
143	cancer	NN	O	cancer	dep	184	SENT_544	[p21l1034t1436r1399b1508],
144	.7	CD	NUMBER	.7	dep	184	SENT_544	[p21l1034t1436r1399b1508],
145	°	CD	NUMBER	°	dep	184	SENT_544	[p21l1034t1436r1399b1508],
146	Although	IN	O	although	dep	184	SENT_544	[p21l1427t1429r1827b1530],
147	the	DT	O	the	dep	184	SENT_544	[p21l1859t1429r1989b1507],
148	increase	NN	O	increase	dep	184	SENT_544	[p21l2020t1430r2133b1507, p21l12t1584r270b1636],
149	in	IN	O	in	dep	184	SENT_544	[p21l311t1559r393b1636],
150	survival	NN	O	survival	dep	184	SENT_544	[p21l435t1558r759b1637],
151	could	MD	O	could	dep	184	SENT_544	[p21l801t1558r1031b1637],
152	be	VB	O	be	dep	184	SENT_544	[p21l1072t1558r1167b1637],
153	considered	VBN	O	consider	dep	184	SENT_544	[p21l1209t1558r1663b1637],
154	modest	JJ	O	modest	dep	184	SENT_544	[p21l1703t1558r2017b1637],
155	in	IN	O	in	dep	184	SENT_544	[p21l2051t1559r2134b1636],
156	absolute	JJ	O	absolute	dep	184	SENT_544	[p21l11t1686r353b1765],
157	terms	NNS	O	term	dep	184	SENT_544	[p21l382t1703r639b1782],
158	,	,	O	,	_	0	SENT_544	[p21l382t1703r639b1782],
159	it	PRP	O	it	dep	184	SENT_544	[p21l674t1687r731b1764],
160	showed	VBD	O	show	dep	184	SENT_544	[p21l756t1686r1068b1765],
161	that	IN	O	that	dep	184	SENT_544	[p21l1098t1686r1264b1764],
162	there	EX	O	there	dep	184	SENT_544	[p21l1288t1686r1496b1765],
163	is	VBZ	O	be	dep	184	SENT_544	[p21l1525t1687r1588b1764],
164	a	DT	O	a	dep	184	SENT_544	[p21l1619t1712r1663b1764],
165	significant	JJ	O	significant	dep	184	SENT_544	[p21l1693t1685r2139b1787],
166	advantage	NN	O	advantage	dep	184	SENT_544	[p21l11t1814r433b1915],
167	in	IN	O	in	dep	184	SENT_544	[p21l475t1815r558b1892],
168	adding	VBG	O	add	dep	184	SENT_544	[p21l600t1814r893b1915],
169	an	DT	O	a	dep	184	SENT_544	[p21l932t1840r1033b1892],
170	anticancer	JJ	O	anticancer	dep	184	SENT_544	[p21l1075t1815r1516b1892],
171	drug	NN	O	drug	dep	184	SENT_544	[p21l1557t1814r1757b1915],
172	to	TO	O	to	dep	184	SENT_544	[p21l1797t1831r1877b1893],
173	gemcitabine	NN	O	gemcitabine	dep	184	SENT_544	[p21l1921t1840r2133b1915, p21l12t1941r343b2020],
174	in	IN	O	in	dep	184	SENT_544	[p21l378t1942r460b2019],
175	the	DT	O	the	dep	184	SENT_544	[p21l497t1941r627b2019],
176	treatment	NN	O	treatment	dep	184	SENT_544	[p21l664t1958r1079b2019],
177	of	IN	O	of	dep	184	SENT_544	[p21l1111t1940r1209b2020],
178	metastatic	JJ	O	metastatic	dep	184	SENT_544	[p21l1227t1942r1665b2019],
179	pancreatic	JJ	O	pancreatic	dep	184	SENT_544	[p21l1698t1942r2135b2041],
180	cancer	NN	O	cancer	dep	184	SENT_544	[p21l12t2096r288b2148],
181	—	VBD	O	—	dep	184	SENT_544	[p21l314t2115r421b2123],
182	a	DT	O	a	dep	184	SENT_544	[p21l449t2096r493b2148],
183	unique	JJ	O	unique	dep	184	SENT_544	[p21l524t2071r813b2170],
184	finding	NN	O	finding	_	0	SENT_544	[p21l845t2069r1181b2171],
185	.	.	O	.	_	0	SENT_544	[p21l845t2069r1181b2171],

1	PREDICTING	VBG	O	predict	_	0	SENT_545	[p21l275t2395r984b2454],
2	THE	DT	O	the	det	3	SENT_545	[p21l1031t2396r1249b2453],
3	RESPONSE	NN	O	response	dobj	1	SENT_545	[p21l1305t2395r1873b2454],

1	TO	TO	O	to	dep	3	SENT_546	[p21l454t2502r593b2561],
2	ANTI-EGFR	NN	O	anti-egfr	nn	3	SENT_546	[p21l642t2502r1271b2561],
3	DRUGS	NNS	O	drug	_	0	SENT_546	[p21l1320t2502r1686b2561],

1	Since	IN	O	since	mark	9	SENT_547	[p21l14t2698r236b2776],
2	only	RB	O	only	advmod	4	SENT_547	[p21l291t2697r475b2797],
3	a	DT	O	a	det	4	SENT_547	[p21l524t2723r568b2775],
4	subgroup	NN	O	subgroup	nsubj	9	SENT_547	[p21l622t2697r1025b2798],
5	of	IN	O	of	_	0	SENT_547	[p21l1080t2696r1181b2776],
6	patients	NNS	O	patient	prep_of	4	SENT_547	[p21l1214t2698r1556b2797],
7	with	IN	O	with	_	0	SENT_547	[p21l1607t2697r1803b2776],
8	cancer	NN	O	cancer	prep_with	6	SENT_547	[p21l1857t2723r2138b2775],
9	have	VBP	O	have	advcl	20	SENT_547	[p21l12t2825r202b2904],
10	a	DT	O	a	det	12	SENT_547	[p21l231t2851r276b2903],
11	clinical	JJ	O	clinical	amod	12	SENT_547	[p21l306t2825r619b2903],
12	benefit	NN	O	benefit	dobj	9	SENT_547	[p21l649t2824r954b2904],
13	from	IN	O	from	_	0	SENT_547	[p21l979t2824r1190b2904],
14	treatment	NN	O	treatment	prep_from	9	SENT_547	[p21l1221t2842r1644b2903],
15	with	IN	O	with	_	0	SENT_547	[p21l1665t2825r1860b2904],
16	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_547	[p21l1889t2831r2145b2908],
17	inhibitors	NNS	O	inhibitor	prep_with	14	SENT_547	[p21l11t2953r457b3049],
18	,	,	O	,	_	0	SENT_547	[p21l11t2953r457b3049],
19	there	EX	O	there	expl	20	SENT_547	[p21l498t2953r715b3031],
20	is	VBZ	O	be	_	0	SENT_547	[p21l749t2954r815b3031],
21	an	DT	O	a	det	23	SENT_547	[p21l851t2979r954b3031],
22	urgent	JJ	O	urgent	amod	23	SENT_547	[p21l989t2970r1273b3054],
23	need	NN	O	need	nsubj	20	SENT_547	[p21l1302t2953r1504b3032],
24	for	IN	O	for	_	0	SENT_547	[p21l1538t2952r1662b3032],
25	identification	NN	O	identification	nn	28	SENT_547	[p21l1693t2952r2133b3032, p21l12t3082r181b3160],
26	and	CC	O	and	_	0	SENT_547	[p21l222t3081r380b3160],
27	clinical	JJ	O	clinical	nn	28	SENT_547	[p21l422t3081r735b3159],
28	validation	NN	O	validation	prep_for	23	SENT_547	[p21l772t3081r1200b3160],
29	of	IN	O	of	_	0	SENT_547	[p21l1242t3080r1342b3160],
30	useful	JJ	O	useful	amod	31	SENT_547	[p21l1365t3080r1629b3160],
31	criteria	NNS	O	criterion	prep_of	28	SENT_547	[p21l1671t3082r1974b3159],
32	for	IN	O	for	_	0	SENT_547	[p21l2014t3080r2137b3160],
33	selecting	VBG	O	select	prepc_for	31	SENT_547	[p21l13t3209r397b3310],
34	patients	NNS	O	patient	dobj	33	SENT_547	[p21l427t3210r768b3309],
35	for	IN	O	for	_	0	SENT_547	[p21l807t3208r930b3288],
36	such	JJ	O	such	amod	37	SENT_547	[p21l964t3209r1158b3288],
37	treatment	NN	O	treatment	prep_for	33	SENT_547	[p21l1193t3226r1638b3288],
38	.	.	O	.	_	0	SENT_547	[p21l1193t3226r1638b3288],

1	A	DT	O	a	det	2	SENT_548	[p21l1676t3217r1742b3287],
2	series	NN	O	series	nsubj	5	SENT_548	[p21l1775t3210r2014b3287],
3	of	IN	O	of	_	0	SENT_548	[p21l2053t3208r2152b3288],
4	studies	NNS	O	study	prep_of	2	SENT_548	[p21l13t3337r313b3416],
5	suggests	VBZ	O	suggest	_	0	SENT_548	[p21l347t3354r714b3438],
6	that	IN	O	that	complm	20	SENT_548	[p21l747t3337r919b3415],
7	considering	VBG	O	consider	dep	20	SENT_548	[p21l945t3337r1452b3438],
8	certain	JJ	O	certain	amod	10	SENT_548	[p21l1480t3338r1779b3415],
9	clinicopathological	JJ	O	clinicopathological	amod	10	SENT_548	[p21l1810t3337r2133b3416, p21l11t3465r548b3566],
10	characteristics	NNS	O	characteristic	dobj	7	SENT_548	[p21l600t3465r1245b3561],
11	,	,	O	,	_	0	SENT_548	[p21l600t3465r1245b3561],
12	as	IN	O	as	mark	13	SENT_548	[p21l1302t3491r1387b3543],
13	Well	NNP	O	Well	dep	20	SENT_548	[p21l1437t3465r1614b3544],
14	as	IN	O	as	dep	13	SENT_548	[p21l1665t3491r1750b3543],
15	specific	JJ	O	specific	amod	17	SENT_548	[p21l1805t3464r2135b3565],
16	gene	NN	O	gene	nn	17	SENT_548	[p21l12t3619r211b3694],
17	alterations	NNS	O	alteration	pobj	14	SENT_548	[p21l252t3593r731b3689],
18	,	,	O	,	_	0	SENT_548	[p21l252t3593r731b3689],
19	might	MD	O	might	aux	20	SENT_548	[p21l778t3593r1038b3694],
20	help	VB	O	help	ccomp	5	SENT_548	[p21l1075t3593r1254b3693],
21	to	TO	O	to	aux	22	SENT_548	[p21l1298t3610r1380b3672],
22	identify	VB	O	identify	xcomp	20	SENT_548	[p21l1422t3592r1755b3693],
23	patients	NNS	O	patient	dobj	22	SENT_548	[p21l1791t3594r2132b3693],
24	Whose	WP$	O	whose	poss	25	SENT_548	[p21l7t3722r282b3801],
25	cancers	NNS	O	cancer	nsubj	29	SENT_548	[p21l322t3748r642b3800],
26	could	MD	O	could	aux	29	SENT_548	[p21l684t3722r918b3801],
27	be	VB	O	be	cop	29	SENT_548	[p21l957t3722r1054b3801],
28	either	RB	O	either	advmod	29	SENT_548	[p21l1094t3722r1341b3801],
29	sensitive	JJ	O	sensitive	rcmod	23	SENT_548	[p21l1378t3723r1742b3801],
30	or	CC	O	or	_	0	SENT_548	[p21l1782t3748r1870b3801],
31	resistant	JJ	O	resistant	rcmod	23	SENT_548	[p21l1906t3723r2133b3800, p22l12t55r185b116],

1	to	TO	O	to	_	0	SENT_549	[p22l216t56r296b117],
2	anti-EGFR	JJ	O	anti-egfr	amod	3	SENT_549	[p22l332t40r787b122],
3	therapy	NN	O	therapy	pobj	1	SENT_549	[p22l812t39r1146b138],
4	.	.	O	.	_	0	SENT_549	[p22l812t39r1146b138],

1	CLINICAL	JJ	O	clinical	nsubj	20	SENT_550	[p22l13t313r379b363],
2	AND	CC	O	and	_	0	SENT_550	[p22l408t314r577b362],
3	PATHOLOGICAL	JJ	O	pathological	amod	4	SENT_550	[p22l617t313r1233b363],
4	pmamcrons	NNS	O	pmamcron	conj_and	1	SENT_550	[p22l1271t313r1764b363],
5	Most	JJS	O	most	amod	7	SENT_550	[p22l9t419r228b490],
6	clinical	JJ	O	clinical	amod	7	SENT_550	[p22l266t411r580b489],
7	studies	NNS	O	study	dep	4	SENT_550	[p22l623t411r923b490],
8	of	IN	O	of	_	0	SENT_550	[p22l969t410r1070b490],
9	gefitinib	NN	O	gefitinib	prep_of	7	SENT_550	[p22l1094t410r1466b512],
10	or	CC	O	or	_	0	SENT_550	[p22l1511t437r1600b490],
11	erlotinib	NN	O	erlotinib	conj_or	1	SENT_550	[p22l1640t411r2007b490],
12	in	IN	O	in	_	0	SENT_550	[p22l2051t412r2134b489],
13	non	JJ	O	non	amod	19	SENT_550	[p22l12t538r655b617],
14	—	JJ	O	—	amod	19	SENT_550	[p22l12t538r655b617],
15	small	JJ	O	small	amod	19	SENT_550	[p22l12t538r655b617],
16	—	NN	O	—	nn	19	SENT_550	[p22l12t538r655b617],
17	cell	NN	O	cell	nn	19	SENT_550	[p22l12t538r655b617],
18	lung	NN	O	lung	nn	19	SENT_550	[p22l709t538r902b639],
19	cancer	NN	O	cancer	prep_in	11	SENT_550	[p22l956t564r1236b616],
20	suggest	VBP	O	suggest	_	0	SENT_550	[p22l1291t555r1618b639],
21	that	IN	O	that	dep	22	SENT_550	[p22l1670t538r1843b616],
22	Asian	JJ	LOCATION	asian	acomp	20	SENT_550	[p22l1890t539r2134b616],

1	1163	CD	DATE	1163	num	4	SENT_551	[p22l149t714r224b737],
2	N	NN	O	n	nn	4	SENT_551	[p22l914t725r927b740],
3	ENGLJ	NN	O	englj	nn	4	SENT_551	[p22l942t725r1020b747],
4	MED	NN	O	med	_	0	SENT_551	[p22l1035t725r1086b740],
5	358	CD	NUMBER	358	num	7	SENT_551	[p22l1097t719r1165b747],
6	;	:	O	;	_	0	SENT_551	[p22l1097t719r1165b747],
7	11	CD	NUMBER	11	dep	4	SENT_551	[p22l1097t719r1165b747],
8	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	9	SENT_551	[p22l1201t725r1402b747],
9	MARCH	NNP	DATE	MARCH	dep	4	SENT_551	[p22l1439t725r1524b740],
10	13	CD	DATE	13	num	9	SENT_551	[p22l1538t725r1570b747],
11	,	,	DATE	,	_	0	SENT_551	[p22l1538t725r1570b747],
12	2008	CD	DATE	2008	num	9	SENT_551	[p22l1581t719r1644b741],

1	The	DT	O	the	det	4	SENT_552	[p22l935t758r986b782],
2	New	NNP	O	New	nn	4	SENT_552	[p22l995t759r1057b782],
3	England	NNP	O	England	nn	4	SENT_552	[p22l1066t758r1177b789],
4	Journal	NNP	O	Journal	_	0	SENT_552	[p22l1186t758r1283b782],
5	of	IN	O	of	_	0	SENT_552	[p22l1293t758r1322b782],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_552	[p22l1329t758r1454b782],

1	Downloaded	VBN	O	download	_	0	SENT_553	[p22l377t799r547b822],
2	from	IN	O	from	_	0	SENT_553	[p22l556t799r621b822],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_553	[p22l629t799r748b829],
4	at	IN	O	at	_	0	SENT_553	[p22l758t803r781b822],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_553	[p22l789t799r972b822],
6	on	IN	O	on	_	0	SENT_553	[p22l981t806r1014b822],
7	January	NNP	DATE	January	prep_on	1	SENT_553	[p22l1022t799r1125b829],
8	5	CD	DATE	5	num	7	SENT_553	[p22l1135t799r1158b826],
9	,	,	DATE	,	_	0	SENT_553	[p22l1135t799r1158b826],
10	2014	CD	DATE	2014	num	7	SENT_553	[p22l1168t799r1240b822],
11	.	.	O	.	_	0	SENT_553	[p22l1168t799r1240b822],

1	For	IN	O	for	_	0	SENT_554	[p22l1251t799r1298b822],
2	personal	JJ	O	personal	amod	3	SENT_554	[p22l1306t799r1418b829],
3	use	NN	O	use	pobj	1	SENT_554	[p22l1427t806r1471b822],
4	only	RB	O	only	advmod	3	SENT_554	[p22l1480t799r1545b829],
5	.	.	O	.	_	0	SENT_554	[p22l1480t799r1545b829],

1	No	DT	O	no	det	3	SENT_555	[p22l1556t799r1595b822],
2	other	JJ	O	other	amod	3	SENT_555	[p22l1605t799r1673b822],
3	uses	NNS	O	use	_	0	SENT_555	[p22l1682t806r1738b822],
4	without	IN	O	without	_	0	SENT_555	[p22l1748t799r1849b822],
5	permission	NN	O	permission	prep_without	3	SENT_555	[p22l1857t799r2010b829],
6	.	.	O	.	_	0	SENT_555	[p22l1857t799r2010b829],

1	Copyright	NN	O	copyright	_	0	SENT_556	[p22l728t840r862b871],
2	©	CD	NUMBER	©	num	6	SENT_556	[p22l871t840r895b864],
3	2008	CD	DATE	2008	num	6	SENT_556	[p22l905t840r969b864],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_556	[p22l979t840r1170b864],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_556	[p22l1180t840r1288b864],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_556	[p22l1299t840r1404b871],
7	.	.	O	.	_	0	SENT_556	[p22l1299t840r1404b871],

1	All	DT	O	all	det	2	SENT_557	[p22l1415t840r1456b864],
2	rights	NNS	O	rights	nsubj	3	SENT_557	[p22l1465t840r1540b871],
3	reserved	VBN	O	reserve	_	0	SENT_557	[p22l1550t840r1668b864],
4	.	.	O	.	_	0	SENT_557	[p22l1550t840r1668b864],

1	DRUG	NN	O	drug	nn	2	SENT_558	[p22l951t946r1043b965],
2	THERAPY	NN	O	therapy	_	0	SENT_558	[p22l1056t946r1209b965],

1	ethnic	JJ	O	ethnic	amod	2	SENT_559	[p22l12t1160r282b1238],
2	background	NN	O	background	nsubj	25	SENT_559	[p22l319t1160r859b1261],
3	,	,	O	,	_	0	SENT_559	[p22l319t1160r859b1261],
4	female	JJ	O	female	amod	5	SENT_559	[p22l902t1159r1191b1238],
5	sex	NN	O	sex	appos	2	SENT_559	[p22l1231t1186r1387b1256],
6	,	,	O	,	_	0	SENT_559	[p22l1231t1186r1387b1256],
7	the	DT	O	the	det	8	SENT_559	[p22l1431t1160r1564b1239],
8	absence	NN	O	absence	conj_and	2	SENT_559	[p22l1602t1160r1941b1239],
9	of	IN	O	of	_	0	SENT_559	[p22l1980t1159r2080b1239],
10	a	DT	O	a	det	11	SENT_559	[p22l2099t1186r2144b1238],
11	history	NN	O	history	prep_of	8	SENT_559	[p22l11t1288r317b1388],
12	of	IN	O	of	_	0	SENT_559	[p22l350t1287r450b1367],
13	smoking	NN	O	smoking	prep_of	11	SENT_559	[p22l470t1288r867b1389],
14	,	,	O	,	_	0	SENT_559	[p22l470t1288r867b1389],
15	and	CC	O	and	_	0	SENT_559	[p22l909t1288r1068b1367],
16	a	DT	O	a	det	17	SENT_559	[p22l1104t1314r1148b1366],
17	tumor	NN	O	tumor	conj_and	2	SENT_559	[p22l1184t1305r1453b1367],
18	with	IN	O	with	_	0	SENT_559	[p22l1483t1288r1679b1367],
19	histologic	JJ	O	histologic	amod	20	SENT_559	[p22l1715t1288r2143b1389],
20	features	NNS	O	feature	prep_with	17	SENT_559	[p22l11t1414r354b1495],
21	of	IN	O	of	_	0	SENT_559	[p22l394t1414r494b1494],
22	adenocarcinoma	NN	O	adenocarcinoma	prep_of	20	SENT_559	[p22l511t1415r1228b1494],
23	are	VBP	O	be	cop	25	SENT_559	[p22l1252t1441r1381b1493],
24	potential	JJ	O	potential	amod	25	SENT_559	[p22l1417t1415r1806b1515],
25	predictors	NNS	O	predictor	_	0	SENT_559	[p22l1840t1415r2140b1515, p22l12t1560r174b1622],
26	of	IN	O	of	_	0	SENT_559	[p22l218t1542r318b1622],
27	a	DT	O	a	det	30	SENT_559	[p22l340t1569r384b1621],
28	positive	JJ	O	positive	amod	30	SENT_559	[p22l421t1544r753b1643],
29	clinical	JJ	O	clinical	amod	30	SENT_559	[p22l795t1543r1109b1621],
30	response	NN	O	response	prep_of	25	SENT_559	[p22l1149t1569r1532b1643],
31	to	TO	O	to	_	0	SENT_559	[p22l1573t1560r1655b1622],
32	anti	JJ	O	anti	prep_to	30	SENT_559	[p22l1696t1544r2153b1627],
33	.	.	O	.	_	0	SENT_559	[p22l1696t1544r2153b1627],

1	—	NN	O	—	_	0	SENT_560	[p22l1696t1544r2153b1627],
2	.	.	O	.	_	0	SENT_560	[p22l1696t1544r2153b1627],

1	EGFR	NN	ORGANIZATION	egfr	nn	3	SENT_561	[p22l1696t1544r2153b1627],
2	therapy	NN	O	therapy	nn	3	SENT_561	[p22l12t1672r616b1772],
3	.2	NN	NUMBER	.2	nsubj	33	SENT_561	[p22l12t1672r616b1772],
4	°	CD	NUMBER	°	number	5	SENT_561	[p22l12t1672r616b1772],
5	»	CD	NUMBER	»	num	7	SENT_561	[p22l12t1672r616b1772],
6	23	CD	NUMBER	23	number	7	SENT_561	[p22l12t1672r616b1772],
7	’71	CD	NUMBER	’71	dep	3	SENT_561	[p22l12t1672r616b1772],
8	However	RB	O	however	advmod	7	SENT_561	[p22l653t1680r1049b1768],
9	,	,	O	,	_	0	SENT_561	[p22l653t1680r1049b1768],
10	the	DT	O	the	det	11	SENT_561	[p22l1093t1672r1227b1751],
11	presence	NN	O	presence	nsubj	33	SENT_561	[p22l1263t1698r1640b1772],
12	or	CC	O	or	_	0	SENT_561	[p22l1679t1698r1768b1751],
13	absence	NN	O	absence	conj_and	3	SENT_561	[p22l1803t1672r2142b1751],
14	of	IN	O	of	_	0	SENT_561	[p22l12t1799r112b1879],
15	cutaneous	JJ	O	cutaneous	amod	17	SENT_561	[p22l144t1817r581b1879],
16	toxic	JJ	O	toxic	amod	17	SENT_561	[p22l635t1801r841b1879],
17	effects	NNS	O	effect	prep_of	11	SENT_561	[p22l891t1799r1198b1896],
18	,	,	O	,	_	0	SENT_561	[p22l891t1799r1198b1896],
19	such	JJ	O	such	_	0	SENT_561	[p22l1255t1800r1450b1879],
20	as	IN	O	as	_	0	SENT_561	[p22l1500t1826r1585b1878],
21	an	DT	O	a	det	23	SENT_561	[p22l1637t1826r1740b1878],
22	acnelike	JJ	O	acnelike	amod	23	SENT_561	[p22l1790t1800r2142b1879],
23	rash	NN	O	rash	prep_such_as	11	SENT_561	[p22l11t1929r217b2025],
24	,	,	O	,	_	0	SENT_561	[p22l11t1929r217b2025],
25	and	CC	O	and	_	0	SENT_561	[p22l268t1929r427b2008],
26	their	PRP$	O	they	poss	27	SENT_561	[p22l473t1929r678b2007],
27	severity	NN	O	severity	nsubj	33	SENT_561	[p22l723t1930r1050b2029],
28	are	VBP	O	be	cop	33	SENT_561	[p22l1091t1955r1220b2007],
29	the	DT	O	the	det	33	SENT_561	[p22l1267t1929r1400b2007],
30	most	RBS	O	most	advmod	31	SENT_561	[p22l1447t1946r1664b2008],
31	important	JJ	O	important	amod	33	SENT_561	[p22l1705t1930r2147b2029],
32	clinical	JJ	O	clinical	amod	33	SENT_561	[p22l12t2057r326b2135],
33	correlates	NNS	O	correlate	_	0	SENT_561	[p22l380t2057r797b2136],
34	of	IN	O	of	_	0	SENT_561	[p22l854t2056r954b2136],
35	the	DT	O	the	det	36	SENT_561	[p22l989t2057r1122b2135],
36	efficacy	NN	O	efficacy	prep_of	33	SENT_561	[p22l1175t2056r1513b2157],
37	of	IN	O	of	_	0	SENT_561	[p22l1562t2056r1662b2136],
38	anti	JJ	O	anti	prep_of	36	SENT_561	[p22l1696t2058r2153b2141],
39	.	.	O	.	_	0	SENT_561	[p22l1696t2058r2153b2141],

1	—	NN	O	—	_	0	SENT_562	[p22l1696t2058r2153b2141],
2	.	.	O	.	_	0	SENT_562	[p22l1696t2058r2153b2141],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_563	[p22l1696t2058r2153b2141],
2	therapy	NN	O	therapy	dep	1	SENT_563	[p22l12t2186r348b2286],
3	.	.	O	.	_	0	SENT_563	[p22l12t2186r348b2286],

1	In	IN	O	in	dep	107	SENT_564	[p22l385t2194r475b2264],
2	fact	NN	O	fact	dep	107	SENT_564	[p22l508t2185r688b2282],
3	,	,	O	,	_	0	SENT_564	[p22l508t2185r688b2282],
4	a	DT	O	a	dep	107	SENT_564	[p22l727t2212r772b2264],
5	significant	JJ	O	significant	dep	107	SENT_564	[p22l806t2185r1276b2287],
6	positive	JJ	O	positive	dep	107	SENT_564	[p22l1303t2187r1635b2286],
7	correlation	NN	O	correlation	dep	107	SENT_564	[p22l1670t2186r2142b2265],
8	between	IN	O	between	dep	107	SENT_564	[p22l12t2313r371b2393],
9	cutaneous	JJ	O	cutaneous	dep	107	SENT_564	[p22l398t2330r835b2393],
10	toxicity	NN	O	toxicity	dep	107	SENT_564	[p22l865t2314r1183b2413],
11	and	CC	O	and	dep	107	SENT_564	[p22l1205t2313r1363b2392],
12	rates	NNS	O	rate	dep	107	SENT_564	[p22l1390t2330r1593b2391],
13	of	IN	O	of	dep	107	SENT_564	[p22l1623t2312r1723b2392],
14	response	NN	O	response	dep	107	SENT_564	[p22l1731t2339r2136b2413],
15	,	,	O	,	_	0	SENT_564	[p22l1731t2339r2136b2413],
16	progression	NN	O	progression	dep	107	SENT_564	[p22l10t2441r721b2543],
17	—	CD	NUMBER	—	dep	107	SENT_564	[p22l10t2441r721b2543],
18	free	JJ	O	free	dep	107	SENT_564	[p22l10t2441r721b2543],
19	survival	NN	O	survival	dep	107	SENT_564	[p22l792t2442r1148b2538],
20	,	,	O	,	_	0	SENT_564	[p22l792t2442r1148b2538],
21	and	CC	O	and	dep	107	SENT_564	[p22l1223t2442r1381b2521],
22	overall	JJ	O	overall	dep	107	SENT_564	[p22l1452t2442r1738b2521],
23	survival	NN	O	survival	dep	107	SENT_564	[p22l1809t2442r2143b2521],
24	has	VBZ	O	have	dep	107	SENT_564	[p22l11t2569r156b2647],
25	been	VBN	O	be	dep	107	SENT_564	[p22l195t2569r397b2648],
26	noted	VBN	O	note	dep	107	SENT_564	[p22l434t2569r677b2648],
27	in	IN	O	in	dep	107	SENT_564	[p22l713t2570r796b2647],
28	virtually	RB	O	virtually	dep	107	SENT_564	[p22l829t2569r1194b2669],
29	all	DT	O	all	dep	107	SENT_564	[p22l1226t2569r1331b2647],
30	trials	NNS	O	trial	dep	107	SENT_564	[p22l1367t2569r1587b2647],
31	of	IN	O	of	dep	107	SENT_564	[p22l1627t2568r1727b2648],
32	erlotinib	NN	O	erlotinib	dep	107	SENT_564	[p22l1746t2569r2136b2665],
33	,	,	O	,	_	0	SENT_564	[p22l1746t2569r2136b2665],
34	cetuximab	NN	O	cetuximab	dep	107	SENT_564	[p22l12t2698r488b2794],
35	,	,	O	,	_	0	SENT_564	[p22l12t2698r488b2794],
36	or	CC	O	or	dep	107	SENT_564	[p22l543t2724r633b2777],
37	panitumumab	NN	O	panitumumab	dep	107	SENT_564	[p22l678t2698r1295b2798],
38	in	IN	O	in	dep	107	SENT_564	[p22l1346t2699r1429b2776],
39	advanced	JJ	O	advanced	dep	107	SENT_564	[p22l1478t2698r1876b2777],
40	nonsmall	JJ	O	nonsmall	dep	107	SENT_564	[p22l1925t2724r2145b2777, p22l12t2827r432b2905],
41	—	NN	O	—	dep	107	SENT_564	[p22l1925t2724r2145b2777, p22l12t2827r432b2905],
42	cell	NN	O	cell	dep	107	SENT_564	[p22l1925t2724r2145b2777, p22l12t2827r432b2905],
43	lung	NN	O	lung	dep	107	SENT_564	[p22l482t2827r676b2928],
44	cancer	NN	O	cancer	dep	107	SENT_564	[p22l724t2853r1024b2923],
45	,	,	O	,	_	0	SENT_564	[p22l724t2853r1024b2923],
46	colorectal	JJ	O	colorectal	dep	107	SENT_564	[p22l1082t2827r1503b2906],
47	cancer	NN	O	cancer	dep	107	SENT_564	[p22l1555t2853r1854b2923],
48	,	,	O	,	_	0	SENT_564	[p22l1555t2853r1854b2923],
49	squamous	JJ	O	squamous	dep	107	SENT_564	[p22l1912t2853r2140b2927, p22l11t2954r433b3033],
50	—	NN	O	—	dep	107	SENT_564	[p22l1912t2853r2140b2927, p22l11t2954r433b3033],
51	cell	NN	O	cell	dep	107	SENT_564	[p22l1912t2853r2140b2927, p22l11t2954r433b3033],
52	carcinoma	NN	O	carcinoma	dep	107	SENT_564	[p22l476t2955r931b3033],
53	of	IN	O	of	dep	107	SENT_564	[p22l972t2953r1072b3033],
54	the	DT	O	the	dep	107	SENT_564	[p22l1096t2954r1229b3032],
55	head	NN	O	head	dep	107	SENT_564	[p22l1271t2954r1474b3033],
56	and	CC	O	and	dep	107	SENT_564	[p22l1516t2954r1674b3033],
57	neck	NN	O	neck	dep	107	SENT_564	[p22l1715t2954r1937b3050],
58	,	,	O	,	_	0	SENT_564	[p22l1715t2954r1937b3050],
59	and	CC	O	and	dep	107	SENT_564	[p22l1984t2954r2143b3033],
60	pancreatic	JJ	O	pancreatic	dep	107	SENT_564	[p22l9t3084r458b3183],
61	cancer	NN	O	cancer	dep	107	SENT_564	[p22l491t3088r1055b3162],
62	.53	CD	NUMBER	.53	dep	107	SENT_564	[p22l491t3088r1055b3162],
63	>	JJR	O	>	dep	107	SENT_564	[p22l491t3088r1055b3162],
64	54	CD	NUMBER	54	dep	107	SENT_564	[p22l491t3088r1055b3162],
65	’72	CD	NUMBER	’72	dep	107	SENT_564	[p22l491t3088r1055b3162],
66	It	PRP	O	it	dep	107	SENT_564	[p22l1087t3091r1152b3161],
67	is	VBZ	O	be	dep	107	SENT_564	[p22l1179t3084r1245b3161],
68	conceivable	JJ	O	conceivable	dep	107	SENT_564	[p22l1281t3083r1774b3162],
69	that	IN	O	that	dep	107	SENT_564	[p22l1807t3083r1981b3161],
70	the	DT	O	the	dep	107	SENT_564	[p22l2009t3083r2142b3161],
71	effects	NNS	O	effect	dep	107	SENT_564	[p22l12t3210r294b3289],
72	in	IN	O	in	dep	107	SENT_564	[p22l343t3212r427b3289],
73	skin	NN	O	skin	dep	107	SENT_564	[p22l476t3211r656b3291],
74	not	RB	O	not	dep	107	SENT_564	[p22l704t3228r848b3290],
75	influenced	VBN	O	influence	dep	107	SENT_564	[p22l889t3210r1351b3291],
76	by	IN	O	by	dep	107	SENT_564	[p22l1399t3211r1497b3311],
77	cancer	NN	O	cancer	dep	107	SENT_564	[p22l1540t3237r1823b3289],
78	reflect	VBP	O	reflect	dep	107	SENT_564	[p22l1867t3210r2147b3289],
79	the	DT	O	the	dep	107	SENT_564	[p22l12t3340r145b3418],
80	extent	NN	O	extent	dep	107	SENT_564	[p22l187t3357r450b3418],
81	of	IN	O	of	dep	107	SENT_564	[p22l486t3339r587b3419],
82	EGFR	NN	ORGANIZATION	egfr	dep	107	SENT_564	[p22l608t3346r865b3424],
83	blockade	NN	O	blockade	dep	107	SENT_564	[p22l895t3340r1276b3419],
84	achieved	VBN	O	achieve	dep	107	SENT_564	[p22l1316t3340r1686b3419],
85	in	IN	O	in	dep	107	SENT_564	[p22l1725t3341r1809b3417],
86	the	DT	O	the	dep	107	SENT_564	[p22l1850t3340r1983b3418],
87	tumor	NN	O	tumor	dep	107	SENT_564	[p22l2025t3357r2140b3419, p22l11t3494r206b3564],
88	,	,	O	,	_	0	SENT_564	[p22l2025t3357r2140b3419, p22l11t3494r206b3564],
89	in	IN	O	in	dep	107	SENT_564	[p22l244t3469r327b3546],
90	which	WDT	O	which	dep	107	SENT_564	[p22l355t3468r619b3547],
91	case	NN	O	case	dep	107	SENT_564	[p22l652t3494r832b3546],
92	the	DT	O	the	dep	107	SENT_564	[p22l865t3468r999b3547],
93	rash	NN	O	rash	dep	107	SENT_564	[p22l1031t3468r1214b3546],
94	would	MD	O	would	dep	107	SENT_564	[p22l1242t3468r1509b3547],
95	correlate	VB	O	correlate	dep	107	SENT_564	[p22l1543t3468r1918b3547],
96	with	IN	O	with	dep	107	SENT_564	[p22l1947t3468r2143b3547],
97	EGFR	NN	ORGANIZATION	egfr	dep	107	SENT_564	[p22l9t3603r266b3680],
98	saturation	NN	O	saturation	dep	107	SENT_564	[p22l293t3598r732b3676],
99	or	CC	O	or	dep	107	SENT_564	[p22l769t3623r858b3676],
100	with	IN	O	with	dep	107	SENT_564	[p22l886t3597r1082b3676],
101	a	DT	O	a	dep	107	SENT_564	[p22l1117t3623r1162b3675],
102	relevant	JJ	O	relevant	dep	107	SENT_564	[p22l1196t3597r1538b3676],
103	drug	NN	O	drug	dep	107	SENT_564	[p22l1570t3597r1774b3698],
104	concentration	NN	O	concentration	dep	107	SENT_564	[p22l1807t3623r2140b3676, p22l12t3727r303b3805],
105	within	IN	O	within	dep	107	SENT_564	[p22l333t3726r620b3805],
106	the	DT	O	the	dep	107	SENT_564	[p22l654t3726r788b3804],
107	tumor	NN	O	tumor	_	0	SENT_564	[p22l823t3743r1110b3805],
108	.	.	O	.	_	0	SENT_564	[p22l823t3743r1110b3805],

1	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_565	[p23l16t186r209b237],
2	pnonam	NN	O	pnonam	nn	5	SENT_565	[p23l249t186r586b237],
3	EXPRESSION	NN	O	expression	nn	5	SENT_565	[p23l631t186r1120b237],
4	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_565	[p23l10t292r266b370],
5	expression	NN	O	expression	nsubj	16	SENT_565	[p23l300t287r758b386],
6	as	IN	O	as	_	0	SENT_565	[p23l800t312r886b364],
7	determined	VBN	O	determine	amod	12	SENT_565	[p23l932t286r1428b365],
8	by	IN	O	by	_	0	SENT_565	[p23l1471t286r1569b386],
9	immunohis	NN	O	immunohi	nn	10	SENT_565	[p23l1606t286r2140b365],
10	—	NN	O	—	prep_by	7	SENT_565	[p23l1606t286r2140b365],
11	tochemical	JJ	O	tochemical	amod	12	SENT_565	[p23l12t415r488b494],
12	methods	NNS	O	method	prep_as	5	SENT_565	[p23l528t415r902b494],
13	was	VBD	O	be	cop	16	SENT_565	[p23l941t441r1104b494],
14	the	DT	O	the	det	16	SENT_565	[p23l1147t415r1280b494],
15	first	JJ	ORDINAL	first	amod	16	SENT_565	[p23l1320t414r1505b493],
16	biomarker	NN	O	biomarker	_	0	SENT_565	[p23l1541t415r1989b494],
17	investigated	VBN	O	investigate	partmod	16	SENT_565	[p23l2025t416r2140b493, p23l7t543r440b644],
18	as	IN	O	as	_	0	SENT_565	[p23l489t569r575b621],
19	a	DT	O	a	det	21	SENT_565	[p23l626t569r670b621],
20	potential	JJ	O	potential	amod	21	SENT_565	[p23l718t543r1107b643],
21	predictor	NN	O	predictor	prep_as	17	SENT_565	[p23l1155t543r1552b643],
22	of	IN	O	of	_	0	SENT_565	[p23l1599t542r1700b622],
23	response	NN	O	response	prep_of	21	SENT_565	[p23l1731t569r2136b643],
24	.	.	O	.	_	0	SENT_565	[p23l1731t569r2136b643],

1	However	RB	O	however	advmod	6	SENT_566	[p23l11t678r406b766],
2	,	,	O	,	_	0	SENT_566	[p23l11t678r406b766],
3	most	RBS	O	most	advmod	4	SENT_566	[p23l459t687r677b749],
4	studies	NNS	O	study	nsubj	6	SENT_566	[p23l719t670r1021b749],
5	have	VBP	O	have	aux	6	SENT_566	[p23l1070t670r1261b750],
6	failed	VBN	O	fail	_	0	SENT_566	[p23l1308t669r1548b749],
7	to	TO	O	to	aux	8	SENT_566	[p23l1596t687r1678b749],
8	show	VB	O	show	xcomp	6	SENT_566	[p23l1727t670r1953b750],
9	any	DT	O	any	det	10	SENT_566	[p23l1996t696r2147b770],
10	relationship	NN	O	relationship	dobj	8	SENT_566	[p23l11t799r528b899],
11	between	IN	O	between	_	0	SENT_566	[p23l582t799r941b879],
12	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_566	[p23l991t805r1248b883],
13	expression	NN	O	expression	prep_between	10	SENT_566	[p23l1289t800r1748b899],
14	and	CC	O	and	_	0	SENT_566	[p23l1798t799r1956b878],
15	the	DT	O	the	det	17	SENT_566	[p23l2008t799r2142b877],
16	clinical	JJ	O	clinical	amod	17	SENT_566	[p23l12t928r326b1006],
17	activity	NN	O	activity	conj_and	10	SENT_566	[p23l378t929r689b1028],
18	of	IN	O	of	_	0	SENT_566	[p23l737t927r838b1007],
19	anti	JJ	O	anti	prep_of	17	SENT_566	[p23l871t929r1328b1011],
20	.	.	O	.	_	0	SENT_566	[p23l871t929r1328b1011],

1	—	NN	O	—	_	0	SENT_567	[p23l871t929r1328b1011],
2	.	.	O	.	_	0	SENT_567	[p23l871t929r1328b1011],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_568	[p23l871t929r1328b1011],
2	drugs	NNS	O	drug	nsubj	49	SENT_568	[p23l1371t928r1811b1029],
3	.24	CD	NUMBER	.24	number	4	SENT_568	[p23l1371t928r1811b1029],
4	’51	CD	NUMBER	’51	num	5	SENT_568	[p23l1371t928r1811b1029],
5	CetuX	NN	O	cetux	dep	2	SENT_568	[p23l1864t934r2140b1007],
6	—	CD	NUMBER	—	num	7	SENT_568	[p23l1864t934r2140b1007],
7	imab	NN	O	imab	nsubjpass	11	SENT_568	[p23l11t1057r227b1136],
8	has	VBZ	O	have	aux	11	SENT_568	[p23l265t1057r410b1135],
9	also	RB	O	also	advmod	11	SENT_568	[p23l447t1057r619b1136],
10	been	VBN	O	be	auxpass	11	SENT_568	[p23l657t1057r859b1136],
11	shown	VBN	O	show	rcmod	2	SENT_568	[p23l897t1057r1180b1136],
12	to	TO	O	to	aux	13	SENT_568	[p23l1216t1074r1298b1136],
13	have	VB	O	have	xcomp	11	SENT_568	[p23l1336t1057r1526b1136],
14	clinical	JJ	O	clinical	amod	15	SENT_568	[p23l1563t1057r1877b1135],
15	activity	NN	O	activity	dobj	13	SENT_568	[p23l1913t1058r2140b1136, p23l11t1186r118b1285],
16	in	IN	O	in	_	0	SENT_568	[p23l143t1186r226b1263],
17	patients	NNS	O	patient	prep_in	15	SENT_568	[p23l255t1186r598b1285],
18	with	IN	O	with	_	0	SENT_568	[p23l625t1185r821b1264],
19	colorectal	JJ	O	colorectal	amod	20	SENT_568	[p23l851t1185r1274b1264],
20	cancer	NN	O	cancer	prep_with	17	SENT_568	[p23l1304t1211r1586b1264],
21	that	WDT	O	that	nsubj	23	SENT_568	[p23l1613t1185r1786b1263],
22	is	VBZ	O	be	cop	23	SENT_568	[p23l1810t1186r1876b1263],
23	negative	JJ	O	negative	rcmod	15	SENT_568	[p23l1908t1211r2140b1286, p23l12t1313r159b1392],
24	for	IN	O	for	_	0	SENT_568	[p23l194t1311r318b1391],
25	EGFR73	NN	O	egfr73	prep_for	23	SENT_568	[p23l349t1318r694b1396],
26	Similarly	RB	O	similarly	advmod	23	SENT_568	[p23l733t1312r1134b1412],
27	,	,	O	,	_	0	SENT_568	[p23l733t1312r1134b1412],
28	in	IN	O	in	_	0	SENT_568	[p23l1173t1313r1257b1390],
29	a	DT	O	a	det	34	SENT_568	[p23l1291t1338r1335b1390],
30	prospective	JJ	O	prospective	amod	34	SENT_568	[p23l1367t1313r1858b1412],
31	phase	NN	O	phase	nn	34	SENT_568	[p23l1892t1312r2142b1412],
32	2	CD	NUMBER	2	num	34	SENT_568	[p23l11t1447r58b1519],
33	clinical	JJ	O	clinical	amod	34	SENT_568	[p23l92t1441r398b1519],
34	trial	NN	O	trial	prep_in	23	SENT_568	[p23l430t1441r626b1537],
35	,	,	O	,	_	0	SENT_568	[p23l430t1441r626b1537],
36	the	DT	O	the	det	37	SENT_568	[p23l664t1441r795b1519],
37	response	NN	O	response	appos	34	SENT_568	[p23l827t1467r1202b1541],
38	to	TO	O	to	_	0	SENT_568	[p23l1235t1458r1315b1520],
39	treatment	NN	O	treatment	prep_to	37	SENT_568	[p23l1349t1458r1765b1519],
40	with	IN	O	with	_	0	SENT_568	[p23l1788t1441r1980b1521],
41	panitumumab	NN	O	panitumumab	prep_with	13	SENT_568	[p23l2010t1467r2140b1541, p23l11t1570r511b1649],
42	in	IN	O	in	_	0	SENT_568	[p23l547t1571r629b1648],
43	patients	NNS	O	patient	prep_in	41	SENT_568	[p23l662t1571r997b1670],
44	with	IN	O	with	_	0	SENT_568	[p23l1029t1570r1222b1649],
45	metastatic	JJ	O	metastatic	amod	47	SENT_568	[p23l1257t1571r1696b1648],
46	colorectal	JJ	O	colorectal	amod	47	SENT_568	[p23l1730t1570r2142b1649],
47	cancer	NN	O	cancer	prep_with	43	SENT_568	[p23l12t1725r294b1777],
48	was	VBD	O	be	cop	49	SENT_568	[p23l315t1725r477b1778],
49	similar	JJ	O	similar	_	0	SENT_568	[p23l509t1699r817b1777],
50	whether	IN	O	whether	complm	55	SENT_568	[p23l837t1699r1194b1778],
51	EGFR	NN	ORGANIZATION	egfr	nn	53	SENT_568	[p23l1218t1705r1475b1783],
52	protein	NN	O	protein	nn	53	SENT_568	[p23l1491t1700r1804b1799],
53	expression	NN	O	expression	nsubj	55	SENT_568	[p23l1833t1725r2140b1799, p23l12t1829r189b1907],
54	was	VBD	O	be	cop	55	SENT_568	[p23l231t1854r394b1907],
55	high	JJ	O	high	ccomp	49	SENT_568	[p23l442t1828r661b1929],
56	,	,	O	,	_	0	SENT_568	[p23l442t1828r661b1929],
57	low	JJ	O	low	conj_or	55	SENT_568	[p23l713t1828r882b1924],
58	,	,	O	,	_	0	SENT_568	[p23l713t1828r882b1924],
59	or	CC	O	or	_	0	SENT_568	[p23l935t1854r1024b1907],
60	negative	JJ	O	negative	conj_or	55	SENT_568	[p23l1068t1829r1446b1929],
61	,	,	O	,	_	0	SENT_568	[p23l1068t1829r1446b1929],
62	as	IN	O	as	mark	63	SENT_568	[p23l1497t1854r1583b1906],
63	assessed	VBN	O	assess	advcl	55	SENT_568	[p23l1631t1828r2001b1907],
64	by	IN	O	by	_	0	SENT_568	[p23l2048t1828r2146b1928],
65	immunohistochemical	JJ	O	immunohistochemical	amod	66	SENT_568	[p23l11t1956r994b2035],
66	methods	NNS	O	method	prep_by	63	SENT_568	[p23l1074t1956r1548b2035],
67	.	.	O	.	_	0	SENT_568	[p23l1074t1956r1548b2035],

1	”	NN	O	”	ccomp	6	SENT_569	[p23l1074t1956r1548b2035],
2	Collectively	RB	O	collectively	advmod	1	SENT_569	[p23l1628t1956r2136b2056],
3	,	,	O	,	_	0	SENT_569	[p23l1628t1956r2136b2056],
4	these	DT	O	these	det	5	SENT_569	[p23l12t2085r236b2163],
5	data	NNS	O	datum	nsubj	6	SENT_569	[p23l298t2085r482b2164],
6	suggest	VBP	O	suggest	_	0	SENT_569	[p23l544t2102r872b2186],
7	that	IN	O	that	complm	16	SENT_569	[p23l930t2085r1103b2163],
8	immunohistochemical	JJ	O	immunohistochemical	amod	9	SENT_569	[p23l1158t2085r2143b2164],
9	testing	NN	O	testing	nsubj	16	SENT_569	[p23l12t2214r310b2314],
10	for	IN	O	for	_	0	SENT_569	[p23l353t2212r477b2292],
11	EGFR	NN	ORGANIZATION	egfr	prep_for	9	SENT_569	[p23l518t2219r775b2296],
12	is	VBZ	O	be	cop	16	SENT_569	[p23l810t2214r876b2291],
13	not	RB	O	not	neg	16	SENT_569	[p23l925t2230r1068b2292],
14	an	DT	O	a	det	16	SENT_569	[p23l1109t2239r1212b2291],
15	optimal	JJ	O	optimal	amod	16	SENT_569	[p23l1259t2213r1597b2313],
16	method	NN	O	method	ccomp	6	SENT_569	[p23l1643t2213r1976b2292],
17	for	IN	O	for	_	0	SENT_569	[p23l2022t2212r2145b2292],
18	identifying	VBG	O	identify	prepc_for	16	SENT_569	[p23l11t2340r487b2442],
19	patients	NNS	O	patient	dobj	18	SENT_569	[p23l520t2342r862b2441],
20	who	WP	O	who	nsubj	22	SENT_569	[p23l897t2341r1081b2420],
21	may	MD	O	may	aux	22	SENT_569	[p23l1119t2367r1299b2441],
22	have	VB	O	have	rcmod	19	SENT_569	[p23l1332t2341r1521b2420],
23	a	DT	O	a	det	24	SENT_569	[p23l1558t2367r1603b2419],
24	response	NN	O	response	dobj	22	SENT_569	[p23l1639t2367r2021b2441],
25	to	TO	O	to	_	0	SENT_569	[p23l2058t2358r2140b2420],
26	treatment	NN	O	treatment	prep_to	24	SENT_569	[p23l12t2486r437b2548],
27	with	IN	O	with	_	0	SENT_569	[p23l463t2469r658b2548],
28	anti	JJ	O	anti	prep_with	22	SENT_569	[p23l692t2470r1149b2552],
29	.	.	O	.	_	0	SENT_569	[p23l692t2470r1149b2552],

1	—	NN	O	—	_	0	SENT_570	[p23l692t2470r1149b2552],
2	.	.	O	.	_	0	SENT_570	[p23l692t2470r1149b2552],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_571	[p23l692t2470r1149b2552],
2	drugs	NNS	O	drug	_	0	SENT_571	[p23l1174t2469r1443b2570],
3	.	.	O	.	_	0	SENT_571	[p23l1174t2469r1443b2570],

1	SOMATIC	NNP	O	SOMATIC	nn	4	SENT_572	[p23l11t2744r370b2795],
2	EGFR	NN	O	egfr	nn	4	SENT_572	[p23l403t2744r600b2795],
3	GENE	NN	O	gene	nn	4	SENT_572	[p23l636t2744r847b2795],
4	MUTATIONS	NNS	O	mutation	nsubj	71	SENT_572	[p23l889t2744r1355b2795],
5	The	DT	O	the	det	6	SENT_572	[p23l7t2844r165b2922],
6	discovery	NN	O	discovery	nsubj	42	SENT_572	[p23l193t2844r585b2944],
7	that	WDT	O	that	dobj	25	SENT_572	[p23l608t2844r776b2922],
8	certain	JJ	O	certain	amod	10	SENT_572	[p23l799t2845r1090b2922],
9	somatic	JJ	O	somatic	amod	10	SENT_572	[p23l1118t2845r1446b2923],
10	mutations	NNS	O	mutation	nsubjpass	25	SENT_572	[p23l1472t2845r1895b2923],
11	within	IN	O	within	_	0	SENT_572	[p23l1920t2844r2140b2924, p23l11t2974r93b3051],
12	the	DT	O	the	det	14	SENT_572	[p23l121t2973r252b3051],
13	tyrosine	NN	O	tyrosine	nn	14	SENT_572	[p23l281t2974r621b3073],
14	kinase	NN	O	kinase	prep_within	10	SENT_572	[p23l651t2973r947b3069],
15	,	,	O	,	_	0	SENT_572	[p23l651t2973r947b3069],
16	ATP	NN	O	atp	nn	19	SENT_572	[p23l978t2973r1519b3074],
17	—	NN	O	—	nn	19	SENT_572	[p23l978t2973r1519b3074],
18	binding	NN	O	binding	nn	19	SENT_572	[p23l978t2973r1519b3074],
19	domain	NN	O	domain	appos	14	SENT_572	[p23l1545t2973r1871b3052],
20	of	IN	O	of	_	0	SENT_572	[p23l1900t2972r2000b3052],
21	the	DT	O	the	det	23	SENT_572	[p23l2010t2973r2142b3051],
22	EGFR	NN	ORGANIZATION	egfr	nn	23	SENT_572	[p23l9t3107r220b3181],
23	gene	NN	O	gene	prep_of	19	SENT_572	[p23l243t3127r439b3202],
24	are	VBP	O	be	auxpass	25	SENT_572	[p23l469t3127r596b3179],
25	associated	VBN	O	associate	rcmod	6	SENT_572	[p23l626t3101r1062b3180],
26	with	IN	O	with	_	0	SENT_572	[p23l1087t3101r1280b3180],
27	a	DT	O	a	det	28	SENT_572	[p23l1310t3127r1354b3179],
28	response	NN	O	response	prep_with	25	SENT_572	[p23l1382t3127r1757b3201],
29	to	TO	O	to	_	0	SENT_572	[p23l1788t3118r1868b3180],
30	EGFR	NN	ORGANIZATION	egfr	nn	33	SENT_572	[p23l1899t3107r2152b3184],
31	tyrosine	NN	O	tyrosine	nn	33	SENT_572	[p23l12t3230r352b3329],
32	kinase	NN	O	kinase	nn	33	SENT_572	[p23l392t3229r666b3308],
33	inhibitors	NNS	O	inhibitor	prep_to	25	SENT_572	[p23l706t3229r1120b3308],
34	in	IN	O	in	_	0	SENT_572	[p23l1161t3230r1244b3307],
35	non	JJ	O	non	amod	41	SENT_572	[p23l1284t3229r1915b3308],
36	—	JJ	O	—	amod	41	SENT_572	[p23l1284t3229r1915b3308],
37	small	JJ	O	small	amod	41	SENT_572	[p23l1284t3229r1915b3308],
38	—	NN	O	—	nn	41	SENT_572	[p23l1284t3229r1915b3308],
39	cell	NN	O	cell	nn	41	SENT_572	[p23l1284t3229r1915b3308],
40	lung	NN	O	lung	nn	41	SENT_572	[p23l1954t3229r2145b3330],
41	cancer	NN	O	cancer	prep_in	25	SENT_572	[p23l12t3383r294b3435],
42	suggested	VBD	O	suggest	rcmod	4	SENT_572	[p23l344t3357r773b3458],
43	that	IN	O	that	complm	53	SENT_572	[p23l825t3357r998b3435],
44	the	DT	O	the	det	45	SENT_572	[p23l1045t3357r1178b3435],
45	selection	NN	O	selection	nsubj	53	SENT_572	[p23l1232t3357r1612b3436],
46	of	IN	O	of	_	0	SENT_572	[p23l1665t3356r1765b3436],
47	patients	NNS	O	patient	prep_of	45	SENT_572	[p23l1797t3358r2140b3457],
48	through	IN	O	through	_	0	SENT_572	[p23l12t3485r361b3586],
49	molecular	JJ	O	molecular	amod	50	SENT_572	[p23l431t3485r866b3564],
50	screening	NN	O	screening	prep_through	47	SENT_572	[p23l934t3486r1353b3586],
51	might	MD	O	might	aux	53	SENT_572	[p23l1419t3485r1680b3586],
52	be	VB	O	be	cop	53	SENT_572	[p23l1745t3485r1842b3564],
53	feasible	JJ	O	feasible	ccomp	42	SENT_572	[p23l1912t3484r2140b3563, p23l12t3612r323b3691],
54	.75	CD	NUMBER	.75	num	55	SENT_572	[p23l1912t3484r2140b3563, p23l12t3612r323b3691],
55	>	JJR	O	>	tmod	53	SENT_572	[p23l1912t3484r2140b3563, p23l12t3612r323b3691],
56	75	CD	NUMBER	75	dep	55	SENT_572	[p23l1912t3484r2140b3563, p23l12t3612r323b3691],
57	Approximately	RB	O	approximately	quantmod	58	SENT_572	[p23l375t3612r1014b3712],
58	90	CD	PERCENT	90	num	59	SENT_572	[p23l1064t3618r1254b3691],
59	%	NN	PERCENT	%	nsubj	63	SENT_572	[p23l1064t3618r1254b3691],
60	of	IN	O	of	_	0	SENT_572	[p23l1308t3611r1409b3691],
61	EGFR	NN	ORGANIZATION	egfr	nn	62	SENT_572	[p23l1443t3619r1656b3692],
62	mutations	NNS	O	mutation	prep_of	59	SENT_572	[p23l1704t3613r2140b3692],
63	affect	VBP	O	affect	ccomp	53	SENT_572	[p24l11t21r249b100],
64	small	JJ	O	small	amod	65	SENT_572	[p24l271t22r500b100],
65	regions	NNS	O	region	dobj	63	SENT_572	[p24l525t23r833b123],
66	of	IN	O	of	_	0	SENT_572	[p24l862t21r960b101],
67	the	DT	O	the	det	68	SENT_572	[p24l968t22r1098b100],
68	gene	NN	O	gene	prep_of	65	SENT_572	[p24l1123t48r1318b123],
69	within	IN	O	within	_	0	SENT_572	[p24l1339t22r1617b101],
70	exons	NNS	O	exon	prep_within	68	SENT_572	[p24l1643t48r1880b101],
71	(	VBP	O	(	_	0	SENT_572	[p24l1912t28r2033b113],
72	18	CD	NUMBER	18	number	74	SENT_572	[p24l1912t28r2033b113],
73	to	TO	O	to	dep	74	SENT_572	[p24l2061t39r2140b101],
74	24	CD	NUMBER	24	num	75	SENT_572	[p24l11t155r132b240],
75	)	NN	O	)	dobj	71	SENT_572	[p24l11t155r132b240],
76	that	WDT	O	that	nsubj	77	SENT_572	[p24l165t149r331b227],
77	code	VBP	O	code	rcmod	75	SENT_572	[p24l354t149r545b228],
78	for	IN	O	for	_	0	SENT_572	[p24l572t148r691b228],
79	the	DT	O	the	det	83	SENT_572	[p24l716t149r845b227],
80	EGFR	NN	ORGANIZATION	egfr	nn	83	SENT_572	[p24l871t155r1121b233],
81	tyrosine	NN	O	tyrosine	nn	83	SENT_572	[p24l1139t150r1471b249],
82	kinase	NN	O	kinase	nn	83	SENT_572	[p24l1498t149r1767b229],
83	domain	NN	O	domain	prep_for	77	SENT_572	[p24l1795t149r2136b228],
84	.	.	O	.	_	0	SENT_572	[p24l1795t149r2136b228],

1	The	DT	O	the	det	4	SENT_573	[p24l7t278r168b357],
2	most	RBS	O	most	advmod	4	SENT_573	[p24l198t295r414b357],
3	common	JJ	O	common	amod	4	SENT_573	[p24l438t304r820b357],
4	mutations	NNS	O	mutation	nsubj	5	SENT_573	[p24l849t279r1283b357],
5	are	VBP	O	be	_	0	SENT_573	[p24l1313t304r1443b357],
6	an	DT	O	a	dep	5	SENT_573	[p24l1471t304r1574b356],
7	in	IN	O	in	_	0	SENT_573	[p24l1602t277r1973b356],
8	—	NN	O	—	nn	10	SENT_573	[p24l1602t277r1973b356],
9	frame	NN	O	frame	nn	10	SENT_573	[p24l1602t277r1973b356],
10	deletion	NN	O	deletion	prep_in	5	SENT_573	[p24l2003t278r2132b357, p24l10t406r255b484],

1	in	IN	O	in	_	0	SENT_574	[p24l293t407r376b483],
2	exon	NN	O	exon	prep_in	55	SENT_574	[p24l416t432r616b484],
3	19	CD	NUMBER	19	num	2	SENT_574	[p24l658t412r754b484],
4	around	IN	O	around	_	0	SENT_574	[p24l794t406r1100b485],
5	codons	NNS	O	codon	prep_around	2	SENT_574	[p24l1139t406r1443b484],
6	746	CD	NUMBER	746	num	5	SENT_574	[p24l1485t412r1631b484],
7	to	TO	O	to	dep	5	SENT_574	[p24l1671t422r1752b484],
8	750	CD	NUMBER	750	num	5	SENT_574	[p24l1794t412r1943b484],
9	(	CD	NUMBER	(	num	10	SENT_574	[p24l1988t412r2132b496, p24l12t535r399b635],
10	accounting	NN	O	accounting	nsubjpass	55	SENT_574	[p24l1988t412r2132b496, p24l12t535r399b635],
11	for	IN	O	for	_	0	SENT_574	[p24l429t533r552b613],
12	45	CD	NUMBER	45	number	14	SENT_574	[p24l581t540r676b613],
13	to	TO	O	to	dep	14	SENT_574	[p24l713t551r794b613],
14	50	CD	PERCENT	50	num	15	SENT_574	[p24l831t539r1016b613],
15	%	NN	PERCENT	%	prep_for	10	SENT_574	[p24l831t539r1016b613],
16	of	IN	O	of	_	0	SENT_574	[p24l1049t533r1150b613],
17	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_574	[p24l1163t541r1375b614],
18	mutations	NNS	O	mutation	prep_of	15	SENT_574	[p24l1402t535r1862b625],
19	)	CD	NUMBER	)	dep	18	SENT_574	[p24l1402t535r1862b625],
20	and	CC	O	and	_	0	SENT_574	[p24l1900t534r2058b613],
21	a	DT	O	a	det	23	SENT_574	[p24l2090t560r2135b612],
22	missense	NN	O	missense	nn	23	SENT_574	[p24l11t663r406b740],
23	mutation	NN	O	mutation	conj_and	18	SENT_574	[p24l455t663r847b741],
24	leading	VBG	O	lead	partmod	23	SENT_574	[p24l895t662r1214b763],
25	to	TO	O	to	_	0	SENT_574	[p24l1261t679r1342b741],
26	a	DT	O	a	det	27	SENT_574	[p24l1392t688r1436b740],
27	substitution	NN	O	substitution	prep_to	24	SENT_574	[p24l1485t662r2002b741],
28	of	IN	O	of	_	0	SENT_574	[p24l2052t661r2152b741],
29	arginine	NN	O	arginine	prep_of	27	SENT_574	[p24l11t791r372b891],
30	for	IN	O	for	_	0	SENT_574	[p24l402t789r525b869],
31	leucine	NN	O	leucine	prep_for	29	SENT_574	[p24l549t790r852b869],
32	at	IN	O	at	_	0	SENT_574	[p24l880t807r959b868],
33	codon	NN	O	codon	prep_at	24	SENT_574	[p24l983t790r1245b869],
34	858	CD	NUMBER	858	number	35	SENT_574	[p24l1275t796r1421b869],
35	(	CD	NUMBER	(	num	37	SENT_574	[p24l1457t796r1788b881],
36	L858R	NN	O	l858r	nn	37	SENT_574	[p24l1457t796r1788b881],
37	)	NN	O	)	dobj	49	SENT_574	[p24l1457t796r1788b881],
38	in	IN	O	in	_	0	SENT_574	[p24l1822t791r1905b868],
39	exon	NN	O	exon	prep_in	37	SENT_574	[p24l1934t816r2134b869],
40	21	CD	NUMBER	21	num	39	SENT_574	[p24l11t924r110b996],
41	(	CD	NUMBER	(	number	42	SENT_574	[p24l149t924r270b1009],
42	35	CD	NUMBER	35	nsubj	49	SENT_574	[p24l149t924r270b1009],
43	to	TO	O	to	_	0	SENT_574	[p24l307t935r389b997],
44	45	CD	PERCENT	45	num	45	SENT_574	[p24l421t923r606b998],
45	%	NN	PERCENT	%	prep_to	42	SENT_574	[p24l421t923r606b998],
46	of	IN	O	of	_	0	SENT_574	[p24l639t917r738b997],
47	EGFR	NN	ORGANIZATION	egfr	nn	48	SENT_574	[p24l751t925r964b998],
48	mutations	NNS	O	mutation	prep_of	45	SENT_574	[p24l991t919r1518b1009],
49	)	VBP	O	)	rcmod	33	SENT_574	[p24l991t919r1518b1009],
50	.6	CD	NUMBER	.6	num	53	SENT_574	[p24l991t919r1518b1009],
51	Somatic	JJ	O	somatic	amod	53	SENT_574	[p24l1553t919r1897b997],
52	EGFR	NN	O	egfr	nn	53	SENT_574	[p24l1927t925r2139b998],
53	mutations	NNS	O	mutation	dobj	49	SENT_574	[p24l11t1047r445b1125],
54	are	VBP	O	be	auxpass	55	SENT_574	[p24l489t1072r618b1124],
55	found	VBN	O	find	_	0	SENT_574	[p24l661t1045r913b1126],
56	in	IN	O	in	_	0	SENT_574	[p24l954t1047r1037b1124],
57	approximately	RB	O	approximately	quantmod	60	SENT_574	[p24l1079t1046r1695b1146],
58	5	CD	NUMBER	5	number	60	SENT_574	[p24l1735t1054r1777b1125],
59	to	TO	O	to	dep	60	SENT_574	[p24l1823t1063r1905b1125],
60	15	CD	PERCENT	15	num	61	SENT_574	[p24l1952t1052r2134b1126],
61	%	NN	PERCENT	%	prep_in	55	SENT_574	[p24l1952t1052r2134b1126],
62	of	IN	O	of	_	0	SENT_574	[p24l12t1173r112b1253],
63	unselected	JJ	O	unselected	amod	65	SENT_574	[p24l129t1174r585b1254],
64	white	JJ	O	white	amod	65	SENT_574	[p24l616t1174r855b1254],
65	patients	NNS	O	patient	prep_of	61	SENT_574	[p24l889t1175r1230b1274],
66	and	CC	O	and	_	0	SENT_574	[p24l1267t1174r1425b1253],
67	in	IN	O	in	_	0	SENT_574	[p24l1460t1175r1543b1252],
68	25	CD	NUMBER	25	number	70	SENT_574	[p24l1579t1180r1676b1253],
69	to	TO	O	to	dep	70	SENT_574	[p24l1716t1191r1797b1253],
70	35	CD	PERCENT	35	num	71	SENT_574	[p24l1835t1180r2016b1254],
71	%	NN	PERCENT	%	conj_and	61	SENT_574	[p24l1835t1180r2016b1254],
72	of	IN	O	of	_	0	SENT_574	[p24l2052t1173r2152b1253],
73	unselected	JJ	O	unselected	amod	75	SENT_574	[p24l11t1303r467b1382],
74	Asian	JJ	MISC	asian	amod	75	SENT_574	[p24l526t1304r771b1381],
75	patients	NNS	O	patient	prep_of	71	SENT_574	[p24l831t1304r1173b1402],
76	with	IN	O	with	_	0	SENT_574	[p24l1233t1303r1429b1382],
77	non	JJ	O	non	amod	83	SENT_574	[p24l1491t1303r2134b1381],
78	—	JJ	O	—	amod	83	SENT_574	[p24l1491t1303r2134b1381],
79	small	JJ	O	small	amod	83	SENT_574	[p24l1491t1303r2134b1381],
80	—	NN	O	—	nn	83	SENT_574	[p24l1491t1303r2134b1381],
81	cell	NN	O	cell	nn	83	SENT_574	[p24l1491t1303r2134b1381],
82	lung	NN	O	lung	nn	83	SENT_574	[p24l10t1431r203b1532],
83	cancer	NN	O	cancer	prep_with	55	SENT_574	[p24l235t1457r533b1510],
84	.	.	O	.	_	0	SENT_574	[p24l235t1457r533b1510],

1	These	DT	O	these	det	2	SENT_575	[p24l569t1431r820b1510],
2	mutations	NNS	O	mutation	nsubj	3	SENT_575	[p24l854t1432r1289b1510],
3	seem	VBP	O	seem	_	0	SENT_575	[p24l1326t1457r1544b1509],
4	to	TO	O	to	aux	6	SENT_575	[p24l1578t1448r1660b1510],
5	be	VB	O	be	auxpass	6	SENT_575	[p24l1696t1431r1792b1510],
6	limited	VBN	O	limit	xcomp	3	SENT_575	[p24l1825t1431r2134b1510],
7	to	TO	O	to	_	0	SENT_575	[p24l12t1576r92b1638],
8	non	JJ	O	non	amod	14	SENT_575	[p24l147t1559r790b1638],
9	—	JJ	O	—	amod	14	SENT_575	[p24l147t1559r790b1638],
10	small	JJ	O	small	amod	14	SENT_575	[p24l147t1559r790b1638],
11	—	NN	O	—	nn	14	SENT_575	[p24l147t1559r790b1638],
12	cell	NN	O	cell	nn	14	SENT_575	[p24l147t1559r790b1638],
13	lung	NN	O	lung	nn	14	SENT_575	[p24l841t1559r1035b1660],
14	cancer	NN	O	cancer	prep_to	6	SENT_575	[p24l1085t1585r1383b1655],
15	,	,	O	,	_	0	SENT_575	[p24l1085t1585r1383b1655],
16	since	IN	O	since	mark	21	SENT_575	[p24l1444t1560r1658b1637],
17	they	PRP	O	they	nsubjpass	21	SENT_575	[p24l1712t1559r1895b1659],
18	have	VBP	O	have	aux	21	SENT_575	[p24l1943t1559r2133b1638],
19	rarely	RB	O	rarely	advmod	21	SENT_575	[p24l11t1686r250b1786],
20	been	VBN	O	be	auxpass	21	SENT_575	[p24l278t1686r475b1765],
21	detected	VBN	O	detect	advcl	6	SENT_575	[p24l508t1686r858b1765],
22	in	IN	O	in	_	0	SENT_575	[p24l889t1687r971b1764],
23	other	JJ	O	other	amod	24	SENT_575	[p24l1004t1686r1227b1765],
24	types	NNS	O	type	prep_in	21	SENT_575	[p24l1256t1703r1475b1786],
25	of	IN	O	of	_	0	SENT_575	[p24l1510t1685r1609b1765],
26	human	JJ	O	human	amod	27	SENT_575	[p24l1622t1686r1922b1766],
27	cancer	NN	O	cancer	prep_of	24	SENT_575	[p24l1955t1712r2132b1764, p24l12t1841r153b1894],
28	.	.	O	.	_	0	SENT_575	[p24l1955t1712r2132b1764, p24l12t1841r153b1894],

1	Somatic	JJ	O	somatic	amod	2	SENT_576	[p24l189t1816r532b1894],
2	mutations	NNS	O	mutation	nsubjpass	10	SENT_576	[p24l560t1816r995b1894],
3	in	IN	O	in	_	0	SENT_576	[p24l1026t1816r1109b1893],
4	the	DT	O	the	det	6	SENT_576	[p24l1139t1815r1272b1893],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_576	[p24l1300t1821r1512b1895],
6	gene	NN	O	gene	prep_in	2	SENT_576	[p24l1535t1841r1734b1916],
7	are	VBP	O	be	auxpass	10	SENT_576	[p24l1764t1841r1892b1894],
8	most	RBS	O	most	advmod	9	SENT_576	[p24l1922t1832r2138b1894],
9	frequently	RB	O	frequently	advmod	10	SENT_576	[p24l11t1941r451b2042],
10	detected	VBN	O	detect	_	0	SENT_576	[p24l509t1942r866b2021],
11	in	IN	O	in	_	0	SENT_576	[p24l927t1943r1010b2020],
12	a	DT	O	a	det	13	SENT_576	[p24l1071t1968r1115b2020],
13	subpopulation	NN	O	subpopulation	prep_in	10	SENT_576	[p24l1177t1942r1797b2042],
14	of	IN	O	of	_	0	SENT_576	[p24l1859t1941r1959b2021],
15	patients	NNS	O	patient	prep_of	13	SENT_576	[p24l2001t1968r2132b2042, p24l12t2072r247b2149],
16	with	IN	O	with	_	0	SENT_576	[p24l284t2071r479b2150],
17	this	DT	O	this	det	18	SENT_576	[p24l519t2071r679b2149],
18	form	NN	O	form	prep_with	10	SENT_576	[p24l720t2070r930b2150],
19	of	IN	O	of	_	0	SENT_576	[p24l970t2070r1070b2150],
20	cancer	NN	O	cancer	prep_of	18	SENT_576	[p24l1091t2097r1372b2150],
21	who	WP	O	who	nsubj	22	SENT_576	[p24l1404t2071r1586b2150],
22	have	VBP	O	have	rcmod	18	SENT_576	[p24l1627t2071r1817b2150],
23	one	CD	NUMBER	one	dobj	22	SENT_576	[p24l1857t2097r2008b2150],
24	or	CC	O	or	_	0	SENT_576	[p24l2049t2097r2137b2150],
25	more	JJR	O	more	conj_or	23	SENT_576	[p24l11t2225r230b2278],
26	of	IN	O	of	_	0	SENT_576	[p24l271t2198r371b2278],
27	the	DT	O	the	det	29	SENT_576	[p24l394t2199r526b2277],
28	following	VBG	O	follow	amod	29	SENT_576	[p24l566t2198r981b2300],
29	characteristics	NNS	O	characteristic	prep_of	23	SENT_576	[p24l1018t2199r1664b2278],
30	:	:	O	:	_	0	SENT_576	[p24l1018t2199r1664b2278],
31	histologic	JJ	O	histologic	amod	32	SENT_576	[p24l1708t2199r2134b2300],
32	features	NNS	O	feature	dep	23	SENT_576	[p24l11t2325r353b2406],
33	of	IN	O	of	_	0	SENT_576	[p24l409t2325r509b2405],
34	adenocarcinoma	NN	O	adenocarcinoma	prep_of	32	SENT_576	[p24l542t2326r1257b2405],
35	and	CC	O	and	_	0	SENT_576	[p24l1307t2326r1488b2422],
36	,	,	O	,	_	0	SENT_576	[p24l1307t2326r1488b2422],
37	in	IN	O	in	dep	32	SENT_576	[p24l1546t2327r1629b2404],
38	particular	JJ	O	particular	pobj	37	SENT_576	[p24l1680t2326r2128b2426],
39	,	,	O	,	_	0	SENT_576	[p24l1680t2326r2128b2426],
40	nonmucinous	JJ	O	nonmucinous	amod	41	SENT_576	[p24l11t2455r600b2533],
41	bronchioloalveolar	JJ	O	bronchioloalveolar	amod	42	SENT_576	[p24l651t2454r1458b2533],
42	carcinoma	NN	O	carcinoma	conj_and	32	SENT_576	[p24l1503t2455r1979b2549],
43	;	:	O	;	_	0	SENT_576	[p24l1503t2455r1979b2549],
44	an	DT	O	a	det	45	SENT_576	[p24l2031t2480r2134b2531],
45	absence	NN	O	absence	dep	32	SENT_576	[p24l11t2582r348b2661],
46	of	IN	O	of	_	0	SENT_576	[p24l394t2581r493b2661],
47	a	DT	O	a	det	48	SENT_576	[p24l519t2608r563b2660],
48	history	NN	O	history	prep_of	45	SENT_576	[p24l606t2582r910b2682],
49	of	IN	O	of	_	0	SENT_576	[p24l951t2581r1051b2661],
50	smoking	NN	O	smoking	prep_of	48	SENT_576	[p24l1079t2582r1475b2683],
51	;	:	O	;	_	0	SENT_576	[p24l1079t2582r1475b2683],
52	an	DT	O	a	det	53	SENT_576	[p24l1522t2608r1626b2660],
53	absence	NN	O	absence	dep	32	SENT_576	[p24l1669t2582r2006b2661],
54	of	IN	O	of	_	0	SENT_576	[p24l2052t2581r2152b2661],
55	K	NN	O	k	prep_of	53	SENT_576	[p24l9t2716r259b2790],
56	.	.	O	.	_	0	SENT_576	[p24l9t2716r259b2790],

1	—	NN	O	—	_	0	SENT_577	[p24l9t2716r259b2790],
2	.	.	O	.	_	0	SENT_577	[p24l9t2716r259b2790],

1	RAS	NN	O	ra	nn	3	SENT_578	[p24l9t2716r259b2790],
2	gene	NN	O	gene	nn	3	SENT_578	[p24l306t2736r506b2811],
3	mutations	NNS	O	mutation	_	0	SENT_578	[p24l556t2711r1016b2805],
4	;	:	O	;	_	0	SENT_578	[p24l556t2711r1016b2805],
5	Asian	JJ	LOCATION	asian	conj_and	3	SENT_578	[p24l1067t2711r1311b2788],
6	ethnicity	NN	O	ethnicity	dep	5	SENT_578	[p24l1362t2710r1760b2810],
7	;	:	O	;	_	0	SENT_578	[p24l1362t2710r1760b2810],
8	and	CC	O	and	_	0	SENT_578	[p24l1814t2710r1972b2789],
9	female	JJ	O	female	amod	10	SENT_578	[p24l2023t2709r2132b2788, p24l11t2838r219b2916],
10	S	NN	O	s	conj_and	3	SENT_578	[p24l264t2844r595b2917],
11	€	CD	NUMBER	€	dep	16	SENT_578	[p24l264t2844r595b2917],
12	X.	NNP	O	X.	dep	11	SENT_578	[p24l264t2844r595b2917],
13	77	CD	NUMBER	77	num	12	SENT_578	[p24l264t2844r595b2917],
14	'80	CD	NUMBER	'80	dep	16	SENT_578	[p24l264t2844r595b2917],
15	The	DT	O	the	det	16	SENT_578	[p24l636t2838r797b2916],
16	likelihood	NN	O	likelihood	dep	20	SENT_578	[p24l840t2838r1279b2917],
17	of	IN	O	of	_	0	SENT_578	[p24l1324t2837r1423b2917],
18	EGFR	NN	ORGANIZATION	egfr	prep_of	16	SENT_578	[p24l1447t2845r1659b2918],
19	mutations	NNS	O	mutation	nsubj	62	SENT_578	[p24l1697t2839r2131b2917],
20	decreases	VBZ	O	decrease	dep	3	SENT_578	[p24l12t2966r420b3044],
21	as	IN	O	as	_	0	SENT_578	[p24l464t2992r549b3043],
22	the	DT	O	the	det	23	SENT_578	[p24l594t2966r727b3044],
23	exposure	NN	O	exposure	prep_as	20	SENT_578	[p24l770t2992r1156b3065],
24	to	TO	O	to	_	0	SENT_578	[p24l1199t2983r1280b3044],
25	tobacco	NN	O	tobacco	nn	27	SENT_578	[p24l1325t2966r1654b3044],
26	smoke	NN	O	smoke	nn	27	SENT_578	[p24l1699t2966r1975b3045],
27	increases	NNS	O	increase	prep_to	20	SENT_578	[p24l2017t2967r2132b3043, p24l12t3120r343b3190],
28	,	,	O	,	_	0	SENT_578	[p24l2017t2967r2132b3043, p24l12t3120r343b3190],
29	leading	VBG	O	lead	xcomp	20	SENT_578	[p24l383t3094r703b3195],
30	to	TO	O	to	_	0	SENT_578	[p24l737t3111r818b3173],
31	the	DT	O	the	det	32	SENT_578	[p24l856t3094r989b3172],
32	hypothesis	NN	O	hypothesis	prep_to	29	SENT_578	[p24l1026t3094r1488b3194],
33	that	IN	O	that	complm	45	SENT_578	[p24l1527t3094r1699b3172],
34	lung	NN	O	lung	nn	35	SENT_578	[p24l1729t3094r1923b3195],
35	adenocarcinoma	NN	O	adenocarcinoma	nsubj	45	SENT_578	[p24l1956t3094r2132b3173, p24l11t3223r577b3300],
36	in	IN	O	in	_	0	SENT_578	[p24l609t3223r692b3299],
37	patients	NNS	O	patient	prep_in	35	SENT_578	[p24l725t3223r1066b3321],
38	who	WP	O	who	nsubj	41	SENT_578	[p24l1098t3222r1280b3301],
39	have	VBP	O	have	aux	41	SENT_578	[p24l1316t3222r1506b3301],
40	never	RB	O	never	neg	41	SENT_578	[p24l1539t3248r1769b3301],
41	smoked	VBN	O	smoke	rcmod	37	SENT_578	[p24l1801t3222r2133b3301],
42	is	VBZ	O	be	cop	45	SENT_578	[p24l11t3351r76b3428],
43	a	DT	O	a	det	45	SENT_578	[p24l119t3376r163b3428],
44	distinct	JJ	O	distinct	amod	45	SENT_578	[p24l203t3350r532b3429],
45	form	NN	O	form	ccomp	29	SENT_578	[p24l568t3349r777b3429],
46	of	IN	O	of	_	0	SENT_578	[p24l819t3349r919b3429],
47	non	JJ	O	non	amod	53	SENT_578	[p24l942t3350r1585b3429],
48	—	JJ	O	—	amod	53	SENT_578	[p24l942t3350r1585b3429],
49	small	JJ	O	small	amod	53	SENT_578	[p24l942t3350r1585b3429],
50	—	NN	O	—	nn	53	SENT_578	[p24l942t3350r1585b3429],
51	cell	NN	O	cell	nn	53	SENT_578	[p24l942t3350r1585b3429],
52	lung	NN	O	lung	nn	53	SENT_578	[p24l1624t3350r1817b3451],
53	cancer	NN	O	cancer	prep_of	45	SENT_578	[p24l1856t3376r2137b3429],
54	with	IN	O	with	_	0	SENT_578	[p24l7t3478r202b3557],
55	a	DT	O	a	det	57	SENT_578	[p24l236t3504r281b3556],
56	high	JJ	O	high	amod	57	SENT_578	[p24l314t3478r509b3579],
57	frequency	NN	O	frequency	prep_with	53	SENT_578	[p24l544t3477r967b3578],
58	of	IN	O	of	_	0	SENT_578	[p24l999t3477r1098b3557],
59	EGFR	NN	ORGANIZATION	egfr	nn	60	SENT_578	[p24l1114t3485r1326b3558],
60	mutations	NNS	O	mutation	prep_of	57	SENT_578	[p24l1355t3479r1788b3557],
61	and	CC	O	and	_	0	SENT_578	[p24l1825t3478r1983b3557],
62	increased	VBD	O	increase	conj_and	20	SENT_578	[p24l2018t3479r2132b3556, p24l12t3606r332b3684],
63	sensitivity	NN	O	sensitivity	dobj	62	SENT_578	[p24l384t3607r817b3705],
64	to	TO	O	to	_	0	SENT_578	[p24l863t3623r945b3684],
65	EGFR	NN	ORGANIZATION	egfr	nn	68	SENT_578	[p24l995t3612r1251b3689],
66	tyrosine	NN	O	tyrosine	nn	68	SENT_578	[p24l1292t3607r1638b3705],
67	kinase	NN	O	kinase	nn	68	SENT_578	[p24l1688t3606r1967b3685],
68	inhibitors	NNS	O	inhibitor	prep_to	62	SENT_578	[p24l2017t3607r2132b3683, p25l11t21r542b100],
69	.81	CD	NUMBER	.81	num	70	SENT_578	[p24l2017t3607r2132b3683, p25l11t21r542b100],
70	’82	CD	NUMBER	’82	dobj	20	SENT_578	[p24l2017t3607r2132b3683, p25l11t21r542b100],

1	The	DT	O	the	dep	112	SENT_579	[p25l583t21r744b99],
2	association	NN	O	association	dep	112	SENT_579	[p25l787t22r1271b100],
3	between	IN	O	between	dep	112	SENT_579	[p25l1315t21r1673b100],
4	EGFR	NN	ORGANIZATION	egfr	dep	112	SENT_579	[p25l1715t27r1927b101],
5	mutations	NNS	O	mutation	dep	112	SENT_579	[p25l1965t47r2132b100, p25l12t150r305b228],
6	and	CC	O	and	dep	112	SENT_579	[p25l355t149r513b228],
7	a	DT	O	a	dep	112	SENT_579	[p25l559t175r604b227],
8	response	NN	O	response	dep	112	SENT_579	[p25l650t175r1030b249],
9	to	TO	O	to	dep	112	SENT_579	[p25l1079t166r1160b228],
10	erlotinib	NN	O	erlotinib	dep	112	SENT_579	[p25l1210t149r1577b228],
11	or	CC	O	or	dep	112	SENT_579	[p25l1627t175r1716b228],
12	gefitinib	NN	O	gefitinib	dep	112	SENT_579	[p25l1760t148r2132b250],
13	has	VBZ	O	have	dep	112	SENT_579	[p25l11t276r155b354],
14	been	VBN	O	be	dep	112	SENT_579	[p25l222t276r424b355],
15	retrospectively	RB	O	retrospectively	dep	112	SENT_579	[p25l488t276r1116b376],
16	confirmed	VBN	O	confirm	dep	112	SENT_579	[p25l1177t275r1630b355],
17	in	IN	O	in	dep	112	SENT_579	[p25l1694t277r1777b354],
18	several	JJ	O	several	dep	112	SENT_579	[p25l1842t276r2134b356],
19	clinical	JJ	O	clinical	dep	112	SENT_579	[p25l12t405r325b483],
20	studies	NNS	O	study	dep	112	SENT_579	[p25l364t405r731b484],
21	.6	CD	NUMBER	.6	dep	112	SENT_579	[p25l364t405r731b484],
22	It	PRP	O	it	dep	112	SENT_579	[p25l768t413r833b483],
23	has	VBZ	O	have	dep	112	SENT_579	[p25l865t405r1009b483],
24	been	VBN	O	be	dep	112	SENT_579	[p25l1050t405r1252b484],
25	also	RB	O	also	dep	112	SENT_579	[p25l1289t405r1460b484],
26	suggested	VBD	O	suggest	dep	112	SENT_579	[p25l1501t405r1928b506],
27	that	IN	O	that	dep	112	SENT_579	[p25l1966t405r2138b483],
28	this	DT	O	this	dep	112	SENT_579	[p25l12t533r171b611],
29	association	NN	O	association	dep	112	SENT_579	[p25l214t534r698b611],
30	translates	VBZ	O	translate	dep	112	SENT_579	[p25l728t533r1146b611],
31	into	IN	O	into	dep	112	SENT_579	[p25l1188t534r1358b611],
32	improved	VBN	O	improve	dep	112	SENT_579	[p25l1400t533r1804b632],
33	survival	NN	O	survival	dep	112	SENT_579	[p25l1847t534r2132b612, p25l11t661r149b740],
34	.6	CD	NUMBER	.6	dep	112	SENT_579	[p25l1847t534r2132b612, p25l11t661r149b740],
35	However	RB	O	however	dep	112	SENT_579	[p25l182t669r577b757],
36	,	,	O	,	_	0	SENT_579	[p25l182t669r577b757],
37	in	IN	O	in	dep	112	SENT_579	[p25l617t662r700b739],
38	larger	JJR	O	larger	dep	112	SENT_579	[p25l732t661r987b762],
39	randomized	JJ	O	randomized	dep	112	SENT_579	[p25l1018t661r1539b740],
40	studies	NNS	O	study	dep	112	SENT_579	[p25l1574t661r1898b757],
41	,	,	O	,	_	0	SENT_579	[p25l1574t661r1898b757],
42	such	JJ	O	such	dep	112	SENT_579	[p25l1939t661r2133b740],
43	as	IN	O	as	dep	112	SENT_579	[p25l11t815r96b867],
44	the	DT	O	the	dep	112	SENT_579	[p25l146t789r278b867],
45	BR	NN	O	br	dep	112	SENT_579	[p25l324t795r580b872],
46	.21	CD	NUMBER	.21	dep	112	SENT_579	[p25l324t795r580b872],
47	trial	NN	O	trial	dep	112	SENT_579	[p25l628t789r828b885],
48	,	,	O	,	_	0	SENT_579	[p25l628t789r828b885],
49	a	DT	O	a	dep	112	SENT_579	[p25l880t815r925b867],
50	similar	JJ	O	similar	dep	112	SENT_579	[p25l973t789r1278b867],
51	survival	NN	O	survival	dep	112	SENT_579	[p25l1324t789r1656b868],
52	advantage	NN	O	advantage	dep	112	SENT_579	[p25l1702t789r2133b890],
53	was	VBD	O	be	dep	112	SENT_579	[p25l7t942r169b996],
54	observed	VBN	O	observe	dep	112	SENT_579	[p25l211t916r592b995],
55	for	IN	O	for	dep	112	SENT_579	[p25l630t915r754b995],
56	patients	NNS	O	patient	dep	112	SENT_579	[p25l788t917r1129b1016],
57	treated	VBN	O	treat	dep	112	SENT_579	[p25l1171t916r1470b995],
58	with	IN	O	with	dep	112	SENT_579	[p25l1503t916r1698b996],
59	erlotinib	NN	O	erlotinib	dep	112	SENT_579	[p25l1738t916r2128b1012],
60	,	,	O	,	_	0	SENT_579	[p25l1738t916r2128b1012],
61	independently	RB	O	independently	dep	112	SENT_579	[p25l11t1044r624b1144],
62	of	IN	O	of	dep	112	SENT_579	[p25l654t1043r754b1123],
63	the	DT	O	the	dep	112	SENT_579	[p25l769t1044r902b1122],
64	presence	NN	O	presence	dep	112	SENT_579	[p25l934t1070r1310b1144],
65	of	IN	O	of	dep	112	SENT_579	[p25l1344t1043r1444b1123],
66	EGFR	NN	ORGANIZATION	egfr	dep	112	SENT_579	[p25l1458t1051r1670b1124],
67	mutations	NNS	O	mutation	dep	112	SENT_579	[p25l1697t1045r2131b1124],
68	or	CC	O	or	dep	112	SENT_579	[p25l12t1199r100b1252],
69	of	IN	O	of	dep	112	SENT_579	[p25l141t1172r241b1252],
70	a	DT	O	a	dep	112	SENT_579	[p25l264t1199r309b1251],
71	wild	JJ	O	wild	dep	112	SENT_579	[p25l345t1173r750b1273],
72	—	NN	O	—	dep	112	SENT_579	[p25l345t1173r750b1273],
73	type	NN	O	type	dep	112	SENT_579	[p25l345t1173r750b1273],
74	EGFR	NN	ORGANIZATION	egfr	dep	112	SENT_579	[p25l792t1180r1004b1253],
75	gene	NN	O	gene	dep	112	SENT_579	[p25l1040t1199r1262b1274],
76	,	,	O	,	_	0	SENT_579	[p25l1040t1199r1262b1274],
77	indicating	VBG	O	indicate	dep	112	SENT_579	[p25l1309t1173r1751b1274],
78	that	IN	O	that	dep	112	SENT_579	[p25l1790t1173r1963b1251],
79	the	DT	O	the	dep	112	SENT_579	[p25l2001t1173r2133b1252],
80	presence	NN	O	presence	dep	112	SENT_579	[p25l9t1326r385b1400],
81	of	IN	O	of	dep	112	SENT_579	[p25l428t1299r528b1379],
82	EGFR	NN	ORGANIZATION	egfr	dep	112	SENT_579	[p25l550t1307r763b1380],
83	mutations	NNS	O	mutation	dep	112	SENT_579	[p25l799t1301r1233b1379],
84	is	VBZ	O	be	dep	112	SENT_579	[p25l1277t1301r1343b1378],
85	not	RB	O	not	dep	112	SENT_579	[p25l1387t1317r1530b1379],
86	the	DT	O	the	dep	112	SENT_579	[p25l1569t1300r1701b1378],
87	only	JJ	O	only	dep	112	SENT_579	[p25l1744t1300r1928b1400],
88	biomarker	NN	O	biomarker	dep	112	SENT_579	[p25l1967t1300r2132b1379, p25l11t1429r322b1508],
89	for	IN	O	for	dep	112	SENT_579	[p25l358t1428r481b1508],
90	predicting	VBG	O	predict	dep	112	SENT_579	[p25l515t1429r962b1530],
91	a	DT	O	a	dep	112	SENT_579	[p25l996t1455r1040b1507],
92	survival	NN	O	survival	dep	112	SENT_579	[p25l1079t1429r1411b1508],
93	benefit	NN	O	benefit	dep	112	SENT_579	[p25l1450t1428r1755b1508],
94	of	IN	O	of	dep	112	SENT_579	[p25l1789t1428r1889b1508],
95	treatment	NN	O	treatment	dep	112	SENT_579	[p25l1909t1446r2132b1507, p25l11t1573r232b1635],
96	with	IN	O	with	dep	112	SENT_579	[p25l260t1557r456b1636],
97	small-molecule	JJ	O	small-molecule	dep	112	SENT_579	[p25l495t1557r1150b1636],
98	EGFR	NN	ORGANIZATION	egfr	dep	112	SENT_579	[p25l1187t1563r1443b1640],
99	tyrosine	NN	O	tyrosine	dep	112	SENT_579	[p25l1471t1558r1817b1656],
100	kinase	NN	O	kinase	dep	112	SENT_579	[p25l1854t1557r2133b1636],
101	inhibitors	NNS	O	inhibitor	dep	112	SENT_579	[p25l11t1685r432b1764],
102	in	IN	O	in	dep	112	SENT_579	[p25l484t1686r568b1763],
103	patients	NNS	O	patient	dep	112	SENT_579	[p25l617t1686r958b1785],
104	with	IN	O	with	dep	112	SENT_579	[p25l1006t1685r1202b1764],
105	non	JJ	O	non	dep	112	SENT_579	[p25l1252t1685r1894b1764],
106	—	JJ	O	—	dep	112	SENT_579	[p25l1252t1685r1894b1764],
107	small	JJ	O	small	dep	112	SENT_579	[p25l1252t1685r1894b1764],
108	—	NN	O	—	dep	112	SENT_579	[p25l1252t1685r1894b1764],
109	cell	NN	O	cell	dep	112	SENT_579	[p25l1252t1685r1894b1764],
110	lung	NN	O	lung	dep	112	SENT_579	[p25l1943t1685r2137b1786],
111	cancer	NN	O	cancer	dep	112	SENT_579	[p25l12t1819r388b1893],
112	.83	CD	NUMBER	.83	_	0	SENT_579	[p25l12t1819r388b1893],

1	INCREASED	VBN	O	increase	dep	10	SENT_580	[p25l17t2087r462b2137],
2	EGFR	NN	ORGANIZATION	egfr	nn	4	SENT_580	[p25l498t2087r694b2137],
3	copv	NN	O	copv	nn	4	SENT_580	[p25l728t2087r935b2137],
4	NUMBER	NN	O	number	dobj	1	SENT_580	[p25l974t2088r1307b2137],
5	The	DT	O	the	det	7	SENT_580	[p25l7t2186r168b2264],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_580	[p25l200t2193r412b2266],
7	gene	NN	O	gene	nsubjpass	10	SENT_580	[p25l439t2212r638b2287],
8	is	VBZ	O	be	auxpass	10	SENT_580	[p25l672t2187r737b2264],
9	rarely	RB	O	rarely	advmod	10	SENT_580	[p25l773t2186r1017b2286],
10	amplified	VBN	O	amplify	_	0	SENT_580	[p25l1045t2185r1463b2286],
11	in	IN	O	in	_	0	SENT_580	[p25l1496t2187r1579b2264],
12	human	JJ	O	human	amod	13	SENT_580	[p25l1613t2186r1917b2265],
13	cancers	NNS	O	cancer	prep_in	10	SENT_580	[p25l1952t2212r2132b2264, p25l12t2339r203b2392],
14	.	.	O	.	_	0	SENT_580	[p25l1952t2212r2132b2264, p25l12t2339r203b2392],

1	However	RB	O	however	advmod	10	SENT_581	[p25l242t2321r637b2409],
2	,	,	O	,	_	0	SENT_581	[p25l242t2321r637b2409],
3	fluorescence	NN	O	fluorescence	nsubj	10	SENT_581	[p25l675t2312r1218b2393],
4	in	FW	O	in	prep	3	SENT_581	[p25l1251t2314r1334b2391],
5	situ	FW	O	situ	pobj	4	SENT_581	[p25l1369t2314r1524b2393],
6	hybridization	NN	O	hybridization	nn	9	SENT_581	[p25l1557t2313r2133b2413],
7	(	CD	NUMBER	(	num	9	SENT_581	[p25l16t2448r285b2532],
8	FISH	NN	O	fish	nn	9	SENT_581	[p25l16t2448r285b2532],
9	)	NN	O	)	dep	5	SENT_581	[p25l16t2448r285b2532],
10	shows	VBZ	O	show	_	0	SENT_581	[p25l348t2442r611b2521],
11	an	DT	O	a	det	15	SENT_581	[p25l668t2468r771b2519],
12	increased	VBN	O	increase	amod	15	SENT_581	[p25l826t2442r1235b2520],
13	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_581	[p25l1288t2448r1501b2521],
14	copy	NN	O	copy	nn	15	SENT_581	[p25l1551t2468r1747b2541],
15	number	NN	O	number	dobj	10	SENT_581	[p25l1799t2442r2136b2521],
16	with	IN	O	with	_	0	SENT_581	[p25l7t2570r202b2649],
17	balanced	JJ	O	balanced	amod	18	SENT_581	[p25l242t2570r626b2649],
18	polysomy	NN	O	polysomy	prep_with	15	SENT_581	[p25l663t2570r1075b2670],
19	in	IN	O	in	_	0	SENT_581	[p25l1108t2571r1192b2648],
20	a	DT	O	a	det	22	SENT_581	[p25l1230t2596r1274b2648],
21	high	JJ	O	high	amod	22	SENT_581	[p25l1311t2570r1506b2671],
22	proportion	NN	O	proportion	prep_in	15	SENT_581	[p25l1543t2571r2013b2670],
23	of	IN	O	of	_	0	SENT_581	[p25l2052t2569r2152b2649],
24	cancer	NN	O	cancer	nn	25	SENT_581	[p25l12t2723r292b2775],
25	cells	NNS	O	cell	prep_of	22	SENT_581	[p25l337t2697r524b2775],
26	in	IN	O	in	_	0	SENT_581	[p25l573t2698r656b2775],
27	approximately	RB	O	approximately	quantmod	30	SENT_581	[p25l702t2697r1318b2797],
28	25	CD	NUMBER	25	number	30	SENT_581	[p25l1360t2703r1458b2776],
29	to	TO	O	to	dep	30	SENT_581	[p25l1508t2714r1590b2776],
30	40	CD	PERCENT	40	num	31	SENT_581	[p25l1636t2702r1827b2776],
31	%	NN	PERCENT	%	prep_in	15	SENT_581	[p25l1636t2702r1827b2776],
32	of	IN	O	of	_	0	SENT_581	[p25l1874t2696r1974b2776],
33	patients	NNS	O	patient	prep_of	31	SENT_581	[p25l2001t2723r2132b2797, p25l12t2827r247b2904],
34	with	IN	O	with	_	0	SENT_581	[p25l311t2826r506b2905],
35	non	JJ	O	non	amod	41	SENT_581	[p25l572t2826r1213b2905],
36	—	JJ	O	—	amod	41	SENT_581	[p25l572t2826r1213b2905],
37	small	JJ	O	small	amod	41	SENT_581	[p25l572t2826r1213b2905],
38	—	NN	O	—	nn	41	SENT_581	[p25l572t2826r1213b2905],
39	cell	NN	O	cell	nn	41	SENT_581	[p25l572t2826r1213b2905],
40	lung	NN	O	lung	nn	41	SENT_581	[p25l1277t2826r1471b2927],
41	cancer	NN	O	cancer	prep_with	33	SENT_581	[p25l1534t2852r1832b2922],
42	,	,	O	,	_	0	SENT_581	[p25l1534t2852r1832b2922],
43	squamous	JJ	O	squamous	amod	46	SENT_581	[p25l1905t2852r2132b2926, p25l11t2953r432b3032],
44	—	NN	O	—	nn	46	SENT_581	[p25l1905t2852r2132b2926, p25l11t2953r432b3032],
45	cell	NN	O	cell	nn	46	SENT_581	[p25l1905t2852r2132b2926, p25l11t2953r432b3032],
46	carcinoma	NN	O	carcinoma	dobj	10	SENT_581	[p25l484t2954r937b3032],
47	of	IN	O	of	_	0	SENT_581	[p25l988t2952r1088b3032],
48	the	DT	O	the	det	49	SENT_581	[p25l1121t2953r1254b3031],
49	head	NN	O	head	prep_of	46	SENT_581	[p25l1306t2953r1509b3032],
50	and	CC	O	and	_	0	SENT_581	[p25l1560t2953r1717b3032],
51	neck	NN	O	neck	prep_of	46	SENT_581	[p25l1769t2953r1990b3049],
52	,	,	O	,	_	0	SENT_581	[p25l1769t2953r1990b3049],
53	or	CC	O	or	_	0	SENT_581	[p25l2048t2979r2137b3032],
54	colorectal	JJ	O	colorectal	amod	55	SENT_581	[p25l12t3082r432b3161],
55	cancer	NN	O	cancer	dobj	10	SENT_581	[p25l462t3108r761b3161],
56	.	.	O	.	_	0	SENT_581	[p25l462t3108r761b3161],

1	A	DT	O	a	det	4	SENT_582	[p25l793t3090r859b3160],
2	single	JJ	O	single	amod	4	SENT_582	[p25l888t3082r1453b3183],
3	—	NN	O	—	nn	4	SENT_582	[p25l888t3082r1453b3183],
4	group	NN	O	group	_	0	SENT_582	[p25l888t3082r1453b3183],
5	,	,	O	,	_	0	SENT_582	[p25l888t3082r1453b3183],
6	phase	NN	O	phase	appos	4	SENT_582	[p25l1487t3082r1736b3182],
7	2	CD	NUMBER	2	num	8	SENT_582	[p25l1765t3088r1813b3160],
8	trial	NN	O	trial	dep	4	SENT_582	[p25l1844t3082r2022b3160],
9	of	IN	O	of	prep	8	SENT_582	[p25l2052t3081r2152b3161],

1	N	NN	O	n	nn	3	SENT_583	[p25l522t3269r535b3284],
2	ENGLJ	NN	O	englj	nn	3	SENT_583	[p25l550t3269r628b3291],
3	MED	NN	O	med	_	0	SENT_583	[p25l643t3269r695b3284],
4	358	CD	NUMBER	358	dep	3	SENT_583	[p25l705t3263r773b3291],
5	;	:	O	;	_	0	SENT_583	[p25l705t3263r773b3291],
6	11	CD	NUMBER	11	num	7	SENT_583	[p25l705t3263r773b3291],
7	WWW	NNP	O	WWW	dep	3	SENT_583	[p25l809t3269r916b3285],
8	,	,	O	,	_	0	SENT_583	[p25l809t3269r916b3285],
9	NE	NN	O	ne	nn	11	SENT_583	[p25l809t3269r916b3285],
10	M.ORG	NNP	O	M.ORG	nn	11	SENT_583	[p25l931t3269r1010b3285],
11	MARCH	NNP	DATE	MARCH	appos	7	SENT_583	[p25l1047t3269r1132b3284],
12	13	CD	DATE	13	num	11	SENT_583	[p25l1147t3269r1178b3291],
13	,	,	DATE	,	_	0	SENT_583	[p25l1147t3269r1178b3291],
14	2008	CD	DATE	2008	num	15	SENT_583	[p25l1189t3263r1252b3285],
15	1169	CD	DATE	1169	appos	7	SENT_583	[p25l1940t3258r2016b3282],

1	The	DT	O	the	det	4	SENT_584	[p25l702t3302r753b3326],
2	New	NNP	O	New	nn	4	SENT_584	[p25l762t3303r824b3326],
3	Englan	NNP	O	Englan	nn	4	SENT_584	[p25l833t3302r927b3333],
4	oumal	NN	O	oumal	_	0	SENT_584	[p25l966t3302r1050b3326],
5	of	IN	O	of	_	0	SENT_584	[p25l1059t3302r1088b3326],
6	Medicine	NN	MISC	medicine	prep_of	4	SENT_584	[p25l1095t3302r1220b3326],

1	Downloaded	VBN	O	download	_	0	SENT_585	[p25l144t3343r314b3366],
2	from	IN	O	from	_	0	SENT_585	[p25l323t3343r387b3366],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_585	[p25l396t3343r514b3373],
4	at	IN	O	at	_	0	SENT_585	[p25l524t3347r547b3366],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_585	[p25l556t3343r738b3366],
6	on	IN	O	on	_	0	SENT_585	[p25l748t3350r780b3366],
7	January	NNP	DATE	January	prep_on	1	SENT_585	[p25l789t3343r892b3373],
8	5	CD	DATE	5	num	7	SENT_585	[p25l902t3343r924b3371],
9	,	,	DATE	,	_	0	SENT_585	[p25l902t3343r924b3371],
10	2014	CD	DATE	2014	num	7	SENT_585	[p25l935t3343r1007b3366],
11	.	.	O	.	_	0	SENT_585	[p25l935t3343r1007b3366],

1	For	IN	O	for	_	0	SENT_586	[p25l1018t3343r1064b3366],
2	personal	JJ	O	personal	amod	3	SENT_586	[p25l1072t3343r1185b3373],
3	use	NN	O	use	pobj	1	SENT_586	[p25l1194t3350r1237b3366],
4	only	RB	O	only	advmod	3	SENT_586	[p25l1247t3343r1312b3373],
5	.	.	O	.	_	0	SENT_586	[p25l1247t3343r1312b3373],

1	No	DT	O	no	det	3	SENT_587	[p25l1322t3343r1362b3366],
2	other	JJ	O	other	amod	3	SENT_587	[p25l1372t3343r1440b3366],
3	uses	NNS	O	use	_	0	SENT_587	[p25l1448t3350r1504b3366],
4	without	IN	O	without	_	0	SENT_587	[p25l1514t3343r1616b3366],
5	permission	NN	O	permission	prep_without	3	SENT_587	[p25l1624t3343r1776b3373],
6	.	.	O	.	_	0	SENT_587	[p25l1624t3343r1776b3373],

1	Copyright	NN	O	copyright	_	0	SENT_588	[p25l494t3384r629b3415],
2	©	CD	NUMBER	©	num	6	SENT_588	[p25l638t3384r661b3408],
3	2008	CD	DATE	2008	num	6	SENT_588	[p25l671t3384r736b3408],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_588	[p25l746t3384r937b3408],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_588	[p25l947t3384r1055b3408],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_588	[p25l1065t3384r1170b3415],
7	.	.	O	.	_	0	SENT_588	[p25l1065t3384r1170b3415],

1	All	DT	O	all	det	2	SENT_589	[p25l1181t3384r1223b3408],
2	rights	NNS	O	rights	nsubj	3	SENT_589	[p25l1232t3384r1306b3415],
3	reserved	VBN	O	reserve	_	0	SENT_589	[p25l1316t3384r1435b3408],
4	.	.	O	.	_	0	SENT_589	[p25l1316t3384r1435b3408],

1	The	DT	O	the	det	4	SENT_590	[p25l673t3490r718b3511],
2	NEW	NNP	O	NEW	nn	4	SENT_590	[p25l737t3492r822b3511],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_590	[p25l841t3492r1029b3511],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_590	[p25l1048t3492r1227b3518],
5	of	IN	O	of	_	0	SENT_590	[p25l1247t3490r1275b3517],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_590	[p25l1287t3492r1486b3511],

1	treatment	NN	O	treatment	nsubj	81	SENT_591	[p26l11t122r435b183],
2	with	IN	O	with	_	0	SENT_591	[p26l488t105r684b184],
3	gefitinib	NN	O	gefitinib	prep_with	1	SENT_591	[p26l746t104r1117b206],
4	in	IN	O	in	_	0	SENT_591	[p26l1181t106r1264b183],
5	advanced	JJ	O	advanced	amod	16	SENT_591	[p26l1326t105r1745b201],
6	,	,	O	,	_	0	SENT_591	[p26l1326t105r1745b201],
7	chemotherapy	NN	O	chemotherapy	dep	5	SENT_591	[p26l1815t105r2133b184, p26l11t232r789b333],
8	—	CD	NUMBER	—	num	14	SENT_591	[p26l1815t105r2133b184, p26l11t232r789b333],
9	refractory	JJ	O	refractory	amod	14	SENT_591	[p26l1815t105r2133b184, p26l11t232r789b333],
10	non	JJ	O	non	amod	14	SENT_591	[p26l864t233r1507b312],
11	—	NN	O	—	nn	14	SENT_591	[p26l864t233r1507b312],
12	small	JJ	O	small	amod	14	SENT_591	[p26l864t233r1507b312],
13	—	NN	O	—	nn	14	SENT_591	[p26l864t233r1507b312],
14	cell	NN	O	cell	dep	7	SENT_591	[p26l864t233r1507b312],
15	lung	NN	O	lung	nn	16	SENT_591	[p26l1585t233r1779b334],
16	cancer	NN	O	cancer	prep_in	3	SENT_591	[p26l1856t259r2137b311],
17	was	VBD	O	be	cop	81	SENT_591	[p26l6t386r169b440],
18	the	DT	O	the	det	81	SENT_591	[p26l222t360r355b438],
19	first	JJ	ORDINAL	first	amod	81	SENT_591	[p26l405t359r589b438],
20	to	TO	O	to	aux	21	SENT_591	[p26l635t377r717b439],
21	show	VB	O	show	xcomp	19	SENT_591	[p26l770t360r995b440],
22	that	IN	O	that	complm	27	SENT_591	[p26l1042t360r1214b438],
23	patients	NNS	O	patient	nsubj	27	SENT_591	[p26l1258t361r1600b460],
24	with	IN	O	with	_	0	SENT_591	[p26l1647t360r1842b440],
25	FISHpositive	JJ	O	fishpositive	amod	26	SENT_591	[p26l1892t366r2133b439, p26l10t490r340b589],
26	tumors	NNS	O	tumor	prep_with	23	SENT_591	[p26l378t506r685b568],
27	had	VBD	O	have	ccomp	21	SENT_591	[p26l725t489r881b568],
28	significantly	RB	O	significantly	advmod	29	SENT_591	[p26l919t488r1463b590],
29	higher	JJR	O	higher	amod	30	SENT_591	[p26l1495t489r1776b590],
30	rates	NNS	O	rate	dobj	27	SENT_591	[p26l1810t506r2012b567],
31	of	IN	O	of	_	0	SENT_591	[p26l2052t488r2152b568],
32	response	NN	O	response	prep_of	30	SENT_591	[p26l11t643r392b716],
33	and	CC	O	and	_	0	SENT_591	[p26l438t617r596b695],
34	survival	NN	O	survival	prep_of	30	SENT_591	[p26l644t617r976b696],
35	than	IN	O	than	_	0	SENT_591	[p26l1023t617r1219b695],
36	patients	NNS	O	patient	prep_than	27	SENT_591	[p26l1264t618r1606b716],
37	with	IN	O	with	_	0	SENT_591	[p26l1651t617r1846b696],
38	FISHnegative	JJ	O	fishnegative	amod	39	SENT_591	[p26l1891t623r2132b695, p26l11t746r364b846],
39	tumors	NNS	O	tumor	prep_with	27	SENT_591	[p26l420t750r835b824],
40	.84	CD	NUMBER	.84	rel	53	SENT_591	[p26l420t750r835b824],
41	In	IN	O	in	_	0	SENT_591	[p26l888t753r977b823],
42	the	DT	O	the	det	45	SENT_591	[p26l1033t745r1165b824],
43	BR	NN	O	br	nn	45	SENT_591	[p26l1220t751r1474b828],
44	.21	CD	NUMBER	.21	num	45	SENT_591	[p26l1220t751r1474b828],
45	trial	NN	O	trial	prep_in	40	SENT_591	[p26l1531t745r1731b841],
46	,	,	O	,	_	0	SENT_591	[p26l1531t745r1731b841],
47	patients	NNS	O	patient	appos	45	SENT_591	[p26l1790t746r2131b845],
48	with	IN	O	with	_	0	SENT_591	[p26l6t872r198b952],
49	FISH	NN	O	fish	prep_with	47	SENT_591	[p26l233t873r794b972],
50	—	CD	NUMBER	—	num	52	SENT_591	[p26l233t873r794b972],
51	positive	JJ	O	positive	amod	52	SENT_591	[p26l233t873r794b972],
52	tumors	NNS	O	tumor	nsubj	53	SENT_591	[p26l830t889r1132b952],
53	(	VBP	O	(	rcmod	39	SENT_591	[p26l1174t872r1801b972],
54	approximately	RB	O	approximately	quantmod	55	SENT_591	[p26l1174t872r1801b972],
55	40	CD	PERCENT	40	num	56	SENT_591	[p26l1830t878r2019b951],
56	%	NN	PERCENT	%	nsubj	68	SENT_591	[p26l1830t878r2019b951],
57	of	IN	O	of	_	0	SENT_591	[p26l2054t871r2153b951],
58	the	DT	O	the	det	59	SENT_591	[p26l11t1001r144b1079],
59	patients	NNS	O	patient	prep_of	56	SENT_591	[p26l180t1002r548b1101],
60	)	IN	O	)	_	0	SENT_591	[p26l180t1002r548b1101],
61	who	WP	O	who	nsubjpass	64	SENT_591	[p26l586t1001r769b1080],
62	were	VBD	O	be	auxpass	64	SENT_591	[p26l803t1027r1005b1080],
63	randomly	RB	O	randomly	advmod	64	SENT_591	[p26l1042t1001r1456b1101],
64	assigned	VBN	O	assign	prepc_)	59	SENT_591	[p26l1489t1001r1863b1102],
65	to	TO	O	to	aux	66	SENT_591	[p26l1900t1018r1981b1080],
66	receive	VB	O	receive	xcomp	64	SENT_591	[p26l2020t1027r2133b1079, p26l11t1130r215b1208],
67	erlotinib	NN	O	erlotinib	dobj	66	SENT_591	[p26l266t1129r633b1208],
68	had	VBD	O	have	ccomp	53	SENT_591	[p26l684t1129r841b1208],
69	significantly	RB	O	significantly	advmod	70	SENT_591	[p26l891t1128r1435b1230],
70	longer	JJR	O	longer	amod	71	SENT_591	[p26l1479t1129r1754b1230],
71	survival	NN	O	survival	dobj	68	SENT_591	[p26l1802t1129r2134b1208],
72	as	IN	O	as	prep	68	SENT_591	[p26l10t1283r95b1334],
73	compared	VBN	O	compare	_	0	SENT_591	[p26l131t1257r557b1356],
74	with	IN	O	with	prepc_compared_with	68	SENT_591	[p26l585t1257r780b1336],
75	patients	NNS	O	patient	pobj	68	SENT_591	[p26l811t1258r1152b1356],
76	with	IN	O	with	_	0	SENT_591	[p26l1183t1257r1378b1336],
77	FISH-positive	JJ	O	fish-positive	amod	78	SENT_591	[p26l1408t1258r1983b1356],
78	tumors	NNS	O	tumor	prep_with	75	SENT_591	[p26l2016t1273r2133b1336, p26l11t1411r227b1463],
79	who	WP	O	who	nsubj	80	SENT_591	[p26l263t1385r446b1464],
80	received	VBD	O	receive	rcmod	75	SENT_591	[p26l486t1385r832b1464],
81	placebo	NN	O	placebo	_	0	SENT_591	[p26l868t1385r1220b1484],
82	.	.	O	.	_	0	SENT_591	[p26l868t1385r1220b1484],

1	In	IN	O	in	_	0	SENT_592	[p26l1263t1392r1352b1462],
2	the	DT	O	the	det	3	SENT_592	[p26l1391t1385r1524b1463],
3	patients	NNS	O	patient	prep_in	11	SENT_592	[p26l1561t1386r1903b1484],
4	with	IN	O	with	_	0	SENT_592	[p26l1939t1385r2134b1464],
5	FISH	NN	O	fish	npadvmod	7	SENT_592	[p26l10t1514r608b1614],
6	—	CD	NUMBER	—	num	5	SENT_592	[p26l10t1514r608b1614],
7	negative	JJ	O	negative	amod	8	SENT_592	[p26l10t1514r608b1614],
8	tumors	NNS	O	tumor	prep_with	3	SENT_592	[p26l656t1530r988b1609],
9	,	,	O	,	_	0	SENT_592	[p26l656t1530r988b1609],
10	there	EX	O	there	expl	11	SENT_592	[p26l1042t1513r1259b1591],
11	was	VBD	O	be	_	0	SENT_592	[p26l1303t1539r1465b1592],
12	no	DT	O	no	det	14	SENT_592	[p26l1515t1539r1620b1592],
13	significant	JJ	O	significant	amod	14	SENT_592	[p26l1671t1512r2139b1614],
14	difference	NN	O	difference	nsubj	11	SENT_592	[p26l11t1640r444b1720],
15	in	IN	O	in	_	0	SENT_592	[p26l483t1642r566b1719],
16	survival	NN	O	survival	prep_in	14	SENT_592	[p26l607t1641r1040b1720],
17	.83	CD	NUMBER	.83	num	19	SENT_592	[p26l607t1641r1040b1720],
18	Similar	JJ	O	similar	amod	19	SENT_592	[p26l1083t1641r1396b1720],
19	results	NNS	O	result	nsubjpass	21	SENT_592	[p26l1433t1641r1716b1720],
20	were	VBD	O	be	auxpass	21	SENT_592	[p26l1753t1667r1954b1720],
21	observed	VBN	O	observe	rcmod	14	SENT_592	[p26l1995t1641r2132b1720, p26l12t1768r283b1847],

1	in	IN	O	in	_	0	SENT_593	[p26l334t1769r417b1846],
2	the	DT	O	the	det	4	SENT_593	[p26l469t1768r602b1846],
3	ISEL	NN	MISC	isel	nn	4	SENT_593	[p26l652t1774r844b1847],
4	trial	NN	O	trial	prep_in	35	SENT_593	[p26l893t1768r1094b1864],
5	,	,	O	,	_	0	SENT_593	[p26l893t1768r1094b1864],
6	which	WDT	O	which	nsubj	7	SENT_593	[p26l1146t1768r1409b1848],
7	confirmed	VBD	O	confirm	rcmod	4	SENT_593	[p26l1461t1767r1915b1847],
8	that	IN	O	that	complm	18	SENT_593	[p26l1967t1768r2139b1846],
9	patients	NNS	O	patient	nsubj	18	SENT_593	[p26l10t1898r339b1996],
10	with	IN	O	with	_	0	SENT_593	[p26l365t1897r555b1976],
11	FISH-positive	JJ	O	fish-positive	amod	12	SENT_593	[p26l581t1898r1136b1996],
12	tumors	NNS	O	tumor	prep_with	9	SENT_593	[p26l1164t1914r1464b1976],
13	who	WP	O	who	nsubjpass	15	SENT_593	[p26l1489t1897r1668b1976],
14	were	VBD	O	be	auxpass	15	SENT_593	[p26l1693t1923r1890b1976],
15	treated	VBN	O	treat	rcmod	12	SENT_593	[p26l1918t1914r2133b1975, p26l11t2025r107b2104],
16	with	IN	O	with	_	0	SENT_593	[p26l140t2025r335b2104],
17	gefitinib	NN	O	gefitinib	prep_with	15	SENT_593	[p26l377t2024r748b2126],
18	had	VBD	O	have	ccomp	7	SENT_593	[p26l792t2025r948b2104],
19	higher	JJR	O	higher	amod	21	SENT_593	[p26l989t2025r1270b2126],
20	response	NN	O	response	nn	21	SENT_593	[p26l1308t2051r1689b2125],
21	rates	NNS	O	rate	dobj	18	SENT_593	[p26l1731t2042r1934b2103],
22	and	CC	O	and	_	0	SENT_593	[p26l1976t2025r2134b2104],
23	longer	JJR	O	longer	amod	24	SENT_593	[p26l10t2153r285b2254],
24	survival	NN	O	survival	conj_and	21	SENT_593	[p26l317t2153r648b2232],
25	than	IN	O	than	_	0	SENT_593	[p26l681t2153r877b2231],
26	patients	NNS	O	patient	prep_than	18	SENT_593	[p26l909t2154r1250b2253],
27	receiving	VBG	O	receive	partmod	26	SENT_593	[p26l1286t2154r1676b2254],
28	placebo	NN	O	placebo	dobj	27	SENT_593	[p26l1704t2153r2131b2253],
29	.85	CD	NUMBER	.85	num	28	SENT_593	[p26l1704t2153r2131b2253],
30	No	DT	O	no	det	31	SENT_593	[p26l9t2289r133b2360],
31	difference	NN	O	difference	nsubjpass	35	SENT_593	[p26l170t2280r602b2360],
32	in	IN	O	in	_	0	SENT_593	[p26l636t2282r720b2359],
33	survival	NN	O	survival	prep_in	31	SENT_593	[p26l755t2281r1087b2360],
34	was	VBD	O	be	auxpass	35	SENT_593	[p26l1117t2307r1279b2360],
35	seen	VBN	O	see	_	0	SENT_593	[p26l1317t2307r1505b2360],
36	in	IN	O	in	_	0	SENT_593	[p26l1539t2282r1623b2359],
37	FISH	NN	O	fish	prep_in	35	SENT_593	[p26l1656t2287r2133b2382],
38	—	CD	NUMBER	—	num	40	SENT_593	[p26l1656t2287r2133b2382],
39	nega	JJ	O	nega	amod	40	SENT_593	[p26l1656t2287r2133b2382],
40	—	NN	O	—	dep	37	SENT_593	[p26l1656t2287r2133b2382],
41	tive	JJ	O	tive	amod	42	SENT_593	[p26l11t2409r158b2488],
42	patients	NNS	O	patient	dep	40	SENT_593	[p26l193t2409r559b2508],
43	,	,	O	,	_	0	SENT_593	[p26l193t2409r559b2508],
44	irrespective	RB	O	irrespective	_	0	SENT_593	[p26l599t2409r1095b2508],
45	of	IN	O	of	_	0	SENT_593	[p26l1131t2407r1231b2487],
46	treatment	NN	O	treatment	prep_irrespective_of	40	SENT_593	[p26l1248t2425r1693b2487],
47	.	.	O	.	_	0	SENT_593	[p26l1248t2425r1693b2487],

1	However	RB	O	however	advmod	5	SENT_594	[p26l1734t2416r2129b2504],
2	,	,	O	,	_	0	SENT_594	[p26l1734t2416r2129b2504],
3	FISH	NN	O	fish	nn	4	SENT_594	[p26l10t2542r216b2615],
4	analysis	NN	O	analysis	nsubj	5	SENT_594	[p26l245t2536r577b2636],
5	failed	VBD	O	fail	_	0	SENT_594	[p26l608t2535r842b2615],
6	to	TO	O	to	aux	7	SENT_594	[p26l872t2553r952b2615],
7	demonstrate	VB	O	demonstrate	xcomp	5	SENT_594	[p26l983t2536r1510b2615],
8	any	DT	O	any	det	9	SENT_594	[p26l1538t2562r1686b2636],
9	difference	NN	O	difference	dobj	7	SENT_594	[p26l1712t2535r2134b2615],
10	in	IN	O	in	_	0	SENT_594	[p26l10t2666r94b2743],
11	progression	NN	O	progression	nn	14	SENT_594	[p26l127t2664r836b2766],
12	—	CD	NUMBER	—	num	14	SENT_594	[p26l127t2664r836b2766],
13	free	JJ	O	free	amod	14	SENT_594	[p26l127t2664r836b2766],
14	survival	NN	O	survival	prep_in	9	SENT_594	[p26l873t2665r1205b2744],
15	or	CC	O	or	_	0	SENT_594	[p26l1241t2691r1329b2744],
16	overall	JJ	O	overall	amod	17	SENT_594	[p26l1362t2665r1648b2744],
17	survival	NN	O	survival	prep_in	9	SENT_594	[p26l1684t2665r2016b2744],
18	in	IN	O	in	_	0	SENT_594	[p26l2051t2666r2134b2743],
19	a	DT	O	a	det	22	SENT_594	[p26l10t2819r55b2871],
20	phase	NN	O	phase	nn	22	SENT_594	[p26l116t2793r365b2893],
21	3	CD	NUMBER	3	num	22	SENT_594	[p26l430t2799r473b2872],
22	trial	NN	O	trial	prep_in	7	SENT_594	[p26l541t2793r720b2871],
23	that	IN	O	that	complm	42	SENT_594	[p26l784t2793r956b2871],
24	compared	VBN	O	compare	prep	42	SENT_594	[p26l1016t2793r1442b2893],
25	gefitinib	NN	O	gefitinib	dep	24	SENT_594	[p26l1505t2792r1877b2894],
26	with	IN	O	with	_	0	SENT_594	[p26l1939t2793r2134b2872],
27	docetaxel	NN	O	docetaxel	prep_with	25	SENT_594	[p26l11t2920r418b2999],
28	as	IN	O	as	_	0	SENT_594	[p26l478t2946r563b2998],
29	second	JJ	ORDINAL	second	amod	32	SENT_594	[p26l628t2920r1118b2999],
30	—	NN	O	—	nn	32	SENT_594	[p26l628t2920r1118b2999],
31	line	NN	O	line	nn	32	SENT_594	[p26l628t2920r1118b2999],
32	therapy	NN	O	therapy	prep_as	27	SENT_594	[p26l1180t2920r1502b3020],
33	for	IN	O	for	_	0	SENT_594	[p26l1558t2919r1681b2999],
34	advanced	JJ	O	advanced	amod	39	SENT_594	[p26l1739t2920r2135b2999],
35	non	JJ	O	non	amod	39	SENT_594	[p26l11t3049r654b3128],
36	—	NN	O	—	nn	39	SENT_594	[p26l11t3049r654b3128],
37	small	JJ	O	small	amod	39	SENT_594	[p26l11t3049r654b3128],
38	—	NN	O	—	nn	39	SENT_594	[p26l11t3049r654b3128],
39	cell	NN	O	cell	prep_for	32	SENT_594	[p26l11t3049r654b3128],
40	lung	NN	O	lung	nn	41	SENT_594	[p26l726t3049r919b3150],
41	cancer	NN	O	cancer	nsubj	42	SENT_594	[p26l990t3075r1271b3127],
42	(	VBD	O	(	ccomp	7	SENT_594	[p26l1346t3049r1503b3140],
43	the	DT	O	the	det	45	SENT_594	[p26l1346t3049r1503b3140],
44	Iressa	NNP	MISC	Iressa	nn	45	SENT_594	[p26l1576t3057r1829b3127],
45	NonSmall	NNP	MISC	NonSmall	dobj	42	SENT_594	[p26l1899t3057r2137b3128, p26l13t3177r459b3256],
46	.	.	O	.	_	0	SENT_594	[p26l1899t3057r2137b3128, p26l13t3177r459b3256],

1	—	NN	O	—	_	0	SENT_595	[p26l1899t3057r2137b3128, p26l13t3177r459b3256],
2	.	.	O	.	_	0	SENT_595	[p26l1899t3057r2137b3128, p26l13t3177r459b3256],

1	Cell	NN	O	cell	nn	3	SENT_596	[p26l1899t3057r2137b3128, p26l13t3177r459b3256],
2	Cancer	NN	O	cancer	nn	3	SENT_596	[p26l491t3183r790b3256],
3	Trial	NN	O	trial	_	0	SENT_596	[p26l816t3177r1019b3255],
4	Evaluating	VBG	O	evaluate	partmod	3	SENT_596	[p26l1050t3177r1506b3278],
5	Response	NN	O	response	dobj	4	SENT_596	[p26l1533t3183r1944b3277],
6	and	CC	O	and	_	0	SENT_596	[p26l1976t3177r2134b3256],
7	Survival	NN	O	survival	conj_and	5	SENT_596	[p26l13t3305r353b3384],
8	against	IN	O	against	_	0	SENT_596	[p26l386t3306r702b3406],
9	Taxotene	NN	O	taxotene	prep_against	4	SENT_596	[p26l728t3311r1117b3384],
10	[	CD	NUMBER	[	num	9	SENT_596	[p26l1145t3311r1285b3396],
11	IN	IN	O	in	_	0	SENT_596	[p26l1145t3311r1285b3396],
12	TEREST	NNP	O	TEREST	prep_in	9	SENT_596	[p26l1287t3309r1810b3396],
13	]	CD	NUMBER	]	num	12	SENT_596	[p26l1287t3309r1810b3396],
14	)	CD	NUMBER	)	number	15	SENT_596	[p26l1287t3309r1810b3396],
15	.36	CD	NUMBER	.36	num	12	SENT_596	[p26l1287t3309r1810b3396],

1	The	DT	O	the	det	3	SENT_597	[p26l136t3432r297b3510],
2	predictive	JJ	O	predictive	amod	3	SENT_597	[p26l357t3432r778b3532],
3	role	NN	O	role	nsubjpass	12	SENT_597	[p26l839t3432r999b3511],
4	of	IN	O	of	_	0	SENT_597	[p26l1061t3431r1161b3511],
5	increased	VBN	O	increase	amod	8	SENT_597	[p26l1204t3432r1613b3511],
6	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_597	[p26l1673t3439r1885b3512],
7	copy	NN	O	copy	nn	8	SENT_597	[p26l1941t3458r2138b3532],
8	numbers	NNS	O	number	prep_of	3	SENT_597	[p26l11t3561r388b3640],
9	has	VBZ	O	have	aux	12	SENT_597	[p26l456t3561r600b3639],
10	also	RB	O	also	advmod	12	SENT_597	[p26l668t3561r839b3639],
11	been	VBN	O	be	auxpass	12	SENT_597	[p26l908t3561r1108b3639],
12	evaluated	VBN	O	evaluate	_	0	SENT_597	[p26l1175t3561r1577b3640],
13	in	IN	O	in	_	0	SENT_597	[p26l1642t3562r1725b3638],
14	patients	NNS	O	patient	prep_in	12	SENT_597	[p26l1790t3562r2131b3660],
15	with	IN	O	with	_	0	SENT_597	[p26l6t3689r202b3768],
16	metastatic	JJ	O	metastatic	amod	18	SENT_597	[p26l250t3690r697b3768],
17	colorectal	JJ	O	colorectal	amod	18	SENT_597	[p26l745t3689r1165b3768],
18	cancer	NN	O	cancer	prep_with	14	SENT_597	[p26l1214t3715r1495b3767],
19	in	IN	O	in	_	0	SENT_597	[p26l1539t3690r1623b3767],
20	a	DT	O	a	det	21	SENT_597	[p26l1670t3715r1714b3767],
21	series	NN	O	series	prep_in	12	SENT_597	[p26l1762t3690r2001b3768],
22	of	IN	O	of	_	0	SENT_597	[p26l2052t3688r2152b3768],
23	retrospective	JJ	O	retrospective	amod	24	SENT_597	[p27l11t32r563b131],
24	studies	NNS	O	study	prep_of	21	SENT_597	[p27l598t31r923b111],
25	.	.	O	.	_	0	SENT_597	[p27l598t31r923b111],

1	The	DT	O	the	det	3	SENT_598	[p27l959t31r1120b109],
2	first	JJ	ORDINAL	first	amod	3	SENT_598	[p27l1153t30r1338b109],
3	report	NN	O	report	nsubj	21	SENT_598	[p27l1366t48r1633b131],
4	on	IN	O	on	_	0	SENT_598	[p27l1662t57r1768b110],
5	the	DT	O	the	det	6	SENT_598	[p27l1802t31r1935b109],
6	correlation	NN	O	correlation	prep_on	3	SENT_598	[p27l1970t57r2133b110, p27l11t159r342b238],
7	between	IN	O	between	_	0	SENT_598	[p27l379t159r737b239],
8	positive	JJ	O	positive	amod	9	SENT_598	[p27l772t160r1103b259],
9	results	NNS	O	result	prep_between	6	SENT_598	[p27l1140t159r1423b239],
10	for	IN	O	for	_	0	SENT_598	[p27l1461t158r1584b238],
11	EGFR	NN	ORGANIZATION	egfr	prep_for	9	SENT_598	[p27l1616t165r1873b243],
12	and	CC	O	and	_	0	SENT_598	[p27l1898t159r2055b238],
13	a	DT	O	a	det	14	SENT_598	[p27l2091t185r2136b237],
14	response	NN	O	response	conj_and	9	SENT_598	[p27l11t314r392b387],
15	to	TO	O	to	_	0	SENT_598	[p27l442t304r524b366],
16	therapy	NN	O	therapy	prep_to	14	SENT_598	[p27l575t288r897b387],
17	with	IN	O	with	_	0	SENT_598	[p27l938t288r1133b367],
18	cetuximab	NN	O	cetuximab	prep_with	16	SENT_598	[p27l1184t288r1635b367],
19	or	CC	O	or	_	0	SENT_598	[p27l1687t314r1776b366],
20	panitumumab	NN	O	panitumumab	conj_or	18	SENT_598	[p27l1821t289r2132b387, p27l11t415r339b495],
21	involved	VBD	O	involve	_	0	SENT_598	[p27l388t415r739b495],
22	a	DT	O	a	det	24	SENT_598	[p27l786t441r831b493],
23	small	JJ	O	small	amod	24	SENT_598	[p27l878t415r1112b493],
24	cohort	NN	O	cohort	dobj	21	SENT_598	[p27l1160t415r1442b494],
25	of	IN	O	of	_	0	SENT_598	[p27l1485t414r1584b494],
26	patients	NNS	O	patient	prep_of	24	SENT_598	[p27l1612t416r1954b515],
27	(	IN	O	(	_	0	SENT_598	[p27l2008t421r2134b506],
28	31	CD	NUMBER	31	num	29	SENT_598	[p27l2008t421r2134b506],
29	patients	NNS	O	patient	prep_(	21	SENT_598	[p27l10t544r377b643],
30	)	RB	O	)	advmod	21	SENT_598	[p27l10t544r377b643],
31	with	IN	O	with	_	0	SENT_598	[p27l419t543r614b623],
32	advanced	JJ	O	advanced	amod	36	SENT_598	[p27l655t543r1073b639],
33	,	,	O	,	_	0	SENT_598	[p27l655t543r1073b639],
34	chemotherapy	NN	O	chemotherapy	dep	36	SENT_598	[p27l1121t542r2133b643],
35	—	NN	O	—	nn	36	SENT_598	[p27l1121t542r2133b643],
36	refracto	NN	O	refracto	prep_with	21	SENT_598	[p27l1121t542r2133b643],
37	—	CD	NUMBER	—	num	38	SENT_598	[p27l1121t542r2133b643],
38	ry	NN	O	ry	dep	36	SENT_598	[p27l11t698r96b771],
39	colorectal	JJ	O	colorectal	amod	40	SENT_598	[p27l136t672r556b750],
40	cancer	NN	O	cancer	dep	38	SENT_598	[p27l601t676r980b750],
41	.	.	O	.	_	0	SENT_598	[p27l601t676r980b750],

1	“	NN	O	“	nsubj	45	SENT_599	[p27l601t676r980b750],
2	Recently	RB	DATE	recently	advmod	45	SENT_599	[p27l1023t672r1405b771],
3	,	,	O	,	_	0	SENT_599	[p27l1023t672r1405b771],
4	a	DT	O	a	det	6	SENT_599	[p27l1454t698r1498b749],
5	FISH	NN	O	fish	nn	6	SENT_599	[p27l1539t678r1748b750],
6	analysis	NN	O	analysis	nsubjpass	30	SENT_599	[p27l1792t672r2131b771],
7	of	IN	O	of	_	0	SENT_599	[p27l11t798r112b878],
8	EGFR	NN	ORGANIZATION	egfr	prep_of	6	SENT_599	[p27l154t805r410b883],
9	in	IN	O	in	_	0	SENT_599	[p27l442t800r526b877],
10	tumor	NN	O	tumor	nn	11	SENT_599	[p27l588t816r856b879],
11	samples	NNS	O	sample	prep_in	8	SENT_599	[p27l917t799r1261b899],
12	from	IN	O	from	_	0	SENT_599	[p27l1326t798r1535b878],
13	patients	NNS	O	patient	prep_from	11	SENT_599	[p27l1596t800r1938b899],
14	enrolled	VBN	O	enrol	partmod	13	SENT_599	[p27l2003t825r2133b877, p27l11t928r258b1007],
15	in	IN	O	in	_	0	SENT_599	[p27l291t929r375b1006],
16	the	DT	O	the	det	19	SENT_599	[p27l410t928r543b1006],
17	phase	NN	O	phase	nn	19	SENT_599	[p27l576t928r825b1028],
18	3	CD	NUMBER	3	num	19	SENT_599	[p27l861t934r905b1007],
19	study	NN	O	study	prep_in	14	SENT_599	[p27l945t928r1175b1028],
20	comparing	VBG	O	compare	partmod	19	SENT_599	[p27l1206t929r1676b1029],
21	the	DT	O	the	det	22	SENT_599	[p27l1708t928r1841b1007],
22	use	NN	O	use	dobj	20	SENT_599	[p27l1875t954r2016b1007],
23	of	IN	O	of	_	0	SENT_599	[p27l2052t927r2152b1007],
24	panitumumab	NN	O	panitumumab	prep_of	22	SENT_599	[p27l10t1056r624b1155],
25	with	IN	O	with	_	0	SENT_599	[p27l662t1056r858b1135],
26	best	JJS	O	best	dep	27	SENT_599	[p27l899t1056r1076b1134],
27	supportive	JJ	O	supportive	amod	28	SENT_599	[p27l1113t1057r1561b1155],
28	care	NN	O	care	prep_with	20	SENT_599	[p27l1603t1082r1778b1134],
29	was	VBD	O	be	auxpass	30	SENT_599	[p27l1815t1082r1976b1135],
30	reported	VBN	O	report	parataxis	45	SENT_599	[p27l2020t1082r2132b1134, p27l10t1184r397b1284],
31	.87	CD	NUMBER	.87	dobj	30	SENT_599	[p27l2020t1082r2132b1134, p27l10t1184r397b1284],
32	In	IN	O	in	_	0	SENT_599	[p27l434t1192r522b1262],
33	the	DT	O	the	det	34	SENT_599	[p27l562t1184r694b1263],
34	group	NN	O	group	prep_in	30	SENT_599	[p27l732t1210r984b1285],
35	treated	VBN	O	treat	partmod	34	SENT_599	[p27l1025t1184r1323b1263],
36	with	IN	O	with	_	0	SENT_599	[p27l1357t1184r1552b1263],
37	panitumumab	NN	LOCATION	panitumumab	prep_with	35	SENT_599	[p27l1589t1185r2132b1284, p27l10t1312r130b1407],
38	,	,	O	,	_	0	SENT_599	[p27l1589t1185r2132b1284, p27l10t1312r130b1407],
39	patients	NNS	O	patient	nsubj	45	SENT_599	[p27l197t1313r538b1411],
40	with	IN	O	with	_	0	SENT_599	[p27l598t1312r793b1391],
41	normal	JJ	O	normal	amod	44	SENT_599	[p27l856t1312r1170b1390],
42	EGFR	NN	ORGANIZATION	egfr	nn	44	SENT_599	[p27l1230t1318r1442b1391],
43	copy	NN	O	copy	nn	44	SENT_599	[p27l1499t1338r1696b1411],
44	numbers	NNS	O	number	prep_with	45	SENT_599	[p27l1754t1312r2131b1391],
45	had	VBD	O	have	_	0	SENT_599	[p27l11t1440r167b1519],
46	a	DT	O	a	det	49	SENT_599	[p27l218t1466r262b1518],
47	shorter	JJR	O	shorter	amod	49	SENT_599	[p27l313t1440r620b1519],
48	median	NN	O	median	nn	49	SENT_599	[p27l668t1440r992b1519],
49	progression	NN	O	progression	dobj	45	SENT_599	[p27l1042t1439r1749b1541],
50	—	CD	NUMBER	—	num	52	SENT_599	[p27l1042t1439r1749b1541],
51	free	JJ	O	free	amod	52	SENT_599	[p27l1042t1439r1749b1541],
52	survival	NN	O	survival	dep	49	SENT_599	[p27l1802t1440r2134b1519],
53	and	CC	O	and	_	0	SENT_599	[p27l10t1568r168b1647],
54	overall	JJ	O	overall	amod	55	SENT_599	[p27l239t1568r525b1647],
55	survival	NN	O	survival	dobj	45	SENT_599	[p27l596t1568r928b1647],
56	than	IN	O	than	_	0	SENT_599	[p27l998t1568r1195b1646],
57	patients	NNS	O	patient	prep_than	55	SENT_599	[p27l1264t1569r1605b1668],
58	with	IN	O	with	_	0	SENT_599	[p27l1673t1568r1868b1647],
59	high	JJ	O	high	amod	62	SENT_599	[p27l1939t1568r2134b1669],
60	EGFR	NN	ORGANIZATION	egfr	nn	62	SENT_599	[p27l9t1702r222b1776],
61	copy	NN	O	copy	nn	62	SENT_599	[p27l286t1722r483b1796],
62	numbers	NNS	O	number	prep_with	45	SENT_599	[p27l549t1696r951b1775],
63	.	.	O	.	_	0	SENT_599	[p27l549t1696r951b1775],

1	Moreover	RB	O	moreover	advmod	22	SENT_600	[p27l1024t1704r1449b1792],
2	,	,	O	,	_	0	SENT_600	[p27l1024t1704r1449b1792],
3	in	IN	O	in	_	0	SENT_600	[p27l1523t1697r1607b1774],
4	the	DT	O	the	det	5	SENT_600	[p27l1677t1696r1810b1775],
5	group	NN	O	group	prep_in	22	SENT_600	[p27l1880t1722r2132b1797],
6	treated	VBN	O	treat	partmod	5	SENT_600	[p27l11t1824r309b1902],
7	only	RB	O	only	advmod	6	SENT_600	[p27l361t1824r544b1923],
8	with	IN	O	with	_	0	SENT_600	[p27l586t1824r782b1903],
9	best	JJS	O	best	dep	10	SENT_600	[p27l833t1824r1010b1902],
10	supportive	JJ	O	supportive	amod	11	SENT_600	[p27l1057t1825r1506b1923],
11	care	NN	O	care	prep_with	6	SENT_600	[p27l1557t1850r1756b1919],
12	,	,	O	,	_	0	SENT_600	[p27l1557t1850r1756b1919],
13	no	DT	O	no	det	14	SENT_600	[p27l1811t1850r1917b1902],
14	correlation	NN	O	correlation	nsubjpass	22	SENT_600	[p27l1970t1850r2132b1902, p27l11t1952r342b2030],
15	between	IN	O	between	_	0	SENT_600	[p27l398t1952r756b2031],
16	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_600	[p27l810t1958r1022b2031],
17	copy	NN	O	copy	nn	18	SENT_600	[p27l1072t1978r1269b2051],
18	numbers	NNS	O	number	prep_between	14	SENT_600	[p27l1321t1952r1698b2031],
19	and	CC	O	and	_	0	SENT_600	[p27l1755t1952r1913b2030],
20	survival	NN	O	survival	conj_and	18	SENT_600	[p27l1971t1978r2132b2031, p27l7t2080r202b2159],
21	was	VBD	O	be	auxpass	22	SENT_600	[p27l234t2106r397b2159],
22	observed	VBN	O	observe	_	0	SENT_600	[p27l438t2080r841b2176],
23	,	,	O	,	_	0	SENT_600	[p27l438t2080r841b2176],
24	suggesting	VBG	O	suggest	xcomp	22	SENT_600	[p27l886t2081r1357b2181],
25	a	DT	O	a	det	26	SENT_600	[p27l1390t2106r1435b2158],
26	predictive	JJ	O	predictive	dobj	24	SENT_600	[p27l1470t2080r1890b2180],
27	rather	RB	O	rather	advmod	24	SENT_600	[p27l1927t2080r2132b2158, p27l12t2234r93b2287],
28	than	IN	O	than	_	0	SENT_600	[p27l131t2208r328b2286],
29	a	DT	O	a	det	31	SENT_600	[p27l368t2234r413b2286],
30	prognostic	JJ	O	prognostic	amod	31	SENT_600	[p27l451t2209r916b2309],
31	role	NN	O	role	prep_than	24	SENT_600	[p27l957t2208r1116b2287],
32	of	IN	O	of	_	0	SENT_600	[p27l1158t2207r1259b2287],
33	this	DT	O	this	det	35	SENT_600	[p27l1282t2208r1441b2286],
34	genetic	JJ	O	genetic	amod	35	SENT_600	[p27l1484t2209r1793b2309],
35	feature	NN	O	feature	prep_of	31	SENT_600	[p27l1834t2207r2134b2287],
36	in	IN	O	in	_	0	SENT_600	[p27l11t2337r94b2413],
37	patients	NNS	O	patient	prep_in	35	SENT_600	[p27l164t2337r506b2435],
38	with	IN	O	with	_	0	SENT_600	[p27l576t2336r771b2415],
39	metastatic	JJ	O	metastatic	amod	41	SENT_600	[p27l843t2337r1291b2414],
40	colorectal	JJ	O	colorectal	amod	41	SENT_600	[p27l1363t2336r1784b2414],
41	cancer	NN	O	cancer	prep_with	24	SENT_600	[p27l1856t2362r2137b2414],
42	who	WP	O	who	nsubjpass	44	SENT_600	[p27l7t2464r189b2543],
43	are	VBP	O	be	auxpass	44	SENT_600	[p27l264t2490r393b2542],
44	treated	VBN	O	treat	rcmod	41	SENT_600	[p27l468t2464r766b2543],
45	with	IN	O	with	_	0	SENT_600	[p27l835t2464r1031b2543],
46	anti	JJ	O	anti	prep_with	44	SENT_600	[p27l1104t2465r1558b2547],
47	.	.	O	.	_	0	SENT_600	[p27l1104t2465r1558b2547],

1	—	NN	O	—	_	0	SENT_601	[p27l1104t2465r1558b2547],
2	.	.	O	.	_	0	SENT_601	[p27l1104t2465r1558b2547],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_602	[p27l1104t2465r1558b2547],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_602	[p27l1622t2464r2135b2543],
3	antibodies	NNS	O	antibody	dep	1	SENT_602	[p27l11t2593r485b2672],
4	.	.	O	.	_	0	SENT_602	[p27l11t2593r485b2672],

1	RESISTANCE	NN	O	resistance	_	0	SENT_603	[p27l41t2923r735b2983],
2	TO	TO	O	to	infmod	1	SENT_603	[p27l783t2923r924b2982],
3	EGFR	NN	O	egfr	nn	4	SENT_603	[p27l981t2923r1270b2982],
4	ANTAGONISTS	NNS	O	antagonist	dep	1	SENT_603	[p27l1311t2923r2119b2983],

1	INTRINSIC	JJ	O	intrinsic	amod	2	SENT_604	[p27l15t3169r425b3220],
2	RESISTANCE	NN	O	resistance	_	0	SENT_604	[p27l462t3169r940b3220],
3	Activating	VBG	O	activate	partmod	2	SENT_604	[p27l6t3271r451b3371],
4	mutations	NNS	O	mutation	dobj	3	SENT_604	[p27l499t3271r936b3349],
5	in	IN	O	in	_	0	SENT_604	[p27l989t3270r1072b3347],
6	the	DT	O	the	det	7	SENT_604	[p27l1124t3270r1257b3348],
7	K	NN	O	k	prep_in	4	SENT_604	[p27l1306t3275r1561b3349],
8	.	.	O	.	_	0	SENT_604	[p27l1306t3275r1561b3349],

1	—	NN	O	—	_	0	SENT_605	[p27l1306t3275r1561b3349],
2	.	.	O	.	_	0	SENT_605	[p27l1306t3275r1561b3349],

1	RAS	NN	O	ra	nn	2	SENT_606	[p27l1306t3275r1561b3349],
2	gene	NN	O	gene	nsubjpass	21	SENT_606	[p27l1609t3295r1833b3371],
3	,	,	O	,	_	0	SENT_606	[p27l1609t3295r1833b3371],
4	which	WDT	O	which	nsubj	5	SENT_606	[p27l1885t3270r2149b3349],
5	result	VBP	O	result	rcmod	2	SENT_606	[p27l10t3398r255b3477],
6	in	IN	O	in	_	0	SENT_606	[p27l286t3399r370b3475],
7	EGFR	NN	ORGANIZATION	egfr	prep_in	5	SENT_606	[p27l405t3398r1225b3498],
8	—	CD	NUMBER	—	num	10	SENT_606	[p27l405t3398r1225b3498],
9	independent	JJ	O	independent	amod	10	SENT_606	[p27l405t3398r1225b3498],
10	activation	NN	O	activation	dobj	5	SENT_606	[p27l1255t3399r1676b3477],
11	of	IN	O	of	_	0	SENT_606	[p27l1713t3397r1814b3476],
12	the	DT	O	the	det	18	SENT_606	[p27l1833t3398r1966b3476],
13	mitogen	NN	O	mitogen	nn	18	SENT_606	[p27l2003t3399r2148b3475, p27l10t3526r656b3628],
14	—	NN	O	—	nn	18	SENT_606	[p27l2003t3399r2148b3475, p27l10t3526r656b3628],
15	activated	VBN	O	activate	amod	18	SENT_606	[p27l2003t3399r2148b3475, p27l10t3526r656b3628],
16	protein	NN	O	protein	nn	18	SENT_606	[p27l686t3527r994b3627],
17	kinase	NN	O	kinase	nn	18	SENT_606	[p27l1025t3526r1301b3606],
18	pathway	NN	O	pathway	prep_of	10	SENT_606	[p27l1332t3526r1702b3627],
19	,	,	O	,	_	0	SENT_606	[p27l1332t3526r1702b3627],
20	are	VBP	O	be	auxpass	21	SENT_606	[p27l1739t3552r1867b3605],
21	found	VBN	O	find	_	0	SENT_606	[p27l1899t3525r2149b3606],
22	in	IN	O	in	_	0	SENT_606	[p27l9t3656r92b3732],
23	approximately	RB	O	approximately	quantmod	26	SENT_606	[p27l124t3655r732b3755],
24	15	CD	NUMBER	15	number	26	SENT_606	[p27l764t3660r858b3733],
25	to	TO	O	to	dep	26	SENT_606	[p27l894t3671r975b3733],
26	30	CD	PERCENT	30	num	27	SENT_606	[p27l1011t3660r1197b3734],
27	%	NN	PERCENT	%	prep_in	21	SENT_606	[p27l1011t3660r1197b3734],
28	of	IN	O	of	_	0	SENT_606	[p27l1229t3654r1329b3733],
29	patients	NNS	O	patient	prep_of	27	SENT_606	[p27l1342t3656r1678b3755],
30	with	IN	O	with	_	0	SENT_606	[p27l1709t3655r1902b3734],
31	nonsmall	JJ	O	nonsmall	amod	33	SENT_606	[p27l1935t3680r2153b3733, p28l11t21r433b100],
32	—	NN	O	—	nn	33	SENT_606	[p27l1935t3680r2153b3733, p28l11t21r433b100],
33	cell	NN	O	cell	prep_with	29	SENT_606	[p27l1935t3680r2153b3733, p28l11t21r433b100],

1	lung	NN	O	lung	nn	2	SENT_607	[p28l467t21r663b123],
2	cancer	NN	O	cancer	nsubj	18	SENT_607	[p28l696t47r979b100],
3	and	CC	O	and	_	0	SENT_607	[p28l1011t21r1171b100],
4	40	CD	NUMBER	40	number	6	SENT_607	[p28l1205t27r1309b100],
5	to	TO	O	to	dep	6	SENT_607	[p28l1346t38r1428b100],
6	45	CD	PERCENT	45	num	7	SENT_607	[p28l1464t26r1650b101],
7	%	NN	PERCENT	%	conj_and	2	SENT_607	[p28l1464t26r1650b101],
8	of	IN	O	of	_	0	SENT_607	[p28l1686t20r1786b100],
9	patients	NNS	O	patient	prep_of	7	SENT_607	[p28l1803t22r2147b122],
10	with	IN	O	with	_	0	SENT_607	[p28l6t150r202b229],
11	colorectal	JJ	O	colorectal	amod	12	SENT_607	[p28l237t150r661b228],
12	cancer	NN	O	cancer	prep_with	9	SENT_607	[p28l695t175r997b245],
13	,	,	O	,	_	0	SENT_607	[p28l695t175r997b245],
14	and	CC	O	and	_	0	SENT_607	[p28l1036t150r1195b228],
15	their	PRP$	O	they	poss	16	SENT_607	[p28l1230t150r1435b228],
16	presence	NN	O	presence	conj_and	2	SENT_607	[p28l1465t176r1843b250],
17	generally	RB	O	generally	advmod	18	SENT_607	[p28l1877t176r2148b251, p28l9t278r159b378],
18	correlates	VBZ	O	correlate	_	0	SENT_607	[p28l183t278r593b356],
19	with	IN	O	with	_	0	SENT_607	[p28l618t278r812b357],
20	a	DT	O	a	det	22	SENT_607	[p28l839t304r884b356],
21	worse	JJR	O	worse	amod	22	SENT_607	[p28l905t303r1157b357],
22	prognosis	NN	O	prognosis	prep_with	18	SENT_607	[p28l1183t278r1603b379],
23	with	IN	O	with	_	0	SENT_607	[p28l1629t278r1822b357],
24	respect	NN	O	respect	prep_with	22	SENT_607	[p28l1850t294r2154b378],
25	to	TO	O	to	_	0	SENT_607	[p28l10t423r92b486],
26	the	DT	O	the	det	27	SENT_607	[p28l142t407r276b486],
27	outcome	NN	O	outcome	prep_to	18	SENT_607	[p28l326t423r697b487],
28	of	IN	O	of	_	0	SENT_607	[p28l746t406r846b486],
29	the	DT	O	the	det	30	SENT_607	[p28l876t407r1010b486],
30	cancer	NN	O	cancer	prep_of	27	SENT_607	[p28l1059t433r1360b486],
31	.	.	O	.	_	0	SENT_607	[p28l1059t433r1360b486],

1	K	NN	O	k	_	0	SENT_608	[p28l1412t412r1663b487],
2	.	.	O	.	_	0	SENT_608	[p28l1412t412r1663b487],

1	—	NN	O	—	_	0	SENT_609	[p28l1412t412r1663b487],
2	.	.	O	.	_	0	SENT_609	[p28l1412t412r1663b487],

1	RAS	NN	O	ra	nn	2	SENT_610	[p28l1412t412r1663b487],
2	mutations	NNS	O	mutation	nsubj	3	SENT_610	[p28l1709t408r2147b487],
3	occur	VBP	O	occur	_	0	SENT_610	[p28l11t562r251b615],
4	in	IN	O	in	_	0	SENT_610	[p28l301t537r385b613],
5	patients	NNS	O	patient	prep_in	3	SENT_610	[p28l436t537r781b636],
6	with	IN	O	with	_	0	SENT_610	[p28l831t536r1028b615],
7	a	DT	O	a	det	8	SENT_610	[p28l1081t562r1126b614],
8	history	NN	O	history	prep_with	5	SENT_610	[p28l1177t536r1484b636],
9	of	IN	O	of	_	0	SENT_610	[p28l1534t535r1634b614],
10	substantial	JJ	O	substantial	amod	12	SENT_610	[p28l1670t536r2150b615],
11	cigarette	NN	O	cigarette	nn	12	SENT_610	[p28l11t665r383b766],
12	use	NN	O	use	prep_of	8	SENT_610	[p28l423t669r767b744],
13	.88	CD	NUMBER	.88	npadvmod	14	SENT_610	[p28l423t669r767b744],
14	>	JJR	O	>	amod	12	SENT_610	[p28l423t669r767b744],
15	89	CD	NUMBER	89	dobj	3	SENT_610	[p28l423t669r767b744],
16	These	DT	O	these	det	17	SENT_610	[p28l803t664r1057b743],
17	mutations	NNS	O	mutation	nsubjpass	21	SENT_610	[p28l1097t665r1534b744],
18	are	VBP	O	be	auxpass	21	SENT_610	[p28l1575t690r1705b743],
19	most	RBS	O	most	advmod	20	SENT_610	[p28l1744t681r1963b743],
20	frequently	RB	O	frequently	advmod	21	SENT_610	[p28l1997t663r2148b743, p28l10t794r331b894],
21	recorded	VBN	O	record	rcmod	15	SENT_610	[p28l356t794r734b872],
22	in	IN	O	in	_	0	SENT_610	[p28l763t795r846b871],
23	codons	NNS	O	codon	prep_in	21	SENT_610	[p28l877t794r1184b872],
24	12	CD	NUMBER	12	num	23	SENT_610	[p28l1219t799r1318b871],
25	and	CC	O	and	_	0	SENT_610	[p28l1348t794r1507b872],
26	13	CD	NUMBER	13	conj_and	23	SENT_610	[p28l1540t799r1636b873],
27	in	IN	O	in	_	0	SENT_610	[p28l1669t794r1753b871],
28	the	DT	O	the	det	29	SENT_610	[p28l1783t794r1916b872],
29	exon	NN	O	exon	prep_in	23	SENT_610	[p28l1948t819r2149b872],
30	2	CD	NUMBER	2	num	29	SENT_610	[p28l10t928r57b999],
31	of	IN	O	of	_	0	SENT_610	[p28l105t921r205b1001],
32	the	DT	O	the	det	33	SENT_610	[p28l232t922r366b1001],
33	K	NN	O	k	prep_of	23	SENT_610	[p28l410t928r661b1002],
34	.	.	O	.	_	0	SENT_610	[p28l410t928r661b1002],

1	—	NN	O	—	_	0	SENT_611	[p28l410t928r661b1002],
2	.	.	O	.	_	0	SENT_611	[p28l410t928r661b1002],

1	RAS	NN	O	ra	nn	2	SENT_612	[p28l410t928r661b1002],
2	gene	NN	O	gene	nsubj	7	SENT_612	[p28l704t948r905b1024],
3	and	CC	O	and	advmod	7	SENT_612	[p28l950t922r1109b1001],
4	are	VBP	O	be	cop	7	SENT_612	[p28l1153t948r1283b1001],
5	generally	RB	O	generally	advmod	7	SENT_612	[p28l1328t922r1726b1024],
6	mutually	RB	O	mutually	advmod	7	SENT_612	[p28l1767t922r2154b1023],
7	exclusive	JJ	O	exclusive	_	0	SENT_612	[p28l11t1052r389b1132],
8	with	IN	O	with	_	0	SENT_612	[p28l414t1052r611b1132],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_612	[p28l638t1058r853b1132],
10	mutations	NNS	O	mutation	prep_with	7	SENT_612	[p28l876t1053r1338b1131],
11	.	.	O	.	_	0	SENT_612	[p28l876t1053r1338b1131],

1	In	IN	O	in	dep	5	SENT_613	[p28l1372t1059r1461b1129],
2	several	JJ	O	several	amod	3	SENT_613	[p28l1492t1052r1786b1132],
3	studies	NNS	O	study	pobj	1	SENT_613	[p28l1816t1052r2144b1147],
4	,	,	O	,	_	0	SENT_613	[p28l1816t1052r2144b1147],
5	K	NNP	O	K	_	0	SENT_613	[p28l8t1185r260b1260],
6	.	.	O	.	_	0	SENT_613	[p28l8t1185r260b1260],

1	—	NN	O	—	_	0	SENT_614	[p28l8t1185r260b1260],
2	.	.	O	.	_	0	SENT_614	[p28l8t1185r260b1260],

1	RAS	NN	O	ra	nn	2	SENT_615	[p28l8t1185r260b1260],
2	mutations	NNS	O	mutation	nsubjpass	6	SENT_615	[p28l301t1181r738b1260],
3	have	VBP	O	have	aux	6	SENT_615	[p28l784t1180r976b1260],
4	been	VBN	O	be	auxpass	6	SENT_615	[p28l1020t1180r1223b1259],
5	significantly	RB	O	significantly	advmod	6	SENT_615	[p28l1268t1179r1816b1282],
6	associated	VBN	O	associate	conj_and	6	SENT_615	[p28l1854t1181r2148b1259, p28l9t1309r189b1387],
7	with	IN	O	with	_	0	SENT_615	[p28l227t1309r424b1388],
8	lack	NN	O	lack	prep_with	6	SENT_615	[p28l465t1309r642b1388],
9	of	IN	O	of	_	0	SENT_615	[p28l680t1308r781b1387],
10	response	NN	O	response	prep_of	8	SENT_615	[p28l804t1334r1188b1409],
11	to	TO	O	to	_	0	SENT_615	[p28l1231t1326r1313b1387],
12	EFGR	NN	O	efgr	nn	15	SENT_615	[p28l1355t1314r1613b1392],
13	tyrosine	NN	O	tyrosine	nn	15	SENT_615	[p28l1645t1310r1993b1409],
14	kinase	NN	O	kinase	nn	15	SENT_615	[p28l2036t1309r2148b1388, p28l10t1464r207b1516],
15	inhibitors	NNS	O	inhibitor	prep_to	6	SENT_615	[p28l249t1438r684b1516],
16	in	IN	O	in	_	0	SENT_615	[p28l727t1439r813b1515],
17	patients	NNS	O	patient	prep_in	15	SENT_615	[p28l854t1439r1205b1538],
18	with	IN	O	with	_	0	SENT_615	[p28l1246t1438r1446b1517],
19	non	JJ	O	non	amod	23	SENT_615	[p28l1488t1438r2150b1516],
20	—	JJ	O	—	amod	23	SENT_615	[p28l1488t1438r2150b1516],
21	small-cell	NN	O	small-cell	nn	23	SENT_615	[p28l1488t1438r2150b1516],
22	lung	NN	O	lung	nn	23	SENT_615	[p28l9t1566r207b1668],
23	cancer	NN	O	cancer	prep_with	17	SENT_615	[p28l242t1592r530b1645],
24	and	CC	O	and	_	0	SENT_615	[p28l565t1566r726b1645],
25	with	IN	O	with	_	0	SENT_615	[p28l759t1566r959b1646],
26	lack	NN	O	lack	prep_with	6	SENT_615	[p28l996t1566r1176b1646],
27	of	IN	O	of	_	0	SENT_615	[p28l1210t1565r1312b1645],
28	response	NN	O	response	prep_of	26	SENT_615	[p28l1331t1591r1723b1667],
29	to	TO	O	to	_	0	SENT_615	[p28l1761t1582r1845b1645],
30	cetux	NN	O	cetux	nn	32	SENT_615	[p28l1885t1583r2148b1646],
31	—	NN	O	—	nn	32	SENT_615	[p28l1885t1583r2148b1646],
32	imab	NN	O	imab	prep_to	28	SENT_615	[p28l9t1696r230b1774],
33	or	CC	O	or	_	0	SENT_615	[p28l283t1722r373b1774],
34	to	TO	O	to	aux	35	SENT_615	[p28l420t1712r503b1774],
35	panitumumab	VB	O	panitumumab	prep_to	28	SENT_615	[p28l553t1696r1183b1796],
36	in	IN	O	in	_	0	SENT_615	[p28l1233t1697r1319b1773],
37	patients	NNS	O	patient	prep_in	35	SENT_615	[p28l1367t1697r1719b1796],
38	with	IN	O	with	_	0	SENT_615	[p28l1766t1696r1967b1775],
39	advanced	JJ	O	advanced	prep_with	37	SENT_615	[p28l2016t1696r2148b1774, p28l6t1824r315b1919],
40	,	,	O	,	_	0	SENT_615	[p28l2016t1696r2148b1774, p28l6t1824r315b1919],
41	chemotherapy	NN	O	chemotherapy	appos	39	SENT_615	[p28l357t1823r1384b1924],
42	—	CD	NUMBER	—	num	45	SENT_615	[p28l357t1823r1384b1924],
43	refractory	JJ	O	refractory	amod	45	SENT_615	[p28l357t1823r1384b1924],
44	colorectal	JJ	O	colorectal	amod	45	SENT_615	[p28l1416t1824r1820b1902],
45	cancer	NN	O	cancer	dep	41	SENT_615	[p28l1856t1850r2144b1902],
46	.	.	O	.	_	0	SENT_615	[p28l1856t1850r2144b1902],

1	Both	DT	O	both	det	2	SENT_616	[p28l8t1952r218b2031],
2	findings	NNS	O	finding	nsubj	3	SENT_616	[p28l265t1951r639b2054],
3	suggest	VBP	O	suggest	_	0	SENT_616	[p28l690t1968r1027b2054],
4	that	IN	O	that	_	0	SENT_616	[p28l1069t1952r1246b2031],
5	EGFR-independent	JJ	O	egfr-independent	amod	8	SENT_616	[p28l1286t1952r2144b2053],
6	,	,	O	,	_	0	SENT_616	[p28l1286t1952r2144b2053],
7	constitutive	JJ	O	constitutive	amod	8	SENT_616	[p28l11t2082r526b2161],
8	activation	NN	O	activation	prep_that	3	SENT_616	[p28l582t2082r1013b2161],
9	of	IN	O	of	_	0	SENT_616	[p28l1069t2080r1171b2160],
10	the	DT	O	the	det	11	SENT_616	[p28l1209t2081r1345b2160],
11	K	NN	O	k	prep_of	8	SENT_616	[p28l1401t2086r1677b2165],
12	.	.	O	.	_	0	SENT_616	[p28l1401t2086r1677b2165],

1	—	NN	O	—	_	0	SENT_617	[p28l1401t2086r1677b2165],
2	.	.	O	.	_	0	SENT_617	[p28l1401t2086r1677b2165],

1	RAS	NN	O	ra	nn	3	SENT_618	[p28l1401t2086r1677b2165],
2	signaling	NN	O	signaling	nn	3	SENT_618	[p28l1738t2081r2153b2183],
3	pathway	NN	O	pathway	nsubj	5	SENT_618	[p28l8t2211r386b2311],
4	could	MD	O	could	aux	5	SENT_618	[p28l447t2211r692b2290],
5	impair	VB	O	impair	_	0	SENT_618	[p28l757t2211r1058b2311],
6	the	DT	O	the	det	7	SENT_618	[p28l1121t2211r1260b2289],
7	response	NN	O	response	dobj	5	SENT_618	[p28l1326t2236r1724b2311],
8	to	TO	O	to	_	0	SENT_618	[p28l1791t2227r1875b2289],
9	antiEGFR	NN	O	antiegfr	nn	10	SENT_618	[p28l1941t2212r2148b2289, p28l8t2344r273b2422],
10	drugs	NNS	O	drug	prep_to	5	SENT_618	[p28l314t2339r786b2440],
11	.9	CD	NUMBER	.9	number	12	SENT_618	[p28l314t2339r786b2440],
12	°	CD	NUMBER	°	num	13	SENT_618	[p28l314t2339r786b2440],
13	'98	CD	NUMBER	'98	dep	10	SENT_618	[p28l314t2339r786b2440],
14	However	RB	O	however	advmod	13	SENT_618	[p28l836t2346r1249b2434],
15	,	,	O	,	_	0	SENT_618	[p28l836t2346r1249b2434],
16	no	DT	O	no	det	17	SENT_618	[p28l1305t2364r1413b2417],
17	correlation	NN	O	correlation	appos	10	SENT_618	[p28l1466t2339r1961b2417],
18	between	IN	O	between	_	0	SENT_618	[p28l2012t2339r2148b2417, p28l10t2483r268b2546],
19	K	NN	O	k	prep_between	17	SENT_618	[p28l294t2472r546b2546],
20	.	.	O	.	_	0	SENT_618	[p28l294t2472r546b2546],

1	—	NN	O	—	_	0	SENT_619	[p28l294t2472r546b2546],
2	.	.	O	.	_	0	SENT_619	[p28l294t2472r546b2546],

1	RAS	NN	O	ra	nn	2	SENT_620	[p28l294t2472r546b2546],
2	mutations	NNS	O	mutation	nsubjpass	6	SENT_620	[p28l571t2468r1009b2546],
3	and	CC	O	and	_	0	SENT_620	[p28l1039t2467r1198b2545],
4	efficacy	NN	O	efficacy	conj_and	2	SENT_620	[p28l1227t2466r1566b2567],
5	was	VBD	O	be	auxpass	6	SENT_620	[p28l1586t2493r1750b2546],
6	reported	VBN	O	report	_	0	SENT_620	[p28l1780t2467r2149b2567],
7	in	IN	O	in	_	0	SENT_620	[p28l9t2597r92b2673],
8	the	DT	O	the	det	10	SENT_620	[p28l123t2596r254b2674],
9	INTEREST	NN	O	interest	nn	10	SENT_620	[p28l284t2601r747b2679],
10	trial	NN	O	trial	prep_in	6	SENT_620	[p28l776t2596r972b2691],
11	,	,	O	,	_	0	SENT_620	[p28l776t2596r972b2691],
12	which	WDT	O	which	nsubj	13	SENT_620	[p28l1004t2596r1265b2675],
13	compared	VBD	O	compare	rcmod	10	SENT_620	[p28l1296t2596r1718b2696],
14	docetaxel	NN	O	docetaxel	dobj	13	SENT_620	[p28l1749t2596r2149b2674],
15	and	CC	O	and	_	0	SENT_620	[p28l9t2724r168b2803],
16	gefitinib	NN	O	gefitinib	conj_and	14	SENT_620	[p28l203t2723r578b2826],
17	as	IN	O	as	_	0	SENT_620	[p28l614t2750r701b2803],
18	second-line	JJ	O	second-line	amod	19	SENT_620	[p28l740t2724r1234b2803],
19	treatments	NNS	O	treatment	prep_as	14	SENT_620	[p28l1270t2740r1737b2803],
20	for	IN	O	for	_	0	SENT_620	[p28l1774t2723r1899b2803],
21	nonsmall	JJ	O	nonsmall	amod	24	SENT_620	[p28l1931t2750r2153b2803, p28l11t2853r443b2931],
22	—	NN	O	—	nn	24	SENT_620	[p28l1931t2750r2153b2803, p28l11t2853r443b2931],
23	cell	NN	O	cell	nn	24	SENT_620	[p28l1931t2750r2153b2803, p28l11t2853r443b2931],
24	lung	NN	O	lung	prep_for	13	SENT_620	[p28l477t2853r675b2954],
25	cancer	NN	O	cancer	tmod	13	SENT_620	[p28l708t2858r1092b2931],
26	.35	CD	NUMBER	.35	num	25	SENT_620	[p28l708t2858r1092b2931],
27	In	IN	O	in	_	0	SENT_620	[p28l1129t2860r1220b2930],
28	contrast	NN	O	contrast	prep_in	53	SENT_620	[p28l1257t2869r1641b2949],
29	,	,	O	,	_	0	SENT_620	[p28l1257t2869r1641b2949],
30	the	DT	O	the	det	31	SENT_620	[p28l1683t2853r1819b2931],
31	results	NNS	O	result	appos	28	SENT_620	[p28l1855t2853r2147b2932],
32	of	IN	O	of	_	0	SENT_620	[p28l10t2980r112b3060],
33	the	DT	O	the	det	36	SENT_620	[p28l134t2981r270b3060],
34	phase	NN	O	phase	nn	36	SENT_620	[p28l309t2981r564b3082],
35	3	CD	NUMBER	3	num	36	SENT_620	[p28l605t2987r650b3061],
36	trial	NN	O	trial	prep_of	31	SENT_620	[p28l694t2981r877b3060],
37	comparing	VBG	O	compare	partmod	36	SENT_620	[p28l918t2982r1400b3083],
38	the	DT	O	the	det	39	SENT_620	[p28l1437t2981r1573b3060],
39	use	NN	O	use	dobj	37	SENT_620	[p28l1613t3007r1757b3061],
40	of	IN	O	of	_	0	SENT_620	[p28l1798t2980r1900b3060],
41	panitumumab	NN	LOCATION	panitumumab	prep_of	39	SENT_620	[p28l1920t2982r2148b3082, p28l10t3111r440b3190],
42	with	IN	O	with	_	0	SENT_620	[p28l483t3111r683b3190],
43	best	JJS	O	best	dep	44	SENT_620	[p28l730t3111r911b3189],
44	supportive	JJ	O	supportive	amod	45	SENT_620	[p28l954t3112r1417b3211],
45	care	NN	O	care	prep_with	37	SENT_620	[p28l1464t3137r1643b3189],
46	in	IN	O	in	_	0	SENT_620	[p28l1690t3112r1774b3188],
47	chemotherapy	NN	O	chemotherapy	prep_in	45	SENT_620	[p28l1821t3111r2148b3189, p28l10t3238r812b3339],
48	—	CD	NUMBER	—	num	51	SENT_620	[p28l1821t3111r2148b3189, p28l10t3238r812b3339],
49	refractory	JJ	O	refractory	amod	51	SENT_620	[p28l1821t3111r2148b3189, p28l10t3238r812b3339],
50	colorectal	JJ	O	colorectal	amod	51	SENT_620	[p28l868t3239r1301b3317],
51	cancer	NN	O	cancer	nsubj	53	SENT_620	[p28l1361t3265r1649b3317],
52	have	VBP	O	have	aux	53	SENT_620	[p28l1705t3239r1899b3318],
53	confirmed	VBN	O	confirm	rcmod	25	SENT_620	[p28l1960t3264r2148b3317, p28l10t3366r312b3445],
54	that	IN	O	that	complm	60	SENT_620	[p28l379t3367r556b3445],
55	the	DT	O	the	det	56	SENT_620	[p28l619t3367r755b3445],
56	efficacy	NN	O	efficacy	nsubjpass	60	SENT_620	[p28l823t3366r1169b3467],
57	of	IN	O	of	_	0	SENT_620	[p28l1232t3366r1334b3445],
58	panitumumab	NN	LOCATION	panitumumab	prep_of	56	SENT_620	[p28l1381t3367r2011b3467],
59	is	VBZ	O	be	auxpass	60	SENT_620	[p28l2080t3368r2146b3445],
60	limited	VBN	O	limit	ccomp	53	SENT_620	[p28l8t3496r326b3574],
61	to	TO	O	to	_	0	SENT_620	[p28l356t3512r439b3574],
62	patients	NNS	O	patient	prep_to	60	SENT_620	[p28l469t3496r820b3596],
63	whose	WP$	O	whose	poss	64	SENT_620	[p28l848t3496r1128b3575],
64	tumors	NNS	O	tumor	nsubj	65	SENT_620	[p28l1159t3512r1474b3575],
65	carry	VBP	O	carry	rcmod	62	SENT_620	[p28l1507t3522r1734b3596],
66	the	DT	O	the	det	68	SENT_620	[p28l1760t3496r1896b3574],
67	wildtype	JJ	O	wildtype	amod	68	SENT_620	[p28l1921t3496r2148b3575, p28l10t3641r196b3725],
68	K	NN	O	k	dobj	65	SENT_620	[p28l231t3630r487b3704],
69	.	.	O	.	_	0	SENT_620	[p28l231t3630r487b3704],

1	—	NN	O	—	_	0	SENT_621	[p28l231t3630r487b3704],
2	.	.	O	.	_	0	SENT_621	[p28l231t3630r487b3704],

1	RAS	NN	O	ra	nn	2	SENT_622	[p28l231t3630r487b3704],
2	gene	NN	O	gene	_	0	SENT_622	[p28l521t3630r829b3726],
3	.99	CD	NUMBER	.99	dep	2	SENT_622	[p28l521t3630r829b3726],

1	ACQUIRED	VBN	O	acquire	dep	113	SENT_623	[p29l8t128r424b193],
2	RESISTANCE	NN	O	resistance	dep	113	SENT_623	[p29l463t128r942b178],
3	In	IN	O	in	dep	113	SENT_623	[p29l8t236r97b306],
4	patients	NNS	O	patient	dep	113	SENT_623	[p29l140t230r476b329],
5	with	IN	O	with	dep	113	SENT_623	[p29l518t229r711b308],
6	non	JJ	O	non	dep	113	SENT_623	[p29l755t229r1389b307],
7	—	JJ	O	—	dep	113	SENT_623	[p29l755t229r1389b307],
8	small	JJ	O	small	dep	113	SENT_623	[p29l755t229r1389b307],
9	—	NN	O	—	dep	113	SENT_623	[p29l755t229r1389b307],
10	cell	NN	O	cell	dep	113	SENT_623	[p29l755t229r1389b307],
11	lung	NN	O	lung	dep	113	SENT_623	[p29l1431t229r1623b330],
12	cancer	NN	O	cancer	dep	113	SENT_623	[p29l1665t255r1942b307],
13	that	WDT	O	that	dep	113	SENT_623	[p29l1984t229r2154b307],
14	initially	RB	O	initially	dep	113	SENT_623	[p29l9t357r337b458],
15	responds	VBZ	O	respond	dep	113	SENT_623	[p29l373t357r756b458],
16	to	TO	O	to	dep	113	SENT_623	[p29l799t373r880b436],
17	gefitinib	NN	O	gefitinib	dep	113	SENT_623	[p29l922t356r1288b459],
18	or	CC	O	or	dep	113	SENT_623	[p29l1331t382r1420b436],
19	erlotinib	NN	O	erlotinib	dep	113	SENT_623	[p29l1458t357r1841b453],
20	,	,	O	,	_	0	SENT_623	[p29l1458t357r1841b453],
21	an	DT	O	a	dep	113	SENT_623	[p29l1886t383r1989b436],
22	acquired	VBN	O	acquire	dep	113	SENT_623	[p29l2029t383r2148b436, p29l10t486r283b586],
23	resistance	NN	O	resistance	dep	113	SENT_623	[p29l319t487r741b564],
24	to	TO	O	to	dep	113	SENT_623	[p29l777t502r858b564],
25	EGFR	NN	ORGANIZATION	egfr	dep	113	SENT_623	[p29l894t491r1149b569],
26	inhibitors	NNS	O	inhibitor	dep	113	SENT_623	[p29l1173t486r1612b582],
27	,	,	O	,	_	0	SENT_623	[p29l1173t486r1612b582],
28	resulting	VBG	O	result	dep	113	SENT_623	[p29l1653t486r2034b587],
29	in	IN	O	in	dep	113	SENT_623	[p29l2066t487r2149b563],
30	treatment	NN	O	treatment	dep	113	SENT_623	[p29l10t630r429b692],
31	failure	NN	O	failure	dep	113	SENT_623	[p29l464t613r759b710],
32	,	,	O	,	_	0	SENT_623	[p29l464t613r759b710],
33	is	VBZ	O	be	dep	113	SENT_623	[p29l804t615r870b692],
34	associated	VBN	O	associate	dep	113	SENT_623	[p29l912t614r1351b692],
35	with	IN	O	with	dep	113	SENT_623	[p29l1387t614r1580b693],
36	the	DT	O	the	dep	113	SENT_623	[p29l1621t614r1752b692],
37	development	NN	O	development	dep	113	SENT_623	[p29l1794t614r2148b714, p29l10t759r229b822],
38	of	IN	O	of	dep	113	SENT_623	[p29l266t742r366b822],
39	an	DT	O	a	dep	113	SENT_623	[p29l388t769r491b822],
40	additional	JJ	O	additional	dep	113	SENT_623	[p29l532t743r963b822],
41	EGFR	NN	ORGANIZATION	egfr	dep	113	SENT_623	[p29l1002t750r1213b823],
42	mutation	NN	O	mutation	dep	113	SENT_623	[p29l1248t744r1699b823],
43	.5	CD	NUMBER	.5	dep	113	SENT_623	[p29l1248t744r1699b823],
44	The	DT	O	the	dep	113	SENT_623	[p29l1738t743r1897b822],
45	most	RBS	O	most	dep	113	SENT_623	[p29l1939t759r2154b822],
46	extensively	RB	O	extensively	dep	113	SENT_623	[p29l10t872r468b972],
47	studied	VBN	O	study	dep	113	SENT_623	[p29l496t872r806b951],
48	of	IN	O	of	dep	113	SENT_623	[p29l837t871r937b950],
49	such	JJ	O	such	dep	113	SENT_623	[p29l951t872r1143b951],
50	EGFR	NN	ORGANIZATION	egfr	dep	113	SENT_623	[p29l1172t879r1383b952],
51	mutations	NNS	O	mutation	dep	113	SENT_623	[p29l1408t873r1837b951],
52	occurs	VBZ	O	occur	dep	113	SENT_623	[p29l1872t897r2147b951],
53	in	IN	O	in	dep	113	SENT_623	[p29l9t1001r92b1077],
54	exon	NN	O	exon	dep	113	SENT_623	[p29l131t1026r329b1079],
55	20	CD	NUMBER	20	dep	113	SENT_623	[p29l366t1005r486b1097],
56	,	,	O	,	_	0	SENT_623	[p29l366t1005r486b1097],
57	resulting	VBG	O	result	dep	113	SENT_623	[p29l530t1000r910b1102],
58	in	IN	O	in	dep	113	SENT_623	[p29l944t1001r1027b1077],
59	a	DT	O	a	dep	113	SENT_623	[p29l1064t1026r1109b1079],
60	substitution	NN	O	substitution	dep	113	SENT_623	[p29l1146t1000r1655b1080],
61	of	IN	O	of	dep	113	SENT_623	[p29l1693t999r1793b1079],
62	methionine	NN	O	methionine	dep	113	SENT_623	[p29l1812t1000r2148b1079, p29l10t1131r195b1208],
63	for	IN	O	for	dep	113	SENT_623	[p29l244t1129r366b1208],
64	threonine	NN	O	threonine	dep	113	SENT_623	[p29l412t1130r827b1208],
65	in	IN	O	in	dep	113	SENT_623	[p29l875t1131r958b1207],
66	codon	NN	O	codon	dep	113	SENT_623	[p29l1007t1130r1267b1208],
67	790	CD	NUMBER	790	dep	113	SENT_623	[p29l1317t1135r1468b1208],
68	(	NN	O	(	dep	113	SENT_623	[p29l1522t1135r2149b1221],
69	T79OM	NN	O	t79om	dep	113	SENT_623	[p29l1522t1135r2149b1221],
70	)	CD	NUMBER	)	dep	113	SENT_623	[p29l1522t1135r2149b1221],
71	.1	CD	NUMBER	.1	dep	113	SENT_623	[p29l1522t1135r2149b1221],
72	°	CD	NUMBER	°	dep	113	SENT_623	[p29l1522t1135r2149b1221],
73	°	NN	O	°	dep	113	SENT_623	[p29l1522t1135r2149b1221],
74	'	''	O	'	_	0	SENT_623	[p29l1522t1135r2149b1221],
75	1	CD	NUMBER	1	dep	113	SENT_623	[p29l1522t1135r2149b1221],
76	°	NN	O	°	dep	113	SENT_623	[p29l1522t1135r2149b1221],
77	2	CD	NUMBER	2	dep	113	SENT_623	[p29l1522t1135r2149b1221],
78	This	DT	O	this	dep	113	SENT_623	[p29l6t1258r192b1336],
79	mutation	NN	O	mutation	dep	113	SENT_623	[p29l241t1259r629b1337],
80	causes	VBZ	O	cause	dep	113	SENT_623	[p29l677t1284r949b1337],
81	a	DT	O	a	dep	113	SENT_623	[p29l998t1284r1043b1336],
82	change	NN	O	change	dep	113	SENT_623	[p29l1089t1258r1391b1359],
83	in	IN	O	in	dep	113	SENT_623	[p29l1437t1259r1521b1335],
84	the	DT	O	the	dep	113	SENT_623	[p29l1568t1258r1699b1336],
85	tridimen	NN	O	tridiman	dep	113	SENT_623	[p29l1747t1258r2148b1336],
86	—	CD	NUMBER	—	dep	113	SENT_623	[p29l1747t1258r2148b1336],
87	sional	JJ	O	sional	dep	113	SENT_623	[p29l11t1386r264b1464],
88	structure	NN	O	structure	dep	113	SENT_623	[p29l291t1402r674b1465],
89	of	IN	O	of	dep	113	SENT_623	[p29l701t1385r801b1464],
90	the	DT	O	the	dep	113	SENT_623	[p29l809t1386r941b1464],
91	tyrosine	NN	O	tyrosine	dep	113	SENT_623	[p29l968t1387r1310b1486],
92	kinase	NN	O	kinase	dep	113	SENT_623	[p29l1336t1386r1612b1465],
93	domain	NN	O	domain	dep	113	SENT_623	[p29l1639t1386r1967b1464],
94	and	CC	O	and	dep	113	SENT_623	[p29l1993t1386r2149b1464],
95	prevents	VBZ	O	prevent	dep	113	SENT_623	[p29l8t1530r362b1615],
96	both	DT	O	both	dep	113	SENT_623	[p29l392t1514r588b1593],
97	erlotinib	NN	O	erlotinib	dep	113	SENT_623	[p29l616t1514r977b1593],
98	and	CC	O	and	dep	113	SENT_623	[p29l1005t1514r1162b1593],
99	gefitinib	NN	O	gefitinib	dep	113	SENT_623	[p29l1188t1513r1555b1616],
100	from	IN	O	from	dep	113	SENT_623	[p29l1583t1513r1791b1593],
101	binding	VBG	O	bind	dep	113	SENT_623	[p29l1819t1514r2153b1616],
102	to	TO	O	to	dep	113	SENT_623	[p29l10t1659r91b1722],
103	EGFR	NN	ORGANIZATION	egfr	dep	113	SENT_623	[p29l124t1648r501b1727],
104	.1	CD	NUMBER	.1	dep	113	SENT_623	[p29l124t1648r501b1727],
105	°	NN	O	°	dep	113	SENT_623	[p29l124t1648r501b1727],
106	3	CD	NUMBER	3	dep	113	SENT_623	[p29l124t1648r501b1727],
107	According	VBG	O	accord	dep	113	SENT_623	[p29l532t1643r975b1745],
108	to	TO	O	to	dep	113	SENT_623	[p29l1004t1660r1085b1722],
109	a	DT	O	a	dep	113	SENT_623	[p29l1119t1669r1164b1722],
110	recent	JJ	O	recent	dep	113	SENT_623	[p29l1195t1660r1457b1722],
111	report	NN	O	report	dep	113	SENT_623	[p29l1484t1659r1768b1744],
112	,	,	O	,	_	0	SENT_623	[p29l1484t1659r1768b1744],
113	ampliﬁ1170	IN	O	ampliﬁ1170	_	0	SENT_623	[p29l1806t1642r2148b1744, p29l149t1820r225b1842],

1	N	NN	O	n	nn	3	SENT_624	[p29l914t1830r927b1845],
2	ENGLJ	NN	O	englj	nn	3	SENT_624	[p29l942t1830r1020b1852],
3	MED	NN	O	med	_	0	SENT_624	[p29l1035t1830r1086b1845],
4	358	CD	NUMBER	358	dep	3	SENT_624	[p29l1097t1824r1165b1852],
5	;	:	O	;	_	0	SENT_624	[p29l1097t1824r1165b1852],
6	11	CD	NUMBER	11	dep	3	SENT_624	[p29l1097t1824r1165b1852],
7	WWW	NNP	O	WWW	dep	6	SENT_624	[p29l1201t1830r1308b1846],
8	.	.	O	.	_	0	SENT_624	[p29l1201t1830r1308b1846],

1	NE	NN	O	ne	nn	3	SENT_625	[p29l1201t1830r1308b1846],
2	M.ORG	NN	O	m.org	nn	3	SENT_625	[p29l1322t1830r1402b1846],
3	MARCH	NN	DATE	march	_	0	SENT_625	[p29l1439t1830r1524b1845],
4	13,2008	CD	DATE	13,2008	dep	3	SENT_625	[p29l1538t1824r1644b1852],

1	The	DT	O	the	det	5	SENT_626	[p29l935t1863r986b1887],
2	New	NNP	O	New	nn	5	SENT_626	[p29l995t1864r1057b1887],
3	England	NNP	O	England	nn	5	SENT_626	[p29l1066t1863r1177b1894],
4	Joumal	NNP	PERSON	Joumal	nn	5	SENT_626	[p29l1186t1863r1283b1887],
5	o	NN	O	o	_	0	SENT_626	[p29l1293t1871r1308b1887],
6	edicine	NN	O	edicine	dep	5	SENT_626	[p29l1359t1863r1454b1887],

1	Downloaded	VBN	O	download	_	0	SENT_627	[p29l377t1904r547b1927],
2	from	IN	O	from	_	0	SENT_627	[p29l556t1904r621b1927],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_627	[p29l629t1904r748b1934],
4	at	IN	O	at	_	0	SENT_627	[p29l758t1908r781b1927],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_627	[p29l789t1904r972b1927],
6	on	IN	O	on	_	0	SENT_627	[p29l981t1911r1014b1927],
7	January	NNP	DATE	January	prep_on	1	SENT_627	[p29l1022t1904r1125b1934],
8	5	CD	DATE	5	num	7	SENT_627	[p29l1135t1904r1158b1931],
9	,	,	DATE	,	_	0	SENT_627	[p29l1135t1904r1158b1931],
10	2014	CD	DATE	2014	num	7	SENT_627	[p29l1168t1904r1241b1927],
11	.	.	O	.	_	0	SENT_627	[p29l1168t1904r1241b1927],

1	For	IN	O	for	_	0	SENT_628	[p29l1251t1904r1298b1927],
2	personal	JJ	O	personal	amod	3	SENT_628	[p29l1306t1904r1418b1934],
3	use	NN	O	use	pobj	1	SENT_628	[p29l1427t1911r1471b1927],
4	only	RB	O	only	advmod	3	SENT_628	[p29l1480t1904r1545b1934],
5	.	.	O	.	_	0	SENT_628	[p29l1480t1904r1545b1934],

1	No	DT	O	no	det	3	SENT_629	[p29l1556t1904r1595b1927],
2	other	JJ	O	other	amod	3	SENT_629	[p29l1605t1904r1673b1927],
3	uses	NNS	O	use	_	0	SENT_629	[p29l1682t1911r1738b1927],
4	without	IN	O	without	_	0	SENT_629	[p29l1748t1904r1849b1927],
5	permission	NN	O	permission	prep_without	3	SENT_629	[p29l1857t1904r2010b1934],
6	.	.	O	.	_	0	SENT_629	[p29l1857t1904r2010b1934],

1	Copyright	NN	O	copyright	_	0	SENT_630	[p29l728t1945r862b1976],
2	©	CD	NUMBER	©	num	6	SENT_630	[p29l871t1945r895b1969],
3	2008	CD	DATE	2008	num	6	SENT_630	[p29l905t1945r969b1969],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_630	[p29l979t1945r1170b1969],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_630	[p29l1180t1945r1288b1969],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_630	[p29l1299t1945r1404b1976],
7	.	.	O	.	_	0	SENT_630	[p29l1299t1945r1404b1976],

1	All	DT	O	all	det	2	SENT_631	[p29l1415t1945r1456b1969],
2	rights	NNS	O	rights	nsubj	3	SENT_631	[p29l1465t1945r1540b1976],
3	reserved	VBN	O	reserve	_	0	SENT_631	[p29l1550t1945r1668b1969],
4	.	.	O	.	_	0	SENT_631	[p29l1550t1945r1668b1969],

1	RRRRRRRRR	NNP	O	RRRRRRRRR	nn	2	SENT_632	[p29l951t2051r1169b2070],
2	PY	NNP	O	PY	_	0	SENT_632	[p29l1174t2051r1209b2070],

1	cation	NN	O	cation	nsubjpass	10	SENT_633	[p29l11t2266r270b2344],
2	of	IN	O	of	_	0	SENT_633	[p29l322t2265r422b2344],
3	the	DT	O	the	det	7	SENT_633	[p29l456t2266r587b2344],
4	MET	NN	O	met	nn	7	SENT_633	[p29l638t2272r832b2344],
5	proto	NN	O	proto	nn	7	SENT_633	[p29l873t2282r1545b2366],
6	—	NN	O	—	nn	7	SENT_633	[p29l873t2282r1545b2366],
7	oncogene	NN	O	oncogene	prep_of	1	SENT_633	[p29l873t2282r1545b2366],
8	could	MD	O	could	aux	10	SENT_633	[p29l1598t2265r1829b2345],
9	be	VB	O	be	auxpass	10	SENT_633	[p29l1882t2265r1978b2344],
10	involved	VBN	O	involve	dep	34	SENT_633	[p29l2029t2266r2142b2343, p29l6t2393r269b2473],
11	in	IN	O	in	_	0	SENT_633	[p29l325t2394r408b2471],
12	acquired	VBN	O	acquire	amod	13	SENT_633	[p29l465t2394r829b2494],
13	resistance	NN	O	resistance	prep_in	10	SENT_633	[p29l886t2394r1306b2472],
14	to	TO	O	to	_	0	SENT_633	[p29l1365t2410r1445b2472],
15	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_633	[p29l1502t2399r1756b2477],
16	tyrosine	NN	O	tyrosine	nn	18	SENT_633	[p29l1803t2394r2143b2494],
17	kinase	NN	O	kinase	nn	18	SENT_633	[p29l10t2522r285b2601],
18	inhibitors	NNS	O	inhibitor	prep_to	13	SENT_633	[p29l325t2521r739b2600],
19	in	IN	O	in	_	0	SENT_633	[p29l782t2522r864b2599],
20	patients	NNS	O	patient	prep_in	13	SENT_633	[p29l904t2522r1239b2622],
21	with	IN	O	with	_	0	SENT_633	[p29l1278t2522r1471b2601],
22	non	JJ	O	non	amod	30	SENT_633	[p29l1512t2521r2144b2600],
23	—	JJ	O	—	amod	30	SENT_633	[p29l1512t2521r2144b2600],
24	small	JJ	O	small	amod	30	SENT_633	[p29l1512t2521r2144b2600],
25	—	NN	O	—	nn	30	SENT_633	[p29l1512t2521r2144b2600],
26	cell	NN	O	cell	nn	30	SENT_633	[p29l1512t2521r2144b2600],
27	lung	NN	O	lung	nn	30	SENT_633	[p29l9t2650r200b2750],
28	cancer	NN	O	cancer	nn	30	SENT_633	[p29l234t2654r642b2728],
29	.1	CD	NUMBER	.1	num	30	SENT_633	[p29l234t2654r642b2728],
30	°	NN	O	°	prep_with	20	SENT_633	[p29l234t2654r642b2728],
31	4	CD	NUMBER	4	num	33	SENT_633	[p29l234t2654r642b2728],
32	MET	NN	O	met	nn	33	SENT_633	[p29l676t2656r871b2728],
33	amplification	NN	O	amplification	nsubj	34	SENT_633	[p29l897t2649r1471b2750],
34	leads	VBZ	O	lead	_	0	SENT_633	[p29l1506t2649r1718b2728],
35	to	TO	O	to	_	0	SENT_633	[p29l1756t2666r1837b2728],
36	EGFRindependent	JJ	O	egfrindependent	amod	37	SENT_633	[p29l1874t2655r2142b2733, p29l10t2777r540b2878],
37	activation	NN	O	activation	prep_to	34	SENT_633	[p29l575t2778r984b2857],
38	of	IN	O	of	_	0	SENT_633	[p29l1025t2777r1124b2856],
39	the	DT	O	the	det	40	SENT_633	[p29l1147t2778r1278b2856],
40	PI3K	NN	O	pi3k	prep_of	37	SENT_633	[p29l1317t2783r1755b2859],
41	.	.	O	.	_	0	SENT_633	[p29l1317t2783r1755b2859],

1	—	NN	O	—	_	0	SENT_634	[p29l1317t2783r1755b2859],
2	.	.	O	.	_	0	SENT_634	[p29l1317t2783r1755b2859],

1	AKT	NN	O	akt	nn	2	SENT_635	[p29l1317t2783r1755b2859],
2	pathway	NN	O	pathway	_	0	SENT_635	[p29l1791t2778r2148b2878],
3	through	IN	O	through	_	0	SENT_635	[p29l11t2906r354b3006],
4	activation	NN	O	activation	prep_through	2	SENT_635	[p29l391t2906r800b2985],
5	of	IN	O	of	_	0	SENT_635	[p29l838t2905r937b2984],
6	HER3	NN	O	her3	nn	7	SENT_635	[p29l955t2905r1690b3006],
7	—	NN	O	—	prep_of	4	SENT_635	[p29l955t2905r1690b3006],
8	dependent	JJ	O	dependent	dep	9	SENT_635	[p29l955t2905r1690b3006],
9	signaling	NN	O	signaling	amod	2	SENT_635	[p29l1724t2906r2138b3006],
10	.	.	O	.	_	0	SENT_635	[p29l1724t2906r2138b3006],

1	In	IN	O	in	_	0	SENT_636	[p29l8t3041r97b3111],
2	a	DT	O	a	det	4	SENT_636	[p29l143t3060r188b3112],
3	gefitinib	NN	O	gefitinib	nn	4	SENT_636	[p29l232t3033r994b3134],
4	—	NN	O	—	prep_in	27	SENT_636	[p29l232t3033r994b3134],
5	sensitive	JJ	O	sensitive	amod	10	SENT_636	[p29l232t3033r994b3134],
6	lung	NN	O	lung	nn	10	SENT_636	[p29l1039t3034r1543b3134],
7	—	NN	O	—	nn	10	SENT_636	[p29l1039t3034r1543b3134],
8	cancer	NN	O	cancer	nn	10	SENT_636	[p29l1039t3034r1543b3134],
9	cell	NN	O	cell	nn	10	SENT_636	[p29l1587t3034r1730b3112],
10	line	NN	O	line	dep	4	SENT_636	[p29l1774t3033r1931b3112],
11	that	WDT	O	that	nsubj	12	SENT_636	[p29l1978t3034r2148b3112],
12	developed	VBD	O	develop	rcmod	10	SENT_636	[p29l11t3161r431b3262],
13	resistance	NN	O	resistance	dobj	12	SENT_636	[p29l458t3162r879b3240],
14	to	TO	O	to	_	0	SENT_636	[p29l906t3178r987b3240],
15	gefitinib	NN	O	gefitinib	prep_to	12	SENT_636	[p29l1015t3161r1380b3262],
16	as	IN	O	as	_	0	SENT_636	[p29l1407t3188r1492b3240],
17	a	DT	O	a	det	18	SENT_636	[p29l1520t3188r1565b3240],
18	result	NN	O	result	prep_as	12	SENT_636	[p29l1590t3162r1830b3241],
19	of	IN	O	of	_	0	SENT_636	[p29l1852t3161r1952b3240],
20	MET	NN	O	met	nn	21	SENT_636	[p29l1959t3168r2153b3240],
21	amplification	NN	O	amplification	prep_of	18	SENT_636	[p29l10t3289r605b3390],
22	,	,	O	,	_	0	SENT_636	[p29l10t3289r605b3390],
23	inhibition	NN	O	inhibition	appos	21	SENT_636	[p29l675t3289r1096b3368],
24	of	IN	O	of	_	0	SENT_636	[p29l1162t3289r1261b3368],
25	MET	NN	O	met	nn	26	SENT_636	[p29l1304t3295r1510b3368],
26	signaling	NN	O	signaling	prep_of	23	SENT_636	[p29l1573t3290r1969b3390],
27	restored	VBD	O	restore	_	0	SENT_636	[p29l2031t3316r2142b3368, p29l11t3418r272b3496],
28	sensitivity	NN	O	sensitivity	dobj	27	SENT_636	[p29l300t3418r724b3518],
29	to	TO	O	to	aux	30	SENT_636	[p29l747t3434r828b3496],
30	geﬁtinib	VB	O	geﬁtinib	xcomp	27	SENT_636	[p29l855t3417r1356b3518],
31	.1	CD	NUMBER	.1	dobj	30	SENT_636	[p29l855t3417r1356b3518],
32	°	CD	NUMBER	°	number	33	SENT_636	[p29l855t3417r1356b3518],
33	4	CD	NUMBER	4	num	36	SENT_636	[p29l855t3417r1356b3518],
34	A	DT	O	a	det	36	SENT_636	[p29l1379t3425r1445b3495],
35	pilot	NN	O	pilot	nn	36	SENT_636	[p29l1467t3418r1664b3518],
36	study	NN	O	study	nsubj	27	SENT_636	[p29l1687t3417r1914b3518],
37	of	IN	O	of	_	0	SENT_636	[p29l1937t3417r2036b3496],
38	18	CD	NUMBER	18	num	40	SENT_636	[p29l2048t3423r2141b3496],
39	tumor	NN	O	tumor	nn	40	SENT_636	[p29l11t3562r276b3625],
40	specimens	NNS	O	specimen	prep_of	36	SENT_636	[p29l316t3546r757b3646],
41	from	IN	O	from	_	0	SENT_636	[p29l801t3545r1009b3624],
42	patients	NNS	O	patient	prep_from	40	SENT_636	[p29l1050t3546r1386b3646],
43	with	IN	O	with	_	0	SENT_636	[p29l1425t3545r1618b3625],
44	non	JJ	O	non	amod	48	SENT_636	[p29l1660t3545r2142b3624, p29l11t3673r154b3752],
45	—	NN	O	—	nn	48	SENT_636	[p29l1660t3545r2142b3624, p29l11t3673r154b3752],
46	smallcell	NN	O	smallcell	nn	48	SENT_636	[p29l1660t3545r2142b3624, p29l11t3673r154b3752],
47	lung	NN	O	lung	nn	48	SENT_636	[p29l189t3674r381b3774],
48	cancer	NN	O	cancer	prep_with	42	SENT_636	[p29l415t3699r692b3752],
49	that	WDT	O	that	nsubj	52	SENT_636	[p29l726t3673r896b3752],
50	had	VBD	O	have	aux	52	SENT_636	[p29l928t3673r1082b3752],
51	previously	RB	DATE	previously	advmod	52	SENT_636	[p29l1118t3674r1550b3774],
52	responded	VBN	O	respond	rcmod	48	SENT_636	[p29l1582t3673r2024b3774],
53	to	TO	O	to	_	0	SENT_636	[p29l2061t3690r2142b3752],
54	geﬁtinib	NN	O	geﬁtinib	prep_to	52	SENT_636	[p30l10t20r374b121],
55	but	CC	O	but	_	0	SENT_636	[p30l415t21r553b100],
56	that	IN	O	that	dep	61	SENT_636	[p30l587t21r757b99],
57	subsequently	RB	O	subsequently	advmod	58	SENT_636	[p30l791t20r1343b121],
58	developed	VBN	O	develop	amod	60	SENT_636	[p30l1377t20r1798b121],
59	clinical	JJ	O	clinical	amod	60	SENT_636	[p30l1836t20r2144b99],
60	resistance	NN	O	resistance	nsubj	61	SENT_636	[p30l10t149r430b227],
61	showed	VBD	O	show	rcmod	48	SENT_636	[p30l474t149r793b228],
62	MET	NN	O	met	nn	63	SENT_636	[p30l833t155r1028b227],
63	ampliﬁcation	NN	O	ampliﬁcation	dobj	61	SENT_636	[p30l1059t148r1633b249],
64	in	IN	O	in	_	0	SENT_636	[p30l1674t149r1757b226],
65	4	CD	NUMBER	4	prep_in	61	SENT_636	[p30l1797t154r1847b227],
66	of	IN	O	of	_	0	SENT_636	[p30l1889t148r1988b227],
67	the	DT	O	the	det	68	SENT_636	[p30l2012t149r2143b227],
68	tumors	NNS	O	tumor	prep_of	65	SENT_636	[p30l11t281r452b356],
69	.1	CD	NUMBER	.1	number	70	SENT_636	[p30l11t281r452b356],
70	°	CD	NUMBER	°	dep	68	SENT_636	[p30l11t281r452b356],
71	4	CD	NUMBER	4	dep	70	SENT_636	[p30l11t281r452b356],

1	FUTURE	JJ	DATE	future	amod	2	SENT_637	[p30l474t578r923b638],
2	DIRECTIONS	NNS	O	direction	_	0	SENT_637	[p30l978t578r1680b638],

1	Appropriate	JJ	O	appropriate	amod	2	SENT_638	[p30l6t833r513b933],
2	selection	NN	O	selection	nsubj	8	SENT_638	[p30l555t832r927b911],
3	of	IN	O	of	_	0	SENT_638	[p30l968t832r1067b911],
4	patients	NNS	O	patient	prep_of	2	SENT_638	[p30l1086t833r1422b933],
5	is	VBZ	O	be	cop	8	SENT_638	[p30l1463t833r1528b911],
6	a	DT	O	a	det	8	SENT_638	[p30l1569t859r1614b911],
7	major	JJ	O	major	amod	8	SENT_638	[p30l1652t833r1899b933],
8	challenge	NN	O	challenge	_	0	SENT_638	[p30l1937t833r2142b911, p30l9t961r232b1061],
9	for	IN	O	for	_	0	SENT_638	[p30l268t960r389b1039],
10	the	DT	O	the	det	12	SENT_638	[p30l422t961r553b1039],
11	clinical	JJ	O	clinical	amod	12	SENT_638	[p30l589t961r897b1039],
12	use	NN	O	use	prep_for	8	SENT_638	[p30l932t987r1071b1040],
13	of	IN	O	of	_	0	SENT_638	[p30l1107t960r1206b1039],
14	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_638	[p30l1222t966r1475b1044],
15	antagonists	NNS	O	antagonist	prep_of	12	SENT_638	[p30l1499t961r2015b1061],
16	.	.	O	.	_	0	SENT_638	[p30l1499t961r2015b1061],

1	In	IN	O	in	_	0	SENT_639	[p30l2055t968r2143b1038],
2	fact	NN	O	fact	prep_in	25	SENT_639	[p30l10t1088r186b1184],
3	,	,	O	,	_	0	SENT_639	[p30l10t1088r186b1184],
4	although	IN	O	although	mark	12	SENT_639	[p30l233t1088r614b1189],
5	long	JJ	O	long	amod	6	SENT_639	[p30l655t1088r1166b1189],
6	—	NN	O	—	nsubjpass	12	SENT_639	[p30l655t1088r1166b1189],
7	lasting	VBG	O	last	partmod	6	SENT_639	[p30l655t1088r1166b1189],
8	therapeutic	JJ	O	therapeutic	amod	9	SENT_639	[p30l1205t1089r1683b1189],
9	responses	NNS	O	response	dobj	7	SENT_639	[p30l1724t1114r2141b1189],
10	have	VBP	O	have	aux	12	SENT_639	[p30l10t1217r197b1296],
11	been	VBN	O	be	auxpass	12	SENT_639	[p30l239t1217r438b1295],
12	observed	VBN	O	observe	advcl	25	SENT_639	[p30l480t1217r855b1296],
13	even	RB	O	even	advmod	12	SENT_639	[p30l897t1242r1083b1296],
14	in	IN	O	in	_	0	SENT_639	[p30l1123t1217r1206b1294],
15	patients	NNS	O	patient	prep_in	12	SENT_639	[p30l1245t1217r1581b1317],
16	with	IN	O	with	_	0	SENT_639	[p30l1620t1217r1812b1296],
17	heavily	RB	O	heavily	advmod	18	SENT_639	[p30l1853t1217r2148b1317],
18	pretreated	JJ	O	pretreated	amod	21	SENT_639	[p30l9t1345r463b1446],
19	,	,	O	,	_	0	SENT_639	[p30l9t1345r463b1446],
20	metastatic	JJ	O	metastatic	amod	21	SENT_639	[p30l519t1346r959b1424],
21	cancer	NN	O	cancer	prep_with	15	SENT_639	[p30l1009t1371r1303b1441],
22	,	,	O	,	_	0	SENT_639	[p30l1009t1371r1303b1441],
23	responses	NNS	O	response	nsubjpass	25	SENT_639	[p30l1358t1371r1775b1446],
24	are	VBP	O	be	auxpass	25	SENT_639	[p30l1827t1372r1955b1424],
25	observed	VBN	O	observe	_	0	SENT_639	[p30l2005t1346r2142b1424, p30l11t1474r278b1553],
26	in	IN	O	in	_	0	SENT_639	[p30l333t1474r415b1551],
27	only	RB	O	only	quantmod	28	SENT_639	[p30l471t1474r653b1574],
28	10	CD	NUMBER	10	prep_in	25	SENT_639	[p30l707t1479r800b1552],
29	to	TO	O	to	_	0	SENT_639	[p30l856t1490r937b1552],
30	20	CD	NUMBER	20	number	31	SENT_639	[p30l994t1479r1180b1553],
31	°	CD	NUMBER	°	prep_to	25	SENT_639	[p30l994t1479r1180b1553],
32	/	:	O	/	punct	33	SENT_639	[p30l994t1479r1180b1553],
33	o	NN	O	o	dep	25	SENT_639	[p30l994t1479r1180b1553],
34	of	IN	O	of	_	0	SENT_639	[p30l1235t1473r1335b1552],
35	patients	NNS	O	patient	prep_of	33	SENT_639	[p30l1370t1474r1706b1574],
36	receiving	VBG	O	receive	partmod	35	SENT_639	[p30l1763t1474r2147b1574],
37	these	DT	O	these	det	38	SENT_639	[p30l11t1601r230b1680],
38	drugs	NNS	O	drug	dobj	36	SENT_639	[p30l284t1602r656b1702],
39	.1	CD	NUMBER	.1	tmod	36	SENT_639	[p30l284t1602r656b1702],
40	°	CD	NUMBER	°	number	41	SENT_639	[p30l284t1602r656b1702],
41	5	CD	NUMBER	5	num	43	SENT_639	[p30l284t1602r656b1702],
42	Cancer	NN	O	cancer	nn	43	SENT_639	[p30l712t1607r1007b1680],
43	cells	NNS	O	cell	nsubj	45	SENT_639	[p30l1056t1602r1240b1680],
44	must	MD	O	must	aux	45	SENT_639	[p30l1295t1618r1508b1681],
45	express	VB	O	express	rcmod	39	SENT_639	[p30l1556t1628r1867b1702],
46	functional	JJ	O	functional	amod	47	SENT_639	[p30l1921t1601r2142b1681, p30l11t1730r256b1808],
47	EGFRS	NNS	O	egfr	dobj	45	SENT_639	[p30l286t1735r573b1813],
48	to	TO	O	to	aux	49	SENT_639	[p30l608t1746r689b1808],
49	respond	VB	O	respond	xcomp	25	SENT_639	[p30l722t1729r1063b1830],
50	to	TO	O	to	_	0	SENT_639	[p30l1095t1746r1176b1808],
51	these	DT	O	these	det	52	SENT_639	[p30l1210t1730r1430b1808],
52	agents	NNS	O	agent	prep_to	49	SENT_639	[p30l1462t1746r1758b1830],
53	.	.	O	.	_	0	SENT_639	[p30l1462t1746r1758b1830],

1	An	DT	O	a	det	3	SENT_640	[p30l1791t1737r1915b1807],
2	optimal	JJ	O	optimal	amod	3	SENT_640	[p30l1947t1730r2142b1830, p30l10t1858r171b1936],
3	response	NN	O	response	nsubj	8	SENT_640	[p30l215t1883r590b1958],
4	to	TO	O	to	_	0	SENT_640	[p30l635t1874r715b1936],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_640	[p30l760t1863r1014b1941],
6	antagonists	NNS	O	antagonist	prep_to	3	SENT_640	[p30l1047t1858r1539b1958],
7	also	RB	O	also	advmod	8	SENT_640	[p30l1584t1857r1753b1936],
8	requires	VBZ	O	require	_	0	SENT_640	[p30l1799t1858r2140b1958],
9	the	DT	O	the	det	11	SENT_640	[p30l11t1986r141b2064],
10	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_640	[p30l191t1986r836b2069],
11	—	NN	O	—	dobj	8	SENT_640	[p30l191t1986r836b2069],
12	activated	VBN	O	activate	partmod	11	SENT_640	[p30l191t1986r836b2069],
13	intracellular	JJ	O	intracellular	amod	19	SENT_640	[p30l886t1985r1405b2065],
14	signal	NN	O	signal	nn	19	SENT_640	[p30l1455t1985r2142b2086],
15	—	NN	O	—	nn	19	SENT_640	[p30l1455t1985r2142b2086],
16	transduc	NN	O	transduc	nn	19	SENT_640	[p30l1455t1985r2142b2086],
17	—	CD	NUMBER	—	num	19	SENT_640	[p30l1455t1985r2142b2086],
18	tion	NN	O	tion	nn	19	SENT_640	[p30l11t2114r177b2192],
19	machinery	NN	O	machinery	dobj	12	SENT_640	[p30l226t2114r678b2214],
20	to	TO	O	to	aux	22	SENT_640	[p30l723t2130r803b2192],
21	be	VB	O	be	cop	22	SENT_640	[p30l854t2114r949b2192],
22	intact	JJ	O	intact	infmod	19	SENT_640	[p30l998t2114r1260b2192],
23	.	.	O	.	_	0	SENT_640	[p30l998t2114r1260b2192],

1	In	IN	O	in	_	0	SENT_641	[p30l1312t2121r1400b2191],
2	addition	NN	O	addition	prep_in	10	SENT_641	[p30l1448t2113r1821b2209],
3	,	,	O	,	_	0	SENT_641	[p30l1448t2113r1821b2209],
4	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_641	[p30l1874t2119r2142b2197],
5	—	NN	O	—	nn	8	SENT_641	[p30l1874t2119r2142b2197],
6	dependent	JJ	O	dependent	amod	8	SENT_641	[p30l11t2241r455b2342],
7	cancer	NN	O	cancer	nn	8	SENT_641	[p30l501t2267r778b2320],
8	cells	NNS	O	cell	nsubj	10	SENT_641	[p30l826t2242r1010b2320],
9	may	MD	O	may	aux	10	SENT_641	[p30l1063t2268r1241b2342],
10	escape	VB	O	escape	_	0	SENT_641	[p30l1288t2268r1565b2342],
11	from	IN	O	from	_	0	SENT_641	[p30l1616t2241r1824b2320],
12	EGFRtargeted	VBN	O	egfrtarget	prepc_from	10	SENT_641	[p30l1874t2247r2143b2325, p30l12t2369r362b2470],
13	growth	NN	O	growth	nn	14	SENT_641	[p30l419t2369r731b2470],
14	inhibition	NN	O	inhibition	dobj	12	SENT_641	[p30l787t2369r1210b2448],
15	by	IN	O	by	_	0	SENT_641	[p30l1268t2369r1365b2469],
16	using	VBG	O	use	prepc_by	12	SENT_641	[p30l1418t2370r1653b2470],
17	alternative	JJ	O	alternative	amod	21	SENT_641	[p30l1707t2369r2150b2448],
18	growth	NN	O	growth	nn	21	SENT_641	[p30l11t2497r322b2599],
19	factor	NN	O	factor	nn	21	SENT_641	[p30l370t2496r617b2577],
20	receptor	NN	O	receptor	nn	21	SENT_641	[p30l662t2514r1012b2598],
21	pathways	NNS	O	pathway	dobj	16	SENT_641	[p30l1056t2497r1450b2598],
22	or	CC	O	or	_	0	SENT_641	[p30l1500t2523r1589b2577],
23	by	IN	O	by	_	0	SENT_641	[p30l1634t2497r1731b2598],
24	constitutively	RB	O	constitutively	advmod	25	SENT_641	[p30l1775t2498r2148b2577, p30l12t2626r232b2726],
25	activating	VBG	O	activate	conj_or	16	SENT_641	[p30l269t2627r684b2727],
26	downstream	JJ	O	downstream	amod	29	SENT_641	[p30l726t2626r1259b2705],
27	intracellular	JJ	O	intracellular	amod	29	SENT_641	[p30l1302t2626r1822b2705],
28	signaling	NN	O	signaling	nn	29	SENT_641	[p30l1864t2626r2148b2727, p30l11t2755r149b2856],
29	effectors	NNS	O	effector	dobj	25	SENT_641	[p30l185t2753r824b2851],
30	,1	CD	NUMBER	,1	num	31	SENT_641	[p30l185t2753r824b2851],
31	°	CD	NUMBER	°	dep	29	SENT_641	[p30l185t2753r824b2851],
32	6	CD	NUMBER	6	num	33	SENT_641	[p30l185t2753r824b2851],
33	‘	NN	O	‘	dobj	31	SENT_641	[p30l185t2753r824b2851],
34	1	CD	NUMBER	1	number	35	SENT_641	[p30l185t2753r824b2851],
35	°	CD	NUMBER	°	dep	33	SENT_641	[p30l185t2753r824b2851],
36	9	CD	NUMBER	9	dep	35	SENT_641	[p30l185t2753r824b2851],
37	indicating	VBG	O	indicate	xcomp	31	SENT_641	[p30l863t2754r1298b2856],
38	the	DT	O	the	det	39	SENT_641	[p30l1334t2754r1466b2833],
39	need	NN	O	need	dobj	37	SENT_641	[p30l1505t2754r1705b2834],
40	for	IN	O	for	_	0	SENT_641	[p30l1743t2753r1866b2834],
41	therapeutic	JJ	O	therapeutic	amod	42	SENT_641	[p30l1902t2754r2148b2833, p30l10t2884r270b2983],
42	strategies	NNS	O	strategy	prep_for	39	SENT_641	[p30l308t2884r710b2984],
43	designed	VBN	O	design	partmod	42	SENT_641	[p30l751t2883r1129b2984],
44	to	TO	O	to	aux	45	SENT_641	[p30l1166t2900r1247b2962],
45	overcome	VB	O	overcome	xcomp	43	SENT_641	[p30l1286t2909r1689b2962],
46	resistance	NN	O	resistance	dobj	45	SENT_641	[p30l1728t2884r2149b2962],
47	to	TO	O	to	_	0	SENT_641	[p30l12t3028r93b3090],
48	EGFR	NN	ORGANIZATION	egfr	nn	49	SENT_641	[p30l140t3017r395b3095],
49	inhibitors	NNS	O	inhibitor	prep_to	25	SENT_641	[p30l431t3011r1118b3090],
50	.11	CD	NUMBER	.11	num	51	SENT_641	[p30l431t3011r1118b3090],
51	°	NN	O	°	dobj	25	SENT_641	[p30l431t3011r1118b3090],
52	'	''	O	'	_	0	SENT_641	[p30l431t3011r1118b3090],
53	112	CD	NUMBER	112	num	56	SENT_641	[p30l431t3011r1118b3090],
54	Several	JJ	O	several	amod	56	SENT_641	[p30l1169t3011r1463b3090],
55	molecular	JJ	O	molecular	amod	56	SENT_641	[p30l1510t3011r1938b3090],
56	predictors	NNS	O	predictor	nsubjpass	59	SENT_641	[p30l1981t3037r2148b3111, p30l12t3140r301b3220],
57	have	VBP	O	have	aux	59	SENT_641	[p30l333t3140r522b3220],
58	been	VBN	O	be	auxpass	59	SENT_641	[p30l553t3140r753b3220],
59	detected	VBN	O	detect	rcmod	51	SENT_641	[p30l785t3140r1138b3220],
60	for	IN	O	for	_	0	SENT_641	[p30l1169t3139r1290b3220],
61	identifying	VBG	O	identify	prepc_for	59	SENT_641	[p30l1317t3139r1785b3242],
62	patients	NNS	O	patient	dobj	61	SENT_641	[p30l1811t3141r2148b3241],
63	who	WP	O	who	nsubj	67	SENT_641	[p30l7t3268r189b3348],
64	would	MD	O	would	aux	67	SENT_641	[p30l231t3268r495b3348],
65	be	VB	O	be	cop	67	SENT_641	[p30l541t3268r636b3347],
66	most	RBS	O	most	advmod	67	SENT_641	[p30l682t3285r897b3347],
67	likely	JJ	O	likely	rcmod	62	SENT_641	[p30l936t3268r1164b3368],
68	to	TO	O	to	aux	69	SENT_641	[p30l1205t3285r1286b3347],
69	benefit	VB	O	benefit	xcomp	67	SENT_641	[p30l1334t3267r1635b3347],
70	from	IN	O	from	_	0	SENT_641	[p30l1675t3267r1884b3347],
71	treatment	NN	O	treatment	prep_from	69	SENT_641	[p30l1929t3285r2148b3346, p30l11t3414r231b3475],
72	with	IN	O	with	_	0	SENT_641	[p30l254t3397r448b3476],
73	anti	JJ	O	anti	prep_with	69	SENT_641	[p30l480t3398r929b3480],
74	.	.	O	.	_	0	SENT_641	[p30l480t3398r929b3480],

1	—	NN	O	—	_	0	SENT_642	[p30l480t3398r929b3480],
2	.	.	O	.	_	0	SENT_642	[p30l480t3398r929b3480],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_643	[p30l480t3398r929b3480],
2	drugs	NNS	O	drug	_	0	SENT_643	[p30l952t3397r1217b3498],
3	.	.	O	.	_	0	SENT_643	[p30l952t3397r1217b3498],

1	However	RB	O	however	advmod	18	SENT_644	[p30l1255t3404r1645b3493],
2	,	,	O	,	_	0	SENT_644	[p30l1255t3404r1645b3493],
3	most	JJS	O	most	dobj	9	SENT_644	[p30l1684t3414r1899b3476],
4	avail	NN	O	avail	npadvmod	6	SENT_644	[p30l1926t3397r2148b3476],
5	—	CD	NUMBER	—	num	4	SENT_644	[p30l1926t3397r2148b3476],
6	able	JJ	O	able	amod	3	SENT_644	[p30l11t3524r179b3603],
7	clinical	JJ	O	clinical	amod	8	SENT_644	[p30l231t3524r539b3602],
8	data	NNS	O	datum	nsubj	9	SENT_644	[p30l590t3524r770b3603],
9	are	VBP	O	be	dep	18	SENT_644	[p30l819t3550r947b3602],
10	from	IN	O	from	_	0	SENT_644	[p30l997t3523r1206b3603],
11	retrospective	JJ	O	retrospective	amod	12	SENT_644	[p30l1256t3525r1800b3624],
12	studies	NNS	O	study	prep_from	9	SENT_644	[p30l1852t3524r2148b3603],
13	and	CC	O	and	_	0	SENT_644	[p30l11t3653r167b3732],
14	subgroup	NN	O	subgroup	nn	15	SENT_644	[p30l201t3653r600b3754],
15	analyses	NNS	O	analysis	conj_and	12	SENT_644	[p30l633t3653r1011b3753],
16	;	:	O	;	_	0	SENT_644	[p30l633t3653r1011b3753],
17	there	EX	O	there	expl	18	SENT_644	[p30l1048t3653r1262b3731],
18	is	VBZ	O	be	_	0	SENT_644	[p30l1294t3654r1359b3731],
19	an	DT	O	a	det	21	SENT_644	[p30l1393t3679r1495b3731],
20	urgent	JJ	O	urgent	amod	21	SENT_644	[p30l1528t3670r1808b3754],
21	need	NN	O	need	nsubj	18	SENT_644	[p30l1836t3653r2035b3732],
22	to	TO	O	to	aux	23	SENT_644	[p30l2067t3670r2148b3732],
23	validate	VB	O	validate	infmod	21	SENT_644	[p31l7t20r335b99],
24	these	DT	O	these	det	25	SENT_644	[p31l385t20r605b99],
25	observations	NNS	O	observation	dobj	23	SENT_644	[p31l656t20r1190b99],
26	in	IN	O	in	_	0	SENT_644	[p31l1242t21r1324b98],
27	properly	RB	O	properly	advmod	28	SENT_644	[p31l1372t20r1727b120],
28	designed	VBN	O	design	amod	30	SENT_644	[p31l1772t20r2150b121],
29	prospective	JJ	O	prospective	amod	30	SENT_644	[p31l9t149r492b248],
30	studies	NNS	O	study	prep_in	23	SENT_644	[p31l538t148r858b227],
31	.	.	O	.	_	0	SENT_644	[p31l538t148r858b227],

1	Another	DT	O	another	det	3	SENT_645	[p31l905t148r1257b227],
2	clinical	JJ	O	clinical	amod	3	SENT_645	[p31l1300t148r1608b226],
3	issue	NN	O	issue	nsubj	6	SENT_645	[p31l1652t149r1861b227],
4	is	VBZ	O	be	cop	6	SENT_645	[p31l1905t149r1970b226],
5	the	DT	O	the	det	6	SENT_645	[p31l2018t148r2149b226],
6	need	NN	O	need	_	0	SENT_645	[p31l11t276r211b355],
7	to	TO	O	to	aux	8	SENT_645	[p31l261t293r342b355],
8	determine	VB	O	determine	infmod	6	SENT_645	[p31l394t276r826b355],
9	the	DT	O	the	det	12	SENT_645	[p31l877t276r1008b354],
10	most	RBS	O	most	advmod	11	SENT_645	[p31l1058t293r1273b355],
11	effective	JJ	O	effective	amod	12	SENT_645	[p31l1319t275r1671b356],
12	sequences	NNS	O	sequence	dobj	8	SENT_645	[p31l1722t302r2148b376],
13	and	CC	O	and	_	0	SENT_645	[p31l11t405r167b485],
14	combinations	NNS	O	combination	conj_and	12	SENT_645	[p31l203t405r784b485],
15	of	IN	O	of	_	0	SENT_645	[p31l822t404r922b485],
16	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_645	[p31l937t411r1192b489],
17	inhibitors	NNS	O	inhibitor	prep_of	14	SENT_645	[p31l1216t405r1631b485],
18	to	TO	O	to	aux	19	SENT_645	[p31l1669t422r1750b485],
19	use	VB	O	use	xcomp	8	SENT_645	[p31l1786t432r1926b485],
20	with	IN	O	with	_	0	SENT_645	[p31l1957t405r2151b485],
21	chemotherapy	NN	O	chemotherapy	prep_with	19	SENT_645	[p31l12t534r627b634],
22	,	,	O	,	_	0	SENT_645	[p31l12t534r627b634],
23	radiotherapy	NN	O	radiotherapy	conj_or	21	SENT_645	[p31l681t534r1233b634],
24	,	,	O	,	_	0	SENT_645	[p31l681t534r1233b634],
25	or	CC	O	or	_	0	SENT_645	[p31l1287t560r1375b613],
26	both	DT	O	both	conj_or	21	SENT_645	[p31l1421t534r1617b613],
27	in	IN	O	in	mark	30	SENT_645	[p31l1665t535r1748b612],
28	order	NN	O	order	dep	30	SENT_645	[p31l1797t534r2022b613],
29	to	TO	O	to	aux	30	SENT_645	[p31l2067t551r2148b613],
30	optimize	VB	O	optimize	purpcl	19	SENT_645	[p31l12t663r392b762],
31	cytotoxicity	NN	O	cytotoxicity	nn	32	SENT_645	[p31l457t663r948b762],
32	potentiation	NN	O	potentiation	dobj	30	SENT_645	[p31l1005t663r1550b762],
33	.	.	O	.	_	0	SENT_645	[p31l1005t663r1550b762],

1	In	IN	O	in	_	0	SENT_646	[p31l1619t670r1707b740],
2	fact	NN	O	fact	prep_in	14	SENT_646	[p31l1772t661r1948b758],
3	,	,	O	,	_	0	SENT_646	[p31l1772t661r1948b758],
4	the	DT	O	the	det	5	SENT_646	[p31l2018t662r2149b740],
5	schedules	NNS	O	schedule	nsubj	14	SENT_646	[p31l12t792r421b872],
6	that	WDT	O	that	nsubjpass	9	SENT_646	[p31l464t792r634b871],
7	have	VBP	O	have	aux	9	SENT_646	[p31l670t792r857b872],
8	been	VBN	O	be	auxpass	9	SENT_646	[p31l900t792r1099b872],
9	tested	VBN	O	test	rcmod	5	SENT_646	[p31l1140t792r1390b872],
10	so	RB	O	so	advmod	11	SENT_646	[p31l1432t818r1522b872],
11	far	RB	O	far	advmod	9	SENT_646	[p31l1564t791r1683b871],
12	have	VBP	O	have	aux	14	SENT_646	[p31l1720t792r1909b872],
13	been	VBN	O	be	aux	14	SENT_646	[p31l1950t792r2149b872],
14	based	VBN	O	base	_	0	SENT_646	[p31l12t920r254b999],
15	on	IN	O	on	_	0	SENT_646	[p31l294t946r400b999],
16	the	DT	O	the	det	18	SENT_646	[p31l441t920r573b998],
17	empirical	JJ	O	empirical	amod	18	SENT_646	[p31l614t920r1013b1020],
18	association	NN	O	association	prep_on	14	SENT_646	[p31l1052t921r1529b999],
19	of	IN	O	of	_	0	SENT_646	[p31l1570t919r1670b999],
20	a	DT	O	a	det	23	SENT_646	[p31l1690t946r1735b998],
21	standard	JJ	O	standard	amod	23	SENT_646	[p31l1776t920r2149b999],
22	chemotherapy	NN	O	chemotherapy	nn	23	SENT_646	[p31l12t1049r615b1149],
23	regimen	NN	O	regimen	prep_of	18	SENT_646	[p31l663t1050r1016b1150],
24	with	IN	O	with	_	0	SENT_646	[p31l1064t1049r1257b1128],
25	the	DT	O	the	det	27	SENT_646	[p31l1310t1049r1442b1128],
26	continuous	JJ	O	continuous	amod	27	SENT_646	[p31l1495t1050r1967b1128],
27	administration	NN	O	administration	prep_with	14	SENT_646	[p31l2021t1049r2148b1128, p31l11t1178r545b1257],
28	of	IN	O	of	_	0	SENT_646	[p31l607t1176r706b1257],
29	an	DT	O	a	det	31	SENT_646	[p31l749t1203r851b1256],
30	EGFR-targeting	JJ	O	egfr-targeting	amod	31	SENT_646	[p31l911t1178r1578b1279],
31	drug	NN	O	drug	prep_of	27	SENT_646	[p31l1637t1177r1839b1279],
32	rather	RB	O	rather	_	0	SENT_646	[p31l1897t1177r2153b1256],
33	than	IN	O	than	_	0	SENT_646	[p31l12t1305r206b1383],
34	derived	VBN	O	derive	conj_negcc	14	SENT_646	[p31l264t1305r569b1385],
35	from	IN	O	from	_	0	SENT_646	[p31l626t1304r834b1384],
36	molecular	JJ	O	molecular	amod	42	SENT_646	[p31l892t1305r1336b1401],
37	,	,	O	,	_	0	SENT_646	[p31l892t1305r1336b1401],
38	pharmacokinetic	JJ	O	pharmacokinetic	amod	42	SENT_646	[p31l1398t1305r2144b1405],
39	,	,	O	,	_	0	SENT_646	[p31l1398t1305r2144b1405],
40	and	CC	O	and	_	0	SENT_646	[p31l11t1434r167b1513],
41	pharmacodynamic	JJ	O	pharmacodynamic	amod	42	SENT_646	[p31l198t1434r1000b1534],
42	studies	NNS	O	study	prep_from	14	SENT_646	[p31l1034t1434r1353b1513],
43	.	.	O	.	_	0	SENT_646	[p31l1034t1434r1353b1513],

1	Supported	VBN	O	support	_	0	SENT_647	[p31l98t1583r438b1659],
2	in	IN	O	in	_	0	SENT_647	[p31l462t1584r526b1642],
3	part	NN	O	part	prep_in	1	SENT_647	[p31l549t1596r688b1659],
4	by	IN	O	by	_	0	SENT_647	[p31l709t1583r784b1659],
5	grants	NNS	O	grant	prep_by	1	SENT_647	[p31l805t1596r1016b1659],
6	from	IN	O	from	_	0	SENT_647	[p31l1042t1582r1203b1642],
7	Associazione	NNP	LOCATION	Associazione	nn	8	SENT_647	[p31l1225t1584r1662b1642],
8	Italiana	NNP	LOCATION	Italiana	prep_from	1	SENT_647	[p31l1686t1583r1943b1642],
9	per	IN	O	per	_	0	SENT_647	[p31l1965t1603r2073b1659],
10	la	NNP	O	la	prep_per	8	SENT_647	[p31l2094t1583r2152b1642],

1	Ricerca	NNP	PERSON	Ricerca	nn	2	SENT_648	[p31l9t1668r254b1730],
2	sul	NN	O	sul	_	0	SENT_648	[p31l280t1668r374b1727],
3	Cancro	NNP	PERSON	Cancro	dep	2	SENT_648	[p31l399t1672r651b1727],
4	.	.	O	.	_	0	SENT_648	[p31l399t1672r651b1727],

1	Dr.	NNP	O	Dr.	nn	2	SENT_649	[p31l95t1760r193b1814],
2	Ciardiello	NNP	PERSON	Ciardiello	nsubj	3	SENT_649	[p31l233t1755r557b1814],
3	reports	VBZ	O	report	_	0	SENT_649	[p31l593t1768r829b1831],
4	receiving	VBG	O	receive	xcomp	3	SENT_649	[p31l866t1756r1168b1831],
5	consulting	NN	O	consulting	nn	6	SENT_649	[p31l1200t1755r1555b1831],
6	fees	NNS	O	fee	dobj	4	SENT_649	[p31l1587t1754r1714b1814],
7	from	IN	O	from	_	0	SENT_649	[p31l1751t1754r1912b1814],
8	Merck	NNP	ORGANIZATION	Merck	nn	9	SENT_649	[p31l1945t1755r2153b1815],
9	Serono	NNP	ORGANIZATION	Serono	prep_from	6	SENT_649	[p31l12t1847r255b1915],
10	,	,	O	,	_	0	SENT_649	[p31l12t1847r255b1915],
11	Roche	NNP	PERSON	Roche	prep_from	6	SENT_649	[p31l295t1843r518b1915],
12	,	,	O	,	_	0	SENT_649	[p31l295t1843r518b1915],
13	and	CC	O	and	_	0	SENT_649	[p31l559t1843r680b1902],
14	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	prep_from	6	SENT_649	[p31l714t1848r1128b1902],
15	and	CC	O	and	_	0	SENT_649	[p31l1163t1843r1285b1902],
16	lecture	NN	O	lecture	nn	17	SENT_649	[p31l1321t1843r1546b1903],
17	fees	NNS	O	fee	conj_and	6	SENT_649	[p31l1583t1842r1710b1902],
18	from	IN	O	from	_	0	SENT_649	[p31l1749t1842r1910b1902],
19	Merck	NNP	ORGANIZATION	Merck	nn	20	SENT_649	[p31l1945t1843r2153b1903],
20	Serono	NNP	ORGANIZATION	Serono	prep_from	17	SENT_649	[p31l12t1933r255b2000],
21	,	,	O	,	_	0	SENT_649	[p31l12t1933r255b2000],
22	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	prep_from	17	SENT_649	[p31l298t1934r730b2000],
23	,	,	O	,	_	0	SENT_649	[p31l298t1934r730b2000],
24	and	CC	O	and	_	0	SENT_649	[p31l775t1929r896b1987],
25	GlaxoSmithKline	NNP	ORGANIZATION	GlaxoSmithKline	prep_from	17	SENT_649	[p31l939t1929r1533b2000],
26	;	:	O	;	_	0	SENT_649	[p31l939t1929r1533b2000],
27	and	CC	O	and	_	0	SENT_649	[p31l1577t1929r1698b1987],
28	Dr.	NNP	O	Dr.	nn	34	SENT_649	[p31l1739t1934r1837b1987],
29	Tortora	NNP	PERSON	Tortora	nn	34	SENT_649	[p31l1880t1933r2146b2000],
30	,	,	O	,	_	0	SENT_649	[p31l1880t1933r2146b2000],
31	consulting	VBG	O	consult	amod	29	SENT_649	[p31l11t2016r365b2092],
32	and	CC	O	and	_	0	SENT_649	[p31l406t2016r527b2075],
33	lecture	NN	O	lecture	nn	34	SENT_649	[p31l571t2016r796b2076],
34	fees	NNS	O	fee	dobj	4	SENT_649	[p31l841t2015r968b2075],
35	from	IN	O	from	_	0	SENT_649	[p31l1013t2015r1175b2075],
36	Merck	NNP	ORGANIZATION	Merck	nn	37	SENT_649	[p31l1217t2016r1425b2076],
37	Serono	NNP	ORGANIZATION	Serono	prep_from	34	SENT_649	[p31l1468t2020r1712b2088],
38	,	,	O	,	_	0	SENT_649	[p31l1468t2020r1712b2088],
39	Roche	NNP	PERSON	Roche	conj_and	37	SENT_649	[p31l1759t2016r1982b2088],
40	,	,	O	,	_	0	SENT_649	[p31l1759t2016r1982b2088],
41	and	CC	O	and	_	0	SENT_649	[p31l2030t2016r2151b2075],
42	GlaXoSmithKline	NNP	ORGANIZATION	GlaXoSmithKline	conj_and	37	SENT_649	[p31l11t2104r605b2165],
43	.	.	O	.	_	0	SENT_649	[p31l11t2104r605b2165],

1	Roche	NNP	PERSON	Roche	nsubj	4	SENT_650	[p31l639t2104r844b2167],
2	is	VBZ	O	be	cop	4	SENT_650	[p31l875t2105r926b2163],
3	the	DT	O	the	det	4	SENT_650	[p31l959t2104r1061b2163],
4	manufacturer	NN	O	manufacturer	_	0	SENT_650	[p31l1093t2103r1549b2164],
5	of	IN	O	of	_	0	SENT_650	[p31l1578t2103r1655b2163],
6	erlotinib	NN	O	erlotinib	nn	9	SENT_650	[p31l1673t2104r1957b2163],
7	(	CD	NUMBER	(	num	9	SENT_650	[p31l1994t2109r2149b2173, p31l11t2196r189b2260],
8	Tarceva	NNP	O	Tarceva	nn	9	SENT_650	[p31l1994t2109r2149b2173, p31l11t2196r189b2260],
9	)	NN	O	)	prep_of	4	SENT_650	[p31l1994t2109r2149b2173, p31l11t2196r189b2260],
10	.	.	O	.	_	0	SENT_650	[p31l1994t2109r2149b2173, p31l11t2196r189b2260],

1	No	DT	O	no	det	4	SENT_651	[p31l220t2196r315b2251],
2	other	JJ	O	other	amod	4	SENT_651	[p31l346t2191r521b2250],
3	potential	JJ	O	potential	amod	4	SENT_651	[p31l546t2191r846b2267],
4	conflict	NN	O	conflict	nsubjpass	12	SENT_651	[p31l875t2190r1134b2250],
5	of	IN	O	of	_	0	SENT_651	[p31l1160t2190r1237b2250],
6	interest	NN	O	interest	prep_of	4	SENT_651	[p31l1251t2192r1503b2250],
7	relevant	JJ	O	relevant	amod	6	SENT_651	[p31l1528t2191r1791b2251],
8	to	TO	O	to	_	0	SENT_651	[p31l1816t2204r1879b2250],
9	this	DT	O	this	det	10	SENT_651	[p31l1908t2191r2031b2250],
10	article	NN	O	article	prep_to	7	SENT_651	[p31l2061t2211r2149b2250, p31l11t2278r147b2336],
11	was	VBD	O	be	auxpass	12	SENT_651	[p31l169t2297r294b2338],
12	reported	VBN	O	report	_	0	SENT_651	[p31l321t2278r623b2353],
13	.	.	O	.	_	0	SENT_651	[p31l321t2278r623b2353],

1	REFERENCES	NNS	O	reference	_	0	SENT_652	[p31l12t2454r336b2485],
2	1	CD	NUMBER	1	num	1	SENT_652	[p31l10t2518r47b2557],
3	.	.	O	.	_	0	SENT_652	[p31l10t2518r47b2557],

1	Sporn	NNP	O	Sporn	nn	2	SENT_653	[p31l106t2516r250b2569],
2	MB	NNP	O	MB	_	0	SENT_653	[p31l276t2516r373b2566],
3	,	,	O	,	_	0	SENT_653	[p31l276t2516r373b2566],
4	Todaro	NNP	PERSON	Todaro	nn	6	SENT_653	[p31l402t2513r576b2557],
5	G	NNP	O	G	nn	6	SENT_653	[p31l605t2516r674b2564],
6	]	NN	O	]	appos	2	SENT_653	[p31l605t2516r674b2564],
7	.	.	O	.	_	0	SENT_653	[p31l605t2516r674b2564],

1	Autocrine	NN	O	autocrine	nn	2	SENT_654	[p31l703t2513r945b2557],
2	secretion	NN	O	secretion	_	0	SENT_654	[p31l974t2527r1041b2557, p31l9t2584r180b2628],
3	and	CC	O	and	_	0	SENT_654	[p31l203t2584r293b2628],
4	malignant	JJ	O	malignant	amod	5	SENT_654	[p31l317t2584r574b2640],
5	transformation	NN	O	transformation	conj_and	2	SENT_654	[p31l595t2583r972b2628],
6	of	IN	O	of	_	0	SENT_654	[p31l996t2583r1052b2628],
7	cells	NNS	O	cell	prep_of	2	SENT_654	[p31l9t2654r131b2699],
8	.	.	O	.	_	0	SENT_654	[p31l9t2654r131b2699],

1	N	NN	O	n	nn	3	SENT_655	[p31l152t2659r194b2699],
2	Engll	NNP	O	Engll	nn	3	SENT_655	[p31l212t2655r357b2711],
3	Med	NNP	O	Med	_	0	SENT_655	[p31l374t2654r480b2699],
4	1980	CD	DATE	1980	num	3	SENT_655	[p31l501t2658r918b2708],
5	;	:	O	;	_	0	SENT_655	[p31l501t2658r918b2708],
6	303:878	CD	NUMBER	303:878	number	7	SENT_655	[p31l501t2658r918b2708],
7	-80	CD	NUMBER	-80	dep	3	SENT_655	[p31l501t2658r918b2708],
8	.	.	O	.	_	0	SENT_655	[p31l501t2658r918b2708],

1	2	LS	NUMBER	2	_	0	SENT_656	[p31l8t2731r48b2770],
2	.	.	O	.	_	0	SENT_656	[p31l8t2731r48b2770],

1	Salomon	NNP	O	Salomon	nn	2	SENT_657	[p31l106t2725r321b2770],
2	DS	NN	O	d	_	0	SENT_657	[p31l348t2729r429b2779],
3	,	,	O	,	_	0	SENT_657	[p31l348t2729r429b2779],
4	Brandt	NNP	PERSON	Brandt	nn	5	SENT_657	[p31l460t2726r627b2770],
5	R	NNP	PERSON	R	appos	2	SENT_657	[p31l652t2729r701b2779],
6	,	,	O	,	_	0	SENT_657	[p31l652t2729r701b2779],
7	Ciardiello	NNP	PERSON	Ciardiello	nn	8	SENT_657	[p31l732t2725r973b2770],
8	F	NN	O	f	appos	2	SENT_657	[p31l1001t2730r1039b2779],
9	,	,	O	,	_	0	SENT_657	[p31l1001t2730r1039b2779],
10	Normanno	NNP	O	Normanno	nn	13	SENT_657	[p31l7t2801r277b2841],
11	N.	NNP	O	N.	nn	13	SENT_657	[p31l306t2801r359b2841],
12	Epidermal	NNP	O	Epidermal	nn	13	SENT_657	[p31l390t2796r644b2853],
13	growth	NN	O	growth	appos	2	SENT_657	[p31l673t2796r852b2853],
14	factorrelated	VBN	O	factorrelate	partmod	13	SENT_657	[p31l881t2796r1041b2841, p31l8t2867r176b2912],
15	peptides	NNS	O	peptide	dobj	14	SENT_657	[p31l191t2868r399b2924],
16	and	CC	O	and	_	0	SENT_657	[p31l416t2867r506b2912],
17	their	PRP$	O	they	poss	18	SENT_657	[p31l523t2867r640b2912],
18	receptors	NNS	O	receptor	dobj	14	SENT_657	[p31l654t2877r881b2924],
19	in	IN	O	in	_	0	SENT_657	[p31l899t2868r946b2911],
20	human	JJ	O	human	amod	21	SENT_657	[p31l963t2867r1041b2912, p31l8t2953r117b2982],
21	malignancies	NNS	O	malignancy	prep_in	14	SENT_657	[p31l135t2938r480b2995],
22	.	.	O	.	_	0	SENT_657	[p31l135t2938r480b2995],

1	Crit	NNP	O	Crit	nn	4	SENT_658	[p31l502t2939r594b2983],
2	Rev	NN	O	rev	nn	4	SENT_658	[p31l609t2942r699b2985],
3	Oncol	NNP	O	Oncol	nn	4	SENT_658	[p31l715t2938r860b2983],
4	Hematol	NNP	O	Hematol	_	0	SENT_658	[p31l878t2943r1041b2983, p31l9t3011r72b3055],
5	1995	CD	DATE	1995	num	4	SENT_658	[p31l93t3014r504b3064],
6	;	:	O	;	_	0	SENT_658	[p31l93t3014r504b3064],
7	19:183	CD	NUMBER	19:183	number	8	SENT_658	[p31l93t3014r504b3064],
8	-232	CD	NUMBER	-232	dep	4	SENT_658	[p31l93t3014r504b3064],
9	.	.	O	.	_	0	SENT_658	[p31l93t3014r504b3064],

1	3	LS	NUMBER	3	_	0	SENT_659	[p31l9t3086r46b3125],
2	.	.	O	.	_	0	SENT_659	[p31l9t3086r46b3125],

1	Citri	NNP	MISC	Citri	nn	2	SENT_660	[p31l105t3081r214b3125],
2	A	NNP	MISC	A	_	0	SENT_660	[p31l239t3085r289b3134],
3	,	,	O	,	_	0	SENT_660	[p31l239t3085r289b3134],
4	Yarden	NNP	PERSON	Yarden	nn	6	SENT_660	[p31l318t3080r488b3125],
5	Y.	NNP	PERSON	Y.	nn	6	SENT_660	[p31l513t3085r554b3125],
6	EGF	NN	O	egf	appos	2	SENT_660	[p31l585t3084r846b3127],
7	.	.	O	.	_	0	SENT_660	[p31l585t3084r846b3127],

1	—	NN	O	—	_	0	SENT_661	[p31l585t3084r846b3127],
2	.	.	O	.	_	0	SENT_661	[p31l585t3084r846b3127],

1	ERBB	NN	ORGANIZATION	erbb	nn	2	SENT_662	[p31l585t3084r846b3127],
2	signalling	NN	O	signalling	_	0	SENT_662	[p31l875t3081r1041b3137, p31l8t3153r117b3209],
3	:	:	O	:	_	0	SENT_662	[p31l875t3081r1041b3137, p31l8t3153r117b3209],
4	towards	IN	O	towards	_	0	SENT_662	[p31l146t3153r342b3197],
5	the	DT	O	the	det	7	SENT_662	[p31l370t3153r445b3196],
6	systems	NNS	O	system	nn	7	SENT_662	[p31l474t3161r665b3209],
7	level	NN	O	level	prep_towards	2	SENT_662	[p31l692t3152r814b3197],
8	.	.	O	.	_	0	SENT_662	[p31l692t3152r814b3197],

1	Nat	NNP	O	Nat	nn	5	SENT_663	[p31l843t3157r931b3197],
2	Rev	NN	O	rev	nn	5	SENT_663	[p31l955t3156r1044b3199],
3	Mol	NNP	O	Mol	nn	5	SENT_663	[p31l7t3224r102b3268],
4	Cell	NNP	O	Cell	nn	5	SENT_663	[p31l121t3224r216b3268],
5	Biol	NNP	O	Biol	_	0	SENT_663	[p31l234t3224r329b3268],
6	2006	CD	DATE	2006	num	5	SENT_663	[p31l348t3227r700b3277],
7	;	:	O	;	_	0	SENT_663	[p31l348t3227r700b3277],
8	7:505	CD	NUMBER	7:505	number	9	SENT_663	[p31l348t3227r700b3277],
9	—	CD	NUMBER	—	dep	5	SENT_663	[p31l348t3227r700b3277],
10	16	CD	NUMBER	16	dep	9	SENT_663	[p31l348t3227r700b3277],
11	.	.	O	.	_	0	SENT_663	[p31l348t3227r700b3277],

1	4	LS	NUMBER	4	_	0	SENT_664	[p31l7t3300r47b3339],
2	.	.	O	.	_	0	SENT_664	[p31l7t3300r47b3339],

1	Hynes	NNP	PERSON	Hynes	nn	2	SENT_665	[p31l104t3299r255b3351],
2	NH	NNP	O	NH	_	0	SENT_665	[p31l276t3299r375b3348],
3	,	,	O	,	_	0	SENT_665	[p31l276t3299r375b3348],
4	Lane	NNP	PERSON	Lane	nn	5	SENT_665	[p31l399t3299r516b3339],
5	HA	NNP	O	HA	appos	2	SENT_665	[p31l537t3299r630b3339],
6	.	.	O	.	_	0	SENT_665	[p31l537t3299r630b3339],

1	ERBB	NN	O	erbb	nn	2	SENT_666	[p31l654t3298r792b3341],
2	receptors	NNS	O	receptor	_	0	SENT_666	[p31l814t3304r1041b3351],
3	and	CC	O	and	_	0	SENT_666	[p31l8t3365r98b3410],
4	cancer	NN	O	cancer	conj_and	2	SENT_666	[p31l116t3380r289b3410],
5	:	:	O	:	_	0	SENT_666	[p31l116t3380r289b3410],
6	the	DT	O	the	det	7	SENT_666	[p31l310t3365r385b3409],
7	complexity	NN	O	complexity	dep	2	SENT_666	[p31l404t3365r674b3422],
8	of	IN	O	of	_	0	SENT_666	[p31l690t3365r747b3410],
9	targeted	VBN	O	target	amod	10	SENT_666	[p31l755t3366r958b3422],
10	inhibitors	NNS	O	inhibitor	prep_of	7	SENT_666	[p31l976t3366r1041b3409, p31l8t3437r214b3481],
11	.	.	O	.	_	0	SENT_666	[p31l976t3366r1041b3409, p31l8t3437r214b3481],

1	Nat	NNP	O	Nat	nn	3	SENT_667	[p31l235t3441r323b3481],
2	Rev	NN	O	rev	nn	3	SENT_667	[p31l339t3440r428b3483],
3	Cancer	NN	O	cancer	_	0	SENT_667	[p31l446t3440r616b3481],
4	2005	CD	DATE	2005	dep	3	SENT_667	[p31l634t3440r988b3490],
5	;	:	O	;	_	0	SENT_667	[p31l634t3440r988b3490],
6	5:341	CD	NUMBER	5:341	num	7	SENT_667	[p31l634t3440r988b3490],
7	-54	CD	NUMBER	-54	dep	3	SENT_667	[p31l634t3440r988b3490],
8	.	.	O	.	_	0	SENT_667	[p31l634t3440r988b3490],

1	5	CD	NUMBER	5	_	0	SENT_668	[p31l9t3513r46b3552],
2	.	.	O	.	_	0	SENT_668	[p31l9t3513r46b3552],

1	Normanno	NNP	O	Normanno	nn	2	SENT_669	[p31l104t3512r374b3552],
2	N	NNP	O	N	_	0	SENT_669	[p31l401t3512r455b3561],
3	,	,	O	,	_	0	SENT_669	[p31l401t3512r455b3561],
4	Bianco	NNP	PERSON	Bianco	nn	5	SENT_669	[p31l485t3508r652b3552],
5	C	NNP	O	C	conj_and	2	SENT_669	[p31l680t3511r727b3561],
6	,	,	O	,	_	0	SENT_669	[p31l680t3511r727b3561],
7	De	NNP	PERSON	De	nn	9	SENT_669	[p31l757t3511r823b3552],
8	Luca	NNP	PERSON	Luca	nn	9	SENT_669	[p31l850t3512r964b3552],
9	A	NNP	O	A	conj_and	2	SENT_669	[p31l989t3512r1039b3561],
10	,	,	O	,	_	0	SENT_669	[p31l989t3512r1039b3561],
11	Maiello	NNP	PERSON	Maiello	nn	12	SENT_669	[p31l7t3579r191b3623],
12	MR	NN	PERSON	mr	conj_and	2	SENT_669	[p31l223t3582r324b3632],
13	,	,	O	,	_	0	SENT_669	[p31l223t3582r324b3632],
14	Salomon	NNP	O	Salomon	nn	15	SENT_669	[p31l361t3579r576b3623],
15	DS	NN	O	d	conj_and	2	SENT_669	[p31l608t3582r690b3623],
16	,	,	O	,	_	0	SENT_669	[p31l608t3582r690b3623],
17	Target-based	JJ	MISC	target-based	amod	18	SENT_669	[p31l725t3578r1042b3635],
18	agents	NNS	O	agent	conj_and	2	SENT_669	[p31l8t3659r166b3706],
19	against	IN	O	against	_	0	SENT_669	[p31l196t3650r377b3706],
20	ErbB	NN	O	erbb	nn	21	SENT_669	[p31l403t3650r519b3694],
21	receptors	NNS	O	receptor	prep_against	18	SENT_669	[p31l550t3659r777b3706],
22	and	CC	O	and	_	0	SENT_669	[p31l808t3649r897b3694],
23	their	PRP$	O	they	poss	24	SENT_669	[p31l927t3650r1044b3694],
24	ligands	NNS	O	ligand	conj_and	2	SENT_669	[p31l8t3721r201b3777],
25	:	:	O	:	_	0	SENT_669	[p31l8t3721r201b3777],
26	a	DT	O	a	det	28	SENT_669	[p31l224t3735r249b3764],
27	novel	JJ	O	novel	amod	28	SENT_669	[p31l269t3721r398b3765],
28	approach	NN	O	approach	dep	2	SENT_669	[p31l418t3721r644b3777],
29	to	TO	O	to	_	0	SENT_669	[p31l665t3730r711b3765],
30	cancer	NN	O	cancer	nn	31	SENT_669	[p31l733t3735r894b3765],
31	treatnisms	NNS	O	treatnism	prep_to	28	SENT_669	[p31l913t3730r1041b3765, p31l1118t2513r1264b2556],
32	for	IN	O	for	_	0	SENT_669	[p31l1284t2512r1354b2557],
33	oncogenic	JJ	O	oncogenic	amod	34	SENT_669	[p31l1372t2513r1623b2569],
34	activation	NN	O	activation	prep_for	31	SENT_669	[p31l1642t2513r1881b2557],
35	of	IN	O	of	_	0	SENT_669	[p31l1901t2512r1957b2557],
36	the	DT	O	the	det	40	SENT_669	[p31l1966t2513r2042b2556],
37	epidermal	JJ	O	epidermal	amod	40	SENT_669	[p31l2061t2513r2150b2569, p31l1118t2584r1291b2628],
38	growth	NN	O	growth	nn	40	SENT_669	[p31l1318t2584r1497b2640],
39	factor	NN	O	factor	nn	40	SENT_669	[p31l1524t2583r1668b2628],
40	receptor	NN	O	receptor	prep_of	34	SENT_669	[p31l1693t2593r1908b2640],
41	.	.	O	.	_	0	SENT_669	[p31l1693t2593r1908b2640],

1	Cell	NN	O	cell	nn	2	SENT_670	[p31l1938t2583r2033b2628],
2	Signal	NN	O	signal	_	0	SENT_670	[p31l2061t2584r2150b2640, p31l1118t2655r1194b2698],
3	2007	CD	DATE	2007	dep	2	SENT_670	[p31l1213t2658r1625b2708],
4	;	:	O	;	_	0	SENT_670	[p31l1213t2658r1625b2708],
5	19:2013	CD	NUMBER	19:2013	num	6	SENT_670	[p31l1213t2658r1625b2708],
6	-23	CD	NUMBER	-23	dep	2	SENT_670	[p31l1213t2658r1625b2708],
7	.	.	O	.	_	0	SENT_670	[p31l1213t2658r1625b2708],

1	8	CD	NUMBER	8	_	0	SENT_671	[p31l1117t2730r1157b2770],
2	.	.	O	.	_	0	SENT_671	[p31l1117t2730r1157b2770],

1	Godin-Heymann	NNP	PERSON	Godin-Heymann	nn	2	SENT_672	[p31l1214t2726r1630b2782],
2	N	NNP	PERSON	N	_	0	SENT_672	[p31l1659t2730r1713b2779],
3	,	,	O	,	_	0	SENT_672	[p31l1659t2730r1713b2779],
4	Bryant	NNP	PERSON	Bryant	appos	2	SENT_672	[p31l1746t2729r1908b2782],
5	1	CD	NUMBER	1	num	4	SENT_672	[p31l1935t2730r1965b2779],
6	,	,	O	,	_	0	SENT_672	[p31l1935t2730r1965b2779],
7	Rivera	NNP	PERSON	Rivera	nn	8	SENT_672	[p31l1998t2726r2152b2772],
8	MN	NN	O	mn	appos	2	SENT_672	[p31l1116t2801r1220b2850],
9	,	,	O	,	_	0	SENT_672	[p31l1116t2801r1220b2850],
10	et	FW	O	et	nn	11	SENT_672	[p31l1240t2806r1284b2841],
11	al.	FW	O	al.	appos	2	SENT_672	[p31l1297t2797r1352b2841],
12	.	.	O	.	_	0	SENT_672	[p31l1297t2797r1352b2841],

1	Oncogenic	JJ	O	oncogenic	amod	2	SENT_673	[p31l1371t2797r1635b2853],
2	activity	NN	O	activity	nsubjpass	12	SENT_673	[p31l1649t2797r1828b2853],
3	of	IN	O	of	_	0	SENT_673	[p31l1841t2796r1898b2841],
4	epidermal	JJ	O	epidermal	amod	10	SENT_673	[p31l1904t2796r2152b2853],
5	growth	NN	O	growth	nn	10	SENT_673	[p31l1117t2868r1297b2924],
6	factor	NN	O	factor	nn	10	SENT_673	[p31l1320t2867r1463b2912],
7	receptor	NN	O	receptor	nn	10	SENT_673	[p31l1484t2877r1688b2924],
8	kinase	NN	O	kinase	nn	10	SENT_673	[p31l1709t2868r1869b2912],
9	mutant	JJ	O	mutant	amod	10	SENT_673	[p31l1892t2877r2071b2912],
10	alleles	NNS	O	allele	prep_of	2	SENT_673	[p31l2090t2868r2150b2911, p31l1117t2939r1224b2983],
11	is	VBZ	O	be	auxpass	12	SENT_673	[p31l1249t2939r1287b2982],
12	enhanced	VBN	O	enhance	_	0	SENT_673	[p31l1313t2938r1549b2983],
13	by	IN	O	by	_	0	SENT_673	[p31l1574t2938r1629b2995],
14	the	DT	O	the	det	18	SENT_673	[p31l1651t2938r1727b2983],
15	T79OM	NN	O	t79om	nn	18	SENT_673	[p31l1750t2942r1922b2983],
16	drug	NN	O	drug	nn	18	SENT_673	[p31l1947t2939r2064b2995],
17	resistance	NN	O	resistance	nn	18	SENT_673	[p31l2086t2953r2150b2983, p31l1118t3011r1315b3054],
18	mutation	NN	O	mutation	agent	12	SENT_673	[p31l1349t3011r1588b3055],
19	.	.	O	.	_	0	SENT_673	[p31l1349t3011r1588b3055],

1	Cancer	NN	O	cancer	_	0	SENT_674	[p31l1625t3014r1796b3055],
2	Res	NNP	O	Res	dep	1	SENT_674	[p31l1828t3014r1914b3057],
3	2007	CD	DATE	2007	num	2	SENT_674	[p31l1950t3014r2149b3064],
4	;	:	O	;	_	0	SENT_674	[p31l1950t3014r2149b3064],
5	67	CD	NUMBER	67	num	7	SENT_674	[p31l1950t3014r2149b3064],
6	:	:	O	:	_	0	SENT_674	[p31l1950t3014r2149b3064],
7	7319-26	CD	NUMBER	7319-26	dep	1	SENT_674	[p31l1118t3084r1322b3125],
8	.	.	O	.	_	0	SENT_674	[p31l1118t3084r1322b3125],

1	9	CD	NUMBER	9	_	0	SENT_675	[p31l1117t3158r1155b3197],
2	.	.	O	.	_	0	SENT_675	[p31l1117t3158r1155b3197],

1	Padron	NNP	PERSON	Padron	nn	2	SENT_676	[p31l1213t3151r1387b3197],
2	D	NNP	PERSON	D	_	0	SENT_676	[p31l1415t3156r1466b3206],
3	,	,	O	,	_	0	SENT_676	[p31l1415t3156r1466b3206],
4	Sato	NNP	PERSON	Sato	nn	5	SENT_676	[p31l1499t3156r1601b3197],
5	M	NNP	O	M	appos	2	SENT_676	[p31l1629t3157r1691b3206],
6	,	,	O	,	_	0	SENT_676	[p31l1629t3157r1691b3206],
7	Shay	NNP	PERSON	Shay	nn	8	SENT_676	[p31l1724t3153r1836b3209],
8	JW	NNP	O	JW	appos	5	SENT_676	[p31l1857t3157r1941b3206],
9	,	,	O	,	_	0	SENT_676	[p31l1857t3157r1941b3206],
10	Gadzar	NNP	O	Gadzar	nn	11	SENT_676	[p31l1973t3152r2153b3197],
11	AF	NNP	O	AF	appos	5	SENT_676	[p31l1116t3228r1194b3277],
12	,	,	O	,	_	0	SENT_676	[p31l1116t3228r1194b3277],
13	Minna	NNP	PERSON	Minna	nn	14	SENT_676	[p31l1245t3224r1406b3267],
14	JD	NNP	PERSON	JD	appos	5	SENT_676	[p31l1449t3227r1523b3277],
15	,	,	O	,	_	0	SENT_676	[p31l1449t3227r1523b3277],
16	Roth	NNP	PERSON	Roth	nn	17	SENT_676	[p31l1575t3224r1695b3270],
17	MG	NN	O	mg	appos	5	SENT_676	[p31l1743t3227r1846b3268],
18	.	.	O	.	_	0	SENT_676	[p31l1743t3227r1846b3268],

1	Epidermal	JJ	O	epidermal	amod	4	SENT_677	[p31l1898t3223r2152b3280],
2	growth	NN	O	growth	nn	4	SENT_677	[p31l1117t3295r1297b3351],
3	factor	NN	O	factor	nn	4	SENT_677	[p31l1319t3294r1463b3339],
4	receptors	NNS	O	receptor	nsubj	10	SENT_677	[p31l1484t3304r1711b3351],
5	with	IN	O	with	_	0	SENT_677	[p31l1732t3294r1843b3339],
6	tyrosine	NN	O	tyrosine	nn	9	SENT_677	[p31l1866t3295r2065b3351],
7	kinase	NN	O	kinase	nn	9	SENT_677	[p31l2087t3294r2150b3339, p31l1118t3380r1227b3410],
8	domain	NN	O	domain	nn	9	SENT_677	[p31l1259t3366r1448b3410],
9	mutations	NNS	O	mutation	prep_with	4	SENT_677	[p31l1478t3366r1727b3410],
10	exhibit	VBP	O	exhibit	_	0	SENT_677	[p31l1760t3365r1930b3410],
11	reduced	VBN	O	reduce	amod	13	SENT_677	[p31l1959t3365r2151b3410],
12	Cbl	NN	O	cbl	nn	13	SENT_677	[p31l1118t3436r1199b3481],
13	association	NN	O	association	dobj	10	SENT_677	[p31l1221t3437r1512b3490],
14	,	,	O	,	_	0	SENT_677	[p31l1221t3437r1512b3490],
15	poor	JJ	O	poor	amod	16	SENT_677	[p31l1538t3451r1654b3493],
16	ubiquitylation	NN	O	ubiquitylation	conj_and	13	SENT_677	[p31l1676t3437r2035b3493],
17	,	,	O	,	_	0	SENT_677	[p31l1676t3437r2035b3493],
18	and	CC	O	and	_	0	SENT_677	[p31l2061t3436r2151b3481],
19	down-regulation	NN	O	down-regulation	dobj	10	SENT_677	[p31l1118t3508r1531b3564],
20	but	CC	O	but	_	0	SENT_677	[p31l1553t3508r1633b3552],
21	are	VBP	O	be	conj_but	10	SENT_677	[p31l1652t3522r1726b3552],
22	efficiently	RB	O	efficiently	advmod	21	SENT_677	[p31l1749t3507r1999b3564],
23	internalized	VBN	O	internalize	dep	22	SENT_677	[p31l2018t3508r2150b3552, p31l1118t3578r1313b3623],
24	.	.	O	.	_	0	SENT_677	[p31l2018t3508r2150b3552, p31l1118t3578r1313b3623],

1	Cancer	NN	O	cancer	_	0	SENT_678	[p31l1335t3582r1506b3623],
2	Res	NNP	O	Res	dep	1	SENT_678	[p31l1523t3582r1609b3625],
3	2007	CD	DATE	2007	num	2	SENT_678	[p31l1630t3582r2062b3632],
4	;	:	O	;	_	0	SENT_678	[p31l1630t3582r2062b3632],
5	67:7695	CD	NUMBER	67:7695	num	6	SENT_678	[p31l1630t3582r2062b3632],
6	-702	CD	NUMBER	-702	dep	1	SENT_678	[p31l1630t3582r2062b3632],
7	.	.	O	.	_	0	SENT_678	[p31l1630t3582r2062b3632],

1	10	CD	NUMBER	10	_	0	SENT_679	[p31l1119t3654r1183b3694],
2	.	.	O	.	_	0	SENT_679	[p31l1119t3654r1183b3694],

1	Ciardiello	NNP	PERSON	Ciardiello	nn	2	SENT_680	[p31l1214t3649r1455b3694],
2	F	NN	PERSON	f	_	0	SENT_680	[p31l1485t3654r1523b3703],
3	,	,	O	,	_	0	SENT_680	[p31l1485t3654r1523b3703],
4	Tortora	NNP	PERSON	Tortora	nn	8	SENT_680	[p31l1555t3653r1739b3694],
5	G.	NNP	O	G.	nn	8	SENT_680	[p31l1768t3653r1820b3694],
6	A	NNP	O	A	nn	8	SENT_680	[p31l1852t3654r1889b3693],
7	novel	JJ	O	novel	amod	8	SENT_680	[p31l1917t3650r2046b3694],
8	approach	NN	O	approach	appos	2	SENT_680	[p31l2075t3664r2150b3706, p31l1117t3721r1285b3777],
9	in	IN	O	in	_	0	SENT_680	[p31l1305t3721r1352b3764],
10	the	DT	O	the	det	11	SENT_680	[p31l1372t3721r1448b3765],
11	treatment	NN	O	treatment	prep_in	8	SENT_680	[p31l1468t3730r1711b3765],
12	of	IN	O	of	_	0	SENT_680	[p31l1728t3720r1785b3765],
13	cancer	NN	O	cancer	prep_of	11	SENT_680	[p31l1795t3735r1968b3765],
14	:	:	O	:	_	0	SENT_680	[p31l1795t3735r1968b3765],
15	targetment	NN	O	targetment	dep	2	SENT_680	[p31l1990t3730r2150b3777, p32l8t24r146b59],
16	.	.	O	.	_	0	SENT_680	[p31l1990t3730r2150b3777, p32l8t24r146b59],

1	Endocr	NNP	MISC	Endocr	nn	3	SENT_681	[p32l168t14r343b59],
2	Relat	NNP	MISC	Relat	nn	3	SENT_681	[p32l360t15r487b61],
3	Cancer	NNP	O	Cancer	_	0	SENT_681	[p32l504t18r675b59],
4	2003	CD	DATE	2003	num	3	SENT_681	[p32l692t18r1012b68],
5	;	:	O	;	_	0	SENT_681	[p32l692t18r1012b68],
6	10:1	CD	NUMBER	10:1	number	7	SENT_681	[p32l692t18r1012b68],
7	—	CD	NUMBER	—	dep	3	SENT_681	[p32l692t18r1012b68],
8	21	CD	NUMBER	21	dep	7	SENT_681	[p32l692t18r1012b68],
9	.	.	O	.	_	0	SENT_681	[p32l692t18r1012b68],

1	ing	VBG	O	ing	_	0	SENT_682	[p32l1117t15r1197b71],
2	the	DT	O	the	det	6	SENT_682	[p32l1214t14r1290b59],
3	epidermal	JJ	O	epidermal	amod	6	SENT_682	[p32l1309t14r1557b71],
4	growth	NN	O	growth	nn	6	SENT_682	[p32l1575t15r1754b71],
5	factor	NN	O	factor	nn	6	SENT_682	[p32l1773t14r1917b59],
6	receptor	NN	O	receptor	dobj	1	SENT_682	[p32l1934t24r2148b71],
7	.	.	O	.	_	0	SENT_682	[p32l1934t24r2148b71],

1	6	CD	NUMBER	6	_	0	SENT_683	[p32l9t92r48b131],
2	.	.	O	.	_	0	SENT_683	[p32l9t92r48b131],

1	Sharma	FW	PERSON	sharma	nn	2	SENT_684	[p32l106t86r294b131],
2	SV	FW	O	sv	_	0	SENT_684	[p32l335t90r404b140],
3	,	,	O	,	_	0	SENT_684	[p32l335t90r404b140],
4	Bell	NNP	ORGANIZATION	Bell	nn	5	SENT_684	[p32l447t86r540b130],
5	DW	NNP	ORGANIZATION	DW	appos	2	SENT_684	[p32l580t90r679b140],
6	,	,	O	,	_	0	SENT_684	[p32l580t90r679b140],
7	Settleman	NNP	O	Settleman	nn	8	SENT_684	[p32l724t86r971b131],
8	J	NNP	O	J	appos	2	SENT_684	[p32l1006t91r1039b140],
9	,	,	O	,	_	0	SENT_684	[p32l1006t91r1039b140],
10	Clin	NNP	O	Clin	nn	12	SENT_684	[p32l1118t86r1219b131],
11	Cancer	NNP	O	Cancer	nn	12	SENT_684	[p32l1238t90r1409b131],
12	Res	NNP	O	Res	appos	2	SENT_684	[p32l1426t90r1512b133],
13	2001	CD	DATE	2001	dep	12	SENT_684	[p32l1532t90r1912b140],
14	;	:	O	;	_	0	SENT_684	[p32l1532t90r1912b140],
15	7:2958	CD	NUMBER	7:2958	number	16	SENT_684	[p32l1532t90r1912b140],
16	—	CD	NUMBER	—	dep	2	SENT_684	[p32l1532t90r1912b140],
17	70	CD	NUMBER	70	dep	16	SENT_684	[p32l1532t90r1912b140],
18	.	.	O	.	_	0	SENT_684	[p32l1532t90r1912b140],

1	Haber	NNP	O	Haber	nn	2	SENT_685	[p32l8t156r159b201],
2	DA	NNP	O	DA	_	0	SENT_685	[p32l187t160r275b201],
3	.	.	O	.	_	0	SENT_685	[p32l187t160r275b201],

1	Epidermal	JJ	O	epidermal	amod	4	SENT_686	[p32l309t156r563b213],
2	growth	NN	O	growth	nn	4	SENT_686	[p32l593t156r773b213],
3	factor	NN	O	factor	nn	4	SENT_686	[p32l804t156r947b201],
4	re	NN	O	re	_	0	SENT_686	[p32l977t171r1041b201],
5	—	CD	NUMBER	—	number	6	SENT_686	[p32l977t171r1041b201],
6	11	CD	NUMBER	11	num	4	SENT_686	[p32l1119t162r1183b201],
7	.	.	O	.	_	0	SENT_686	[p32l1119t162r1183b201],

1	Griinwald	NNP	MISC	Griinwald	nn	2	SENT_687	[p32l1214t156r1460b201],
2	V	NNP	O	V	_	0	SENT_687	[p32l1486t161r1528b210],
3	,	,	O	,	_	0	SENT_687	[p32l1486t161r1528b210],
4	Hidalgo	NNP	PERSON	Hidalgo	nn	5	SENT_687	[p32l1558t156r1755b213],
5	M.	NNP	O	M.	appos	2	SENT_687	[p32l1782t161r1844b201],
6	Developing	VBG	O	develop	partmod	5	SENT_687	[p32l1874t157r2153b213],
7	ceptor	NN	O	ceptor	nn	8	SENT_687	[p32l9t237r164b284],
8	mutations	NNS	O	mutation	dobj	6	SENT_687	[p32l183t228r432b272],
9	in	IN	O	in	_	0	SENT_687	[p32l455t228r502b271],
10	lung	NN	O	lung	nn	11	SENT_687	[p32l523t228r633b284],
11	cancer	NN	O	cancer	prep_in	6	SENT_687	[p32l653t242r825b272],
12	.	.	O	.	_	0	SENT_687	[p32l653t242r825b272],

1	Nat	NNP	PERSON	Nat	nn	3	SENT_688	[p32l848t232r936b272],
2	Rev	NN	PERSON	rev	nn	3	SENT_688	[p32l955t231r1044b274],
3	inhibitors	NNS	O	inhibitor	_	0	SENT_688	[p32l1117t228r1360b272],
4	of	IN	O	of	_	0	SENT_688	[p32l1381t227r1438b272],
5	the	DT	O	the	det	9	SENT_688	[p32l1447t228r1523b271],
6	epidermal	JJ	O	epidermal	amod	9	SENT_688	[p32l1543t228r1791b284],
7	growth	NN	O	growth	nn	9	SENT_688	[p32l1810t228r1990b284],
8	factor	NN	O	factor	nn	9	SENT_688	[p32l2009t227r2153b272],
9	Cancer	NN	O	cancer	prep_of	3	SENT_688	[p32l9t302r179b343],
10	2007	CD	DATE	2007	dep	3	SENT_688	[p32l197t302r546b352],
11	;	:	O	;	_	0	SENT_688	[p32l197t302r546b352],
12	7:169	CD	NUMBER	7:169	number	13	SENT_688	[p32l197t302r546b352],
13	—	CD	NUMBER	—	dep	3	SENT_688	[p32l197t302r546b352],
14	81	CD	NUMBER	81	dep	13	SENT_688	[p32l197t302r546b352],
15	.	.	O	.	_	0	SENT_688	[p32l197t302r546b352],

1	receptor	NN	O	receptor	_	0	SENT_689	[p32l1118t308r1322b355],
2	for	IN	O	for	_	0	SENT_689	[p32l1339t298r1409b343],
3	cancer	NN	O	cancer	nn	4	SENT_689	[p32l1427t313r1588b343],
4	treatment	NN	O	treatment	prep_for	1	SENT_689	[p32l1606t308r1860b343],
5	.	.	O	.	_	0	SENT_689	[p32l1606t308r1860b343],

1	J	NN	O	j	_	0	SENT_690	[p32l1877t303r1898b350],
2	Natl	NN	O	natl	nn	3	SENT_690	[p32l1914t298r2018b343],
3	Can7	NN	O	can7	dep	1	SENT_690	[p32l2037t302r2150b343, p32l10t376r43b414],
4	.	.	O	.	_	0	SENT_690	[p32l2037t302r2150b343, p32l10t376r43b414],

1	Zandi	NNP	PERSON	Zandi	nn	2	SENT_691	[p32l104t370r246b415],
2	R	NNP	PERSON	R	_	0	SENT_691	[p32l289t374r338b424],
3	,	,	O	,	_	0	SENT_691	[p32l289t374r338b424],
4	Larsen	NNP	ORGANIZATION	Larsen	nn	5	SENT_691	[p32l385t375r550b414],
5	AB	NNP	ORGANIZATION	AB	appos	2	SENT_691	[p32l592t374r678b424],
6	,	,	O	,	_	0	SENT_691	[p32l592t374r678b424],
7	Andersen	NNP	PERSON	Andersen	nn	8	SENT_691	[p32l723t370r958b415],
8	P	NN	PERSON	p	appos	2	SENT_691	[p32l1002t374r1039b424],
9	,	,	O	,	_	0	SENT_691	[p32l1002t374r1039b424],
10	cer	NN	O	cer	appos	2	SENT_691	[p32l1118t385r1190b414],
11	Inst	NNP	O	Inst	dep	10	SENT_691	[p32l1207t375r1304b414],
12	2003	CD	DATE	2003	num	11	SENT_691	[p32l1321t374r1699b424],
13	;	:	O	;	_	0	SENT_691	[p32l1321t374r1699b424],
14	95:851	CD	NUMBER	95:851	number	15	SENT_691	[p32l1321t374r1699b424],
15	—	CD	NUMBER	—	dep	2	SENT_691	[p32l1321t374r1699b424],
16	67	CD	NUMBER	67	dep	15	SENT_691	[p32l1321t374r1699b424],
17	.	.	O	.	_	0	SENT_691	[p32l1321t374r1699b424],

1	Stockhausen	NNP	PERSON	Stockhausen	nn	2	SENT_692	[p32l10t441r321b485],
2	M-T	NNP	O	M-T	_	0	SENT_692	[p32l358t444r465b494],
3	,	,	O	,	_	0	SENT_692	[p32l358t444r465b494],
4	Poulsen	NNP	PERSON	Poulsen	nn	5	SENT_692	[p32l506t440r699b485],
5	HS	NN	O	h	appos	2	SENT_692	[p32l738t444r822b485],
6	.	.	O	.	_	0	SENT_692	[p32l738t444r822b485],

1	Mecha	NNP	O	Mecha	_	0	SENT_693	[p32l862t441r1041b485],
2	—	CD	NUMBER	—	number	3	SENT_693	[p32l862t441r1041b485],
3	12	CD	NUMBER	12	num	1	SENT_693	[p32l1119t446r1184b485],
4	.	.	O	.	_	0	SENT_693	[p32l1119t446r1184b485],

1	Mendelsohn	NNP	PERSON	Mendelsohn	nn	2	SENT_694	[p32l1213t441r1517b485],
2	J	NNP	PERSON	J	_	0	SENT_694	[p32l1528t445r1561b494],
3	,	,	O	,	_	0	SENT_694	[p32l1528t445r1561b494],
4	Baselgal	NNP	PERSON	Baselgal	appos	2	SENT_694	[p32l1580t440r1810b497],
5	.	.	O	.	_	0	SENT_694	[p32l1580t440r1810b497],

1	Status	NN	O	status	_	0	SENT_695	[p32l1831t444r1979b485],
2	of	IN	O	of	_	0	SENT_695	[p32l1998t440r2055b485],
3	epidermal	JJ	O	epidermal	prep_of	1	SENT_695	[p32l2061t441r2150b497, p32l10t796r369b888],

1	growth	NN	O	growth	nn	2	SENT_696	[p32l445t798r816b914],
2	factor	NN	O	factor	_	0	SENT_696	[p32l892t796r1189b888],
3	receptor	NN	O	receptor	nn	4	SENT_696	[p32l1263t816r1684b914],
4	antagonists	NNS	O	antagonist	dep	2	SENT_696	[p32l1758t816r2145b914, p32l10t948r250b1038],
5	in	IN	O	in	_	0	SENT_696	[p32l289t948r387b1036],
6	the	DT	O	the	det	7	SENT_696	[p32l427t948r585b1038],
7	biology	NN	O	biology	prep_in	4	SENT_696	[p32l624t948r1002b1064],
8	and	CC	O	and	_	0	SENT_696	[p32l1035t948r1221b1038],
9	treatment	NN	O	treatment	prep_in	4	SENT_696	[p32l1261t966r1762b1038],
10	of	IN	O	of	prep	9	SENT_696	[p32l1796t946r1914b1038],
11	cancer	NN	O	cancer	dep	10	SENT_696	[p32l1933t976r2145b1038, p32l10t1128r182b1188],
12	.	.	O	.	_	0	SENT_696	[p32l1933t976r2145b1038, p32l10t1128r182b1188],
13	]	SYM	O	]	dep	9	SENT_696	[p32l217t1106r261b1202],

1	Clin	NNP	O	Clin	nn	2	SENT_697	[p32l299t1098r507b1188],
2	Oncol	NNP	O	Oncol	_	0	SENT_697	[p32l547t1098r848b1188],
3	2003	CD	DATE	2003	num	2	SENT_697	[p32l886t1104r1742b1208],
4	;	:	O	;	_	0	SENT_697	[p32l886t1104r1742b1208],
5	21:2787	CD	NUMBER	21:2787	number	6	SENT_697	[p32l886t1104r1742b1208],
6	—	CD	NUMBER	—	dep	2	SENT_697	[p32l886t1104r1742b1208],
7	99	CD	NUMBER	99	dep	6	SENT_697	[p32l886t1104r1742b1208],
8	.	.	O	.	_	0	SENT_697	[p32l886t1104r1742b1208],

1	13	CD	NUMBER	13	_	0	SENT_698	[p32l14t1258r144b1338],
2	.	.	O	.	_	0	SENT_698	[p32l14t1258r144b1338],

1	Imai	NNP	PERSON	Imai	nn	2	SENT_699	[p32l207t1248r443b1338],
2	K	NNP	PERSON	K	_	0	SENT_699	[p32l493t1256r595b1358],
3	,	,	O	,	_	0	SENT_699	[p32l493t1256r595b1358],
4	Takaoka	NNP	PERSON	Takaoka	nn	5	SENT_699	[p32l648t1248r1078b1340],
5	A.	NNP	O	A.	appos	2	SENT_699	[p32l1123t1256r1227b1338],
6	Comparing	VBG	O	compare	partmod	5	SENT_699	[p32l1285t1248r1864b1364],
7	antibody	NN	O	antibody	dobj	6	SENT_699	[p32l1911t1248r2145b1338, p32l10t1398r257b1512],
8	and	CC	O	and	_	0	SENT_699	[p32l331t1398r517b1488],
9	small	JJ	O	small	amod	12	SENT_699	[p32l600t1398r1377b1488],
10	—	NN	O	—	nn	12	SENT_699	[p32l600t1398r1377b1488],
11	molecule	NN	O	molecule	nn	12	SENT_699	[p32l600t1398r1377b1488],
12	therapies	NNS	O	therapy	dobj	6	SENT_699	[p32l1459t1398r1922b1514],
13	for	IN	O	for	_	0	SENT_699	[p32l2005t1396r2151b1488],
14	cancer	NN	O	cancer	prep_for	12	SENT_699	[p32l10t1576r365b1638],
15	.	.	O	.	_	0	SENT_699	[p32l10t1576r365b1638],

1	Nat	NNP	O	Nat	nn	3	SENT_700	[p32l409t1556r591b1638],
2	Rev	NN	O	rev	nn	3	SENT_700	[p32l624t1554r810b1644],
3	Cancer	NN	O	cancer	_	0	SENT_700	[p32l844t1554r1198b1638],
4	2006	CD	DATE	2006	dep	3	SENT_700	[p32l1235t1554r1958b1656],
5	;	:	O	;	_	0	SENT_700	[p32l1235t1554r1958b1656],
6	6:714	CD	NUMBER	6:714	number	7	SENT_700	[p32l1235t1554r1958b1656],
7	—	CD	NUMBER	—	dep	3	SENT_700	[p32l1235t1554r1958b1656],
8	27	CD	NUMBER	27	dep	7	SENT_700	[p32l1235t1554r1958b1656],
9	.	.	O	.	_	0	SENT_700	[p32l1235t1554r1958b1656],

1	14	CD	NUMBER	14	_	0	SENT_701	[p32l14t1708r144b1788],
2	.	.	O	.	_	0	SENT_701	[p32l14t1708r144b1788],

1	Perez	NNP	PERSON	Perez	_	0	SENT_702	[p32l207t1704r834b1788],
2	.	.	O	.	_	0	SENT_702	[p32l207t1704r834b1788],

1	—	NN	O	—	_	0	SENT_703	[p32l207t1704r834b1788],
2	.	.	O	.	_	0	SENT_703	[p32l207t1704r834b1788],

1	Torres	NNP	O	Torres	nn	2	SENT_704	[p32l207t1704r834b1788],
2	M	NNP	O	M	_	0	SENT_704	[p32l878t1706r1006b1808],
3	,	,	O	,	_	0	SENT_704	[p32l878t1706r1006b1808],
4	Guix	NNP	O	Guix	nn	5	SENT_704	[p32l1057t1698r1303b1788],
5	M	NNP	O	M	appos	2	SENT_704	[p32l1341t1706r1469b1808],
6	,	,	O	,	_	0	SENT_704	[p32l1341t1706r1469b1808],
7	Gonzales	NNP	PERSON	Gonzales	nn	8	SENT_704	[p32l1520t1698r1994b1788],
8	A	NNP	O	A	appos	2	SENT_704	[p32l2037t1706r2141b1808],
9	,	,	O	,	_	0	SENT_704	[p32l2037t1706r2141b1808],
10	Arteaga	NNP	PERSON	Arteaga	nn	11	SENT_704	[p32l6t1856r407b1964],
11	CL	NN	O	cl	appos	2	SENT_704	[p32l455t1854r617b1938],
12	.	.	O	.	_	0	SENT_704	[p32l455t1854r617b1938],

1	Epidermal	JJ	O	epidermal	amod	6	SENT_705	[p32l672t1848r1197b1964],
2	growth	NN	O	growth	nn	6	SENT_705	[p32l1247t1848r1618b1964],
3	factor	NN	O	factor	nn	6	SENT_705	[p32l1668t1846r1965b1938],
4	re	NN	O	re	nn	6	SENT_705	[p32l2011t1878r2145b1938],
5	—	NN	O	—	nn	6	SENT_705	[p32l2011t1878r2145b1938],
6	ceptor	NN	O	ceptor	nsubj	17	SENT_705	[p32l10t2016r331b2114],
7	(	CD	NUMBER	(	num	8	SENT_705	[p32l403t2004r764b2102],
8	EGFR	NN	ORGANIZATION	egfr	dep	6	SENT_705	[p32l403t2004r764b2102],
9	)	CD	NUMBER	)	num	10	SENT_705	[p32l403t2004r764b2102],
10	antibody	NN	O	antibody	npadvmod	11	SENT_705	[p32l840t1998r1289b2112],
11	down	RB	O	down	advmod	13	SENT_705	[p32l1355t1998r2143b2114],
12	—	RB	O	—	advmod	13	SENT_705	[p32l1355t1998r2143b2114],
13	regulates	VBZ	O	regulate	_	0	SENT_705	[p32l1355t1998r2143b2114],
14	mutant	JJ	O	mutant	amod	15	SENT_705	[p32l10t2166r379b2238],
15	receptors	NNS	O	receptor	dobj	13	SENT_705	[p32l417t2166r886b2264],
16	and	CC	O	and	_	0	SENT_705	[p32l932t2146r1117b2238],
17	inhibits	VBZ	O	inhibit	conj_and	13	SENT_705	[p32l1159t2148r1551b2238],
18	tumors	NNS	O	tumor	dobj	17	SENT_705	[p32l1596t2166r1960b2238],
19	expressing	VBG	O	express	partmod	18	SENT_705	[p32l2007t2178r2145b2238, p32l8t2298r443b2414],
20	EGFR	NN	ORGANIZATION	egfr	nn	21	SENT_705	[p32l508t2304r810b2394],
21	mutations	NNS	O	mutation	dobj	19	SENT_705	[p32l868t2298r1413b2388],
22	.	.	O	.	_	0	SENT_705	[p32l868t2298r1413b2388],

1	J	NNP	O	J	nn	3	SENT_706	[p32l1477t2306r1521b2402],
2	Biol	NNP	O	Biol	nn	3	SENT_706	[p32l1588t2298r1784b2388],
3	Chem	NNP	O	Chem	_	0	SENT_706	[p32l1854t2298r2147b2388],
4	2006	CD	DATE	2006	num	3	SENT_706	[p32l10t2454r1004b2556],
5	;	:	O	;	_	0	SENT_706	[p32l10t2454r1004b2556],
6	281:40183	CD	NUMBER	281:40183	number	7	SENT_706	[p32l10t2454r1004b2556],
7	—	CD	NUMBER	—	dep	3	SENT_706	[p32l10t2454r1004b2556],
8	92	CD	NUMBER	92	dep	7	SENT_706	[p32l10t2454r1004b2556],
9	.	.	O	.	_	0	SENT_706	[p32l10t2454r1004b2556],

1	15	CD	NUMBER	15	_	0	SENT_707	[p32l14t2608r144b2688],
2	.	.	O	.	_	0	SENT_707	[p32l14t2608r144b2688],

1	Steiner	NNP	PERSON	Steiner	nn	2	SENT_708	[p32l211t2598r565b2688],
2	P	NN	O	p	_	0	SENT_708	[p32l602t2604r680b2708],
3	,	,	O	,	_	0	SENT_708	[p32l602t2604r680b2708],
4	Joynes	NNP	PERSON	Joynes	nn	5	SENT_708	[p32l718t2606r1050b2712],
5	C	NNP	O	C	appos	2	SENT_708	[p32l1095t2604r1192b2708],
6	,	,	O	,	_	0	SENT_708	[p32l1095t2604r1192b2708],
7	Bassi	NNP	PERSON	Bassi	nn	8	SENT_708	[p32l1239t2598r1503b2688],
8	R	NNP	O	R	appos	2	SENT_708	[p32l1542t2604r1644b2708],
9	,	,	O	,	_	0	SENT_708	[p32l1542t2604r1644b2708],
10	et	FW	O	et	nn	11	SENT_708	[p32l1696t2616r1786b2688],
11	al.	FW	O	al.	appos	2	SENT_708	[p32l1822t2598r1938b2688],
12	.	.	O	.	_	0	SENT_708	[p32l1822t2598r1938b2688],

1	Tumor	NN	O	tumor	nn	3	SENT_709	[p32l1983t2604r2145b2688, p32l10t2776r216b2838],
2	growth	NN	O	growth	nn	3	SENT_709	[p32l287t2748r658b2864],
3	inhibition	NN	O	inhibition	_	0	SENT_709	[p32l730t2748r1239b2838],
4	with	IN	O	with	_	0	SENT_709	[p32l1307t2748r1538b2838],
5	cetuximab	NN	O	cetuximab	prep_with	3	SENT_709	[p32l1612t2748r2145b2838],
6	and	CC	O	and	_	0	SENT_709	[p32l8t2896r194b2988],
7	chemotherapy	NN	O	chemotherapy	nn	27	SENT_709	[p32l240t2898r964b3014],
8	in	IN	O	in	dep	27	SENT_709	[p32l1002t2898r1100b2986],
9	non	JJ	O	non	amod	15	SENT_709	[p32l1145t2898r1662b2988],
10	—	JJ	O	—	amod	15	SENT_709	[p32l1145t2898r1662b2988],
11	small	JJ	O	small	amod	15	SENT_709	[p32l1145t2898r1662b2988],
12	cell	NN	O	cell	nn	15	SENT_709	[p32l1708t2898r1880b2988],
13	lung	NN	O	lung	nn	15	SENT_709	[p32l1922t2898r2151b3014],
14	cancer	NN	O	cancer	nn	15	SENT_709	[p32l10t3076r343b3138],
15	Xenografts	NNS	MISC	xenograft	pobj	8	SENT_709	[p32l417t3046r962b3164],
16	expressing	VBG	O	express	partmod	15	SENT_709	[p32l1047t3048r1594b3164],
17	wild	JJ	O	wild	amod	19	SENT_709	[p32l1666t3048r2147b3164],
18	—	NN	O	—	nn	19	SENT_709	[p32l1666t3048r2147b3164],
19	type	NN	O	type	dobj	16	SENT_709	[p32l1666t3048r2147b3164],
20	and	CC	O	and	_	0	SENT_709	[p32l8t3196r194b3288],
21	mutated	VBN	O	mutate	conj_and	8	SENT_709	[p32l239t3198r657b3288],
22	epidermal	JJ	O	epidermal	amod	26	SENT_709	[p32l702t3198r1214b3314],
23	growth	NN	O	growth	nn	26	SENT_709	[p32l1257t3198r1629b3314],
24	factor	NN	O	factor	nn	26	SENT_709	[p32l1674t3196r1971b3288],
25	re	NN	O	re	nn	26	SENT_709	[p32l2011t3228r2145b3288],
26	—	NN	O	—	dobj	21	SENT_709	[p32l2011t3228r2145b3288],
27	ceptor	NN	O	ceptor	prep_with	3	SENT_709	[p32l10t3366r353b3464],
28	.	.	O	.	_	0	SENT_709	[p32l10t3366r353b3464],

1	Clin	NNP	O	Clin	nn	3	SENT_710	[p32l399t3348r609b3438],
2	Cancer	NNP	O	Cancer	nn	3	SENT_710	[p32l648t3354r1002b3438],
3	Res	NNP	O	Res	_	0	SENT_710	[p32l1036t3354r1214b3444],
4	2007	CD	DATE	2007	num	3	SENT_710	[p32l1257t3354r2115b3456],
5	;	:	O	;	_	0	SENT_710	[p32l1257t3354r2115b3456],
6	13:1540	CD	NUMBER	13:1540	number	7	SENT_710	[p32l1257t3354r2115b3456],
7	—	CD	NUMBER	—	dep	3	SENT_710	[p32l1257t3354r2115b3456],
8	51	CD	NUMBER	51	dep	7	SENT_710	[p32l1257t3354r2115b3456],
9	.	.	O	.	_	0	SENT_710	[p32l1257t3354r2115b3456],

1	16	CD	NUMBER	16	_	0	SENT_711	[p32l14t3508r140b3588],
2	.	.	O	.	_	0	SENT_711	[p32l14t3508r140b3588],

1	Kimura	NNP	PERSON	Kimura	nn	2	SENT_712	[p32l207t3498r581b3590],
2	H	NNP	PERSON	H	dep	22	SENT_712	[p32l610t3506r720b3608],
3	,	,	O	,	_	0	SENT_712	[p32l610t3506r720b3608],
4	Sakai	NNP	LOCATION	Sakai	nn	5	SENT_712	[p32l760t3498r1020b3588],
5	K	NNP	LOCATION	K	appos	2	SENT_712	[p32l1049t3506r1149b3608],
6	,	,	O	,	_	0	SENT_712	[p32l1049t3506r1149b3608],
7	Arao	NNP	PERSON	Arao	nn	8	SENT_712	[p32l1183t3506r1415b3588],
8	T	NN	O	t	appos	2	SENT_712	[p32l1445t3504r1533b3608],
9	,	,	O	,	_	0	SENT_712	[p32l1445t3504r1533b3608],
10	Shimoyama	NNP	ORGANIZATION	Shimoyama	nn	11	SENT_712	[p32l1572t3498r2149b3612],
11	T	NN	ORGANIZATION	t	appos	2	SENT_712	[p32l6t3654r94b3758],
12	,	,	O	,	_	0	SENT_712	[p32l6t3654r94b3758],
13	Tamura	NNP	ORGANIZATION	Tamura	nn	14	SENT_712	[p32l127t3654r509b3738],
14	T	NN	ORGANIZATION	t	appos	2	SENT_712	[p32l535t3654r623b3758],
15	,	,	O	,	_	0	SENT_712	[p32l535t3654r623b3758],
16	Nishio	NNP	PERSON	Nishio	nn	19	SENT_712	[p32l656t3648r980b3738],
17	K.	NNP	PERSON	K.	nn	19	SENT_712	[p32l1012t3656r1112b3740],
18	Antibody	NN	PERSON	antibody	nn	19	SENT_712	[p32l1145t3648r2153b3764],
19	—	NN	O	—	appos	2	SENT_712	[p32l1145t3648r2153b3764],
20	dependent	JJ	O	dependent	amod	22	SENT_712	[p32l1145t3648r2153b3764],
21	cellular	JJ	O	cellular	amod	22	SENT_712	[p33l10t25r375b115],
22	cytotoxicity	NN	O	cytotoxicity	_	0	SENT_712	[p33l431t25r996b139],
23	of	IN	O	of	_	0	SENT_712	[p33l1051t23r1166b115],
24	cetuximab	NN	O	cetuximab	prep_of	22	SENT_712	[p33l1205t25r1718b115],
25	against	IN	O	against	_	0	SENT_712	[p33l1778t25r2153b141],
26	tumor	NN	O	tumor	nn	27	SENT_712	[p33l10t193r326b265],
27	cells	NNS	O	cell	prep_against	24	SENT_712	[p33l365t175r587b265],
28	with	IN	O	with	_	0	SENT_712	[p33l624t175r854b265],
29	wild	JJ	O	wild	amod	31	SENT_712	[p33l890t175r1371b291],
30	—	NN	O	—	nn	31	SENT_712	[p33l890t175r1371b291],
31	type	NN	O	type	prep_with	27	SENT_712	[p33l890t175r1371b291],
32	or	CC	O	or	_	0	SENT_712	[p33l1413t203r1517b265],
33	mutant	JJ	O	mutant	amod	35	SENT_712	[p33l1554t193r1926b265],
34	epidermal	JJ	O	epidermal	amod	35	SENT_712	[p33l1961t175r2145b291, p33l10t325r369b415],
35	growth	NN	O	growth	conj_or	22	SENT_712	[p33l401t325r773b441],
36	factor	NN	O	factor	nn	37	SENT_712	[p33l808t323r1104b415],
37	receptor	NN	O	receptor	dep	35	SENT_712	[p33l1135t343r1579b441],
38	.	.	O	.	_	0	SENT_712	[p33l1135t343r1579b441],

1	Cancer	NN	O	cancer	_	0	SENT_713	[p33l1620t331r1974b415],
2	Sci	NNP	O	Sci	dep	1	SENT_713	[p33l2007t325r2147b415],
3	2007	CD	DATE	2007	num	2	SENT_713	[p33l10t481r870b585],
4	;	:	O	;	_	0	SENT_713	[p33l10t481r870b585],
5	98:1275	CD	NUMBER	98:1275	number	6	SENT_713	[p33l10t481r870b585],
6	—	CD	NUMBER	—	dep	1	SENT_713	[p33l10t481r870b585],
7	80	CD	NUMBER	80	dep	6	SENT_713	[p33l10t481r870b585],
8	.	.	O	.	_	0	SENT_713	[p33l10t481r870b585],

1	17	CD	NUMBER	17	_	0	SENT_714	[p33l14t635r134b715],
2	.	.	O	.	_	0	SENT_714	[p33l14t635r134b715],

1	Mukohara	NN	ORGANIZATION	mukohara	nn	2	SENT_715	[p33l205t625r730b715],
2	T	NN	ORGANIZATION	t	_	0	SENT_715	[p33l806t631r896b735],
3	,	,	O	,	_	0	SENT_715	[p33l806t631r896b735],
4	Engelman	NNP	ORGANIZATION	Engelman	nn	7	SENT_715	[p33l985t625r1501b741],
5	IA	NNP	ORGANIZATION	IA	nn	7	SENT_715	[p33l1572t633r1716b735],
6	,	,	O	,	_	0	SENT_715	[p33l1572t633r1716b735],
7	Hanna	NNP	PERSON	Hanna	appos	2	SENT_715	[p33l1806t633r2149b715],

1	35	CD	NUMBER	35	num	3	SENT_716	[p33l705t826r729b848],
2	;	:	O	;	_	0	SENT_716	[p33l747t826r773b846],
3	11	CD	NUMBER	11	_	0	SENT_716	[p33l747t826r773b846],
4	WWW	NNP	O	WWW	nn	8	SENT_716	[p33l809t826r900b842],
5	,	,	O	,	_	0	SENT_716	[p33l809t826r900b842],
6	N	NNP	O	N	appos	8	SENT_716	[p33l809t826r900b842],
7	EJ	NNP	O	EJ	nn	8	SENT_716	[p33l907t826r924b848],
8	M.ORG	NNP	O	M.ORG	dep	3	SENT_716	[p33l931t826r1010b842],
9	MARCH	NNP	DATE	MARCH	dep	3	SENT_716	[p33l1047t826r1132b841],
10	13	CD	DATE	13	num	9	SENT_716	[p33l1147t826r1178b848],
11	,	,	O	,	_	0	SENT_716	[p33l1147t826r1178b848],
12	20	CD	NUMBER	20	num	9	SENT_716	[p33l1189t826r1220b842],
13	The	DT	O	the	det	16	SENT_716	[p33l702t859r753b883],
14	New	NNP	O	New	nn	16	SENT_716	[p33l762t860r824b883],
15	England	NNP	O	England	nn	16	SENT_716	[p33l833t859r944b890],
16	Journal	NNP	O	Journal	dep	3	SENT_716	[p33l952t859r1050b883],
17	of	IN	O	of	_	0	SENT_716	[p33l1059t859r1088b883],
18	Medicine	NNP	O	Medicine	prep_of	16	SENT_716	[p33l1095t859r1220b883],

1	Downloaded	VBN	O	download	_	0	SENT_717	[p33l144t900r314b923],
2	from	IN	O	from	_	0	SENT_717	[p33l323t900r387b923],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_717	[p33l396t900r514b930],
4	at	IN	O	at	_	0	SENT_717	[p33l524t904r547b923],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_717	[p33l556t900r738b923],
6	on	IN	O	on	_	0	SENT_717	[p33l748t907r780b923],
7	J	NN	O	j	nn	8	SENT_717	[p33l789t900r801b923],
8	anu	NN	O	anu	prep_on	1	SENT_717	[p33l803t907r849b923],
9	,	,	O	,	_	0	SENT_717	[p33l919t919r924b928],
10	2014	CD	DATE	2014	appos	8	SENT_717	[p33l935t900r1007b923],
11	.	.	O	.	_	0	SENT_717	[p33l935t900r1007b923],

1	For	IN	O	for	_	0	SENT_718	[p33l1018t900r1064b923],
2	personal	JJ	O	personal	amod	3	SENT_718	[p33l1072t900r1185b930],
3	use	NN	O	use	pobj	1	SENT_718	[p33l1194t907r1237b923],
4	only	RB	O	only	advmod	3	SENT_718	[p33l1247t900r1312b930],
5	.	.	O	.	_	0	SENT_718	[p33l1247t900r1312b930],

1	No	DT	O	no	det	3	SENT_719	[p33l1322t900r1362b923],
2	other	JJ	O	other	amod	3	SENT_719	[p33l1372t900r1440b923],
3	uses	NNS	O	use	_	0	SENT_719	[p33l1448t907r1504b923],
4	without	IN	O	without	_	0	SENT_719	[p33l1515t900r1616b923],
5	permission	NN	O	permission	prep_without	3	SENT_719	[p33l1624t900r1776b930],
6	.	.	O	.	_	0	SENT_719	[p33l1624t900r1776b930],

1	Copyright	NN	O	copyright	nn	5	SENT_720	[p33l494t941r629b972],
2	©	CD	NUMBER	©	num	5	SENT_720	[p33l638t941r661b965],
3	2008	CD	DATE	2008	num	5	SENT_720	[p33l671t941r736b965],
4	Massac	NNP	LOCATION	Massac	nn	5	SENT_720	[p33l746t942r844b965],
5	usetts	NNP	O	usetts	_	0	SENT_720	[p33l862t945r937b965],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_720	[p33l947t941r1055b965],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_720	[p33l1065t941r1170b972],
8	.	.	O	.	_	0	SENT_720	[p33l1065t941r1170b972],

1	All	DT	O	all	det	2	SENT_721	[p33l1181t941r1223b965],
2	rights	NNS	O	rights	nsubj	3	SENT_721	[p33l1232t941r1306b972],
3	reserved	VBN	O	reserve	_	0	SENT_721	[p33l1316t941r1435b965],
4	.	.	O	.	_	0	SENT_721	[p33l1316t941r1435b965],

1	T	NN	O	t	nn	2	SENT_722	[p33l673t1049r689b1068],
2	h	NN	O	h	_	0	SENT_722	[p33l693t1047r704b1068],
3	e	SYM	O	e	dep	5	SENT_722	[p33l710t1054r718b1068],
4	N	NN	O	n	nn	5	SENT_722	[p33l737t1049r760b1068],
5	E	NN	O	e	rcmod	2	SENT_722	[p33l768t1049r785b1068],
6	W	NN	O	w	nn	13	SENT_722	[p33l792t1049r822b1068],
7	E	NN	O	e	nn	13	SENT_722	[p33l841t1049r858b1068],
8	N	NN	O	n	nn	13	SENT_722	[p33l866t1049r889b1068],
9	G	NN	O	g	nn	13	SENT_722	[p33l896t1049r918b1068],
10	L	NN	O	l	nn	13	SENT_722	[p33l925t1049r941b1068],
11	A	NN	O	a	nn	13	SENT_722	[p33l948t1049r968b1068],
12	ND	NN	O	nd	nn	13	SENT_722	[p33l976t1049r1029b1068],
13	JOURNAL	NN	O	journal	dep	2	SENT_722	[p33l1048t1049r1227b1075],
14	of	IN	O	of	_	0	SENT_722	[p33l1247t1047r1275b1074],
15	MEDICINE	NNP	O	MEDICINE	prep_of	13	SENT_722	[p33l1287t1049r1486b1068],

1	NH	NNP	O	NH	_	0	SENT_723	[p33l16t1381r219b1481],
2	,	,	O	,	_	0	SENT_723	[p33l16t1381r219b1481],
3	et	FW	O	et	nn	4	SENT_723	[p33l268t1392r357b1462],
4	al.	FW	O	al.	appos	1	SENT_723	[p33l393t1373r507b1463],
5	.	.	O	.	_	0	SENT_723	[p33l393t1373r507b1463],

1	Differential	JJ	O	differential	amod	2	SENT_724	[p33l553t1371r1142b1462],
2	effects	NNS	O	effect	_	0	SENT_724	[p33l1184t1371r1514b1462],
3	of	IN	O	of	_	0	SENT_724	[p33l1559t1373r1675b1463],
4	gefitinib	NN	O	gefitinib	prep_of	2	SENT_724	[p33l1695t1373r2132b1489],
5	and	CC	O	and	_	0	SENT_724	[p33l18t1520r201b1610],
6	cetuximab	NN	O	cetuximab	prep_of	2	SENT_724	[p33l284t1520r811b1611],
7	on	IN	O	on	_	0	SENT_724	[p33l896t1549r1020b1610],
8	non	JJ	O	non	amod	14	SENT_724	[p33l1101t1520r1830b1610],
9	—	JJ	O	—	amod	14	SENT_724	[p33l1101t1520r1830b1610],
10	small	JJ	O	small	amod	14	SENT_724	[p33l1101t1520r1830b1610],
11	—	NN	O	—	nn	14	SENT_724	[p33l1101t1520r1830b1610],
12	cell	NN	O	cell	nn	14	SENT_724	[p33l1101t1520r1830b1610],
13	lung	NN	O	lung	nn	14	SENT_724	[p33l1910t1520r2137b1636],
14	cancers	NNS	O	cancer	prep_on	4	SENT_724	[p33l19t1696r395b1756],
15	bearing	VBG	O	bear	partmod	14	SENT_724	[p33l444t1667r833b1783],
16	epidermal	JJ	O	epidermal	amod	20	SENT_724	[p33l876t1667r1383b1781],
17	growth	NN	O	growth	nn	20	SENT_724	[p33l1429t1667r1796b1783],
18	factor	NN	O	factor	nn	20	SENT_724	[p33l1843t1667r2137b1757],
19	receptor	NN	O	receptor	nn	20	SENT_724	[p33l18t1834r436b1929],
20	mutations	NNS	O	mutation	dobj	15	SENT_724	[p33l507t1817r1046b1906],
21	.	.	O	.	_	0	SENT_724	[p33l507t1817r1046b1906],

1	J	NNP	O	J	nn	4	SENT_725	[p33l1117t1823r1161b1919],
2	Natl	NNP	O	Natl	nn	4	SENT_725	[p33l1231t1815r1445b1905],
3	Cancer	NNP	O	Cancer	nn	4	SENT_725	[p33l1520t1821r1869b1905],
4	Inst	NNP	O	Inst	_	0	SENT_725	[p33l1940t1823r2138b1904],
5	2005	CD	DATE	2005	num	4	SENT_725	[p33l18t1969r864b2072],
6	;	:	O	;	_	0	SENT_725	[p33l18t1969r864b2072],
7	97:1185	CD	NUMBER	97:1185	number	8	SENT_725	[p33l18t1969r864b2072],
8	—	CD	NUMBER	—	dep	4	SENT_725	[p33l18t1969r864b2072],
9	94	CD	NUMBER	94	dep	8	SENT_725	[p33l18t1969r864b2072],
10	.	.	O	.	_	0	SENT_725	[p33l18t1969r864b2072],

1	18	CD	NUMBER	18	_	0	SENT_726	[p33l22t2122r154b2203],
2	.	.	O	.	_	0	SENT_726	[p33l22t2122r154b2203],

1	Masui	NNP	PERSON	Masui	nn	2	SENT_727	[p33l213t2114r519b2203],
2	H	NNP	PERSON	H	dep	19	SENT_727	[p33l562t2120r673b2221],
3	,	,	O	,	_	0	SENT_727	[p33l562t2120r673b2221],
4	Kawamoto	NNP	PERSON	Kawamoto	nn	5	SENT_727	[p33l724t2120r1265b2205],
5	T	NN	O	t	appos	2	SENT_727	[p33l1308t2120r1397b2223],
6	,	,	O	,	_	0	SENT_727	[p33l1308t2120r1397b2223],
7	Sato	NNP	PERSON	Sato	nn	8	SENT_727	[p33l1452t2118r1660b2203],
8	JD	NNP	O	JD	appos	2	SENT_727	[p33l1697t2120r1847b2221],
9	,	,	O	,	_	0	SENT_727	[p33l1697t2120r1847b2221],
10	Wolf	NNP	PERSON	Wolf	nn	11	SENT_727	[p33l1894t2112r2153b2203],
11	B	NNP	O	B	appos	2	SENT_727	[p33l16t2269r111b2370],
12	,	,	O	,	_	0	SENT_727	[p33l16t2269r111b2370],
13	Sato	NNP	PERSON	Sato	nn	14	SENT_727	[p33l166t2267r375b2352],
14	G	NNP	O	G	appos	2	SENT_727	[p33l424t2267r533b2370],
15	,	,	O	,	_	0	SENT_727	[p33l424t2267r533b2370],
16	Mendelsohn	NNP	PERSON	Mendelsohn	nn	18	SENT_727	[p33l584t2261r1206b2352],
17	J.	NNP	O	J.	nn	18	SENT_727	[p33l1241t2269r1307b2366],
18	Growth	NNP	O	Growth	appos	2	SENT_727	[p33l1362t2261r1749b2352],
19	inhibition	NN	O	inhibition	_	0	SENT_727	[p33l1794t2261r2131b2352, p33l18t2411r217b2499],
20	of	IN	O	of	_	0	SENT_727	[p33l290t2409r407b2499],
21	human	JJ	O	human	amod	23	SENT_727	[p33l458t2409r813b2500],
22	tumor	NN	O	tumor	nn	23	SENT_727	[p33l886t2428r1198b2500],
23	cells	NNS	O	cell	prep_of	19	SENT_727	[p33l1267t2409r1488b2498],
24	in	IN	O	in	_	0	SENT_727	[p33l1563t2411r1658b2498],
25	athymic	JJ	O	athymic	amod	26	SENT_727	[p33l1731t2409r2133b2523],
26	mice	NNS	O	mouse	prep_in	23	SENT_727	[p33l18t2558r255b2645],
27	by	IN	O	by	_	0	SENT_727	[p33l304t2556r416b2670],
28	anti	JJ	O	anti	amod	35	SENT_727	[p33l456t2556r1204b2670],
29	—	NN	O	—	nn	35	SENT_727	[p33l456t2556r1204b2670],
30	epidermal	JJ	O	epidermal	amod	35	SENT_727	[p33l456t2556r1204b2670],
31	growth	NN	O	growth	nn	35	SENT_727	[p33l1249t2556r1616b2672],
32	factor	NN	O	factor	nn	35	SENT_727	[p33l1662t2556r1956b2646],
33	receptor	NN	O	receptor	nn	35	SENT_727	[p33l1999t2585r2131b2645, p33l19t2723r336b2818],
34	monoclonal	JJ	O	monoclonal	amod	35	SENT_727	[p33l430t2704r1030b2794],
35	antibodies	NNS	O	antibody	prep_by	26	SENT_727	[p33l1125t2704r1683b2794],
36	.	.	O	.	_	0	SENT_727	[p33l1125t2704r1683b2794],

1	Cancer	NNP	O	Cancer	nn	2	SENT_728	[p33l1786t2710r2137b2794],
2	Res	NNP	O	Res	_	0	SENT_728	[p33l16t2860r192b2949],
3	1984	CD	DATE	1984	num	2	SENT_728	[p33l237t2860r1009b2961],
4	;	:	O	;	_	0	SENT_728	[p33l237t2860r1009b2961],
5	44:1002	CD	NUMBER	44:1002	number	6	SENT_728	[p33l237t2860r1009b2961],
6	-7	CD	NUMBER	-7	dep	2	SENT_728	[p33l237t2860r1009b2961],
7	.	.	O	.	_	0	SENT_728	[p33l237t2860r1009b2961],

1	19	CD	NUMBER	19	_	0	SENT_729	[p33l22t3010r148b3090],
2	.	.	O	.	_	0	SENT_729	[p33l22t3010r148b3090],

1	Li	NNP	PERSON	Li	nn	2	SENT_730	[p33l213t3002r306b3089],
2	S	NNP	PERSON	S	_	0	SENT_730	[p33l347t3006r426b3108],
3	,	,	O	,	_	0	SENT_730	[p33l347t3006r426b3108],
4	Schmitz	NNP	PERSON	Schmitz	nn	5	SENT_730	[p33l473t3000r882b3090],
5	KR	NNP	O	KR	appos	2	SENT_730	[p33l920t3008r1103b3108],
6	,	,	O	,	_	0	SENT_730	[p33l920t3008r1103b3108],
7	Jeffrey	NNP	PERSON	Jeffrey	nn	8	SENT_730	[p33l1136t3000r1474b3114],
8	PD	NN	PERSON	pd	appos	5	SENT_730	[p33l1506t3008r1670b3110],
9	,	,	O	,	_	0	SENT_730	[p33l1506t3008r1670b3110],
10	Wiltzius	NNP	O	Wiltzius	nn	11	SENT_730	[p33l1711t3000r2130b3091],
11	JJW	NNP	O	JJW	appos	5	SENT_730	[p33l6t3154r219b3254],
12	,	,	O	,	_	0	SENT_730	[p33l6t3154r219b3254],
13	Kussie	NNP	PERSON	Kussie	nn	14	SENT_730	[p33l288t3148r612b3238],
14	P	NN	PERSON	p	appos	5	SENT_730	[p33l673t3154r750b3256],
15	,	,	O	,	_	0	SENT_730	[p33l673t3154r750b3256],
16	Ferguson	NNP	PERSON	Ferguson	nn	17	SENT_730	[p33l819t3154r1287b3262],
17	KM	NNP	O	KM	appos	5	SENT_730	[p33l1350t3154r1557b3238],
18	.	.	O	.	_	0	SENT_730	[p33l1350t3154r1557b3238],

1	Structural	JJ	O	structural	amod	2	SENT_731	[p33l1628t3146r2133b3237],
2	basis	NN	O	basis	_	0	SENT_731	[p33l18t3294r267b3384],
3	for	IN	O	for	_	0	SENT_731	[p33l361t3294r505b3384],
4	inhibition	NN	O	inhibition	prep_for	2	SENT_731	[p33l594t3294r1097b3384],
5	of	IN	O	of	_	0	SENT_731	[p33l1190t3294r1307b3384],
6	the	DT	O	the	det	10	SENT_731	[p33l1379t3294r1534b3383],
7	epidermal	JJ	O	epidermal	amod	10	SENT_731	[p33l1628t3294r2133b3408],
8	growth	NN	O	growth	nn	10	SENT_731	[p33l18t3440r385b3556],
9	factor	NN	O	factor	nn	10	SENT_731	[p33l478t3440r772b3530],
10	receptor	NN	O	receptor	prep_of	2	SENT_731	[p33l862t3459r1279b3554],
11	by	IN	O	by	_	0	SENT_731	[p33l1369t3440r1482b3554],
12	cetuximab	NN	O	cetuximab	prep_by	10	SENT_731	[p33l1571t3440r2126b3531],
13	.	.	O	.	_	0	SENT_731	[p33l1571t3440r2126b3531],

1	Cancer	NN	O	cancer	nn	2	SENT_732	[p33l18t3595r367b3680],
2	Cell	NN	O	cell	_	0	SENT_732	[p33l404t3589r598b3680],
3	2005	CD	DATE	2005	dep	2	SENT_732	[p33l637t3595r1348b3698],
4	;	:	O	;	_	0	SENT_732	[p33l637t3595r1348b3698],
5	7:301	CD	NUMBER	7:301	num	6	SENT_732	[p33l637t3595r1348b3698],
6	-11	CD	NUMBER	-11	dep	2	SENT_732	[p33l637t3595r1348b3698],
7	.	.	O	.	_	0	SENT_732	[p33l637t3595r1348b3698],

1	20	CD	NUMBER	20	_	0	SENT_733	[p34l16t36r154b116],
2	.	.	O	.	_	0	SENT_733	[p34l16t36r154b116],

1	Karamouzis	NNP	PERSON	Karamouzis	nn	2	SENT_734	[p34l215t28r821b119],
2	MV	NNP	O	MV	nsubj	10	SENT_734	[p34l876t34r1064b136],
3	,	,	O	,	_	0	SENT_734	[p34l876t34r1064b136],
4	Grandis	NNP	PERSON	Grandis	nn	5	SENT_734	[p34l1125t26r1526b116],
5	JR	NNP	PERSON	JR	appos	2	SENT_734	[p34l1573t34r1721b136],
6	,	,	O	,	_	0	SENT_734	[p34l1573t34r1721b136],
7	Argiris	NNP	PERSON	Argiris	nn	9	SENT_734	[p34l1778t28r2130b142],
8	A.	NNP	O	A.	nn	9	SENT_734	[p34l14t181r116b263],
9	Therapies	NNP	O	Therapies	appos	5	SENT_734	[p34l179t173r669b287],
10	directed	VBD	O	direct	_	0	SENT_734	[p34l734t173r1141b263],
11	against	IN	O	against	_	0	SENT_734	[p34l1202t175r1571b289],
12	epidermal	JJ	O	epidermal	amod	15	SENT_734	[p34l1628t173r2133b287],
13	growth	NN	O	growth	nn	15	SENT_734	[p34l18t320r385b436],
14	factor	NN	O	factor	nn	15	SENT_734	[p34l456t320r750b410],
15	receptor	NN	O	receptor	prep_against	10	SENT_734	[p34l819t339r1236b434],
16	in	IN	O	in	_	0	SENT_734	[p34l1304t322r1401b409],
17	aerodigestive	JJ	O	aerodigestive	amod	18	SENT_734	[p34l1472t320r2133b436],
18	carcinomas	NNS	O	carcinoma	prep_in	10	SENT_734	[p34l19t471r628b560],
19	.	.	O	.	_	0	SENT_734	[p34l19t471r628b560],

1	JAMA	NNP	O	JAMA	_	0	SENT_735	[p34l661t477r961b574],
2	2007	CD	DATE	2007	num	1	SENT_735	[p34l998t475r1786b578],
3	;	:	O	;	_	0	SENT_735	[p34l998t475r1786b578],
4	298:70	CD	NUMBER	298:70	number	5	SENT_735	[p34l998t475r1786b578],
5	-82	CD	NUMBER	-82	dep	1	SENT_735	[p34l998t475r1786b578],
6	.	.	O	.	_	0	SENT_735	[p34l998t475r1786b578],

1	21	CD	NUMBER	21	_	0	SENT_736	[p34l16t630r152b709],
2	.	.	O	.	_	0	SENT_736	[p34l16t630r152b709],

1	Gridelli	NN	PERSON	gridellus	nn	2	SENT_737	[p34l215t618r600b709],
2	C	NN	O	c	_	0	SENT_737	[p34l643t624r740b729],
3	,	,	O	,	_	0	SENT_737	[p34l643t624r740b729],
4	Bareschino	NNP	O	Bareschino	nn	5	SENT_737	[p34l791t618r1354b709],
5	MA	NNP	O	MA	appos	2	SENT_737	[p34l1399t626r1603b729],
6	,	,	O	,	_	0	SENT_737	[p34l1399t626r1603b729],
7	Schettino	NNP	PERSON	Schettino	nn	8	SENT_737	[p34l1658t618r2131b709],
8	C	NNP	O	C	appos	2	SENT_737	[p34l18t775r115b878],
9	,	,	O	,	_	0	SENT_737	[p34l18t775r115b878],
10	Rossi	NNP	PERSON	Rossi	nn	11	SENT_737	[p34l172t769r444b864],
11	A	NNP	O	A	appos	2	SENT_737	[p34l491t775r594b876],
12	,	,	O	,	_	0	SENT_737	[p34l491t775r594b876],
13	Maione	NNP	PERSON	Maione	nn	14	SENT_737	[p34l649t769r1022b858],
14	P	NN	O	p	appos	2	SENT_737	[p34l1074t775r1151b876],
15	,	,	O	,	_	0	SENT_737	[p34l1074t775r1151b876],
16	Ciardiello	NNP	PERSON	Ciardiello	nn	20	SENT_737	[p34l1208t767r1701b858],
17	F.	NNP	O	F.	nn	20	SENT_737	[p34l1753t775r1832b858],
18	Erlo	NNP	O	Erlo	nn	20	SENT_737	[p34l1889t767r2131b858],
19	—	NN	O	—	nn	20	SENT_737	[p34l1889t767r2131b858],
20	tinib	NN	O	tinib	appos	2	SENT_737	[p34l18t914r255b1004],
21	in	IN	O	in	_	0	SENT_737	[p34l304t916r401b1003],
22	non-small	JJ	O	non-small	amod	26	SENT_737	[p34l448t914r959b1004],
23	cell	NN	O	cell	nn	26	SENT_737	[p34l1008t914r1178b1003],
24	lung	NN	O	lung	nn	26	SENT_737	[p34l1224t914r1451b1030],
25	cancer	NN	O	cancer	nn	26	SENT_737	[p34l1496t943r1824b1003],
26	treatment	NN	O	treatment	prep_in	20	SENT_737	[p34l1869t933r2131b1003, p34l18t1081r302b1152],
27	:	:	O	:	_	0	SENT_737	[p34l1869t933r2131b1003, p34l18t1081r302b1152],
28	current	JJ	DATE	current	amod	29	SENT_737	[p34l357t1081r726b1153],
29	status	NN	O	status	dep	2	SENT_737	[p34l772t1081r1066b1153],
30	and	CC	O	and	_	0	SENT_737	[p34l1119t1062r1303b1152],
31	future	JJ	DATE	future	amod	32	SENT_737	[p34l1352t1062r1660b1153],
32	development	NN	O	development	conj_and	29	SENT_737	[p34l1711t1062r2131b1176, p34l18t1227r300b1298],
33	.	.	O	.	_	0	SENT_737	[p34l1711t1062r2131b1176, p34l18t1227r300b1298],

1	Oncologist	NN	O	oncologist	_	0	SENT_738	[p34l347t1208r900b1324],
2	2007	CD	DATE	2007	num	1	SENT_738	[p34l933t1214r1666b1316],
3	;	:	O	;	_	0	SENT_738	[p34l933t1214r1666b1316],
4	12:840	CD	NUMBER	12:840	number	5	SENT_738	[p34l933t1214r1666b1316],
5	—	CD	NUMBER	—	dep	1	SENT_738	[p34l933t1214r1666b1316],
6	9	CD	NUMBER	9	dep	5	SENT_738	[p34l933t1214r1666b1316],
7	.	.	O	.	_	0	SENT_738	[p34l933t1214r1666b1316],

1	22	CD	NUMBER	22	_	0	SENT_739	[p34l16t1367r156b1445],
2	.	.	O	.	_	0	SENT_739	[p34l16t1367r156b1445],

1	Messersmith	NNP	ORGANIZATION	Messersmith	nn	2	SENT_740	[p34l213t1355r863b1444],
2	WA	NNP	ORGANIZATION	WA	_	0	SENT_740	[p34l902t1363r1103b1465],
3	,	,	O	,	_	0	SENT_740	[p34l902t1363r1103b1465],
4	Hidalgo	NNP	PERSON	Hidalgo	nn	8	SENT_740	[p34l1152t1355r1553b1471],
5	M.	NNP	PERSON	M.	nn	8	SENT_740	[p34l1595t1363r1721b1445],
6	Panitu	NNP	PERSON	Panitu	nn	8	SENT_740	[p34l1768t1357r2131b1446],
7	—	NN	O	—	nn	8	SENT_740	[p34l1768t1357r2131b1446],
8	mumab	NN	O	mumab	appos	2	SENT_740	[p34l18t1503r427b1613],
9	,	,	O	,	_	0	SENT_740	[p34l18t1503r427b1613],
10	a	DT	O	a	det	17	SENT_740	[p34l521t1532r572b1592],
11	monoclonal	JJ	O	monoclonal	amod	17	SENT_740	[p34l657t1503r1259b1593],
12	anti	JJ	O	anti	amod	17	SENT_740	[p34l1346t1505r1539b1592],
13	epidermal	JJ	O	epidermal	amod	17	SENT_740	[p34l1628t1503r2133b1617],
14	growth	NN	O	growth	nn	17	SENT_740	[p34l18t1649r385b1765],
15	factor	NN	O	factor	nn	17	SENT_740	[p34l511t1649r805b1739],
16	receptor	NN	O	receptor	nn	17	SENT_740	[p34l929t1668r1346b1763],
17	antibody	NN	O	antibody	appos	2	SENT_740	[p34l1470t1649r1914b1763],
18	in	IN	O	in	_	0	SENT_740	[p34l2036t1651r2133b1738],
19	colorectal	JJ	O	colorectal	amod	20	SENT_740	[p34l19t1797r513b1888],
20	cancer	NN	O	cancer	prep_in	17	SENT_740	[p34l550t1827r904b1888],
21	:	:	O	:	_	0	SENT_740	[p34l550t1827r904b1888],
22	another	DT	O	another	det	23	SENT_740	[p34l943t1797r1336b1888],
23	one	CD	NUMBER	one	dep	2	SENT_740	[p34l1370t1826r1546b1888],
24	or	CC	O	or	_	0	SENT_740	[p34l1583t1826r1687b1888],
25	the	DT	O	the	det	26	SENT_740	[p34l1720t1797r1875b1888],
26	one	CD	NUMBER	one	dep	2	SENT_740	[p34l1912t1795r2133b1888],
27	?	.	O	?	_	0	SENT_740	[p34l1912t1795r2133b1888],

1	Clin	NNP	O	Clin	nn	3	SENT_741	[p34l18t1946r225b2037],
2	Cancer	NNP	O	Cancer	nn	3	SENT_741	[p34l264t1952r614b2037],
3	Res	NNP	O	Res	_	0	SENT_741	[p34l649t1954r823b2043],
4	2007	CD	DATE	2007	num	3	SENT_741	[p34l866t1952r1670b2055],
5	;	:	O	;	_	0	SENT_741	[p34l866t1952r1670b2055],
6	13:4664	CD	NUMBER	13:4664	number	7	SENT_741	[p34l866t1952r1670b2055],
7	—	CD	NUMBER	—	dep	3	SENT_741	[p34l866t1952r1670b2055],
8	6	CD	NUMBER	6	dep	7	SENT_741	[p34l866t1952r1670b2055],
9	.	.	O	.	_	0	SENT_741	[p34l866t1952r1670b2055],

1	23	CD	NUMBER	23	_	0	SENT_742	[p34l16t2105r152b2184],
2	.	.	O	.	_	0	SENT_742	[p34l16t2105r152b2184],

1	Sridhar	NNP	O	Sridhar	nn	2	SENT_743	[p34l219t2094r588b2184],
2	SS	NNP	O	SS	_	0	SENT_743	[p34l636t2100r774b2204],
3	,	,	O	,	_	0	SENT_743	[p34l636t2100r774b2204],
4	Seymour	NNP	PERSON	Seymour	nn	5	SENT_743	[p34l831t2100r1271b2208],
5	L	NNP	PERSON	L	appos	2	SENT_743	[p34l1314t2102r1401b2204],
6	,	,	O	,	_	0	SENT_743	[p34l1314t2102r1401b2204],
7	Shepherd	NNP	ORGANIZATION	Shepherd	nn	8	SENT_743	[p34l1458t2094r1924b2208],
8	FA	NNP	ORGANIZATION	FA	appos	5	SENT_743	[p34l1971t2102r2126b2184],
9	.	.	O	.	_	0	SENT_743	[p34l1971t2102r2126b2184],

1	Inhibitors	NNS	O	inhibitor	_	0	SENT_744	[p34l16t2241r517b2331],
2	of	IN	O	of	_	0	SENT_744	[p34l566t2239r681b2331],
3	epidermal	JJ	O	epidermal	amod	8	SENT_744	[p34l705t2241r1958b2357],
4	—	NN	O	—	nn	8	SENT_744	[p34l705t2241r1958b2357],
5	growth	NN	O	growth	nn	8	SENT_744	[p34l705t2241r1958b2357],
6	—	NN	O	—	nn	8	SENT_744	[p34l705t2241r1958b2357],
7	factor	NN	O	factor	nn	8	SENT_744	[p34l705t2241r1958b2357],
8	receptors	NNS	O	receptor	prep_of	1	SENT_744	[p34l1999t2270r2131b2330, p34l19t2408r413b2503],
9	:	:	O	:	_	0	SENT_744	[p34l1999t2270r2131b2330, p34l19t2408r413b2503],
10	a	DT	O	a	det	11	SENT_744	[p34l456t2418r506b2478],
11	review	NN	O	review	dep	1	SENT_744	[p34l543t2391r870b2480],
12	of	IN	O	of	_	0	SENT_744	[p34l906t2387r1022b2479],
13	clinical	JJ	O	clinical	amod	14	SENT_744	[p34l1040t2389r1409b2478],
14	research	NN	O	research	prep_of	11	SENT_744	[p34l1446t2389r1871b2478],
15	with	IN	O	with	_	0	SENT_744	[p34l1904t2389r2133b2480],
16	a	DT	O	a	det	17	SENT_744	[p34l18t2565r69b2624],
17	focus	NN	O	focus	prep_with	14	SENT_744	[p34l140t2535r407b2626],
18	on	IN	O	on	_	0	SENT_744	[p34l483t2564r606b2625],
19	non	JJ	O	non	amod	25	SENT_744	[p34l679t2535r1407b2625],
20	—	JJ	O	—	amod	25	SENT_744	[p34l679t2535r1407b2625],
21	small	JJ	O	small	amod	25	SENT_744	[p34l679t2535r1407b2625],
22	—	NN	O	—	nn	25	SENT_744	[p34l679t2535r1407b2625],
23	cell	NN	O	cell	nn	25	SENT_744	[p34l679t2535r1407b2625],
24	lung	NN	O	lung	nn	25	SENT_744	[p34l1480t2535r1705b2651],
25	cancer	NN	O	cancer	prep_on	17	SENT_744	[p34l1776t2564r2126b2625],
26	.	.	O	.	_	0	SENT_744	[p34l1776t2564r2126b2625],

1	Lancet	NNP	O	Lancet	nn	2	SENT_745	[p34l16t2692r353b2775],
2	Oncol	NNP	O	Oncol	_	0	SENT_745	[p34l387t2684r683b2775],
3	2003	CD	DATE	2003	num	2	SENT_745	[p34l722t2690r1516b2793],
4	;	:	O	;	_	0	SENT_745	[p34l722t2690r1516b2793],
5	4:397	CD	NUMBER	4:397	number	6	SENT_745	[p34l722t2690r1516b2793],
6	-406	CD	NUMBER	-406	dep	2	SENT_745	[p34l722t2690r1516b2793],
7	.	.	O	.	_	0	SENT_745	[p34l722t2690r1516b2793],

1	24	CD	NUMBER	24	_	0	SENT_746	[p34l16t2845r154b2924],
2	.	.	O	.	_	0	SENT_746	[p34l16t2845r154b2924],

1	Galizia	NNP	O	Galizia	nn	2	SENT_747	[p34l215t2833r577b2924],
2	G	NNP	O	G	_	0	SENT_747	[p34l636t2839r744b2942],
3	,	,	O	,	_	0	SENT_747	[p34l636t2839r744b2942],
4	Lieto	NNP	O	Lieto	nn	5	SENT_747	[p34l809t2835r1058b2924],
5	E	NNP	O	E	appos	2	SENT_747	[p34l1119t2841r1208b2944],
6	,	,	O	,	_	0	SENT_747	[p34l1119t2841r1208b2944],
7	De	NNP	PERSON	De	nn	9	SENT_747	[p34l1275t2841r1407b2924],
8	Vita	NNP	PERSON	Vita	nn	9	SENT_747	[p34l1464t2835r1664b2924],
9	F	NN	PERSON	f	appos	2	SENT_747	[p34l1721t2841r1800b2942],
10	,	,	O	,	_	0	SENT_747	[p34l1721t2841r1800b2942],
11	et	FW	O	et	nn	12	SENT_747	[p34l1868t2853r1958b2923],
12	al.	FW	O	al.	appos	2	SENT_747	[p34l2013t2833r2126b2924],
13	.	.	O	.	_	0	SENT_747	[p34l2013t2833r2126b2924],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_748	[p34l18t2982r596b3091],
2	,	,	O	,	_	0	SENT_748	[p34l18t2982r596b3091],
3	a	DT	O	a	det	8	SENT_748	[p34l692t3012r742b3072],
4	chimeric	JJ	O	chimeric	amod	8	SENT_748	[p34l831t2982r1271b3073],
5	human	JJ	O	human	amod	8	SENT_748	[p34l1360t2982r1715b3073],
6	mouse	NN	O	mouse	nn	8	SENT_748	[p34l1804t3012r2133b3073],
7	anti	JJ	O	anti	amod	8	SENT_748	[p34l18t3130r764b3244],
8	—	NN	O	—	appos	1	SENT_748	[p34l18t3130r764b3244],
9	epidermal	JJ	O	epidermal	amod	14	SENT_748	[p34l18t3130r764b3244],
10	growth	NN	O	growth	nn	14	SENT_748	[p34l862t3130r1230b3246],
11	factor	NN	O	factor	nn	14	SENT_748	[p34l1330t3128r1622b3220],
12	receptor	NN	O	receptor	nn	14	SENT_748	[p34l1719t3149r2136b3244],
13	monoclonal	JJ	O	monoclonal	amod	14	SENT_748	[p34l18t3278r618b3368],
14	antibody	NN	O	antibody	dep	8	SENT_748	[p34l659t3278r1121b3392],
15	,	,	O	,	_	0	SENT_748	[p34l659t3278r1121b3392],
16	in	IN	O	in	_	0	SENT_748	[p34l1168t3280r1265b3367],
17	the	DT	O	the	det	18	SENT_748	[p34l1307t3278r1462b3367],
18	treatment	NN	O	treatment	prep_in	1	SENT_748	[p34l1504t3297r2001b3367],
19	of	IN	O	of	_	0	SENT_748	[p34l2038t3278r2153b3368],
20	human	JJ	O	human	amod	22	SENT_748	[p34l18t3424r373b3515],
21	colorectal	JJ	O	colorectal	amod	22	SENT_748	[p34l408t3424r902b3514],
22	cancer	NN	O	cancer	prep_of	18	SENT_748	[p34l937t3453r1289b3514],
23	.	.	O	.	_	0	SENT_748	[p34l937t3453r1289b3514],

1	Oncogene	NN	O	oncogene	_	0	SENT_749	[p34l1330t3430r1833b3540],
2	2007	CD	DATE	2007	num	1	SENT_749	[p34l1869t3430r2129b3532],
3	;	:	O	;	_	0	SENT_749	[p34l1869t3430r2129b3532],
4	263654-60	CD	NUMBER	263654-60	dep	1	SENT_749	[p34l18t3578r606b3663],
5	.	.	O	.	_	0	SENT_749	[p34l18t3578r606b3663],

1	25	CD	NUMBER	25	_	0	SENT_750	[p35l16t47r152b125],
2	.	.	O	.	_	0	SENT_750	[p35l16t47r152b125],

1	Ranson	NNP	PERSON	Ranson	nn	2	SENT_751	[p35l213t43r598b130],
2	M	NNP	O	M	_	0	SENT_751	[p35l635t43r760b145],
3	,	,	O	,	_	0	SENT_751	[p35l635t43r760b145],
4	Hammond	NNP	ORGANIZATION	Hammond	nn	5	SENT_751	[p35l807t35r1350b125],
5	LA	NNP	ORGANIZATION	LA	appos	2	SENT_751	[p35l1389t43r1555b143],
6	,	,	O	,	_	0	SENT_751	[p35l1389t43r1555b143],
7	Ferry	NN	O	ferry	nn	8	SENT_751	[p35l1600t43r1861b149],
8	D	NN	O	d	appos	2	SENT_751	[p35l1896t43r1999b143],
9	,	,	O	,	_	0	SENT_751	[p35l1896t43r1999b143],
10	et	FW	O	et	nn	11	SENT_751	[p35l2048t54r2139b124],
11	al.	FW	O	al.	appos	2	SENT_751	[p35l18t182r131b272],
12	.	.	O	.	_	0	SENT_751	[p35l18t182r131b272],

1	ZD1839	NN	O	zd1839	nsubj	15	SENT_752	[p35l217t188r626b292],
2	,	,	O	,	_	0	SENT_752	[p35l217t188r626b292],
3	a	DT	O	a	det	13	SENT_752	[p35l714t211r766b271],
4	selective	JJ	O	selective	amod	13	SENT_752	[p35l847t182r1267b273],
5	oral	JJ	O	oral	amod	13	SENT_752	[p35l1350t182r1545b272],
6	epidermal	JJ	O	epidermal	amod	13	SENT_752	[p35l1628t182r2133b296],
7	growth	NN	O	growth	nn	13	SENT_752	[p35l18t328r385b444],
8	factor	NN	O	factor	nn	13	SENT_752	[p35l474t328r768b418],
9	receptor	NN	O	receptor	nn	13	SENT_752	[p35l852t330r1717b442],
10	—	NN	O	—	nn	13	SENT_752	[p35l852t330r1717b442],
11	tyrosine	NN	O	tyrosine	nn	13	SENT_752	[p35l852t330r1717b442],
12	kinase	NN	O	kinase	nn	13	SENT_752	[p35l1806t328r2133b419],
13	inhibitor	NN	O	inhibitor	appos	1	SENT_752	[p35l18t477r488b586],
14	,	,	O	,	_	0	SENT_752	[p35l18t477r488b586],
15	is	VBZ	O	be	_	0	SENT_752	[p35l552t479r630b567],
16	well	RB	O	well	advmod	17	SENT_752	[p35l686t477r892b568],
17	tolerated	VBN	O	tolerate	dep	15	SENT_752	[p35l951t477r1395b568],
18	and	CC	O	and	_	0	SENT_752	[p35l1452t477r1636b568],
19	active	JJ	O	active	conj_and	17	SENT_752	[p35l1695t479r1977b568],
20	in	IN	O	in	_	0	SENT_752	[p35l2036t479r2133b566],
21	patients	NNS	O	patient	nn	33	SENT_752	[p35l16t626r417b738],
22	with	IN	O	with	_	0	SENT_752	[p35l489t624r718b715],
23	solid	JJ	O	solid	amod	26	SENT_752	[p35l795t624r1062b734],
24	,	,	O	,	_	0	SENT_752	[p35l795t624r1062b734],
25	malignant	JJ	O	malignant	amod	26	SENT_752	[p35l1143t624r1670b740],
26	tumors	NNS	O	tumor	prep_with	21	SENT_752	[p35l1739t643r2128b715],
27	:	:	O	:	_	0	SENT_752	[p35l1739t643r2128b715],
28	results	NNS	O	result	dep	21	SENT_752	[p35l18t772r350b863],
29	of	IN	O	of	_	0	SENT_752	[p35l420t772r537b862],
30	a	DT	O	a	det	31	SENT_752	[p35l582t801r634b861],
31	phase	NN	O	phase	prep_of	28	SENT_752	[p35l697t772r989b886],
32	I	PRP	O	I	dep	31	SENT_752	[p35l1054t780r1090b861],
33	trial	NN	O	trial	prep_in	19	SENT_752	[p35l1156t772r1392b862],
34	.	.	O	.	_	0	SENT_752	[p35l1156t772r1392b862],

1	J	NNP	O	J	nn	3	SENT_753	[p35l1454t780r1498b876],
2	Clin	NNP	O	Clin	nn	3	SENT_753	[p35l1563t772r1770b862],
3	Oncol	NNP	O	Oncol	_	0	SENT_753	[p35l1837t772r2133b862],
4	2002	CD	DATE	2002	num	3	SENT_753	[p35l18t928r878b1029],
5	;	:	O	;	_	0	SENT_753	[p35l18t928r878b1029],
6	20:2240	CD	NUMBER	20:2240	number	7	SENT_753	[p35l18t928r878b1029],
7	—	CD	NUMBER	—	dep	3	SENT_753	[p35l18t928r878b1029],
8	50	CD	NUMBER	50	dep	7	SENT_753	[p35l18t928r878b1029],
9	.	.	O	.	_	0	SENT_753	[p35l18t928r878b1029],

1	26	CD	NUMBER	26	_	0	SENT_754	[p35l16t1077r156b1157],
2	.	.	O	.	_	0	SENT_754	[p35l16t1077r156b1157],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_755	[p35l215t1067r555b1157],
2	RS	NN	ORGANIZATION	r	_	0	SENT_755	[p35l594t1073r756b1177],
3	,	,	O	,	_	0	SENT_755	[p35l594t1073r756b1177],
4	Maddox	NNP	PERSON	Maddox	nn	5	SENT_755	[p35l807t1067r1210b1157],
5	A	NNP	O	A	appos	2	SENT_755	[p35l1251t1075r1488b1176],
6	.	.	O	.	_	0	SENT_755	[p35l1251t1075r1488b1176],

1	—	NN	O	—	_	0	SENT_756	[p35l1251t1075r1488b1176],
2	.	.	O	.	_	0	SENT_756	[p35l1251t1075r1488b1176],

1	M	NN	O	m	_	0	SENT_757	[p35l1251t1075r1488b1176],
2	,	,	O	,	_	0	SENT_757	[p35l1251t1075r1488b1176],
3	Rothenberg	NNP	PERSON	Rothenberg	nn	4	SENT_757	[p35l1539t1067r2137b1183],
4	ML	NNP	O	ML	appos	1	SENT_757	[p35l14t1222r207b1324],
5	,	,	O	,	_	0	SENT_757	[p35l14t1222r207b1324],
6	et	FW	O	et	nn	7	SENT_757	[p35l250t1233r340b1303],
7	al.	FW	O	al.	appos	4	SENT_757	[p35l369t1214r484b1304],
8	.	.	O	.	_	0	SENT_757	[p35l369t1214r484b1304],

1	Selective	JJ	O	selective	amod	10	SENT_758	[p35l529t1214r957b1305],
2	oral	JJ	O	oral	amod	10	SENT_758	[p35l994t1214r1188b1304],
3	epidermal	JJ	O	epidermal	amod	10	SENT_758	[p35l1224t1214r1729b1328],
4	growth	NN	O	growth	nn	10	SENT_758	[p35l1766t1214r2133b1330],
5	factor	NN	O	factor	nn	10	SENT_758	[p35l18t1362r312b1452],
6	receptor	NN	O	receptor	nn	10	SENT_758	[p35l367t1381r784b1476],
7	tyrosine	NN	O	tyrosine	nn	10	SENT_758	[p35l839t1364r1245b1476],
8	kinase	NN	O	kinase	nn	10	SENT_758	[p35l1304t1362r1630b1453],
9	inhibitor	NN	O	inhibitor	nn	10	SENT_758	[p35l1687t1362r2137b1452],
10	ZD1839	NN	O	zd1839	nsubj	17	SENT_758	[p35l16t1514r399b1599],
11	is	VBZ	O	be	cop	15	SENT_758	[p35l481t1510r557b1597],
12	generally	RB	O	generally	advmod	14	SENT_758	[p35l641t1508r1103b1624],
13	well	RB	O	well	advmod	14	SENT_758	[p35l1174t1508r1869b1599],
14	—	JJ	O	—	dep	15	SENT_758	[p35l1174t1508r1869b1599],
15	toIerated	JJ	O	toierated	_	0	SENT_758	[p35l1174t1508r1869b1599],
16	and	CC	O	and	_	0	SENT_758	[p35l1949t1508r2133b1598],
17	has	VBZ	O	have	conj_and	15	SENT_758	[p35l18t1655r186b1744],
18	activity	NN	O	activity	nn	37	SENT_758	[p35l231t1657r594b1769],
19	in	IN	O	in	_	0	SENT_758	[p35l631t1657r728b1744],
20	non	JJ	O	non	amod	26	SENT_758	[p35l771t1655r1500b1745],
21	—	JJ	O	—	amod	26	SENT_758	[p35l771t1655r1500b1745],
22	small	JJ	O	small	amod	26	SENT_758	[p35l771t1655r1500b1745],
23	—	NN	O	—	nn	26	SENT_758	[p35l771t1655r1500b1745],
24	cell	NN	O	cell	nn	26	SENT_758	[p35l771t1655r1500b1745],
25	lung	NN	O	lung	nn	26	SENT_758	[p35l1541t1655r1768b1771],
26	cancer	NN	O	cancer	prep_in	18	SENT_758	[p35l1807t1684r2135b1744],
27	and	CC	O	and	_	0	SENT_758	[p35l18t1803r201b1893],
28	other	JJ	O	other	amod	30	SENT_758	[p35l239t1803r505b1893],
29	solid	JJ	O	solid	amod	30	SENT_758	[p35l542t1803r782b1893],
30	tumors	NNS	O	tumor	prep_in	18	SENT_758	[p35l819t1822r1208b1894],
31	:	:	O	:	_	0	SENT_758	[p35l819t1822r1208b1894],
32	results	NNS	O	result	dep	18	SENT_758	[p35l1251t1803r1583b1894],
33	of	IN	O	of	_	0	SENT_758	[p35l1624t1803r1741b1893],
34	a	DT	O	a	det	35	SENT_758	[p35l1756t1832r1808b1892],
35	phase	NN	O	phase	prep_of	32	SENT_758	[p35l1841t1803r2132b1917],
36	I	PRP	O	I	dep	35	SENT_758	[p35l16t1959r52b2040],
37	trial	NN	O	trial	dobj	17	SENT_758	[p35l91t1951r326b2042],
38	.	.	O	.	_	0	SENT_758	[p35l91t1951r326b2042],

1	J	NNP	O	J	nn	3	SENT_759	[p35l361t1959r405b2056],
2	Clin	NNP	O	Clin	nn	3	SENT_759	[p35l442t1951r648b2042],
3	Oncol	NNP	O	Oncol	_	0	SENT_759	[p35l687t1951r985b2042],
4	2002	CD	DATE	2002	num	3	SENT_759	[p35l1024t1957r1875b2060],
5	;	:	O	;	_	0	SENT_759	[p35l1024t1957r1875b2060],
6	20:3815	CD	NUMBER	20:3815	number	7	SENT_759	[p35l1024t1957r1875b2060],
7	—	CD	NUMBER	—	dep	3	SENT_759	[p35l1024t1957r1875b2060],
8	25	CD	NUMBER	25	dep	7	SENT_759	[p35l1024t1957r1875b2060],
9	.	.	O	.	_	0	SENT_759	[p35l1024t1957r1875b2060],

1	27	CD	NUMBER	27	_	0	SENT_760	[p35l16t2110r144b2187],
2	.	.	O	.	_	0	SENT_760	[p35l16t2110r144b2187],

1	Baselga	NNP	PERSON	Baselga	nn	2	SENT_761	[p35l213t2098r598b2214],
2	J	NNP	PERSON	J	_	0	SENT_761	[p35l623t2106r689b2208],
3	,	,	O	,	_	0	SENT_761	[p35l623t2106r689b2208],
4	Rischin	NNP	PERSON	Rischin	nn	5	SENT_761	[p35l732t2098r1117b2193],
5	D	NNP	O	D	appos	2	SENT_761	[p35l1154t2106r1257b2208],
6	,	,	O	,	_	0	SENT_761	[p35l1154t2106r1257b2208],
7	Ranson	NNP	PERSON	Ranson	nn	8	SENT_761	[p35l1300t2106r1684b2193],
8	M	NNP	O	M	appos	2	SENT_761	[p35l1719t2106r1845b2206],
9	,	,	O	,	_	0	SENT_761	[p35l1719t2106r1845b2206],
10	et	FW	O	et	nn	11	SENT_761	[p35l1890t2117r1980b2187],
11	al.	FW	O	al.	appos	2	SENT_761	[p35l2013t2098r2126b2188],
12	.	.	O	.	_	0	SENT_761	[p35l2013t2098r2126b2188],

1	Phase	NN	O	phase	nn	9	SENT_762	[p35l16t2246r304b2335],
2	I	CD	NUMBER	i	num	3	SENT_762	[p35l403t2254r438b2335],
3	safety	NN	O	safety	nn	9	SENT_762	[p35l539t2246r851b2360],
4	,	,	O	,	_	0	SENT_762	[p35l539t2246r851b2360],
5	pharmacokinetic	JJ	O	pharmacokinetic	amod	3	SENT_762	[p35l955t2246r1843b2360],
6	,	,	O	,	_	0	SENT_762	[p35l955t2246r1843b2360],
7	and	CC	O	and	_	0	SENT_762	[p35l1949t2246r2133b2336],
8	pharmacodynamic	JJ	O	pharmacodynamic	conj_and	3	SENT_762	[p35l16t2393r965b2507],
9	trial	NN	O	trial	nsubj	32	SENT_762	[p35l1016t2393r1226b2482],
10	of	IN	O	of	_	0	SENT_762	[p35l1279t2393r1395b2483],
11	ZD1839	NN	O	zd1839	prep_of	9	SENT_762	[p35l1425t2399r1832b2503],
12	,	,	O	,	_	0	SENT_762	[p35l1425t2399r1832b2503],
13	a	DT	O	a	det	16	SENT_762	[p35l1890t2422r1940b2482],
14	se	FW	O	se	nn	16	SENT_762	[p35l1995t2422r2131b2482],
15	—	FW	O	—	nn	16	SENT_762	[p35l1995t2422r2131b2482],
16	lective	FW	O	lective	appos	11	SENT_762	[p35l16t2540r332b2631],
17	oral	JJ	O	oral	amod	19	SENT_762	[p35l395t2540r590b2630],
18	epidermal	JJ	O	epidermal	amod	19	SENT_762	[p35l651t2540r1157b2654],
19	growth	NN	O	growth	dep	16	SENT_762	[p35l1218t2540r1585b2656],
20	factor	NN	O	factor	nn	24	SENT_762	[p35l1646t2538r1940b2630],
21	receptor	NN	O	receptor	nn	24	SENT_762	[p35l1999t2569r2131b2629, p35l19t2707r336b2802],
22	tyrosine	NN	O	tyrosine	nn	24	SENT_762	[p35l401t2690r807b2802],
23	kinase	NN	O	kinase	nn	24	SENT_762	[p35l876t2688r1202b2779],
24	inhibitor	NN	O	inhibitor	dep	16	SENT_762	[p35l1269t2688r1741b2796],
25	,	,	O	,	_	0	SENT_762	[p35l1269t2688r1741b2796],
26	in	IN	O	in	_	0	SENT_762	[p35l1814t2690r1911b2777],
27	pa	NN	O	pa	nn	29	SENT_762	[p35l1977t2717r2131b2802],
28	—	NN	O	—	nn	29	SENT_762	[p35l1977t2717r2131b2802],
29	tients	NNS	O	tient	prep_in	9	SENT_762	[p35l18t2837r296b2924],
30	with	IN	O	with	_	0	SENT_762	[p35l324t2835r552b2926],
31	five	CD	NUMBER	five	prep_with	29	SENT_762	[p35l582t2835r762b2925],
32	selected	VBN	O	select	_	0	SENT_762	[p35l794t2835r1192b2925],
33	solid	JJ	O	solid	amod	35	SENT_762	[p35l1225t2835r1464b2925],
34	tumor	NN	O	tumor	nn	35	SENT_762	[p35l1496t2854r1808b2926],
35	types	NNS	O	type	dobj	32	SENT_762	[p35l1835t2854r2126b2949],
36	.	.	O	.	_	0	SENT_762	[p35l1835t2854r2126b2949],

1	J	NNP	O	J	nn	3	SENT_763	[p35l6t2991r50b3088],
2	Clin	NNP	O	Clin	nn	3	SENT_763	[p35l87t2983r294b3074],
3	Oncol	NNP	O	Oncol	_	0	SENT_763	[p35l333t2983r630b3074],
4	2002	CD	DATE	2002	num	3	SENT_763	[p35l669t2989r1577b3092],
5	;	:	O	;	_	0	SENT_763	[p35l669t2989r1577b3092],
6	20:4292	CD	NUMBER	20:4292	num	7	SENT_763	[p35l669t2989r1577b3092],
7	—	NN	O	—	dep	3	SENT_763	[p35l669t2989r1577b3092],
8	302	CD	NUMBER	302	dep	7	SENT_763	[p35l669t2989r1577b3092],
9	.	.	O	.	_	0	SENT_763	[p35l669t2989r1577b3092],

1	28	CD	NUMBER	28	_	0	SENT_764	[p35l16t3142r156b3223],
2	.	.	O	.	_	0	SENT_764	[p35l16t3142r156b3223],

1	LoRusso	NNP	PERSON	LoRusso	nn	2	SENT_765	[p35l213t3140r643b3229],
2	P	NN	O	p	_	0	SENT_765	[p35l698t3140r774b3243],
3	,	,	O	,	_	0	SENT_765	[p35l698t3140r774b3243],
4	Herbst	NNP	ORGANIZATION	Herbst	nn	5	SENT_765	[p35l835t3132r1176b3223],
5	RS	NN	ORGANIZATION	r	appos	2	SENT_765	[p35l1223t3140r1384b3241],
6	,	,	O	,	_	0	SENT_765	[p35l1223t3140r1384b3241],
7	Rischin	NN	PERSON	rischin	nn	8	SENT_765	[p35l1444t3132r1830b3229],
8	D	NN	O	d	appos	2	SENT_765	[p35l1883t3140r1986b3241],
9	,	,	O	,	_	0	SENT_765	[p35l1883t3140r1986b3241],
10	et	FW	O	et	nn	11	SENT_765	[p35l2048t3152r2139b3223],
11	al.	FW	O	al.	appos	2	SENT_765	[p35l18t3280r131b3370],
12	.	.	O	.	_	0	SENT_765	[p35l18t3280r131b3370],

1	Improvements	NNP	O	Improvements	dep	14	SENT_766	[p35l201t3288r926b3394],
2	in	IN	O	in	_	0	SENT_766	[p35l993t3282r1090b3369],
3	quality	NN	O	quality	prep_in	1	SENT_766	[p35l1156t3280r1506b3394],
4	of	IN	O	of	_	0	SENT_766	[p35l1567t3280r1682b3370],
5	life	NN	O	life	nn	10	SENT_766	[p35l1725t3280r1885b3369],
6	and	CC	O	and	_	0	SENT_766	[p35l1950t3280r2133b3370],
7	disease	NN	O	disease	nn	10	SENT_766	[p35l19t3427r772b3517],
8	—	NN	O	—	nn	10	SENT_766	[p35l19t3427r772b3517],
9	related	JJ	O	related	amod	10	SENT_766	[p35l19t3427r772b3517],
10	symptoms	NNS	O	symptom	prep_of	3	SENT_766	[p35l827t3446r1344b3541],
11	in	IN	O	in	_	0	SENT_766	[p35l1399t3429r1496b3516],
12	phase	NN	O	phase	prep_in	3	SENT_766	[p35l1547t3427r1839b3541],
13	I	PRP	O	I	dep	14	SENT_766	[p35l1892t3435r1926b3516],
14	trials	NNS	O	trial	dep	25	SENT_766	[p35l1979t3429r2131b3516, p35l18t3573r152b3662],
15	of	IN	O	of	_	0	SENT_766	[p35l195t3573r312b3663],
16	the	DT	O	the	det	21	SENT_766	[p35l331t3573r486b3662],
17	selective	JJ	O	selective	amod	21	SENT_766	[p35l527t3573r946b3664],
18	oral	JJ	O	oral	amod	21	SENT_766	[p35l987t3573r1182b3663],
19	epidermal	JJ	O	epidermal	amod	21	SENT_766	[p35l1221t3573r1727b3687],
20	growth	NN	O	growth	nn	21	SENT_766	[p35l1766t3573r2133b3689],
21	factor	NN	O	factor	prep_of	14	SENT_766	[p36l18t23r312b113],
22	receptor	NN	O	receptor	nn	25	SENT_766	[p36l367t42r784b137],
23	tyrosine	NN	O	tyrosine	nn	25	SENT_766	[p36l839t25r1245b137],
24	kinase	NN	O	kinase	nn	25	SENT_766	[p36l1304t23r1630b114],
25	inhibitor	NN	O	inhibitor	_	0	SENT_766	[p36l1687t23r2137b113],

1	ZD1839	NN	O	zd1839	_	0	SENT_767	[p36l16t175r399b260],
2	in	IN	O	in	_	0	SENT_767	[p36l436t171r533b258],
3	non-small	JJ	O	non-small	amod	6	SENT_767	[p36l572t169r1082b259],
4	cell	NN	O	cell	nn	6	SENT_767	[p36l1121t169r1291b258],
5	lung	NN	O	lung	nn	6	SENT_767	[p36l1326t169r1553b285],
6	cancer	NN	O	cancer	prep_in	1	SENT_767	[p36l1587t198r1916b258],
7	and	CC	O	and	_	0	SENT_767	[p36l1949t169r2132b259],
8	other	JJ	O	other	amod	10	SENT_767	[p36l13t429r143b473],
9	solid	JJ	O	solid	amod	10	SENT_767	[p36l189t429r306b473],
10	tumors	NNS	O	tumor	conj_and	6	SENT_767	[p36l353t438r543b474],
11	.	.	O	.	_	0	SENT_767	[p36l353t438r543b474],

1	Clin	NNP	O	Clin	nn	3	SENT_768	[p36l593t429r694b473],
2	Cancer	NNP	O	Cancer	nn	3	SENT_768	[p36l741t432r912b473],
3	Res	NNP	O	Res	_	0	SENT_768	[p36l956t433r1042b476],

1	2003	CD	DATE	2003	num	3	SENT_769	[p36l13t503r375b553],
2	;	:	O	;	_	0	SENT_769	[p36l13t503r375b553],
3	9:2040	CD	NUMBER	9:2040	_	0	SENT_769	[p36l13t503r375b553],
4	—	CD	NUMBER	—	number	5	SENT_769	[p36l13t503r375b553],
5	8	CD	NUMBER	8	num	3	SENT_769	[p36l13t503r375b553],
6	.	.	O	.	_	0	SENT_769	[p36l13t503r375b553],

1	29	CD	NUMBER	29	_	0	SENT_770	[p36l12t576r78b615],
2	.	.	O	.	_	0	SENT_770	[p36l12t576r78b615],

1	Hidalgo	NNP	PERSON	Hidalgo	nn	2	SENT_771	[p36l109t571r304b628],
2	M	NNP	O	M	_	0	SENT_771	[p36l332t575r393b625],
3	,	,	O	,	_	0	SENT_771	[p36l332t575r393b625],
4	Siu	NNP	PERSON	Siu	nn	5	SENT_771	[p36l426t572r497b616],
5	LL	NNP	O	LL	appos	2	SENT_771	[p36l524t575r598b625],
6	,	,	O	,	_	0	SENT_771	[p36l524t575r598b625],
7	Nemunaitis	NNP	PERSON	Nemunaitis	nn	8	SENT_771	[p36l628t572r915b616],
8	J	NNP	PERSON	J	appos	2	SENT_771	[p36l938t575r971b625],
9	,	,	O	,	_	0	SENT_771	[p36l938t575r971b625],
10	et	FW	O	et	nn	11	SENT_771	[p36l1002t580r1046b615],
11	al.	FW	O	al.	appos	2	SENT_771	[p36l13t642r68b686],
12	.	.	O	.	_	0	SENT_771	[p36l13t642r68b686],

1	Phase	NN	O	phase	_	0	SENT_772	[p36l101t642r241b686],
2	I	NN	O	i	nn	5	SENT_772	[p36l271t646r288b686],
3	and	CC	O	and	_	0	SENT_772	[p36l318t642r407b686],
4	pharmacologic	JJ	O	pharmacologic	conj_and	2	SENT_772	[p36l437t642r807b699],
5	study	NN	O	study	dep	1	SENT_772	[p36l837t642r968b698],
6	of	IN	O	of	_	0	SENT_772	[p36l997t642r1053b686],
7	OSI	NNP	O	OSI	prep_of	5	SENT_772	[p36l13t717r213b768],
8	—	CD	NUMBER	—	dep	1	SENT_772	[p36l13t717r213b768],
9	774	CD	NUMBER	774	dep	8	SENT_772	[p36l13t717r213b768],
10	,	,	O	,	_	0	SENT_772	[p36l13t717r213b768],
11	an	DT	O	a	det	18	SENT_772	[p36l243t728r301b758],
12	epidermal	JJ	O	epidermal	amod	18	SENT_772	[p36l329t714r576b770],
13	growth	NN	O	growth	nn	18	SENT_772	[p36l603t714r782b771],
14	factor	NN	O	factor	nn	18	SENT_772	[p36l809t714r952b758],
15	receptor	NN	O	receptor	nn	18	SENT_772	[p36l978t729r1043b758, p36l13t795r168b842],
16	tyrosine	NN	O	tyrosine	nn	18	SENT_772	[p36l199t787r397b842],
17	kinase	NN	O	kinase	nn	18	SENT_772	[p36l431t786r590b831],
18	inhibitor	NN	O	inhibitor	appos	1	SENT_772	[p36l623t786r852b839],
19	,	,	O	,	_	0	SENT_772	[p36l623t786r852b839],
20	in	IN	O	in	_	0	SENT_772	[p36l888t787r935b830],
21	patients	NNS	O	patient	prep_in	1	SENT_772	[p36l967t800r1043b842, p36l13t857r148b900],
22	with	IN	O	with	_	0	SENT_772	[p36l171t856r282b901],
23	advanced	JJ	O	advanced	amod	25	SENT_772	[p36l306t856r531b901],
24	solid	JJ	O	solid	amod	25	SENT_772	[p36l556t856r673b900],
25	malignancies	NNS	O	malignancy	prep_with	21	SENT_772	[p36l697t856r1040b913],
26	.	.	O	.	_	0	SENT_772	[p36l697t856r1040b913],

1	J	NNP	O	J	nn	3	SENT_773	[p36l7t932r28b979],
2	Clin	NNP	O	Clin	nn	3	SENT_773	[p36l46t928r147b972],
3	Oncol	NNP	O	Oncol	_	0	SENT_773	[p36l166t928r311b972],
4	2001	CD	DATE	2001	num	3	SENT_773	[p36l330t931r736b981],
5	;	:	O	;	_	0	SENT_773	[p36l330t931r736b981],
6	19:3267	CD	NUMBER	19:3267	number	7	SENT_773	[p36l330t931r736b981],
7	—	CD	NUMBER	—	dep	3	SENT_773	[p36l330t931r736b981],
8	79	CD	NUMBER	79	dep	7	SENT_773	[p36l330t931r736b981],
9	.	.	O	.	_	0	SENT_773	[p36l330t931r736b981],

1	30	CD	NUMBER	30	_	0	SENT_774	[p36l13t1004r79b1043],
2	.	.	O	.	_	0	SENT_774	[p36l13t1004r79b1043],

1	Lacouture	NNP	O	Lacouture	nn	2	SENT_775	[p36l108t1003r353b1044],
2	ME	NNP	O	ME	_	0	SENT_775	[p36l380t1003r475b1043],
3	.	.	O	.	_	0	SENT_775	[p36l380t1003r475b1043],

1	Mechanisms	NNS	O	mechanism	_	0	SENT_776	[p36l506t999r817b1043],
2	of	IN	O	of	_	0	SENT_776	[p36l847t999r904b1043],
3	cutaneous	JJ	O	cutaneous	amod	4	SENT_776	[p36l923t1008r1043b1044, p36l13t1083r155b1114],
4	toxicities	NNS	O	toxicity	prep_of	1	SENT_776	[p36l184t1070r404b1113],
5	to	TO	O	to	_	0	SENT_776	[p36l433t1078r479b1113],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_776	[p36l507t1072r651b1116],
7	inhibitors	NNS	O	inhibitor	prep_to	1	SENT_776	[p36l673t1069r928b1113],
8	.	.	O	.	_	0	SENT_776	[p36l673t1069r928b1113],

1	Nat	NN	PERSON	nat	_	0	SENT_777	[p36l958t1073r1045b1113],

1	Rev	NN	O	rev	nn	2	SENT_778	[p36l12t1145r101b1188],
2	Cancer	NN	O	cancer	_	0	SENT_778	[p36l118t1144r289b1185],
3	2006	CD	DATE	2006	dep	2	SENT_778	[p36l307t1144r666b1194],
4	;	:	O	;	_	0	SENT_778	[p36l307t1144r666b1194],
5	6:803	CD	NUMBER	6:803	number	6	SENT_778	[p36l307t1144r666b1194],
6	—	CD	NUMBER	—	dep	2	SENT_778	[p36l307t1144r666b1194],
7	12	CD	NUMBER	12	dep	6	SENT_778	[p36l307t1144r666b1194],
8	.	.	O	.	_	0	SENT_778	[p36l307t1144r666b1194],

1	31	CD	NUMBER	31	_	0	SENT_779	[p36l13t1217r77b1256],
2	.	.	O	.	_	0	SENT_779	[p36l13t1217r77b1256],

1	Fukuoka	NNP	LOCATION	Fukuoka	nn	2	SENT_780	[p36l108t1212r322b1257],
2	M	NNP	O	M	_	0	SENT_780	[p36l336t1216r398b1265],
3	,	,	O	,	_	0	SENT_780	[p36l336t1216r398b1265],
4	Yano	NNP	PERSON	Yano	nn	5	SENT_780	[p36l415t1216r535b1256],
5	S	NNP	O	S	appos	2	SENT_780	[p36l554t1215r592b1265],
6	,	,	O	,	_	0	SENT_780	[p36l554t1215r592b1265],
7	Giaccone	NNP	PERSON	Giaccone	nn	8	SENT_780	[p36l612t1213r837b1256],
8	G	NNP	O	G	appos	2	SENT_780	[p36l854t1215r906b1265],
9	,	,	O	,	_	0	SENT_780	[p36l854t1215r906b1265],
10	et	FW	O	et	nn	11	SENT_780	[p36l927t1221r971b1256],
11	al.	FW	O	al.	appos	2	SENT_780	[p36l984t1212r1040b1256],
12	.	.	O	.	_	0	SENT_780	[p36l984t1212r1040b1256],

1	Multi-institutional	JJ	O	multi-institutional	nsubj	17	SENT_781	[p36l11t1282r470b1327],
2	randomized	VBN	O	randomize	partmod	1	SENT_781	[p36l503t1282r799b1326],
3	phase	NN	O	phase	nn	5	SENT_781	[p36l832t1282r974b1338],
4	II	CD	NUMBER	ii	num	5	SENT_781	[p36l1007t1286r1044b1326],
5	trial	NN	O	trial	dobj	2	SENT_781	[p36l13t1354r115b1398],
6	of	IN	O	of	_	0	SENT_781	[p36l133t1354r190b1398],
7	gefitinib	NN	O	gefitinib	prep_of	5	SENT_781	[p36l197t1354r409b1411],
8	for	IN	O	for	_	0	SENT_781	[p36l428t1354r498b1398],
9	previously	RB	DATE	previously	advmod	10	SENT_781	[p36l513t1354r765b1410],
10	treated	VBN	O	treat	amod	11	SENT_781	[p36l780t1354r951b1398],
11	patients	NNS	O	patient	prep_for	2	SENT_781	[p36l967t1368r1043b1410, p36l13t1426r148b1469],
12	with	IN	O	with	_	0	SENT_781	[p36l171t1425r282b1470],
13	advanced	JJ	O	advanced	amod	16	SENT_781	[p36l306t1425r532b1469],
14	non-small-cell	JJ	O	non-small-cell	amod	16	SENT_781	[p36l556t1425r911b1469],
15	lung	NN	O	lung	nn	16	SENT_781	[p36l935t1425r1045b1482],
16	cancer	NN	O	cancer	prep_with	11	SENT_781	[p36l13t1511r173b1541],
17	(	VBD	O	(	_	0	SENT_781	[p36l201t1497r291b1548],
18	the	DT	O	the	det	22	SENT_781	[p36l201t1497r291b1548],
19	IDEAL	NNP	O	IDEAL	nn	22	SENT_781	[p36l317t1501r477b1541],
20	1	CD	NUMBER	1	num	22	SENT_781	[p36l505t1500r529b1541],
21	Trial	NN	O	trial	nn	22	SENT_781	[p36l554t1497r701b1548],
22	)	NN	O	)	dobj	17	SENT_781	[p36l554t1497r701b1548],
23	.	.	O	.	_	0	SENT_781	[p36l554t1497r701b1548],

1	J	NNP	O	J	nn	3	SENT_782	[p36l725t1501r746b1548],
2	Clin	NNP	O	Clin	nn	3	SENT_782	[p36l771t1497r872b1541],
3	Oncol	NNP	O	Oncol	_	0	SENT_782	[p36l899t1497r1044b1541],
4	2003	CD	DATE	2003	num	3	SENT_782	[p36l13t1570r430b1620],
5	;	:	O	;	_	0	SENT_782	[p36l13t1570r430b1620],
6	21:2237	CD	NUMBER	21:2237	number	7	SENT_782	[p36l13t1570r430b1620],
7	-46	CD	NUMBER	-46	dep	3	SENT_782	[p36l13t1570r430b1620],
8	.	.	O	.	_	0	SENT_782	[p36l13t1570r430b1620],

1	[	NNP	O	[	_	0	SENT_783	[p36l466t1571r699b1620],
2	Erratum	NNP	O	Erratum	nn	6	SENT_783	[p36l466t1571r699b1620],
3	,	,	O	,	_	0	SENT_783	[p36l466t1571r699b1620],
4	J	NNP	O	J	appos	6	SENT_783	[p36l724t1571r745b1618],
5	Clin	NNP	O	Clin	nn	6	SENT_783	[p36l771t1567r872b1611],
6	Oncol	NNP	O	Oncol	dep	1	SENT_783	[p36l899t1567r1044b1611],
7	2004	CD	DATE	2004	rcmod	6	SENT_783	[p36l13t1642r371b1692],
8	;	:	O	;	_	0	SENT_783	[p36l13t1642r371b1692],
9	22:4811	CD	NUMBER	22:4811	dep	7	SENT_783	[p36l13t1642r371b1692],
10	.	.	O	.	_	0	SENT_783	[p36l13t1642r371b1692],
11	]	SYM	O	]	dep	7	SENT_783	[p36l13t1642r371b1692],

1	32	CD	NUMBER	32	_	0	SENT_784	[p36l13t1715r79b1754],
2	.	.	O	.	_	0	SENT_784	[p36l13t1715r79b1754],

1	Kris	NNP	PERSON	Kris	nn	2	SENT_785	[p36l109t1711r209b1755],
2	MG	NN	PERSON	mg	_	0	SENT_785	[p36l229t1713r331b1763],
3	,	,	O	,	_	0	SENT_785	[p36l229t1713r331b1763],
4	Natale	NNP	PERSON	Natale	nn	5	SENT_785	[p36l353t1710r511b1754],
5	RB	NN	O	rb	appos	2	SENT_785	[p36l531t1714r616b1763],
6	,	,	O	,	_	0	SENT_785	[p36l531t1714r616b1763],
7	Herbst	NNP	ORGANIZATION	Herbst	nn	8	SENT_785	[p36l639t1710r805b1754],
8	RS	NN	ORGANIZATION	r	appos	2	SENT_785	[p36l821t1713r900b1763],
9	,	,	O	,	_	0	SENT_785	[p36l821t1713r900b1763],
10	et	FW	O	et	nn	11	SENT_785	[p36l923t1719r967b1754],
11	al.	FW	O	al.	appos	2	SENT_785	[p36l984t1710r1040b1754],
12	.	.	O	.	_	0	SENT_785	[p36l984t1710r1040b1754],

1	Efficacy	NN	O	efficacy	_	0	SENT_786	[p36l12t1780r211b1836],
2	of	IN	O	of	_	0	SENT_786	[p36l236t1780r293b1824],
3	gefitinib	NN	O	gefitinib	prep_of	1	SENT_786	[p36l309t1780r535b1837],
4	,	,	O	,	_	0	SENT_786	[p36l309t1780r535b1837],
5	an	DT	O	a	det	6	SENT_786	[p36l565t1794r623b1824],
6	inhibitor	NN	O	inhibitor	appos	3	SENT_786	[p36l650t1780r868b1824],
7	of	IN	O	of	_	0	SENT_786	[p36l894t1780r950b1824],
8	the	DT	O	the	det	14	SENT_786	[p36l967t1780r1043b1824],
9	epidermal	JJ	O	epidermal	amod	14	SENT_786	[p36l13t1852r260b1908],
10	growth	NN	O	growth	nn	14	SENT_786	[p36l275t1852r454b1909],
11	factor	NN	O	factor	nn	14	SENT_786	[p36l470t1852r613b1896],
12	receptor	NN	O	receptor	nn	14	SENT_786	[p36l627t1861r830b1908],
13	tyrosine	NN	O	tyrosine	nn	14	SENT_786	[p36l845t1853r1043b1908],
14	kinase	NN	O	kinase	prep_of	6	SENT_786	[p36l13t1923r185b1977],
15	,	,	O	,	_	0	SENT_786	[p36l13t1923r185b1977],
16	in	IN	O	in	_	0	SENT_786	[p36l234t1924r281b1967],
17	symptomatic	JJ	O	symptomatic	amod	18	SENT_786	[p36l329t1924r647b1979],
18	patients	NNS	O	patient	prep_in	3	SENT_786	[p36l692t1924r887b1979],
19	with	IN	O	with	_	0	SENT_786	[p36l932t1923r1043b1968],
20	non-small	JJ	O	non-small	amod	23	SENT_786	[p36l13t1994r262b2038],
21	cell	NN	O	cell	nn	23	SENT_786	[p36l281t1994r364b2038],
22	lung	NN	O	lung	nn	23	SENT_786	[p36l382t1994r492b2051],
23	cancer	NN	O	cancer	prep_with	18	SENT_786	[p36l510t2008r682b2038],
24	:	:	O	:	_	0	SENT_786	[p36l510t2008r682b2038],
25	a	DT	O	a	det	27	SENT_786	[p36l703t2009r728b2038],
26	randomized	JJ	O	randomized	amod	27	SENT_786	[p36l746t1994r1043b2038],
27	trial	NN	O	trial	dep	1	SENT_786	[p36l13t2065r128b2109],
28	.	.	O	.	_	0	SENT_786	[p36l13t2065r128b2109],

1	JAMA	NNP	O	JAMA	_	0	SENT_787	[p36l145t2069r291b2116],
2	2003	CD	DATE	2003	num	1	SENT_787	[p36l309t2068r755b2118],
3	;	:	O	;	_	0	SENT_787	[p36l309t2068r755b2118],
4	290:2149	CD	NUMBER	290:2149	number	5	SENT_787	[p36l309t2068r755b2118],
5	-58	CD	NUMBER	-58	dep	1	SENT_787	[p36l309t2068r755b2118],
6	.	.	O	.	_	0	SENT_787	[p36l309t2068r755b2118],

1	33	CD	NUMBER	33	_	0	SENT_788	[p36l13t2141r77b2180],
2	.	.	O	.	_	0	SENT_788	[p36l13t2141r77b2180],

1	Thatcher	NNP	PERSON	Thatcher	nn	2	SENT_789	[p36l107t2136r327b2180],
2	N	NNP	O	N	_	0	SENT_789	[p36l346t2140r400b2189],
3	,	,	O	,	_	0	SENT_789	[p36l346t2140r400b2189],
4	Chang	NNP	PERSON	Chang	nn	5	SENT_789	[p36l424t2136r584b2193],
5	A	NNP	O	A	appos	2	SENT_789	[p36l602t2140r652b2190],
6	,	,	O	,	_	0	SENT_789	[p36l602t2140r652b2190],
7	Parikh	NNP	ORGANIZATION	Parikh	nn	8	SENT_789	[p36l676t2136r838b2181],
8	P	NN	ORGANIZATION	p	appos	2	SENT_789	[p36l859t2140r896b2190],
9	,	,	O	,	_	0	SENT_789	[p36l859t2140r896b2190],
10	et	FW	O	et	nn	11	SENT_789	[p36l922t2145r966b2180],
11	al.	FW	O	al.	appos	2	SENT_789	[p36l985t2136r1040b2180],
12	.	.	O	.	_	0	SENT_789	[p36l985t2136r1040b2180],

1	Gefitinib	NN	O	gefitinib	nsubj	8	SENT_790	[p36l13t2207r237b2251],
2	plus	CC	O	plus	prep	1	SENT_790	[p36l255t2207r355b2263],
3	best	JJS	O	best	dep	4	SENT_790	[p36l374t2207r475b2251],
4	supportive	JJ	O	supportive	amod	5	SENT_790	[p36l490t2208r747b2263],
5	care	NN	O	care	dep	2	SENT_790	[p36l765t2222r864b2251],
6	in	IN	O	in	prep	5	SENT_790	[p36l882t2208r929b2251],
7	previously	RB	DATE	previously	pcomp	6	SENT_790	[p36l945t2221r1043b2263, p36l10t2278r182b2334],
8	treated	VBN	O	treat	_	0	SENT_790	[p36l217t2278r388b2322],
9	patients	NNS	O	patient	dobj	8	SENT_790	[p36l423t2279r619b2334],
10	with	IN	O	with	_	0	SENT_790	[p36l655t2278r766b2323],
11	refractory	JJ	O	refractory	amod	15	SENT_790	[p36l803t2278r1046b2334],
12	advanced	JJ	O	advanced	amod	15	SENT_790	[p36l13t2350r239b2395],
13	non-small-cell	JJ	O	non-small-cell	amod	15	SENT_790	[p36l264t2350r619b2394],
14	lung	NN	O	lung	nn	15	SENT_790	[p36l643t2350r754b2407],
15	cancer	NN	O	cancer	prep_with	8	SENT_790	[p36l778t2364r950b2394],
16	:	:	O	:	_	0	SENT_790	[p36l778t2364r950b2394],
17	results	NNS	O	result	nsubj	20	SENT_790	[p36l978t2364r1043b2394, p36l14t2421r126b2466],
18	from	IN	O	from	advmod	20	SENT_790	[p36l164t2421r283b2465],
19	a	DT	O	a	dep	18	SENT_790	[p36l319t2436r344b2465],
20	randomised	VBN	O	randomise	parataxis	8	SENT_790	[p36l380t2421r686b2475],
21	,	,	O	,	_	0	SENT_790	[p36l380t2421r686b2475],
22	placebo	NN	O	placebo	nn	23	SENT_790	[p36l725t2421r1043b2477, p36l13t2493r188b2547],
23	—	NN	O	—	nsubj	24	SENT_790	[p36l725t2421r1043b2477, p36l13t2493r188b2547],
24	controlled	VBN	O	control	dep	8	SENT_790	[p36l725t2421r1043b2477, p36l13t2493r188b2547],
25	,	,	O	,	_	0	SENT_790	[p36l725t2421r1043b2477, p36l13t2493r188b2547],
26	multicentre	JJ	O	multicentre	amod	31	SENT_790	[p36l211t2493r494b2538],
27	study	NN	O	study	nn	31	SENT_790	[p36l515t2493r646b2549],
28	(	CD	NUMBER	(	num	31	SENT_790	[p36l667t2497r829b2544],
29	Iressa	NNP	O	Iressa	nn	31	SENT_790	[p36l667t2497r829b2544],
30	Survival	NNP	O	Survival	nn	31	SENT_790	[p36l849t2493r1044b2538],
31	Evaluation	NN	O	evaluation	ccomp	8	SENT_790	[p36l12t2564r270b2609],
32	in	IN	O	in	dep	31	SENT_790	[p36l330t2565r377b2608],
33	Lung	NN	O	lung	nn	35	SENT_790	[p36l437t2568r562b2621],
34	Cancer	NN	O	cancer	nn	35	SENT_790	[p36l621t2567r819b2615],
35	)	NN	O	)	pobj	32	SENT_790	[p36l621t2567r819b2615],
36	.	.	O	.	_	0	SENT_790	[p36l621t2567r819b2615],

1	Lancet	NNP	O	Lancet	_	0	SENT_791	[p36l882t2568r1046b2608],
2	2005	CD	DATE	2005	num	1	SENT_791	[p36l13t2639r448b2689],
3	;	:	O	;	_	0	SENT_791	[p36l13t2639r448b2689],
4	366:1527	CD	NUMBER	366:1527	number	5	SENT_791	[p36l13t2639r448b2689],
5	-37	CD	NUMBER	-37	dep	1	SENT_791	[p36l13t2639r448b2689],
6	.	.	O	.	_	0	SENT_791	[p36l13t2639r448b2689],

1	34	CD	NUMBER	34	_	0	SENT_792	[p36l13t2712r79b2751],
2	.	.	O	.	_	0	SENT_792	[p36l13t2712r79b2751],

1	Niho	NNP	O	Niho	nn	2	SENT_793	[p36l108t2707r229b2751],
2	S	NNP	O	S	_	0	SENT_793	[p36l258t2710r296b2760],
3	,	,	O	,	_	0	SENT_793	[p36l258t2710r296b2760],
4	Ichinose	NNP	PERSON	Ichinose	nn	5	SENT_793	[p36l326t2707r534b2751],
5	Y	NN	PERSON	y	appos	2	SENT_793	[p36l559t2711r600b2760],
6	,	,	O	,	_	0	SENT_793	[p36l559t2711r600b2760],
7	Tamura	NNP	PERSON	Tamura	nn	8	SENT_793	[p36l628t2710r819b2751],
8	T	NN	O	t	appos	2	SENT_793	[p36l842t2711r886b2761],
9	,	,	O	,	_	0	SENT_793	[p36l842t2711r886b2761],
10	et	FW	O	et	nn	11	SENT_793	[p36l916t2716r961b2751],
11	al.	FW	O	al.	appos	2	SENT_793	[p36l984t2707r1040b2751],
12	.	.	O	.	_	0	SENT_793	[p36l984t2707r1040b2751],

1	Results	NNS	O	result	_	0	SENT_794	[p36l12t2778r190b2825],
2	of	IN	O	of	_	0	SENT_794	[p36l208t2778r264b2822],
3	a	DT	O	a	det	7	SENT_794	[p36l269t2793r295b2822],
4	randomized	JJ	O	randomized	amod	7	SENT_794	[p36l309t2778r606b2822],
5	phase	NN	O	phase	nn	7	SENT_794	[p36l621t2778r763b2834],
6	III	CD	NUMBER	iii	num	7	SENT_794	[p36l778t2782r835b2821],
7	study	NN	O	study	prep_of	1	SENT_794	[p36l852t2778r982b2834],
8	to	TO	O	to	aux	9	SENT_794	[p36l996t2787r1042b2822],
9	compare	VB	O	compare	infmod	1	SENT_794	[p36l13t2863r224b2905],
10	the	DT	O	the	det	12	SENT_794	[p36l250t2849r326b2893],
11	overall	JJ	O	overall	amod	12	SENT_794	[p36l352t2849r516b2893],
12	survival	NN	O	survival	dobj	9	SENT_794	[p36l542t2849r731b2894],
13	of	IN	O	of	_	0	SENT_794	[p36l758t2849r814b2893],
14	gefitinib	NN	O	gefitinib	prep_of	12	SENT_794	[p36l830t2849r1042b2906],
15	versus	CC	O	versus	_	0	SENT_794	[p36l10t2935r163b2966],
16	docetaxel	NN	O	docetaxel	dobj	9	SENT_794	[p36l181t2921r413b2965],
17	in	IN	O	in	_	0	SENT_794	[p36l429t2922r476b2965],
18	Japanese	JJ	MISC	japanese	amod	19	SENT_794	[p36l488t2925r705b2977],
19	patients	NNS	O	patient	prep_in	16	SENT_794	[p36l721t2922r917b2977],
20	with	IN	O	with	_	0	SENT_794	[p36l932t2921r1043b2966],
21	non-small	JJ	O	non-small	amod	24	SENT_794	[p36l13t2991r262b3035],
22	cell	NN	O	cell	nn	24	SENT_794	[p36l280t2991r363b3035],
23	lung	NN	O	lung	nn	24	SENT_794	[p36l380t2991r490b3048],
24	cancer	NN	O	cancer	prep_with	9	SENT_794	[p36l506t3005r666b3035],
25	who	WP	O	who	nsubj	26	SENT_794	[p36l680t2991r783b3036],
26	failed	VBD	O	fail	rcmod	24	SENT_794	[p36l802t2991r939b3035],
27	one	CD	NUMBER	one	nn	31	SENT_794	[p36l957t3005r1043b3035],
28	or	CC	O	or	_	0	SENT_794	[p36l13t3076r63b3106],
29	two	CD	NUMBER	two	conj_or	27	SENT_794	[p36l99t3071r188b3107],
30	chemotherapy	NN	O	chemotherapy	nn	31	SENT_794	[p36l227t3062r575b3118],
31	regimens	NNS	O	regimen	dobj	26	SENT_794	[p36l610t3063r851b3119],
32	.	.	O	.	_	0	SENT_794	[p36l610t3063r851b3119],

1	J	NNP	O	J	nn	3	SENT_795	[p36l886t3066r907b3113],
2	Clin	NNP	O	Clin	nn	3	SENT_795	[p36l942t3062r1043b3106],
3	Oncol	NNP	O	Oncol	_	0	SENT_795	[p36l13t3134r157b3178],
4	2007:25	CD	NUMBER	2007:25	num	3	SENT_795	[p36l176t3134r660b3190],
5	:	:	O	:	_	0	SENT_795	[p36l176t3134r660b3190],
6	Suppl	NNP	O	Suppl	dep	3	SENT_795	[p36l176t3134r660b3190],
7	:387	CD	NUMBER	:387	num	8	SENT_795	[p36l176t3134r660b3190],
8	s.	NN	O	s.	npadvmod	9	SENT_795	[p36l176t3134r660b3190],
9	abstract	JJ	O	abstract	amod	6	SENT_795	[p36l682t3134r891b3178],
10	.	.	O	.	_	0	SENT_795	[p36l682t3134r891b3178],

1	35	CD	NUMBER	35	_	0	SENT_796	[p36l13t3209r77b3248],
2	.	.	O	.	_	0	SENT_796	[p36l13t3209r77b3248],

1	Douillard	NNP	PERSON	Douillard	nn	2	SENT_797	[p36l108t3204r345b3249],
2	J-Y	NNP	O	J-Y	nsubj	31	SENT_797	[p36l367t3208r445b3258],
3	,	,	O	,	_	0	SENT_797	[p36l367t3208r445b3258],
4	Kim	NNP	PERSON	Kim	nn	5	SENT_797	[p36l475t3205r579b3249],
5	E	NNP	PERSON	E	appos	2	SENT_797	[p36l606t3208r650b3257],
6	,	,	O	,	_	0	SENT_797	[p36l606t3208r650b3257],
7	Hirsh	NNP	PERSON	Hirsh	nn	9	SENT_797	[p36l681t3204r819b3248],
8	V.	NNP	PERSON	V.	nn	9	SENT_797	[p36l845t3208r887b3248],
9	Gefitinib	NNP	PERSON	Gefitinib	appos	2	SENT_797	[p36l917t3204r1043b3248, p36l13t3276r128b3320],
10	(	CD	NUMBER	(	num	11	SENT_797	[p36l169t3279r386b3327],
11	IRESSA	NNP	O	IRESSA	dep	9	SENT_797	[p36l169t3279r386b3327],
12	)	CD	NUMBER	)	num	11	SENT_797	[p36l169t3279r386b3327],
13	versus	CC	O	versus	_	0	SENT_797	[p36l424t3290r576b3321],
14	docetaxel	NN	O	docetaxel	appos	2	SENT_797	[p36l615t3276r847b3320],
15	in	IN	O	in	_	0	SENT_797	[p36l884t3277r931b3320],
16	patients	NNS	O	patient	prep_in	14	SENT_797	[p36l967t3290r1043b3332, p36l13t3348r148b3391],
17	with	IN	O	with	_	0	SENT_797	[p36l166t3347r277b3392],
18	locally	RB	O	locally	advmod	19	SENT_797	[p36l296t3347r458b3403],
19	advanced	VBN	O	advance	prep_with	16	SENT_797	[p36l474t3347r700b3391],
20	or	CC	O	or	_	0	SENT_797	[p36l720t3361r770b3391],
21	metastatic	JJ	O	metastatic	amod	24	SENT_797	[p36l788t3348r1044b3391],
22	non-small-cell	JJ	O	non-small-cell	amod	24	SENT_797	[p36l13t3417r368b3461],
23	lung	NN	O	lung	nn	24	SENT_797	[p36l413t3417r523b3474],
24	cancer	NN	O	cancer	conj_or	19	SENT_797	[p36l568t3431r728b3461],
25	pre-treated	VBN	O	pre-treat	partmod	24	SENT_797	[p36l772t3417r1043b3473],
26	with	IN	O	with	_	0	SENT_797	[p36l10t3489r121b3534],
27	platinum-based	JJ	O	platinum-based	amod	28	SENT_797	[p36l171t3489r557b3545],
28	chemotherapy	NN	O	chemotherapy	prep_with	25	SENT_797	[p36l607t3489r967b3545],
29	:	:	O	:	_	0	SENT_797	[p36l607t3489r967b3545],
30	a	DT	O	a	advmod	31	SENT_797	[p36l1019t3504r1044b3533],
31	randomized	VBN	O	randomize	_	0	SENT_797	[p36l13t3560r323b3613],
32	,	,	O	,	_	0	SENT_797	[p36l13t3560r323b3613],
33	open-label	JJ	O	open-label	amod	38	SENT_797	[p36l360t3560r616b3616],
34	phase	NN	O	phase	nn	38	SENT_797	[p36l649t3560r790b3616],
35	III	CD	NUMBER	iii	num	38	SENT_797	[p36l823t3564r881b3604],
36	study	NN	O	study	nn	38	SENT_797	[p36l915t3560r1045b3616],
37	(	CD	NUMBER	(	num	38	SENT_797	[p36l15t3633r329b3681],
38	INTEREST	NN	O	interest	dep	39	SENT_797	[p36l15t3633r329b3681],
39	)	CD	NUMBER	)	ccomp	31	SENT_797	[p36l15t3633r329b3681],
40	.	.	O	.	_	0	SENT_797	[p36l15t3633r329b3681],

1	Presented	VBN	O	present	_	0	SENT_798	[p36l351t3630r591b3674],
2	at	IN	O	at	_	0	SENT_798	[p36l610t3639r654b3674],
3	the	DT	O	the	det	6	SENT_798	[p36l671t3630r747b3674],
4	12th	JJ	ORDINAL	12th	amod	6	SENT_798	[p36l768t3630r877b3674],
5	World	NN	MISC	world	nn	6	SENT_798	[p36l894t3630r1043b3674],
6	Conference	NN	MISC	conference	prep_at	1	SENT_798	[p36l13t3702r291b3746],
7	on	IN	MISC	on	_	0	SENT_798	[p36l310t3716r370b3746],
8	Lung	NN	MISC	lung	nn	9	SENT_798	[p36l388t3706r513b3759],
9	Cancer	NN	MISC	cancer	prep_on	6	SENT_798	[p36l530t3705r711b3756],
10	,	,	O	,	_	0	SENT_798	[p36l530t3705r711b3756],
11	Seoul	NNP	LOCATION	Seoul	nn	14	SENT_798	[p36l735t3702r880b3756],
12	,	,	O	,	_	0	SENT_798	[p36l735t3702r880b3756],
13	South	NNP	LOCATION	South	appos	14	SENT_798	[p36l903t3702r1043b3747],
14	Korea	NNP	LOCATION	Korea	appos	9	SENT_798	[p36l13t3778r168b3828],
15	,	,	O	,	_	0	SENT_798	[p36l13t3778r168b3828],
16	September	NNP	DATE	September	tmod	6	SENT_798	[p36l192t3774r452b3830],
17	2-6	CD	DATE	2-6	num	16	SENT_798	[p36l470t3777r572b3827],
18	,	,	DATE	,	_	0	SENT_798	[p36l470t3777r572b3827],
19	2007	CD	DATE	2007	num	16	SENT_798	[p36l594t3777r718b3818],
20	.	.	O	.	_	0	SENT_798	[p36l594t3777r718b3818],

1	abstract	JJ	O	abstract	_	0	SENT_799	[p36l740t3774r949b3818],
2	.	.	O	.	_	0	SENT_799	[p36l740t3774r949b3818],

1	40	CD	NUMBER	40	_	0	SENT_800	[p36l1117t434r1186b473],
2	.	.	O	.	_	0	SENT_800	[p36l1117t434r1186b473],

1	Giaccone	NNP	PERSON	Giaccone	nn	2	SENT_801	[p36l1215t430r1439b473],
2	G	NNP	PERSON	G	_	0	SENT_801	[p36l1463t432r1515b482],
3	,	,	O	,	_	0	SENT_801	[p36l1463t432r1515b482],
4	Herbst	NNP	ORGANIZATION	Herbst	nn	5	SENT_801	[p36l1541t429r1707b473],
5	RS	NN	ORGANIZATION	r	appos	2	SENT_801	[p36l1727t432r1806b483],
6	,	,	O	,	_	0	SENT_801	[p36l1727t432r1806b483],
7	Manegold	NNP	ORGANIZATION	Manegold	nn	8	SENT_801	[p36l1831t429r2075b486],
8	C	NNP	ORGANIZATION	C	appos	2	SENT_801	[p36l2099t432r2146b483],
9	,	,	O	,	_	0	SENT_801	[p36l2099t432r2146b483],
10	et	FW	O	et	nn	11	SENT_801	[p36l1119t509r1163b544],
11	al.	FW	O	al.	appos	2	SENT_801	[p36l1179t500r1234b544],
12	.	.	O	.	_	0	SENT_801	[p36l1179t500r1234b544],

1	Gefitinib	NNP	O	Gefitinib	_	0	SENT_802	[p36l1257t500r1481b544],
2	in	IN	O	in	_	0	SENT_802	[p36l1501t501r1548b544],
3	combination	NN	O	combination	prep_in	1	SENT_802	[p36l1568t500r1879b544],
4	with	IN	O	with	_	0	SENT_802	[p36l1896t500r2007b545],
5	gemcitabine	NN	O	gemcitabine	prep_with	3	SENT_802	[p36l2026t514r2148b557, p36l1119t571r1312b615],
6	and	CC	O	and	_	0	SENT_802	[p36l1342t571r1432b615],
7	cisplatin	NN	O	cisplatin	conj_and	5	SENT_802	[p36l1463t571r1672b627],
8	in	IN	O	in	_	0	SENT_802	[p36l1703t572r1750b615],
9	advanced	JJ	O	advanced	amod	12	SENT_802	[p36l1780t571r2006b616],
10	nonsmall-cell	JJ	O	nonsmall-cell	amod	12	SENT_802	[p36l2037t585r2148b615, p36l1119t642r1359b686],
11	lung	NN	O	lung	nn	12	SENT_802	[p36l1389t642r1499b699],
12	cancer	NN	O	cancer	prep_in	1	SENT_802	[p36l1528t656r1701b686],
13	:	:	O	:	_	0	SENT_802	[p36l1528t656r1701b686],
14	a	DT	O	a	det	17	SENT_802	[p36l1734t657r1758b686],
15	phase	NN	O	phase	nn	17	SENT_802	[p36l1787t642r1929b698],
16	III	CD	NUMBER	iii	num	17	SENT_802	[p36l1959t646r2017b686],
17	trial	NN	O	trial	dep	1	SENT_802	[p36l2047t642r2149b686],
18	—	CD	NUMBER	—	num	19	SENT_802	[p36l1116t739r1177b744],
19	INTACT	NN	O	intact	dep	17	SENT_802	[p36l1200t717r1402b759],
20	1	CD	NUMBER	1	dep	19	SENT_802	[p36l1429t717r1467b758],
21	.	.	O	.	_	0	SENT_802	[p36l1429t717r1467b758],

1	J	NNP	O	J	nn	3	SENT_803	[p36l1491t718r1512b765],
2	Clin	NNP	O	Clin	nn	3	SENT_803	[p36l1536t714r1637b758],
3	Oncol	NNP	O	Oncol	_	0	SENT_803	[p36l1663t714r1808b758],
4	2004	CD	DATE	2004	num	3	SENT_803	[p36l1834t717r2148b767, p36l1119t789r1189b830],
5	;	:	O	;	_	0	SENT_803	[p36l1834t717r2148b767, p36l1119t789r1189b830],
6	22:77784	CD	NUMBER	22:77784	dep	3	SENT_803	[p36l1834t717r2148b767, p36l1119t789r1189b830],
7	.	.	O	.	_	0	SENT_803	[p36l1834t717r2148b767, p36l1119t789r1189b830],

1	41	CD	NUMBER	41	_	0	SENT_804	[p36l1117t862r1184b900],
2	.	.	O	.	_	0	SENT_804	[p36l1117t862r1184b900],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_805	[p36l1214t856r1380b900],
2	RS	NN	ORGANIZATION	r	_	0	SENT_805	[p36l1395t859r1473b909],
3	,	,	O	,	_	0	SENT_805	[p36l1395t859r1473b909],
4	Giaccone	NNP	PERSON	Giaccone	nn	5	SENT_805	[p36l1494t857r1719b900],
5	G	NNP	PERSON	G	appos	2	SENT_805	[p36l1737t859r1790b910],
6	,	,	O	,	_	0	SENT_805	[p36l1737t859r1790b910],
7	Schiller	NNP	PERSON	Schiller	nn	8	SENT_805	[p36l1812t856r1998b900],
8	JH	NNP	O	JH	appos	2	SENT_805	[p36l2009t860r2086b909],
9	,	,	O	,	_	0	SENT_805	[p36l2009t860r2086b909],
10	et	FW	O	et	nn	11	SENT_805	[p36l2108t865r2152b900],
11	al.	FW	O	al.	appos	2	SENT_805	[p36l1118t928r1174b972],
12	.	.	O	.	_	0	SENT_805	[p36l1118t928r1174b972],

1	Gefitinib	NNP	O	Gefitinib	_	0	SENT_806	[p36l1206t928r1430b972],
2	in	IN	O	in	_	0	SENT_806	[p36l1460t929r1507b972],
3	combination	NN	O	combination	prep_in	1	SENT_806	[p36l1536t928r1848b972],
4	with	IN	O	with	_	0	SENT_806	[p36l1875t928r1986b973],
5	paclitaxel	NN	O	paclitaxel	prep_with	3	SENT_806	[p36l2013t928r2148b984, p36l1119t999r1235b1043],
6	and	CC	O	and	_	0	SENT_806	[p36l1266t999r1355b1043],
7	carboplatin	NN	O	carboplatin	conj_and	5	SENT_806	[p36l1387t999r1670b1055],
8	in	IN	O	in	_	0	SENT_806	[p36l1701t1000r1748b1043],
9	advanced	JJ	O	advanced	amod	12	SENT_806	[p36l1780t999r2005b1043],
10	nonsmall-cell	JJ	O	nonsmall-cell	amod	12	SENT_806	[p36l2037t1013r2148b1043, p36l1119t1069r1359b1113],
11	lung	NN	O	lung	nn	12	SENT_806	[p36l1389t1069r1499b1126],
12	cancer	NN	O	cancer	prep_in	1	SENT_806	[p36l1528t1083r1701b1113],
13	:	:	O	:	_	0	SENT_806	[p36l1528t1083r1701b1113],
14	a	DT	O	a	det	17	SENT_806	[p36l1734t1084r1758b1113],
15	phase	NN	O	phase	nn	17	SENT_806	[p36l1787t1069r1929b1125],
16	III	CD	NUMBER	iii	num	17	SENT_806	[p36l1959t1073r2017b1113],
17	trial	NN	O	trial	dep	1	SENT_806	[p36l2047t1069r2149b1113],
18	—	CD	NUMBER	—	num	19	SENT_806	[p36l1116t1166r1177b1171],
19	INTACT	NN	O	intact	dep	17	SENT_806	[p36l1199t1144r1402b1185],
20	2	CD	NUMBER	2	dep	19	SENT_806	[p36l1426t1144r1467b1185],
21	.	.	O	.	_	0	SENT_806	[p36l1426t1144r1467b1185],

1	J	NNP	O	J	nn	3	SENT_807	[p36l1490t1145r1512b1192],
2	Clin	NNP	O	Clin	nn	3	SENT_807	[p36l1536t1141r1637b1185],
3	Oncol	NNP	O	Oncol	_	0	SENT_807	[p36l1662t1141r1807b1185],
4	2004	CD	DATE	2004	num	3	SENT_807	[p36l1833t1144r2148b1194, p36l1118t1215r1189b1256],
5	;	:	O	;	_	0	SENT_807	[p36l1833t1144r2148b1194, p36l1118t1215r1189b1256],
6	22:78594	CD	NUMBER	22:78594	dep	3	SENT_807	[p36l1833t1144r2148b1194, p36l1118t1215r1189b1256],
7	.	.	O	.	_	0	SENT_807	[p36l1833t1144r2148b1194, p36l1118t1215r1189b1256],

1	42	CD	NUMBER	42	_	0	SENT_808	[p36l1117t1288r1186b1326],
2	.	.	O	.	_	0	SENT_808	[p36l1117t1288r1186b1326],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_809	[p36l1214t1282r1380b1326],
2	RS	NN	ORGANIZATION	r	_	0	SENT_809	[p36l1402t1285r1481b1336],
3	,	,	O	,	_	0	SENT_809	[p36l1402t1285r1481b1336],
4	Prager	NN	PERSON	prager	nn	5	SENT_809	[p36l1509t1286r1668b1339],
5	D	NN	PERSON	d	appos	2	SENT_809	[p36l1691t1286r1742b1336],
6	,	,	O	,	_	0	SENT_809	[p36l1691t1286r1742b1336],
7	Hermann	NNP	PERSON	Hermann	nn	8	SENT_809	[p36l1770t1286r2005b1326],
8	R	NNP	PERSON	R	appos	2	SENT_809	[p36l2029t1286r2078b1336],
9	,	,	O	,	_	0	SENT_809	[p36l2029t1286r2078b1336],
10	et	FW	O	et	nn	11	SENT_809	[p36l2108t1291r2151b1326],
11	al.	FW	O	al.	appos	2	SENT_809	[p36l1118t1354r1174b1398],
12	.	.	O	.	_	0	SENT_809	[p36l1118t1354r1174b1398],

1	TRIBUTE	NN	O	tribute	_	0	SENT_810	[p36l1195t1357r1443b1401],
2	:	:	O	:	_	0	SENT_810	[p36l1195t1357r1443b1401],
3	a	DT	O	a	det	6	SENT_810	[p36l1465t1369r1491b1398],
4	phase	NN	O	phase	nn	6	SENT_810	[p36l1509t1354r1651b1410],
5	III	CD	NUMBER	iii	num	6	SENT_810	[p36l1671t1358r1728b1398],
6	trial	NN	O	trial	dep	1	SENT_810	[p36l1748t1354r1850b1398],
7	of	IN	O	of	_	0	SENT_810	[p36l1871t1354r1927b1398],
8	erlotinib	NN	O	erlotinib	nn	9	SENT_810	[p36l1938t1354r2148b1398],
9	hydrochloride	NN	O	hydrochloride	prep_of	6	SENT_810	[p36l1118t1425r1461b1481],
10	(	CD	NUMBER	(	num	14	SENT_810	[p36l1502t1428r1719b1476],
11	OSI	NNP	O	OSI	amod	14	SENT_810	[p36l1502t1428r1719b1476],
12	—	CD	NUMBER	—	num	11	SENT_810	[p36l1502t1428r1719b1476],
13	774	CD	NUMBER	774	dep	11	SENT_810	[p36l1502t1428r1719b1476],
14	)	NN	O	)	dep	9	SENT_810	[p36l1502t1428r1719b1476],
15	combined	VBN	O	combine	partmod	9	SENT_810	[p36l1761t1425r2002b1469],
16	with	IN	O	with	_	0	SENT_810	[p36l2038t1425r2149b1470],
17	carboplatin	NN	O	carboplatin	nn	20	SENT_810	[p36l1119t1497r1401b1553],
18	and	CC	O	and	_	0	SENT_810	[p36l1427t1497r1517b1541],
19	paclitaxel	NN	O	paclitaxel	nn	20	SENT_810	[p36l1541t1497r1777b1553],
20	chemotherapy	NN	O	chemotherapy	prep_with	15	SENT_810	[p36l1803t1497r2151b1553],
21	in	IN	O	in	_	0	SENT_810	[p36l1118t1568r1165b1611],
22	advanced	JJ	O	advanced	amod	25	SENT_810	[p36l1195t1567r1421b1612],
23	non-small-cell	JJ	O	non-small-cell	amod	25	SENT_810	[p36l1451t1567r1806b1611],
24	lung	NN	O	lung	nn	25	SENT_810	[p36l1836t1567r1946b1624],
25	cancer	NN	O	cancer	prep_in	15	SENT_810	[p36l1975t1581r2145b1611],
26	.	.	O	.	_	0	SENT_810	[p36l1975t1581r2145b1611],

1	JClin	NN	O	jclin	nn	2	SENT_811	[p36l1113t1639r1253b1690],
2	Oncol	NN	O	oncol	_	0	SENT_811	[p36l1272t1639r1417b1683],
3	2005	CD	DATE	2005	dep	2	SENT_811	[p36l1436t1642r1819b1692],
4	;	:	O	;	_	0	SENT_811	[p36l1436t1642r1819b1692],
5	23:5892	CD	NUMBER	23:5892	number	6	SENT_811	[p36l1436t1642r1819b1692],
6	—	CD	NUMBER	—	dep	2	SENT_811	[p36l1436t1642r1819b1692],
7	9	CD	NUMBER	9	dep	6	SENT_811	[p36l1436t1642r1819b1692],
8	.	.	O	.	_	0	SENT_811	[p36l1436t1642r1819b1692],

1	43	CD	NUMBER	43	_	0	SENT_812	[p36l1117t1715r1184b1754],
2	.	.	O	.	_	0	SENT_812	[p36l1117t1715r1184b1754],

1	Gatzemeier	NNP	PERSON	Gatzemeier	nn	2	SENT_813	[p36l1215t1711r1498b1754],
2	U	NNP	PERSON	U	_	0	SENT_813	[p36l1516t1714r1566b1764],
3	,	,	O	,	_	0	SENT_813	[p36l1516t1714r1566b1764],
4	Pluzanska	NNP	O	Pluzanska	nn	5	SENT_813	[p36l1588t1710r1837b1755],
5	A	NNP	O	A	appos	2	SENT_813	[p36l1855t1714r1905b1763],
6	,	,	O	,	_	0	SENT_813	[p36l1855t1714r1905b1763],
7	Szczesna	NNP	O	Szczesna	nn	8	SENT_813	[p36l1929t1713r2150b1754],
8	A	NNP	O	A	appos	2	SENT_813	[p36l1116t1784r1166b1833],
9	,	,	O	,	_	0	SENT_813	[p36l1116t1784r1166b1833],
10	et	FW	O	et	nn	11	SENT_813	[p36l1201t1789r1245b1824],
11	al.	FW	O	al.	appos	2	SENT_813	[p36l1273t1780r1328b1824],
12	.	.	O	.	_	0	SENT_813	[p36l1273t1780r1328b1824],

1	Phase	NN	O	phase	nn	3	SENT_814	[p36l1362t1780r1502b1824],
2	III	CD	NUMBER	iii	num	3	SENT_814	[p36l1533t1784r1590b1824],
3	study	NN	O	study	_	0	SENT_814	[p36l1622t1780r1753b1836],
4	of	IN	O	of	_	0	SENT_814	[p36l1782t1780r1839b1824],
5	erlotinib	NN	O	erlotinib	prep_of	3	SENT_814	[p36l1860t1780r2070b1824],
6	in	IN	O	in	_	0	SENT_814	[p36l2102t1781r2149b1824],
7	combination	NN	O	combination	prep_in	5	SENT_814	[p36l1119t1852r1431b1896],
8	with	IN	O	with	_	0	SENT_814	[p36l1475t1852r1586b1897],
9	cisplatin	NN	O	cisplatin	prep_with	7	SENT_814	[p36l1633t1852r1843b1908],
10	and	CC	O	and	_	0	SENT_814	[p36l1889t1852r1979b1896],
11	gemcitabine	NN	O	gemcitabine	conj_and	9	SENT_814	[p36l2026t1866r2148b1909, p36l1119t1923r1312b1967],
12	in	IN	O	in	_	0	SENT_814	[p36l1337t1924r1384b1967],
13	advanced	JJ	O	advanced	amod	17	SENT_814	[p36l1409t1923r1634b1968],
14	non-small	JJ	O	non-small	amod	17	SENT_814	[p36l1659t1923r1908b1967],
15	cell	NN	O	cell	nn	17	SENT_814	[p36l1933t1923r2017b1967],
16	lung	NN	O	lung	nn	17	SENT_814	[p36l2040t1923r2151b1980],
17	cancer	NN	O	cancer	prep_in	3	SENT_814	[p36l1119t2008r1292b2038],
18	:	:	O	:	_	0	SENT_814	[p36l1119t2008r1292b2038],
19	the	DT	O	the	det	22	SENT_814	[p36l1318t1994r1394b2038],
20	Tarceva	NNP	O	Tarceva	nn	22	SENT_814	[p36l1417t1998r1604b2038],
21	Lung	NN	O	lung	nn	22	SENT_814	[p36l1627t1998r1752b2051],
22	Cancer	NN	O	cancer	dep	3	SENT_814	[p36l1775t1997r1945b2038],
23	Investigation	NN	O	investigation	nn	24	SENT_814	[p36l1967t1995r2148b2039, p36l1118t2066r1274b2122],
24	Trial	NN	O	trial	dep	22	SENT_814	[p36l1301t2065r1430b2109],
25	.	.	O	.	_	0	SENT_814	[p36l1301t2065r1430b2109],

1	J	NNP	O	J	nn	3	SENT_815	[p36l1456t2069r1477b2116],
2	Clin	NNP	O	Clin	nn	3	SENT_815	[p36l1505t2065r1605b2109],
3	Oncol	NNP	O	Oncol	_	0	SENT_815	[p36l1634t2065r1778b2109],
4	2007	CD	DATE	2007	num	3	SENT_815	[p36l1807t2068r2148b2118, p36l1120t2139r1188b2180],
5	;	:	O	;	_	0	SENT_815	[p36l1807t2068r2148b2118, p36l1120t2139r1188b2180],
6	25:154552	CD	NUMBER	25:154552	dep	3	SENT_815	[p36l1807t2068r2148b2118, p36l1120t2139r1188b2180],
7	.	.	O	.	_	0	SENT_815	[p36l1807t2068r2148b2118, p36l1120t2139r1188b2180],

1	44	CD	NUMBER	44	_	0	SENT_816	[p36l1117t2213r1187b2251],
2	.	.	O	.	_	0	SENT_816	[p36l1117t2213r1187b2251],

1	Dancey	NNP	O	Dancey	nn	2	SENT_817	[p36l1214t2211r1394b2263],
2	IE	NN	O	ie	nsubj	12	SENT_817	[p36l1412t2211r1478b2261],
3	,	,	O	,	_	0	SENT_817	[p36l1412t2211r1478b2261],
4	Freidlin	NNP	O	Freidlin	nn	11	SENT_817	[p36l1506t2207r1697b2251],
5	B.	NNP	O	B.	nn	11	SENT_817	[p36l1722t2211r1768b2251],
6	Targeting	NN	O	targeting	nn	11	SENT_817	[p36l1794t2208r2036b2264],
7	epidermal	JJ	O	epidermal	amod	11	SENT_817	[p36l2059t2208r2148b2263, p36l1119t2278r1292b2322],
8	growth	NN	O	growth	nn	11	SENT_817	[p36l1315t2278r1494b2335],
9	factor	NN	O	factor	nn	11	SENT_817	[p36l1517t2278r1660b2322],
10	receptor	NN	O	receptor	nn	11	SENT_817	[p36l1683t2287r1886b2334],
11	—	NN	O	—	nsubj	12	SENT_817	[p36l1906t2303r1966b2308],
12	are	VBP	O	be	_	0	SENT_817	[p36l1987t2292r2061b2322],
13	we	PRP	O	we	nsubj	14	SENT_817	[p36l2082t2293r2149b2323],
14	missing	VBG	O	miss	dep	12	SENT_817	[p36l1118t2351r1315b2407],
15	the	DT	O	the	det	16	SENT_817	[p36l1332t2350r1408b2394],
16	mark	NN	O	mark	dobj	14	SENT_817	[p36l1427t2349r1576b2395],
17	?	.	O	?	_	0	SENT_817	[p36l1427t2349r1576b2395],

1	Lancet	NNP	O	Lancet	_	0	SENT_818	[p36l1595t2354r1759b2394],
2	2003	CD	DATE	2003	num	1	SENT_818	[p36l1775t2353r2132b2403],
3	;	:	O	;	_	0	SENT_818	[p36l1775t2353r2132b2403],
4	362:62	CD	NUMBER	362:62	number	5	SENT_818	[p36l1775t2353r2132b2403],
5	-4	CD	NUMBER	-4	dep	1	SENT_818	[p36l1775t2353r2132b2403],
6	.	.	O	.	_	0	SENT_818	[p36l1775t2353r2132b2403],

1	45	CD	NUMBER	45	_	0	SENT_819	[p36l1117t2427r1184b2465],
2	.	.	O	.	_	0	SENT_819	[p36l1117t2427r1184b2465],

1	Baselga	NNP	PERSON	Baselga	nn	2	SENT_820	[p36l1214t2421r1401b2478],
2	J	NNP	PERSON	J	_	0	SENT_820	[p36l1413t2425r1445b2474],
3	,	,	O	,	_	0	SENT_820	[p36l1413t2425r1445b2474],
4	Pfister	NNP	PERSON	Pfister	nn	5	SENT_820	[p36l1466t2421r1628b2465],
5	D	NNP	O	D	appos	2	SENT_820	[p36l1644t2425r1695b2474],
6	,	,	O	,	_	0	SENT_820	[p36l1644t2425r1695b2474],
7	Cooper	NNP	PERSON	Cooper	nn	8	SENT_820	[p36l1716t2424r1894b2477],
8	MR	NN	PERSON	mr	appos	2	SENT_820	[p36l1909t2425r2009b2475],
9	,	,	O	,	_	0	SENT_820	[p36l1909t2425r2009b2475],
10	et	FW	O	et	nn	11	SENT_820	[p36l2031t2430r2075b2465],
11	al.	FW	O	al.	appos	2	SENT_820	[p36l2090t2421r2145b2465],
12	.	.	O	.	_	0	SENT_820	[p36l2090t2421r2145b2465],

1	Phase	NN	O	phase	_	0	SENT_821	[p36l1118t2493r1258b2537],
2	1	CD	NUMBER	1	num	3	SENT_821	[p36l1280t2497r1297b2537],
3	studies	NNS	O	study	dep	1	SENT_821	[p36l1320t2493r1491b2538],
4	of	IN	O	of	_	0	SENT_821	[p36l1515t2493r1572b2537],
5	anti-epidermal	JJ	O	anti-epidermal	amod	11	SENT_821	[p36l1584t2493r1948b2549],
6	growth	NN	O	growth	nn	11	SENT_821	[p36l1970t2493r2149b2550],
7	factor	NN	O	factor	nn	11	SENT_821	[p36l1118t2564r1262b2608],
8	receptor	NN	O	receptor	nn	11	SENT_821	[p36l1294t2573r1497b2620],
9	chimeric	JJ	O	chimeric	amod	11	SENT_821	[p36l1530t2564r1744b2608],
10	antibody	NN	O	antibody	nn	11	SENT_821	[p36l1777t2564r1994b2620],
11	C225	NN	O	c225	prep_of	3	SENT_821	[p36l2025t2567r2147b2608],
12	alone	RB	O	alone	dep	11	SENT_821	[p36l1118t2636r1249b2680],
13	and	CC	O	and	_	0	SENT_821	[p36l1273t2636r1362b2680],
14	in	IN	O	in	dep	11	SENT_821	[p36l1385t2637r1432b2680],
15	combination	NN	O	combination	pobj	14	SENT_821	[p36l1456t2636r1768b2680],
16	with	IN	O	with	_	0	SENT_821	[p36l1788t2636r1899b2681],
17	cisplatin	NN	O	cisplatin	prep_with	15	SENT_821	[p36l1923t2636r2146b2692],
18	.	.	O	.	_	0	SENT_821	[p36l1923t2636r2146b2692],
19	)	SYM	O	)	dep	3	SENT_821	[p36l1113t2707r1253b2758],

1	Clin	NNP	O	Clin	nn	2	SENT_822	[p36l1113t2707r1253b2758],
2	Oncol	NNP	O	Oncol	_	0	SENT_822	[p36l1272t2707r1417b2751],
3	2000	CD	DATE	2000	num	2	SENT_822	[p36l1436t2710r1823b2760],
4	;	:	O	;	_	0	SENT_822	[p36l1436t2710r1823b2760],
5	18:904	CD	NUMBER	18:904	number	6	SENT_822	[p36l1436t2710r1823b2760],
6	-14	CD	NUMBER	-14	dep	2	SENT_822	[p36l1436t2710r1823b2760],
7	.	.	O	.	_	0	SENT_822	[p36l1436t2710r1823b2760],

1	46	CD	NUMBER	46	_	0	SENT_823	[p36l1117t2783r1186b2822],
2	.	.	O	.	_	0	SENT_823	[p36l1117t2783r1186b2822],

1	Rossi	NNP	PERSON	Rossi	nn	2	SENT_824	[p36l1214t2779r1347b2825],
2	A	NNP	O	A	_	0	SENT_824	[p36l1367t2782r1417b2832],
3	,	,	O	,	_	0	SENT_824	[p36l1367t2782r1417b2832],
4	Maione	NNP	PERSON	Maione	nn	5	SENT_824	[p36l1441t2779r1623b2822],
5	P	NN	O	p	appos	2	SENT_824	[p36l1645t2782r1682b2832],
6	,	,	O	,	_	0	SENT_824	[p36l1645t2782r1682b2832],
7	Gridelli	NNP	PERSON	Gridelli	nn	9	SENT_824	[p36l1708t2778r1895b2822],
8	C.	NNP	PERSON	C.	nn	9	SENT_824	[p36l1917t2781r1965b2822],
9	Cetuximab	NNP	PERSON	Cetuximab	appos	2	SENT_824	[p36l1990t2781r2148b2823, p36l1118t2849r1241b2893],
10	in	IN	O	in	_	0	SENT_824	[p36l1285t2850r1332b2893],
11	advanced	JJ	O	advanced	amod	14	SENT_824	[p36l1374t2849r1600b2894],
12	non-small-cell	JJ	O	non-small-cell	amod	14	SENT_824	[p36l1643t2849r1998b2893],
13	lung	NN	O	lung	nn	14	SENT_824	[p36l2040t2849r2150b2906],
14	cancer	NN	O	cancer	prep_in	9	SENT_824	[p36l1119t2935r1290b2965],
15	.	.	O	.	_	0	SENT_824	[p36l1119t2935r1290b2965],

1	Crit	NNP	O	Crit	nn	4	SENT_825	[p36l1331t2922r1423b2965],
2	Rev	NN	O	rev	nn	4	SENT_825	[p36l1458t2925r1547b2968],
3	Oncol	NNP	O	Oncol	nn	4	SENT_825	[p36l1584t2921r1728b2965],
4	Hematol	NNP	O	Hematol	_	0	SENT_825	[p36l1766t2921r1976b2965],
5	2006	CD	DATE	2006	num	4	SENT_825	[p36l2014t2924r2147b2974],
6	;	:	O	;	_	0	SENT_825	[p36l2014t2924r2147b2974],
7	59:139	CD	NUMBER	59:139	number	8	SENT_825	[p36l1120t2994r1370b3036],
8	-49	CD	NUMBER	-49	dep	4	SENT_825	[p36l1120t2994r1370b3036],
9	.	.	O	.	_	0	SENT_825	[p36l1120t2994r1370b3036],

1	47	CD	NUMBER	47	_	0	SENT_826	[p36l1117t3068r1179b3106],
2	.	.	O	.	_	0	SENT_826	[p36l1117t3068r1179b3106],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_827	[p36l1214t3062r1380b3106],
2	RS	NN	ORGANIZATION	r	_	0	SENT_827	[p36l1399t3065r1477b3115],
3	,	,	O	,	_	0	SENT_827	[p36l1399t3065r1477b3115],
4	Chansky	NNP	PERSON	Chansky	nn	5	SENT_827	[p36l1503t3062r1716b3118],
5	K	NNP	PERSON	K	appos	2	SENT_827	[p36l1736t3066r1785b3116],
6	,	,	O	,	_	0	SENT_827	[p36l1736t3066r1785b3116],
7	Kelly	NNP	PERSON	Kelly	nn	8	SENT_827	[p36l1810t3062r1932b3118],
8	K	NNP	O	K	appos	2	SENT_827	[p36l1952t3066r2001b3116],
9	,	,	O	,	_	0	SENT_827	[p36l1952t3066r2001b3116],
10	et	FW	O	et	nn	11	SENT_827	[p36l2027t3071r2070b3106],
11	al.	FW	O	al.	appos	2	SENT_827	[p36l2090t3062r2145b3106],
12	.	.	O	.	_	0	SENT_827	[p36l2090t3062r2145b3106],

1	A	DT	O	a	det	2	SENT_828	[p36l1116t3138r1153b3178],
2	phase	NN	O	phase	_	0	SENT_828	[p36l1191t3134r1333b3190],
3	II	CD	NUMBER	ii	num	2	SENT_828	[p36l1373t3138r1411b3177],
4	randomized	VBN	O	randomize	partmod	2	SENT_828	[p36l1451t3134r1748b3178],
5	selection	NN	O	selection	nn	6	SENT_828	[p36l1789t3134r2006b3178],
6	trial	NN	O	trial	dobj	4	SENT_828	[p36l2047t3134r2149b3178],
7	evaluating	VBG	O	evaluate	xcomp	4	SENT_828	[p36l1119t3204r1374b3261],
8	concurrent	JJ	O	concurrent	amod	9	SENT_828	[p36l1393t3213r1662b3249],
9	chemotherapy	NN	O	chemotherapy	dobj	7	SENT_828	[p36l1681t3204r2030b3260],
10	plus	CC	O	plus	prep	9	SENT_828	[p36l2048t3204r2148b3260],
11	cetuximab	NN	O	cetuximab	dep	10	SENT_828	[p36l1119t3276r1376b3321],
12	or	CC	O	or	_	0	SENT_828	[p36l1405t3290r1456b3320],
13	chemotherapy	NN	O	chemotherapy	dep	10	SENT_828	[p36l1482t3276r1831b3332],
14	followed	VBN	O	follow	partmod	11	SENT_828	[p36l1857t3276r2068b3321],
15	by	IN	O	by	_	0	SENT_828	[p36l2096t3276r2151b3332],
16	cetuximab	NN	O	cetuximab	agent	14	SENT_828	[p36l1119t3347r1376b3392],
17	in	IN	O	in	_	0	SENT_828	[p36l1393t3348r1441b3391],
18	patients	NNS	O	patient	prep_in	14	SENT_828	[p36l1456t3348r1652b3403],
19	with	IN	O	with	_	0	SENT_828	[p36l1667t3347r1778b3392],
20	advanced	JJ	O	advanced	amod	24	SENT_828	[p36l1794t3347r2020b3392],
21	nonsmall	JJ	O	nonsmall	amod	24	SENT_828	[p36l2037t3361r2148b3391, p36l1119t3417r1253b3461],
22	cell	NN	O	cell	nn	24	SENT_828	[p36l1276t3417r1359b3461],
23	lung	NN	O	lung	nn	24	SENT_828	[p36l1382t3417r1492b3474],
24	cancer	NN	O	cancer	prep_with	18	SENT_828	[p36l1513t3431r1673b3461],
25	(	CD	NUMBER	(	num	26	SENT_828	[p36l1697t3420r1919b3468],
26	NSCLC	NN	O	nsclc	dep	2	SENT_828	[p36l1697t3420r1919b3468],
27	)	CD	NUMBER	)	dep	26	SENT_828	[p36l1697t3420r1919b3468],
28	:	:	O	:	_	0	SENT_828	[p36l1697t3420r1919b3468],
29	final	JJ	O	final	amod	30	SENT_828	[p36l1944t3417r2061b3461],
30	report	NN	O	report	dep	2	SENT_828	[p36l2084t3432r2148b3461, p36l1117t3498r1222b3545],
31	of	IN	O	of	_	0	SENT_828	[p36l1238t3489r1295b3533],
32	SWOG	NNP	O	SWOG	prep_of	30	SENT_828	[p36l1303t3492r1465b3533],
33	0342	CD	DATE	0342	num	32	SENT_828	[p36l1483t3492r1611b3533],
34	.	.	O	.	_	0	SENT_828	[p36l1483t3492r1611b3533],

1	J	NNP	O	J	nn	3	SENT_829	[p36l1626t3493r1647b3540],
2	Clin	NNP	O	Clin	nn	3	SENT_829	[p36l1663t3489r1764b3533],
3	Oncol	NNP	O	Oncol	_	0	SENT_829	[p36l1782t3489r1927b3533],
4	2007	CD	DATE	2007	num	6	SENT_829	[p36l1944t3492r2146b3542],
5	;	:	O	;	_	0	SENT_829	[p36l1944t3492r2146b3542],
6	25	CD	NUMBER	25	dep	3	SENT_829	[p36l1944t3492r2146b3542],
7	:	:	O	:	_	0	SENT_829	[p36l1944t3492r2146b3542],
8	Suppl	NNP	O	Suppl	dep	3	SENT_829	[p36l1120t3560r1396b3616],
9	:395	CD	NUMBER	:395	num	10	SENT_829	[p36l1120t3560r1396b3616],
10	s.	NN	O	s.	npadvmod	11	SENT_829	[p36l1120t3560r1396b3616],
11	abstract	JJ	O	abstract	amod	8	SENT_829	[p36l1418t3560r1627b3604],
12	.	.	O	.	_	0	SENT_829	[p36l1418t3560r1627b3604],

1	48	CD	NUMBER	48	_	0	SENT_830	[p36l1117t3635r1188b3675],
2	.	.	O	.	_	0	SENT_830	[p36l1117t3635r1188b3675],

1	Belani	NNP	PERSON	Belani	nn	2	SENT_831	[p36l1214t3630r1372b3674],
2	CP	NNP	O	CP	_	0	SENT_831	[p36l1393t3633r1467b3683],
3	,	,	O	,	_	0	SENT_831	[p36l1393t3633r1467b3683],
4	Ramalingam	NNP	PERSON	Ramalingam	nn	5	SENT_831	[p36l1491t3630r1817b3687],
5	S	NNP	PERSON	S	appos	2	SENT_831	[p36l1839t3633r1878b3684],
6	,	,	O	,	_	0	SENT_831	[p36l1839t3633r1878b3684],
7	Schreeder	NNP	O	Schreeder	nn	8	SENT_831	[p36l1904t3630r2150b3674],
8	M	NNP	O	M	appos	2	SENT_831	[p36l1117t3706r1179b3756],
9	,	,	O	,	_	0	SENT_831	[p36l1117t3706r1179b3756],
10	et	FW	O	et	nn	11	SENT_831	[p36l1207t3711r1251b3746],
11	al.	FW	O	al.	appos	2	SENT_831	[p36l1273t3702r1329b3746],
12	.	.	O	.	_	0	SENT_831	[p36l1273t3702r1329b3746],

1	Phase	NN	O	phase	_	0	SENT_832	[p36l1357t3702r1499b3746],
2	II	CD	NUMBER	ii	num	3	SENT_832	[p36l1523t3706r1561b3746],
3	study	NN	O	study	dep	1	SENT_832	[p36l1586t3702r1719b3758],
4	of	IN	O	of	_	0	SENT_832	[p36l1742t3702r1799b3746],
5	cetuximab	NN	O	cetuximab	prep_of	3	SENT_832	[p36l1814t3702r2075b3747],
6	in	IN	O	in	_	0	SENT_832	[p36l2101t3703r2148b3746],
7	combination	NN	O	combination	prep_in	5	SENT_832	[p36l1119t3774r1437b3818],
8	with	IN	O	with	_	0	SENT_832	[p36l1509t3774r1621b3819],
9	carboplatin	NN	O	carboplatin	prep_with	7	SENT_832	[p36l1696t3774r1984b3830],
10	and	CC	O	and	advmod	7	SENT_832	[p36l2058t3774r2149b3818],

1	36	CD	NUMBER	36	_	0	SENT_833	[p37l13t25r79b64],
2	.	.	O	.	_	0	SENT_833	[p37l13t25r79b64],

1	Perez-Soler	NNP	O	Perez-Soler	nn	2	SENT_834	[p37l108t20r383b64],
2	R	NNP	O	R	_	0	SENT_834	[p37l426t24r475b73],
3	,	,	O	,	_	0	SENT_834	[p37l426t24r475b73],
4	Chachoua	NNP	O	Chachoua	nn	5	SENT_834	[p37l523t20r766b65],
5	A	NNP	O	A	appos	2	SENT_834	[p37l808t24r857b74],
6	,	,	O	,	_	0	SENT_834	[p37l808t24r857b74],
7	Hammond	NNP	ORGANIZATION	Hammond	nn	8	SENT_834	[p37l905t24r1043b64, p37l13t90r154b134],
8	LA	NNP	ORGANIZATION	LA	appos	2	SENT_834	[p37l181t94r261b144],
9	,	,	O	,	_	0	SENT_834	[p37l181t94r261b144],
10	et	FW	O	et	nn	11	SENT_834	[p37l293t99r337b134],
11	al.	FW	O	al.	appos	2	SENT_834	[p37l362t90r417b134],
12	.	.	O	.	_	0	SENT_834	[p37l362t90r417b134],

1	Determinants	NNS	O	determinant	_	0	SENT_835	[p37l448t91r788b134],
2	of	IN	O	of	_	0	SENT_835	[p37l818t90r874b134],
3	tumor	NN	O	tumor	nn	4	SENT_835	[p37l892t99r1045b135],
4	response	NN	O	response	prep_of	1	SENT_835	[p37l13t176r230b218],
5	and	CC	O	and	_	0	SENT_835	[p37l263t162r353b206],
6	survival	NN	O	survival	prep_of	1	SENT_835	[p37l387t162r577b207],
7	with	IN	O	with	_	0	SENT_835	[p37l607t162r718b207],
8	erlotinib	NN	O	erlotinib	prep_with	1	SENT_835	[p37l752t162r962b206],
9	in	IN	O	in	_	0	SENT_835	[p37l996t163r1043b206],
10	patients	NNS	O	patient	prep_in	1	SENT_835	[p37l12t233r207b288],
11	with	IN	O	with	_	0	SENT_835	[p37l225t232r336b277],
12	non	JJ	O	non	amod	18	SENT_835	[p37l356t232r723b276],
13	—	JJ	O	—	amod	18	SENT_835	[p37l356t232r723b276],
14	small	JJ	O	small	amod	18	SENT_835	[p37l356t232r723b276],
15	—	NN	O	—	nn	18	SENT_835	[p37l356t232r723b276],
16	cell	NN	O	cell	nn	18	SENT_835	[p37l356t232r723b276],
17	lung	NN	O	lung	nn	18	SENT_835	[p37l741t232r851b289],
18	cancer	NN	O	cancer	prep_with	10	SENT_835	[p37l869t246r1040b276],
19	.	.	O	.	_	0	SENT_835	[p37l869t246r1040b276],

1	JClin	NN	O	jclin	nn	2	SENT_836	[p37l7t304r147b355],
2	Oncol	NN	O	oncol	_	0	SENT_836	[p37l166t304r311b348],
3	2004	CD	DATE	2004	dep	2	SENT_836	[p37l330t307r746b357],
4	;	:	O	;	_	0	SENT_836	[p37l330t307r746b357],
5	22:3238	CD	NUMBER	22:3238	num	6	SENT_836	[p37l330t307r746b357],
6	-47	CD	NUMBER	-47	dep	2	SENT_836	[p37l330t307r746b357],
7	.	.	O	.	_	0	SENT_836	[p37l330t307r746b357],

1	37	CD	NUMBER	37	_	0	SENT_837	[p37l13t379r73b418],
2	.	.	O	.	_	0	SENT_837	[p37l13t379r73b418],

1	Shepherd	NNP	ORGANIZATION	Shepherd	nn	2	SENT_838	[p37l110t374r337b430],
2	FA	NNP	ORGANIZATION	FA	_	0	SENT_838	[p37l358t378r434b428],
3	,	,	O	,	_	0	SENT_838	[p37l358t378r434b428],
4	Rodrigues	NNP	PERSON	Rodrigues	nn	6	SENT_838	[p37l458t374r710b431],
5	Pereira	NNP	PERSON	Pereira	nn	6	SENT_838	[p37l732t375r903b418],
6	J	NNP	PERSON	J	appos	2	SENT_838	[p37l918t378r950b428],
7	,	,	O	,	_	0	SENT_838	[p37l918t378r950b428],
8	Ciuleanu	NNP	O	Ciuleanu	nn	9	SENT_838	[p37l975t375r1043b418, p37l13t446r178b491],
9	T	NN	O	t	appos	2	SENT_838	[p37l210t450r254b499],
10	,	,	O	,	_	0	SENT_838	[p37l210t450r254b499],
11	et	FW	O	et	nn	12	SENT_838	[p37l292t455r336b490],
12	al.	FW	O	al.	appos	2	SENT_838	[p37l368t446r423b490],
13	.	.	O	.	_	0	SENT_838	[p37l368t446r423b490],

1	Erlotinib	NNP	O	Erlotinib	nsubj	4	SENT_839	[p37l461t446r677b490],
2	in	IN	O	in	prep	1	SENT_839	[p37l713t447r760b490],
3	previously	RB	DATE	previously	pcomp	2	SENT_839	[p37l794t446r1046b502],
4	treated	VBN	O	treat	_	0	SENT_839	[p37l13t516r180b560],
5	non	JJ	O	non	amod	8	SENT_839	[p37l196t516r555b560],
6	—	JJ	O	—	amod	8	SENT_839	[p37l196t516r555b560],
7	small	JJ	O	small	amod	8	SENT_839	[p37l196t516r555b560],
8	—	NN	O	—	tmod	4	SENT_839	[p37l196t516r555b560],
9	cell	NN	O	cell	nn	11	SENT_839	[p37l196t516r555b560],
10	lung	NN	O	lung	nn	11	SENT_839	[p37l570t516r679b573],
11	cancer	NN	O	cancer	dep	8	SENT_839	[p37l693t530r861b560],
12	.	.	O	.	_	0	SENT_839	[p37l693t530r861b560],

1	N	NN	O	n	nn	3	SENT_840	[p37l879t520r920b561],
2	Engl	NNP	O	Engl	nn	3	SENT_840	[p37l935t516r1043b573],
3	J	NNP	O	J	nsubj	4	SENT_840	[p37l7t591r28b638],
4	Med	VBD	O	med	_	0	SENT_840	[p37l45t587r150b631],
5	2005	CD	DATE	2005	dobj	4	SENT_840	[p37l169t590r583b640],
6	;	:	O	;	_	0	SENT_840	[p37l169t590r583b640],
7	353:123	CD	NUMBER	353:123	num	8	SENT_840	[p37l169t590r583b640],
8	-32	CD	NUMBER	-32	dep	5	SENT_840	[p37l169t590r583b640],
9	.	.	O	.	_	0	SENT_840	[p37l169t590r583b640],

1	38	CD	NUMBER	38	_	0	SENT_841	[p37l13t663r79b703],
2	.	.	O	.	_	0	SENT_841	[p37l13t663r79b703],

1	Bezjak	NNP	MISC	Bezjak	nn	2	SENT_842	[p37l108t659r271b715],
2	A	NNP	MISC	A	_	0	SENT_842	[p37l303t663r353b712],
3	,	,	O	,	_	0	SENT_842	[p37l303t663r353b712],
4	Tu	NNP	O	Tu	nn	5	SENT_842	[p37l390t663r450b704],
5	D	NNP	O	D	appos	2	SENT_842	[p37l486t663r536b713],
6	,	,	O	,	_	0	SENT_842	[p37l486t663r536b713],
7	Seymour	NNP	PERSON	Seymour	nn	8	SENT_842	[p37l577t662r792b715],
8	L	NNP	PERSON	L	appos	2	SENT_842	[p37l825t663r868b713],
9	,	,	O	,	_	0	SENT_842	[p37l825t663r868b713],
10	et	FW	O	et	nn	11	SENT_842	[p37l908t668r951b703],
11	al.	FW	O	al.	appos	2	SENT_842	[p37l985t659r1040b703],
12	.	.	O	.	_	0	SENT_842	[p37l985t659r1040b703],

1	Symptom	NN	O	symptom	nn	2	SENT_843	[p37l14t732r246b785],
2	improvement	NN	O	improvement	_	0	SENT_843	[p37l263t730r590b785],
3	in	IN	O	in	_	0	SENT_843	[p37l604t730r651b773],
4	lung	NN	O	lung	nn	6	SENT_843	[p37l667t729r777b786],
5	cancer	NN	O	cancer	nn	6	SENT_843	[p37l793t743r953b773],
6	patients	NNS	O	patient	prep_in	2	SENT_843	[p37l967t743r1043b785, p37l13t802r148b845],
7	treated	VBN	O	treat	partmod	6	SENT_843	[p37l184t801r355b845],
8	with	IN	O	with	_	0	SENT_843	[p37l387t801r498b846],
9	erlotinib	NN	O	erlotinib	prep_with	7	SENT_843	[p37l533t801r757b845],
10	:	:	O	:	_	0	SENT_843	[p37l533t801r757b845],
11	quality	NN	O	quality	dep	2	SENT_843	[p37l794t801r965b857],
12	of	IN	O	of	_	0	SENT_843	[p37l997t801r1053b845],
13	life	NN	O	life	nn	14	SENT_843	[p37l12t872r90b916],
14	analysis	NN	O	analysis	prep_of	11	SENT_843	[p37l111t872r305b928],
15	of	IN	O	of	_	0	SENT_843	[p37l327t872r384b916],
16	the	DT	O	the	det	19	SENT_843	[p37l395t872r470b916],
17	National	NNP	ORGANIZATION	National	nn	19	SENT_843	[p37l490t872r703b916],
18	Cancer	NNP	ORGANIZATION	Cancer	nn	19	SENT_843	[p37l723t875r894b916],
19	Institute	NNP	ORGANIZATION	Institute	prep_of	14	SENT_843	[p37l912t873r1043b916, p37l13t952r106b988],
20	of	IN	ORGANIZATION	of	_	0	SENT_843	[p37l122t943r179b987],
21	Canada	NNP	ORGANIZATION	Canada	prep_of	19	SENT_843	[p37l183t943r366b987],
22	Clinical	JJ	ORGANIZATION	clinical	amod	26	SENT_843	[p37l381t943r571b987],
23	Trials	NNPS	ORGANIZATION	Trials	nn	26	SENT_843	[p37l584t943r724b987],
24	Group	NNP	ORGANIZATION	Group	nn	26	SENT_843	[p37l740t946r893b999],
25	Study	NNP	ORGANIZATION	Study	nn	26	SENT_843	[p37l910t943r1045b999],
26	BR	NNP	O	BR	dep	11	SENT_843	[p37l12t1016r171b1060],
27	.21	CD	NUMBER	.21	num	26	SENT_843	[p37l12t1016r171b1060],
28	.	.	O	.	_	0	SENT_843	[p37l12t1016r171b1060],

1	J	NNP	O	J	nn	3	SENT_844	[p37l196t1017r217b1064],
2	Clin	NNP	O	Clin	nn	3	SENT_844	[p37l243t1013r344b1057],
3	Oncol	NNP	O	Oncol	_	0	SENT_844	[p37l372t1013r517b1057],
4	2006	CD	DATE	2006	num	3	SENT_844	[p37l544t1016r920b1066],
5	;	:	O	;	_	0	SENT_844	[p37l544t1016r920b1066],
6	24:3831	CD	NUMBER	24:3831	number	7	SENT_844	[p37l544t1016r920b1066],
7	-7	CD	NUMBER	-7	dep	3	SENT_844	[p37l544t1016r920b1066],
8	.	.	O	.	_	0	SENT_844	[p37l544t1016r920b1066],

1	[	NNP	O	[	_	0	SENT_845	[p37l956t1017r1043b1064, p37l13t1093r174b1137],
2	Erratum	NNP	O	Erratum	nn	6	SENT_845	[p37l956t1017r1043b1064, p37l13t1093r174b1137],
3	,	,	O	,	_	0	SENT_845	[p37l956t1017r1043b1064, p37l13t1093r174b1137],
4	J	NNP	O	J	appos	6	SENT_845	[p37l191t1088r212b1135],
5	Clin	NNP	O	Clin	nn	6	SENT_845	[p37l230t1084r331b1128],
6	Oncol	NNP	O	Oncol	dep	1	SENT_845	[p37l350t1084r495b1128],
7	2007	CD	DATE	2007	rcmod	6	SENT_845	[p37l514t1087r827b1137],
8	;	:	O	;	_	0	SENT_845	[p37l514t1087r827b1137],
9	25:167	CD	NUMBER	25:167	dep	7	SENT_845	[p37l514t1087r827b1137],
10	.	.	O	.	_	0	SENT_845	[p37l514t1087r827b1137],
11	]	SYM	O	]	dep	7	SENT_845	[p37l514t1087r827b1137],

1	39	CD	NUMBER	39	_	0	SENT_846	[p37l13t1161r77b1200],
2	.	.	O	.	_	0	SENT_846	[p37l13t1161r77b1200],

1	Blackhall	NNP	PERSON	Blackhall	nn	2	SENT_847	[p37l108t1156r338b1201],
2	F	NN	O	f	_	0	SENT_847	[p37l366t1160r404b1209],
3	,	,	O	,	_	0	SENT_847	[p37l366t1160r404b1209],
4	Ranson	NNP	ORGANIZATION	Ranson	nn	5	SENT_847	[p37l435t1160r622b1203],
5	M	NNP	ORGANIZATION	M	appos	2	SENT_847	[p37l649t1160r711b1210],
6	,	,	O	,	_	0	SENT_847	[p37l649t1160r711b1210],
7	Thatcher	NNP	PERSON	Thatcher	nn	8	SENT_847	[p37l741t1156r961b1200],
8	N.	NNP	O	N.	appos	2	SENT_847	[p37l987t1160r1040b1200],
9	Where	WRB	O	where	advmod	10	SENT_847	[p37l11t1227r170b1271],
10	next	JJ	O	next	rcmod	8	SENT_847	[p37l193t1236r298b1271],
11	for	IN	O	for	dep	10	SENT_847	[p37l318t1227r389b1271],
12	gefitinib	NN	O	gefitinib	pobj	11	SENT_847	[p37l410t1227r623b1284],
13	in	IN	O	in	_	0	SENT_847	[p37l646t1228r693b1271],
14	patients	NNS	O	patient	prep_in	12	SENT_847	[p37l715t1228r911b1283],
15	with	IN	O	with	_	0	SENT_847	[p37l932t1227r1043b1272],
16	lung	NN	O	lung	nn	17	SENT_847	[p37l12t1299r122b1356],
17	cancer	NN	O	cancer	prep_with	14	SENT_847	[p37l159t1298r338b1343],
18	?	.	O	?	_	0	SENT_847	[p37l159t1298r338b1343],

1	Lancet	NNP	O	Lancet	nn	2	SENT_848	[p37l376t1303r540b1343],
2	Oncol	NNP	O	Oncol	_	0	SENT_848	[p37l576t1299r720b1343],
3	2006	CD	DATE	2006	num	2	SENT_848	[p37l759t1302r1042b1352, p37l14t1374r106b1415],
4	;	:	O	;	_	0	SENT_848	[p37l759t1302r1042b1352, p37l14t1374r106b1415],
5	7:499507	CD	NUMBER	7:499507	dep	2	SENT_848	[p37l759t1302r1042b1352, p37l14t1374r106b1415],
6	.	.	O	.	_	0	SENT_848	[p37l759t1302r1042b1352, p37l14t1374r106b1415],

1	[	NN	O	[	_	0	SENT_849	[p37l133t1375r367b1425],
2	Erratum	NN	O	erratum	dep	1	SENT_849	[p37l133t1375r367b1425],
3	,	,	O	,	_	0	SENT_849	[p37l133t1375r367b1425],
4	Lancet	NNP	O	Lancet	nn	5	SENT_849	[p37l389t1375r552b1415],
5	Oncol	NNP	O	Oncol	appos	2	SENT_849	[p37l569t1371r713b1415],
6	2007	CD	DATE	2007	rcmod	5	SENT_849	[p37l733t1374r1023b1424],
7	;	:	O	;	_	0	SENT_849	[p37l733t1374r1023b1424],
8	8:670	CD	NUMBER	8:670	dep	6	SENT_849	[p37l733t1374r1023b1424],
9	.	.	O	.	_	0	SENT_849	[p37l733t1374r1023b1424],
10	]	SYM	O	]	dep	6	SENT_849	[p37l733t1374r1023b1424],

1	docetaxel	NN	O	docetaxel	_	0	SENT_850	[p37l1119t20r1355b64],
2	for	IN	O	for	_	0	SENT_850	[p37l1396t20r1468b64],
3	patients	NNS	O	patient	prep_for	1	SENT_850	[p37l1507t21r1707b76],
4	with	IN	O	with	_	0	SENT_850	[p37l1747t20r1860b65],
5	advanced	JJ	O	advanced	amod	6	SENT_850	[p37l1901t20r2147b70],
6	]	NN	O	]	prep_with	3	SENT_850	[p37l1901t20r2147b70],
7	metastatic	JJ	O	metastatic	amod	10	SENT_850	[p37l1118t91r1379b134],
8	non-small	JJ	O	non-small	amod	10	SENT_850	[p37l1419t90r1673b134],
9	cell	NN	O	cell	nn	10	SENT_850	[p37l1713t90r1798b134],
10	lung	NN	O	lung	dep	1	SENT_850	[p37l1837t90r1949b147],
11	cancer	NN	O	cancer	nn	14	SENT_850	[p37l1987t104r2150b134],
12	(	CD	NUMBER	(	num	14	SENT_850	[p37l1121t165r1346b213],
13	NSCLC	NN	O	nsclc	nn	14	SENT_850	[p37l1121t165r1346b213],
14	)	NN	O	)	dep	10	SENT_850	[p37l1121t165r1346b213],
15	.	.	O	.	_	0	SENT_850	[p37l1121t165r1346b213],

1	J	NNP	O	J	nn	3	SENT_851	[p37l1386t166r1407b213],
2	Clin	NNP	O	Clin	nn	3	SENT_851	[p37l1448t162r1551b206],
3	Oncol	NNP	O	Oncol	_	0	SENT_851	[p37l1593t162r1740b206],
4	2007	CD	DATE	2007	num	3	SENT_851	[p37l1782t162r2146b218],
5	;	:	O	;	_	0	SENT_851	[p37l1782t162r2146b218],
6	25	CD	NUMBER	25	dep	3	SENT_851	[p37l1782t162r2146b218],
7	:	:	O	:	_	0	SENT_851	[p37l1782t162r2146b218],
8	Suppl	NNP	O	Suppl	dep	3	SENT_851	[p37l1782t162r2146b218],
9	:	:	O	:	_	0	SENT_851	[p37l1782t162r2146b218],
10	420s	NNS	O	420	dep	8	SENT_851	[p37l1117t235r1245b276],
11	.	.	O	.	_	0	SENT_851	[p37l1117t235r1245b276],

1	abstract	JJ	O	abstract	_	0	SENT_852	[p37l1268t232r1483b276],
2	.	.	O	.	_	0	SENT_852	[p37l1268t232r1483b276],

1	49	CD	NUMBER	49	_	0	SENT_853	[p37l1117t309r1184b348],
2	.	.	O	.	_	0	SENT_853	[p37l1117t309r1184b348],

1	Butts	NNPS	O	Butts	nn	2	SENT_854	[p37l1214t308r1340b348],
2	CA	NNP	O	CA	_	0	SENT_854	[p37l1367t307r1452b357],
3	,	,	O	,	_	0	SENT_854	[p37l1367t307r1452b357],
4	Bodkin	NNP	PERSON	Bodkin	nn	5	SENT_854	[p37l1481t304r1660b349],
5	D	NNP	O	D	appos	2	SENT_854	[p37l1685t308r1735b358],
6	,	,	O	,	_	0	SENT_854	[p37l1685t308r1735b358],
7	Middleman	NNP	ORGANIZATION	Middleman	nn	8	SENT_854	[p37l1763t304r2045b348],
8	EL	NNP	ORGANIZATION	EL	appos	2	SENT_854	[p37l2071t308r2146b357],
9	,	,	O	,	_	0	SENT_854	[p37l2071t308r2146b357],
10	et	FW	O	et	nn	11	SENT_854	[p37l1119t383r1163b418],
11	al.	FW	O	al.	appos	2	SENT_854	[p37l1189t374r1245b418],
12	.	.	O	.	_	0	SENT_854	[p37l1189t374r1245b418],

1	Gemcitabinelplatinum	NN	O	gemcitabinelplatinum	_	0	SENT_855	[p37l1277t374r1833b430],
2	alone	RB	O	alone	dep	15	SENT_855	[p37l1862t374r1994b418],
3	or	CC	O	or	_	0	SENT_855	[p37l2024t388r2074b418],
4	in	IN	O	in	dep	15	SENT_855	[p37l2102t375r2149b418],
5	combination	NN	O	combination	pobj	4	SENT_855	[p37l1119t446r1431b490],
6	with	IN	O	with	_	0	SENT_855	[p37l1451t446r1562b491],
7	cetuximab	NN	O	cetuximab	prep_with	5	SENT_855	[p37l1584t446r1841b491],
8	as	IN	O	as	_	0	SENT_855	[p37l1864t461r1913b490],
9	first-line	JJ	O	first-line	amod	10	SENT_855	[p37l1936t446r2149b490],
10	treatment	NN	O	treatment	prep_as	7	SENT_855	[p37l1119t525r1361b560],
11	for	IN	O	for	_	0	SENT_855	[p37l1399t516r1469b560],
12	advanced	JJ	O	advanced	amod	14	SENT_855	[p37l1509t516r1734b561],
13	non-small	JJ	O	non-small	amod	14	SENT_855	[p37l1775t516r2024b560],
14	cell	NN	O	cell	prep_for	10	SENT_855	[p37l2066t516r2149b560],
15	lung	NN	O	lung	dep	1	SENT_855	[p37l1118t587r1228b644],
16	cancer	NN	O	cancer	nn	19	SENT_855	[p37l1282t601r1442b631],
17	(	CD	NUMBER	(	num	19	SENT_855	[p37l1499t590r1720b638],
18	NSCLC	NN	O	nsclc	nn	19	SENT_855	[p37l1499t590r1720b638],
19	)	NN	O	)	dep	15	SENT_855	[p37l1499t590r1720b638],
20	.	.	O	.	_	0	SENT_855	[p37l1499t590r1720b638],

1	J	NNP	O	J	nn	3	SENT_856	[p37l1773t591r1794b638],
2	Clin	NNP	O	Clin	nn	3	SENT_856	[p37l1848t587r1949b631],
3	Oncol	NNP	O	Oncol	_	0	SENT_856	[p37l2005t587r2149b631],
4	2007	CD	DATE	2007	num	6	SENT_856	[p37l1118t659r1605b715],
5	;	:	O	;	_	0	SENT_856	[p37l1118t659r1605b715],
6	25	CD	NUMBER	25	dep	3	SENT_856	[p37l1118t659r1605b715],
7	:	:	O	:	_	0	SENT_856	[p37l1118t659r1605b715],
8	Suppl	NNP	O	Suppl	dep	3	SENT_856	[p37l1118t659r1605b715],
9	:394	CD	NUMBER	:394	num	10	SENT_856	[p37l1118t659r1605b715],
10	s.	NN	O	s.	npadvmod	11	SENT_856	[p37l1118t659r1605b715],
11	abstract	JJ	O	abstract	amod	8	SENT_856	[p37l1628t659r1837b703],
12	.	.	O	.	_	0	SENT_856	[p37l1628t659r1837b703],

1	50	CD	NUMBER	50	_	0	SENT_857	[p37l1119t734r1185b773],
2	.	.	O	.	_	0	SENT_857	[p37l1119t734r1185b773],

1	Rosell	NNP	PERSON	Rosell	nn	2	SENT_858	[p37l1214t729r1366b776],
2	R	NNP	PERSON	R	_	0	SENT_858	[p37l1382t733r1431b783],
3	,	,	O	,	_	0	SENT_858	[p37l1382t733r1431b783],
4	Robinet	NNP	PERSON	Robinet	nn	5	SENT_858	[p37l1449t729r1644b776],
5	G	NNP	PERSON	G	appos	2	SENT_858	[p37l1657t732r1710b783],
6	,	,	O	,	_	0	SENT_858	[p37l1657t732r1710b783],
7	Szczesna	NNP	O	Szczesna	nn	8	SENT_858	[p37l1730t732r1950b773],
8	A	NNP	O	A	appos	2	SENT_858	[p37l1964t733r2013b782],
9	,	,	O	,	_	0	SENT_858	[p37l1964t733r2013b782],
10	et	FW	O	et	nn	11	SENT_858	[p37l2033t738r2077b773],
11	al.	FW	O	al.	appos	2	SENT_858	[p37l2090t729r2146b773],
12	.	.	O	.	_	0	SENT_858	[p37l2090t729r2146b773],

1	Randomized	VBN	O	randomize	_	0	SENT_859	[p37l1118t801r1432b848],
2	phase	NN	O	phase	nn	4	SENT_859	[p37l1452t801r1594b857],
3	II	CD	NUMBER	ii	num	4	SENT_859	[p37l1615t805r1652b844],
4	study	NN	O	study	dobj	1	SENT_859	[p37l1673t801r1804b857],
5	of	IN	O	of	_	0	SENT_859	[p37l1823t801r1880b845],
6	cetuximab	NN	O	cetuximab	prep_of	4	SENT_859	[p37l1891t801r2148b846],
7	plus	CC	O	plus	prep	6	SENT_859	[p37l1117t872r1218b928],
8	cisplatinlvinorelbine	NN	O	cisplatinlvinorelbine	dep	7	SENT_859	[p37l1243t872r1749b928],
9	compared	VBN	O	compare	_	0	SENT_859	[p37l1773t872r2017b928],
10	with	IN	O	with	prepc_compared_with	1	SENT_859	[p37l2038t872r2149b916],
11	cisplatinlvinorelbine	NN	O	cisplatinlvinorelbine	pobj	1	SENT_859	[p37l1119t943r1625b999],
12	alone	RB	O	alone	advmod	11	SENT_859	[p37l1668t943r1799b987],
13	as	IN	O	as	_	0	SENT_859	[p37l1843t958r1892b987],
14	first-line	JJ	O	first-line	amod	15	SENT_859	[p37l1936t943r2149b987],
15	therapy	NN	O	therapy	prep_as	11	SENT_859	[p37l1119t1013r1302b1069],
16	in	IN	O	in	_	0	SENT_859	[p37l1352t1014r1399b1057],
17	EGFR-expressing	JJ	O	egfr-expressing	amod	21	SENT_859	[p37l1450t1014r1873b1070],
18	advanced	JJ	O	advanced	amod	21	SENT_859	[p37l1923t1013r2149b1057],
19	non-small-cell	JJ	O	non-small-cell	amod	21	SENT_859	[p37l1118t1084r1474b1128],
20	lung	NN	O	lung	nn	21	SENT_859	[p37l1489t1084r1599b1141],
21	cancer	NN	O	cancer	prep_in	15	SENT_859	[p37l1614t1098r1785b1128],
22	.	.	O	.	_	0	SENT_859	[p37l1614t1098r1785b1128],

1	Ann	NNP	PERSON	Ann	nn	2	SENT_860	[p37l1802t1088r1906b1128],
2	Oncol	NNP	PERSON	Oncol	_	0	SENT_860	[p37l1922t1084r2067b1128],
3	(	NN	O	(	dep	2	SENT_860	[p37l2085t1085r2149b1135],
4	in	IN	O	in	_	0	SENT_860	[p37l2085t1085r2149b1135],
5	press	NN	O	press	nn	6	SENT_860	[p37l1117t1160r1274b1212],
6	)	NN	O	)	prep_in	3	SENT_860	[p37l1117t1160r1274b1212],
7	.	.	O	.	_	0	SENT_860	[p37l1117t1160r1274b1212],

1	51	CD	NUMBER	51	_	0	SENT_861	[p37l1119t1233r1183b1271],
2	.	.	O	.	_	0	SENT_861	[p37l1119t1233r1183b1271],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_862	[p37l1216t1227r1333b1271],
2	L	NNP	O	L	_	0	SENT_862	[p37l1359t1231r1401b1281],
3	,	,	O	,	_	0	SENT_862	[p37l1359t1231r1401b1281],
4	Rubin	NNP	PERSON	Rubin	nn	5	SENT_862	[p37l1430t1227r1577b1274],
5	M	NNP	O	M	appos	2	SENT_862	[p37l1601t1231r1663b1281],
6	,	,	O	,	_	0	SENT_862	[p37l1601t1231r1663b1281],
7	Hochster	NNP	PERSON	Hochster	nn	8	SENT_862	[p37l1691t1227r1916b1271],
8	H	NNP	O	H	appos	2	SENT_862	[p37l1940t1231r1994b1281],
9	,	,	O	,	_	0	SENT_862	[p37l1940t1231r1994b1281],
10	et	FW	O	et	nn	11	SENT_862	[p37l2023t1236r2067b1271],
11	al.	FW	O	al.	appos	2	SENT_862	[p37l2090t1227r2145b1271],
12	.	.	O	.	_	0	SENT_862	[p37l2090t1227r2145b1271],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_863	[p37l1118t1299r1387b1344],
2	(	CD	NUMBER	(	num	1	SENT_863	[p37l1430t1302r1715b1350],
3	IMC-C225	CD	NUMBER	imc-c225	num	4	SENT_863	[p37l1430t1302r1715b1350],
4	)	NN	O	)	nsubj	11	SENT_863	[p37l1430t1302r1715b1350],
5	plus	CC	O	plus	prep	4	SENT_863	[p37l1756t1299r1856b1355],
6	irinotecan	NN	O	irinotecan	nn	9	SENT_863	[p37l1896t1300r2149b1343],
7	(	CD	NUMBER	(	num	9	SENT_863	[p37l1121t1374r1321b1422],
8	CPT-11	NN	O	cpt-11	nn	9	SENT_863	[p37l1121t1374r1321b1422],
9	)	NN	O	)	dep	5	SENT_863	[p37l1121t1374r1321b1422],
10	is	VBZ	O	be	cop	11	SENT_863	[p37l1367t1372r1404b1415],
11	active	JJ	O	active	rcmod	1	SENT_863	[p37l1448t1372r1586b1416],
12	in	IN	O	in	_	0	SENT_863	[p37l1629t1372r1676b1415],
13	CPT-11-refractory	JJ	O	cpt-11-refractory	prep_in	11	SENT_863	[p37l1720t1371r2151b1427],

1	N	NN	O	n	nn	3	SENT_864	[p37l914t1512r927b1527],
2	ENGLJ	NN	O	englj	nn	3	SENT_864	[p37l942t1512r1020b1534],
3	MED	NN	O	med	_	0	SENT_864	[p37l1035t1512r1086b1527],
4	358	CD	NUMBER	358	dep	3	SENT_864	[p37l1097t1506r1165b1534],
5	;	:	O	;	_	0	SENT_864	[p37l1097t1506r1165b1534],
6	11	CD	NUMBER	11	dep	3	SENT_864	[p37l1097t1506r1165b1534],
7	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	8	SENT_864	[p37l1201t1512r1402b1534],
8	MARCH	NNP	DATE	MARCH	dep	6	SENT_864	[p37l1439t1512r1524b1527],
9	13	CD	DATE	13	num	8	SENT_864	[p37l1538t1512r1570b1534],
10	,	,	DATE	,	_	0	SENT_864	[p37l1538t1512r1570b1534],
11	2008	CD	DATE	2008	num	8	SENT_864	[p37l1581t1506r1644b1528],
12	The	DT	O	the	det	15	SENT_864	[p37l935t1545r986b1569],
13	New	NNP	O	New	nn	15	SENT_864	[p37l995t1546r1057b1569],
14	England	NNP	O	England	nn	15	SENT_864	[p37l1066t1545r1177b1576],
15	Joumal	NNP	O	Joumal	dep	3	SENT_864	[p37l1186t1545r1283b1569],
16	of	IN	O	of	_	0	SENT_864	[p37l1293t1545r1322b1569],
17	Medicine	NNP	O	Medicine	prep_of	15	SENT_864	[p37l1329t1545r1454b1569],

1	Downloaded	VBN	O	download	_	0	SENT_865	[p37l377t1586r547b1609],
2	from	IN	O	from	_	0	SENT_865	[p37l556t1586r621b1609],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_865	[p37l629t1586r748b1616],
4	at	IN	O	at	_	0	SENT_865	[p37l758t1590r781b1609],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_865	[p37l789t1586r972b1609],
6	on	IN	O	on	_	0	SENT_865	[p37l981t1593r1014b1609],
7	January	NNP	DATE	January	prep_on	1	SENT_865	[p37l1022t1586r1125b1616],
8	5	CD	DATE	5	num	7	SENT_865	[p37l1135t1586r1158b1613],
9	,	,	DATE	,	_	0	SENT_865	[p37l1135t1586r1158b1613],
10	2014	CD	DATE	2014	num	7	SENT_865	[p37l1168t1586r1241b1609],
11	.	.	O	.	_	0	SENT_865	[p37l1168t1586r1241b1609],

1	For	IN	O	for	_	0	SENT_866	[p37l1251t1586r1298b1609],
2	personal	JJ	O	personal	amod	3	SENT_866	[p37l1306t1586r1418b1616],
3	use	NN	O	use	pobj	1	SENT_866	[p37l1427t1593r1471b1609],
4	only	RB	O	only	advmod	3	SENT_866	[p37l1480t1586r1545b1616],
5	.	.	O	.	_	0	SENT_866	[p37l1480t1586r1545b1616],

1	No	DT	O	no	det	3	SENT_867	[p37l1556t1586r1595b1609],
2	other	JJ	O	other	amod	3	SENT_867	[p37l1605t1586r1673b1609],
3	uses	NNS	O	use	_	0	SENT_867	[p37l1682t1593r1738b1609],
4	without	IN	O	without	_	0	SENT_867	[p37l1748t1586r1849b1609],
5	permission	NN	O	permission	prep_without	3	SENT_867	[p37l1857t1586r2010b1616],
6	.	.	O	.	_	0	SENT_867	[p37l1857t1586r2010b1616],

1	Copyright	NN	O	copyright	_	0	SENT_868	[p37l728t1627r862b1658],
2	©	CD	NUMBER	©	num	6	SENT_868	[p37l871t1627r895b1651],
3	2008	CD	DATE	2008	num	6	SENT_868	[p37l905t1627r969b1651],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_868	[p37l979t1627r1170b1651],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_868	[p37l1180t1627r1288b1651],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_868	[p37l1299t1627r1404b1658],
7	.	.	O	.	_	0	SENT_868	[p37l1299t1627r1404b1658],

1	All	DT	O	all	det	2	SENT_869	[p37l1415t1627r1456b1651],
2	rights	NNS	O	rights	nsubj	3	SENT_869	[p37l1465t1627r1540b1658],
3	reserved	VBN	O	reserve	_	0	SENT_869	[p37l1550t1627r1668b1651],
4	.	.	O	.	_	0	SENT_869	[p37l1550t1627r1668b1651],

1	colorectal	JJ	O	colorectal	amod	5	SENT_870	[p37l13t1982r253b2026],
2	cancer	NN	O	cancer	nn	5	SENT_870	[p37l292t1996r452b2026],
3	(	CD	NUMBER	(	num	5	SENT_870	[p37l492t1985r629b2033],
4	CRC	NN	ORGANIZATION	crc	nn	5	SENT_870	[p37l492t1985r629b2033],
5	)	NN	O	)	dep	7	SENT_870	[p37l492t1985r629b2033],
6	that	WDT	O	that	nsubj	7	SENT_870	[p37l671t1982r769b2026],
7	expresses	VBZ	O	express	_	0	SENT_870	[p37l806t1996r1038b2038],
8	epidermal	JJ	O	epidermal	amod	10	SENT_870	[p37l13t2054r258b2110],
9	growth	NN	O	growth	nn	10	SENT_870	[p37l274t2054r453b2111],
10	factor	NN	O	factor	dobj	7	SENT_870	[p37l469t2054r612b2098],
11	receptor	NN	O	receptor	nn	14	SENT_870	[p37l627t2063r830b2110],
12	(	CD	NUMBER	(	num	14	SENT_870	[p37l847t2057r1036b2105],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_870	[p37l847t2057r1036b2105],
14	)	NN	O	)	dep	10	SENT_870	[p37l847t2057r1036b2105],
15	.	.	O	.	_	0	SENT_870	[p37l847t2057r1036b2105],

1	Proc	NNP	O	Proc	nn	5	SENT_871	[p37l12t2130r119b2170],
2	Am	NNP	O	Am	nn	5	SENT_871	[p37l142t2130r228b2169],
3	Soc	NNP	O	Soc	nn	5	SENT_871	[p37l255t2129r337b2170],
4	Clin	NNP	O	Clin	nn	5	SENT_871	[p37l362t2126r462b2170],
5	Oncol	NNP	O	Oncol	_	0	SENT_871	[p37l488t2126r632b2170],
6	2001	CD	DATE	2001	num	5	SENT_871	[p37l657t2129r936b2179],
7	;	:	O	;	_	0	SENT_871	[p37l657t2129r936b2179],
8	20:3	CD	NUMBER	20:3	num	9	SENT_871	[p37l657t2129r936b2179],
9	a.	NN	O	a.	dep	5	SENT_871	[p37l657t2129r936b2179],
10	abstract	JJ	O	abstract	amod	9	SENT_871	[p37l963t2126r1038b2170, p37l13t2206r162b2241],
11	.	.	O	.	_	0	SENT_871	[p37l963t2126r1038b2170, p37l13t2206r162b2241],

1	52	CD	NUMBER	52	_	0	SENT_872	[p37l13t2274r79b2312],
2	.	.	O	.	_	0	SENT_872	[p37l13t2274r79b2312],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_873	[p37l109t2268r227b2312],
2	L	NNP	PERSON	L	_	0	SENT_873	[p37l247t2272r290b2322],
3	,	,	O	,	_	0	SENT_873	[p37l247t2272r290b2322],
4	Meropol	NNP	ORGANIZATION	Meropol	nn	5	SENT_873	[p37l313t2268r518b2324],
5	NJ	NNP	ORGANIZATION	NJ	appos	2	SENT_873	[p37l538t2272r611b2322],
6	,	,	O	,	_	0	SENT_873	[p37l538t2272r611b2322],
7	Loehrer	NNP	O	Loehrer	nn	8	SENT_873	[p37l635t2268r826b2312],
8	PJ	NNP	O	PJ	appos	2	SENT_873	[p37l845t2272r903b2321],
9	,	,	O	,	_	0	SENT_873	[p37l845t2272r903b2321],
10	Needle	NNP	O	Needle	nn	11	SENT_873	[p37l926t2272r1039b2312, p37l13t2339r84b2383],
11	MN	NN	O	mn	appos	2	SENT_873	[p37l99t2343r203b2393],
12	,	,	O	,	_	0	SENT_873	[p37l99t2343r203b2393],
13	Kopit	NNP	PERSON	Kopit	nn	14	SENT_873	[p37l222t2340r355b2395],
14	J	NNP	PERSON	J	appos	2	SENT_873	[p37l364t2343r396b2392],
15	,	,	O	,	_	0	SENT_873	[p37l364t2343r396b2392],
16	Mayer	NNP	PERSON	Mayer	nn	17	SENT_873	[p37l414t2343r563b2395],
17	R	NNP	O	R	appos	2	SENT_873	[p37l577t2343r646b2390],
18	]	NN	O	]	dep	17	SENT_873	[p37l577t2343r646b2390],
19	.	.	O	.	_	0	SENT_873	[p37l577t2343r646b2390],

1	Phase	NN	O	phase	nn	3	SENT_874	[p37l665t2339r805b2383],
2	II	CD	NUMBER	ii	num	3	SENT_874	[p37l821t2343r858b2382],
3	trial	NN	O	trial	_	0	SENT_874	[p37l875t2339r976b2383],
4	of	IN	O	of	_	0	SENT_874	[p37l993t2339r1050b2383],
5	cetuximab	NN	O	cetuximab	prep_of	3	SENT_874	[p37l13t2410r269b2455],
6	in	IN	O	in	_	0	SENT_874	[p37l314t2411r362b2454],
7	patients	NNS	O	patient	prep_in	5	SENT_874	[p37l405t2411r600b2466],
8	with	IN	O	with	_	0	SENT_874	[p37l644t2410r755b2455],
9	refractory	JJ	O	refractory	amod	11	SENT_874	[p37l799t2410r1042b2466],
10	colorectal	JJ	O	colorectal	amod	11	SENT_874	[p37l13t2480r253b2524],
11	cancer	NN	O	cancer	prep_with	7	SENT_874	[p37l274t2494r434b2524],
12	that	WDT	O	that	nsubj	13	SENT_874	[p37l454t2480r552b2524],
13	express	VBP	O	express	rcmod	11	SENT_874	[p37l571t2494r751b2536],
14	the	DT	O	the	det	18	SENT_874	[p37l774t2480r849b2524],
15	epidermal	JJ	O	epidermal	amod	18	SENT_874	[p37l871t2480r1039b2536, p37l12t2551r104b2595],
16	growth	NN	O	growth	nn	18	SENT_874	[p37l127t2551r306b2608],
17	factor	NN	O	factor	nn	18	SENT_874	[p37l329t2551r472b2595],
18	receptor	NN	O	receptor	dobj	13	SENT_874	[p37l494t2560r707b2607],
19	.	.	O	.	_	0	SENT_874	[p37l494t2560r707b2607],

1	J	NNP	O	J	nn	3	SENT_875	[p37l728t2555r749b2602],
2	Clin	NNP	O	Clin	nn	3	SENT_875	[p37l771t2551r872b2595],
3	Oncol	NNP	O	Oncol	_	0	SENT_875	[p37l895t2551r1039b2595],
4	2004	CD	DATE	2004	num	3	SENT_875	[p37l12t2626r400b2676],
5	;	:	O	;	_	0	SENT_875	[p37l12t2626r400b2676],
6	22:1201	CD	NUMBER	22:1201	number	7	SENT_875	[p37l12t2626r400b2676],
7	-8	CD	NUMBER	-8	dep	3	SENT_875	[p37l12t2626r400b2676],
8	.	.	O	.	_	0	SENT_875	[p37l12t2626r400b2676],

1	53	CD	NUMBER	53	_	0	SENT_876	[p37l13t2699r76b2738],
2	.	.	O	.	_	0	SENT_876	[p37l13t2699r76b2738],

1	Lenz	NNP	PERSON	Lenz	nn	3	SENT_877	[p37l107t2698r224b2738],
2	H	NNP	O	H	nn	3	SENT_877	[p37l253t2698r325b2747],
3	]	NN	O	]	_	0	SENT_877	[p37l253t2698r325b2747],
4	,	,	O	,	_	0	SENT_877	[p37l253t2698r325b2747],
5	Van	NNP	PERSON	Van	nn	7	SENT_877	[p37l356t2698r447b2738],
6	Cutsem	NNP	PERSON	Cutsem	nn	7	SENT_877	[p37l477t2697r661b2739],
7	E	NNP	O	E	appos	3	SENT_877	[p37l690t2698r734b2748],
8	,	,	O	,	_	0	SENT_877	[p37l690t2698r734b2748],
9	KhambataFord	NNP	O	KhambataFord	nn	10	SENT_877	[p37l767t2694r1039b2739, p37l12t2765r122b2809],
10	S	NNP	O	S	appos	3	SENT_877	[p37l156t2768r194b2819],
11	,	,	O	,	_	0	SENT_877	[p37l156t2768r194b2819],
12	et	FW	O	et	nn	13	SENT_877	[p37l230t2774r274b2809],
13	al.	FW	O	al.	appos	3	SENT_877	[p37l304t2765r359b2809],
14	.	.	O	.	_	0	SENT_877	[p37l304t2765r359b2809],

1	Multicenter	JJ	O	multicenter	amod	6	SENT_878	[p37l393t2765r678b2810],
2	phase	NN	O	phase	nn	6	SENT_878	[p37l708t2765r849b2821],
3	II	CD	NUMBER	ii	num	2	SENT_878	[p37l881t2769r918b2808],
4	and	CC	O	and	_	0	SENT_878	[p37l950t2765r1039b2809],
5	translational	JJ	O	translational	conj_and	2	SENT_878	[p37l13t2835r327b2879],
6	study	NN	O	study	_	0	SENT_878	[p37l346t2835r477b2891],
7	of	IN	O	of	_	0	SENT_878	[p37l494t2835r550b2879],
8	cetuximab	NN	O	cetuximab	prep_of	6	SENT_878	[p37l559t2835r815b2880],
9	in	IN	O	in	_	0	SENT_878	[p37l835t2836r882b2879],
10	metastatic	JJ	O	metastatic	amod	12	SENT_878	[p37l901t2844r1039b2879, p37l13t2908r143b2951],
11	colorectal	JJ	O	colorectal	amod	12	SENT_878	[p37l171t2907r412b2951],
12	carcinoma	NN	O	carcinoma	prep_in	8	SENT_878	[p37l440t2908r697b2951],
13	refractory	JJ	O	refractory	amod	6	SENT_878	[p37l725t2907r967b2963],
14	to	TO	O	to	_	0	SENT_878	[p37l993t2916r1039b2951],
15	irinotecan	NN	O	irinotecan	prep_to	13	SENT_878	[p37l12t2979r277b3031],
16	,	,	O	,	_	0	SENT_878	[p37l12t2979r277b3031],
17	oxaliplatin	NN	O	oxaliplatin	prep_to	13	SENT_878	[p37l299t2978r575b3034],
18	,	,	O	,	_	0	SENT_878	[p37l299t2978r575b3034],
19	and	CC	O	and	_	0	SENT_878	[p37l597t2978r687b3022],
20	fluoropyrimidines	NNS	O	fluoropyrimidine	prep_to	13	SENT_878	[p37l705t2978r1039b3034, p37l13t3049r156b3093],
21	.	.	O	.	_	0	SENT_878	[p37l705t2978r1039b3034, p37l13t3049r156b3093],

1	J	NNP	O	J	nn	3	SENT_879	[p37l173t3053r194b3100],
2	Clin	NNP	O	Clin	nn	3	SENT_879	[p37l212t3049r312b3093],
3	Oncol	NNP	O	Oncol	_	0	SENT_879	[p37l332t3049r476b3093],
4	2006	CD	DATE	2006	num	3	SENT_879	[p37l495t3052r907b3102],
5	;	:	O	;	_	0	SENT_879	[p37l495t3052r907b3102],
6	24:4914	CD	NUMBER	24:4914	number	7	SENT_879	[p37l495t3052r907b3102],
7	—	CD	NUMBER	—	dep	3	SENT_879	[p37l495t3052r907b3102],
8	21	CD	NUMBER	21	dep	7	SENT_879	[p37l495t3052r907b3102],
9	.	.	O	.	_	0	SENT_879	[p37l495t3052r907b3102],

1	54	CD	NUMBER	54	_	0	SENT_880	[p37l13t3125r79b3163],
2	.	.	O	.	_	0	SENT_880	[p37l13t3125r79b3163],

1	Cunningham	NNP	ORGANIZATION	Cunningham	nn	2	SENT_881	[p37l108t3119r433b3176],
2	D	NNP	ORGANIZATION	D	_	0	SENT_881	[p37l458t3123r508b3172],
3	,	,	O	,	_	0	SENT_881	[p37l458t3123r508b3172],
4	Humblet	NNP	O	Humblet	nn	5	SENT_881	[p37l537t3119r752b3164],
5	Y	NN	O	y	appos	2	SENT_881	[p37l773t3123r813b3172],
6	,	,	O	,	_	0	SENT_881	[p37l773t3123r813b3172],
7	Siena	NNP	LOCATION	Siena	nn	8	SENT_881	[p37l844t3120r972b3163],
8	S	NNP	O	S	appos	2	SENT_881	[p37l998t3122r1036b3172],
9	,	,	O	,	_	0	SENT_881	[p37l998t3122r1036b3172],
10	et	FW	O	et	nn	11	SENT_881	[p37l13t3199r56b3234],
11	al.	FW	O	al.	appos	2	SENT_881	[p37l73t3190r128b3234],
12	.	.	O	.	_	0	SENT_881	[p37l73t3190r128b3234],

1	Cetuximab	JJ	O	cetuximab	amod	2	SENT_882	[p37l152t3190r419b3235],
2	monotherapy	NN	O	monotherapy	_	0	SENT_882	[p37l440t3190r766b3246],
3	and	CC	O	and	_	0	SENT_882	[p37l783t3190r873b3234],
4	cetuximab	NN	O	cetuximab	conj_and	2	SENT_882	[p37l893t3199r1039b3235, p37l12t3262r134b3306],
5	plus	CC	O	plus	prep	2	SENT_882	[p37l153t3262r253b3318],
6	irinotecan	NN	O	irinotecan	dep	5	SENT_882	[p37l272t3263r524b3306],
7	in	IN	O	in	_	0	SENT_882	[p37l542t3263r589b3306],
8	irinotecan	NN	O	irinotecan	prep_in	2	SENT_882	[p37l607t3262r1039b3306, p37l13t3341r110b3388],
9	—	CD	NUMBER	—	num	13	SENT_882	[p37l607t3262r1039b3306, p37l13t3341r110b3388],
10	refractory	JJ	O	refractory	amod	13	SENT_882	[p37l607t3262r1039b3306, p37l13t3341r110b3388],
11	metastatic	JJ	O	metastatic	amod	13	SENT_882	[p37l124t3333r379b3376],
12	colorectal	JJ	O	colorectal	amod	13	SENT_882	[p37l396t3332r636b3376],
13	cancer	NN	O	cancer	dep	8	SENT_882	[p37l653t3346r823b3376],
14	.	.	O	.	_	0	SENT_882	[p37l653t3346r823b3376],

1	N	NN	O	n	nn	2	SENT_883	[p37l842t3336r883b3376],
2	EnglJ	NN	O	englj	nsubj	3	SENT_883	[p37l899t3332r1040b3389],
3	Med	VBD	O	med	_	0	SENT_883	[p37l11t3404r116b3448],
4	2004	CD	DATE	2004	dobj	3	SENT_883	[p37l135t3407r545b3457],
5	;	:	O	;	_	0	SENT_883	[p37l135t3407r545b3457],
6	351:337	CD	NUMBER	351:337	num	7	SENT_883	[p37l135t3407r545b3457],
7	-45	CD	NUMBER	-45	dep	4	SENT_883	[p37l135t3407r545b3457],
8	.	.	O	.	_	0	SENT_883	[p37l135t3407r545b3457],

1	55	CD	NUMBER	55	_	0	SENT_884	[p37l13t3480r75b3518],
2	.	.	O	.	_	0	SENT_884	[p37l13t3480r75b3518],

1	Eng	NN	O	eng	nn	2	SENT_885	[p37l107t3478r201b3531],
2	C	NN	O	c	_	0	SENT_885	[p37l221t3477r267b3528],
3	,	,	O	,	_	0	SENT_885	[p37l221t3477r267b3528],
4	Maurel	NNP	PERSON	Maurel	nn	5	SENT_885	[p37l291t3474r460b3519],
5	J	NNP	PERSON	J	appos	2	SENT_885	[p37l476t3478r508b3528],
6	,	,	O	,	_	0	SENT_885	[p37l476t3478r508b3528],
7	Scheithauer	NNP	PERSON	Scheithauer	nn	8	SENT_885	[p37l535t3474r815b3519],
8	W	NNP	O	W	appos	2	SENT_885	[p37l833t3478r894b3528],
9	,	,	O	,	_	0	SENT_885	[p37l833t3478r894b3528],
10	et	FW	O	et	nn	11	SENT_885	[p37l919t3483r963b3518],
11	al.	FW	O	al.	appos	2	SENT_885	[p37l982t3474r1036b3518],
12	.	.	O	.	_	0	SENT_885	[p37l982t3474r1036b3518],

1	Impact	NN	O	impact	_	0	SENT_886	[p37l12t3550r180b3602],
2	of	IN	O	of	_	0	SENT_886	[p37l203t3546r259b3590],
3	quality	NN	O	quality	prep_of	1	SENT_886	[p37l274t3546r440b3602],
4	of	IN	O	of	_	0	SENT_886	[p37l463t3546r519b3590],
5	life	NN	O	life	prep_of	3	SENT_886	[p37l534t3546r609b3590],
6	of	IN	O	of	_	0	SENT_886	[p37l635t3546r691b3590],
7	adding	VBG	O	add	prepc_of	5	SENT_886	[p37l705t3546r872b3603],
8	cetuximab	NN	O	cetuximab	dobj	7	SENT_886	[p37l896t3555r1039b3591, p37l12t3618r136b3662],
9	to	TO	O	to	_	0	SENT_886	[p37l160t3627r207b3662],
10	irinotecan	NN	O	irinotecan	prep_to	7	SENT_886	[p37l230t3619r487b3662],
11	in	IN	O	in	_	0	SENT_886	[p37l510t3619r558b3662],
12	patients	NNS	O	patient	prep_in	7	SENT_886	[p37l580t3619r779b3674],
13	who	WP	O	who	nsubj	15	SENT_886	[p37l801t3618r906b3663],
14	have	VBP	O	have	aux	15	SENT_886	[p37l930t3618r1039b3663],
15	failed	VBN	O	fail	rcmod	12	SENT_886	[p37l12t3689r152b3733],
16	prior	RB	O	prior	prep	15	SENT_886	[p37l195t3690r319b3745],
17	oxaliplatin-based	JJ	O	oxaliplatin-based	amod	18	SENT_886	[p37l362t3689r795b3745],
18	therapy	NN	O	therapy	pobj	16	SENT_886	[p37l839t3689r1037b3745],
19	:	:	O	:	_	0	SENT_886	[p37l839t3689r1037b3745],
20	the	DT	O	the	det	21	SENT_886	[p37l13t3760r89b3804],
21	EPIC	NN	O	epic	dep	1	SENT_886	[p37l134t3763r249b3804],
22	trial	NN	O	trial	dep	21	SENT_886	[p37l296t3760r408b3804],
23	.	.	O	.	_	0	SENT_886	[p37l296t3760r408b3804],

1	J	NNP	O	J	nn	3	SENT_887	[p37l449t3764r470b3811],
2	Clin	NNP	O	Clin	nn	3	SENT_887	[p37l512t3760r611b3804],
3	Oncol	NNP	O	Oncol	_	0	SENT_887	[p37l655t3760r796b3804],
4	2007	CD	DATE	2007	num	3	SENT_887	[p37l840t3763r1037b3813],
5	;	:	O	;	_	0	SENT_887	[p37l840t3763r1037b3813],
6	25	CD	NUMBER	25	dep	3	SENT_887	[p37l840t3763r1037b3813],
7	:	:	O	:	_	0	SENT_887	[p37l840t3763r1037b3813],

1	DRUG	NN	O	drug	nn	2	SENT_888	[p37l1383t1802r1560b1838],
2	THERAPY	NN	O	therapy	_	0	SENT_888	[p37l1583t1803r1877b1838],

1	Clinical	JJ	O	clinical	amod	2	SENT_889	[p37l1115t1982r1304b2026],
2	Oncology	NNP	O	Oncology	nsubj	3	SENT_889	[p37l1331t1982r1567b2039],
3	Annual	JJ	SET	annual	_	0	SENT_889	[p37l1590t1982r1770b2027],
4	Meeting	VBG	O	meet	dobj	3	SENT_889	[p37l1795t1983r2009b2039],
5	,	,	O	,	_	0	SENT_889	[p37l1795t1983r2009b2039],
6	Chicago	NNP	LOCATION	Chicago	nn	8	SENT_889	[p37l2040t1982r2141b2026, p37l1115t2068r1239b2111],
7	,	,	O	,	_	0	SENT_889	[p37l2040t1982r2141b2026, p37l1115t2068r1239b2111],
8	June	NNP	DATE	June	appos	4	SENT_889	[p37l1256t2058r1366b2105],
9	1-5	CD	DATE	1-5	num	8	SENT_889	[p37l1387t2057r1481b2107],
10	,	,	DATE	,	_	0	SENT_889	[p37l1387t2057r1481b2107],
11	2007	CD	DATE	2007	num	8	SENT_889	[p37l1503t2057r1627b2098],
12	.	.	O	.	_	0	SENT_889	[p37l1503t2057r1627b2098],

1	63	CD	NUMBER	63	_	0	SENT_890	[p37l1115t2131r1179b2170],
2	.	.	O	.	_	0	SENT_890	[p37l1115t2131r1179b2170],

1	Burtness	NN	O	burtness	nn	2	SENT_891	[p37l1210t2130r1425b2170],
2	B	NN	O	b	_	0	SENT_891	[p37l1442t2130r1487b2180],
3	,	,	O	,	_	0	SENT_891	[p37l1442t2130r1487b2180],
4	Goldwasser	NNP	PERSON	Goldwasser	nn	5	SENT_891	[p37l1507t2126r1794b2170],
5	MA	NNP	PERSON	MA	appos	2	SENT_891	[p37l1807t2130r1907b2180],
6	,	,	O	,	_	0	SENT_891	[p37l1807t2130r1907b2180],
7	Flood	NNP	O	Flood	nn	8	SENT_891	[p37l1926t2126r2063b2170],
8	W	NNP	O	W	appos	2	SENT_891	[p37l2078t2130r2138b2179],
9	,	,	O	,	_	0	SENT_891	[p37l2078t2130r2138b2179],
10	Mattar	NNP	PERSON	Mattar	nn	11	SENT_891	[p37l1113t2201r1279b2241],
11	B	NNP	O	B	appos	2	SENT_891	[p37l1309t2201r1354b2250],
12	,	,	O	,	_	0	SENT_891	[p37l1309t2201r1354b2250],
13	Forastiere	NNP	O	Forastiere	nn	14	SENT_891	[p37l1388t2198r1631b2241],
14	AA	NNP	O	AA	appos	2	SENT_891	[p37l1661t2201r1749b2241],
15	.	.	O	.	_	0	SENT_891	[p37l1661t2201r1749b2241],

1	Phase	NN	O	phase	npadvmod	3	SENT_892	[p37l1783t2197r1923b2241],
2	III	CD	NUMBER	iii	num	1	SENT_892	[p37l1954t2201r2011b2240],
3	randomized	JJ	O	randomized	amod	4	SENT_892	[p37l2043t2211r2141b2241, p37l1115t2268r1328b2312],
4	trial	NN	O	trial	_	0	SENT_892	[p37l1362t2268r1463b2312],
5	of	IN	O	of	_	0	SENT_892	[p37l1497t2268r1553b2312],
6	cisplatin	NN	O	cisplatin	prep_of	4	SENT_892	[p37l1577t2268r1786b2324],
7	plus	CC	O	plus	_	0	SENT_892	[p37l1819t2268r1919b2324],
8	placebo	NN	O	placebo	conj_plus	4	SENT_892	[p37l1953t2268r2141b2324],
9	compared	VBN	O	compare	_	0	SENT_892	[p37l1115t2339r1357b2395],
10	with	IN	O	with	prepc_compared_with	8	SENT_892	[p37l1382t2339r1492b2384],
11	cisplatin	NN	O	cisplatin	pobj	8	SENT_892	[p37l1520t2339r1729b2395],
12	plus	CC	O	plus	prep	11	SENT_892	[p37l1755t2339r1855b2395],
13	cetuximab	NN	O	cetuximab	dep	12	SENT_892	[p37l1884t2339r2141b2384],
14	in	IN	O	in	_	0	SENT_892	[p37l1114t2411r1161b2454],
15	metastatic/recurrent	JJ	O	metastatic/recurrent	amod	16	SENT_892	[p37l1203t2411r1704b2460],
16	head	NN	O	head	prep_in	13	SENT_892	[p37l1743t2410r1858b2454],
17	and	CC	O	and	_	0	SENT_892	[p37l1899t2410r1988b2454],
18	neck	NN	O	neck	nn	19	SENT_892	[p37l2029t2410r2144b2455],
19	cancer	NN	O	cancer	prep_in	13	SENT_892	[p37l1115t2494r1287b2524],
20	:	:	O	:	_	0	SENT_892	[p37l1115t2494r1287b2524],
21	an	DT	O	a	det	25	SENT_892	[p37l1311t2494r1369b2524],
22	Eastern	NNP	ORGANIZATION	Eastern	nn	25	SENT_892	[p37l1390t2484r1574b2524],
23	Cooperative	NNP	ORGANIZATION	Cooperative	nn	25	SENT_892	[p37l1596t2481r1887b2536],
24	Oncology	NNP	ORGANIZATION	Oncology	nn	25	SENT_892	[p37l1908t2480r2144b2537],
25	Group	NNP	ORGANIZATION	Group	dep	4	SENT_892	[p37l1115t2554r1267b2607],
26	study	NN	O	study	dep	25	SENT_892	[p37l1293t2551r1432b2607],
27	.	.	O	.	_	0	SENT_892	[p37l1293t2551r1432b2607],

1	J	NNP	O	J	nn	3	SENT_893	[p37l1454t2555r1475b2602],
2	Clin	NNP	O	Clin	nn	3	SENT_893	[p37l1498t2551r1599b2595],
3	Oncol	NNP	O	Oncol	_	0	SENT_893	[p37l1623t2551r1768b2595],
4	2005	CD	DATE	2005	num	3	SENT_893	[p37l1792t2554r2141b2604, p37l1116t2627r1184b2667],
5	;	:	O	;	_	0	SENT_893	[p37l1792t2554r2141b2604, p37l1116t2627r1184b2667],
6	23:864654	CD	NUMBER	23:864654	dep	3	SENT_893	[p37l1792t2554r2141b2604, p37l1116t2627r1184b2667],
7	.	.	O	.	_	0	SENT_893	[p37l1792t2554r2141b2604, p37l1116t2627r1184b2667],

1	64	CD	NUMBER	64	_	0	SENT_894	[p37l1115t2699r1182b2738],
2	.	.	O	.	_	0	SENT_894	[p37l1115t2699r1182b2738],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_895	[p37l1210t2694r1375b2738],
2	RS	NN	ORGANIZATION	r	_	0	SENT_895	[p37l1399t2697r1477b2747],
3	,	,	O	,	_	0	SENT_895	[p37l1399t2697r1477b2747],
4	Arquette	NNP	PERSON	Arquette	nn	5	SENT_895	[p37l1505t2698r1718b2750],
5	M	NNP	O	M	appos	2	SENT_895	[p37l1743t2698r1804b2748],
6	,	,	O	,	_	0	SENT_895	[p37l1743t2698r1804b2748],
7	Shin	NNP	PERSON	Shin	nn	8	SENT_895	[p37l1836t2694r1944b2738],
8	DM	NN	PERSON	dm	appos	2	SENT_895	[p37l1970t2698r2070b2748],
9	,	,	O	,	_	0	SENT_895	[p37l1970t2698r2070b2748],
10	et	FW	O	et	nn	11	SENT_895	[p37l2100t2703r2144b2738],
11	al.	FW	O	al.	appos	2	SENT_895	[p37l1114t2765r1169b2809],
12	.	.	O	.	_	0	SENT_895	[p37l1114t2765r1169b2809],

1	Phase	NN	O	phase	_	0	SENT_896	[p37l1196t2765r1336b2809],
2	II	CD	NUMBER	ii	num	4	SENT_896	[p37l1360t2769r1397b2809],
3	multicenter	JJ	O	multicenter	amod	4	SENT_896	[p37l1421t2765r1704b2810],
4	study	NN	O	study	dep	1	SENT_896	[p37l1728t2765r1859b2821],
5	of	IN	O	of	_	0	SENT_896	[p37l1881t2765r1937b2809],
6	the	DT	O	the	det	10	SENT_896	[p37l1952t2765r2027b2809],
7	epidermal	JJ	O	epidermal	amod	10	SENT_896	[p37l2052t2766r2141b2821, p37l1115t2835r1287b2879],
8	growth	NN	O	growth	nn	10	SENT_896	[p37l1317t2835r1495b2892],
9	factor	NN	O	factor	nn	10	SENT_896	[p37l1525t2835r1668b2879],
10	receptor	NN	O	receptor	prep_of	4	SENT_896	[p37l1697t2844r1900b2891],
11	antibody	NN	O	antibody	nn	12	SENT_896	[p37l1928t2835r2144b2891],
12	cetuximab	NN	O	cetuximab	dep	1	SENT_896	[p37l1115t2907r1371b2952],
13	and	CC	O	and	_	0	SENT_896	[p37l1389t2907r1479b2951],
14	cisplatin	NN	O	cisplatin	dep	1	SENT_896	[p37l1497t2907r1706b2963],
15	for	IN	O	for	_	0	SENT_896	[p37l1724t2907r1794b2951],
16	recurrent	JJ	O	recurrent	prep_for	12	SENT_896	[p37l1810t2916r2037b2952],
17	and	CC	O	and	_	0	SENT_896	[p37l2052t2907r2142b2951],
18	refractory	JJ	O	refractory	conj_and	16	SENT_896	[p37l1115t2978r1357b3034],
19	squamous	JJ	O	squamous	amod	21	SENT_896	[p37l1393t2992r1640b3034],
20	cell	NN	O	cell	nn	21	SENT_896	[p37l1679t2978r1763b3022],
21	carcinoma	NN	O	carcinoma	dep	1	SENT_896	[p37l1800t2979r2058b3022],
22	of	IN	O	of	_	0	SENT_896	[p37l2095t2978r2151b3022],
23	the	DT	O	the	det	24	SENT_896	[p37l1115t3049r1190b3093],
24	head	NN	O	head	prep_of	21	SENT_896	[p37l1223t3049r1338b3093],
25	and	CC	O	and	_	0	SENT_896	[p37l1370t3049r1459b3093],
26	neck	NN	O	neck	prep_of	21	SENT_896	[p37l1491t3049r1617b3094],
27	.	.	O	.	_	0	SENT_896	[p37l1491t3049r1617b3094],

1	J	NNP	O	J	nn	3	SENT_897	[p37l1647t3053r1668b3100],
2	Clin	NNP	O	Clin	nn	3	SENT_897	[p37l1700t3049r1800b3093],
3	Oncol	NNP	O	Oncol	_	0	SENT_897	[p37l1833t3049r1977b3093],
4	2005	CD	DATE	2005	num	3	SENT_897	[p37l2009t3052r2139b3102],
5	;	:	O	;	_	0	SENT_897	[p37l2009t3052r2139b3102],
6	23:5578	CD	NUMBER	23:5578	number	7	SENT_897	[p37l1115t3122r1389b3164],
7	-87	CD	NUMBER	-87	dep	3	SENT_897	[p37l1115t3122r1389b3164],
8	.	.	O	.	_	0	SENT_897	[p37l1115t3122r1389b3164],

1	65	CD	NUMBER	65	_	0	SENT_898	[p37l1115t3195r1180b3234],
2	.	.	O	.	_	0	SENT_898	[p37l1115t3195r1180b3234],

1	Baselga	NNP	PERSON	Baselga	nn	2	SENT_899	[p37l1210t3190r1396b3247],
2	J	NNP	PERSON	J	_	0	SENT_899	[p37l1417t3194r1449b3244],
3	,	,	O	,	_	0	SENT_899	[p37l1417t3194r1449b3244],
4	Trigo	NNP	O	Trigo	nn	5	SENT_899	[p37l1476t3191r1607b3247],
5	JM	NN	O	jm	appos	2	SENT_899	[p37l1629t3194r1711b3244],
6	,	,	O	,	_	0	SENT_899	[p37l1629t3194r1711b3244],
7	Bourhis	NNP	PERSON	Bourhis	nn	8	SENT_899	[p37l1740t3190r1931b3235],
8	J	NNP	O	J	appos	2	SENT_899	[p37l1953t3194r1985b3243],
9	,	,	O	,	_	0	SENT_899	[p37l1953t3194r1985b3243],
10	et	FW	O	et	nn	11	SENT_899	[p37l2016t3199r2059b3234],
11	al.	FW	O	al.	appos	2	SENT_899	[p37l2083t3190r2138b3234],
12	.	.	O	.	_	0	SENT_899	[p37l2083t3190r2138b3234],

1	Phase	NN	O	phase	_	0	SENT_900	[p37l1114t3262r1253b3306],
2	II	CD	NUMBER	ii	num	4	SENT_900	[p37l1275t3266r1312b3306],
3	multicenter	JJ	O	multicenter	amod	4	SENT_900	[p37l1334t3262r1617b3307],
4	study	NN	O	study	dep	1	SENT_900	[p37l1638t3262r1769b3318],
5	of	IN	O	of	_	0	SENT_900	[p37l1789t3262r1845b3306],
6	the	DT	O	the	det	10	SENT_900	[p37l1857t3262r1933b3306],
7	antiepidermal	JJ	O	antiepidermal	amod	10	SENT_900	[p37l1954t3263r2141b3318, p37l1115t3332r1287b3376],
8	growth	NN	O	growth	nn	10	SENT_900	[p37l1312t3332r1490b3389],
9	factor	NN	O	factor	nn	10	SENT_900	[p37l1515t3332r1658b3376],
10	receptor	NN	O	receptor	prep_of	4	SENT_900	[p37l1681t3341r1884b3388],
11	monoclonal	JJ	O	monoclonal	amod	13	SENT_900	[p37l1908t3332r2141b3376, p37l1115t3404r1190b3448],
12	antibody	NN	O	antibody	nn	13	SENT_900	[p37l1220t3404r1436b3460],
13	cetuximab	NN	O	cetuximab	dep	1	SENT_900	[p37l1465t3404r1721b3449],
14	in	IN	O	in	_	0	SENT_900	[p37l1752t3405r1799b3448],
15	combination	NN	O	combination	prep_in	13	SENT_900	[p37l1831t3404r2142b3448],
16	with	IN	O	with	_	0	SENT_900	[p37l1112t3474r1222b3519],
17	platinum-based	JJ	O	platinum-based	amod	18	SENT_900	[p37l1239t3474r1623b3530],
18	chemotherapy	NN	O	chemotherapy	prep_with	15	SENT_900	[p37l1641t3474r1988b3530],
19	in	IN	O	in	_	0	SENT_900	[p37l2003t3475r2050b3518],
20	patients	NNS	O	patient	prep_in	18	SENT_900	[p37l2066t3488r2141b3530, p37l1115t3547r1249b3590],
21	with	IN	O	with	_	0	SENT_900	[p37l1263t3546r1374b3591],
22	platinum-refractory	JJ	O	platinum-refractory	amod	24	SENT_900	[p37l1387t3546r1875b3602],
23	metastatic	JJ	O	metastatic	amod	24	SENT_900	[p37l1887t3547r2142b3590],
24	and/or	NN	O	and/or	prep_with	20	SENT_900	[p37l1114t3618r1273b3668],
25	recurrent	JJ	O	recurrent	amod	28	SENT_900	[p37l1299t3627r1527b3663],
26	squamous	JJ	O	squamous	amod	28	SENT_900	[p37l1553t3632r1800b3674],
27	cell	NN	O	cell	nn	28	SENT_900	[p37l1830t3618r1913b3662],
28	carcinoma	NN	O	carcinoma	dep	1	SENT_900	[p37l1941t3619r2141b3662, p37l1115t3703r1189b3733],
29	of	IN	O	of	_	0	SENT_900	[p37l1219t3689r1275b3733],
30	the	DT	O	the	det	31	SENT_900	[p37l1295t3689r1370b3733],
31	head	NN	O	head	prep_of	28	SENT_900	[p37l1401t3689r1515b3733],
32	and	CC	O	and	_	0	SENT_900	[p37l1545t3689r1634b3733],
33	neck	NN	O	neck	prep_of	28	SENT_900	[p37l1664t3689r1790b3734],
34	.	.	O	.	_	0	SENT_900	[p37l1664t3689r1790b3734],

1	J	NNP	O	J	nn	3	SENT_901	[p37l1818t3693r1839b3740],
2	Clin	NNP	O	Clin	nn	3	SENT_901	[p37l1867t3689r1968b3733],
3	Oncol	NNP	O	Oncol	_	0	SENT_901	[p37l1998t3689r2142b3733],
4	2005	CD	DATE	2005	num	3	SENT_901	[p37l1115t3763r1522b3813],
5	;	:	O	;	_	0	SENT_901	[p37l1115t3763r1522b3813],
6	23:5568	CD	NUMBER	23:5568	number	7	SENT_901	[p37l1115t3763r1522b3813],
7	-77	CD	NUMBER	-77	dep	3	SENT_901	[p37l1115t3763r1522b3813],
8	.	.	O	.	_	0	SENT_901	[p37l1115t3763r1522b3813],

1	Suppl	NNP	O	Suppl	dep	4	SENT_902	[p38l14t15r284b71],
2	:164	CD	NUMBER	:164	num	3	SENT_902	[p38l14t15r284b71],
3	s.	NN	O	s.	npadvmod	4	SENT_902	[p38l14t15r284b71],
4	abstract	JJ	O	abstract	_	0	SENT_902	[p38l305t15r509b59],
5	.	.	O	.	_	0	SENT_902	[p38l305t15r509b59],

1	56	CD	NUMBER	56	_	0	SENT_903	[p38l13t91r78b130],
2	.	.	O	.	_	0	SENT_903	[p38l13t91r78b130],

1	Jonker	NNP	PERSON	Jonker	nn	2	SENT_904	[p38l103t86r266b137],
2	DJ	NNP	O	DJ	_	0	SENT_904	[p38l288t90r356b140],
3	,	,	O	,	_	0	SENT_904	[p38l288t90r356b140],
4	O’Callaghan	NN	O	o’callaghan	nn	6	SENT_904	[p38l384t86r690b143],
5	C	NN	O	c	nn	6	SENT_904	[p38l714t89r778b140],
6	]	NN	O	]	appos	2	SENT_904	[p38l714t89r778b140],
7	,	,	O	,	_	0	SENT_904	[p38l714t89r778b140],
8	Karapetis	NNP	PERSON	Karapetis	nn	9	SENT_904	[p38l805t87r1038b142],
9	CS	NNP	O	CS	appos	2	SENT_904	[p38l12t161r88b212],
10	,	,	O	,	_	0	SENT_904	[p38l12t161r88b212],
11	et	FW	O	et	nn	12	SENT_904	[p38l113t167r157b202],
12	al.	FW	O	al.	appos	2	SENT_904	[p38l175t158r231b202],
13	.	.	O	.	_	0	SENT_904	[p38l175t158r231b202],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_905	[p38l255t158r523b203],
2	for	IN	O	for	_	0	SENT_905	[p38l545t158r615b202],
3	the	DT	O	the	det	4	SENT_905	[p38l636t158r711b202],
4	treatment	NN	O	treatment	prep_for	1	SENT_905	[p38l733t167r974b202],
5	of	IN	O	of	_	0	SENT_905	[p38l993t158r1050b202],
6	colorectal	JJ	O	colorectal	amod	7	SENT_905	[p38l13t228r253b272],
7	cancer	NN	O	cancer	prep_of	1	SENT_905	[p38l289t242r460b272],
8	.	.	O	.	_	0	SENT_905	[p38l289t242r460b272],

1	N	NN	O	n	nn	3	SENT_906	[p38l498t232r539b272],
2	Engl	NNP	O	Engl	nn	3	SENT_906	[p38l574t228r684b285],
3	J	NNP	O	J	nsubj	4	SENT_906	[p38l715t232r736b279],
4	Med	VBD	O	med	_	0	SENT_906	[p38l769t228r875b272],
5	2007	CD	DATE	2007	dobj	4	SENT_906	[p38l911t231r1037b281],
6	;	:	O	;	_	0	SENT_906	[p38l911t231r1037b281],
7	357:2040	CD	NUMBER	357:2040	number	8	SENT_906	[p38l13t303r294b344],
8	—	CD	NUMBER	—	dep	5	SENT_906	[p38l13t303r294b344],
9	8	CD	NUMBER	8	dep	8	SENT_906	[p38l13t303r294b344],
10	.	.	O	.	_	0	SENT_906	[p38l13t303r294b344],

1	57	CD	NUMBER	57	_	0	SENT_907	[p38l13t377r72b415],
2	.	.	O	.	_	0	SENT_907	[p38l13t377r72b415],

1	Folprecht	NNP	O	Folprecht	nn	2	SENT_908	[p38l107t371r339b427],
2	G	NNP	O	G	_	0	SENT_908	[p38l360t374r412b424],
3	,	,	O	,	_	0	SENT_908	[p38l360t374r412b424],
4	Lutz	NNP	PERSON	Lutz	nn	5	SENT_908	[p38l438t375r545b416],
5	MP	NNP	O	MP	appos	2	SENT_908	[p38l567t375r654b425],
6	,	,	O	,	_	0	SENT_908	[p38l567t375r654b425],
7	Schoffski	NNP	PERSON	Schoffski	nn	8	SENT_908	[p38l683t371r911b416],
8	P	NN	PERSON	p	appos	2	SENT_908	[p38l934t375r971b424],
9	,	,	O	,	_	0	SENT_908	[p38l934t375r971b424],
10	et	FW	O	et	nn	11	SENT_908	[p38l998t380r1042b415],
11	al.	FW	O	al.	appos	2	SENT_908	[p38l12t442r67b486],
12	.	.	O	.	_	0	SENT_908	[p38l12t442r67b486],

1	Cetuximab	NNP	O	Cetuximab	nsubj	10	SENT_909	[p38l111t442r378b487],
2	and	CC	O	and	_	0	SENT_909	[p38l419t442r509b486],
3	irinotecan/5	JJ	O	irinotecan/5	amod	6	SENT_909	[p38l549t442r1039b492, p38l12t513r327b563],
4	—	NN	O	—	nn	6	SENT_909	[p38l549t442r1039b492, p38l12t513r327b563],
5	fluorouracil/folinic	JJ	O	fluorouracil/folinic	amod	6	SENT_909	[p38l549t442r1039b492, p38l12t513r327b563],
6	acid	NN	O	acid	nsubj	10	SENT_909	[p38l356t513r453b557],
7	is	VBZ	O	be	cop	10	SENT_909	[p38l481t514r519b557],
8	a	DT	O	a	det	10	SENT_909	[p38l549t528r574b557],
9	safe	JJ	O	safe	amod	10	SENT_909	[p38l603t513r698b557],
10	combination	NN	O	combination	_	0	SENT_909	[p38l729t513r1039b557],
11	for	IN	O	for	_	0	SENT_909	[p38l12t584r82b628],
12	the	DT	O	the	det	16	SENT_909	[p38l119t584r194b628],
13	first	JJ	ORDINAL	first	amod	16	SENT_909	[p38l232t584r444b628],
14	—	NN	O	—	nn	16	SENT_909	[p38l232t584r444b628],
15	line	NN	O	line	nn	16	SENT_909	[p38l232t584r444b628],
16	treatment	NN	O	treatment	prep_for	10	SENT_909	[p38l483t593r724b628],
17	of	IN	O	of	_	0	SENT_909	[p38l760t584r816b628],
18	patients	NNS	O	patient	prep_of	16	SENT_909	[p38l843t585r1038b640],
19	with	IN	O	with	_	0	SENT_909	[p38l10t654r120b699],
20	epidermal	JJ	O	epidermal	amod	23	SENT_909	[p38l138t654r384b710],
21	growth	NN	O	growth	nn	23	SENT_909	[p38l400t654r578b711],
22	factor	NN	O	factor	nn	23	SENT_909	[p38l595t654r738b698],
23	receptor	NN	O	receptor	prep_with	18	SENT_909	[p38l753t663r956b710],
24	expressing	VBG	O	express	partmod	23	SENT_909	[p38l972t669r1039b698, p38l11t726r221b782],
25	metastatic	JJ	O	metastatic	amod	27	SENT_909	[p38l236t726r491b769],
26	colorectal	JJ	O	colorectal	amod	27	SENT_909	[p38l508t725r748b769],
27	carcinoma	NN	O	carcinoma	dobj	24	SENT_909	[p38l766t726r1036b769],
28	.	.	O	.	_	0	SENT_909	[p38l766t726r1036b769],

1	Ann	NNP	PERSON	Ann	nn	2	SENT_910	[p38l10t801r113b841],
2	Oncol	NNP	O	Oncol	_	0	SENT_910	[p38l132t797r277b841],
3	2006	CD	DATE	2006	num	2	SENT_910	[p38l295t800r652b850],
4	;	:	O	;	_	0	SENT_910	[p38l295t800r652b850],
5	17:450	CD	NUMBER	17:450	number	6	SENT_910	[p38l295t800r652b850],
6	—	CD	NUMBER	—	dep	2	SENT_910	[p38l295t800r652b850],
7	6	CD	NUMBER	6	dep	6	SENT_910	[p38l295t800r652b850],
8	.	.	O	.	_	0	SENT_910	[p38l295t800r652b850],

1	58	CD	NUMBER	58	_	0	SENT_911	[p38l13t872r79b913],
2	.	.	O	.	_	0	SENT_911	[p38l13t872r79b913],

1	Tabernero	NNP	PERSON	Tabernero	nn	2	SENT_912	[p38l106t868r356b912],
2	J	NNP	PERSON	J	_	0	SENT_912	[p38l375t872r407b922],
3	,	,	O	,	_	0	SENT_912	[p38l375t872r407b922],
4	Van	NNP	PERSON	Van	nn	6	SENT_912	[p38l431t872r523b912],
5	Cutsem	NNP	PERSON	Cutsem	nn	6	SENT_912	[p38l546t871r730b913],
6	E	NNP	O	E	appos	2	SENT_912	[p38l753t872r797b922],
7	,	,	O	,	_	0	SENT_912	[p38l753t872r797b922],
8	D1	NN	O	d1	nn	10	SENT_912	[p38l823t867r1039b915],
9	’	CD	NUMBER	’	num	10	SENT_912	[p38l823t867r1039b915],
10	az	NN	O	az	appos	6	SENT_912	[p38l823t867r1039b915],
11	.	.	O	.	_	0	SENT_912	[p38l823t867r1039b915],

1	—	NN	O	—	_	0	SENT_913	[p38l823t867r1039b915],
2	.	.	O	.	_	0	SENT_913	[p38l823t867r1039b915],

1	Ru	NN	O	ru	nn	3	SENT_914	[p38l823t867r1039b915],
2	bio	NN	O	bio	nn	3	SENT_914	[p38l13t939r86b983],
3	E	NN	O	e	_	0	SENT_914	[p38l106t943r150b993],
4	,	,	O	,	_	0	SENT_914	[p38l106t943r150b993],
5	et	FW	O	et	nn	6	SENT_914	[p38l173t948r217b983],
6	al.	FW	O	al.	appos	3	SENT_914	[p38l234t939r289b983],
7	.	.	O	.	_	0	SENT_914	[p38l234t939r289b983],

1	Phase	NN	O	phase	nn	3	SENT_915	[p38l312t939r451b983],
2	II	CD	NUMBER	ii	num	3	SENT_915	[p38l470t943r507b983],
3	trial	NN	O	trial	_	0	SENT_915	[p38l527t939r629b983],
4	of	IN	O	of	_	0	SENT_915	[p38l649t939r705b983],
5	cetuximab	NN	O	cetuximab	prep_of	3	SENT_915	[p38l715t939r972b984],
6	in	IN	O	in	_	0	SENT_915	[p38l992t940r1039b983],
7	combination	NN	O	combination	prep_in	3	SENT_915	[p38l13t1010r323b1054],
8	with	IN	O	with	_	0	SENT_915	[p38l353t1010r463b1055],
9	fluorouracil	NN	O	fluorouracil	nn	13	SENT_915	[p38l496t1010r801b1064],
10	,	,	O	,	_	0	SENT_915	[p38l496t1010r801b1064],
11	leucovo	NN	O	leucovo	dep	13	SENT_915	[p38l836t1010r1038b1054],
12	—	CD	NUMBER	—	num	13	SENT_915	[p38l836t1010r1038b1054],
13	rin	NN	O	rin	prep_with	7	SENT_915	[p38l12t1082r95b1134],
14	,	,	O	,	_	0	SENT_915	[p38l12t1082r95b1134],
15	and	CC	O	and	_	0	SENT_915	[p38l119t1081r208b1125],
16	oxaliplatin	NN	O	oxaliplatin	conj_and	7	SENT_915	[p38l230t1081r492b1137],
17	in	IN	O	in	_	0	SENT_915	[p38l513t1082r560b1125],
18	the	DT	O	the	det	22	SENT_915	[p38l581t1081r657b1125],
19	first	JJ	ORDINAL	first	amod	22	SENT_915	[p38l678t1081r890b1125],
20	—	NN	O	—	nn	22	SENT_915	[p38l678t1081r890b1125],
21	line	NN	O	line	nn	22	SENT_915	[p38l678t1081r890b1125],
22	treatment	NN	O	treatment	prep_in	16	SENT_915	[p38l911t1090r1039b1125, p38l12t1160r137b1195],
23	of	IN	O	of	_	0	SENT_915	[p38l182t1151r239b1195],
24	metastatic	JJ	O	metastatic	amod	26	SENT_915	[p38l276t1152r531b1195],
25	colorectal	JJ	O	colorectal	amod	26	SENT_915	[p38l578t1151r818b1195],
26	cancer	NN	O	cancer	prep_of	22	SENT_915	[p38l866t1165r1036b1195],
27	.	.	O	.	_	0	SENT_915	[p38l866t1165r1036b1195],

1	JClin	NN	O	jclin	nn	2	SENT_916	[p38l7t1223r146b1274],
2	Oncol	NN	O	oncol	_	0	SENT_916	[p38l165t1223r309b1267],
3	2007	CD	DATE	2007	dep	2	SENT_916	[p38l328t1226r740b1276],
4	;	:	O	;	_	0	SENT_916	[p38l328t1226r740b1276],
5	25:5225	CD	NUMBER	25:5225	num	6	SENT_916	[p38l328t1226r740b1276],
6	-32	CD	NUMBER	-32	dep	2	SENT_916	[p38l328t1226r740b1276],
7	.	.	O	.	_	0	SENT_916	[p38l328t1226r740b1276],

1	59	CD	NUMBER	59	_	0	SENT_917	[p38l13t1298r76b1337],
2	.	.	O	.	_	0	SENT_917	[p38l13t1298r76b1337],

1	Van	NNP	O	Van	nn	3	SENT_918	[p38l106t1297r197b1337],
2	Cutsem	NNP	O	Cutsem	nn	3	SENT_918	[p38l218t1296r402b1338],
3	E	NNP	O	E	_	0	SENT_918	[p38l422t1297r466b1346],
4	,	,	O	,	_	0	SENT_918	[p38l422t1297r466b1346],
5	Nowacki	NNP	ORGANIZATION	Nowacki	nn	6	SENT_918	[p38l488t1293r702b1338],
6	M	NNP	ORGANIZATION	M	appos	3	SENT_918	[p38l720t1297r782b1347],
7	,	,	O	,	_	0	SENT_918	[p38l720t1297r782b1347],
8	Lang	NNP	PERSON	Lang	appos	3	SENT_918	[p38l804t1297r926b1350],
9	1	CD	NUMBER	1	num	8	SENT_918	[p38l944t1297r974b1347],
10	,	,	O	,	_	0	SENT_918	[p38l944t1297r974b1347],
11	et	FW	O	et	nn	12	SENT_918	[p38l998t1302r1042b1337],
12	al.	FW	O	al.	appos	3	SENT_918	[p38l12t1364r67b1408],
13	.	.	O	.	_	0	SENT_918	[p38l12t1364r67b1408],

1	Randomized	VBN	O	randomize	csubj	10	SENT_919	[p38l86t1364r400b1411],
2	phase	NN	O	phase	nn	4	SENT_919	[p38l416t1364r557b1420],
3	III	CD	NUMBER	iii	num	4	SENT_919	[p38l573t1368r631b1408],
4	study	NN	O	study	dobj	1	SENT_919	[p38l648t1364r778b1420],
5	of	IN	O	of	_	0	SENT_919	[p38l793t1364r850b1408],
6	irinote	JJ	O	irinote	amod	7	SENT_919	[p38l856t1365r1039b1408],
7	—	NN	O	—	prep_of	4	SENT_919	[p38l856t1365r1039b1408],
8	can	MD	O	can	aux	10	SENT_919	[p38l13t1450r97b1480],
9	and	CC	O	and	cc	10	SENT_919	[p38l125t1436r213b1480],
10	5-FUIFA	NN	O	5-fuifa	_	0	SENT_919	[p38l243t1439r438b1486],
11	with	IN	O	with	prep	10	SENT_919	[p38l462t1436r573b1481],
12	or	CC	O	or	_	0	SENT_919	[p38l601t1450r651b1480],
13	without	IN	O	without	prep	10	SENT_919	[p38l675t1436r867b1481],
14	cetuXimab	NNP	O	cetuXimab	pobj	13	SENT_919	[p38l893t1445r1039b1481, p38l12t1507r134b1551],
15	in	IN	O	in	_	0	SENT_919	[p38l150t1508r197b1551],
16	the	DT	O	the	det	20	SENT_919	[p38l212t1507r287b1551],
17	first	JJ	ORDINAL	first	amod	20	SENT_919	[p38l302t1507r514b1551],
18	—	NN	O	—	nn	20	SENT_919	[p38l302t1507r514b1551],
19	line	NN	O	line	nn	20	SENT_919	[p38l302t1507r514b1551],
20	treatment	NN	O	treatment	prep_in	14	SENT_919	[p38l529t1516r770b1551],
21	of	IN	O	of	_	0	SENT_919	[p38l783t1507r839b1551],
22	patients	NNS	O	patient	prep_of	20	SENT_919	[p38l843t1508r1038b1563],
23	with	IN	O	with	_	0	SENT_919	[p38l10t1578r120b1622],
24	metastatic	JJ	O	metastatic	amod	27	SENT_919	[p38l135t1579r390b1622],
25	colorectal	JJ	O	colorectal	amod	27	SENT_919	[p38l405t1578r645b1622],
26	cancer	NN	O	cancer	nn	27	SENT_919	[p38l660t1592r820b1622],
27	(	NN	O	(	prep_with	22	SENT_919	[p38l836t1581r1037b1629],
28	mCRC	NN	O	mcrc	dep	27	SENT_919	[p38l836t1581r1037b1629],
29	)	CD	NUMBER	)	num	28	SENT_919	[p38l836t1581r1037b1629],
30	:	:	O	:	_	0	SENT_919	[p38l836t1581r1037b1629],
31	the	DT	O	the	det	33	SENT_919	[p38l13t1648r88b1692],
32	CRYSTAL	NN	O	crystal	nn	33	SENT_919	[p38l111t1651r343b1695],
33	trial	NN	O	trial	dep	27	SENT_919	[p38l365t1648r480b1692],
34	.	.	O	.	_	0	SENT_919	[p38l365t1648r480b1692],

1	J	NNP	O	J	nn	3	SENT_920	[p38l501t1652r522b1699],
2	Clin	NNP	O	Clin	nn	3	SENT_920	[p38l544t1648r645b1692],
3	Oncol	NNP	O	Oncol	_	0	SENT_920	[p38l668t1648r812b1692],
4	2007	CD	DATE	2007	num	6	SENT_920	[p38l836t1651r1037b1701],
5	;	:	O	;	_	0	SENT_920	[p38l836t1651r1037b1701],
6	25	CD	NUMBER	25	dep	3	SENT_920	[p38l836t1651r1037b1701],
7	:	:	O	:	_	0	SENT_920	[p38l836t1651r1037b1701],
8	Suppl	NNP	O	Suppl	dep	3	SENT_920	[p38l14t1719r290b1775],
9	:164	CD	NUMBER	:164	num	10	SENT_920	[p38l14t1719r290b1775],
10	s.	NN	O	s.	npadvmod	11	SENT_920	[p38l14t1719r290b1775],
11	abstract	JJ	O	abstract	amod	8	SENT_920	[p38l312t1719r521b1763],
12	.	.	O	.	_	0	SENT_920	[p38l312t1719r521b1763],

1	60	CD	NUMBER	60	_	0	SENT_921	[p38l12t1794r79b1834],
2	.	.	O	.	_	0	SENT_921	[p38l12t1794r79b1834],

1	Van	NNP	O	Van	nn	3	SENT_922	[p38l106t1794r197b1834],
2	Cutsem	NNP	O	Cutsem	nn	3	SENT_922	[p38l221t1793r405b1835],
3	E	NNP	O	E	_	0	SENT_922	[p38l428t1794r471b1844],
4	,	,	O	,	_	0	SENT_922	[p38l428t1794r471b1844],
5	Peeters	NNP	ORGANIZATION	Peeters	nn	6	SENT_922	[p38l497t1794r670b1834],
6	M	NNP	ORGANIZATION	M	appos	3	SENT_922	[p38l692t1794r754b1844],
7	,	,	O	,	_	0	SENT_922	[p38l692t1794r754b1844],
8	Siena	NNP	LOCATION	Siena	nn	9	SENT_922	[p38l781t1791r909b1834],
9	S	NNP	O	S	appos	3	SENT_922	[p38l933t1793r971b1843],
10	,	,	O	,	_	0	SENT_922	[p38l933t1793r971b1843],
11	et	FW	O	et	nn	12	SENT_922	[p38l998t1799r1042b1834],
12	al.	FW	O	al.	appos	3	SENT_922	[p38l12t1862r67b1906],
13	.	.	O	.	_	0	SENT_922	[p38l12t1862r67b1906],

1	Open-label	JJ	O	open-label	amod	2	SENT_923	[p38l100t1862r367b1918],
2	phase	NN	O	phase	nsubj	4	SENT_923	[p38l396t1862r537b1918],
3	III	CD	NUMBER	iii	num	4	SENT_923	[p38l567t1866r624b1906],
4	trial	NN	O	trial	_	0	SENT_923	[p38l654t1862r756b1906],
5	of	IN	O	of	_	0	SENT_923	[p38l786t1862r842b1906],
6	panitu	FW	O	panitu	nn	8	SENT_923	[p38l861t1863r1039b1918],
7	—	FW	O	—	nn	8	SENT_923	[p38l861t1863r1039b1918],
8	mumab	NN	O	mumab	prep_of	4	SENT_923	[p38l12t1933r198b1978],
9	plus	CC	O	plus	prep	8	SENT_923	[p38l230t1933r330b1989],
10	best	JJS	O	best	dep	11	SENT_923	[p38l364t1933r465b1977],
11	supportive	JJ	O	supportive	amod	12	SENT_923	[p38l496t1934r751b1989],
12	care	NN	O	care	dep	9	SENT_923	[p38l785t1948r884b1977],
13	compared	VBN	O	compare	_	0	SENT_923	[p38l917t1947r1039b1977, p38l11t2004r149b2060],
14	with	IN	O	with	prepc_compared_with	12	SENT_923	[p38l172t2004r282b2049],
15	best	JJS	O	best	dep	16	SENT_923	[p38l308t2004r408b2048],
16	supportive	JJ	O	supportive	amod	17	SENT_923	[p38l431t2005r687b2060],
17	care	NN	O	care	pobj	12	SENT_923	[p38l712t2019r812b2048],
18	alone	RB	O	alone	dep	19	SENT_923	[p38l837t2004r968b2048],
19	in	IN	O	in	dep	4	SENT_923	[p38l992t2005r1039b2048],
20	patients	NNS	O	patient	pobj	19	SENT_923	[p38l11t2076r206b2131],
21	with	IN	O	with	_	0	SENT_923	[p38l264t2075r374b2119],
22	chemotherapy	NN	O	chemotherapy	prep_with	20	SENT_923	[p38l433t2075r1042b2131],
23	—	CD	NUMBER	—	num	27	SENT_923	[p38l433t2075r1042b2131],
24	refractory	JJ	O	refractory	amod	27	SENT_923	[p38l433t2075r1042b2131],
25	metastatic	JJ	O	metastatic	amod	27	SENT_923	[p38l12t2147r267b2190],
26	colorectal	JJ	O	colorectal	amod	27	SENT_923	[p38l287t2146r527b2190],
27	cancer	NN	O	cancer	dep	22	SENT_923	[p38l547t2160r717b2190],
28	.	.	O	.	_	0	SENT_923	[p38l547t2160r717b2190],

1	J	NNP	O	J	nn	3	SENT_924	[p38l735t2150r756b2197],
2	Clin	NNP	O	Clin	nn	3	SENT_924	[p38l775t2146r875b2190],
3	Oncol	NNP	O	Oncol	_	0	SENT_924	[p38l895t2146r1040b2190],
4	2007	CD	DATE	2007	num	3	SENT_924	[p38l12t2219r425b2269],
5	;	:	O	;	_	0	SENT_924	[p38l12t2219r425b2269],
6	25:1658	CD	NUMBER	25:1658	number	7	SENT_924	[p38l12t2219r425b2269],
7	-64	CD	NUMBER	-64	dep	3	SENT_924	[p38l12t2219r425b2269],
8	.	.	O	.	_	0	SENT_924	[p38l12t2219r425b2269],

1	61	CD	NUMBER	61	_	0	SENT_925	[p38l12t2292r77b2331],
2	.	.	O	.	_	0	SENT_925	[p38l12t2292r77b2331],

1	Bonner	NNP	PERSON	Bonner	nn	2	SENT_926	[p38l107t2291r286b2331],
2	JA	NNP	O	JA	_	0	SENT_926	[p38l303t2291r372b2341],
3	,	,	O	,	_	0	SENT_926	[p38l303t2291r372b2341],
4	Harari	NNP	PERSON	Harari	nn	5	SENT_926	[p38l399t2288r558b2331],
5	PM	NNP	O	PM	appos	2	SENT_926	[p38l581t2291r670b2340],
6	,	,	O	,	_	0	SENT_926	[p38l581t2291r670b2340],
7	Giralt	NNP	PERSON	Giralt	nn	8	SENT_926	[p38l698t2287r841b2331],
8	J	NNP	PERSON	J	appos	2	SENT_926	[p38l857t2291r889b2341],
9	,	,	O	,	_	0	SENT_926	[p38l857t2291r889b2341],
10	et	FW	O	et	nn	11	SENT_926	[p38l916t2296r960b2331],
11	al.	FW	O	al.	appos	2	SENT_926	[p38l981t2287r1036b2331],
12	.	.	O	.	_	0	SENT_926	[p38l981t2287r1036b2331],

1	Radiotherapy	NN	O	radiotherapy	_	0	SENT_927	[p38l12t2359r341b2415],
2	plus	CC	O	plus	prep	1	SENT_927	[p38l373t2359r473b2415],
3	cetuximab	NN	O	cetuximab	dep	2	SENT_927	[p38l511t2359r767b2404],
4	for	IN	O	for	_	0	SENT_927	[p38l804t2359r874b2403],
5	squamous-cell	JJ	O	squamous-cell	amod	6	SENT_927	[p38l909t2373r1039b2415, p38l12t2430r252b2474],
6	carcinoma	NN	O	carcinoma	prep_for	1	SENT_927	[p38l293t2431r551b2474],
7	of	IN	O	of	_	0	SENT_927	[p38l591t2430r647b2474],
8	the	DT	O	the	det	9	SENT_927	[p38l679t2430r754b2473],
9	head	NN	O	head	prep_of	1	SENT_927	[p38l795t2430r910b2474],
10	and	CC	O	and	_	0	SENT_927	[p38l950t2430r1039b2474],
11	neck	NN	O	neck	prep_of	1	SENT_927	[p38l12t2500r138b2545],
12	.	.	O	.	_	0	SENT_927	[p38l12t2500r138b2545],

1	N	NN	O	n	nn	3	SENT_928	[p38l159t2504r201b2545],
2	Engl	NNP	O	Engl	nn	3	SENT_928	[p38l219t2500r328b2557],
3	J	NNP	O	J	nsubj	4	SENT_928	[p38l342t2504r363b2551],
4	Med	VBD	O	med	_	0	SENT_928	[p38l379t2500r484b2544],
5	2006	CD	DATE	2006	dobj	4	SENT_928	[p38l503t2503r913b2553],
6	;	:	O	;	_	0	SENT_928	[p38l503t2503r913b2553],
7	354:567	CD	NUMBER	354:567	num	8	SENT_928	[p38l503t2503r913b2553],
8	—	NN	O	—	dep	5	SENT_928	[p38l503t2503r913b2553],
9	78	CD	NUMBER	78	dep	8	SENT_928	[p38l503t2503r913b2553],
10	.	.	O	.	_	0	SENT_928	[p38l503t2503r913b2553],

1	62	CD	NUMBER	62	_	0	SENT_929	[p38l12t2576r80b2615],
2	.	.	O	.	_	0	SENT_929	[p38l12t2576r80b2615],

1	Vermorken	NNP	O	Vermorken	nn	2	SENT_930	[p38l106t2571r376b2616],
2	JB	NNP	O	JB	_	0	SENT_930	[p38l391t2575r460b2625],
3	,	,	O	,	_	0	SENT_930	[p38l391t2575r460b2625],
4	Mesia	NNP	PERSON	Mesia	nn	5	SENT_930	[p38l482t2572r625b2615],
5	R	NNP	PERSON	R	appos	2	SENT_930	[p38l645t2575r693b2624],
6	,	,	O	,	_	0	SENT_930	[p38l645t2575r693b2624],
7	Vega	NNP	PERSON	Vega	nn	8	SENT_930	[p38l716t2575r831b2628],
8	E	NNP	O	E	appos	2	SENT_930	[p38l851t2575r895b2625],
9	,	,	O	,	_	0	SENT_930	[p38l851t2575r895b2625],
10	et	FW	O	et	nn	11	SENT_930	[p38l919t2580r963b2615],
11	al.	FW	O	al.	appos	2	SENT_930	[p38l981t2571r1036b2615],
12	.	.	O	.	_	0	SENT_930	[p38l981t2571r1036b2615],

1	Cetuximab	NNP	O	Cetuximab	nsubj	2	SENT_931	[p38l12t2643r280b2688],
2	extends	VBZ	O	extend	_	0	SENT_931	[p38l299t2643r484b2687],
3	survival	NN	O	survival	dobj	2	SENT_931	[p38l504t2643r694b2688],
4	of	IN	O	of	_	0	SENT_931	[p38l712t2643r768b2687],
5	patients	NNS	O	patient	prep_of	3	SENT_931	[p38l776t2644r970b2699],
6	or	CC	O	or	_	0	SENT_931	[p38l991t2657r1041b2687],
7	recurrent	JJ	O	recurrent	amod	10	SENT_931	[p38l12t2722r240b2758],
8	or	CC	O	or	_	0	SENT_931	[p38l283t2727r333b2757],
9	metastatic	JJ	O	metastatic	conj_or	7	SENT_931	[p38l378t2714r632b2757],
10	SCCHN	NN	O	scchn	prep_of	3	SENT_931	[p38l679t2716r864b2757],
11	when	WRB	O	when	advmod	12	SENT_931	[p38l907t2713r1039b2758],
12	added	VBN	O	add	ccomp	10	SENT_931	[p38l12t2784r157b2828],
13	to	TO	O	to	_	0	SENT_931	[p38l173t2793r218b2828],
14	first	JJ	ORDINAL	first	amod	17	SENT_931	[p38l235t2784r340b2828],
15	line	NN	O	line	nn	17	SENT_931	[p38l353t2784r443b2828],
16	platinum	NN	O	platinum	nn	17	SENT_931	[p38l458t2784r843b2840],
17	—	NN	O	—	prep_to	12	SENT_931	[p38l458t2784r843b2840],
18	based	VBN	O	base	partmod	17	SENT_931	[p38l458t2784r843b2840],
19	therapy	NN	O	therapy	nn	20	SENT_931	[p38l859t2784r1042b2840],
20	results	NNS	O	result	dobj	18	SENT_931	[p38l12t2855r174b2900],
21	of	IN	O	of	_	0	SENT_931	[p38l209t2855r265b2899],
22	a	DT	O	a	det	24	SENT_931	[p38l288t2870r313b2899],
23	randomized	JJ	O	randomized	amod	24	SENT_931	[p38l345t2855r642b2899],
24	phase	NN	O	phase	prep_of	20	SENT_931	[p38l674t2855r815b2911],
25	III	CD	NUMBER	iii	number	26	SENT_931	[p38l848t2859r906b2899],
26	(	CD	NUMBER	(	num	29	SENT_931	[p38l941t2859r1039b2906, p38l10t2930r213b2977],
27	EXTREME	NNP	O	EXTREME	nn	29	SENT_931	[p38l941t2859r1039b2906, p38l10t2930r213b2977],
28	)	CD	NUMBER	)	num	29	SENT_931	[p38l941t2859r1039b2906, p38l10t2930r213b2977],
29	study	NN	O	study	dep	24	SENT_931	[p38l259t2926r398b2982],
30	.	.	O	.	_	0	SENT_931	[p38l259t2926r398b2982],

1	Late	RB	O	late	advmod	2	SENT_932	[p38l442t2930r544b2970],
2	breaking	VBG	O	break	_	0	SENT_932	[p38l586t2926r805b2983],
3	abstract	JJ	O	abstract	dobj	2	SENT_932	[p38l845t2926r1042b2970],
4	presented	VBN	O	present	partmod	3	SENT_932	[p38l11t2997r250b3053],
5	at	IN	O	at	_	0	SENT_932	[p38l268t3006r313b3041],
6	the	DT	O	the	det	9	SENT_932	[p38l328t2997r404b3041],
7	43rd	JJ	ORDINAL	43rd	amod	9	SENT_932	[p38l421t2997r529b3041],
8	American	NNP	MISC	American	nn	9	SENT_932	[p38l546t2998r784b3041],
9	Society	NNP	MISC	Society	prep_at	4	SENT_932	[p38l804t2998r977b3053],
10	of	IN	MISC	of	prep	9	SENT_932	[p38l993t2997r1050b3041],

1	66	CD	NUMBER	66	_	0	SENT_933	[p38l1115t20r1182b59],
2	.	.	O	.	_	0	SENT_933	[p38l1115t20r1182b59],

1	Vermorken	NNP	O	Vermorken	nn	2	SENT_934	[p38l1208t15r1478b60],
2	JB	NNP	O	JB	_	0	SENT_934	[p38l1500t19r1568b68],
3	,	,	O	,	_	0	SENT_934	[p38l1500t19r1568b68],
4	Trigo	NNP	PERSON	Trigo	nn	5	SENT_934	[p38l1597t16r1728b72],
5	J	NNP	PERSON	J	appos	2	SENT_934	[p38l1750t19r1782b68],
6	,	,	O	,	_	0	SENT_934	[p38l1750t19r1782b68],
7	Hitt	NNP	PERSON	Hitt	nn	8	SENT_934	[p38l1813t16r1911b59],
8	R	NNP	O	R	appos	2	SENT_934	[p38l1935t19r1984b68],
9	,	,	O	,	_	0	SENT_934	[p38l1935t19r1984b68],
10	et	FW	O	et	nn	11	SENT_934	[p38l2015t24r2059b59],
11	al.	FW	O	al.	appos	2	SENT_934	[p38l2083t15r2139b59],
12	.	.	O	.	_	0	SENT_934	[p38l2083t15r2139b59],

1	Open-label	JJ	O	open-label	amod	6	SENT_935	[p38l1115t86r1395b142],
2	,	,	O	,	_	0	SENT_935	[p38l1115t86r1395b142],
3	uncontrolled	JJ	O	uncontrolled	amod	6	SENT_935	[p38l1463t86r1791b140],
4	,	,	O	,	_	0	SENT_935	[p38l1463t86r1791b140],
5	multicenter	JJ	O	multicenter	amod	6	SENT_935	[p38l1860t86r2143b131],
6	phase	NN	O	phase	_	0	SENT_935	[p38l1114t158r1255b214],
7	II	CD	NUMBER	ii	num	8	SENT_935	[p38l1272t162r1309b201],
8	study	NN	O	study	nsubj	10	SENT_935	[p38l1327t158r1457b214],
9	to	TO	O	to	aux	10	SENT_935	[p38l1473t167r1519b202],
10	evaluate	VB	O	evaluate	infmod	6	SENT_935	[p38l1537t158r1734b203],
11	the	DT	O	the	det	12	SENT_935	[p38l1752t158r1828b202],
12	efficacy	NN	O	efficacy	dobj	10	SENT_935	[p38l1846t158r2037b214],
13	and	CC	O	and	_	0	SENT_935	[p38l2052t158r2142b202],
14	toxicity	NN	O	toxicity	conj_and	12	SENT_935	[p38l1115t229r1296b284],
15	of	IN	O	of	_	0	SENT_935	[p38l1315t228r1371b272],
16	cetuximab	NN	O	cetuximab	prep_of	12	SENT_935	[p38l1383t228r1639b273],
17	as	IN	O	as	_	0	SENT_935	[p38l1661t243r1709b272],
18	a	DT	O	a	det	20	SENT_935	[p38l1731t243r1756b272],
19	single	JJ	O	single	amod	20	SENT_935	[p38l1777t228r1920b285],
20	agent	NN	O	agent	prep_as	10	SENT_935	[p38l1942t237r2076b285],
21	in	IN	O	in	_	0	SENT_935	[p38l2094t229r2141b272],
22	patients	NNS	O	patient	prep_in	20	SENT_935	[p38l1114t301r1308b356],
23	with	IN	O	with	_	0	SENT_935	[p38l1329t300r1440b345],
24	recurrent	JJ	O	recurrent	amod	25	SENT_935	[p38l1462t309r1689b345],
25	and/or	JJ	O	and/or	amod	29	SENT_935	[p38l1708t300r1867b350],
26	metastatic	JJ	O	metastatic	amod	29	SENT_935	[p38l1887t301r2142b344],
27	squamous	JJ	O	squamous	amod	29	SENT_935	[p38l1115t385r1363b427],
28	cell	NN	O	cell	nn	29	SENT_935	[p38l1383t371r1466b415],
29	carcinoma	NN	O	carcinoma	prep_with	6	SENT_935	[p38l1485t372r1742b415],
30	of	IN	O	of	_	0	SENT_935	[p38l1761t371r1817b415],
31	the	DT	O	the	det	32	SENT_935	[p38l1825t371r1901b415],
32	head	NN	O	head	prep_of	6	SENT_935	[p38l1919t371r2034b415],
33	and	CC	O	and	_	0	SENT_935	[p38l2052t371r2142b415],
34	neck	NN	O	neck	prep_of	6	SENT_935	[p38l1115t442r1229b487],
35	who	WP	O	who	nsubj	36	SENT_935	[p38l1248t442r1351b487],
36	failed	VBD	O	fail	rcmod	32	SENT_935	[p38l1376t442r1513b486],
37	to	TO	O	to	aux	38	SENT_935	[p38l1537t451r1583b486],
38	respond	VB	O	respond	xcomp	36	SENT_935	[p38l1608t442r1804b498],
39	to	TO	O	to	_	0	SENT_935	[p38l1828t451r1874b486],
40	platinumbased	JJ	O	platinumbased	amod	41	SENT_935	[p38l1898t442r2141b498, p38l1115t513r1254b557],
41	therapy	NN	O	therapy	prep_to	38	SENT_935	[p38l1274t513r1465b569],
42	.	.	O	.	_	0	SENT_935	[p38l1274t513r1465b569],

1	J	NNP	O	J	nn	3	SENT_936	[p38l1482t517r1503b564],
2	Clin	NNP	O	Clin	nn	3	SENT_936	[p38l1521t513r1621b557],
3	Oncol	NNP	O	Oncol	_	0	SENT_936	[p38l1641t513r1785b557],
4	2007	CD	DATE	2007	num	3	SENT_936	[p38l1805t516r2141b566],
5	;	:	O	;	_	0	SENT_936	[p38l1805t516r2141b566],
6	25:2171	CD	NUMBER	25:2171	num	7	SENT_936	[p38l1805t516r2141b566],
7	—	NN	O	—	dep	3	SENT_936	[p38l1805t516r2141b566],
8	7	CD	NUMBER	7	dep	7	SENT_936	[p38l1115t588r1149b628],
9	.	.	O	.	_	0	SENT_936	[p38l1115t588r1149b628],

1	67	CD	NUMBER	67	_	0	SENT_937	[p38l1115t659r1176b698],
2	.	.	O	.	_	0	SENT_937	[p38l1115t659r1176b698],

1	Bourhis	NNP	PERSON	Bourhis	nn	2	SENT_938	[p38l1210t654r1400b699],
2	J	NNP	PERSON	J	_	0	SENT_938	[p38l1428t658r1460b707],
3	,	,	O	,	_	0	SENT_938	[p38l1428t658r1460b707],
4	Rivera	NNP	PERSON	Rivera	nn	5	SENT_938	[p38l1495t655r1648b701],
5	F	NN	O	f	appos	2	SENT_938	[p38l1679t658r1717b708],
6	,	,	O	,	_	0	SENT_938	[p38l1679t658r1717b708],
7	Mesia	NNP	PERSON	Mesia	nn	8	SENT_938	[p38l1751t655r1894b698],
8	R	NNP	O	R	appos	2	SENT_938	[p38l1925t658r1974b708],
9	,	,	O	,	_	0	SENT_938	[p38l1925t658r1974b708],
10	et	FW	O	et	nn	11	SENT_938	[p38l2010t663r2054b698],
11	al.	FW	O	al.	appos	2	SENT_938	[p38l2083t654r2138b698],
12	.	.	O	.	_	0	SENT_938	[p38l2083t654r2138b698],

1	Phase	NN	O	phase	nn	3	SENT_939	[p38l1114t725r1253b769],
2	I/II	NN	O	i/ii	nn	3	SENT_939	[p38l1270t728r1344b775],
3	study	NN	O	study	_	0	SENT_939	[p38l1362t725r1493b781],
4	of	IN	O	of	_	0	SENT_939	[p38l1508t725r1565b769],
5	cetuximab	NN	O	cetuximab	prep_of	3	SENT_939	[p38l1572t725r1828b770],
6	in	IN	O	in	_	0	SENT_939	[p38l1846t726r1893b769],
7	combination	NN	O	combination	prep_in	5	SENT_939	[p38l1911t725r2141b769, p38l1115t798r1211b841],
8	with	IN	O	with	_	0	SENT_939	[p38l1247t797r1358b842],
9	cisplatin	NN	O	cisplatin	prep_with	7	SENT_939	[p38l1397t797r1606b853],
10	or	CC	O	or	_	0	SENT_939	[p38l1645t811r1695b841],
11	carboplatin	NN	O	carboplatin	conj_or	9	SENT_939	[p38l1732t797r2014b853],
12	and	CC	O	and	_	0	SENT_939	[p38l2052t797r2142b841],
13	fluorouracil	NN	O	fluorouracil	conj_and	9	SENT_939	[p38l1115t868r1406b913],
14	in	IN	O	in	_	0	SENT_939	[p38l1428t869r1475b912],
15	patients	NNS	O	patient	prep_in	3	SENT_939	[p38l1496t869r1691b924],
16	with	IN	O	with	_	0	SENT_939	[p38l1712t868r1823b913],
17	recurrent	JJ	O	recurrent	amod	22	SENT_939	[p38l1845t877r2073b913],
18	or	CC	O	or	_	0	SENT_939	[p38l2093t882r2143b912],
19	metastatic	JJ	O	metastatic	conj_or	17	SENT_939	[p38l1115t940r1369b983],
20	squamous	JJ	O	squamous	amod	22	SENT_939	[p38l1403t953r1651b995],
21	cell	NN	O	cell	nn	22	SENT_939	[p38l1687t939r1770b983],
22	carcinoma	NN	O	carcinoma	prep_with	15	SENT_939	[p38l1804t940r2062b983],
23	of	IN	O	of	_	0	SENT_939	[p38l2095t939r2152b983],
24	the	DT	O	the	det	25	SENT_939	[p38l1115t1010r1190b1054],
25	head	NN	O	head	prep_of	3	SENT_939	[p38l1250t1010r1365b1054],
26	and	CC	O	and	_	0	SENT_939	[p38l1425t1010r1514b1054],
27	neck	NN	O	neck	conj_and	25	SENT_939	[p38l1574t1010r1700b1055],
28	.	.	O	.	_	0	SENT_939	[p38l1574t1010r1700b1055],

1	J	NNP	O	J	nn	3	SENT_940	[p38l1757t1014r1778b1061],
2	Clin	NNP	O	Clin	nn	3	SENT_940	[p38l1837t1010r1937b1054],
3	Oncol	NNP	O	Oncol	_	0	SENT_940	[p38l1998t1010r2142b1054],
4	2006	CD	DATE	2006	num	3	SENT_940	[p38l1115t1084r1532b1134],
5	;	:	O	;	_	0	SENT_940	[p38l1115t1084r1532b1134],
6	24:2866	CD	NUMBER	24:2866	number	7	SENT_940	[p38l1115t1084r1532b1134],
7	—	CD	NUMBER	—	dep	3	SENT_940	[p38l1115t1084r1532b1134],
8	72	CD	NUMBER	72	dep	7	SENT_940	[p38l1115t1084r1532b1134],
9	.	.	O	.	_	0	SENT_940	[p38l1115t1084r1532b1134],

1	68	CD	NUMBER	68	_	0	SENT_941	[p38l1115t1155r1182b1196],
2	.	.	O	.	_	0	SENT_941	[p38l1115t1155r1182b1196],

1	Xiong	NNP	PERSON	Xiong	nn	2	SENT_942	[p38l1208t1152r1354b1208],
2	HO	NNP	PERSON	HO	_	0	SENT_942	[p38l1374t1154r1468b1205],
3	,	,	O	,	_	0	SENT_942	[p38l1374t1154r1468b1205],
4	Rosenberg	NNP	PERSON	Rosenberg	nn	5	SENT_942	[p38l1493t1151r1756b1208],
5	A	NNP	O	A	appos	2	SENT_942	[p38l1774t1155r1824b1205],
6	,	,	O	,	_	0	SENT_942	[p38l1774t1155r1824b1205],
7	LoBuglio	NNP	O	LoBuglio	nn	8	SENT_942	[p38l1848t1151r2068b1208],
8	A	NNP	O	A	appos	2	SENT_942	[p38l2089t1155r2139b1205],
9	,	,	O	,	_	0	SENT_942	[p38l2089t1155r2139b1205],
10	et	FW	O	et	nn	11	SENT_942	[p38l1115t1232r1158b1267],
11	al.	FW	O	al.	appos	2	SENT_942	[p38l1178t1223r1234b1267],
12	.	.	O	.	_	0	SENT_942	[p38l1178t1223r1234b1267],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_943	[p38l1260t1223r1541b1277],
2	,	,	O	,	_	0	SENT_943	[p38l1260t1223r1541b1277],
3	a	DT	O	a	det	5	SENT_943	[p38l1567t1238r1591b1267],
4	monoclonal	JJ	O	monoclonal	amod	5	SENT_943	[p38l1613t1223r1905b1267],
5	antibody	NN	O	antibody	appos	1	SENT_943	[p38l1928t1223r2144b1279],
6	targeting	VBG	O	target	partmod	5	SENT_943	[p38l1115t1294r1342b1350],
7	the	DT	O	the	det	11	SENT_943	[p38l1359t1293r1435b1337],
8	epidermal	JJ	O	epidermal	amod	11	SENT_943	[p38l1454t1293r1700b1349],
9	growth	NN	O	growth	nn	11	SENT_943	[p38l1719t1293r1897b1350],
10	factor	NN	O	factor	nn	11	SENT_943	[p38l1916t1293r2059b1337],
11	receptor	NN	O	receptor	dobj	6	SENT_943	[p38l2076t1308r2141b1337, p38l1115t1373r1279b1420],
12	,	,	O	,	_	0	SENT_943	[p38l2076t1308r2141b1337, p38l1115t1373r1279b1420],
13	in	IN	O	in	_	0	SENT_943	[p38l1306t1365r1353b1408],
14	combination	NN	O	combination	prep_in	1	SENT_943	[p38l1376t1364r1687b1408],
15	with	IN	O	with	_	0	SENT_943	[p38l1708t1364r1819b1409],
16	gemcitabine	NN	O	gemcitabine	prep_with	14	SENT_943	[p38l1842t1364r2141b1421],
17	for	IN	O	for	_	0	SENT_943	[p38l1115t1436r1184b1480],
18	advanced	JJ	O	advanced	amod	20	SENT_943	[p38l1209t1436r1434b1481],
19	pancreatic	JJ	O	pancreatic	amod	20	SENT_943	[p38l1460t1437r1715b1492],
20	cancer	NN	O	cancer	prep_for	16	SENT_943	[p38l1742t1450r1913b1480],
21	:	:	O	:	_	0	SENT_943	[p38l1742t1450r1913b1480],
22	a	DT	O	a	det	24	SENT_943	[p38l1942t1451r1967b1480],
23	multicenter	JJ	O	multicenter	amod	24	SENT_943	[p38l1993t1436r2141b1481, p38l1115t1516r1265b1551],
24	phase	NN	O	phase	dep	16	SENT_943	[p38l1316t1507r1457b1563],
25	II	CD	NUMBER	ii	num	26	SENT_943	[p38l1511t1511r1548b1551],
26	trial	NN	O	trial	dep	24	SENT_943	[p38l1602t1507r1717b1551],
27	.	.	O	.	_	0	SENT_943	[p38l1602t1507r1717b1551],

1	J	NNP	O	J	nn	3	SENT_944	[p38l1769t1511r1790b1558],
2	Clin	NNP	O	Clin	nn	3	SENT_944	[p38l1843t1507r1943b1551],
3	Oncol	NNP	O	Oncol	_	0	SENT_944	[p38l1998t1507r2142b1551],
4	2004	CD	DATE	2004	num	3	SENT_944	[p38l1115t1581r1505b1631],
5	;	:	O	;	_	0	SENT_944	[p38l1115t1581r1505b1631],
6	22:2610	CD	NUMBER	22:2610	number	7	SENT_944	[p38l1115t1581r1505b1631],
7	—	CD	NUMBER	—	dep	3	SENT_944	[p38l1115t1581r1505b1631],
8	6	CD	NUMBER	6	dep	7	SENT_944	[p38l1115t1581r1505b1631],
9	.	.	O	.	_	0	SENT_944	[p38l1115t1581r1505b1631],

1	69	CD	NUMBER	69	_	0	SENT_945	[p38l1115t1653r1179b1692],
2	.	.	O	.	_	0	SENT_945	[p38l1115t1653r1179b1692],

1	Philip	NNP	ORGANIZATION	Philip	nn	2	SENT_946	[p38l1210t1648r1352b1704],
2	PA	NN	ORGANIZATION	pa	_	0	SENT_946	[p38l1378t1652r1454b1701],
3	,	,	O	,	_	0	SENT_946	[p38l1378t1652r1454b1701],
4	Benedetti	NNP	PERSON	Benedetti	nn	5	SENT_946	[p38l1482t1648r1715b1692],
5	J	NNP	PERSON	J	appos	2	SENT_946	[p38l1735t1652r1767b1702],
6	,	,	O	,	_	0	SENT_946	[p38l1735t1652r1767b1702],
7	Fenoglio	NNP	PERSON	Fenoglio	appos	5	SENT_946	[p38l1795t1648r2141b1705],
8	.	.	O	.	_	0	SENT_946	[p38l1795t1648r2141b1705],

1	—	NN	O	—	_	0	SENT_947	[p38l1795t1648r2141b1705],
2	.	.	O	.	_	0	SENT_947	[p38l1795t1648r2141b1705],

1	Prei	NNP	O	Prei	nn	3	SENT_948	[p38l1795t1648r2141b1705],
2	ser	NN	O	ser	nn	3	SENT_948	[p38l1115t1734r1186b1763],
3	C	NN	O	c	_	0	SENT_948	[p38l1201t1722r1248b1773],
4	,	,	O	,	_	0	SENT_948	[p38l1201t1722r1248b1773],
5	et	FW	O	et	nn	6	SENT_948	[p38l1269t1728r1313b1763],
6	al.	FW	O	al.	appos	3	SENT_948	[p38l1327t1719r1382b1763],
7	.	.	O	.	_	0	SENT_948	[p38l1327t1719r1382b1763],

1	Phase	NN	O	phase	nn	3	SENT_949	[p38l1402t1719r1541b1763],
2	III	CD	NUMBER	iii	num	3	SENT_949	[p38l1558t1723r1615b1763],
3	study	NN	O	study	_	0	SENT_949	[p38l1633t1719r1763b1775],
4	of	IN	O	of	_	0	SENT_949	[p38l1778t1719r1835b1763],
5	gemcitabine	NN	O	gemcitabine	nn	8	SENT_949	[p38l1842t1719r2141b1776],
6	[	CD	NUMBER	[	num	8	SENT_949	[p38l1119t1793r1188b1841],
7	G	NN	O	g	nn	8	SENT_949	[p38l1119t1793r1188b1841],
8	]	NN	O	]	prep_of	3	SENT_949	[p38l1119t1793r1188b1841],
9	plus	CC	O	plus	prep	8	SENT_949	[p38l1214t1790r1314b1846],
10	cetuximab	JJ	O	cetuximab	amod	12	SENT_949	[p38l1337t1790r1593b1835],
11	[	NN	O	[	nn	12	SENT_949	[p38l1620t1793r1684b1841],
12	C	NN	O	c	dep	9	SENT_949	[p38l1620t1793r1684b1841],
13	]	CD	NUMBER	]	nsubj	20	SENT_949	[p38l1620t1793r1684b1841],
14	versus	CC	O	versus	prep	13	SENT_949	[p38l1709t1805r1860b1835],
15	gemcitabine	NN	O	gemcitabine	dep	14	SENT_949	[p38l1883t1790r2141b1847, p38l1115t1876r1170b1906],
16	in	IN	O	in	_	0	SENT_949	[p38l1191t1863r1238b1906],
17	patients	NNS	O	patient	prep_in	15	SENT_949	[p38l1258t1863r1452b1918],
18	[	IN	O	[	_	0	SENT_949	[p38l1480t1866r1582b1918],
19	pts	NNS	O	pt	prep_[	20	SENT_949	[p38l1480t1866r1582b1918],
20	]	VBP	O	]	rcmod	3	SENT_949	[p38l1480t1866r1582b1918],
21	with	IN	O	with	_	0	SENT_949	[p38l1606t1862r1717b1906],
22	locally	RB	O	locally	advmod	23	SENT_949	[p38l1737t1862r1898b1918],
23	advanced	VBN	O	advance	amod	27	SENT_949	[p38l1916t1862r2142b1906],
24	or	CC	O	or	_	0	SENT_949	[p38l1115t1947r1165b1977],
25	metastatic	JJ	O	metastatic	amod	27	SENT_949	[p38l1185t1934r1440b1977],
26	pancreatic	JJ	O	pancreatic	amod	27	SENT_949	[p38l1460t1934r1715b1989],
27	adenocarcinoma	NN	O	adenocarcinoma	prep_with	20	SENT_949	[p38l1736t1933r2142b1977],
28	[	NN	O	[	nn	29	SENT_949	[p38l1119t2008r1249b2055],
29	Pca	NN	O	pca	dep	3	SENT_949	[p38l1119t2008r1249b2055],
30	]	CD	NUMBER	]	dep	29	SENT_949	[p38l1119t2008r1249b2055],
31	:	:	O	:	_	0	SENT_949	[p38l1119t2008r1249b2055],
32	SWOG	NN	O	swog	dep	3	SENT_949	[p38l1283t2007r1444b2048],
33	S0205	NN	O	s0205	nn	34	SENT_949	[p38l1476t2007r1616b2048],
34	study	NN	O	study	dep	32	SENT_949	[p38l1650t2004r1788b2060],
35	.	.	O	.	_	0	SENT_949	[p38l1650t2004r1788b2060],

1	J	NNP	O	J	nn	3	SENT_950	[p38l1816t2008r1837b2055],
2	Clin	NNP	O	Clin	nn	3	SENT_950	[p38l1867t2004r1967b2048],
3	Oncol	NNP	O	Oncol	_	0	SENT_950	[p38l1998t2004r2142b2048],
4	2007	CD	DATE	2007	num	6	SENT_950	[p38l1115t2075r1599b2131],
5	;	:	O	;	_	0	SENT_950	[p38l1115t2075r1599b2131],
6	25	CD	NUMBER	25	dep	3	SENT_950	[p38l1115t2075r1599b2131],
7	:	:	O	:	_	0	SENT_950	[p38l1115t2075r1599b2131],
8	Suppl	NNP	O	Suppl	dep	3	SENT_950	[p38l1115t2075r1599b2131],
9	:199	CD	NUMBER	:199	num	10	SENT_950	[p38l1115t2075r1599b2131],
10	s.	NN	O	s.	npadvmod	11	SENT_950	[p38l1115t2075r1599b2131],
11	abstract	JJ	O	abstract	amod	8	SENT_950	[p38l1621t2075r1830b2119],
12	.	.	O	.	_	0	SENT_950	[p38l1621t2075r1830b2119],

1	70	CD	NUMBER	70	_	0	SENT_951	[p38l1116t2150r1179b2190],
2	.	.	O	.	_	0	SENT_951	[p38l1116t2150r1179b2190],

1	Moore	NNP	PERSON	Moore	nn	3	SENT_952	[p38l1209t2150r1366b2190],
2	M	NNP	O	M	nn	3	SENT_952	[p38l1392t2150r1470b2200],
3	]	NN	O	]	_	0	SENT_952	[p38l1392t2150r1470b2200],
4	,	,	O	,	_	0	SENT_952	[p38l1392t2150r1470b2200],
5	Goldstein	NNP	PERSON	Goldstein	nn	6	SENT_952	[p38l1500t2146r1738b2190],
6	D	NNP	PERSON	D	appos	3	SENT_952	[p38l1765t2150r1816b2200],
7	,	,	O	,	_	0	SENT_952	[p38l1765t2150r1816b2200],
8	Hamm	NNP	PERSON	Hamm	nn	9	SENT_952	[p38l1846t2150r2015b2190],
9	J	NNP	PERSON	J	appos	3	SENT_952	[p38l2037t2150r2070b2199],
10	,	,	O	,	_	0	SENT_952	[p38l2037t2150r2070b2199],
11	et	FW	O	et	nn	12	SENT_952	[p38l2100t2155r2144b2190],
12	al.	FW	O	al.	appos	3	SENT_952	[p38l1114t2216r1169b2260],
13	.	.	O	.	_	0	SENT_952	[p38l1114t2216r1169b2260],

1	Erlotinib	NN	O	erlotinib	_	0	SENT_953	[p38l1199t2216r1416b2260],
2	plus	CC	O	plus	prep	1	SENT_953	[p38l1443t2216r1543b2272],
3	gemcitabine	NN	O	gemcitabine	dep	2	SENT_953	[p38l1572t2216r1871b2273],
4	compared	VBN	O	compare	_	0	SENT_953	[p38l1900t2216r2142b2272],
5	with	IN	O	with	prepc_compared_with	1	SENT_953	[p38l1112t2287r1222b2332],
6	gemcitabine	NN	O	gemcitabine	pobj	1	SENT_953	[p38l1250t2287r1550b2344],
7	alone	RB	O	alone	advmod	6	SENT_953	[p38l1577t2287r1708b2331],
8	in	IN	O	in	_	0	SENT_953	[p38l1736t2288r1783b2331],
9	patients	NNS	O	patient	prep_in	6	SENT_953	[p38l1810t2288r2005b2343],
10	with	IN	O	with	_	0	SENT_953	[p38l2031t2287r2142b2332],
11	advanced	JJ	O	advanced	amod	13	SENT_953	[p38l1114t2359r1339b2404],
12	pancreatic	JJ	O	pancreatic	amod	13	SENT_953	[p38l1369t2360r1624b2415],
13	cancer	NN	O	cancer	prep_with	9	SENT_953	[p38l1655t2373r1827b2403],
14	:	:	O	:	_	0	SENT_953	[p38l1655t2373r1827b2403],
15	a	DT	O	a	det	18	SENT_953	[p38l1859t2374r1884b2403],
16	phase	NN	O	phase	nn	18	SENT_953	[p38l1913t2359r2054b2415],
17	III	CD	NUMBER	iii	num	18	SENT_953	[p38l2085t2363r2142b2403],
18	trial	NN	O	trial	dep	9	SENT_953	[p38l1115t2430r1216b2473],
19	of	IN	O	of	_	0	SENT_953	[p38l1245t2430r1301b2474],
20	the	DT	O	the	det	23	SENT_953	[p38l1320t2430r1395b2473],
21	National	NNP	ORGANIZATION	National	nn	23	SENT_953	[p38l1422t2430r1635b2474],
22	Cancer	NNP	ORGANIZATION	Cancer	nn	23	SENT_953	[p38l1663t2433r1833b2474],
23	Institute	NNP	ORGANIZATION	Institute	prep_of	18	SENT_953	[p38l1859t2431r2066b2474],
24	of	IN	O	of	prep	23	SENT_953	[p38l2095t2430r2152b2474],

1	Canada	NNP	LOCATION	Canada	nn	3	SENT_954	[p38l1115t2500r1297b2544],
2	Clinical	JJ	O	clinical	amod	3	SENT_954	[p38l1320t2500r1509b2544],
3	Trials	NNPS	O	Trials	_	0	SENT_954	[p38l1531t2500r1670b2544],
4	Group	NNP	O	Group	dep	3	SENT_954	[p38l1696t2503r1862b2556],
5	.	.	O	.	_	0	SENT_954	[p38l1696t2503r1862b2556],

1	J	NNP	O	J	nn	3	SENT_955	[p38l1883t2504r1904b2551],
2	Clin	NNP	O	Clin	nn	3	SENT_955	[p38l1927t2500r2027b2544],
3	Oncol	NNP	O	Oncol	_	0	SENT_955	[p38l2051t2503r2141b2544, p38l1115t2571r1184b2615],
4	2007	CD	DATE	2007	num	3	SENT_955	[p38l1203t2574r1591b2624],
5	;	:	O	;	_	0	SENT_955	[p38l1203t2574r1591b2624],
6	25:1960	CD	NUMBER	25:1960	number	7	SENT_955	[p38l1203t2574r1591b2624],
7	-6	CD	NUMBER	-6	dep	3	SENT_955	[p38l1203t2574r1591b2624],
8	.	.	O	.	_	0	SENT_955	[p38l1203t2574r1591b2624],

1	71	CD	NUMBER	71	_	0	SENT_956	[p38l1116t2649r1179b2687],
2	.	.	O	.	_	0	SENT_956	[p38l1116t2649r1179b2687],

1	Miller	NNP	ORGANIZATION	Miller	nn	2	SENT_957	[p38l1209t2643r1357b2687],
2	VA	NNP	ORGANIZATION	VA	_	0	SENT_957	[p38l1386t2647r1465b2697],
3	,	,	O	,	_	0	SENT_957	[p38l1386t2647r1465b2697],
4	Kris	NNP	PERSON	Kris	nn	5	SENT_957	[p38l1500t2644r1600b2688],
5	MG	NN	PERSON	mg	appos	2	SENT_957	[p38l1632t2646r1734b2697],
6	,	,	O	,	_	0	SENT_957	[p38l1632t2646r1734b2697],
7	Shah	NNP	PERSON	Shah	nn	8	SENT_957	[p38l1771t2643r1890b2687],
8	N	NNP	O	N	appos	2	SENT_957	[p38l1921t2647r1974b2697],
9	,	,	O	,	_	0	SENT_957	[p38l1921t2647r1974b2697],
10	et	FW	O	et	nn	11	SENT_957	[p38l2010t2652r2054b2687],
11	al.	FW	O	al.	appos	2	SENT_957	[p38l2083t2643r2138b2687],
12	.	.	O	.	_	0	SENT_957	[p38l2083t2643r2138b2687],

1	Bronchioloalveolar	JJ	O	bronchioloalveolar	amod	3	SENT_958	[p38l1114t2713r1578b2758],
2	pathologic	JJ	O	pathologic	amod	3	SENT_958	[p38l1633t2713r1894b2770],
3	subtype	NN	O	subtype	nsubj	7	SENT_958	[p38l1953t2713r2142b2769],
4	and	CC	O	and	_	0	SENT_958	[p38l1114t2784r1203b2828],
5	smoking	NN	O	smoking	nn	6	SENT_958	[p38l1223t2784r1436b2841],
6	history	NN	O	history	conj_and	3	SENT_958	[p38l1453t2784r1626b2840],
7	predict	VBP	O	predict	_	0	SENT_958	[p38l1641t2784r1814b2840],
8	sensitivity	NN	O	sensitivity	dobj	7	SENT_958	[p38l1831t2785r2078b2840],
9	to	TO	O	to	_	0	SENT_958	[p38l2094t2793r2141b2828],
10	gefitinib	NN	O	gefitinib	prep_to	7	SENT_958	[p38l1114t2855r1326b2912],
11	in	IN	O	in	_	0	SENT_958	[p38l1347t2856r1394b2899],
12	advanced	JJ	O	advanced	amod	15	SENT_958	[p38l1415t2855r1639b2900],
13	non-small-cell	JJ	O	non-small-cell	amod	15	SENT_958	[p38l1660t2855r2014b2899],
14	lung	NN	O	lung	nn	15	SENT_958	[p38l2033t2855r2143b2912],
15	cancer	NN	O	cancer	prep_in	10	SENT_958	[p38l1115t2940r1285b2970],
16	.	.	O	.	_	0	SENT_958	[p38l1115t2940r1285b2970],

1	J	NNP	O	J	nn	3	SENT_959	[p38l1302t2930r1323b2977],
2	Clin	NNP	O	Clin	nn	3	SENT_959	[p38l1341t2926r1441b2970],
3	Oncol	NNP	O	Oncol	_	0	SENT_959	[p38l1461t2926r1605b2970],
4	2004	CD	DATE	2004	num	3	SENT_959	[p38l1624t2929r2009b2979],
5	;	:	O	;	_	0	SENT_959	[p38l1624t2929r2009b2979],
6	22:1103	CD	NUMBER	22:1103	number	7	SENT_959	[p38l1624t2929r2009b2979],
7	—	CD	NUMBER	—	dep	3	SENT_959	[p38l1624t2929r2009b2979],
8	9	CD	NUMBER	9	dep	7	SENT_959	[p38l1624t2929r2009b2979],
9	.	.	O	.	_	0	SENT_959	[p38l1624t2929r2009b2979],

1	72	CD	NUMBER	72	_	0	SENT_960	[p38l1116t3003r1182b3041],
2	.	.	O	.	_	0	SENT_960	[p38l1116t3003r1182b3041],

1	Wacker	NNP	PERSON	Wacker	nn	2	SENT_961	[p38l1208t2997r1389b3042],
2	B	NNP	PERSON	B	_	0	SENT_961	[p38l1403t3001r1448b3050],
3	,	,	O	,	_	0	SENT_961	[p38l1403t3001r1448b3050],
4	Nagrani	NNP	PERSON	Nagrani	nn	5	SENT_961	[p38l1466t2998r1666b3054],
5	T	NN	PERSON	t	appos	2	SENT_961	[p38l1680t3000r1723b3051],
6	,	,	O	,	_	0	SENT_961	[p38l1680t3000r1723b3051],
7	Weinberg	NNP	PERSON	Weinberg	nn	8	SENT_961	[p38l1740t2997r1978b3054],
8	J	NNP	PERSON	J	appos	2	SENT_961	[p38l1987t3001r2019b3051],
9	,	,	O	,	_	0	SENT_961	[p38l1987t3001r2019b3051],
10	Witt	NNP	PERSON	Witt	appos	2	SENT_961	[p38l2036t2998r2144b3041],

1	K	NNP	O	K	_	0	SENT_962	[p38l16t3358r117b3460],
2	,	,	O	,	_	0	SENT_962	[p38l16t3358r117b3460],
3	Clark	NNP	PERSON	Clark	nn	4	SENT_962	[p38l181t3350r454b3441],
4	G	NNP	PERSON	G	appos	1	SENT_962	[p38l509t3356r616b3460],
5	,	,	O	,	_	0	SENT_962	[p38l509t3356r616b3460],
6	Cagnoni	NNP	PERSON	Cagnoni	nn	8	SENT_962	[p38l681t3352r1105b3466],
7	P	NN	O	p	nn	8	SENT_962	[p38l1160t3358r1279b3454],
8	]	NN	O	]	appos	4	SENT_962	[p38l1160t3358r1279b3454],
9	.	.	O	.	_	0	SENT_962	[p38l1160t3358r1279b3454],

1	Correlation	NN	O	correlation	_	0	SENT_963	[p38l1344t3350r1918b3440],
2	between	IN	O	between	dep	1	SENT_963	[p38l1977t3350r2130b3440, p38l18t3516r316b3588],

1	development	NN	O	development	nsubj	8	SENT_964	[p38l349t3497r993b3611],
2	of	IN	O	of	_	0	SENT_964	[p38l1020t3497r1137b3587],
3	rash	NN	O	rash	prep_of	1	SENT_964	[p38l1149t3497r1362b3586],
4	and	CC	O	and	_	0	SENT_964	[p38l1395t3497r1579b3587],
5	efficacy	NN	O	efficacy	conj_and	3	SENT_964	[p38l1612t3497r2007b3611],
6	in	IN	O	in	_	0	SENT_964	[p38l2034t3499r2132b3586],
7	patients	NNS	O	patient	prep_in	3	SENT_964	[p38l16t3646r416b3758],
8	treated	VBN	O	treat	_	0	SENT_964	[p38l539t3644r888b3734],
9	with	IN	O	with	_	0	SENT_964	[p38l1002t3644r1230b3735],
10	the	DT	O	the	det	18	SENT_964	[p38l1350t3644r1506b3733],
11	epidermal	JJ	O	epidermal	amod	18	SENT_964	[p38l1626t3644r2131b3758],
12	growth	NN	O	growth	nn	18	SENT_964	[p39l16t23r383b139],
13	factor	NN	O	factor	nn	18	SENT_964	[p39l462t23r754b113],
14	receptor	NN	O	receptor	nn	18	SENT_964	[p39l829t42r1247b137],
15	tyrosine	NN	O	tyrosine	nn	18	SENT_964	[p39l1322t25r1727b137],
16	kinase	NN	O	kinase	nn	18	SENT_964	[p39l1805t23r2131b114],
17	inhibitor	NN	O	inhibitor	nn	18	SENT_964	[p39l16t170r464b260],
18	erlotinib	NN	O	erlotinib	prep_with	8	SENT_964	[p39l513t170r943b260],
19	in	IN	O	in	_	0	SENT_964	[p39l994t172r1091b259],
20	two	CD	NUMBER	two	num	22	SENT_964	[p39l1142t189r1324b261],
21	large	JJ	O	large	amod	22	SENT_964	[p39l1375t170r1626b286],
22	phase	NN	O	phase	prep_in	18	SENT_964	[p39l1675t170r1966b284],
23	III	CD	NUMBER	iii	num	24	SENT_964	[p39l2015t178r2132b259],
24	studies	NNS	O	study	dep	22	SENT_964	[p39l18t319r399b410],
25	.	.	O	.	_	0	SENT_964	[p39l18t319r399b410],

1	Clin	NNP	O	Clin	nn	3	SENT_965	[p39l480t319r687b410],
2	Cancer	NNP	O	Cancer	nn	3	SENT_965	[p39l760t325r1109b410],
3	Res	NNP	O	Res	_	0	SENT_965	[p39l1178t327r1354b416],
4	2007	CD	DATE	2007	num	3	SENT_965	[p39l1430t325r2129b428],
5	;	:	O	;	_	0	SENT_965	[p39l1430t325r2129b428],
6	13:3913	CD	NUMBER	13:3913	number	7	SENT_965	[p39l1430t325r2129b428],
7	—	CD	NUMBER	—	dep	3	SENT_965	[p39l1430t325r2129b428],
8	21	CD	NUMBER	21	dep	7	SENT_965	[p39l17t473r160b558],
9	.	.	O	.	_	0	SENT_965	[p39l17t473r160b558],

1	73	CD	NUMBER	73	_	0	SENT_966	[p39l20t625r150b703],
2	.	.	O	.	_	0	SENT_966	[p39l20t625r150b703],

1	Chung	NNP	PERSON	Chung	nn	2	SENT_967	[p39l215t614r547b730],
2	KY	NNP	PERSON	KY	_	0	SENT_967	[p39l594t622r756b724],
3	,	,	O	,	_	0	SENT_967	[p39l594t622r756b724],
4	Shia	JJ	O	shia	amod	5	SENT_967	[p39l817t614r1028b704],
5	J	NN	O	j	appos	2	SENT_967	[p39l1066t622r1133b722],
6	,	,	O	,	_	0	SENT_967	[p39l1066t622r1133b722],
7	Kemeny	NNP	PERSON	Kemeny	nn	8	SENT_967	[p39l1190t622r1593b728],
8	NE	NNS	O	ne	appos	2	SENT_967	[p39l1636t622r1817b722],
9	,	,	O	,	_	0	SENT_967	[p39l1636t622r1817b722],
10	et	FW	O	et	nn	11	SENT_967	[p39l1876t633r1966b703],
11	al.	FW	O	al.	appos	2	SENT_967	[p39l2011t614r2124b704],
12	.	.	O	.	_	0	SENT_967	[p39l2011t614r2124b704],

1	Cetuximab	NNP	O	Cetuximab	nsubj	2	SENT_968	[p39l16t762r568b853],
2	shows	VBZ	O	show	_	0	SENT_968	[p39l646t762r954b853],
3	activity	NN	O	activity	dobj	2	SENT_968	[p39l1032t764r1395b876],
4	in	IN	O	in	_	0	SENT_968	[p39l1464t764r1561b851],
5	colorectal	JJ	O	colorectal	amod	7	SENT_968	[p39l1638t762r2132b852],
6	cancer	NN	O	cancer	nn	7	SENT_968	[p39l18t938r346b998],
7	patients	NNS	O	patient	prep_in	3	SENT_968	[p39l395t911r796b1023],
8	with	IN	O	with	_	0	SENT_968	[p39l847t909r1076b1000],
9	tumors	NNS	O	tumor	prep_with	2	SENT_968	[p39l1129t928r1488b1000],
10	that	WDT	O	that	nsubj	13	SENT_968	[p39l1545t909r1747b998],
11	do	VBP	O	do	aux	13	SENT_968	[p39l1796t909r1915b999],
12	not	RB	O	not	neg	13	SENT_968	[p39l1971t928r2137b999],
13	express	VB	O	express	rcmod	9	SENT_968	[p39l18t1084r387b1169],
14	the	DT	O	the	det	20	SENT_968	[p39l448t1055r604b1144],
15	epidermal	JJ	O	epidermal	amod	20	SENT_968	[p39l663t1055r1168b1169],
16	growth	NN	O	growth	nn	20	SENT_968	[p39l1225t1055r1593b1171],
17	factor	NN	O	factor	nn	20	SENT_968	[p39l1650t1055r1944b1145],
18	re	NN	O	re	nn	20	SENT_968	[p39l1997t1084r2130b1144],
19	—	NN	O	—	nn	20	SENT_968	[p39l1997t1084r2130b1144],
20	ceptor	NN	O	ceptor	dobj	13	SENT_968	[p39l18t1222r334b1317],
21	by	IN	O	by	_	0	SENT_968	[p39l391t1203r503b1317],
22	immunohistochemistry	NN	O	immunohistochemistry	prep_by	20	SENT_968	[p39l556t1203r1772b1317],
23	.	.	O	.	_	0	SENT_968	[p39l556t1203r1772b1317],

1	J	NNP	O	J	nn	3	SENT_969	[p39l1825t1211r1867b1307],
2	Clin	NNP	O	Clin	nn	3	SENT_969	[p39l1924t1203r2131b1293],
3	Oncol	NNP	O	Oncol	_	0	SENT_969	[p39l16t1351r314b1442],
4	2005	CD	DATE	2005	num	3	SENT_969	[p39l353t1357r1198b1460],
5	;	:	O	;	_	0	SENT_969	[p39l353t1357r1198b1460],
6	23:1803	CD	DATE	23:1803	number	7	SENT_969	[p39l353t1357r1198b1460],
7	-10	CD	DATE	-10	dep	3	SENT_969	[p39l353t1357r1198b1460],
8	.	.	O	.	_	0	SENT_969	[p39l353t1357r1198b1460],

1	74	CD	NUMBER	74	_	0	SENT_970	[p39l20t1512r148b1591],
2	.	.	O	.	_	0	SENT_970	[p39l20t1512r148b1591],

1	Hecht	NNP	PERSON	Hecht	nn	2	SENT_971	[p39l213t1500r513b1590],
2	J	NNP	PERSON	J	_	0	SENT_971	[p39l550t1508r616b1609],
3	,	,	O	,	_	0	SENT_971	[p39l550t1508r616b1609],
4	Mitchell	NNP	PERSON	Mitchell	nn	5	SENT_971	[p39l673t1500r1088b1591],
5	E	NNP	O	E	appos	2	SENT_971	[p39l1139t1508r1230b1609],
6	,	,	O	,	_	0	SENT_971	[p39l1139t1508r1230b1609],
7	Baranda	NNP	PERSON	Baranda	nn	8	SENT_971	[p39l1288t1500r1707b1591],
8	J	NNP	PERSON	J	appos	2	SENT_971	[p39l1748t1508r1814b1611],
9	,	,	O	,	_	0	SENT_971	[p39l1748t1508r1814b1611],
10	et	FW	O	et	nn	11	SENT_971	[p39l1875t1519r1965b1591],
11	al.	FW	O	al.	appos	2	SENT_971	[p39l2011t1500r2125b1591],
12	.	.	O	.	_	0	SENT_971	[p39l2011t1500r2125b1591],

1	Panitumumab	NNP	LOCATION	Panitumumab	nn	3	SENT_972	[p39l16t1648r731b1739],
2	antitumor	NN	O	antitumor	nn	3	SENT_972	[p39l803t1650r1315b1739],
3	activity	NN	O	activity	nsubj	8	SENT_972	[p39l1381t1650r1746b1762],
4	in	IN	O	in	_	0	SENT_972	[p39l1810t1650r1907b1737],
5	pa	NN	O	pa	nn	7	SENT_972	[p39l1975t1677r2130b1762],
6	—	NN	O	—	nn	7	SENT_972	[p39l1975t1677r2130b1762],
7	tients	NNS	O	tient	prep_in	3	SENT_972	[p39l18t1797r294b1884],
8	(	VBP	O	(	_	0	SENT_972	[p39l395t1803r608b1909],
9	pts	NNS	O	pt	nsubj	17	SENT_972	[p39l395t1803r608b1909],
10	)	CD	NUMBER	)	num	9	SENT_972	[p39l395t1803r608b1909],
11	with	IN	O	with	_	0	SENT_972	[p39l702t1795r930b1886],
12	metastatic	JJ	O	metastatic	amod	16	SENT_972	[p39l1022t1797r1545b1884],
13	colorectal	JJ	O	colorectal	amod	16	SENT_972	[p39l1638t1795r2132b1885],
14	cancer	NN	O	cancer	nn	16	SENT_972	[p39l18t1970r346b2030],
15	(	NN	O	(	nn	16	SENT_972	[p39l400t1947r782b2045],
16	mCRC	NN	O	mcrc	prep_with	9	SENT_972	[p39l400t1947r782b2045],
17	)	CD	NUMBER	)	ccomp	8	SENT_972	[p39l400t1947r782b2045],
18	expressing	VBG	O	express	partmod	17	SENT_972	[p39l841t1943r1382b2057],
19	low	JJ	O	low	amod	20	SENT_972	[p39l1429t1941r1610b2032],
20	(	NN	O	(	dobj	18	SENT_972	[p39l1663t1947r1973b2045],
21	1	CD	NUMBER	1	number	22	SENT_972	[p39l1663t1947r1973b2045],
22	—	CD	NUMBER	—	dep	20	SENT_972	[p39l1663t1947r1973b2045],
23	9	CD	NUMBER	9	num	24	SENT_972	[p39l1663t1947r1973b2045],
24	°	NN	O	°	dep	22	SENT_972	[p39l1663t1947r1973b2045],
25	/	:	O	/	punct	31	SENT_972	[p39l1663t1947r1973b2045],
26	o	NN	O	o	dep	31	SENT_972	[p39l1663t1947r1973b2045],
27	)	CD	NUMBER	)	num	26	SENT_972	[p39l1663t1947r1973b2045],
28	or	CC	O	or	_	0	SENT_972	[p39l2032t1970r2135b2031],
29	negative	JJ	O	negative	amod	30	SENT_972	[p39l16t2090r431b2204],
30	(	NN	O	(	dep	31	SENT_972	[p39l472t2094r742b2192],
31	<	JJR	O	<	dep	22	SENT_972	[p39l472t2094r742b2192],
32	1	CD	NUMBER	1	num	33	SENT_972	[p39l472t2094r742b2192],
33	°	NN	O	°	dep	22	SENT_972	[p39l472t2094r742b2192],
34	/	:	O	/	punct	45	SENT_972	[p39l472t2094r742b2192],
35	o	NN	O	o	nn	37	SENT_972	[p39l472t2094r742b2192],
36	)	NN	O	)	nn	37	SENT_972	[p39l472t2094r742b2192],
37	levels	NNS	O	level	dep	45	SENT_972	[p39l782t2088r1052b2179],
38	of	IN	O	of	_	0	SENT_972	[p39l1091t2088r1208b2178],
39	epidermal	JJ	O	epidermal	amod	42	SENT_972	[p39l1223t2088r1729b2202],
40	growth	NN	O	growth	nn	42	SENT_972	[p39l1764t2088r2131b2204],
41	factor	NN	O	factor	nn	42	SENT_972	[p39l16t2234r310b2326],
42	receptor	NN	O	receptor	prep_of	37	SENT_972	[p39l347t2255r764b2350],
43	(	CD	NUMBER	(	num	45	SENT_972	[p39l807t2242r1155b2340],
44	EGFr	NN	O	egfr	nn	45	SENT_972	[p39l807t2242r1155b2340],
45	)	NN	O	)	parataxis	17	SENT_972	[p39l807t2242r1155b2340],
46	.	.	O	.	_	0	SENT_972	[p39l807t2242r1155b2340],

1	J	NNP	O	J	nn	3	SENT_973	[p39l1190t2244r1233b2340],
2	Clin	NNP	O	Clin	nn	3	SENT_973	[p39l1271t2236r1478b2326],
3	Oncol	NNP	O	Oncol	_	0	SENT_973	[p39l1517t2236r1814b2326],
4	2006	CD	DATE	2006	num	3	SENT_973	[p39l1855t2242r2127b2344],
5	;	:	O	;	_	0	SENT_973	[p39l1855t2242r2127b2344],
6	24:157	CD	NUMBER	24:157	num	7	SENT_973	[p39l17t2389r417b2474],
7	s.	NN	O	s.	dep	3	SENT_973	[p39l17t2389r417b2474],
8	abstract	JJ	O	abstract	amod	7	SENT_973	[p39l462t2383r892b2474],
9	.	.	O	.	_	0	SENT_973	[p39l462t2383r892b2474],

1	75	CD	NUMBER	75	_	0	SENT_974	[p39l20t2543r148b2621],
2	.	.	O	.	_	0	SENT_974	[p39l20t2543r148b2621],

1	Lynch	NNP	PERSON	Lynch	nn	2	SENT_975	[p39l213t2531r509b2645],
2	TJ	NNP	PERSON	TJ	_	0	SENT_975	[p39l558t2537r689b2641],
3	,	,	O	,	_	0	SENT_975	[p39l558t2537r689b2641],
4	Bell	NNP	ORGANIZATION	Bell	nn	5	SENT_975	[p39l748t2531r940b2620],
5	DW	NNP	ORGANIZATION	DW	appos	2	SENT_975	[p39l991t2539r1192b2639],
6	,	,	O	,	_	0	SENT_975	[p39l991t2539r1192b2639],
7	Sordella	NNP	PERSON	Sordella	nn	8	SENT_975	[p39l1255t2531r1663b2621],
8	R	NNP	PERSON	R	appos	2	SENT_975	[p39l1713t2539r1814b2641],
9	,	,	O	,	_	0	SENT_975	[p39l1713t2539r1814b2641],
10	et	FW	O	et	nn	11	SENT_975	[p39l1875t2550r1964b2620],
11	al.	FW	O	al.	appos	2	SENT_975	[p39l2011t2531r2125b2621],
12	.	.	O	.	_	0	SENT_975	[p39l2011t2531r2125b2621],

1	Activating	VBG	O	activate	amod	2	SENT_976	[p39l12t2679r531b2793],
2	mutations	NNS	O	mutation	_	0	SENT_976	[p39l610t2679r1119b2768],
3	in	IN	O	in	_	0	SENT_976	[p39l1206t2679r1302b2766],
4	the	DT	O	the	det	8	SENT_976	[p39l1387t2677r1541b2766],
5	epidermal	JJ	O	epidermal	amod	8	SENT_976	[p39l1626t2677r2132b2791],
6	growth	NN	O	growth	nn	8	SENT_976	[p39l16t2824r383b2940],
7	factor	NN	O	factor	nn	8	SENT_976	[p39l475t2824r770b2914],
8	receptor	NN	O	receptor	prep_in	2	SENT_976	[p39l858t2843r1275b2938],
9	underlying	VBG	O	underlie	amod	12	SENT_976	[p39l1363t2824r1910b2940],
10	re	NN	O	re	nn	12	SENT_976	[p39l1997t2853r2130b2913],
11	—	NN	O	—	nn	12	SENT_976	[p39l1997t2853r2130b2913],
12	sponsiveness	NN	O	sponsiveness	dep	2	SENT_976	[p39l18t2974r669b3086],
13	of	IN	O	of	_	0	SENT_976	[p39l716t2972r833b3062],
14	non	JJ	O	non	prep_of	12	SENT_976	[p39l855t2972r1609b3062],
15	;	:	O	;	_	0	SENT_976	[p39l855t2972r1609b3062],
16	small	JJ	O	small	amod	20	SENT_976	[p39l855t2972r1609b3062],
17	—	JJ	O	—	amod	20	SENT_976	[p39l855t2972r1609b3062],
18	cell	NN	O	cell	nn	20	SENT_976	[p39l855t2972r1609b3062],
19	lung	NN	O	lung	nn	20	SENT_976	[p39l1652t2972r1877b3088],
20	cancer	NN	O	cancer	dep	2	SENT_976	[p39l1918t3001r2130b3061, p39l18t3148r166b3208],
21	to	TO	O	to	_	0	SENT_976	[p39l245t3138r340b3209],
22	gefitinib	NN	O	gefitinib	prep_to	20	SENT_976	[p39l424t3119r888b3235],
23	.	.	O	.	_	0	SENT_976	[p39l424t3119r888b3235],

1	N	NN	O	n	nn	3	SENT_977	[p39l975t3127r1060b3210],
2	Engl	NNP	O	Engl	nn	3	SENT_977	[p39l1139t3119r1366b3235],
3	J	NNP	O	J	nsubj	4	SENT_977	[p39l1435t3127r1478b3223],
4	Med	VBD	O	med	_	0	SENT_977	[p39l1555t3119r1772b3209],
5	200	CD	NUMBER	200	dobj	4	SENT_977	[p39l1855t3125r2127b3227],
6	;	:	O	;	_	0	SENT_977	[p39l1855t3125r2127b3227],
7	350:2129	CD	NUMBER	350:2129	number	8	SENT_977	[p39l18t3273r652b3358],
8	—	CD	NUMBER	—	dep	5	SENT_977	[p39l18t3273r652b3358],
9	39	CD	NUMBER	39	dep	8	SENT_977	[p39l18t3273r652b3358],
10	.	.	O	.	_	0	SENT_977	[p39l18t3273r652b3358],

1	76	CD	NUMBER	76	_	0	SENT_978	[p39l20t3426r150b3507],
2	.	.	O	.	_	0	SENT_978	[p39l20t3426r150b3507],

1	Paez	NNP	PERSON	Paez	nn	2	SENT_979	[p39l213t3424r438b3506],
2	JG	NNP	O	JG	_	0	SENT_979	[p39l466t3424r620b3525],
3	,	,	O	,	_	0	SENT_979	[p39l466t3424r620b3525],
4	Jéinne	NNP	ORGANIZATION	Jéinne	nn	5	SENT_979	[p39l653t3424r941b3521],
5	PA	NN	ORGANIZATION	pa	appos	2	SENT_979	[p39l979t3424r1135b3527],
6	,	,	O	,	_	0	SENT_979	[p39l979t3424r1135b3527],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_979	[p39l1180t3424r1348b3507],
8	JC	NNP	PERSON	JC	appos	2	SENT_979	[p39l1376t3424r1518b3525],
9	,	,	O	,	_	0	SENT_979	[p39l1376t3424r1518b3525],
10	et	FW	O	et	nn	11	SENT_979	[p39l1565t3436r1656b3507],
11	al.	FW	O	al.	appos	2	SENT_979	[p39l1689t3416r1802b3507],
12	.	.	O	.	_	0	SENT_979	[p39l1689t3416r1802b3507],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_980	[p39l1847t3422r2143b3513],
2	mutations	NNS	O	mutation	_	0	SENT_980	[p39l16t3565r525b3654],
3	in	IN	O	in	_	0	SENT_980	[p39l621t3565r718b3652],
4	lung	NN	O	lung	nn	5	SENT_980	[p39l811t3563r1036b3679],
5	cancer	NN	O	cancer	prep_in	2	SENT_980	[p39l1127t3592r1480b3653],
6	:	:	O	:	_	0	SENT_980	[p39l1127t3592r1480b3653],
7	correlation	NN	O	correlation	dep	2	SENT_980	[p39l1581t3563r2132b3653],
8	with	IN	O	with	_	0	SENT_980	[p40l12t22r239b113],
9	clinical	JJ	O	clinical	amod	10	SENT_980	[p40l290t22r657b111],
10	response	NN	O	response	prep_with	7	SENT_980	[p40l706t51r1153b136],
11	to	TO	O	to	_	0	SENT_980	[p40l1203t41r1298b112],
12	gefitinib	NN	O	gefitinib	nn	13	SENT_980	[p40l1348t22r1784b138],
13	therapy	NN	O	therapy	prep_to	10	SENT_980	[p40l1837t22r2130b111, p40l16t199r148b284],
14	.	.	O	.	_	0	SENT_980	[p40l1837t22r2130b111, p40l16t199r148b284],

1	Science	NNP	O	Science	_	0	SENT_981	[p40l197t172r563b260],
2	2004	CD	DATE	2004	num	1	SENT_981	[p40l604t176r1573b278],
3	;	:	O	;	_	0	SENT_981	[p40l604t176r1573b278],
4	304:1497	CD	NUMBER	304:1497	number	5	SENT_981	[p40l604t176r1573b278],
5	—	CD	NUMBER	—	dep	1	SENT_981	[p40l604t176r1573b278],
6	500	CD	NUMBER	500	dep	5	SENT_981	[p40l604t176r1573b278],
7	.	.	O	.	_	0	SENT_981	[p40l604t176r1573b278],

1	77	CD	NUMBER	77	_	0	SENT_982	[p40l20t330r142b409],
2	.	.	O	.	_	0	SENT_982	[p40l20t330r142b409],

1	Sakuma	FW	PERSON	sakuma	_	0	SENT_983	[p40l217t318r622b409],
2	Y	NN	PERSON	y	dep	1	SENT_983	[p40l675t326r758b429],
3	,	,	O	,	_	0	SENT_983	[p40l675t326r758b429],
4	Matsukuma	NNP	PERSON	Matsukuma	nn	5	SENT_983	[p40l821t318r1427b409],
5	S	NNP	O	S	appos	2	SENT_983	[p40l1488t326r1567b427],
6	,	,	O	,	_	0	SENT_983	[p40l1488t326r1567b427],
7	Yoshihara	NNP	PERSON	Yoshihara	nn	8	SENT_983	[p40l1628t318r2133b409],
8	M	NNP	O	M	appos	2	SENT_983	[p40l14t474r138b576],
9	,	,	O	,	_	0	SENT_983	[p40l14t474r138b576],
10	et	FW	O	et	nn	11	SENT_983	[p40l185t485r275b555],
11	al.	FW	O	al.	appos	2	SENT_983	[p40l308t466r421b556],
12	.	.	O	.	_	0	SENT_983	[p40l308t466r421b556],

1	Distinctive	JJ	O	distinctive	amod	2	SENT_984	[p40l464t468r1005b556],
2	evaluation	NN	O	evaluation	_	0	SENT_984	[p40l1046t466r1563b557],
3	of	IN	O	of	_	0	SENT_984	[p40l1602t466r1719b556],
4	nonmu	JJ	O	nonmu	amod	5	SENT_984	[p40l1735t495r2130b557],
5	—	NN	O	—	prep_of	2	SENT_984	[p40l1735t495r2130b557],
6	cinous	JJ	O	cinous	amod	9	SENT_984	[p40l18t615r343b704],
7	and	CC	O	and	_	0	SENT_984	[p40l405t613r588b703],
8	mucinous	JJ	O	mucinous	amod	9	SENT_984	[p40l649t615r1139b704],
9	subtypes	NNS	O	subtype	dep	2	SENT_984	[p40l1202t613r1642b727],
10	of	IN	O	of	_	0	SENT_984	[p40l1705t613r1822b703],
11	bronchioloalveolar	JJ	O	bronchioloalveolar	amod	12	SENT_984	[p40l1861t613r2130b703, p40l18t760r728b851],
12	carcinomas	NNS	O	carcinoma	prep_of	9	SENT_984	[p40l791t762r1370b851],
13	in	IN	O	in	_	0	SENT_984	[p40l1436t762r1534b849],
14	EGFR	NN	ORGANIZATION	egfr	prep_in	12	SENT_984	[p40l1598t766r1895b855],
15	and	CC	O	and	cc	12	SENT_984	[p40l1948t760r2131b851],

1	K	NNP	O	K	nn	6	SENT_985	[p40l16t916r269b1000],
2	—	NNP	O	—	nn	6	SENT_985	[p40l16t916r269b1000],
3	ras	NN	O	ra	nn	6	SENT_985	[p40l16t916r269b1000],
4	gene	NN	O	gene	nn	6	SENT_985	[p40l306t937r537b1024],
5	mutation	NN	O	mutation	nn	6	SENT_985	[p40l572t910r1032b999],
6	analyses	NNS	O	analysis	_	0	SENT_985	[p40l1065t908r1486b1022],
7	for	IN	O	for	_	0	SENT_985	[p40l1522t908r1666b998],
8	Japanese	JJ	MISC	japanese	amod	10	SENT_985	[p40l1685t916r2131b1022],
9	lung	NN	O	lung	nn	10	SENT_985	[p40l16t1056r241b1172],
10	adenocarcinomas	NNS	O	adenocarcinoma	prep_for	6	SENT_985	[p40l306t1056r1220b1146],
11	:	:	O	:	_	0	SENT_985	[p40l306t1056r1220b1146],
12	confirmation	NN	O	confirmation	dep	6	SENT_985	[p40l1294t1056r1968b1146],
13	of	IN	O	of	_	0	SENT_985	[p40l2036t1054r2153b1146],
14	the	DT	O	the	det	15	SENT_985	[p40l18t1203r172b1292],
15	correlations	NNS	O	correlation	prep_of	12	SENT_985	[p40l221t1203r821b1293],
16	with	IN	O	with	_	0	SENT_985	[p40l866t1203r1094b1294],
17	histologic	JJ	O	histologic	amod	18	SENT_985	[p40l1141t1203r1642b1319],
18	subtypes	NNS	O	subtype	prep_with	15	SENT_985	[p40l1689t1203r2129b1317],
19	and	CC	O	and	_	0	SENT_985	[p40l16t1350r200b1440],
20	gene	NN	O	gene	nn	21	SENT_985	[p40l271t1379r503b1466],
21	mutations	NNS	O	mutation	conj_and	18	SENT_985	[p40l576t1352r1113b1441],
22	.	.	O	.	_	0	SENT_985	[p40l576t1352r1113b1441],

1	Am	VBP	O	be	cop	4	SENT_986	[p40l1188t1358r1364b1439],
2	J	NN	O	j	nn	4	SENT_986	[p40l1425t1358r1468b1454],
3	Clin	NN	O	clin	nn	4	SENT_986	[p40l1537t1350r1743b1440],
4	Pathol	NN	O	pathol	_	0	SENT_986	[p40l1813t1350r2133b1440],
5	2007	CD	DATE	2007	dep	4	SENT_986	[p40l17t1507r811b1608],
6	;	:	O	;	_	0	SENT_986	[p40l17t1507r811b1608],
7	128:100	CD	NUMBER	128:100	number	8	SENT_986	[p40l17t1507r811b1608],
8	—	CD	NUMBER	—	dep	4	SENT_986	[p40l17t1507r811b1608],
9	8	CD	NUMBER	8	dep	8	SENT_986	[p40l17t1507r811b1608],
10	.	.	O	.	_	0	SENT_986	[p40l17t1507r811b1608],

1	78	CD	NUMBER	78	_	0	SENT_987	[p40l20t1657r152b1738],
2	.	.	O	.	_	0	SENT_987	[p40l20t1657r152b1738],

1	Sequist	NNP	O	Sequist	nn	2	SENT_988	[p40l217t1649r582b1761],
2	LV	NNP	O	LV	_	0	SENT_988	[p40l622t1655r760b1757],
3	,	,	O	,	_	0	SENT_988	[p40l622t1655r760b1757],
4	Bell	NNP	ORGANIZATION	Bell	nn	5	SENT_988	[p40l811t1647r1003b1736],
5	DW	NNP	ORGANIZATION	DW	appos	2	SENT_988	[p40l1048t1655r1251b1755],
6	,	,	O	,	_	0	SENT_988	[p40l1048t1655r1251b1755],
7	Lynch	NNP	PERSON	Lynch	nn	9	SENT_988	[p40l1302t1647r1599b1761],
8	T	NN	O	t	nn	9	SENT_988	[p40l1642t1653r1774b1755],
9	]	NN	O	]	appos	2	SENT_988	[p40l1642t1653r1774b1755],
10	,	,	O	,	_	0	SENT_988	[p40l1642t1653r1774b1755],
11	Haber	NNP	ORGANIZATION	Haber	nn	12	SENT_988	[p40l1826t1647r2135b1737],
12	DA	NNP	ORGANIZATION	DA	appos	2	SENT_988	[p40l16t1802r194b1884],
13	.	.	O	.	_	0	SENT_988	[p40l16t1802r194b1884],

1	Molecular	JJ	O	molecular	amod	2	SENT_989	[p40l253t1794r762b1885],
2	predictors	NNS	O	predictor	_	0	SENT_989	[p40l813t1794r1324b1908],
3	of	IN	O	of	_	0	SENT_989	[p40l1383t1794r1498b1884],
4	response	NN	O	response	prep_of	2	SENT_989	[p40l1533t1823r1979b1908],
5	to	TO	O	to	_	0	SENT_989	[p40l2035t1813r2130b1884],
6	epidermal	JJ	O	epidermal	amod	12	SENT_989	[p40l18t1941r523b2055],
7	growth	NN	O	growth	nn	12	SENT_989	[p40l561t1941r928b2057],
8	factor	NN	O	factor	nn	12	SENT_989	[p40l967t1939r1259b2031],
9	receptor	NN	O	receptor	nn	12	SENT_989	[p40l1294t1960r1711b2055],
10	antago	NN	O	antago	nn	12	SENT_989	[p40l1746t1960r2130b2057],
11	—	NN	O	—	nn	12	SENT_989	[p40l1746t1960r2130b2057],
12	nists	NNS	O	nist	prep_to	2	SENT_989	[p40l16t2090r253b2177],
13	in	IN	O	in	_	0	SENT_989	[p40l294t2090r391b2177],
14	non	JJ	O	non	amod	20	SENT_989	[p40l432t2088r1160b2178],
15	—	JJ	O	—	amod	20	SENT_989	[p40l432t2088r1160b2178],
16	small	JJ	O	small	amod	20	SENT_989	[p40l432t2088r1160b2178],
17	—	NN	O	—	nn	20	SENT_989	[p40l432t2088r1160b2178],
18	cell	NN	O	cell	nn	20	SENT_989	[p40l432t2088r1160b2178],
19	lung	NN	O	lung	nn	20	SENT_989	[p40l1198t2088r1423b2204],
20	cancer	NN	O	cancer	prep_in	12	SENT_989	[p40l1460t2117r1810b2178],
21	.	.	O	.	_	0	SENT_989	[p40l1460t2117r1810b2178],

1	J	NNP	O	J	nn	3	SENT_990	[p40l1845t2096r1887b2192],
2	Clin	NNP	O	Clin	nn	3	SENT_990	[p40l1924t2088r2131b2178],
3	Oncol	NNP	O	Oncol	_	0	SENT_990	[p40l16t2237r314b2328],
4	2007	CD	DATE	2007	num	3	SENT_990	[p40l353t2243r1131b2346],
5	;	:	O	;	_	0	SENT_990	[p40l353t2243r1131b2346],
6	25:587	CD	NUMBER	25:587	number	7	SENT_990	[p40l353t2243r1131b2346],
7	—	CD	NUMBER	—	dep	3	SENT_990	[p40l353t2243r1131b2346],
8	95	CD	NUMBER	95	dep	7	SENT_990	[p40l353t2243r1131b2346],
9	.	.	O	.	_	0	SENT_990	[p40l353t2243r1131b2346],

1	79	CD	NUMBER	79	_	0	SENT_991	[p40l20t2394r150b2474],
2	.	.	O	.	_	0	SENT_991	[p40l20t2394r150b2474],

1	Shigematsu	NN	PERSON	shigematsu	nn	2	SENT_992	[p40l217t2384r801b2500],
2	H	NN	PERSON	h	_	0	SENT_992	[p40l844t2392r955b2494],
3	,	,	O	,	_	0	SENT_992	[p40l844t2392r955b2494],
4	Lin	NNP	PERSON	Lin	nn	5	SENT_992	[p40l1004t2386r1166b2473],
5	L	NNP	PERSON	L	appos	2	SENT_992	[p40l1209t2392r1297b2492],
6	,	,	O	,	_	0	SENT_992	[p40l1209t2392r1297b2492],
7	Takahashi	NNP	PERSON	Takahashi	nn	8	SENT_992	[p40l1342t2384r1867b2475],
8	T	NN	O	t	appos	2	SENT_992	[p40l1906t2391r1995b2494],
9	,	,	O	,	_	0	SENT_992	[p40l1906t2391r1995b2494],
10	et	FW	O	et	nn	11	SENT_992	[p40l2046t2403r2137b2473],
11	al.	FW	O	al.	appos	2	SENT_992	[p40l16t2531r130b2621],
12	.	.	O	.	_	0	SENT_992	[p40l16t2531r130b2621],

1	Clinical	JJ	O	clinical	amod	4	SENT_993	[p40l172t2531r563b2621],
2	and	CC	O	and	_	0	SENT_993	[p40l596t2531r780b2621],
3	biological	JJ	O	biological	conj_and	1	SENT_993	[p40l817t2531r1313b2647],
4	features	NNS	O	feature	nsubj	5	SENT_993	[p40l1348t2531r1749b2622],
5	associated	VBN	O	associate	_	0	SENT_993	[p40l1788t2533r2130b2621, p40l16t2678r225b2768],
6	with	IN	O	with	_	0	SENT_993	[p40l262t2678r490b2769],
7	epidermal	JJ	O	epidermal	amod	10	SENT_993	[p40l533t2678r1038b2792],
8	growth	NN	O	growth	nn	10	SENT_993	[p40l1080t2678r1447b2794],
9	factor	NN	O	factor	nn	10	SENT_993	[p40l1490t2678r1784b2768],
10	recep	NN	O	recep	prep_with	5	SENT_993	[p40l1823t2707r2130b2792],
11	—	CD	NUMBER	—	num	14	SENT_993	[p40l1823t2707r2130b2792],
12	tor	NN	O	tor	nn	14	SENT_993	[p40l18t2844r160b2915],
13	gene	NN	O	gene	nn	14	SENT_993	[p40l194t2854r426b2941],
14	mutations	NNS	O	mutation	dobj	5	SENT_993	[p40l464t2827r973b2916],
15	in	IN	O	in	_	0	SENT_993	[p40l1012t2827r1109b2914],
16	lung	NN	O	lung	nn	17	SENT_993	[p40l1145t2825r1372b2941],
17	cancers	NNS	O	cancer	prep_in	14	SENT_993	[p40l1405t2854r1810b2915],
18	.	.	O	.	_	0	SENT_993	[p40l1405t2854r1810b2915],

1	J	NNP	O	J	nn	4	SENT_994	[p40l1843t2833r1887b2929],
2	Natl	NNP	O	Natl	nn	4	SENT_994	[p40l1918t2825r2132b2916],
3	Cancer	NNP	O	Cancer	nn	4	SENT_994	[p40l16t2980r367b3065],
4	Inst	NNP	O	Inst	_	0	SENT_994	[p40l401t2982r598b3064],
5	2005	CD	DATE	2005	num	4	SENT_994	[p40l632t2982r1425b3083],
6	;	:	O	;	_	0	SENT_994	[p40l632t2982r1425b3083],
7	97:339	CD	NUMBER	97:339	number	8	SENT_994	[p40l632t2982r1425b3083],
8	-46	CD	NUMBER	-46	dep	4	SENT_994	[p40l632t2982r1425b3083],
9	.	.	O	.	_	0	SENT_994	[p40l632t2982r1425b3083],

1	80	CD	NUMBER	80	_	0	SENT_995	[p40l16t3131r154b3212],
2	.	.	O	.	_	0	SENT_995	[p40l16t3131r154b3212],

1	Nomura	NNP	ORGANIZATION	Nomura	nn	2	SENT_996	[p40l211t3129r626b3212],
2	M	NNP	ORGANIZATION	M	_	0	SENT_996	[p40l677t3129r803b3231],
3	,	,	O	,	_	0	SENT_996	[p40l677t3129r803b3231],
4	Shigematsu	NNP	PERSON	Shigematsu	nn	5	SENT_996	[p40l868t3121r1452b3237],
5	H	NNP	PERSON	H	appos	2	SENT_996	[p40l1508t3129r1618b3231],
6	,	,	O	,	_	0	SENT_996	[p40l1508t3129r1618b3231],
7	Lin	NNP	PERSON	Lin	nn	8	SENT_996	[p40l1679t3123r1841b3210],
8	L	NNP	PERSON	L	appos	2	SENT_996	[p40l1896t3129r1983b3231],
9	,	,	O	,	_	0	SENT_996	[p40l1896t3129r1983b3231],
10	et	FW	O	et	nn	11	SENT_996	[p40l2047t3140r2137b3210],
11	al.	FW	O	al.	appos	2	SENT_996	[p40l16t3269r130b3359],
12	.	.	O	.	_	0	SENT_996	[p40l16t3269r130b3359],

1	Polymorphisms	NNS	O	polymorphism	_	0	SENT_997	[p40l197t3269r1017b3383],
2	,	,	O	,	_	0	SENT_997	[p40l197t3269r1017b3383],
3	mutations	NNS	O	mutation	appos	1	SENT_997	[p40l1085t3271r1624b3379],
4	,	,	O	,	_	0	SENT_997	[p40l1085t3271r1624b3379],
5	and	CC	O	and	_	0	SENT_997	[p40l1693t3269r1877b3359],
6	amplifications	NNS	O	amplification	conj_and	1	SENT_997	[p40l1940t3298r2130b3358, p40l16t3416r592b3530],
7	of	IN	O	of	_	0	SENT_997	[p40l669t3414r786b3506],
8	the	DT	O	the	det	10	SENT_997	[p40l839t3416r995b3505],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_997	[p40l1067t3422r1364b3511],
10	gene	NN	O	gene	prep_of	6	SENT_997	[p40l1425t3445r1658b3532],
11	in	IN	O	in	prep	10	SENT_997	[p40l1731t3418r1829b3505],
12	nonsmall	JJ	O	nonsmall	amod	14	SENT_997	[p40l1902t3445r2130b3506, p40l18t3563r292b3652],
13	cell	NN	O	cell	nn	14	SENT_997	[p40l420t3563r590b3652],
14	lung	NN	O	lung	dep	11	SENT_997	[p40l714t3563r941b3679],
15	cancer	NN	O	cancer	dep	14	SENT_997	[p40l1065t3592r1415b3653],
16	.	.	O	.	_	0	SENT_997	[p40l1065t3592r1415b3653],
17	]	SYM	O	]	dep	6	SENT_997	[p40l1547t3569r1788b3653],

1	PLoS	NNP	O	PLoS	nn	2	SENT_998	[p40l1547t3569r1788b3653],
2	Med	NNP	O	Med	_	0	SENT_998	[p40l1914t3563r2131b3653],

1	2007	CD	DATE	2007	_	0	SENT_999	[p41l17t28r855b129],
2	;	:	O	;	_	0	SENT_999	[p41l17t28r855b129],
3	4	CD	NUMBER	4	number	4	SENT_999	[p41l17t28r855b129],
4	(	CD	NUMBER	(	dep	1	SENT_999	[p41l17t28r855b129],
5	4	CD	NUMBER	4	num	6	SENT_999	[p41l17t28r855b129],
6	)	NN	O	)	dep	4	SENT_999	[p41l17t28r855b129],
7	:715	CD	NUMBER	:715	number	8	SENT_999	[p41l17t28r855b129],
8	—	CD	NUMBER	—	dep	4	SENT_999	[p41l17t28r855b129],
9	27	CD	NUMBER	27	dep	8	SENT_999	[p41l17t28r855b129],
10	.	.	O	.	_	0	SENT_999	[p41l17t28r855b129],

1	81	CD	NUMBER	81	_	0	SENT_1000	[p41l16t178r150b259],
2	.	.	O	.	_	0	SENT_1000	[p41l16t178r150b259],

1	Pham	NNP	PERSON	Pham	nn	2	SENT_1001	[p41l213t168r498b257],
2	DK	NNP	PERSON	DK	_	0	SENT_1001	[p41l557t176r740b278],
3	,	,	O	,	_	0	SENT_1001	[p41l557t176r740b278],
4	Kris	NNP	PERSON	Kris	nn	9	SENT_1001	[p41l807t170r1013b260],
5	MG	NN	PERSON	mg	nn	9	SENT_1001	[p41l1074t174r1285b276],
6	,	,	O	,	_	0	SENT_1001	[p41l1074t174r1285b276],
7	Riely	NNP	PERSON	Riely	dep	9	SENT_1001	[p41l1350t168r1601b282],
8	G	NNP	O	G	nn	9	SENT_1001	[p41l1658t174r1798b278],
9	]	NNS	O	]	appos	2	SENT_1001	[p41l1658t174r1798b278],
10	,	,	O	,	_	0	SENT_1001	[p41l1658t174r1798b278],
11	et	FW	O	et	nn	12	SENT_1001	[p41l1867t187r1956b257],
12	al.	FW	O	al.	appos	9	SENT_1001	[p41l2011t168r2124b258],
13	.	.	O	.	_	0	SENT_1001	[p41l2011t168r2124b258],

1	Use	NN	O	use	npadvmod	6	SENT_1002	[p41l16t322r197b404],
2	of	IN	O	of	_	0	SENT_1002	[p41l249t314r365b404],
3	cigarette	NN	O	cigarette	nn	5	SENT_1002	[p41l396t314r1321b430],
4	—	CD	NUMBER	—	num	5	SENT_1002	[p41l396t314r1321b430],
5	smol	NN	O	smol	prep_of	1	SENT_1002	[p41l396t314r1321b430],
6	<	JJR	O	<	dep	12	SENT_1002	[p41l396t314r1321b430],
7	ing	CD	NUMBER	ing	num	8	SENT_1002	[p41l396t314r1321b430],
8	history	NN	O	history	dep	6	SENT_1002	[p41l1368t314r1725b428],
9	to	TO	O	to	_	0	SENT_1002	[p41l1770t333r1865b404],
10	esti	FW	O	esti	nn	11	SENT_1002	[p41l1918t316r2130b403],
11	—	FW	O	—	prep_to	6	SENT_1002	[p41l1918t316r2130b403],
12	mate	VBP	O	mate	_	0	SENT_1002	[p41l16t481r261b551],
13	the	DT	O	the	det	14	SENT_1002	[p41l314t462r470b551],
14	likelihood	NN	O	likelihood	dobj	12	SENT_1002	[p41l521t462r1036b553],
15	of	IN	O	of	_	0	SENT_1002	[p41l1089t462r1204b552],
16	mutations	NNS	O	mutation	prep_of	14	SENT_1002	[p41l1235t464r1743b553],
17	in	IN	O	in	_	0	SENT_1002	[p41l1798t464r1895b551],
18	epidermal	JJ	O	epidermal	amod	22	SENT_1002	[p41l1948t464r2130b576, p41l18t609r371b699],
19	growth	NN	O	growth	nn	22	SENT_1002	[p41l405t609r772b725],
20	factor	NN	O	factor	nn	22	SENT_1002	[p41l807t607r1099b699],
21	receptor	NN	O	receptor	nn	22	SENT_1002	[p41l1131t628r1549b723],
22	gene	NN	O	gene	prep_in	16	SENT_1002	[p41l1579t638r1812b725],
23	exons	NNS	O	exon	nsubj	12	SENT_1002	[p41l1847t638r2129b699],
24	19	CD	NUMBER	19	num	23	SENT_1002	[p41l20t762r132b846],
25	and	CC	O	and	_	0	SENT_1002	[p41l225t756r409b846],
26	21	CD	NUMBER	21	nsubj	12	SENT_1002	[p41l501t762r616b845],
27	in	IN	O	in	_	0	SENT_1002	[p41l708t758r805b845],
28	lung	NN	O	lung	nn	29	SENT_1002	[p41l896t756r1121b872],
29	adenocarcinomas	NNS	O	adenocarcinoma	prep_in	23	SENT_1002	[p41l1210t756r2125b846],
30	.	.	O	.	_	0	SENT_1002	[p41l1210t756r2125b846],

1	J	NNP	O	J	nn	3	SENT_1003	[p41l6t913r48b1010],
2	Clin	NNP	O	Clin	nn	3	SENT_1003	[p41l85t905r292b996],
3	Oncol	NNP	O	Oncol	_	0	SENT_1003	[p41l332t905r628b996],
4	2006	CD	DATE	2006	num	3	SENT_1003	[p41l667t911r1470b1014],
5	;	:	O	;	_	0	SENT_1003	[p41l667t911r1470b1014],
6	24:1700	CD	NUMBER	24:1700	number	7	SENT_1003	[p41l667t911r1470b1014],
7	—	CD	NUMBER	—	dep	3	SENT_1003	[p41l667t911r1470b1014],
8	4	CD	NUMBER	4	dep	7	SENT_1003	[p41l667t911r1470b1014],
9	.	.	O	.	_	0	SENT_1003	[p41l667t911r1470b1014],

1	82	CD	NUMBER	82	_	0	SENT_1004	[p41l16t1064r154b1145],
2	.	.	O	.	_	0	SENT_1004	[p41l16t1064r154b1145],

1	Toh	NNP	MISC	Toh	nn	2	SENT_1005	[p41l211t1054r401b1145],
2	C-K	NNP	MISC	C-K	_	0	SENT_1005	[p41l436t1062r648b1163],
3	,	,	O	,	_	0	SENT_1005	[p41l436t1062r648b1163],
4	Gao	NNP	O	Gao	nn	5	SENT_1005	[p41l690t1060r888b1145],
5	F	NN	O	f	appos	2	SENT_1005	[p41l924t1062r1002b1163],
6	,	,	O	,	_	0	SENT_1005	[p41l924t1062r1002b1163],
7	Lim	NNP	PERSON	Lim	nn	8	SENT_1005	[p41l1042t1056r1238b1143],
8	W	NNP	O	W	appos	5	SENT_1005	[p41l1269t1062r1492b1163],
9	.	.	O	.	_	0	SENT_1005	[p41l1269t1062r1492b1163],

1	—	NN	O	—	_	0	SENT_1006	[p41l1269t1062r1492b1163],
2	.	.	O	.	_	0	SENT_1006	[p41l1269t1062r1492b1163],

1	T	NN	O	t	_	0	SENT_1007	[p41l1269t1062r1492b1163],
2	,	,	O	,	_	0	SENT_1007	[p41l1269t1062r1492b1163],
3	et	FW	O	et	nn	4	SENT_1007	[p41l1533t1074r1624b1145],
4	al.	FW	O	al.	appos	1	SENT_1007	[p41l1653t1054r1766b1145],
5	.	.	O	.	_	0	SENT_1007	[p41l1653t1054r1766b1145],

1	N	NN	O	n	nn	2	SENT_1008	[p41l1806t1062r1891b1145],
2	eversmokers	NNS	O	eversmoker	_	0	SENT_1008	[p41l1895t1084r2130b1145, p41l18t1201r436b1292],
3	with	IN	O	with	_	0	SENT_1008	[p41l477t1201r705b1292],
4	lung	NN	O	lung	nn	5	SENT_1008	[p41l748t1201r973b1317],
5	cancer	NN	O	cancer	prep_with	2	SENT_1008	[p41l1016t1230r1370b1291],
6	:	:	O	:	_	0	SENT_1008	[p41l1016t1230r1370b1291],
7	epidemiologic	JJ	O	epidemiologic	amod	8	SENT_1008	[p41l1421t1201r2132b1317],
8	evidence	NN	O	evidence	dep	2	SENT_1008	[p41l18t1349r446b1440],
9	of	IN	O	of	_	0	SENT_1008	[p41l483t1349r598b1439],
10	a	DT	O	a	det	13	SENT_1008	[p41l612t1379r663b1438],
11	distinct	JJ	O	distinct	amod	13	SENT_1008	[p41l698t1349r1084b1439],
12	disease	NN	O	disease	nn	13	SENT_1008	[p41l1115t1349r1478b1439],
13	entity	NN	O	entity	prep_of	8	SENT_1008	[p41l1515t1351r1818b1463],
14	.	.	O	.	_	0	SENT_1008	[p41l1515t1351r1818b1463],

1	J	NNP	O	J	nn	3	SENT_1009	[p41l1849t1357r1892b1453],
2	Clin	NNP	O	Clin	nn	3	SENT_1009	[p41l1926t1349r2132b1439],
3	Oncol	NNP	O	Oncol	_	0	SENT_1009	[p41l16t1497r314b1588],
4	2006	CD	DATE	2006	num	3	SENT_1009	[p41l353t1503r1206b1606],
5	;	:	O	;	_	0	SENT_1009	[p41l353t1503r1206b1606],
6	24:2245	CD	NUMBER	24:2245	number	7	SENT_1009	[p41l353t1503r1206b1606],
7	—	CD	NUMBER	—	dep	3	SENT_1009	[p41l353t1503r1206b1606],
8	51	CD	NUMBER	51	dep	7	SENT_1009	[p41l353t1503r1206b1606],
9	.	.	O	.	_	0	SENT_1009	[p41l353t1503r1206b1606],

1	83	CD	NUMBER	83	_	0	SENT_1010	[p41l16t1656r150b1737],
2	.	.	O	.	_	0	SENT_1010	[p41l16t1656r150b1737],

1	Tsao	NNP	PERSON	Tsao	nsubj	2	SENT_1011	[p41l211t1654r442b1737],
2	M	NN	O	m	_	0	SENT_1011	[p41l479t1652r703b1755],
3	.	.	O	.	_	0	SENT_1011	[p41l479t1652r703b1755],

1	—	NN	O	—	_	0	SENT_1012	[p41l479t1652r703b1755],
2	.	.	O	.	_	0	SENT_1012	[p41l479t1652r703b1755],

1	S	NN	O	s	_	0	SENT_1013	[p41l479t1652r703b1755],
2	,	,	O	,	_	0	SENT_1013	[p41l479t1652r703b1755],
3	Sakurada	NNP	ORGANIZATION	Sakurada	nn	4	SENT_1013	[p41l750t1646r1220b1737],
4	A	NNP	ORGANIZATION	A	appos	1	SENT_1013	[p41l1253t1654r1354b1757],
5	,	,	O	,	_	0	SENT_1013	[p41l1253t1654r1354b1757],
6	Cutz	NNP	O	Cutz	appos	1	SENT_1013	[p41l1399t1652r1628b1737],
7	J-C	JJ	O	j-c	dep	6	SENT_1013	[p41l1657t1652r1843b1755],
8	,	,	O	,	_	0	SENT_1013	[p41l1657t1652r1843b1755],
9	et	FW	O	et	nn	10	SENT_1013	[p41l1888t1666r1979b1737],
10	al.	FW	O	al.	appos	1	SENT_1013	[p41l2011t1646r2125b1737],
11	.	.	O	.	_	0	SENT_1013	[p41l2011t1646r2125b1737],

1	Erlotinib	NNP	O	Erlotinib	_	0	SENT_1014	[p41l16t1793r460b1883],
2	in	IN	O	in	_	0	SENT_1014	[p41l499t1795r596b1882],
3	lung	NN	O	lung	nn	4	SENT_1014	[p41l632t1793r859b1909],
4	cancer	NN	O	cancer	prep_in	1	SENT_1014	[p41l892t1822r1222b1882],
5	9	CD	NUMBER	9	number	6	SENT_1014	[p41l1251t1844r1374b1854],
6	molecular	JJ	O	molecular	dep	1	SENT_1014	[p41l1407t1793r1914b1884],
7	and	CC	O	and	_	0	SENT_1014	[p41l1948t1793r2132b1883],
8	clinical	JJ	O	clinical	amod	9	SENT_1014	[p41l18t1940r385b2029],
9	predictors	NNS	O	predictor	dep	1	SENT_1014	[p41l440t1940r951b2054],
10	of	IN	O	of	_	0	SENT_1014	[p41l1010t1940r1127b2030],
11	outcome	NN	O	outcome	prep_of	6	SENT_1014	[p41l1162t1959r1622b2031],
12	.	.	O	.	_	0	SENT_1014	[p41l1162t1959r1622b2031],

1	N	NN	O	n	nn	2	SENT_1015	[p41l1681t1948r1768b2031],
2	EnglJ	NN	O	englj	nsubj	3	SENT_1015	[p41l1821t1940r2134b2056],
3	Med	VBD	O	med	_	0	SENT_1015	[p41l14t2087r231b2177],
4	2005	CD	DATE	2005	dobj	3	SENT_1015	[p41l272t2093r1127b2195],
5	;	:	O	;	_	0	SENT_1015	[p41l272t2093r1127b2195],
6	353:133	CD	NUMBER	353:133	number	7	SENT_1015	[p41l272t2093r1127b2195],
7	—	CD	NUMBER	—	dep	4	SENT_1015	[p41l272t2093r1127b2195],
8	44	CD	NUMBER	44	dep	7	SENT_1015	[p41l272t2093r1127b2195],
9	.	.	O	.	_	0	SENT_1015	[p41l272t2093r1127b2195],

1	[	NN	O	[	nn	2	SENT_1016	[p41l1186t2095r1666b2195],
2	Erratum	NN	O	erratum	_	0	SENT_1016	[p41l1186t2095r1666b2195],
3	,	,	O	,	_	0	SENT_1016	[p41l1186t2095r1666b2195],
4	N	NN	O	n	appos	2	SENT_1016	[p41l1711t2095r1796b2177],
5	EnglJ	NNP	O	EnglJ	nn	6	SENT_1016	[p41l1835t2087r2134b2203],
6	Med	NNP	O	Med	dep	2	SENT_1016	[p41l14t2236r231b2327],
7	2006	CD	DATE	2006	rcmod	6	SENT_1016	[p41l270t2242r1048b2343],
8	;	:	O	;	_	0	SENT_1016	[p41l270t2242r1048b2343],
9	355:1746	CD	NUMBER	355:1746	dep	7	SENT_1016	[p41l270t2242r1048b2343],
10	.	.	O	.	_	0	SENT_1016	[p41l270t2242r1048b2343],
11	]	SYM	O	]	dep	7	SENT_1016	[p41l270t2242r1048b2343],

1	ww	NN	O	ww	nn	3	SENT_1017	[p41l831t2428r874b2444],
2	NEJM.ORG	NN	O	nejm.org	nn	3	SENT_1017	[p41l886t2428r1010b2450],
3	MARCH	NN	DATE	march	tmod	11	SENT_1017	[p41l1047t2428r1132b2443],
4	13	CD	DATE	13	dep	3	SENT_1017	[p41l1147t2428r1178b2450],
5	,	,	O	,	_	0	SENT_1017	[p41l1147t2428r1178b2450],
6	20	CD	NUMBER	20	num	8	SENT_1017	[p41l1189t2428r1220b2444],
7	England	NNP	ORGANIZATION	England	nn	8	SENT_1017	[p41l833t2461r944b2492],
8	Journal	NNP	ORGANIZATION	Journal	nsubj	11	SENT_1017	[p41l952t2461r1050b2485],
9	of	IN	ORGANIZATION	of	_	0	SENT_1017	[p41l1059t2461r1088b2485],
10	Medicine	NNP	ORGANIZATION	Medicine	prep_of	8	SENT_1017	[p41l1095t2461r1220b2485],
11	aded	VBD	O	ade	_	0	SENT_1017	[p41l252t2502r314b2525],
12	from	IN	O	from	_	0	SENT_1017	[p41l323t2502r387b2525],
13	nejm.org	NN	O	nejm.org	prep_from	11	SENT_1017	[p41l396t2502r514b2532],
14	at	IN	O	at	_	0	SENT_1017	[p41l524t2506r547b2525],
15	UW-Madison	NN	O	uw-madison	prep_at	11	SENT_1017	[p41l556t2502r738b2525],
16	on	IN	O	on	_	0	SENT_1017	[p41l748t2509r780b2525],
17	January	NNP	DATE	January	prep_on	15	SENT_1017	[p41l789t2502r892b2532],
18	5	CD	DATE	5	num	17	SENT_1017	[p41l902t2502r924b2530],
19	,	,	DATE	,	_	0	SENT_1017	[p41l902t2502r924b2530],
20	2014	CD	DATE	2014	num	17	SENT_1017	[p41l935t2502r1007b2525],
21	.	.	O	.	_	0	SENT_1017	[p41l935t2502r1007b2525],

1	For	IN	O	for	_	0	SENT_1018	[p41l1018t2502r1064b2525],
2	personal	JJ	O	personal	amod	3	SENT_1018	[p41l1072t2502r1185b2532],
3	use	NN	O	use	pobj	1	SENT_1018	[p41l1194t2509r1237b2525],
4	only	RB	O	only	advmod	3	SENT_1018	[p41l1247t2502r1312b2532],
5	.	.	O	.	_	0	SENT_1018	[p41l1247t2502r1312b2532],

1	No	DT	O	no	det	3	SENT_1019	[p41l1322t2502r1362b2525],
2	other	JJ	O	other	amod	3	SENT_1019	[p41l1372t2502r1440b2525],
3	uses	NNS	O	use	_	0	SENT_1019	[p41l1448t2509r1504b2525],
4	without	IN	O	without	_	0	SENT_1019	[p41l1515t2502r1616b2525],
5	permission	NN	O	permission	prep_without	3	SENT_1019	[p41l1624t2502r1776b2532],
6	.	.	O	.	_	0	SENT_1019	[p41l1624t2502r1776b2532],
7	'	''	O	'	_	0	SENT_1019	[p41l579t2543r583b2547],

1	©	RB	O	©	advmod	2	SENT_1020	[p41l638t2543r661b2567],
2	2008	CD	DATE	2008	_	0	SENT_1020	[p41l671t2543r736b2567],
3	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	5	SENT_1020	[p41l746t2543r937b2567],
4	Medical	NNP	ORGANIZATION	Medical	nn	5	SENT_1020	[p41l947t2543r1055b2567],
5	Society	NNP	ORGANIZATION	Society	dep	2	SENT_1020	[p41l1065t2543r1170b2574],
6	.	.	O	.	_	0	SENT_1020	[p41l1065t2543r1170b2574],

1	All	DT	O	all	det	2	SENT_1021	[p41l1181t2543r1223b2567],
2	rights	NNS	O	rights	nsubj	3	SENT_1021	[p41l1232t2543r1306b2574],
3	reserved	VBN	O	reserve	_	0	SENT_1021	[p41l1316t2543r1435b2567],
4	.	.	O	.	_	0	SENT_1021	[p41l1316t2543r1435b2567],

1	84	CD	NUMBER	84	_	0	SENT_1022	[p41l11t2881r150b2962],
2	.	.	O	.	_	0	SENT_1022	[p41l11t2881r150b2962],

1	Cappuzzo	NNP	PERSON	Cappuzzo	nn	2	SENT_1023	[p41l209t2877r708b2986],
2	F	NN	O	f	_	0	SENT_1023	[p41l745t2879r823b2982],
3	,	,	O	,	_	0	SENT_1023	[p41l745t2879r823b2982],
4	Hirsch	NNP	PERSON	Hirsch	nn	5	SENT_1023	[p41l866t2871r1207b2961],
5	FR	NN	O	fr	appos	2	SENT_1023	[p41l1242t2879r1405b2982],
6	,	,	O	,	_	0	SENT_1023	[p41l1242t2879r1405b2982],
7	Rossi	NNP	PERSON	Rossi	nn	8	SENT_1023	[p41l1448t2873r1721b2968],
8	E	NNP	O	E	appos	2	SENT_1023	[p41l1755t2879r1846b2982],
9	,	,	O	,	_	0	SENT_1023	[p41l1755t2879r1846b2982],
10	et	FW	O	et	nn	11	SENT_1023	[p41l1891t2891r1981b2961],
11	al.	FW	O	al.	appos	2	SENT_1023	[p41l2012t2871r2126b2962],
12	.	.	O	.	_	0	SENT_1023	[p41l2012t2871r2126b2962],

1	Epidermal	JJ	O	epidermal	amod	3	SENT_1024	[p41l9t3020r530b3135],
2	growth	NN	O	growth	nn	3	SENT_1024	[p41l603t3020r971b3137],
3	factor	NN	O	factor	_	0	SENT_1024	[p41l1046t3020r1340b3111],
4	receptor	NN	O	receptor	nn	5	SENT_1024	[p41l1410t3040r1829b3135],
5	gene	NN	O	gene	dep	3	SENT_1024	[p41l1899t3050r2132b3137],
6	and	CC	O	and	_	0	SENT_1024	[p41l11t3169r195b3260],
7	protein	NN	O	protein	nn	10	SENT_1024	[p41l262t3171r629b3284],
8	and	CC	O	and	_	0	SENT_1024	[p41l698t3169r882b3260],
9	gefitinib	NN	O	gefitinib	nn	10	SENT_1024	[p41l951t3169r1389b3286],
10	sensitivity	NN	O	sensitivity	dep	3	SENT_1024	[p41l1462t3171r1973b3284],
11	in	IN	O	in	_	0	SENT_1024	[p41l2036t3171r2133b3258],
12	non	JJ	O	non	amod	16	SENT_1024	[p41l11t3318r742b3409],
13	—	JJ	O	—	amod	16	SENT_1024	[p41l11t3318r742b3409],
14	small-cell	NN	O	small-cell	nn	16	SENT_1024	[p41l11t3318r742b3409],
15	lung	NN	O	lung	nn	16	SENT_1024	[p41l785t3318r1011b3435],
16	cancer	NN	O	cancer	prep_in	3	SENT_1024	[p41l1054t3348r1405b3409],
17	.	.	O	.	_	0	SENT_1024	[p41l1054t3348r1405b3409],

1	J	NNP	O	J	nn	4	SENT_1025	[p41l1444t3326r1488b3423],
2	Natl	NNP	O	Natl	nn	4	SENT_1025	[p41l1527t3318r1741b3409],
3	Cancer	NNP	O	Cancer	nn	4	SENT_1025	[p41l1785t3324r2135b3409],
4	Inst	NNP	O	Inst	_	0	SENT_1025	[p41l9t3475r207b3557],
5	2005	CD	DATE	2005	num	4	SENT_1025	[p41l242t3475r1027b3576],
6	;	:	O	;	_	0	SENT_1025	[p41l242t3475r1027b3576],
7	97:643	CD	NUMBER	97:643	number	8	SENT_1025	[p41l242t3475r1027b3576],
8	-55	CD	NUMBER	-55	dep	4	SENT_1025	[p41l242t3475r1027b3576],
9	.	.	O	.	_	0	SENT_1025	[p41l242t3475r1027b3576],

1	85	CD	NUMBER	85	_	0	SENT_1026	[p41l11t3626r146b3707],
2	.	.	O	.	_	0	SENT_1026	[p41l11t3626r146b3707],

1	Hirsch	NNP	PERSON	Hirsch	nn	2	SENT_1027	[p41l209t3616r548b3706],
2	FR	NN	O	fr	_	0	SENT_1027	[p41l609t3624r773b3725],
3	,	,	O	,	_	0	SENT_1027	[p41l609t3624r773b3725],
4	Varrella	NNP	PERSON	Varrella	appos	2	SENT_1027	[p41l838t3616r1613b3707],
5	.	.	O	.	_	0	SENT_1027	[p41l838t3616r1613b3707],

1	—	NN	O	—	_	0	SENT_1028	[p41l838t3616r1613b3707],
2	.	.	O	.	_	0	SENT_1028	[p41l838t3616r1613b3707],

1	Garcia	NNP	PERSON	Garcia	nn	2	SENT_1029	[p41l838t3616r1613b3707],
2	M	NNP	O	M	_	0	SENT_1029	[p41l1670t3624r1797b3725],
3	,	,	O	,	_	0	SENT_1029	[p41l1670t3624r1797b3725],
4	Bunn	NNP	PERSON	Bunn	appos	2	SENT_1029	[p41l1864t3624r2133b3707],

1	PA	NN	O	pa	nn	2	SENT_1030	[p42l9t34r140b115],
2	Jr	NNP	O	Jr	_	0	SENT_1030	[p42l179t34r288b135],
3	,	,	O	,	_	0	SENT_1030	[p42l179t34r288b135],
4	et	FW	O	et	nn	5	SENT_1030	[p42l349t46r439b116],
5	al.	FW	O	al.	appos	2	SENT_1030	[p42l486t26r601b117],
6	.	.	O	.	_	0	SENT_1030	[p42l486t26r601b117],

1	Molecular	JJ	O	molecular	amod	2	SENT_1031	[p42l658t26r1169b117],
2	predictors	NNS	O	predictor	_	0	SENT_1031	[p42l1218t26r1731b141],
3	of	IN	O	of	_	0	SENT_1031	[p42l1789t26r1906b117],
4	outcome	NN	O	outcome	prep_of	2	SENT_1031	[p42l1939t46r2131b117, p42l13t205r277b266],
5	with	IN	O	with	_	0	SENT_1031	[p42l316t175r544b266],
6	gefitinib	NN	O	gefitinib	prep_with	4	SENT_1031	[p42l587t175r1025b292],
7	in	IN	O	in	_	0	SENT_1031	[p42l1070t177r1167b264],
8	phase	NN	O	phase	prep_in	6	SENT_1031	[p42l1209t175r1500b290],
9	III	CD	NUMBER	iii	num	11	SENT_1031	[p42l1543t183r1662b264],
10	placebocontrolled	JJ	O	placebocontrolled	amod	11	SENT_1031	[p42l1702t175r2131b290, p42l13t324r528b415],
11	study	NN	O	study	dep	2	SENT_1031	[p42l587t324r856b439],
12	in	IN	O	in	_	0	SENT_1031	[p42l906t326r1003b413],
13	advanced	JJ	O	advanced	amod	15	SENT_1031	[p42l1060t324r1525b415],
14	non	JJ	O	non	amod	15	SENT_1031	[p42l1581t324r2131b415],
15	—	NN	O	—	prep_in	11	SENT_1031	[p42l1581t324r2131b415],
16	small	JJ	O	small	amod	20	SENT_1031	[p42l1581t324r2131b415],
17	—	NN	O	—	nn	20	SENT_1031	[p42l1581t324r2131b415],
18	cell	NN	O	cell	nn	20	SENT_1031	[p42l13t473r183b563],
19	lung	NN	O	lung	nn	20	SENT_1031	[p42l249t473r476b590],
20	cancer	NN	O	cancer	dep	11	SENT_1031	[p42l540t503r892b564],
21	.	.	O	.	_	0	SENT_1031	[p42l540t503r892b564],

1	J	NNP	O	J	nn	3	SENT_1032	[p42l955t481r997b578],
2	Clin	NNP	O	Clin	nn	3	SENT_1032	[p42l1062t473r1270b564],
3	Oncol	NNP	O	Oncol	_	0	SENT_1032	[p42l1337t473r1635b564],
4	2006	CD	DATE	2006	num	3	SENT_1032	[p42l1702t479r2127b582],
5	;	:	O	;	_	0	SENT_1032	[p42l1702t479r2127b582],
6	24	CD	NUMBER	24	num	8	SENT_1032	[p42l1702t479r2127b582],
7	:	:	O	:	_	0	SENT_1032	[p42l1702t479r2127b582],
8	5034-42	CD	NUMBER	5034-42	dep	3	SENT_1032	[p42l13t627r443b712],
9	.	.	O	.	_	0	SENT_1032	[p42l13t627r443b712],

1	86	CD	NUMBER	86	_	0	SENT_1033	[p42l11t780r150b861],
2	.	.	O	.	_	0	SENT_1033	[p42l11t780r150b861],

1	Moroni	NNP	LOCATION	Moroni	nn	2	SENT_1034	[p42l205t772r579b861],
2	M	NNP	O	M	_	0	SENT_1034	[p42l611t778r737b879],
3	,	,	O	,	_	0	SENT_1034	[p42l611t778r737b879],
4	Veronese	NNP	PERSON	Veronese	nn	5	SENT_1034	[p42l775t778r1229b861],
5	S	NNP	PERSON	S	appos	2	SENT_1034	[p42l1268t778r1347b879],
6	,	,	O	,	_	0	SENT_1034	[p42l1268t778r1347b879],
7	Benvenuti	NNP	PERSON	Benvenuti	nn	8	SENT_1034	[p42l1389t772r1888b861],
8	S	NNP	O	S	appos	2	SENT_1034	[p42l1925t778r2005b879],
9	,	,	O	,	_	0	SENT_1034	[p42l1925t778r2005b879],
10	et	FW	O	et	nn	11	SENT_1034	[p42l2048t790r2139b861],
11	al.	FW	O	al.	appos	2	SENT_1034	[p42l11t919r124b1010],
12	.	.	O	.	_	0	SENT_1034	[p42l11t919r124b1010],

1	Gene	NNP	O	Gene	nn	3	SENT_1035	[p42l227t925r484b1010],
2	copy	NN	O	copy	nn	3	SENT_1035	[p42l581t949r811b1034],
3	number	NN	O	number	dep	11	SENT_1035	[p42l902t919r1296b1010],
4	for	IN	O	for	_	0	SENT_1035	[p42l1389t919r1533b1010],
5	epidermal	JJ	O	epidermal	amod	7	SENT_1035	[p42l1626t919r2133b1034],
6	growth	NN	O	growth	nn	7	SENT_1035	[p42l11t1068r379b1185],
7	factor	NN	O	factor	prep_for	3	SENT_1035	[p42l425t1068r720b1159],
8	receptor	NN	O	receptor	dep	11	SENT_1035	[p42l763t1088r1181b1183],
9	(	CD	NUMBER	(	num	8	SENT_1035	[p42l1230t1074r1589b1173],
10	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_1035	[p42l1230t1074r1589b1173],
11	)	NN	O	)	dep	24	SENT_1035	[p42l1230t1074r1589b1173],
12	and	CC	O	and	_	0	SENT_1035	[p42l1640t1068r1825b1159],
13	clinical	JJ	O	clinical	amod	14	SENT_1035	[p42l1872t1068r2131b1158, p42l13t1217r154b1307],
14	response	NN	O	response	dep	24	SENT_1035	[p42l225t1247r672b1332],
15	to	TO	O	to	_	0	SENT_1035	[p42l744t1237r839b1308],
16	antiEGFR	NN	O	antiegfr	nn	17	SENT_1035	[p42l912t1219r1413b1314],
17	treatment	NN	O	treatment	prep_to	11	SENT_1035	[p42l1472t1237r1971b1308],
18	in	IN	O	in	_	0	SENT_1035	[p42l2036t1219r2133b1306],
19	colorectal	JJ	O	colorectal	amod	20	SENT_1035	[p42l13t1366r508b1457],
20	cancer	NN	O	cancer	prep_in	17	SENT_1035	[p42l561t1396r916b1457],
21	:	:	O	:	_	0	SENT_1035	[p42l561t1396r916b1457],
22	a	DT	O	a	det	24	SENT_1035	[p42l975t1396r1025b1456],
23	cohort	NN	O	cohort	nn	24	SENT_1035	[p42l1078t1366r1409b1457],
24	study	NN	O	study	_	0	SENT_1035	[p42l1458t1366r1743b1481],
25	.	.	O	.	_	0	SENT_1035	[p42l1458t1366r1743b1481],

1	Lancet	NNP	O	Lancet	nn	2	SENT_1036	[p42l1802t1374r2139b1457],
2	Oncol	NNP	O	Oncol	_	0	SENT_1036	[p42l11t1515r308b1606],
3	2005	CD	DATE	2005	num	2	SENT_1036	[p42l348t1521r1092b1624],
4	;	:	O	;	_	0	SENT_1036	[p42l348t1521r1092b1624],
5	6:279	CD	NUMBER	6:279	number	6	SENT_1036	[p42l348t1521r1092b1624],
6	—	CD	NUMBER	—	dep	2	SENT_1036	[p42l348t1521r1092b1624],
7	86	CD	NUMBER	86	dep	6	SENT_1036	[p42l348t1521r1092b1624],
8	.	.	O	.	_	0	SENT_1036	[p42l348t1521r1092b1624],

1	87	CD	NUMBER	87	_	0	SENT_1037	[p42l11t1674r136b1755],
2	.	.	O	.	_	0	SENT_1037	[p42l11t1674r136b1755],

1	Sartore	NNP	PERSON	Sartore	_	0	SENT_1038	[p42l211t1664r999b1755],
2	.	.	O	.	_	0	SENT_1038	[p42l211t1664r999b1755],

1	—	NN	O	—	_	0	SENT_1039	[p42l211t1664r999b1755],
2	.	.	O	.	_	0	SENT_1039	[p42l211t1664r999b1755],

1	Bianchi	NNP	PERSON	Bianchi	nn	2	SENT_1040	[p42l211t1664r999b1755],
2	A	NNP	O	A	_	0	SENT_1040	[p42l1090t1672r1191b1775],
3	,	,	O	,	_	0	SENT_1040	[p42l1090t1672r1191b1775],
4	Moroni	NNP	LOCATION	Moroni	nn	5	SENT_1040	[p42l1288t1666r1662b1755],
5	M	NNP	O	M	appos	2	SENT_1040	[p42l1753t1672r1878b1773],
6	,	,	O	,	_	0	SENT_1040	[p42l1753t1672r1878b1773],
7	Veronese	NNP	PERSON	Veronese	nn	8	SENT_1040	[p42l1975t1672r2131b1755, p42l11t1843r340b1904],
8	S	NNP	O	S	appos	2	SENT_1040	[p42l397t1819r476b1924],
9	,	,	O	,	_	0	SENT_1040	[p42l397t1819r476b1924],
10	et	FW	O	et	nn	11	SENT_1040	[p42l537t1833r627b1903],
11	al.	FW	O	al.	appos	2	SENT_1040	[p42l674t1813r789b1904],
12	.	.	O	.	_	0	SENT_1040	[p42l674t1813r789b1904],

1	Epidermal	JJ	O	epidermal	amod	7	SENT_1041	[p42l846t1813r1367b1928],
2	growth	NN	O	growth	nn	7	SENT_1041	[p42l1420t1813r1789b1930],
3	factor	NN	O	factor	nn	7	SENT_1041	[p42l1842t1813r2137b1904],
4	receptor	NN	O	receptor	nn	7	SENT_1041	[p42l11t1982r429b2077],
5	gene	NN	O	gene	nn	7	SENT_1041	[p42l486t1992r720b2079],
6	copy	NN	O	copy	nn	7	SENT_1041	[p42l781t1992r1012b2077],
7	number	NN	O	number	nsubj	15	SENT_1041	[p42l1066t1962r1462b2053],
8	and	CC	O	and	_	0	SENT_1041	[p42l1518t1962r1702b2053],
9	clinical	JJ	O	clinical	amod	10	SENT_1041	[p42l1763t1962r2133b2052],
10	outcome	NN	O	outcome	conj_and	7	SENT_1041	[p42l13t2130r445b2201],
11	of	IN	O	of	_	0	SENT_1041	[p42l506t2110r623b2201],
12	metastatic	JJ	O	metastatic	amod	14	SENT_1041	[p42l662t2112r1189b2199],
13	colorectal	JJ	O	colorectal	amod	14	SENT_1041	[p42l1250t2110r1745b2201],
14	cancer	NN	O	cancer	prep_of	7	SENT_1041	[p42l1806t2140r2137b2199],
15	treated	VBN	O	treat	_	0	SENT_1041	[p42l11t2259r363b2350],
16	with	IN	O	with	_	0	SENT_1041	[p42l409t2259r639b2350],
17	panitumumab	NN	O	panitumumab	prep_with	15	SENT_1041	[p42l688t2259r1436b2374],
18	.	.	O	.	_	0	SENT_1041	[p42l688t2259r1436b2374],

1	J	NNP	O	J	nn	3	SENT_1042	[p42l1482t2267r1526b2364],
2	Clin	NNP	O	Clin	nn	3	SENT_1042	[p42l1575t2259r1783b2350],
3	Oncol	NNP	O	Oncol	_	0	SENT_1042	[p42l1834t2259r2133b2350],
4	2007	CD	DATE	2007	num	3	SENT_1042	[p42l11t2416r864b2517],
5	;	:	O	;	_	0	SENT_1042	[p42l11t2416r864b2517],
6	25:3238	CD	NUMBER	25:3238	number	7	SENT_1042	[p42l11t2416r864b2517],
7	-45	CD	NUMBER	-45	dep	3	SENT_1042	[p42l11t2416r864b2517],
8	.	.	O	.	_	0	SENT_1042	[p42l11t2416r864b2517],

1	88	CD	NUMBER	88	_	0	SENT_1043	[p42l11t2567r150b2648],
2	.	.	O	.	_	0	SENT_1043	[p42l11t2567r150b2648],

1	Rodenhuis	NNP	MISC	Rodenhuis	nn	2	SENT_1044	[p42l207t2557r750b2654],
2	S	NNP	O	S	_	0	SENT_1044	[p42l811t2563r890b2666],
3	,	,	O	,	_	0	SENT_1044	[p42l811t2563r890b2666],
4	Slebos	NNP	PERSON	Slebos	nn	5	SENT_1044	[p42l955t2557r1270b2648],
5	RIC	NN	PERSON	ric	appos	2	SENT_1044	[p42l1327t2563r1543b2666],
6	,	,	O	,	_	0	SENT_1044	[p42l1327t2563r1543b2666],
7	Boot	NN	O	boot	nn	8	SENT_1044	[p42l1604t2565r1842b2648],
8	AJM	NN	O	ajm	appos	2	SENT_1044	[p42l1888t2565r2127b2666],
9	,	,	O	,	_	0	SENT_1044	[p42l1888t2565r2127b2666],
10	et	FW	O	et	nn	11	SENT_1044	[p42l13t2726r102b2797],
11	al.	FW	O	al.	appos	2	SENT_1044	[p42l144t2706r258b2797],
12	.	.	O	.	_	0	SENT_1044	[p42l144t2706r258b2797],

1	Incidence	NN	O	incidence	nn	5	SENT_1045	[p42l312t2706r795b2797],
2	and	CC	O	and	_	0	SENT_1045	[p42l842t2706r1027b2797],
3	possible	JJ	O	possible	conj_and	1	SENT_1045	[p42l1074t2706r1486b2821],
4	clinical	JJ	O	clinical	amod	5	SENT_1045	[p42l1535t2706r1906b2796],
5	significance	NN	O	significance	_	0	SENT_1045	[p42l1955t2708r2131b2823, p42l11t2853r480b2945],
6	of	IN	O	of	_	0	SENT_1045	[p42l528t2855r645b2946],
7	I	PRP	O	I	prep_of	5	SENT_1045	[p42l668t2863r922b2948],
8	(	SYM	O	(	dep	5	SENT_1045	[p42l668t2863r922b2948],
9	-	:	O	-	_	0	SENT_1045	[p42l668t2863r922b2948],
10	ras	NN	O	ra	nn	12	SENT_1045	[p42l668t2863r922b2948],
11	oncogene	NN	O	oncogene	nn	12	SENT_1045	[p42l973t2885r1452b2972],
12	activation	NN	O	activation	dep	5	SENT_1045	[p42l1498t2857r1991b2946],
13	in	IN	O	in	_	0	SENT_1045	[p42l2036t2857r2133b2944],
14	adenocarcinoma	NN	O	adenocarcinoma	prep_in	12	SENT_1045	[p42l11t3004r850b3095],
15	of	IN	O	of	_	0	SENT_1045	[p42l888t3004r1003b3095],
16	the	DT	O	the	det	18	SENT_1045	[p42l1020t3004r1175b3094],
17	human	JJ	O	human	amod	18	SENT_1045	[p42l1213t3004r1569b3095],
18	lung	NN	O	lung	prep_of	14	SENT_1045	[p42l1605t3004r1854b3121],
19	.	.	O	.	_	0	SENT_1045	[p42l1605t3004r1854b3121],

1	Cancer	NNP	O	Cancer	nn	2	SENT_1046	[p42l1899t3010r2131b3095, p42l13t3183r160b3243],
2	Res	NNP	O	Res	_	0	SENT_1046	[p42l195t3161r371b3250],
3	1988	CD	DATE	1988	num	2	SENT_1046	[p42l417t3159r1274b3262],
4	;	:	O	;	_	0	SENT_1046	[p42l417t3159r1274b3262],
5	48:5738	CD	NUMBER	48:5738	number	6	SENT_1046	[p42l417t3159r1274b3262],
6	—	CD	NUMBER	—	dep	2	SENT_1046	[p42l417t3159r1274b3262],
7	41	CD	NUMBER	41	dep	6	SENT_1046	[p42l417t3159r1274b3262],
8	.	.	O	.	_	0	SENT_1046	[p42l417t3159r1274b3262],

1	89	CD	NUMBER	89	_	0	SENT_1047	[p42l11t3312r146b3393],
2	.	.	O	.	_	0	SENT_1047	[p42l11t3312r146b3393],

1	Ahrendt	NNP	ORGANIZATION	Ahrendt	nn	2	SENT_1048	[p42l205t3302r625b3393],
2	SA	NNP	ORGANIZATION	SA	_	0	SENT_1048	[p42l670t3310r825b3411],
3	,	,	O	,	_	0	SENT_1048	[p42l670t3310r825b3411],
4	Decker	NNP	ORGANIZATION	Decker	nn	5	SENT_1048	[p42l880t3302r1234b3393],
5	PA	NN	ORGANIZATION	pa	appos	2	SENT_1048	[p42l1278t3310r1435b3413],
6	,	,	O	,	_	0	SENT_1048	[p42l1278t3310r1435b3413],
7	Alawi	NNP	PERSON	Alawi	nn	8	SENT_1048	[p42l1486t3302r1777b3393],
8	EA	NN	PERSON	ea	appos	2	SENT_1048	[p42l1824t3310r1991b3411],
9	,	,	O	,	_	0	SENT_1048	[p42l1824t3310r1991b3411],
10	et	FW	O	et	nn	11	SENT_1048	[p42l2048t3322r2139b3393],
11	al.	FW	O	al.	appos	2	SENT_1048	[p42l11t3451r124b3542],
12	.	.	O	.	_	0	SENT_1048	[p42l11t3451r124b3542],

1	Cigarette	NN	O	cigarette	nn	2	SENT_1049	[p42l185t3453r643b3568],
2	smoking	NN	O	smoking	nsubjpass	5	SENT_1049	[p42l700t3451r1141b3568],
3	is	VBZ	O	be	auxpass	5	SENT_1049	[p42l1191t3453r1266b3541],
4	strongly	RB	O	strongly	advmod	5	SENT_1049	[p42l1325t3451r1739b3568],
5	associated	VBN	O	associate	_	0	SENT_1049	[p42l1787t3453r2131b3542, p42l11t3600r219b3691],
6	with	IN	O	with	_	0	SENT_1049	[p42l270t3600r498b3691],
7	mutation	NN	O	mutation	prep_with	5	SENT_1049	[p42l555t3602r1015b3691],
8	of	IN	O	of	_	0	SENT_1049	[p42l1072t3600r1189b3691],
9	the	DT	O	the	det	11	SENT_1049	[p42l1224t3600r1379b3690],
10	K-ras	NN	MISC	k-ra	nn	11	SENT_1049	[p42l1435t3608r1688b3693],
11	gene	NN	O	gene	prep_of	7	SENT_1049	[p42l1747t3630r1979b3717],
12	in	IN	O	in	_	0	SENT_1049	[p42l2036t3602r2133b3689],
13	patients	NNS	O	patient	prep_in	5	SENT_1049	[p43l9t25r411b138],
14	with	IN	O	with	_	0	SENT_1049	[p43l448t23r678b114],
15	primary	JJ	O	primary	amod	16	SENT_1049	[p43l715t25r1126b138],
16	adenocarcinoma	NN	O	adenocarcinoma	prep_with	13	SENT_1049	[p43l1159t23r1999b114],
17	of	IN	O	of	_	0	SENT_1049	[p43l2038t23r2153b114],
18	the	DT	O	the	det	19	SENT_1049	[p43l11t172r167b262],
19	lung	NN	O	lung	prep_of	16	SENT_1049	[p43l207t172r455b289],
20	.	.	O	.	_	0	SENT_1049	[p43l207t172r455b289],

1	Cancer	NN	O	cancer	_	0	SENT_1050	[p43l502t178r852b263],
2	2001	CD	DATE	2001	num	1	SENT_1050	[p43l888t178r1742b281],
3	;	:	O	;	_	0	SENT_1050	[p43l888t178r1742b281],
4	92:1525	CD	NUMBER	92:1525	number	5	SENT_1050	[p43l888t178r1742b281],
5	-30	CD	NUMBER	-30	dep	1	SENT_1050	[p43l888t178r1742b281],
6	.	.	O	.	_	0	SENT_1050	[p43l888t178r1742b281],

1	90	CD	NUMBER	90	_	0	SENT_1051	[p43l11t331r150b412],
2	.	.	O	.	_	0	SENT_1051	[p43l11t331r150b412],

1	Pao	NNP	PERSON	Pao	nn	2	SENT_1052	[p43l207t329r383b412],
2	W	NNP	PERSON	W	_	0	SENT_1052	[p43l417t329r542b432],
3	,	,	O	,	_	0	SENT_1052	[p43l417t329r542b432],
4	Wang	NNP	PERSON	Wang	nn	5	SENT_1052	[p43l579t329r872b438],
5	TY	NNP	PERSON	TY	appos	2	SENT_1052	[p43l900t329r1058b430],
6	,	,	O	,	_	0	SENT_1052	[p43l900t329r1058b430],
7	Riely	NNP	PERSON	Riely	nn	9	SENT_1052	[p43l1098t321r1350b436],
8	G	NNP	O	G	nn	9	SENT_1052	[p43l1381t327r1521b430],
9	]	NNS	O	]	appos	2	SENT_1052	[p43l1381t327r1521b430],
10	,	,	O	,	_	0	SENT_1052	[p43l1381t327r1521b430],
11	et	FW	O	et	nn	12	SENT_1052	[p43l1563t341r1654b411],
12	al.	FW	O	al.	appos	2	SENT_1052	[p43l1683t321r1797b412],
13	.	.	O	.	_	0	SENT_1052	[p43l1683t321r1797b412],

1	KRAS	NNP	ORGANIZATION	KRAS	_	0	SENT_1053	[p43l1838t327r2129b418],
2	mutations	NNS	O	mutation	dep	1	SENT_1053	[p43l11t472r522b561],
3	and	CC	O	and	_	0	SENT_1053	[p43l563t470r747b561],
4	primary	JJ	O	primary	amod	5	SENT_1053	[p43l785t472r1195b585],
5	resistance	NN	O	resistance	dep	1	SENT_1053	[p43l1230t472r1735b560],
6	of	IN	O	of	_	0	SENT_1053	[p43l1777t470r1892b561],
7	lung	NN	O	lung	nn	8	SENT_1053	[p43l1909t470r2137b587],
8	adenocarcinomas	NNS	O	adenocarcinoma	prep_of	1	SENT_1053	[p43l11t619r898b710],
9	to	TO	O	to	_	0	SENT_1053	[p43l933t639r1029b710],
10	gefitinib	NN	O	gefitinib	prep_to	8	SENT_1053	[p43l1062t619r1500b736],
11	or	CC	O	or	_	0	SENT_1053	[p43l1533t649r1638b710],
12	erlotinib	NN	O	erlotinib	conj_or	10	SENT_1053	[p43l1666t619r2127b710],
13	.	.	O	.	_	0	SENT_1053	[p43l1666t619r2127b710],

1	PLoS	NNP	O	PLoS	nn	2	SENT_1054	[p43l9t774r251b859],
2	Med	NNP	O	Med	_	0	SENT_1054	[p43l292t768r508b859],
3	2005	CD	DATE	2005	num	2	SENT_1054	[p43l549t774r1234b877],
4	;	:	O	;	_	0	SENT_1054	[p43l549t774r1234b877],
5	2	CD	NUMBER	2	number	6	SENT_1054	[p43l549t774r1234b877],
6	(	CD	NUMBER	(	dep	2	SENT_1054	[p43l549t774r1234b877],
7	1	CD	NUMBER	1	num	8	SENT_1054	[p43l549t774r1234b877],
8	)	NN	O	)	dep	6	SENT_1054	[p43l549t774r1234b877],
9	:	:	O	:	_	0	SENT_1054	[p43l549t774r1234b877],
10	e17	NN	O	e17	dep	6	SENT_1054	[p43l549t774r1234b877],
11	.	.	O	.	_	0	SENT_1054	[p43l549t774r1234b877],

1	91	CD	NUMBER	91	_	0	SENT_1055	[p43l11t927r146b1008],
2	.	.	O	.	_	0	SENT_1055	[p43l11t927r146b1008],

1	Han	NNP	O	Han	nn	2	SENT_1056	[p43l209t925r419b1007],
2	SW	NNP	O	SW	_	0	SENT_1056	[p43l460t923r639b1026],
3	,	,	O	,	_	0	SENT_1056	[p43l460t923r639b1026],
4	Kim	NNP	PERSON	Kim	nn	5	SENT_1056	[p43l682t919r896b1010],
5	TY	NNP	PERSON	TY	appos	2	SENT_1056	[p43l930t925r1088b1026],
6	,	,	O	,	_	0	SENT_1056	[p43l930t925r1088b1026],
7	Jeon	NNP	PERSON	Jeon	nn	8	SENT_1056	[p43l1120t925r1345b1022],
8	YK	NNP	O	YK	appos	2	SENT_1056	[p43l1379t925r1549b1026],
9	,	,	O	,	_	0	SENT_1056	[p43l1379t925r1549b1026],
10	et	FW	O	et	nn	11	SENT_1056	[p43l1593t937r1684b1007],
11	al.	FW	O	al.	appos	2	SENT_1056	[p43l1715t917r1829b1008],
12	.	.	O	.	_	0	SENT_1056	[p43l1715t917r1829b1008],

1	Optimization	NN	O	optimization	_	0	SENT_1057	[p43l1872t919r2131b1032, p43l11t1068r464b1157],
2	of	IN	O	of	_	0	SENT_1057	[p43l504t1066r621b1157],
3	patient	NN	O	patient	nn	4	SENT_1057	[p43l637t1068r993b1181],
4	selection	NN	O	selection	prep_of	1	SENT_1057	[p43l1028t1066r1474b1157],
5	for	IN	O	for	_	0	SENT_1057	[p43l1513t1066r1658b1157],
6	gefitinib	NN	O	gefitinib	prep_for	1	SENT_1057	[p43l1694t1066r2131b1183],
7	in	IN	O	in	_	0	SENT_1057	[p43l11t1217r108b1304],
8	non	JJ	O	non	amod	13	SENT_1057	[p43l179t1215r692b1306],
9	—	JJ	O	—	amod	13	SENT_1057	[p43l179t1215r692b1306],
10	small	JJ	O	small	amod	13	SENT_1057	[p43l179t1215r692b1306],
11	cell	NN	O	cell	nn	13	SENT_1057	[p43l765t1215r936b1305],
12	lung	NN	O	lung	nn	13	SENT_1057	[p43l1006t1215r1233b1332],
13	cancer	NN	O	cancer	prep_in	1	SENT_1057	[p43l1302t1245r1631b1305],
14	by	IN	O	by	_	0	SENT_1057	[p43l1701t1215r1814b1330],
15	combined	JJ	O	combined	amod	16	SENT_1057	[p43l1882t1245r2131b1306, p43l13t1364r292b1455],
16	analysis	NN	O	analysis	prep_by	13	SENT_1057	[p43l326t1364r726b1479],
17	of	IN	O	of	_	0	SENT_1057	[p43l765t1364r880b1455],
18	epidermal	JJ	O	epidermal	amod	22	SENT_1057	[p43l896t1364r1403b1479],
19	growth	NN	O	growth	nn	22	SENT_1057	[p43l1438t1364r1807b1481],
20	factor	NN	O	factor	nn	22	SENT_1057	[p43l1842t1364r2137b1455],
21	receptor	NN	O	receptor	nn	22	SENT_1057	[p43l11t1533r429b1628],
22	mutation	NN	O	mutation	prep_of	16	SENT_1057	[p43l496t1515r985b1622],
23	,	,	O	,	_	0	SENT_1057	[p43l496t1515r985b1622],
24	K-ras	NN	O	k-ra	nn	25	SENT_1057	[p43l1060t1521r1314b1606],
25	mutation	NN	O	mutation	prep_of	16	SENT_1057	[p43l1385t1515r1874b1622],
26	,	,	O	,	_	0	SENT_1057	[p43l1385t1515r1874b1622],
27	and	CC	O	and	_	0	SENT_1057	[p43l1949t1513r2133b1604],
28	Akt	NN	O	akt	nn	29	SENT_1057	[p43l7t1662r193b1753],
29	phosphorylation	NN	O	phosphorylation	conj_and	22	SENT_1057	[p43l272t1662r1135b1777],
30	.	.	O	.	_	0	SENT_1057	[p43l272t1662r1135b1777],

1	Clin	NNP	O	Clin	nn	3	SENT_1058	[p43l1228t1662r1436b1753],
2	Cancer	NNP	O	Cancer	nn	3	SENT_1058	[p43l1521t1668r1872b1753],
3	Res	NNP	O	Res	_	0	SENT_1058	[p43l1955t1670r2129b1759],
4	2006	CD	DATE	2006	num	3	SENT_1058	[p43l11t1817r882b1920],
5	;	:	O	;	_	0	SENT_1058	[p43l11t1817r882b1920],
6	12:2538	CD	NUMBER	12:2538	number	7	SENT_1058	[p43l11t1817r882b1920],
7	-44	CD	NUMBER	-44	dep	3	SENT_1058	[p43l11t1817r882b1920],
8	.	.	O	.	_	0	SENT_1058	[p43l11t1817r882b1920],

1	92	CD	NUMBER	92	_	0	SENT_1059	[p43l11t1970r150b2051],
2	.	.	O	.	_	0	SENT_1059	[p43l11t1970r150b2051],

1	Tsao	NNP	PERSON	Tsao	nn	2	SENT_1060	[p43l205t1968r437b2051],
2	M	NNP	O	M	_	0	SENT_1060	[p43l480t1968r605b2071],
3	,	,	O	,	_	0	SENT_1060	[p43l480t1968r605b2071],
4	Zhu	NNP	PERSON	Zhu	nn	5	SENT_1060	[p43l654t1960r847b2051],
5	C	NNP	O	C	appos	2	SENT_1060	[p43l890t1966r987b2071],
6	,	,	O	,	_	0	SENT_1060	[p43l890t1966r987b2071],
7	Sakurada	NNP	ORGANIZATION	Sakurada	nn	8	SENT_1060	[p43l1040t1960r1510b2051],
8	A	NNP	O	A	appos	2	SENT_1060	[p43l1549t1968r1650b2069],
9	,	,	O	,	_	0	SENT_1060	[p43l1549t1968r1650b2069],
10	et	FW	O	et	nn	11	SENT_1060	[p43l1701t1980r1791b2050],
11	al.	FW	O	al.	appos	2	SENT_1060	[p43l1828t1960r1943b2051],
12	.	.	O	.	_	0	SENT_1060	[p43l1828t1960r1943b2051],

1	An	DT	O	a	det	2	SENT_1061	[p43l1989t1968r2133b2049],
2	analysis	NN	O	analysis	_	0	SENT_1061	[p43l11t2109r411b2224],
3	of	IN	O	of	_	0	SENT_1061	[p43l462t2109r579b2200],
4	the	DT	O	the	det	8	SENT_1061	[p43l608t2109r763b2199],
5	prognostic	JJ	O	prognostic	amod	8	SENT_1061	[p43l811t2111r1357b2226],
6	and	CC	O	and	_	0	SENT_1061	[p43l1406t2109r1591b2200],
7	predictive	JJ	O	predictive	conj_and	5	SENT_1061	[p43l1638t2109r2133b2224],
8	importance	NN	O	importance	prep_of	2	SENT_1061	[p43l11t2260r593b2373],
9	of	IN	O	of	_	0	SENT_1061	[p43l660t2258r777b2349],
10	K-ras	NN	MISC	k-ra	nn	12	SENT_1061	[p43l821t2266r1074b2351],
11	mutation	NN	O	mutation	nn	12	SENT_1061	[p43l1143t2260r1605b2349],
12	status	NN	O	status	prep_of	8	SENT_1061	[p43l1672t2278r1967b2349],
13	in	IN	O	in	_	0	SENT_1061	[p43l2036t2260r2133b2347],
14	the	DT	O	the	det	17	SENT_1061	[p43l11t2406r167b2497],
15	National	NNP	ORGANIZATION	National	nn	17	SENT_1061	[p43l221t2406r660b2497],
16	Cancer	NNP	ORGANIZATION	Cancer	nn	17	SENT_1061	[p43l717t2412r1068b2497],
17	Institute	NNP	ORGANIZATION	Institute	prep_in	12	SENT_1061	[p43l1119t2408r1547b2497],
18	of	IN	ORGANIZATION	of	_	0	SENT_1061	[p43l1606t2406r1722b2497],
19	Canada	NNP	ORGANIZATION	Canada	prep_of	2	SENT_1061	[p43l1759t2406r2134b2497],

1	Clinical	JJ	O	clinical	amod	2	SENT_1062	[p43l11t2555r403b2646],
2	Trials	NNPS	O	Trials	nsubj	4	SENT_1062	[p43l437t2555r726b2645],
3	Group	NNP	O	Group	nn	4	SENT_1062	[p43l767t2561r1082b2670],
4	BR	NNP	O	BR	_	0	SENT_1062	[p43l1122t2561r1421b2652],
5	.21	CD	NUMBER	.21	num	6	SENT_1062	[p43l1122t2561r1421b2652],
6	study	NN	O	study	dobj	4	SENT_1062	[p43l1462t2555r1731b2670],
7	of	IN	O	of	_	0	SENT_1062	[p43l1767t2555r1884b2646],
8	erlo	JJ	O	erlo	amod	10	SENT_1062	[p43l1902t2555r2131b2646],
9	—	NN	O	—	nn	10	SENT_1062	[p43l1902t2555r2131b2646],
10	tinib	NN	O	tinib	prep_of	6	SENT_1062	[p43l11t2704r249b2795],
11	versus	CC	O	versus	prep	10	SENT_1062	[p43l302t2734r615b2795],
12	placebo	NN	O	placebo	dep	11	SENT_1062	[p43l674t2704r1060b2819],
13	in	IN	O	in	_	0	SENT_1062	[p43l1119t2706r1215b2793],
14	the	DT	O	the	det	15	SENT_1062	[p43l1274t2704r1429b2795],
15	treatment	NN	O	treatment	prep_in	4	SENT_1062	[p43l1487t2724r1985b2795],
16	of	IN	O	of	_	0	SENT_1062	[p43l2038t2704r2153b2795],
17	non	JJ	O	non	amod	22	SENT_1062	[p43l11t2853r524b2944],
18	—	JJ	O	—	amod	22	SENT_1062	[p43l11t2853r524b2944],
19	small	JJ	O	small	amod	22	SENT_1062	[p43l11t2853r524b2944],
20	cell	NN	O	cell	nn	22	SENT_1062	[p43l579t2853r750b2943],
21	lung	NN	O	lung	nn	22	SENT_1062	[p43l801t2853r1029b2970],
22	cancer	NN	O	cancer	prep_of	15	SENT_1062	[p43l1080t2883r1431b2944],
23	.	.	O	.	_	0	SENT_1062	[p43l1080t2883r1431b2944],

1	J	NNP	O	J	nn	3	SENT_1063	[p43l1480t2861r1523b2958],
2	Clin	NNP	O	Clin	nn	3	SENT_1063	[p43l1575t2853r1781b2944],
3	Oncol	NNP	O	Oncol	_	0	SENT_1063	[p43l1836t2853r2133b2944],
4	2006	CD	DATE	2006	num	6	SENT_1063	[p43l11t3002r1019b3117],
5	;	:	O	;	_	0	SENT_1063	[p43l11t3002r1019b3117],
6	24	CD	NUMBER	24	dep	3	SENT_1063	[p43l11t3002r1019b3117],
7	:	:	O	:	_	0	SENT_1063	[p43l11t3002r1019b3117],
8	Suppl	NNP	O	Suppl	dep	3	SENT_1063	[p43l11t3002r1019b3117],
9	:365	CD	NUMBER	:365	num	10	SENT_1063	[p43l11t3002r1019b3117],
10	s.	NN	O	s.	npadvmod	11	SENT_1063	[p43l11t3002r1019b3117],
11	abstract	JJ	O	abstract	amod	8	SENT_1063	[p43l1064t3002r1494b3093],
12	.	.	O	.	_	0	SENT_1063	[p43l1064t3002r1494b3093],

1	93	CD	NUMBER	93	_	0	SENT_1064	[p43l11t3161r146b3242],
2	.	.	O	.	_	0	SENT_1064	[p43l11t3161r146b3242],

1	Liévre	NNP	O	Liévre	nn	2	SENT_1065	[p43l207t3149r510b3242],
2	A	NNP	O	A	_	0	SENT_1065	[p43l548t3159r651b3262],
3	,	,	O	,	_	0	SENT_1065	[p43l548t3159r651b3262],
4	Bachet	NNP	O	Bachet	nn	5	SENT_1065	[p43l698t3151r1039b3241],
5	JB	NNP	O	JB	appos	2	SENT_1065	[p43l1064t3159r1205b3260],
6	,	,	O	,	_	0	SENT_1065	[p43l1064t3159r1205b3260],
7	Le	NNP	PERSON	Le	nn	9	SENT_1065	[p43l1254t3159r1367b3241],
8	Corre	NNP	PERSON	Corre	nn	9	SENT_1065	[p43l1411t3157r1690b3242],
9	D	NNP	PERSON	D	appos	2	SENT_1065	[p43l1731t3159r1835b3262],
10	,	,	O	,	_	0	SENT_1065	[p43l1731t3159r1835b3262],
11	et	FW	O	et	nn	12	SENT_1065	[p43l1886t3170r1975b3241],
12	al.	FW	O	al.	appos	2	SENT_1065	[p43l2012t3151r2126b3242],
13	.	.	O	.	_	0	SENT_1065	[p43l2012t3151r2126b3242],

1	KRAS	NNP	ORGANIZATION	KRAS	nn	3	SENT_1066	[p43l11t3306r302b3397],
2	mutation	NN	O	mutation	nn	3	SENT_1066	[p43l349t3302r811b3391],
3	status	NN	O	status	nsubj	5	SENT_1066	[p43l856t3320r1151b3391],
4	is	VBZ	O	be	cop	5	SENT_1066	[p43l1197t3302r1274b3390],
5	predictive	JJ	O	predictive	_	0	SENT_1066	[p43l1319t3300r1814b3415],
6	of	IN	O	of	_	0	SENT_1066	[p43l1860t3300r1975b3391],
7	response	NN	O	response	prep_of	5	SENT_1066	[p43l1998t3330r2131b3390, p43l13t3479r358b3564],
8	to	TO	O	to	_	0	SENT_1066	[p43l395t3469r490b3540],
9	cetuximab	NN	O	cetuximab	nn	10	SENT_1066	[p43l528t3449r1058b3540],
10	therapy	NN	O	therapy	prep_to	7	SENT_1066	[p43l1096t3449r1474b3564],
11	in	IN	O	in	_	0	SENT_1066	[p43l1504t3451r1601b3538],
12	colorectal	JJ	O	colorectal	amod	13	SENT_1066	[p43l1638t3449r2133b3540],
13	cancer	NN	O	cancer	prep_in	10	SENT_1066	[p43l13t3628r364b3689],
14	.	.	O	.	_	0	SENT_1066	[p43l13t3628r364b3689],

1	Cancer	NN	O	cancer	_	0	SENT_1067	[p43l409t3604r761b3689],
2	Res	NNP	O	Res	dep	1	SENT_1067	[p43l795t3606r971b3693],
3	2006	CD	DATE	2006	num	2	SENT_1067	[p43l1014t3606r1811b3705],
4	;	:	O	;	_	0	SENT_1067	[p43l1014t3606r1811b3705],
5	66:3992	CD	NUMBER	66:3992	number	6	SENT_1067	[p43l1014t3606r1811b3705],
6	—	CD	NUMBER	—	dep	1	SENT_1067	[p43l1014t3606r1811b3705],
7	5	CD	NUMBER	5	dep	6	SENT_1067	[p43l1014t3606r1811b3705],
8	.	.	O	.	_	0	SENT_1067	[p43l1014t3606r1811b3705],

1	DRUG	NN	O	drug	nn	2	SENT_1068	[p44l279t86r456b123],
2	THERAPY	NN	O	therapy	_	0	SENT_1068	[p44l480t87r775b123],

1	94	CD	NUMBER	94	_	0	SENT_1069	[p44l9t272r76b311],
2	.	.	O	.	_	0	SENT_1069	[p44l9t272r76b311],

1	Benvenuti	NNP	PERSON	Benvenuti	nn	2	SENT_1070	[p44l104t268r347b312],
2	S	NNP	O	S	_	0	SENT_1070	[p44l389t270r427b320],
3	,	,	O	,	_	0	SENT_1070	[p44l389t270r427b320],
4	Bianchi-Sartore	NNP	O	Bianchi-Sartore	nn	5	SENT_1070	[p44l470t267r854b311],
5	A	NNP	O	A	appos	2	SENT_1070	[p44l893t271r942b321],
6	,	,	O	,	_	0	SENT_1070	[p44l893t271r942b321],
7	Di	NNP	MISC	Di	nn	9	SENT_1070	[p44l985t268r1040b311],
8	Nicolantonio	NNP	MISC	Nicolantonio	nn	9	SENT_1070	[p44l8t338r330b382],
9	F	NN	MISC	f	appos	2	SENT_1070	[p44l360t342r398b392],
10	,	,	O	,	_	0	SENT_1070	[p44l360t342r398b392],
11	et	FW	O	et	nn	12	SENT_1070	[p44l431t347r475b382],
12	al.	FW	O	al.	appos	2	SENT_1070	[p44l502t338r558b382],
13	.	.	O	.	_	0	SENT_1070	[p44l502t338r558b382],

1	Oncogenic	JJ	O	oncogenic	amod	2	SENT_1071	[p44l591t339r853b395],
2	activation	NN	O	activation	nsubj	8	SENT_1071	[p44l882t339r1039b383, p44l9t410r106b453],
3	of	IN	O	of	_	0	SENT_1071	[p44l137t409r194b453],
4	the	DT	O	the	det	7	SENT_1071	[p44l214t409r290b453],
5	RASIRAF	NN	O	rasiraf	nn	7	SENT_1071	[p44l319t412r546b459],
6	signaling	NN	O	signaling	nn	7	SENT_1071	[p44l578t409r809b466],
7	pathway	NN	O	pathway	prep_of	2	SENT_1071	[p44l836t409r1042b465],
8	impairs	VBZ	O	impair	_	0	SENT_1071	[p44l9t482r193b537],
9	the	DT	O	the	det	10	SENT_1071	[p44l209t481r283b525],
10	response	NN	O	response	dobj	8	SENT_1071	[p44l297t495r511b537],
11	of	IN	O	of	_	0	SENT_1071	[p44l525t481r581b525],
12	metastatic	JJ	O	metastatic	amod	14	SENT_1071	[p44l586t482r836b525],
13	colorectal	JJ	O	colorectal	amod	14	SENT_1071	[p44l850t481r1039b525, p44l9t551r70b595],
14	cancer	NN	O	cancer	prep_of	10	SENT_1071	[p44l89t565r246b595],
15	to	TO	O	to	_	0	SENT_1071	[p44l264t560r309b595],
16	anti-epidermal	JJ	O	anti-epidermal	amod	21	SENT_1071	[p44l328t551r685b607],
17	growth	NN	O	growth	nn	21	SENT_1071	[p44l703t551r879b608],
18	factor	NN	O	factor	nn	21	SENT_1071	[p44l898t551r1041b595],
19	receptor	NN	O	receptor	nn	21	SENT_1071	[p44l9t631r212b678],
20	antibody	NN	O	antibody	nn	21	SENT_1071	[p44l240t622r457b678],
21	therapies	NNS	O	therapy	prep_to	8	SENT_1071	[p44l485t622r722b678],
22	.	.	O	.	_	0	SENT_1071	[p44l485t622r722b678],

1	Cancer	NN	O	cancer	_	0	SENT_1072	[p44l755t625r926b666],
2	Res	NNP	O	Res	dep	1	SENT_1072	[p44l953t626r1038b669],
3	2007	CD	DATE	2007	num	2	SENT_1072	[p44l9t697r392b747],
4	;	:	O	;	_	0	SENT_1072	[p44l9t697r392b747],
5	67:2643	CD	NUMBER	67:2643	num	6	SENT_1072	[p44l9t697r392b747],
6	-8	CD	NUMBER	-8	dep	1	SENT_1072	[p44l9t697r392b747],
7	.	.	O	.	_	0	SENT_1072	[p44l9t697r392b747],

1	95	CD	NUMBER	95	_	0	SENT_1073	[p44l9t770r75b809],
2	.	.	O	.	_	0	SENT_1073	[p44l9t770r75b809],

1	Khambata	NNP	PERSON	Khambata	_	0	SENT_1074	[p44l105t765r491b810],
2	.	.	O	.	_	0	SENT_1074	[p44l105t765r491b810],

1	—	NN	O	—	_	0	SENT_1075	[p44l105t765r491b810],
2	.	.	O	.	_	0	SENT_1075	[p44l105t765r491b810],

1	Ford	NNP	ORGANIZATION	Ford	nn	2	SENT_1076	[p44l105t765r491b810],
2	S	NN	O	s	_	0	SENT_1076	[p44l516t768r554b818],
3	,	,	O	,	_	0	SENT_1076	[p44l516t768r554b818],
4	Garrett	NNP	PERSON	Garrett	nn	5	SENT_1076	[p44l581t768r762b809],
5	CR	NN	O	cr	appos	2	SENT_1076	[p44l783t768r867b819],
6	,	,	O	,	_	0	SENT_1076	[p44l783t768r867b819],
7	Meropol	NN	O	meropol	nn	9	SENT_1076	[p44l893t769r1039b809, p44l8t836r85b892],
8	N	NN	O	n	nn	9	SENT_1076	[p44l101t840r174b889],
9	]	NN	O	]	appos	2	SENT_1076	[p44l101t840r174b889],
10	,	,	O	,	_	0	SENT_1076	[p44l101t840r174b889],
11	et	FW	O	et	nn	12	SENT_1076	[p44l195t845r239b880],
12	al.	FW	O	al.	appos	2	SENT_1076	[p44l254t836r309b880],
13	.	.	O	.	_	0	SENT_1076	[p44l254t836r309b880],

1	Expression	NN	O	expression	nsubj	10	SENT_1077	[p44l329t837r598b892],
2	of	IN	O	of	_	0	SENT_1077	[p44l615t836r672b880],
3	epiregulin	NN	O	epiregulin	prep_of	1	SENT_1077	[p44l680t836r933b893],
4	and	CC	O	and	_	0	SENT_1077	[p44l950t836r1040b880],
5	amphiregulin	NN	O	amphiregulin	conj_and	3	SENT_1077	[p44l9t907r347b964],
6	and	CC	O	and	_	0	SENT_1077	[p44l374t907r464b951],
7	K-ras	NN	O	k-ra	nn	9	SENT_1077	[p44l491t911r614b952],
8	mutation	NN	O	mutation	nn	9	SENT_1077	[p44l643t908r866b952],
9	status	NN	O	status	conj_and	3	SENT_1077	[p44l895t916r1038b952],
10	predict	VBP	O	predict	_	0	SENT_1077	[p44l8t979r182b1035],
11	disease	NN	O	disease	nn	12	SENT_1077	[p44l231t979r408b1023],
12	control	NN	O	control	dobj	10	SENT_1077	[p44l461t979r635b1023],
13	in	IN	O	in	_	0	SENT_1077	[p44l686t980r733b1023],
14	metastatic	JJ	O	metastatic	amod	17	SENT_1077	[p44l785t980r1040b1023],
15	colorectal	JJ	O	colorectal	amod	17	SENT_1077	[p44l9t1049r250b1093],
16	cancer	NN	O	cancer	nn	17	SENT_1077	[p44l268t1063r428b1093],
17	patients	NNS	O	patient	prep_in	10	SENT_1077	[p44l443t1050r638b1105],
18	treated	VBN	O	treat	partmod	17	SENT_1077	[p44l657t1049r828b1093],
19	with	IN	O	with	_	0	SENT_1077	[p44l842t1049r953b1094],
20	cetuximab	NN	O	cetuximab	prep_with	18	SENT_1077	[p44l971t1064r1039b1093, p44l9t1121r227b1166],
21	.	.	O	.	_	0	SENT_1077	[p44l971t1064r1039b1093, p44l9t1121r227b1166],

1	J	NNP	O	J	nn	3	SENT_1078	[p44l244t1125r265b1172],
2	Clin	NNP	O	Clin	nn	3	SENT_1078	[p44l283t1121r384b1165],
3	Oncol	NNP	O	Oncol	_	0	SENT_1078	[p44l403t1121r548b1165],
4	2007	CD	DATE	2007	num	3	SENT_1078	[p44l567t1124r973b1174],
5	;	:	O	;	_	0	SENT_1078	[p44l567t1124r973b1174],
6	25:3230	CD	NUMBER	25:3230	number	7	SENT_1078	[p44l567t1124r973b1174],
7	—	CD	NUMBER	—	dep	3	SENT_1078	[p44l567t1124r973b1174],
8	27	CD	NUMBER	27	dep	7	SENT_1078	[p44l567t1124r973b1174],
9	.	.	O	.	_	0	SENT_1078	[p44l567t1124r973b1174],

1	96	CD	NUMBER	96	_	0	SENT_1079	[p44l9t1196r77b1235],
2	.	.	O	.	_	0	SENT_1079	[p44l9t1196r77b1235],

1	Eberhard	NNP	PERSON	Eberhard	nn	2	SENT_1080	[p44l104t1191r329b1235],
2	DA	NNP	PERSON	DA	_	0	SENT_1080	[p44l351t1195r438b1245],
3	,	,	O	,	_	0	SENT_1080	[p44l351t1195r438b1245],
4	Johnson	NNP	PERSON	Johnson	nsubj	5	SENT_1080	[p44l458t1191r663b1242],
5	BE	VBP	O	be	dep	2	SENT_1080	[p44l684t1195r762b1245],
6	,	,	O	,	_	0	SENT_1080	[p44l684t1195r762b1245],
7	Amler	NNP	PERSON	Amler	nn	8	SENT_1080	[p44l785t1191r938b1235],
8	LC	NNP	O	LC	appos	2	SENT_1080	[p44l958t1194r1037b1244],
9	,	,	O	,	_	0	SENT_1080	[p44l958t1194r1037b1244],
10	et	FW	O	et	nn	11	SENT_1080	[p44l9t1271r53b1306],
11	al.	FW	O	al.	appos	2	SENT_1080	[p44l72t1262r128b1306],
12	.	.	O	.	_	0	SENT_1080	[p44l72t1262r128b1306],

1	Mutations	NNS	O	mutation	nsubj	15	SENT_1081	[p44l152t1263r401b1307],
2	in	IN	O	in	_	0	SENT_1081	[p44l424t1263r472b1306],
3	the	DT	O	the	det	7	SENT_1081	[p44l494t1262r570b1306],
4	epidermal	JJ	O	epidermal	amod	7	SENT_1081	[p44l593t1262r839b1318],
5	growth	NN	O	growth	nn	7	SENT_1081	[p44l861t1262r1040b1319],
6	factor	NN	O	factor	nn	7	SENT_1081	[p44l9t1334r152b1378],
7	receptor	NN	O	receptor	prep_in	1	SENT_1081	[p44l167t1343r370b1390],
8	and	CC	O	and	_	0	SENT_1081	[p44l384t1334r474b1378],
9	in	IN	O	in	_	0	SENT_1081	[p44l489t1335r536b1378],
10	KRAS	NNP	ORGANIZATION	KRAS	prep_in	1	SENT_1081	[p44l552t1337r693b1381],
11	are	VBP	O	be	cop	15	SENT_1081	[p44l711t1349r784b1378],
12	predictive	JJ	O	predictive	amod	15	SENT_1081	[p44l799t1334r1040b1390],
13	and	CC	O	and	_	0	SENT_1081	[p44l9t1404r98b1448],
14	prognostic	JJ	O	prognostic	conj_and	12	SENT_1081	[p44l113t1405r379b1461],
15	indicators	NNS	O	indicator	_	0	SENT_1081	[p44l394t1404r640b1448],
16	in	IN	O	in	_	0	SENT_1081	[p44l657t1405r704b1448],
17	patients	NNS	O	patient	prep_in	15	SENT_1081	[p44l719t1405r914b1460],
18	with	IN	O	with	_	0	SENT_1081	[p44l929t1404r1040b1449],
19	non-small-cell	JJ	O	non-small-cell	amod	21	SENT_1081	[p44l9t1475r364b1519],
20	lung	NN	O	lung	nn	21	SENT_1081	[p44l396t1475r506b1532],
21	cancer	NN	O	cancer	prep_with	17	SENT_1081	[p44l537t1489r697b1519],
22	treated	VBN	O	treat	conj_and	22	SENT_1081	[p44l728t1475r899b1519],
23	with	IN	O	with	_	0	SENT_1081	[p44l928t1475r1040b1520],
24	chemotherapy	NN	O	chemotherapy	prep_with	22	SENT_1081	[p44l9t1546r358b1602],
25	alone	RB	O	alone	advmod	22	SENT_1081	[p44l382t1546r513b1590],
26	and	CC	O	and	_	0	SENT_1081	[p44l539t1546r629b1590],
27	in	IN	O	in	_	0	SENT_1081	[p44l654t1547r702b1590],
28	combination	NN	O	combination	prep_in	22	SENT_1081	[p44l728t1546r1040b1590],
29	with	IN	O	with	_	0	SENT_1081	[p44l7t1618r118b1663],
30	erlotinib	NN	O	erlotinib	prep_with	22	SENT_1081	[p44l135t1618r359b1662],
31	.	.	O	.	_	0	SENT_1081	[p44l135t1618r359b1662],

1	J	NNP	O	J	nn	3	SENT_1082	[p44l374t1622r395b1669],
2	Clin	NNP	O	Clin	nn	3	SENT_1082	[p44l411t1618r511b1662],
3	Oncol	NNP	O	Oncol	_	0	SENT_1082	[p44l528t1618r674b1662],
4	2005	CD	DATE	2005	num	3	SENT_1082	[p44l690t1621r1039b1671, p44l9t1692r48b1733],
5	;	:	O	;	_	0	SENT_1082	[p44l690t1621r1039b1671, p44l9t1692r48b1733],
6	23:59009	CD	NUMBER	23:59009	dep	3	SENT_1082	[p44l690t1621r1039b1671, p44l9t1692r48b1733],
7	.	.	O	.	_	0	SENT_1082	[p44l690t1621r1039b1671, p44l9t1692r48b1733],

1	97	CD	NUMBER	97	_	0	SENT_1083	[p44l9t1765r70b1804],
2	.	.	O	.	_	0	SENT_1083	[p44l9t1765r70b1804],

1	Massarelli	JJ	O	massarelli	amod	2	SENT_1084	[p44l104t1760r359b1804],
2	E	NN	O	e	_	0	SENT_1084	[p44l383t1764r427b1814],
3	,	,	O	,	_	0	SENT_1084	[p44l383t1764r427b1814],
4	Varella	NNP	PERSON	Varella	appos	2	SENT_1084	[p44l453t1760r806b1804],
5	.	.	O	.	_	0	SENT_1084	[p44l453t1760r806b1804],

1	—	NN	O	—	_	0	SENT_1085	[p44l453t1760r806b1804],
2	.	.	O	.	_	0	SENT_1085	[p44l453t1760r806b1804],

1	Garcia	NNP	PERSON	Garcia	nn	2	SENT_1086	[p44l453t1760r806b1804],
2	M	NNP	O	M	_	0	SENT_1086	[p44l829t1764r890b1814],
3	,	,	O	,	_	0	SENT_1086	[p44l829t1764r890b1814],
4	Tang	NNP	PERSON	Tang	nn	5	SENT_1086	[p44l917t1764r1041b1817],
5	X	NNP	PERSON	X	appos	2	SENT_1086	[p44l7t1836r54b1885],
6	,	,	O	,	_	0	SENT_1086	[p44l7t1836r54b1885],
7	et	FW	O	et	nn	8	SENT_1086	[p44l82t1841r126b1876],
8	al.	FW	O	al.	appos	5	SENT_1086	[p44l147t1832r202b1876],
9	.	.	O	.	_	0	SENT_1086	[p44l147t1832r202b1876],

1	KRAS	NNP	ORGANIZATION	KRAS	nn	2	SENT_1087	[p44l230t1835r372b1879],
2	mutation	NN	O	mutation	nsubj	6	SENT_1087	[p44l397t1833r622b1877],
3	is	VBZ	O	be	cop	6	SENT_1087	[p44l646t1833r683b1876],
4	an	DT	O	a	det	6	SENT_1087	[p44l708t1846r767b1876],
5	important	JJ	O	important	amod	6	SENT_1087	[p44l791t1833r1042b1888],
6	predictor	NN	O	predictor	_	0	SENT_1087	[p44l8t1902r234b1958],
7	of	IN	O	of	_	0	SENT_1087	[p44l269t1902r326b1946],
8	resistance	NN	O	resistance	prep_of	6	SENT_1087	[p44l351t1903r596b1946],
9	to	TO	O	to	_	0	SENT_1087	[p44l632t1911r678b1946],
10	therapy	NN	O	therapy	prep_to	8	SENT_1087	[p44l715t1902r898b1958],
11	with	IN	O	with	_	0	SENT_1087	[p44l929t1902r1040b1947],
12	epidermal	JJ	O	epidermal	amod	18	SENT_1087	[p44l9t1974r256b2030],
13	growth	NN	O	growth	nn	18	SENT_1087	[p44l271t1974r450b2031],
14	factor	NN	O	factor	nn	18	SENT_1087	[p44l466t1974r609b2018],
15	receptor	NN	O	receptor	nn	18	SENT_1087	[p44l623t1983r827b2030],
16	tyrosine	NN	O	tyrosine	nn	18	SENT_1087	[p44l842t1975r1040b2030],
17	kinase	NN	O	kinase	nn	18	SENT_1087	[p44l9t2045r168b2090],
18	inhibitors	NNS	O	inhibitor	prep_with	10	SENT_1087	[p44l197t2045r439b2089],
19	in	IN	O	in	_	0	SENT_1087	[p44l470t2046r517b2089],
20	non-small-cell	JJ	O	non-small-cell	amod	22	SENT_1087	[p44l547t2045r902b2089],
21	lung	NN	O	lung	nn	22	SENT_1087	[p44l931t2045r1041b2102],
22	cancer	NN	O	cancer	prep_in	18	SENT_1087	[p44l9t2130r180b2160],
23	.	.	O	.	_	0	SENT_1087	[p44l9t2130r180b2160],

1	Clin	NNP	O	Clin	nn	3	SENT_1088	[p44l203t2116r304b2160],
2	Cancer	NNP	O	Cancer	nn	3	SENT_1088	[p44l323t2119r493b2160],
3	Res	NNP	O	Res	_	0	SENT_1088	[p44l510t2120r596b2163],
4	2007	CD	DATE	2007	num	3	SENT_1088	[p44l616t2119r1006b2169],
5	;	:	O	;	_	0	SENT_1088	[p44l616t2119r1006b2169],
6	13:2890	CD	NUMBER	13:2890	number	7	SENT_1088	[p44l616t2119r1006b2169],
7	—	CD	NUMBER	—	dep	3	SENT_1088	[p44l616t2119r1006b2169],
8	6	CD	NUMBER	6	dep	7	SENT_1088	[p44l616t2119r1006b2169],
9	.	.	O	.	_	0	SENT_1088	[p44l616t2119r1006b2169],

1	98	CD	NUMBER	98	_	0	SENT_1089	[p44l9t2191r76b2232],
2	.	.	O	.	_	0	SENT_1089	[p44l9t2191r76b2232],

1	De	NNP	O	De	nn	3	SENT_1090	[p44l104t2191r170b2231],
2	Roock	NNP	O	Roock	nn	3	SENT_1090	[p44l189t2187r347b2234],
3	W	NNP	O	W	_	0	SENT_1090	[p44l362t2191r423b2241],
4	,	,	O	,	_	0	SENT_1090	[p44l362t2191r423b2241],
5	Piessevaux	NNP	PERSON	Piessevaux	nn	6	SENT_1090	[p44l445t2188r708b2232],
6	H	NNP	PERSON	H	appos	3	SENT_1090	[p44l726t2191r781b2240],
7	,	,	O	,	_	0	SENT_1090	[p44l726t2191r781b2240],
8	De	NNP	PERSON	De	nn	10	SENT_1090	[p44l803t2191r868b2231],
9	Schutter	NNP	PERSON	Schutter	nn	10	SENT_1090	[p44l890t2187r1039b2232, p44l9t2267r75b2302],
10	J	NNP	PERSON	J	appos	3	SENT_1090	[p44l90t2262r122b2312],
11	,	,	O	,	_	0	SENT_1090	[p44l90t2262r122b2312],
12	et	FW	O	et	nn	13	SENT_1090	[p44l147t2267r191b2302],
13	al.	FW	O	al.	appos	3	SENT_1090	[p44l210t2258r265b2302],
14	.	.	O	.	_	0	SENT_1090	[p44l210t2258r265b2302],

1	KRAS	NNP	ORGANIZATION	KRAS	nn	3	SENT_1091	[p44l290t2261r432b2305],
2	wild-type	JJ	O	wild-type	amod	3	SENT_1091	[p44l453t2258r685b2314],
3	state	NN	O	state	nsubjpass	8	SENT_1091	[p44l708t2267r821b2302],
4	predicts	VBZ	O	predict	_	0	SENT_1091	[p44l842t2258r1039b2314],
5	survival	NN	O	survival	dobj	4	SENT_1091	[p44l10t2330r200b2375],
6	and	CC	O	and	_	0	SENT_1091	[p44l224t2330r314b2374],
7	is	VBZ	O	be	auxpass	8	SENT_1091	[p44l338t2331r376b2374],
8	associated	VBN	O	associate	conj_and	4	SENT_1091	[p44l401t2330r656b2374],
9	to	TO	O	to	_	0	SENT_1091	[p44l681t2339r727b2374],
10	early	JJ	O	early	amod	12	SENT_1091	[p44l753t2330r871b2386],
11	radiological	JJ	O	radiological	amod	12	SENT_1091	[p44l893t2330r1039b2374, p44l8t2400r173b2457],
12	response	NN	O	response	prep_to	8	SENT_1091	[p44l199t2414r417b2456],
13	in	IN	O	in	_	0	SENT_1091	[p44l443t2401r491b2444],
14	metastatic	JJ	O	metastatic	amod	16	SENT_1091	[p44l517t2401r773b2444],
15	colorectal	JJ	O	colorectal	amod	16	SENT_1091	[p44l799t2400r1040b2444],
16	cancer	NN	O	cancer	prep_in	8	SENT_1091	[p44l9t2485r170b2515],
17	treated	VBN	O	treat	partmod	16	SENT_1091	[p44l193t2471r364b2515],
18	with	IN	O	with	_	0	SENT_1091	[p44l387t2471r498b2516],
19	cetuximab	NN	O	cetuximab	prep_with	17	SENT_1091	[p44l523t2471r794b2516],
20	.	.	O	.	_	0	SENT_1091	[p44l523t2471r794b2516],

1	Ann	NNP	PERSON	Ann	nn	2	SENT_1092	[p44l821t2475r924b2515],
2	Oncol	NNP	PERSON	Oncol	_	0	SENT_1092	[p44l949t2474r1039b2515, p44l9t2543r79b2587],

1	(	NN	O	(	_	0	SENT_1093	[p44l101t2544r165b2594],
2	in	IN	O	in	_	0	SENT_1093	[p44l101t2544r165b2594],
3	press	NN	O	press	nn	4	SENT_1093	[p44l183t2547r340b2599],
4	)	NN	O	)	prep_in	1	SENT_1093	[p44l183t2547r340b2599],
5	.	.	O	.	_	0	SENT_1093	[p44l183t2547r340b2599],

1	99	CD	NUMBER	99	_	0	SENT_1094	[p44l9t2618r74b2657],
2	.	.	O	.	_	0	SENT_1094	[p44l9t2618r74b2657],

1	Amado	NNP	PERSON	Amado	nn	2	SENT_1095	[p44l103t2613r277b2657],
2	RG	NNP	O	RG	_	0	SENT_1095	[p44l296t2616r384b2667],
3	,	,	O	,	_	0	SENT_1095	[p44l296t2616r384b2667],
4	Wolf	NNP	PERSON	Wolf	nn	5	SENT_1095	[p44l405t2613r530b2657],
5	M	NNP	O	M	appos	2	SENT_1095	[p44l537t2617r598b2667],
6	,	,	O	,	_	0	SENT_1095	[p44l537t2617r598b2667],
7	Freeman	NNP	PERSON	Freeman	nn	8	SENT_1095	[p44l620t2617r830b2657],
8	D	NNP	O	D	appos	2	SENT_1095	[p44l849t2617r899b2667],
9	,	,	O	,	_	0	SENT_1095	[p44l849t2617r899b2667],
10	et	FW	O	et	nn	11	SENT_1095	[p44l922t2622r966b2657],
11	al.	FW	O	al.	appos	2	SENT_1095	[p44l982t2613r1037b2657],
12	.	.	O	.	_	0	SENT_1095	[p44l982t2613r1037b2657],

1	Analysis	NN	O	analysis	_	0	SENT_1096	[p44l7t2685r208b2741],
2	of	IN	O	of	_	0	SENT_1096	[p44l242t2685r299b2729],
3	KRAS	NNP	ORGANIZATION	KRAS	nn	4	SENT_1096	[p44l320t2688r459b2732],
4	mutations	NNS	O	mutation	prep_of	1	SENT_1096	[p44l493t2686r736b2730],
5	in	IN	O	in	_	0	SENT_1096	[p44l770t2686r816b2729],
6	patients	NNS	O	patient	prep_in	4	SENT_1096	[p44l847t2686r1038b2741],
7	with	IN	O	with	_	0	SENT_1096	[p44l7t2755r116b2800],
8	metastatic	JJ	O	metastatic	amod	10	SENT_1096	[p44l132t2756r382b2799],
9	colorectal	JJ	O	colorectal	amod	10	SENT_1096	[p44l399t2755r634b2799],
10	cancer	NN	O	cancer	prep_with	6	SENT_1096	[p44l651t2769r808b2799],
11	receiving	VBG	O	receive	partmod	10	SENT_1096	[p44l823t2756r1042b2812],
12	panitumumab	NN	O	panitumumab	nn	13	SENT_1096	[p44l8t2826r352b2882],
13	monotherapy	NN	O	monotherapy	dobj	11	SENT_1096	[p44l370t2826r702b2882],
14	:	:	O	:	_	0	SENT_1096	[p44l370t2826r702b2882],
15	ECCO	NN	O	ecco	dep	1	SENT_1096	[p44l720t2829r862b2870],
16	14	CD	NUMBER	14	num	15	SENT_1096	[p44l881t2829r945b2880],
17	,	,	O	,	_	0	SENT_1096	[p44l881t2829r945b2880],
18	the	DT	O	the	det	21	SENT_1096	[p44l965t2826r1039b2870],
19	European	JJ	ORGANIZATION	european	amod	21	SENT_1096	[p44l8t2902r239b2954],
20	Cancer	NN	ORGANIZATION	cancer	nn	21	SENT_1096	[p44l270t2901r437b2942],
21	Conference	NN	ORGANIZATION	conference	appos	15	SENT_1096	[p44l467t2898r752b2952],
22	,	,	O	,	_	0	SENT_1096	[p44l467t2898r752b2952],
23	Barcelona	NNP	ORGANIZATION	Barcelona	nn	25	SENT_1096	[p44l785t2898r1037b2951],
24	,	,	O	,	_	0	SENT_1096	[p44l785t2898r1037b2951],
25	September	NNP	DATE	September	appos	15	SENT_1096	[p44l10t2969r261b3025],
26	23-27	CD	DATE	23-27	num	25	SENT_1096	[p44l275t2972r422b3023],
27	,	,	DATE	,	_	0	SENT_1096	[p44l275t2972r422b3023],
28	2007	CD	DATE	2007	num	25	SENT_1096	[p44l441t2972r560b3013],
29	.	.	O	.	_	0	SENT_1096	[p44l441t2972r560b3013],

1	Euro	NNP	MISC	Euro	nn	3	SENT_1097	[p44l579t2973r722b3020],
2	]	NNP	O	]	nn	3	SENT_1097	[p44l579t2973r722b3020],
3	Cancer	NNP	O	Cancer	_	0	SENT_1097	[p44l737t2972r901b3013],
4	2007	CD	DATE	2007	num	3	SENT_1097	[p44l916t2972r1037b3022],
5	;	:	O	;	_	0	SENT_1097	[p44l916t2972r1037b3022],
6	5	CD	NUMBER	5	dep	3	SENT_1097	[p44l10t3039r244b3095],
7	:	:	O	:	_	0	SENT_1097	[p44l10t3039r244b3095],
8	Suppl	NNP	O	Suppl	dep	6	SENT_1097	[p44l10t3039r244b3095],
9	:8	CD	NUMBER	:8	num	8	SENT_1097	[p44l10t3039r244b3095],
10	.	.	O	.	_	0	SENT_1097	[p44l10t3039r244b3095],

1	abstract	JJ	O	abstract	_	0	SENT_1098	[p44l265t3039r470b3083],
2	.	.	O	.	_	0	SENT_1098	[p44l265t3039r470b3083],

1	100	CD	NUMBER	100	_	0	SENT_1099	[p44l11t3114r103b3154],
2	.	.	O	.	_	0	SENT_1099	[p44l11t3114r103b3154],

1	Kobayashi	NNP	LOCATION	Kobayashi	nn	2	SENT_1100	[p44l159t3110r411b3166],
2	S	NNP	LOCATION	S	_	0	SENT_1100	[p44l425t3113r464b3164],
3	,	,	O	,	_	0	SENT_1100	[p44l425t3113r464b3164],
4	Boggon	NNP	PERSON	Boggon	nn	6	SENT_1100	[p44l480t3114r670b3167],
5	T	NN	O	t	nn	6	SENT_1100	[p44l682t3113r746b3164],
6	]	NN	O	]	appos	2	SENT_1100	[p44l682t3113r746b3164],
7	,	,	O	,	_	0	SENT_1100	[p44l682t3113r746b3164],
8	Dayaram	NN	ORGANIZATION	dayaram	nn	9	SENT_1100	[p44l762t3114r981b3166],
9	T	NN	ORGANIZATION	t	appos	2	SENT_1100	[p44l993t3113r1036b3163],
10	,	,	O	,	_	0	SENT_1100	[p44l993t3113r1036b3163],
11	et	FW	O	et	nn	12	SENT_1100	[p44l9t3191r53b3226],
12	al.	FW	O	al.	appos	2	SENT_1100	[p44l85t3182r141b3226],
13	.	.	O	.	_	0	SENT_1100	[p44l85t3182r141b3226],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_1101	[p44l178t3186r298b3227],
2	mutation	NN	O	mutation	_	0	SENT_1101	[p44l330t3183r554b3227],
3	and	CC	O	and	_	0	SENT_1101	[p44l588t3182r678b3226],
4	resistance	NN	O	resistance	conj_and	2	SENT_1101	[p44l713t3183r958b3226],
5	of	IN	O	of	_	0	SENT_1101	[p44l993t3182r1050b3226],
6	non-small-cell	JJ	O	non-small-cell	amod	8	SENT_1101	[p44l9t3252r377b3296],
7	lung	NN	O	lung	nn	8	SENT_1101	[p44l406t3252r516b3309],
8	cancer	NN	O	cancer	prep_of	2	SENT_1101	[p44l545t3266r705b3296],
9	to	TO	O	to	_	0	SENT_1101	[p44l733t3261r780b3296],
10	gefitinib	NN	O	gefitinib	prep_to	2	SENT_1101	[p44l811t3252r1037b3309],
11	.	.	O	.	_	0	SENT_1101	[p44l811t3252r1037b3309],

1	N	NN	O	n	nn	2	SENT_1102	[p44l8t3327r50b3367],
2	EnglJ	NN	O	englj	nsubj	3	SENT_1102	[p44l67t3323r212b3380],
3	Med	VBD	O	med	_	0	SENT_1102	[p44l229t3323r334b3367],
4	2005	CD	DATE	2005	dobj	3	SENT_1102	[p44l354t3326r767b3376],
5	;	:	O	;	_	0	SENT_1102	[p44l354t3326r767b3376],
6	352:786	CD	NUMBER	352:786	num	7	SENT_1102	[p44l354t3326r767b3376],
7	-92	CD	NUMBER	-92	dep	4	SENT_1102	[p44l354t3326r767b3376],
8	.	.	O	.	_	0	SENT_1102	[p44l354t3326r767b3376],

1	101	CD	NUMBER	101	_	0	SENT_1103	[p44l11t3399r101b3438],
2	.	.	O	.	_	0	SENT_1103	[p44l11t3399r101b3438],

1	Pao	NNP	O	Pao	nn	2	SENT_1104	[p44l175t3398r260b3438],
2	W	NNP	O	W	_	0	SENT_1104	[p44l281t3398r342b3448],
3	,	,	O	,	_	0	SENT_1104	[p44l281t3398r342b3448],
4	Miller	NNP	ORGANIZATION	Miller	nn	5	SENT_1104	[p44l365t3394r514b3438],
5	WA	NNP	ORGANIZATION	WA	appos	2	SENT_1104	[p44l532t3398r630b3447],
6	,	,	O	,	_	0	SENT_1104	[p44l532t3398r630b3447],
7	Politi	NNP	PERSON	Politi	nn	8	SENT_1104	[p44l654t3394r784b3438],
8	KA	NN	O	ka	appos	2	SENT_1104	[p44l804t3398r893b3448],
9	,	,	O	,	_	0	SENT_1104	[p44l804t3398r893b3448],
10	et	FW	O	et	nn	11	SENT_1104	[p44l919t3403r962b3438],
11	al.	FW	O	al.	appos	2	SENT_1104	[p44l981t3394r1036b3438],
12	.	.	O	.	_	0	SENT_1104	[p44l981t3394r1036b3438],

1	Acquired	VBN	O	acquire	csubjpass	11	SENT_1105	[p44l7t3465r230b3521],
2	resistance	NN	O	resistance	dobj	1	SENT_1105	[p44l261t3466r506b3509],
3	of	IN	O	of	_	0	SENT_1105	[p44l539t3465r595b3509],
4	lung	NN	O	lung	nn	5	SENT_1105	[p44l616t3465r726b3522],
5	adenocarcinomas	NNS	O	adenocarcinoma	prep_of	2	SENT_1105	[p44l755t3465r1039b3509, p44l9t3550r171b3580],
6	to	TO	O	to	_	0	SENT_1105	[p44l196t3545r242b3580],
7	gefitinib	NN	O	gefitinib	prep_to	1	SENT_1105	[p44l266t3536r479b3593],
8	or	CC	O	or	_	0	SENT_1105	[p44l503t3550r554b3580],
9	erlotinib	NN	O	erlotinib	prep_to	1	SENT_1105	[p44l576t3536r786b3580],
10	is	VBZ	O	be	auxpass	11	SENT_1105	[p44l810t3537r848b3580],
11	associated	VBN	O	associate	_	0	SENT_1105	[p44l872t3537r1039b3580, p44l9t3608r110b3652],
12	with	IN	O	with	_	0	SENT_1105	[p44l128t3608r239b3653],
13	a	DT	DURATION	a	det	15	SENT_1105	[p44l259t3623r284b3652],
14	second	JJ	DURATION	second	amod	15	SENT_1105	[p44l304t3608r474b3652],
15	mutation	NN	O	mutation	prep_with	11	SENT_1105	[p44l494t3609r718b3653],
16	in	IN	O	in	_	0	SENT_1105	[p44l738t3609r785b3652],
17	the	DT	O	the	det	20	SENT_1105	[p44l805t3608r881b3652],
18	EGFR	NN	ORGANIZATION	egfr	nn	20	SENT_1105	[p44l901t3611r1046b3655],
19	kinase	NN	O	kinase	nn	20	SENT_1105	[p44l9t3678r168b3723],
20	domain	NN	O	domain	prep_in	15	SENT_1105	[p44l188t3678r389b3722],
21	.	.	O	.	_	0	SENT_1105	[p44l188t3678r389b3722],

1	PLoS	NNP	O	PLoS	nn	2	SENT_1106	[p44l411t3681r528b3722],
2	Med	NNP	O	Med	_	0	SENT_1106	[p44l547t3678r653b3722],
3	2005	CD	DATE	2005	num	2	SENT_1106	[p44l672t3681r1030b3731],
4	;	:	O	;	_	0	SENT_1106	[p44l672t3681r1030b3731],
5	2	CD	NUMBER	2	number	6	SENT_1106	[p44l672t3681r1030b3731],
6	(	CD	NUMBER	(	dep	2	SENT_1106	[p44l672t3681r1030b3731],
7	3	CD	NUMBER	3	num	8	SENT_1106	[p44l672t3681r1030b3731],
8	)	NN	O	)	dep	6	SENT_1106	[p44l672t3681r1030b3731],
9	:1	CD	NUMBER	:1	num	10	SENT_1106	[p44l672t3681r1030b3731],
10	-11	CD	NUMBER	-11	dep	6	SENT_1106	[p44l672t3681r1030b3731],
11	.	.	O	.	_	0	SENT_1106	[p44l672t3681r1030b3731],

1	102	CD	NUMBER	102	_	0	SENT_1107	[p44l11t3754r103b3794],
2	.	.	O	.	_	0	SENT_1107	[p44l11t3754r103b3794],

1	Kosaka	NNP	PERSON	Kosaka	nn	2	SENT_1108	[p44l170t3750r349b3795],
2	T	NN	O	t	_	0	SENT_1108	[p44l365t3754r408b3804],
3	,	,	O	,	_	0	SENT_1108	[p44l365t3754r408b3804],
4	Yatabe	NNP	PERSON	Yatabe	nn	5	SENT_1108	[p44l429t3750r589b3794],
5	Y	NN	PERSON	y	appos	2	SENT_1108	[p44l607t3754r647b3803],
6	,	,	O	,	_	0	SENT_1108	[p44l607t3754r647b3803],
7	Endoh	NN	PERSON	endoh	nn	8	SENT_1108	[p44l669t3750r826b3794],
8	H	NN	O	h	appos	2	SENT_1108	[p44l845t3754r899b3804],
9	,	,	O	,	_	0	SENT_1108	[p44l845t3754r899b3804],
10	et	FW	O	et	nn	11	SENT_1108	[p44l922t3759r965b3794],
11	al.	FW	O	al.	appos	2	SENT_1108	[p44l981t3750r1037b3794],
12	.	.	O	.	_	0	SENT_1108	[p44l981t3750r1037b3794],

1	Structures	NNS	O	structure	_	0	SENT_1109	[p44l1117t270r1367b312],
2	of	IN	O	of	_	0	SENT_1109	[p44l1401t267r1457b311],
3	lung	NN	O	lung	prep_of	1	SENT_1109	[p44l1478t267r1588b324],
4	cancer-derived	JJ	O	cancer-derived	amod	6	SENT_1109	[p44l1618t267r1976b312],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_1109	[p44l2007t270r2152b314],
6	mutants	NNS	O	mutant	dep	1	SENT_1109	[p44l1115t347r1316b383],
7	and	CC	O	and	_	0	SENT_1109	[p44l1335t338r1425b382],
8	inhibitor	NN	O	inhibitor	nn	9	SENT_1109	[p44l1443t338r1662b382],
9	complexes	NNS	O	complex	dep	1	SENT_1109	[p44l1679t338r1947b394],
10	:	:	O	:	_	0	SENT_1109	[p44l1679t338r1947b394],
11	mechanisms	NNS	O	mechanism	dep	1	SENT_1109	[p44l1968t338r2145b382, p44l1115t410r1261b453],
12	of	IN	O	of	_	0	SENT_1109	[p44l1284t409r1341b453],
13	activation	NN	O	activation	prep_of	11	SENT_1109	[p44l1352t410r1591b453],
14	and	CC	O	and	_	0	SENT_1109	[p44l1613t409r1703b453],
15	insights	NNS	O	insight	prep_of	11	SENT_1109	[p44l1725t409r1920b466],
16	into	IN	O	into	_	0	SENT_1109	[p44l1943t410r2040b453],
17	differential	JJ	O	differential	amod	19	SENT_1109	[p44l2063t409r2145b453, p44l1115t481r1321b525],
18	inhibitor	NN	O	inhibitor	nn	19	SENT_1109	[p44l1342t481r1561b525],
19	sensitivity	NN	O	sensitivity	prep_into	11	SENT_1109	[p44l1581t482r1837b537],
20	.	.	O	.	_	0	SENT_1109	[p44l1581t482r1837b537],

1	Cancer	NN	O	cancer	nn	2	SENT_1110	[p44l1861t484r2032b525],
2	Cell	NN	O	cell	_	0	SENT_1110	[p44l2052t481r2146b525],
3	2007	CD	DATE	2007	dep	2	SENT_1110	[p44l1115t554r1485b604],
4	;	:	O	;	_	0	SENT_1110	[p44l1115t554r1485b604],
5	11:217	CD	NUMBER	11:217	num	6	SENT_1110	[p44l1115t554r1485b604],
6	-27	CD	NUMBER	-27	dep	2	SENT_1110	[p44l1115t554r1485b604],
7	.	.	O	.	_	0	SENT_1110	[p44l1115t554r1485b604],

1	104	CD	NUMBER	104	_	0	SENT_1111	[p44l1117t627r1209b666],
2	.	.	O	.	_	0	SENT_1111	[p44l1117t627r1209b666],

1	Engelman	NNP	PERSON	Engelman	nn	2	SENT_1112	[p44l1278t622r1527b679],
2	JA	NNP	O	JA	_	0	SENT_1112	[p44l1541t626r1611b676],
3	,	,	O	,	_	0	SENT_1112	[p44l1541t626r1611b676],
4	Zejnullahu	NNP	PERSON	Zejnullahu	nn	5	SENT_1112	[p44l1633t622r1896b678],
5	K	NNP	PERSON	K	appos	2	SENT_1112	[p44l1916t626r1965b675],
6	,	,	O	,	_	0	SENT_1112	[p44l1916t626r1965b675],
7	Mitsudomi	NNP	ORGANIZATION	Mitsudomi	nn	8	SENT_1112	[p44l1987t623r2145b667, p44l1116t694r1241b738],
8	T	NN	ORGANIZATION	t	appos	2	SENT_1112	[p44l1259t698r1303b748],
9	,	,	O	,	_	0	SENT_1112	[p44l1259t698r1303b748],
10	et	FW	O	et	nn	11	SENT_1112	[p44l1327t703r1371b738],
11	al.	FW	O	al.	appos	2	SENT_1112	[p44l1388t694r1443b738],
12	.	.	O	.	_	0	SENT_1112	[p44l1388t694r1443b738],

1	MET	NN	O	met	nn	2	SENT_1113	[p44l1465t697r1582b738],
2	amplification	NN	O	amplification	nsubj	3	SENT_1113	[p44l1601t694r1935b750],
3	leads	VBZ	O	lead	_	0	SENT_1113	[p44l1954t694r2077b738],
4	to	TO	O	to	_	0	SENT_1113	[p44l2099t703r2145b738],
5	gefitinib	JJ	O	gefitinib	amod	6	SENT_1113	[p44l1115t765r1328b822],
6	resistance	NN	O	resistance	prep_to	3	SENT_1113	[p44l1345t766r1590b809],
7	in	IN	O	in	_	0	SENT_1113	[p44l1607t766r1654b809],
8	lung	NN	O	lung	nn	9	SENT_1113	[p44l1670t765r1781b822],
9	cancer	NN	O	cancer	prep_in	6	SENT_1113	[p44l1796t779r1956b809],
10	by	IN	O	by	_	0	SENT_1113	[p44l1971t765r2026b821],
11	activating	VBG	O	activate	prepc_by	3	SENT_1113	[p44l2040t766r2145b809, p44l1113t837r1266b893],
12	ERBB3	NN	O	erbb3	nn	13	SENT_1113	[p44l1278t839r1444b883],
13	signaling	NN	O	signaling	dobj	11	SENT_1113	[p44l1461t836r1703b893],
14	.	.	O	.	_	0	SENT_1113	[p44l1461t836r1703b893],

1	Science	NNP	O	Science	_	0	SENT_1114	[p44l1721t837r1900b880],
2	2007	CD	DATE	2007	num	1	SENT_1114	[p44l1914t839r2144b889],
3	;	:	O	;	_	0	SENT_1114	[p44l1914t839r2144b889],
4	316	CD	NUMBER	316	num	6	SENT_1114	[p44l1914t839r2144b889],
5	:	:	O	:	_	0	SENT_1114	[p44l1914t839r2144b889],
6	1039-43	CD	NUMBER	1039-43	dep	1	SENT_1114	[p44l1117t910r1321b952],
7	.	.	O	.	_	0	SENT_1114	[p44l1117t910r1321b952],

1	105	CD	NUMBER	105	_	0	SENT_1115	[p44l1117t984r1208b1023],
2	.	.	O	.	_	0	SENT_1115	[p44l1117t984r1208b1023],

1	Di	NNP	ORGANIZATION	Di	nn	3	SENT_1116	[p44l1264t980r1319b1023],
2	Maio	NNP	ORGANIZATION	Maio	nn	3	SENT_1116	[p44l1331t980r1454b1023],
3	M	NN	ORGANIZATION	m	_	0	SENT_1116	[p44l1467t983r1528b1033],
4	,	,	O	,	_	0	SENT_1116	[p44l1467t983r1528b1033],
5	Gridelli	NN	PERSON	gridellus	nn	6	SENT_1116	[p44l1545t979r1732b1023],
6	C	NN	PERSON	c	appos	3	SENT_1116	[p44l1745t982r1792b1032],
7	,	,	O	,	_	0	SENT_1116	[p44l1745t982r1792b1032],
8	Normanno	NNP	O	Normanno	nn	9	SENT_1116	[p44l1807t983r2077b1023],
9	N	NNP	O	N	appos	3	SENT_1116	[p44l2090t983r2143b1032],
10	,	,	O	,	_	0	SENT_1116	[p44l2090t983r2143b1032],
11	Perrone	NNP	PERSON	Perrone	nn	12	SENT_1116	[p44l1114t1053r1303b1093],
12	F	NN	O	f	appos	9	SENT_1116	[p44l1319t1053r1357b1103],
13	,	,	O	,	_	0	SENT_1116	[p44l1319t1053r1357b1103],
14	Ciardiello	NNP	PERSON	Ciardiello	nn	15	SENT_1116	[p44l1376t1049r1616b1093],
15	F.	NNP	O	F.	appos	9	SENT_1116	[p44l1632t1053r1670b1093],
16	Trying	VBG	O	try	partmod	15	SENT_1116	[p44l1687t1050r1851b1106],
17	to	TO	O	to	aux	18	SENT_1116	[p44l1865t1058r1912b1093],
18	compose	VB	O	compose	xcomp	16	SENT_1116	[p44l1929t1063r2146b1105],
19	the	DT	O	the	det	20	SENT_1116	[p44l1115t1121r1191b1165],
20	puzzle	NN	O	puzzle	dobj	18	SENT_1116	[p44l1214t1121r1373b1177],
21	with	IN	O	with	_	0	SENT_1116	[p44l1394t1121r1505b1166],
22	all	PDT	O	all	predet	24	SENT_1116	[p44l1528t1121r1588b1165],
23	the	DT	O	the	det	24	SENT_1116	[p44l1612t1121r1687b1165],
24	pieces	NNS	O	piece	prep_with	18	SENT_1116	[p44l1710t1122r1873b1177],
25	:	:	O	:	_	0	SENT_1116	[p44l1710t1122r1873b1177],
26	epidermal	JJ	O	epidermal	amod	32	SENT_1116	[p44l1900t1121r2146b1177],
27	growth	NN	O	growth	nn	32	SENT_1116	[p44l1115t1191r1294b1248],
28	factor	NN	O	factor	nn	32	SENT_1116	[p44l1332t1191r1475b1235],
29	receptor	NN	O	receptor	nn	32	SENT_1116	[p44l1511t1200r1715b1247],
30	tyrosine	NN	O	tyrosine	nn	32	SENT_1116	[p44l1751t1192r1949b1247],
31	kinase	NN	O	kinase	nn	32	SENT_1116	[p44l1987t1191r2146b1236],
32	inhibitors	NNS	O	inhibitor	dep	3	SENT_1116	[p44l1115t1262r1356b1306],
33	in	IN	O	in	_	0	SENT_1116	[p44l1382t1263r1430b1306],
34	non-small	JJ	O	non-small	amod	37	SENT_1116	[p44l1455t1262r1704b1306],
35	cell	NN	O	cell	nn	37	SENT_1116	[p44l1730t1262r1813b1306],
36	lung	NN	O	lung	nn	37	SENT_1116	[p44l1838t1262r1948b1319],
37	cancer	NN	O	cancer	prep_in	32	SENT_1116	[p44l1972t1276r2143b1306],
38	.	.	O	.	_	0	SENT_1116	[p44l1972t1276r2143b1306],

1	J	NN	O	j	nn	2	SENT_1117	[p44l1110t1338r1131b1385],
2	Cell	NN	O	cell	_	0	SENT_1117	[p44l1149t1334r1243b1378],
3	Physiol	NNP	O	Physiol	dep	2	SENT_1117	[p44l1261t1334r1435b1390],
4	2005	CD	DATE	2005	num	3	SENT_1117	[p44l1454t1337r1870b1387],
5	;	:	O	;	_	0	SENT_1117	[p44l1454t1337r1870b1387],
6	205:355	CD	NUMBER	205:355	num	7	SENT_1117	[p44l1454t1337r1870b1387],
7	-63	CD	NUMBER	-63	dep	2	SENT_1117	[p44l1454t1337r1870b1387],
8	.	.	O	.	_	0	SENT_1117	[p44l1454t1337r1870b1387],

1	106	CD	NUMBER	106	_	0	SENT_1118	[p44l1117t1409r1210b1448],
2	.	.	O	.	_	0	SENT_1118	[p44l1117t1409r1210b1448],

1	Viloria-Petit	NNP	O	Viloria-Petit	nn	2	SENT_1119	[p44l1262t1404r1558b1448],
2	A	NNP	O	A	_	0	SENT_1119	[p44l1566t1408r1616b1457],
3	,	,	O	,	_	0	SENT_1119	[p44l1566t1408r1616b1457],
4	Crombet	NNP	PERSON	Crombet	nn	5	SENT_1119	[p44l1632t1404r1846b1448],
5	T	NN	O	t	appos	2	SENT_1119	[p44l1855t1408r1898b1458],
6	,	,	O	,	_	0	SENT_1119	[p44l1855t1408r1898b1458],
7	Jothy	NNP	PERSON	Jothy	nn	8	SENT_1119	[p44l1908t1404r2038b1460],
8	S	NNP	O	S	appos	2	SENT_1119	[p44l2050t1407r2089b1458],
9	,	,	O	,	_	0	SENT_1119	[p44l2050t1407r2089b1458],
10	et	FW	O	et	nn	11	SENT_1119	[p44l2105t1413r2149b1448],
11	al.	FW	O	al.	appos	2	SENT_1119	[p44l1115t1475r1170b1519],
12	.	.	O	.	_	0	SENT_1119	[p44l1115t1475r1170b1519],

1	Acquired	VBN	O	acquire	amod	2	SENT_1120	[p44l1199t1475r1421b1531],
2	resistance	NN	O	resistance	_	0	SENT_1120	[p44l1448t1476r1693b1519],
3	to	TO	O	to	_	0	SENT_1120	[p44l1721t1484r1767b1519],
4	the	DT	O	the	det	6	SENT_1120	[p44l1795t1475r1871b1519],
5	antitumor	NN	O	antitumor	nn	6	SENT_1120	[p44l1898t1476r2147b1520],
6	activity	NN	O	activity	prep_to	2	SENT_1120	[p44l1115t1547r1292b1602],
7	of	IN	O	of	_	0	SENT_1120	[p44l1308t1546r1365b1590],
8	epidermal	JJ	O	epidermal	amod	12	SENT_1120	[p44l1374t1546r1620b1602],
9	growth	NN	O	growth	nn	12	SENT_1120	[p44l1638t1546r1817b1603],
10	factor	NN	O	factor	nn	12	SENT_1120	[p44l1835t1546r1979b1590],
11	receptor-blocking	JJ	O	receptor-blocking	amod	12	SENT_1120	[p44l1995t1560r2145b1602, p44l1115t1618r1421b1675],
12	antibodies	NNS	O	antibody	prep_of	2	SENT_1120	[p44l1443t1618r1701b1662],
13	in	IN	O	in	_	0	SENT_1120	[p44l1728t1619r1766b1662],
14	viva	FW	O	viva	prep_in	2	SENT_1120	[p44l1785t1619r1887b1662],
15	:	:	O	:	_	0	SENT_1120	[p44l1785t1619r1887b1662],
16	a	DT	O	a	det	17	SENT_1120	[p44l1913t1633r1938b1662],
17	role	NN	O	role	dep	2	SENT_1120	[p44l1961t1618r2053b1662],
18	for	IN	O	for	_	0	SENT_1120	[p44l2077t1618r2148b1662],
19	altered	JJ	O	altered	amod	21	SENT_1120	[p44l1115t1689r1283b1733],
20	tumor	NN	O	tumor	nn	21	SENT_1120	[p44l1313t1698r1465b1734],
21	angiogenesis	NN	O	angiogenesis	prep_for	17	SENT_1120	[p44l1494t1690r1827b1746],
22	.	.	O	.	_	0	SENT_1120	[p44l1494t1690r1827b1746],

1	Cancer	NNP	O	Cancer	nn	2	SENT_1121	[p44l1861t1692r2031b1733],
2	Res	NNP	O	Res	_	0	SENT_1121	[p44l2059t1693r2145b1736],
3	2001	CD	DATE	2001	num	2	SENT_1121	[p44l1115t1763r1559b1813],
4	;	:	O	;	_	0	SENT_1121	[p44l1115t1763r1559b1813],
5	61:5090	CD	NUMBER	61:5090	number	6	SENT_1121	[p44l1115t1763r1559b1813],
6	-101	CD	NUMBER	-101	dep	2	SENT_1121	[p44l1115t1763r1559b1813],
7	.	.	O	.	_	0	SENT_1121	[p44l1115t1763r1559b1813],

1	107	CD	NUMBER	107	_	0	SENT_1122	[p44l1117t1837r1203b1876],
2	.	.	O	.	_	0	SENT_1122	[p44l1117t1837r1203b1876],

1	Chakravarti	NNP	MISC	Chakravarti	nn	2	SENT_1123	[p44l1239t1832r1530b1877],
2	A	NNP	MISC	A	_	0	SENT_1123	[p44l1543t1836r1593b1885],
3	,	,	O	,	_	0	SENT_1123	[p44l1543t1836r1593b1885],
4	Loeffler	NNP	PERSON	Loeffler	nn	5	SENT_1123	[p44l1612t1832r1811b1876],
5	JS	NNP	O	JS	appos	2	SENT_1123	[p44l1820t1835r1882b1886],
6	,	,	O	,	_	0	SENT_1123	[p44l1820t1835r1882b1886],
7	Dyson	NNP	PERSON	Dyson	nn	8	SENT_1123	[p44l1901t1836r2055b1888],
8	NJ	NNP	O	NJ	appos	5	SENT_1123	[p44l2070t1836r2143b1883],
9	.	.	O	.	_	0	SENT_1123	[p44l2070t1836r2143b1883],

1	Insulin-like	JJ	O	insulin-like	amod	3	SENT_1124	[p44l1114t1902r1399b1947],
2	growth	NN	O	growth	nn	3	SENT_1124	[p44l1423t1902r1602b1959],
3	factor	NN	O	factor	nsubj	6	SENT_1124	[p44l1625t1902r1768b1946],
4	receptor	NN	O	receptor	nn	5	SENT_1124	[p44l1789t1911r1993b1958],
5	I	NN	O	i	dep	3	SENT_1124	[p44l2014t1906r2031b1946],
6	mediates	VBZ	O	mediate	_	0	SENT_1124	[p44l2054t1916r2145b1946, p44l1116t1974r1259b2018],
7	resistance	NN	O	resistance	dobj	6	SENT_1124	[p44l1273t1975r1518b2018],
8	to	TO	O	to	_	0	SENT_1124	[p44l1531t1983r1577b2018],
9	anti-epidermal	JJ	O	anti-epidermal	amod	13	SENT_1124	[p44l1590t1974r1954b2030],
10	growth	NN	O	growth	nn	13	SENT_1124	[p44l1967t1974r2146b2031],
11	factor	NN	O	factor	nn	13	SENT_1124	[p44l1115t2045r1258b2089],
12	receptor	NN	O	receptor	nn	13	SENT_1124	[p44l1275t2054r1478b2101],
13	therapy	NN	O	therapy	prep_to	6	SENT_1124	[p44l1495t2045r1678b2101],
14	in	IN	O	in	_	0	SENT_1124	[p44l1694t2046r1741b2089],
15	primary	JJ	O	primary	amod	18	SENT_1124	[p44l1758t2046r1958b2101],
16	human	JJ	O	human	amod	18	SENT_1124	[p44l1973t2045r2146b2090],
17	glioblastoma	NN	O	glioblastoma	nn	18	SENT_1124	[p44l1115t2116r1437b2173],
18	cells	NNS	O	cell	prep_in	13	SENT_1124	[p44l1459t2116r1566b2160],
19	through	IN	O	through	_	0	SENT_1124	[p44l1589t2116r1788b2173],
20	continued	JJ	O	continued	amod	21	SENT_1124	[p44l1810t2116r2055b2161],
21	activation	NN	O	activation	prep_through	6	SENT_1124	[p44l2077t2131r2145b2160, p44l1115t2188r1301b2232],
22	of	IN	O	of	_	0	SENT_1124	[p44l1320t2187r1377b2231],
23	phosphoinositide	NN	O	phosphoinositide	nn	25	SENT_1124	[p44l1384t2187r1813b2243],
24	3-kinase	NN	O	3-kinase	nn	25	SENT_1124	[p44l1832t2187r2040b2232],
25	signaling	NN	O	signaling	prep_of	21	SENT_1124	[p44l2059t2188r2145b2244, p44l1115t2258r1285b2315],
26	.	.	O	.	_	0	SENT_1124	[p44l2059t2188r2145b2244, p44l1115t2258r1285b2315],

1	Cancer	NNP	O	Cancer	nn	2	SENT_1125	[p44l1307t2261r1478b2302],
2	Res	NNP	O	Res	_	0	SENT_1125	[p44l1495t2262r1580b2305],
3	2002	CD	DATE	2002	num	2	SENT_1125	[p44l1601t2261r1954b2311],
4	;	:	O	;	_	0	SENT_1125	[p44l1601t2261r1954b2311],
5	62:200	CD	NUMBER	62:200	number	6	SENT_1125	[p44l1601t2261r1954b2311],
6	-7	CD	NUMBER	-7	dep	2	SENT_1125	[p44l1601t2261r1954b2311],
7	.	.	O	.	_	0	SENT_1125	[p44l1601t2261r1954b2311],

1	108	CD	NUMBER	108	_	0	SENT_1126	[p44l1117t2335r1211b2375],
2	.	.	O	.	_	0	SENT_1126	[p44l1117t2335r1211b2375],

1	Bianco	NNP	PERSON	Bianco	nn	2	SENT_1127	[p44l1264t2331r1433b2374],
2	R	NNP	PERSON	R	_	0	SENT_1127	[p44l1447t2334r1496b2384],
3	,	,	O	,	_	0	SENT_1127	[p44l1447t2334r1496b2384],
4	Shin	NNP	PERSON	Shin	nn	8	SENT_1127	[p44l1515t2330r1625b2374],
5	I	PRP	PERSON	I	dep	8	SENT_1127	[p44l1638t2334r1668b2383],
6	,	,	O	,	_	0	SENT_1127	[p44l1638t2334r1668b2383],
7	Ritter	NNP	PERSON	Ritter	dep	8	SENT_1127	[p44l1685t2331r1828b2377],
8	C	NNP	O	C	appos	2	SENT_1127	[p44l1840t2333r1888b2383],
9	,	,	O	,	_	0	SENT_1127	[p44l1840t2333r1888b2383],
10	et	FW	O	et	nn	11	SENT_1127	[p44l1906t2339r1950b2374],
11	al.	FW	O	al.	appos	8	SENT_1127	[p44l1961t2330r2017b2374],
12	.	.	O	.	_	0	SENT_1127	[p44l1961t2330r2017b2374],

1	Loss	NN	O	loss	nsubj	9	SENT_1128	[p44l2034t2334r2145b2374],
2	of	IN	O	of	_	0	SENT_1128	[p44l1116t2400r1173b2444],
3	PTEN/MMAC1/TEP	NN	O	pten/mmac1/tep	prep_of	1	SENT_1128	[p44l1195t2403r1673b2450],
4	in	IN	O	in	_	0	SENT_1128	[p44l1705t2401r1752b2444],
5	EGF	NN	ORGANIZATION	egf	nn	8	SENT_1128	[p44l1784t2403r1887b2444],
6	receptorexpressing	JJ	O	receptorexpressing	amod	8	SENT_1128	[p44l1920t2409r2145b2456, p44l1116t2472r1385b2528],
7	tumor	NN	O	tumor	nn	8	SENT_1128	[p44l1419t2480r1572b2516],
8	cells	NNS	O	cell	prep_in	3	SENT_1128	[p44l1606t2471r1713b2515],
9	counteracts	VBZ	O	counteract	_	0	SENT_1128	[p44l1750t2480r2033b2516],
10	the	DT	O	the	det	12	SENT_1128	[p44l2070t2471r2146b2515],
11	antitumor	JJ	O	antitumor	amod	12	SENT_1128	[p44l1115t2544r1365b2588],
12	action	NN	O	action	dobj	9	SENT_1128	[p44l1381t2544r1531b2587],
13	of	IN	O	of	_	0	SENT_1128	[p44l1550t2543r1606b2587],
14	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_1128	[p44l1613t2546r1758b2590],
15	tyrosine	NN	O	tyrosine	nn	17	SENT_1128	[p44l1771t2544r1969b2599],
16	kinase	NN	O	kinase	nn	17	SENT_1128	[p44l1987t2543r2146b2588],
17	inhibitors	NNS	O	inhibitor	prep_of	12	SENT_1128	[p44l1115t2613r1371b2657],
18	.	.	O	.	_	0	SENT_1128	[p44l1115t2613r1371b2657],

1	Oncogene	NN	O	oncogene	_	0	SENT_1129	[p44l1393t2616r1638b2670],
2	2003	CD	DATE	2003	num	1	SENT_1129	[p44l1657t2616r2073b2666],
3	;	:	O	;	_	0	SENT_1129	[p44l1657t2616r2073b2666],
4	22:2812	CD	NUMBER	22:2812	number	5	SENT_1129	[p44l1657t2616r2073b2666],
5	-22	CD	NUMBER	-22	dep	1	SENT_1129	[p44l1657t2616r2073b2666],
6	.	.	O	.	_	0	SENT_1129	[p44l1657t2616r2073b2666],

1	109	CD	NUMBER	109	_	0	SENT_1130	[p44l1117t2690r1208b2729],
2	.	.	O	.	_	0	SENT_1130	[p44l1117t2690r1208b2729],

1	Ciardiello	NNP	PERSON	Ciardiello	nn	2	SENT_1131	[p44l1274t2685r1514b2729],
2	F	NN	PERSON	f	_	0	SENT_1131	[p44l1531t2689r1570b2738],
3	,	,	O	,	_	0	SENT_1131	[p44l1531t2689r1570b2738],
4	Bianco	NNP	PERSON	Bianco	nn	5	SENT_1131	[p44l1590t2686r1756b2729],
5	R	NNP	PERSON	R	appos	2	SENT_1131	[p44l1774t2689r1823b2739],
6	,	,	O	,	_	0	SENT_1131	[p44l1774t2689r1823b2739],
7	Caputo	NNP	PERSON	Caputo	nn	8	SENT_1131	[p44l1844t2688r2017b2741],
8	R	NNP	O	R	appos	2	SENT_1131	[p44l2035t2689r2084b2739],
9	,	,	O	,	_	0	SENT_1131	[p44l2035t2689r2084b2739],
10	et	FW	O	et	nn	11	SENT_1131	[p44l2105t2694r2149b2729],
11	al.	FW	O	al.	appos	2	SENT_1131	[p44l1115t2755r1170b2799],
12	.	.	O	.	_	0	SENT_1131	[p44l1115t2755r1170b2799],

1	Antitumor	JJ	O	antitumor	amod	2	SENT_1132	[p44l1191t2756r1452b2800],
2	activity	NN	O	activity	_	0	SENT_1132	[p44l1470t2756r1647b2811],
3	of	IN	O	of	_	0	SENT_1132	[p44l1664t2755r1721b2799],
4	ZD6474	NN	O	zd6474	prep_of	2	SENT_1132	[p44l1729t2758r1930b2809],
5	,	,	O	,	_	0	SENT_1132	[p44l1729t2758r1930b2809],
6	a	DT	O	a	det	14	SENT_1132	[p44l1952t2770r1976b2799],
7	vascular	JJ	O	vascular	amod	14	SENT_1132	[p44l1993t2770r2145b2800, p44l1115t2826r1181b2870],
8	endothelial	JJ	O	endothelial	amod	14	SENT_1132	[p44l1201t2826r1478b2870],
9	growth	NN	O	growth	nn	14	SENT_1132	[p44l1498t2826r1677b2883],
10	factor	NN	O	factor	nn	14	SENT_1132	[p44l1699t2826r1842b2870],
11	receptor	NN	O	receptor	nn	14	SENT_1132	[p44l1861t2835r2065b2882],
12	tyrosine	NN	O	tyrosine	nn	14	SENT_1132	[p44l2084t2835r2145b2882, p44l1115t2899r1266b2942],
13	kinase	NN	O	kinase	nn	14	SENT_1132	[p44l1288t2898r1447b2943],
14	inhibitor	NN	O	inhibitor	appos	2	SENT_1132	[p44l1469t2898r1698b2952],
15	,	,	O	,	_	0	SENT_1132	[p44l1469t2898r1698b2952],
16	in	IN	O	in	_	0	SENT_1132	[p44l1723t2899r1770b2942],
17	human	JJ	O	human	amod	19	SENT_1132	[p44l1792t2898r1965b2943],
18	cancer	NN	O	cancer	nn	19	SENT_1132	[p44l1987t2912r2147b2942],
19	cells	NNS	O	cell	prep_in	2	SENT_1132	[p44l1116t2969r1223b3013],
20	with	IN	O	with	_	0	SENT_1132	[p44l1246t2969r1357b3014],
21	acquired	VBN	O	acquire	amod	22	SENT_1132	[p44l1381t2969r1593b3025],
22	resistance	NN	O	resistance	prep_with	19	SENT_1132	[p44l1617t2970r1862b3013],
23	to	TO	O	to	_	0	SENT_1132	[p44l1887t2978r1933b3013],
24	antiepidermal	JJ	O	antiepidermal	amod	28	SENT_1132	[p44l1958t2970r2145b3025, p44l1116t3039r1288b3083],
25	growth	NN	O	growth	nn	28	SENT_1132	[p44l1323t3039r1502b3096],
26	factor	NN	O	factor	nn	28	SENT_1132	[p44l1537t3039r1680b3083],
27	receptor	NN	O	receptor	nn	28	SENT_1132	[p44l1714t3048r1917b3095],
28	therapy	NN	O	therapy	prep_to	22	SENT_1132	[p44l1951t3039r2143b3095],
29	.	.	O	.	_	0	SENT_1132	[p44l1951t3039r2143b3095],

1	Clin	NNP	O	Clin	nn	3	SENT_1133	[p44l1115t3110r1216b3154],
2	Cancer	NNP	O	Cancer	nn	3	SENT_1133	[p44l1235t3113r1406b3154],
3	Res	NNP	O	Res	_	0	SENT_1133	[p44l1422t3114r1508b3157],
4	2004	CD	DATE	2004	num	3	SENT_1133	[p44l1529t3113r1916b3163],
5	;	:	O	;	_	0	SENT_1133	[p44l1529t3113r1916b3163],
6	10:784	CD	NUMBER	10:784	number	7	SENT_1133	[p44l1529t3113r1916b3163],
7	-93	CD	NUMBER	-93	dep	3	SENT_1133	[p44l1529t3113r1916b3163],
8	.	.	O	.	_	0	SENT_1133	[p44l1529t3113r1916b3163],

1	110	CD	NUMBER	110	_	0	SENT_1134	[p44l1117t3187r1206b3226],
2	.	.	O	.	_	0	SENT_1134	[p44l1117t3187r1206b3226],

1	Camp	NNP	O	Camp	nn	2	SENT_1135	[p44l1254t3185r1395b3238],
2	ER	NN	O	er	_	0	SENT_1135	[p44l1419t3186r1501b3236],
3	,	,	O	,	_	0	SENT_1135	[p44l1419t3186r1501b3236],
4	Summy	NNP	PERSON	Summy	nn	5	SENT_1135	[p44l1529t3185r1713b3238],
5	J	NNP	PERSON	J	appos	2	SENT_1135	[p44l1729t3186r1761b3235],
6	,	,	O	,	_	0	SENT_1135	[p44l1729t3186r1761b3235],
7	Bauer	NNP	PERSON	Bauer	nn	8	SENT_1135	[p44l1787t3186r1927b3227],
8	TW	NNP	O	TW	appos	5	SENT_1135	[p44l1948t3185r2044b3235],
9	,	,	O	,	_	0	SENT_1135	[p44l1948t3185r2044b3235],
10	Liu	NNP	PERSON	Liu	nn	11	SENT_1135	[p44l2070t3183r2146b3227],
11	W	NNP	PERSON	W	appos	5	SENT_1135	[p44l1113t3256r1174b3306],
12	,	,	O	,	_	0	SENT_1135	[p44l1113t3256r1174b3306],
13	Gallick	NNP	PERSON	Gallick	nn	14	SENT_1135	[p44l1195t3252r1374b3297],
14	GE	NNP	O	GE	appos	5	SENT_1135	[p44l1389t3255r1475b3306],
15	,	,	O	,	_	0	SENT_1135	[p44l1389t3255r1475b3306],
16	Ellis	NNP	PERSON	Ellis	nn	17	SENT_1135	[p44l1495t3252r1600b3296],
17	LM	NNP	O	LM	appos	5	SENT_1135	[p44l1619t3256r1711b3296],
18	.	.	O	.	_	0	SENT_1135	[p44l1619t3256r1711b3296],

1	Molecular	JJ	O	molecular	amod	2	SENT_1136	[p44l1731t3252r1979b3297],
2	mechanisms	NNS	O	mechanism	_	0	SENT_1136	[p44l1996t3252r2145b3296, p44l1115t3324r1289b3367],
3	of	IN	O	of	_	0	SENT_1136	[p44l1317t3323r1373b3367],
4	resistance	NN	O	resistance	prep_of	2	SENT_1136	[p44l1389t3324r1635b3367],
5	to	TO	O	to	_	0	SENT_1136	[p44l1661t3332r1707b3367],
6	therapies	NNS	O	therapy	prep_to	4	SENT_1136	[p44l1734t3323r1958b3379],
7	targeting	VBG	O	target	partmod	2	SENT_1136	[p44l1985t3332r2145b3380, p44l1115t3395r1194b3451],
8	the	DT	O	the	det	12	SENT_1136	[p44l1211t3394r1287b3438],
9	epidermal	JJ	O	epidermal	amod	12	SENT_1136	[p44l1306t3394r1553b3450],
10	growth	NN	O	growth	nn	12	SENT_1136	[p44l1571t3394r1750b3451],
11	factor	NN	O	factor	nn	12	SENT_1136	[p44l1768t3394r1912b3438],
12	receptor	NN	O	receptor	dobj	7	SENT_1136	[p44l1929t3403r2143b3450],
13	.	.	O	.	_	0	SENT_1136	[p44l1929t3403r2143b3450],

1	Clin	NNP	O	Clin	nn	3	SENT_1137	[p44l1115t3465r1216b3509],
2	Cancer	NNP	O	Cancer	nn	3	SENT_1137	[p44l1235t3468r1406b3509],
3	Res	NNP	O	Res	_	0	SENT_1137	[p44l1422t3469r1508b3512],
4	2005	CD	DATE	2005	num	3	SENT_1137	[p44l1529t3468r1942b3518],
5	;	:	O	;	_	0	SENT_1137	[p44l1529t3468r1942b3518],
6	11:397	CD	NUMBER	11:397	number	7	SENT_1137	[p44l1529t3468r1942b3518],
7	-405	CD	NUMBER	-405	dep	3	SENT_1137	[p44l1529t3468r1942b3518],
8	.	.	O	.	_	0	SENT_1137	[p44l1529t3468r1942b3518],

1	111	CD	NUMBER	111	_	0	SENT_1138	[p44l1117t3542r1207b3580],
2	.	.	O	.	_	0	SENT_1138	[p44l1117t3542r1207b3580],

1	Morgillo	NNP	O	Morgillo	nn	2	SENT_1139	[p44l1252t3536r1466b3593],
2	F	NN	O	f	_	0	SENT_1139	[p44l1490t3540r1528b3590],
3	,	,	O	,	_	0	SENT_1139	[p44l1490t3540r1528b3590],
4	Bareschino	NNP	PERSON	Bareschino	nn	5	SENT_1139	[p44l1555t3536r1830b3580],
5	MA	NNP	PERSON	MA	appos	2	SENT_1139	[p44l1853t3540r1952b3590],
6	,	,	O	,	_	0	SENT_1139	[p44l1853t3540r1952b3590],
7	Bianco	NNP	PERSON	Bianco	nn	8	SENT_1139	[p44l1979t3537r2145b3580],
8	R	NNP	PERSON	R	appos	2	SENT_1139	[p44l1114t3612r1163b3661],
9	,	,	O	,	_	0	SENT_1139	[p44l1114t3612r1163b3661],
10	Tortora	NNP	PERSON	Tortora	nn	14	SENT_1139	[p44l1194t3612r1378b3652],
11	G	NNP	PERSON	G	nn	14	SENT_1139	[p44l1406t3611r1459b3662],
12	,	,	O	,	_	0	SENT_1139	[p44l1406t3611r1459b3662],
13	Ciardiello	NNP	PERSON	Ciardiello	appos	14	SENT_1139	[p44l1491t3608r1731b3652],
14	F.	NNP	PERSON	F.	conj_and	5	SENT_1139	[p44l1761t3612r1799b3652],
15	Primary	JJ	PERSON	primary	amod	14	SENT_1139	[p44l1831t3609r2030b3664],
16	and	CC	O	and	_	0	SENT_1139	[p44l2057t3608r2146b3652],
17	acquired	VBN	O	acquire	amod	18	SENT_1139	[p44l1115t3678r1326b3734],
18	resistance	NN	O	resistance	conj_and	5	SENT_1139	[p44l1344t3679r1589b3722],
19	to	TO	O	to	_	0	SENT_1139	[p44l1607t3687r1653b3722],
20	anti-EGFR	JJ	O	anti-egfr	prep_to	18	SENT_1139	[p44l1672t3679r1931b3725],
21	targeted	VBN	O	target	partmod	20	SENT_1139	[p44l1943t3678r2146b3735],
22	drugs	NNS	O	drug	dobj	21	SENT_1139	[p44l1116t3750r1254b3807],
23	in	IN	O	in	_	0	SENT_1139	[p44l1285t3751r1332b3794],
24	cancer	NN	O	cancer	nn	25	SENT_1139	[p44l1362t3764r1523b3794],
25	therapy	NN	O	therapy	prep_in	22	SENT_1139	[p44l1551t3750r1743b3806],
26	.	.	O	.	_	0	SENT_1139	[p44l1551t3750r1743b3806],

1	Differantiation	NN	O	differantiation	_	0	SENT_1140	[p44l1775t3750r2146b3794],

1	Analysis	NN	O	analysis	nsubj	8	SENT_1141	[p45l7t15r213b71],
2	of	IN	O	of	_	0	SENT_1141	[p45l244t15r301b59],
3	epidermal	JJ	O	epidermal	amod	5	SENT_1141	[p45l320t15r567b71],
4	growth	NN	O	growth	nn	5	SENT_1141	[p45l596t15r774b72],
5	factor	NN	O	factor	prep_of	1	SENT_1141	[p45l804t15r947b59],
6	receptor	NN	O	receptor	nn	8	SENT_1141	[p45l975t30r1039b59, p45l9t95r164b142],
7	gene	NN	O	gene	nn	8	SENT_1141	[p45l200t100r313b143],
8	mutation	NN	O	mutation	_	0	SENT_1141	[p45l351t87r575b131],
9	in	IN	O	in	_	0	SENT_1141	[p45l613t87r660b130],
10	patients	NNS	O	patient	prep_in	8	SENT_1141	[p45l697t87r892b142],
11	with	IN	O	with	_	0	SENT_1141	[p45l929t86r1040b131],
12	non-small	JJ	O	non-small	amod	15	SENT_1141	[p45l9t157r258b201],
13	cell	NN	O	cell	nn	15	SENT_1141	[p45l285t157r368b201],
14	lung	NN	O	lung	nn	15	SENT_1141	[p45l393t157r504b214],
15	cancer	NN	O	cancer	prep_with	8	SENT_1141	[p45l528t171r688b201],
16	and	CC	O	and	_	0	SENT_1141	[p45l713t157r803b201],
17	acquired	VBD	O	acquire	conj_and	8	SENT_1141	[p45l828t157r1040b213],
18	resistance	NN	O	resistance	dobj	17	SENT_1141	[p45l9t229r254b272],
19	to	TO	O	to	_	0	SENT_1141	[p45l285t237r331b272],
20	gefitinib	NN	O	gefitinib	prep_to	17	SENT_1141	[p45l363t228r589b285],
21	.	.	O	.	_	0	SENT_1141	[p45l363t228r589b285],

1	Clin	NNP	O	Clin	nn	3	SENT_1142	[p45l623t228r724b272],
2	Cancer	NNP	O	Cancer	nn	3	SENT_1142	[p45l754t231r925b272],
3	Res	NNP	O	Res	_	0	SENT_1142	[p45l953t232r1038b275],
4	2006	CD	DATE	2006	num	3	SENT_1142	[p45l9t303r399b353],
5	;	:	O	;	_	0	SENT_1142	[p45l9t303r399b353],
6	12:5764	CD	NUMBER	12:5764	number	7	SENT_1142	[p45l9t303r399b353],
7	—	CD	NUMBER	—	dep	3	SENT_1142	[p45l9t303r399b353],
8	9	CD	NUMBER	9	dep	7	SENT_1142	[p45l9t303r399b353],
9	.	.	O	.	_	0	SENT_1142	[p45l9t303r399b353],

1	103	CD	NUMBER	103	_	0	SENT_1143	[p45l11t375r101b414],
2	.	.	O	.	_	0	SENT_1143	[p45l11t375r101b414],

1	Yun	NNP	PERSON	Yun	nn	2	SENT_1144	[p45l189t374r282b415],
2	C-H	NNP	O	C-H	_	0	SENT_1144	[p45l311t373r420b424],
3	,	,	O	,	_	0	SENT_1144	[p45l311t373r420b424],
4	Boggon	NNP	PERSON	Boggon	nn	6	SENT_1144	[p45l452t374r642b427],
5	T	NN	O	t	nn	6	SENT_1144	[p45l670t374r733b423],
6	]	NN	O	]	appos	2	SENT_1144	[p45l670t374r733b423],
7	,	,	O	,	_	0	SENT_1144	[p45l670t374r733b423],
8	Li	NNP	PERSON	Li	nn	9	SENT_1144	[p45l765t371r810b414],
9	Y	NN	PERSON	y	appos	2	SENT_1144	[p45l837t374r878b423],
10	,	,	O	,	_	0	SENT_1144	[p45l837t374r878b423],
11	et	FW	O	et	nn	12	SENT_1144	[p45l911t379r955b414],
12	al.	FW	O	al.	appos	2	SENT_1144	[p45l981t370r1037b414],
13	.	.	O	.	_	0	SENT_1144	[p45l981t370r1037b414],

1	2007	CD	DATE	2007	_	0	SENT_1145	[p45l1115t18r1494b68],
2	;	:	O	;	_	0	SENT_1145	[p45l1115t18r1494b68],
3	75:788	CD	NUMBER	75:788	number	4	SENT_1145	[p45l1115t18r1494b68],
4	—	CD	NUMBER	—	dep	1	SENT_1145	[p45l1115t18r1494b68],
5	99	CD	NUMBER	99	dep	4	SENT_1145	[p45l1115t18r1494b68],
6	.	.	O	.	_	0	SENT_1145	[p45l1115t18r1494b68],

1	112	CD	NUMBER	112	_	0	SENT_1146	[p45l1117t92r1208b130],
2	.	.	O	.	_	0	SENT_1146	[p45l1117t92r1208b130],

1	Dancey	NNP	O	Dancey	nn	2	SENT_1147	[p45l1277t90r1457b142],
2	JE	NNP	O	JE	_	0	SENT_1147	[p45l1469t90r1536b140],
3	,	,	O	,	_	0	SENT_1147	[p45l1469t90r1536b140],
4	Chen	NNP	PERSON	Chen	nn	5	SENT_1147	[p45l1559t86r1684b130],
5	HX	NNP	PERSON	HX	appos	2	SENT_1147	[p45l1703t90r1793b130],
6	.	.	O	.	_	0	SENT_1147	[p45l1703t90r1793b130],

1	Strategies	NNS	O	strategy	_	0	SENT_1148	[p45l1817t87r2056b143],
2	for	IN	O	for	_	0	SENT_1148	[p45l2077t86r2147b130],
3	optimizing	VBG	O	optimize	amod	4	SENT_1148	[p45l1116t158r1390b214],
4	combinations	NNS	O	combination	prep_for	1	SENT_1148	[p45l1418t157r1754b201],
5	of	IN	O	of	_	0	SENT_1148	[p45l1784t157r1841b201],
6	molecularly	RB	O	molecularly	advmod	7	SENT_1148	[p45l1859t157r2148b213],
7	targeted	VBN	O	target	amod	9	SENT_1148	[p45l1115t228r1318b285],
8	anticancer	JJ	O	anticancer	amod	9	SENT_1148	[p45l1339t229r1597b272],
9	agents	NNS	O	agent	prep_of	4	SENT_1148	[p45l1615t237r1787b285],
10	.	.	O	.	_	0	SENT_1148	[p45l1615t237r1787b285],

1	Nat	NNP	PERSON	Nat	nn	3	SENT_1149	[p45l1810t232r1898b272],
2	Rev	NN	PERSON	rev	nn	3	SENT_1149	[p45l1915t232r2004b275],
3	Drug	NN	O	drug	_	0	SENT_1149	[p45l2022t232r2148b285],
4	Discov	NNP	O	Discov	dep	3	SENT_1149	[p45l1114t301r1279b344],
5	2006	CD	DATE	2006	num	4	SENT_1149	[p45l1296t303r1655b353],
6	;	:	O	;	_	0	SENT_1149	[p45l1296t303r1655b353],
7	5:649	CD	NUMBER	5:649	number	8	SENT_1149	[p45l1296t303r1655b353],
8	—	CD	NUMBER	—	dep	3	SENT_1149	[p45l1296t303r1655b353],
9	59	CD	NUMBER	59	dep	8	SENT_1149	[p45l1296t303r1655b353],
10	.	.	O	.	_	0	SENT_1149	[p45l1296t303r1655b353],

1	Copyright	NN	O	copyright	_	0	SENT_1150	[p45l1117t377r1296b426],
2	©	CD	NUMBER	©	num	6	SENT_1150	[p45l1314t381r1354b421],
3	2008	CD	DATE	2008	num	6	SENT_1150	[p45l1374t380r1468b414],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_1150	[p45l1485t377r1754b414],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_1150	[p45l1772t377r1920b414],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_1150	[p45l1935t379r2074b425],
7	.	.	O	.	_	0	SENT_1150	[p45l1935t379r2074b425],

1	N	NN	O	n	nn	3	SENT_1151	[p45l914t512r927b527],
2	ENGLJ	NN	O	englj	nn	3	SENT_1151	[p45l942t512r1020b534],
3	MED	NN	O	med	_	0	SENT_1151	[p45l1035t512r1086b527],
4	358	CD	NUMBER	358	dep	3	SENT_1151	[p45l1097t506r1165b534],
5	;	:	O	;	_	0	SENT_1151	[p45l1097t506r1165b534],
6	11	CD	NUMBER	11	dep	3	SENT_1151	[p45l1097t506r1165b534],
7	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	8	SENT_1151	[p45l1201t512r1402b534],
8	MARCH	NNP	DATE	MARCH	dep	6	SENT_1151	[p45l1439t512r1524b527],
9	13	CD	DATE	13	num	8	SENT_1151	[p45l1538t512r1570b534],
10	,	,	DATE	,	_	0	SENT_1151	[p45l1538t512r1570b534],
11	2008	CD	DATE	2008	num	8	SENT_1151	[p45l1581t506r1644b528],
12	The	DT	O	the	det	15	SENT_1151	[p45l935t545r986b569],
13	New	NNP	O	New	nn	15	SENT_1151	[p45l995t546r1057b569],
14	England	NNP	O	England	nn	15	SENT_1151	[p45l1066t545r1177b576],
15	Joumal	NNP	O	Joumal	dep	3	SENT_1151	[p45l1186t545r1283b569],
16	of	IN	O	of	_	0	SENT_1151	[p45l1293t545r1322b569],
17	Medicine	NNP	O	Medicine	prep_of	15	SENT_1151	[p45l1329t545r1454b569],

1	Downloaded	VBN	O	download	_	0	SENT_1152	[p45l377t586r547b609],
2	from	IN	O	from	_	0	SENT_1152	[p45l556t586r621b609],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_1152	[p45l629t586r748b616],
4	at	IN	O	at	_	0	SENT_1152	[p45l758t590r781b609],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_1152	[p45l789t586r972b609],
6	on	IN	O	on	_	0	SENT_1152	[p45l981t593r1014b609],
7	January	NNP	DATE	January	prep_on	1	SENT_1152	[p45l1022t586r1125b616],
8	5	CD	DATE	5	num	7	SENT_1152	[p45l1135t586r1158b613],
9	,	,	DATE	,	_	0	SENT_1152	[p45l1135t586r1158b613],
10	2014	CD	DATE	2014	num	7	SENT_1152	[p45l1168t586r1241b609],
11	.	.	O	.	_	0	SENT_1152	[p45l1168t586r1241b609],

1	For	IN	O	for	_	0	SENT_1153	[p45l1251t586r1298b609],
2	personal	JJ	O	personal	amod	3	SENT_1153	[p45l1306t586r1418b616],
3	use	NN	O	use	pobj	1	SENT_1153	[p45l1427t593r1471b609],
4	only	RB	O	only	advmod	3	SENT_1153	[p45l1480t586r1545b616],
5	.	.	O	.	_	0	SENT_1153	[p45l1480t586r1545b616],

1	No	DT	O	no	det	3	SENT_1154	[p45l1556t586r1595b609],
2	other	JJ	O	other	amod	3	SENT_1154	[p45l1605t586r1673b609],
3	uses	NNS	O	use	_	0	SENT_1154	[p45l1682t593r1738b609],
4	without	IN	O	without	_	0	SENT_1154	[p45l1748t586r1849b609],
5	permission	NN	O	permission	prep_without	3	SENT_1154	[p45l1857t586r2010b616],
6	.	.	O	.	_	0	SENT_1154	[p45l1857t586r2010b616],

1	Copyright	NN	O	copyright	_	0	SENT_1155	[p45l728t627r862b658],
2	©	CD	NUMBER	©	num	6	SENT_1155	[p45l871t627r895b651],
3	2008	CD	DATE	2008	num	6	SENT_1155	[p45l905t627r969b651],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_1155	[p45l979t627r1170b651],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_1155	[p45l1180t627r1288b651],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_1155	[p45l1299t627r1404b658],
7	.	.	O	.	_	0	SENT_1155	[p45l1299t627r1404b658],

1	All	DT	O	all	det	2	SENT_1156	[p45l1415t627r1456b651],
2	rights	NNS	O	rights	nsubj	3	SENT_1156	[p45l1465t627r1540b658],
3	reserved	VBN	O	reserve	_	0	SENT_1156	[p45l1550t627r1668b651],
4	.	.	O	.	_	0	SENT_1156	[p45l1550t627r1668b651],

